

MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING DYSTROPHINOPATHIES

RELATED APPLICATIONS

[0001] This application claims priority under 35 U.S.C. § 119(e) to U.S. Provisional Application Serial No. 63/219977, entitled “MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING DYSTROPHINOPATHIES”, filed on July 9, 2021, the contents of which are incorporated herein by reference in their entirety.

FIELD OF THE INVENTION

[0002] The present application relates to targeting complexes for delivering molecular payloads (e.g., oligonucleotides) to cells and uses thereof, particularly uses relating to treatment of disease.

REFERENCE TO AN ELECTRONIC SEQUENCE LISTING

[0003] The contents of the electronic sequence listing (D082470064WO00-SEQ-COB.xml; Size: 1,479,992 bytes; and Date of Creation: July 7, 2022) are herein incorporated by reference in their entirety.

BACKGROUND OF INVENTION

[0004] Dystrophinopathies are a group of distinct neuromuscular diseases that result from mutations in the gene encoding dystrophin. Dystrophinopathies include Duchenne muscular dystrophy, Becker muscular dystrophy, and X-linked dilated cardiomyopathy. The DMD gene (“DMD”), which encodes dystrophin, is a large gene, containing 79 exons and about 2.6 million total base pairs. Numerous mutations in DMD, including exonic frameshift, deletion, substitution, and duplicative mutations, are able to diminish the expression of functional dystrophin, leading to dystrophinopathies. Several agents that target exons of human DMD have been approved by the U.S. Food and Drug Administration (FDA), including casimersen, viltolarsen, golodirsen, and eteplirsen. Of these, casimersen targets exon 45.

SUMMARY OF INVENTION

[0005] According to some aspects, the disclosure provides complexes that target muscle cells for purposes of delivering molecular payloads to those cells, as well as molecular payloads that can be used therein. In some embodiments, complexes provided herein are particularly useful for delivering molecular payloads that increase or restore expression or activity of functional

dystrophin protein. In some embodiments, complexes comprise oligonucleotide based molecular payloads that promote expression of functional dystrophin protein through an in-frame exon skipping mechanism or suppression of stop codons, such as by facilitating skipping of DMD exon 45. In some embodiments, molecular payloads provided herein are useful for facilitating exon skipping in a DMD sequence, such as skipping of DMD exon 45. Accordingly, in some embodiments, complexes provided herein comprise muscle-targeting agents (e.g., muscle targeting antibodies) that specifically bind to receptors on the surface of muscle cells for purposes of delivering molecular payloads to the muscle cells. In some embodiments, the complexes are taken up into the cells via a receptor mediated internalization, following which the molecular payload may be released to perform a function inside the cells. For example, complexes engineered to deliver oligonucleotides may release the oligonucleotides such that the oligonucleotides can promote expression of functional dystrophin protein (e.g., through an exon skipping mechanism, such as by facilitating skipping of DMD exon 45) in the muscle cells. In some embodiments, the oligonucleotides are released by endosomal cleavage of covalent linkers connecting oligonucleotides and muscle-targeting agents of the complexes. Complexes and molecular payloads provided herein can be used for treating subjects having a mutated DMD gene, such as a mutated DMD gene that is amenable to exon 45 skipping.

[0006] According to some aspects, complexes comprising an anti-transferrin receptor 1 (TfR1) antibody covalently linked to an oligonucleotide configured for inducing skipping of exon 45 in a DMD pre-mRNA are provided herein, wherein the oligonucleotide comprises a region of complementarity that is complementary with at least 8 consecutive nucleotides of any one of SEQ ID NOs: 240, 236, 280, 211, 197, 212, 208, 217, 213, 195, 160-194, 196, 198-207, 209, 210, 214-216, 218-235, 237-239, 241-279, and 281-399.

[0007] In some embodiments, the anti-TfR1 antibody comprises:

(i) a heavy chain complementarity determining region 1 (CDR-H1) of SEQ ID NO: 33, a heavy chain complementarity determining region 2 (CDR-H2) of SEQ ID NO: 34, a heavy chain complementarity determining region 3 (CDR-H3) of SEQ ID NO: 35, a light chain complementarity determining region 1 (CDR-L1) of SEQ ID NO: 36, a light chain complementarity determining region 2 (CDR-L2) of SEQ ID NO: 37, and a light chain complementarity determining region 3 (CDR-L3) of SEQ ID NO: 32;

(ii) a CDR-H1 of SEQ ID NO: 7, a CDR-H2 of SEQ ID NO: 8, a CDR-H3 of SEQ ID NO: 9, a CDR-L1 of SEQ ID NO: 10, a CDR-L2 of SEQ ID NO: 11, and a CDR-L3 of SEQ ID NO: 6;

(iii) a CDR-H1 of SEQ ID NO: 7, a CDR-H2 of SEQ ID NO: 20, a CDR-H3 of SEQ ID NO: 9, a CDR-L1 of SEQ ID NO: 10, a CDR-L2 of SEQ ID NO: 11, and a CDR-L3 of SEQ ID

NO: 6;

(iv) a CDR-H1 of SEQ ID NO: 7, a CDR-H2 of SEQ ID NO: 24, a CDR-H3 of SEQ ID NO: 9, a CDR-L1 of SEQ ID NO: 10, a CDR-L2 of SEQ ID NO: 11, and a CDR-L3 of SEQ ID NO: 6;

(v) a CDR-H1 of SEQ ID NO: 51, a CDR-H2 of SEQ ID NO: 52, a CDR-H3 of SEQ ID NO: 53, a CDR-L1 of SEQ ID NO: 54, a CDR-L2 of SEQ ID NO: 55, and a CDR-L3 of SEQ ID NO: 50;

(vi) a CDR-H1 of SEQ ID NO: 64, a CDR-H2 of SEQ ID NO: 52, a CDR-H3 of SEQ ID NO: 53, a CDR-L1 of SEQ ID NO: 54, a CDR-L2 of SEQ ID NO: 55, and a CDR-L3 of SEQ ID NO: 50; or

(vii) a CDR-H1 of SEQ ID NO: 67, a CDR-H2 of SEQ ID NO: 52, a CDR-H3 of SEQ ID NO: 53, a CDR-L1 of SEQ ID NO: 54, a CDR-L2 of SEQ ID NO: 55, and a CDR-L3 of SEQ ID NO: 50.

[0008] In some embodiments, the anti-TfR1 antibody comprises:

(i) a heavy chain variable region (VH) comprising an amino acid sequence at least 85% identical to SEQ ID NO: 76; and/or a light chain variable region (VL) comprising an amino acid sequence at least 85% identical to SEQ ID NO: 75;

(ii) a VH comprising an amino acid sequence at least 85% identical to SEQ ID NO: 69; and/or a VL comprising an amino acid sequence at least 85% identical to SEQ ID NO: 70;

(iii) a VH comprising an amino acid sequence at least 85% identical to SEQ ID NO: 71; and/or a VL comprising an amino acid sequence at least 85% identical to SEQ ID NO: 70;

(iv) a VH comprising an amino acid sequence at least 85% identical to SEQ ID NO: 72; and/or a VL comprising an amino acid sequence at least 85% identical to SEQ ID NO: 70;

(v) a VH comprising an amino acid sequence at least 85% identical to SEQ ID NO: 73; and/or a VL comprising an amino acid sequence at least 85% identical to SEQ ID NO: 74;

(vi) a VH comprising an amino acid sequence at least 85% identical to SEQ ID NO: 73; and/or a VL comprising an amino acid sequence at least 85% identical to SEQ ID NO: 75;

(vii) a VH comprising an amino acid sequence at least 85% identical to SEQ ID NO: 76; and/or a VL comprising an amino acid sequence at least 85% identical to SEQ ID NO: 74;

(viii) a VH comprising an amino acid sequence at least 85% identical to SEQ ID NO: 77; and/or a VL comprising an amino acid sequence at least 85% identical to SEQ ID NO: 78;

(ix) a VH comprising an amino acid sequence at least 85% identical to SEQ ID NO: 79; and/or a VL comprising an amino acid sequence at least 85% identical to SEQ ID NO: 80; or

(x) a VH comprising an amino acid sequence at least 85% identical to SEQ ID NO: 77; and/or a VL comprising an amino acid sequence at least 85% identical to SEQ ID NO: 80.

[0009] In some embodiments, the anti-TfR1 antibody comprises:

- (i) a VH comprising the amino acid sequence of SEQ ID NO: 76 and a VL comprising the amino acid sequence of SEQ ID NO: 75;
- (ii) a VH comprising the amino acid sequence of SEQ ID NO: 69 and a VL comprising the amino acid sequence of SEQ ID NO: 70;
- (iii) a VH comprising the amino acid sequence of SEQ ID NO: 71 and a VL comprising the amino acid sequence of SEQ ID NO: 70;
- (iv) a VH comprising the amino acid sequence of SEQ ID NO: 72 and a VL comprising the amino acid sequence of SEQ ID NO: 70;
- (v) a VH comprising the amino acid sequence of SEQ ID NO: 73 and a VL comprising the amino acid sequence of SEQ ID NO: 74;
- (vi) a VH comprising the amino acid sequence of SEQ ID NO: 73 and a VL comprising the amino acid sequence of SEQ ID NO: 75;
- (vii) a VH comprising the amino acid sequence of SEQ ID NO: 76 and a VL comprising the amino acid sequence of SEQ ID NO: 74;
- (viii) a VH comprising the amino acid sequence of SEQ ID NO: 77 and a VL comprising the amino acid sequence of SEQ ID NO: 78;
- (ix) a VH comprising the amino acid sequence of SEQ ID NO: 79 and a VL comprising the amino acid sequence of SEQ ID NO: 80; or
- (x) a VH comprising the amino acid sequence of SEQ ID NO: 77 and a VL comprising the amino acid sequence of SEQ ID NO: 80.

[00010] In some embodiments, the anti-TfR1 antibody is a Fab fragment, a Fab' fragment, a F(ab')₂ fragment, an scFv, an Fv, or a full-length IgG.

[00011] In some embodiments, the anti-TfR1 antibody is a Fab fragment.

[00012] In some embodiments, the anti-TfR1 antibody comprises:

- (i) a heavy chain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 101; and/or a light chain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 90;
- (ii) a heavy chain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 97; and/or a light chain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 85;
- (iii) a heavy chain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 98; and/or a light chain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 85;
- (iv) a heavy chain comprising an amino acid sequence at least 85% identical to SEQ ID

NO: 99; and/or a light chain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 85;

(v) a heavy chain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 100; and/or a light chain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 89;

(vi) a heavy chain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 100; and/or a light chain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 90;

(vii) a heavy chain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 101; and/or a light chain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 89;

(viii) a heavy chain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 102; and/or a light chain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 93;

(ix) a heavy chain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 103; and/or a light chain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 95; or

(x) a heavy chain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 102; and/or a light chain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 95.

[00013] In some embodiments, the anti-TfR1 antibody comprises:

(i) a heavy chain comprising the amino acid sequence of SEQ ID NO: 101; and a light chain comprising the amino acid sequence of SEQ ID NO: 90;

(ii) a heavy chain comprising the amino acid sequence of SEQ ID NO: 97; and a light chain comprising the amino acid sequence of SEQ ID NO: 85;

(iii) a heavy chain comprising the amino acid sequence of SEQ ID NO: 98; and a light chain comprising the amino acid sequence of SEQ ID NO: 85;

(iv) a heavy chain comprising the amino acid sequence of SEQ ID NO: 99; and a light chain comprising the amino acid sequence of SEQ ID NO: 85;

(v) a heavy chain comprising the amino acid sequence of SEQ ID NO: 100; and a light chain comprising the amino acid sequence of SEQ ID NO: 89;

(vi) a heavy chain comprising the amino acid sequence of SEQ ID NO: 100; and a light chain comprising the amino acid sequence of SEQ ID NO: 90;

(vii) a heavy chain comprising the amino acid sequence of SEQ ID NO: 101; and a light chain comprising the amino acid sequence of SEQ ID NO: 89;

(viii) a heavy chain comprising the amino acid sequence of SEQ ID NO: 102; and a light chain comprising the amino acid sequence of SEQ ID NO: 93;

(ix) a heavy chain comprising the amino acid sequence of SEQ ID NO: 103; and a light chain comprising the amino acid sequence of SEQ ID NO: 95; or

(x) a heavy chain comprising the amino acid sequence of SEQ ID NO: 102; and a light chain comprising the amino acid sequence of SEQ ID NO: 95.

[00014] In some embodiments, the anti-TfR1 antibody does not specifically bind to the transferrin binding site of the transferrin receptor 1 and/or the anti-TfR1 antibody does not inhibit binding of transferrin to the transferrin receptor 1.

[00015] In some embodiments, the oligonucleotide comprises a region of complementarity to at least 4 consecutive nucleotides of a splicing feature of the DMD pre-mRNA.

[00016] In some embodiments, the splicing feature is an exonic splicing enhancer (ESE) in exon 45 of the DMD pre-mRNA, optionally wherein the ESE comprises a sequence of any one of SEQ ID NOs: 885-912.

[00017] In some embodiments, the splicing feature is a branch point, a splice donor site, or a splice acceptor site, optionally wherein the splicing feature is across the junction of exon 44 and intron 44, in intron 44, across the junction of intron 44 and exon 45, across the junction of exon 45 and intron 45, in intron 45, or across the junction of intron 45 and exon 46 of the DMD pre-mRNA, and further optionally wherein the splicing feature comprises a sequence of any one of SEQ ID NOs: 880-884 and 913-916.

[00018] In some embodiments, the oligonucleotide comprises a sequence complementary to any one of SEQ ID NOs: 160-399 or comprises a sequence of any one of SEQ ID NOs: 400-879, wherein each thymine base (T) may independently and optionally be replaced with a uracil base (U), and each U may independently and optionally be replaced with a T.

[00019] In some embodiments, the oligonucleotide comprises a sequence of any one of SEQ ID NOs: 720, 712, 760, 691, 677, 692, 688, 697, 693, and 675, wherein each thymine base (T) may independently and optionally be replaced with a uracil base (U), and each U may independently and optionally be replaced with a T.

[00020] In some embodiments, the oligonucleotide comprises one or more phosphorodiamidate morpholinos, optionally wherein the oligonucleotide is a phosphorodiamidate morpholino oligomer (PMO).

[00021] In some embodiments, the anti-TfR1 antibody is covalently linked to the molecular payload via a cleavable linker, optionally wherein the cleavable linker comprises a valine-citrulline sequence.

[00022] In some embodiments, the anti-TfR1 antibody is covalently linked to the molecular payload via conjugation to a lysine residue or a cysteine residue of the antibody.

[00023] According to some aspects, oligonucleotides that target DMD are provided herein, wherein the oligonucleotide comprises a region of complementarity to any one of SEQ ID NOs: 160-399, optionally wherein the region of complementarity comprises at least 15 consecutive nucleosides complementary to any one of SEQ ID NOs: 160-399.

[00024] In some embodiments, the oligonucleotide comprises at least 15 consecutive nucleosides of any one of SEQ ID NOs: 400-879, optionally wherein the oligonucleotide comprises a sequence of any one of SEQ ID NOs: 400-879, wherein each thymine base (T) may independently and optionally be replaced with a uracil base (U), and each U may independently and optionally be replaced with a T.

[00025] According to some aspects, methods of delivering an oligonucleotide to a cell are provided herein, the method comprising contacting the cell with a complex disclosed herein or with an oligonucleotide disclosed herein.

[00026] According to some aspects, methods of promoting the expression or activity of a dystrophin protein in a cell are provided herein, the method comprising contacting the cell with a complex disclosed herein or with an oligonucleotide disclosed herein in an amount effective for promoting internalization of the oligonucleotide to the cell, optionally wherein the cell is a muscle cell.

[00027] In some embodiments, the cell comprises a DMD gene that is amenable to skipping of exon 45.

[00028] In some embodiments, the dystrophin protein is a truncated dystrophin protein.

BRIEF DESCRIPTION OF THE DRAWINGS

[00029] **FIG. 1** shows data illustrating that conjugates containing anti-TfR1 Fab (3M12 VH4/Vκ3) conjugated to a DMD exon-skipping oligonucleotide resulted in enhanced exon skipping compared to the naked DMD exon skipping oligo in Duchenne muscular dystrophy patient myotubes.

DETAILED DESCRIPTION OF INVENTION

[00030] Aspects of the disclosure relate to a recognition that while certain molecular payloads (*e.g.*, oligonucleotides, peptides, small molecules) can have beneficial effects in muscle cells, it has proven challenging to effectively target such cells. Accordingly, as described herein, the present disclosure provides complexes comprising muscle-targeting agents covalently linked to molecular payloads in order to overcome such challenges. In some embodiments, the

complexes are particularly useful for delivering molecular payloads that modulate (e.g., promote) the expression or activity of dystrophin protein (e.g., a truncated dystrophin protein) or DMD (e.g., a mutated DMD allele). In some embodiments, complexes provided herein may comprise oligonucleotides that promote expression and activity of dystrophin protein or DMD, such as by facilitating in-frame exon skipping and/or suppression of premature stop codons. For example, complexes may comprise oligonucleotides that induce skipping of exon(s) of DMD RNA (e.g., pre-mRNA), such as oligonucleotides that induce skipping of exon 45. In some embodiments, synthetic nucleic acid payloads (e.g., DNA or RNA payloads) may be used that express one or more proteins that promote normal expression and activity of dystrophin protein or DMD.

[00031] Duchenne muscular dystrophy is an X-linked muscular disorder caused by one or more mutations in the DMD gene located on Xp21. Dystrophin protein typically forms the dystrophin-associated glycoprotein complex (DGC) at the sarcolemma, which links the muscle sarcomeric structure to the extracellular matrix and protects the sarcolemma from contraction-induced injury. In patients with Duchenne muscular dystrophy, the dystrophin protein is generally absent and muscle fibers typically become damaged due to mechanical overextension. Mutations in the DMD gene are associated with two types of muscular dystrophy, Duchenne muscular dystrophy and Becker muscular dystrophy, depending on whether the translational reading frame is lost or maintained. Becker muscular dystrophy is a clinically milder form of Duchenne muscular dystrophy, and is characterized by features similar to Duchenne muscular dystrophy. In some embodiments, exon skipping induced by oligonucleotides (e.g., delivered using complexes provided herein) can be used to restore the reading frame of a mutated DMD allele resulting in production of a truncated dystrophin protein that is sufficiently functional to improve muscle function. In some embodiments, such exon skipping could convert a Duchenne muscular dystrophy phenotype into a milder Becker muscular dystrophy phenotype.

[00032] Further aspects of the disclosure, including a description of defined terms, are provided below.

I. Definitions

[00033] **Administering:** As used herein, the terms “administering” or “administration” means to provide a complex to a subject in a manner that is physiologically and/or (e.g., and) pharmacologically useful (e.g., to treat a condition in the subject).

[00034] **Approximately:** As used herein, the term “approximately” or “about,” as applied to one or more values of interest, refers to a value that is similar to a stated reference value. In certain embodiments, the term “approximately” or “about” refers to a range of values that fall

within 15%, 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, or less in either direction (greater than or less than) of the stated reference value unless otherwise stated or otherwise evident from the context (except where such number would exceed 100% of a possible value).

[00035] Antibody: As used herein, the term “antibody” refers to a polypeptide that includes at least one immunoglobulin variable domain or at least one antigenic determinant, e.g., paratope that specifically binds to an antigen. In some embodiments, an antibody is a full-length antibody. In some embodiments, an antibody is a chimeric antibody. In some embodiments, an antibody is a humanized antibody. However, in some embodiments, an antibody is a Fab fragment, a Fab' fragment, a F(ab')₂ fragment, a Fv fragment or a scFv fragment. In some embodiments, an antibody is a nanobody derived from a camelid antibody or a nanobody derived from shark antibody. In some embodiments, an antibody is a diabody. In some embodiments, an antibody comprises a framework having a human germline sequence. In another embodiment, an antibody comprises a heavy chain constant domain selected from the group consisting of IgG, IgG1, IgG2, IgG2A, IgG2B, IgG2C, IgG3, IgG4, IgA1, IgA2, IgD, IgM, and IgE constant domains. In some embodiments, an antibody comprises a heavy (H) chain variable region (abbreviated herein as VH), and/or (e.g., and) a light (L) chain variable region (abbreviated herein as VL). In some embodiments, an antibody comprises a constant domain, e.g., an Fc region. An immunoglobulin constant domain refers to a heavy or light chain constant domain. Human IgG heavy chain and light chain constant domain amino acid sequences and their functional variations are known. With respect to the heavy chain, in some embodiments, the heavy chain of an antibody described herein can be an alpha (α), delta (Δ), epsilon (ϵ), gamma (γ) or mu (μ) heavy chain. In some embodiments, the heavy chain of an antibody described herein can comprise a human alpha (α), delta (Δ), epsilon (ϵ), gamma (γ) or mu (μ) heavy chain. In a particular embodiment, an antibody described herein comprises a human gamma 1 CH1, CH2, and/or (e.g., and) CH3 domain. In some embodiments, the amino acid sequence of the VH domain comprises the amino acid sequence of a human gamma (γ) heavy chain constant region, such as any known in the art. Non-limiting examples of human constant region sequences have been described in the art, e.g., see U.S. Pat. No. 5,693,780 and Kabat E A et al., (1991) supra. In some embodiments, the VH domain comprises an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, or at least 99% identical to any of the variable chain constant regions provided herein. In some embodiments, an antibody is modified, e.g., modified via glycosylation, phosphorylation, sumoylation, and/or (e.g., and) methylation. In some embodiments, an antibody is a glycosylated antibody, which is conjugated to one or more sugar or carbohydrate molecules. In some embodiments, the one or more sugar

or carbohydrate molecule are conjugated to the antibody via N-glycosylation, O-glycosylation, C-glycosylation, glypiation (GPI anchor attachment), and/or (e.g., and) phosphoglycosylation. In some embodiments, the one or more sugar or carbohydrate molecule are monosaccharides, disaccharides, oligosaccharides, or glycans. In some embodiments, the one or more sugar or carbohydrate molecule is a branched oligosaccharide or a branched glycan. In some embodiments, the one or more sugar or carbohydrate molecule includes a mannose unit, a glucose unit, an N-acetylglucosamine unit, an N-acetylgalactosamine unit, a galactose unit, a fucose unit, or a phospholipid unit. In some embodiments, an antibody is a construct that comprises a polypeptide comprising one or more antigen binding fragments of the disclosure linked to a linker polypeptide or an immunoglobulin constant domain. Linker polypeptides comprise two or more amino acid residues joined by peptide bonds and are used to link one or more antigen binding portions. Examples of linker polypeptides have been reported (see e.g., Holliger, P., et al. (1993) Proc. Natl. Acad. Sci. USA 90:6444-6448; Poljak, R. J., et al. (1994) Structure 2:1121-1123). Still further, an antibody may be part of a larger immunoadhesion molecule, formed by covalent or noncovalent association of the antibody or antibody portion with one or more other proteins or peptides. Examples of such immunoadhesion molecules include use of the streptavidin core region to make a tetrameric scFv molecule (Kipriyanov, S. M., et al. (1995) Human Antibodies and Hybridomas 6:93-101) and use of a cysteine residue, a marker peptide and a C-terminal polyhistidine tag to make bivalent and biotinylated scFv molecules (Kipriyanov, S. M., et al. (1994) Mol. Immunol. 31:1047-1058).

[00036] Branch point: As used herein, the term “branch point” or “branch site” refers to a nucleic acid sequence motif within an intron of a gene or pre-mRNA that is involved in splicing of pre-mRNA into mRNA (*i.e.*, removing introns from the pre-mRNA), and can be referred to as a splicing feature. A branch point is typically located 18 to 40 nucleotides from the 3' end of an intron, and contains an adenine but is otherwise relatively unrestricted in sequence. Common sequence motifs for branch points are YNYRAY, YTRAC, and YNYTRAY, where Y is a pyrimidine, N is any nucleotide, R is any purine, and A is adenine. During splicing, the pre-mRNA is cleaved at the 5' end of the intron, which then attaches to the branch point region downstream through transesterification bonding between guanines and adenines from the 5' end and the branch point, respectively, to form a looped lariat structure.

[00037] CDR: As used herein, the term "CDR" refers to the complementarity determining region within antibody variable sequences. A typical antibody molecule comprises a heavy chain variable region (VH) and a light chain variable region (VL), which are usually involved in antigen binding. The VH and VL regions can be further subdivided into regions of hypervariability, also known as “complementarity determining regions” (“CDR”), interspersed

with regions that are more conserved, which are known as “framework regions” (“FR”). Each VH and VL is typically composed of three CDRs and four FRs, arranged from amino-terminus to carboxy-terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. The extent of the framework region and CDRs can be precisely identified using methodology known in the art, for example, by the Kabat definition, the IMGT definition, the Chothia definition, the AbM definition, and/or (e.g., and) the contact definition, all of which are well known in the art. See, e.g., Kabat, E.A., et al. (1991) Sequences of Proteins of Immunological Interest, Fifth Edition, U.S. Department of Health and Human Services, NIH Publication No. 91-3242; IMGT®, the international ImMunoGeneTics information system® www.imgt.org, Lefranc, M.-P. et al., Nucleic Acids Res., 27:209-212 (1999); Ruiz, M. et al., Nucleic Acids Res., 28:219-221 (2000); Lefranc, M.-P., Nucleic Acids Res., 29:207-209 (2001); Lefranc, M.-P., Nucleic Acids Res., 31:307-310 (2003); Lefranc, M.-P. et al., In Silico Biol., 5, 0006 (2004) [Epub], 5:45-60 (2005); Lefranc, M.-P. et al., Nucleic Acids Res., 33:D593-597 (2005); Lefranc, M.-P. et al., Nucleic Acids Res., 37:D1006-1012 (2009); Lefranc, M.-P. et al., Nucleic Acids Res., 43:D413-422 (2015); Chothia et al., (1989) Nature 342:877; Chothia, C. et al. (1987) J. Mol. Biol. 196:901-917, Al-lazikani et al (1997) J. Molec. Biol. 273:927-948; and Almagro, J. Mol. Recognit. 17:132-143 (2004). See also bioinf.org.uk/abs. As used herein, a CDR may refer to the CDR defined by any method known in the art. Two antibodies having the same CDR means that the two antibodies have the same amino acid sequence of that CDR as determined by the same method, for example, the IMGT definition.

[00038] There are three CDRs in each of the variable regions of the heavy chain and the light chain, which are designated CDR1, CDR2 and CDR3, for each of the variable regions. The term “CDR set” as used herein refers to a group of three CDRs that occur in a single variable region capable of binding the antigen. The exact boundaries of these CDRs have been defined differently according to different systems. The system described by Kabat (Kabat *et al.*, Sequences of Proteins of Immunological Interest (National Institutes of Health, Bethesda, Md. (1987) and (1991)) not only provides an unambiguous residue numbering system applicable to any variable region of an antibody, but also provides precise residue boundaries defining the three CDRs. These CDRs may be referred to as Kabat CDRs. Sub-portions of CDRs may be designated as L1, L2 and L3 or H1, H2 and H3 where the “L” and the “H” designates the light chain and the heavy chains regions, respectively. These regions may be referred to as Chothia CDRs, which have boundaries that overlap with Kabat CDRs. Other boundaries defining CDRs overlapping with the Kabat CDRs have been described by Padlan (FASEB J. 9:133-139 (1995)) and MacCallum (J Mol Biol 262(5):732-45 (1996)). Still other CDR boundary definitions may not strictly follow one of the above systems, but will nonetheless overlap with the Kabat CDRs,

although they may be shortened or lengthened in light of prediction or experimental findings that particular residues or groups of residues or even entire CDRs do not significantly impact antigen binding. The methods used herein may utilize CDRs defined according to any of these systems. Examples of CDR definition systems are provided in Table 1.

Table 1. CDR Definitions

	IMGT¹	Kabat²	Chothia³
CDR-H1	27-38	31-35	26-32
CDR-H2	56-65	50-65	53-55
CDR-H3	105-116/117	95-102	96-101
CDR-L1	27-38	24-34	26-32
CDR-L2	56-65	50-56	50-52
CDR-L3	105-116/117	89-97	91-96

¹ IMGT®, the international ImMunoGeneTics information system®, imgt.org, Lefranc, M.-P. et al., Nucleic Acids Res., 27:209-212 (1999)

² Kabat et al. (1991) Sequences of Proteins of Immunological Interest, Fifth Edition, U.S. Department of Health and Human Services, NIH Publication No. 91-3242

³ Chothia et al., J. Mol. Biol. 196:901-917 (1987))

[00039] CDR-grafted antibody: The term "CDR-grafted antibody" refers to antibodies which comprise heavy and light chain variable region sequences from one species but in which the sequences of one or more of the CDR regions of VH and/or (e.g., and) VL are replaced with CDR sequences of another species, such as antibodies having murine heavy and light chain variable regions in which one or more of the murine CDRs (e.g., CDR3) has been replaced with human CDR sequences.

[00040] Chimeric antibody: The term "chimeric antibody" refers to antibodies which comprise heavy and light chain variable region sequences from one species and constant region sequences from another species, such as antibodies having murine heavy and light chain variable regions linked to human constant regions.

[00041] Complementary: As used herein, the term "complementary" refers to the capacity for precise pairing between two nucleosides or two sets of nucleosides. In particular, complementary is a term that characterizes an extent of hydrogen bond pairing that brings about binding between two nucleosides or two sets of nucleosides. For example, if a base at one position of an oligonucleotide is capable of hydrogen bonding with a base at the corresponding position of a target nucleic acid (e.g., an mRNA), then the bases are considered to be complementary to each other at that position. Base pairings may include both canonical Watson-Crick base pairing and non-Watson-Crick base pairing (e.g., Wobble base pairing and Hoogsteen base pairing). For example, in some embodiments, for complementary base pairings, adenosine-type bases (A) are complementary to thymidine-type bases (T) or uracil-type bases (U), that cytosine-type bases (C) are complementary to guanosine-type bases (G), and that universal bases such as 3-nitropyrrole or 5-nitroindole can hybridize to and are considered

complementary to any A, C, U, or T. Inosine (I) has also been considered in the art to be a universal base and is considered complementary to any A, C, U or T.

[00042] Conservative amino acid substitution: As used herein, a “conservative amino acid substitution” refers to an amino acid substitution that does not alter the relative charge or size characteristics of the protein in which the amino acid substitution is made. Variants can be prepared according to methods for altering polypeptide sequence known to one of ordinary skill in the art such as are found in references which compile such methods, e.g. *Molecular Cloning: A Laboratory Manual*, J. Sambrook, et al., eds., Fourth Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 2012, or *Current Protocols in Molecular Biology*, F.M. Ausubel, et al., eds., John Wiley & Sons, Inc., New York. Conservative substitutions of amino acids include substitutions made amongst amino acids within the following groups: (a) M, I, L, V; (b) F, Y, W; (c) K, R, H; (d) A, G; (e) S, T; (f) Q, N; and (g) E, D.

[00043] Covalently linked: As used herein, the term “covalently linked” refers to a characteristic of two or more molecules being linked together via at least one covalent bond. In some embodiments, two molecules can be covalently linked together by a single bond, e.g., a disulfide bond or disulfide bridge, that serves as a linker between the molecules. However, in some embodiments, two or more molecules can be covalently linked together via a molecule that serves as a linker that joins the two or more molecules together through multiple covalent bonds. In some embodiments, a linker may be a cleavable linker. However, in some embodiments, a linker may be a non-cleavable linker.

[00044] Cross-reactive: As used herein and in the context of a targeting agent (e.g., antibody), the term “cross-reactive,” refers to a property of the agent being capable of specifically binding to more than one antigen of a similar type or class (e.g., antigens of multiple homologs, paralogs, or orthologs) with similar affinity or avidity. For example, in some embodiments, an antibody that is cross-reactive against human and non-human primate antigens of a similar type or class (e.g., a human transferrin receptor and non-human primate transferrin receptor) is capable of binding to the human antigen and non-human primate antigens with a similar affinity or avidity. In some embodiments, an antibody is cross-reactive against a human antigen and a rodent antigen of a similar type or class. In some embodiments, an antibody is cross-reactive against a rodent antigen and a non-human primate antigen of a similar type or class. In some embodiments, an antibody is cross-reactive against a human antigen, a non-human primate antigen, and a rodent antigen of a similar type or class.

[00045] DMD: As used herein, the term “DMD” refers to a gene that encodes dystrophin protein, a key component of the dystrophin-glycoprotein complex, which bridges the inner cytoskeleton and the extracellular matrix in muscle cells, particularly muscle fibers. Deletions,

duplications, and point mutations in DMD may cause dystrophinopathies, such as Duchenne muscular dystrophy, Becker muscular dystrophy, or cardiomyopathy. Alternative promoter usage and alternative splicing result in numerous distinct transcript variants and protein isoforms for this gene. In some embodiments, a dystrophin gene (DMD or DMD gene) may be a human (Gene ID: 1756), non-human primate (e.g., Gene ID: 465559), or rodent gene (e.g., Gene ID: 13405; Gene ID: 24907). In addition, multiple human transcript variants (e.g., as annotated under GenBank RefSeq Accession Numbers: NM_000109.3, NM_004006.2, NM_004009.3, NM_004010.3 and NM_004011.3) have been characterized that encode different protein isoforms.

[00046] DMD allele: As used herein, the term “DMD allele” refers to any one of alternative forms (e.g., wild-type or mutant forms) of a DMD gene. In some embodiments, a DMD allele may encode for dystrophin that retains its normal and typical functions. In some embodiments, a DMD allele may comprise one or more mutations that results in muscular dystrophy. Common mutations that lead to Duchenne muscular dystrophy involve frameshift, deletion, substitution, and duplicative mutations of one or more of 79 exons present in a dystrophin allele, e.g., exon 8, exon 23, exon 41, exon 44, exon 45, exon 50, exon 51, exon 52, exon 53, or exon 55. Further examples of DMD mutations are disclosed, for example, in Flanigan KM, et al., *Mutational spectrum of DMD mutations in dystrophinopathy patients: application of modern diagnostic techniques to a large cohort*. Hum Mutat. 2009 Dec; 30 (12):1657-66, the contents of which are incorporated herein by reference in its entirety.

[00047] Dystrophinopathy: As used herein, the term “dystrophinopathy” refers to a muscle disease results from one or more mutated DMD alleles. Dystrophinopathies include a spectrum of conditions (ranging from mild to severe) that includes Duchenne muscular dystrophy, Becker muscular dystrophy, and DMD-associated dilated cardiomyopathy (DCM). In some embodiments, at one end of the spectrum, dystrophinopathy is phenotypically associated with an asymptomatic increase in serum concentration of creatine phosphokinase (CK) and/or (e.g., and) muscle cramps with myoglobinuria. In some embodiments, at the other end of the spectrum, dystrophinopathy is phenotypically associated with progressive muscle diseases that are generally classified as Duchenne or Becker muscular dystrophy when skeletal muscle is primarily affected and as DMD-associated dilated cardiomyopathy (DCM) when the heart is primarily affected. Symptoms of Duchenne muscular dystrophy include muscle loss or degeneration, diminished muscle function, pseudohypertrophy of the tongue and calf muscles, higher risk of neurological abnormalities, and a shortened lifespan. Duchenne muscular dystrophy is associated with Online Mendelian Inheritance in Man (OMIM) Entry # 310200.

Becker muscular dystrophy is associated with OMIM Entry # 300376. Dilated cardiomyopathy is associated with OMIM Entry X# 302045.

[00048] Exonic splicing enhancer (ESE): As used herein, the term “exonic splicing enhancer” or “ESE” refers to a nucleic acid sequence motif within an exon of a gene, pre-mRNA, or mRNA that directs or enhances splicing of pre-mRNA into mRNA, e.g., as described in Blencowe et al., Trends Biochem Sci 25, 106-10. (2000), incorporated herein by reference. ESEs can be referred to as splicing features. ESEs may direct or enhance splicing, for example, to remove one or more introns and/or one or more exons from a gene transcript. ESE motifs are typically 6-8 nucleobases in length. SR proteins (e.g., proteins encoded by the gene SRSF1, SRSF2, SRSF3, SRSF4, SRSF5, SRSF6, SRSF7, SRSF8, SRSF9, SRSF10, SRSF11, SRSF12, TRA2A or TRA2B) bind to ESEs through their RNA recognition motif region to facilitate splicing. ESE motifs can be identified through a number of methods, including those described in Cartegni et al., Nucleic Acids Research, 2003, Vol. 31, No. 13, 3568–3571, incorporated herein by reference.

[00049] Framework: As used herein, the term "framework" or "framework sequence" refers to the remaining sequences of a variable region minus the CDRs. Because the exact definition of a CDR sequence can be determined by different systems, the meaning of a framework sequence is subject to correspondingly different interpretations. The six CDRs (CDR-L1, CDR-L2, and CDR-L3 of light chain and CDR-H1, CDR-H2, and CDR-H3 of heavy chain) also divide the framework regions on the light chain and the heavy chain into four sub-regions (FR1, FR2, FR3 and FR4) on each chain, in which CDR1 is positioned between FR1 and FR2, CDR2 between FR2 and FR3, and CDR3 between FR3 and FR4. Without specifying the particular sub-regions as FR1, FR2, FR3 or FR4, a framework region, as referred by others, represents the combined FRs within the variable region of a single, naturally occurring immunoglobulin chain. As used herein, a FR represents one of the four sub-regions, and FRs represents two or more of the four sub-regions constituting a framework region. Human heavy chain and light chain acceptor sequences are known in the art. In one embodiment, the acceptor sequences known in the art may be used in the antibodies disclosed herein.

[00050] Human antibody: The term "human antibody", as used herein, is intended to include antibodies having variable and constant regions derived from human germline immunoglobulin sequences. The human antibodies of the disclosure may include amino acid residues not encoded by human germline immunoglobulin sequences (*e.g.*, mutations introduced by random or site-specific mutagenesis *in vitro* or by somatic mutation *in vivo*), for example in the CDRs and in particular CDR3. However, the term "human antibody", as used herein, is not

intended to include antibodies in which CDR sequences derived from the germline of another mammalian species, such as a mouse, have been grafted onto human framework sequences.

[00051] Humanized antibody: The term "humanized antibody" refers to antibodies which comprise heavy and light chain variable region sequences from a non-human species (*e.g.*, a mouse) but in which at least a portion of the VH and/or (*e.g.*, and) VL sequence has been altered to be more "human-like", *i.e.*, more similar to human germline variable sequences. One type of humanized antibody is a CDR-grafted antibody, in which human CDR sequences are introduced into non-human VH and VL sequences to replace the corresponding non-human CDR sequences. In one embodiment, humanized anti-TfR1 antibodies and antigen binding portions are provided. Such antibodies may be generated by obtaining murine anti-TfR1 monoclonal antibodies using traditional hybridoma technology followed by humanization using *in vitro* genetic engineering, such as those disclosed in Kasaian et al PCT publication No. WO 2005/123126 A2.

[00052] Internalizing cell surface receptor: As used herein, the term, "internalizing cell surface receptor" refers to a cell surface receptor that is internalized by cells, *e.g.*, upon external stimulation, *e.g.*, ligand binding to the receptor. In some embodiments, an internalizing cell surface receptor is internalized by endocytosis. In some embodiments, an internalizing cell surface receptor is internalized by clathrin-mediated endocytosis. However, in some embodiments, an internalizing cell surface receptor is internalized by a clathrin-independent pathway, such as, for example, phagocytosis, macropinocytosis, caveolae- and raft-mediated uptake or constitutive clathrin-independent endocytosis. In some embodiments, the internalizing cell surface receptor comprises an intracellular domain, a transmembrane domain, and/or (*e.g.*, and) an extracellular domain, which may optionally further comprise a ligand-binding domain. In some embodiments, a cell surface receptor becomes internalized by a cell after ligand binding. In some embodiments, a ligand may be a muscle-targeting agent or a muscle-targeting antibody. In some embodiments, an internalizing cell surface receptor is a transferrin receptor.

[00053] Isolated antibody: An "isolated antibody", as used herein, is intended to refer to an antibody that is substantially free of other antibodies having different antigenic specificities (*e.g.*, an isolated antibody that specifically binds transferrin receptor is substantially free of antibodies that specifically bind antigens other than transferrin receptor). An isolated antibody that specifically binds transferrin receptor complex may, however, have cross-reactivity to other antigens, such as transferrin receptor molecules from other species. Moreover, an isolated antibody may be substantially free of other cellular material and/or (*e.g.*, and) chemicals.

[00054] Kabat numbering: The terms "Kabat numbering", "Kabat definitions and "Kabat labeling" are used interchangeably herein. These terms, which are recognized in the art,

refer to a system of numbering amino acid residues which are more variable (i.e. hypervariable) than other amino acid residues in the heavy and light chain variable regions of an antibody, or an antigen binding portion thereof (Kabat et al. (1971) Ann. NY Acad. Sci. 190:382-391 and, Kabat, E. A., *et al.* (1991) Sequences of Proteins of Immunological Interest, Fifth Edition, U.S. Department of Health and Human Services, NIH Publication No. 91-3242). For the heavy chain variable region, the hypervariable region ranges from amino acid positions 31 to 35 for CDR1, amino acid positions 50 to 65 for CDR2, and amino acid positions 95 to 102 for CDR3. For the light chain variable region, the hypervariable region ranges from amino acid positions 24 to 34 for CDR1, amino acid positions 50 to 56 for CDR2, and amino acid positions 89 to 97 for CDR3.

[00055] Molecular payload: As used herein, the term “molecular payload” refers to a molecule or species that functions to modulate a biological outcome. In some embodiments, a molecular payload is linked to, or otherwise associated with a muscle-targeting agent. In some embodiments, the molecular payload is a small molecule, a protein, a peptide, a nucleic acid, or an oligonucleotide. In some embodiments, the molecular payload functions to modulate the transcription of a DNA sequence, to modulate the expression of a protein, or to modulate the activity of a protein. In some embodiments, the molecular payload is an oligonucleotide that comprises a strand having a region of complementarity to a target gene.

[00056] Muscle-targeting agent: As used herein, the term, “muscle-targeting agent,” refers to a molecule that specifically binds to an antigen expressed on muscle cells. The antigen in or on muscle cells may be a membrane protein, for example an integral membrane protein or a peripheral membrane protein. Typically, a muscle-targeting agent specifically binds to an antigen on muscle cells that facilitates internalization of the muscle-targeting agent (and any associated molecular payload) into the muscle cells. In some embodiments, a muscle-targeting agent specifically binds to an internalizing, cell surface receptor on muscles and is capable of being internalized into muscle cells through receptor mediated internalization. In some embodiments, the muscle-targeting agent is a small molecule, a protein, a peptide, a nucleic acid (*e.g.*, an aptamer), or an antibody. In some embodiments, the muscle-targeting agent is linked to a molecular payload.

[00057] Muscle-targeting antibody: As used herein, the term, “muscle-targeting antibody,” refers to a muscle-targeting agent that is an antibody that specifically binds to an antigen found in or on muscle cells. In some embodiments, a muscle-targeting antibody specifically binds to an antigen on muscle cells that facilitates internalization of the muscle-targeting antibody (and any associated molecular payment) into the muscle cells. In some embodiments, the muscle-targeting antibody specifically binds to an internalizing, cell surface

receptor present on muscle cells. In some embodiments, the muscle-targeting antibody is an antibody that specifically binds to a transferrin receptor.

[00058] Oligonucleotide: As used herein, the term “oligonucleotide” refers to an oligomeric nucleic acid compound of up to 200 nucleotides in length. Examples of oligonucleotides include, but are not limited to, RNAi oligonucleotides (e.g., siRNAs, shRNAs), microRNAs, gapmers, mixmers, phosphorodiamidate morpholinos, peptide nucleic acids, aptamers, guide nucleic acids (e.g., Cas9 guide RNAs), etc. Oligonucleotides may be single-stranded or double-stranded. In some embodiments, an oligonucleotide may comprise one or more modified nucleosides (e.g., 2'-O-methyl sugar modifications, purine or pyrimidine modifications). In some embodiments, an oligonucleotide may comprise one or more modified internucleoside linkages. In some embodiments, an oligonucleotide may comprise one or more phosphorothioate linkages, which may be in the Rp or Sp stereochemical conformation.

[00059] Recombinant antibody: The term "recombinant human antibody", as used herein, is intended to include all human antibodies that are prepared, expressed, created or isolated by recombinant means, such as antibodies expressed using a recombinant expression vector transfected into a host cell (described in more details in this disclosure), antibodies isolated from a recombinant, combinatorial human antibody library (Hoogenboom H. R., (1997) TIB Tech. 15:62-70; Azzazy H., and Highsmith W. E., (2002) Clin. Biochem. 35:425-445; Gavilondo J. V., and Larrick J. W. (2002) BioTechniques 29:128-145; Hoogenboom H., and Chames P. (2000) Immunology Today 21:371-378), antibodies isolated from an animal (e.g., a mouse) that is transgenic for human immunoglobulin genes (see e.g., Taylor, L. D., et al. (1992) Nucl. Acids Res. 20:6287-6295; Kellermann S-A., and Green L. L. (2002) Current Opinion in Biotechnology 13:593-597; Little M. et al (2000) Immunology Today 21:364-370) or antibodies prepared, expressed, created or isolated by any other means that involves splicing of human immunoglobulin gene sequences to other DNA sequences. Such recombinant human antibodies have variable and constant regions derived from human germline immunoglobulin sequences. In certain embodiments, however, such recombinant human antibodies are subjected to *in vitro* mutagenesis (or, when an animal transgenic for human Ig sequences is used, *in vivo* somatic mutagenesis) and thus the amino acid sequences of the VH and VL regions of the recombinant antibodies are sequences that, while derived from and related to human germline VH and VL sequences, may not naturally exist within the human antibody germline repertoire *in vivo*. One embodiment of the disclosure provides fully human antibodies capable of binding human transferrin receptor which can be generated using techniques well known in the art, such as, but not limited to, using human Ig phage libraries such as those disclosed in Jeremius et al., PCT publication No. WO 2005/007699 A2.

[00060] Region of complementarity: As used herein, the term “region of complementarity” refers to a nucleotide sequence, e.g., of an oligonucleotide, that is sufficiently complementary to a cognate nucleotide sequence, e.g., of a target nucleic acid, such that the two nucleotide sequences are capable of annealing to one another under physiological conditions (e.g., in a cell). In some embodiments, a region of complementarity is fully complementary to a cognate nucleotide sequence of target nucleic acid. However, in some embodiments, a region of complementarity is partially complementary to a cognate nucleotide sequence of target nucleic acid (e.g., at least 80%, 90%, 95% or 99% complementarity). In some embodiments, a region of complementarity contains 1, 2, 3, or 4 mismatches compared with a cognate nucleotide sequence of a target nucleic acid.

[00061] Specifically binds: As used herein, the term “specifically binds” refers to the ability of a molecule to bind to a binding partner with a degree of affinity or avidity that enables the molecule to be used to distinguish the binding partner from an appropriate control in a binding assay or other binding context. With respect to an antibody, the term, “specifically binds”, refers to the ability of the antibody to bind to a specific antigen with a degree of affinity or avidity, compared with an appropriate reference antigen or antigens, that enables the antibody to be used to distinguish the specific antigen from others, e.g., to an extent that permits preferential targeting to certain cells, e.g., muscle cells, through binding to the antigen, as described herein. In some embodiments, an antibody specifically binds to a target if the antibody has a K_D for binding the target of at least about 10^{-4} M, 10^{-5} M, 10^{-6} M, 10^{-7} M, 10^{-8} M, 10^{-9} M, 10^{-10} M, 10^{-11} M, 10^{-12} M, 10^{-13} M, or less. In some embodiments, an antibody specifically binds to the transferrin receptor, e.g., an epitope of the apical domain of transferrin receptor.

[00062] Splice acceptor site: As used herein, the term “splice acceptor site” or “splice acceptor” refers to a nucleic acid sequence motif at the 3' end of an intron or across an intron/exon junction of a gene or pre-mRNA that is involved in splicing of pre-mRNA into mRNA (*i.e.*, removing introns from the pre-mRNA), and can be referred to as a splicing feature. A splice acceptor site includes a terminal AG sequence at the 3' end of an intron, which is typically preceded (5'-ward) by a region high in pyrimidines (C/U). Upstream from the splice acceptor site is the branch point. Formation of a lariat loop intermediate structure by a transesterification reaction between the branch point and the splice donor site releases a 3'-OH of the 5' exon, which subsequently reacts with the first nucleotide of the 3' exon, thereby joining the exons and releasing the intron lariat. The AG sequence at the 3' end of the intron in the splice acceptor site is known to be critical for proper splicing, as changing one of these nucleotides results in inhibition of splicing. Rarely, alternative splice acceptor sites have an AC


at the 3' end of the intron, instead of the more common AG. A common splice acceptor site motif has a sequence of or similar to [Y-rich region]-NCAGG or Y_xNYAGG, in which Y represents a pyrimidine, N represents any nucleotide, and x is a number from 4 to 20. The cut site follows the AG, which represent the 3'-terminal nucleotides of the excised intron.

[00063] Splice donor site: As used herein, the term “splice donor site” or “splice donor” refers to a nucleic acid sequence motif at the 5' end of an intron or across an exon/intron junction of a gene or pre-mRNA that is involved in splicing of pre-mRNA into mRNA (*i.e.*, removing introns from the pre-mRNA), and can be referred to as a splicing feature. A splice donor site includes a terminal GU sequence at the 5' end of the intron, within a larger and fairly unconstrained sequence. During splicing, the 2'-OH of a nucleotide within the branch point initiates a transesterification reaction via a nucleophilic attack on the 5' G of the intron within the splice donor site. The G is thereby cleaved from the pre-mRNA and bonds instead to the branch point nucleotide, forming a loop lariat structure. The 3' nucleotide of the upstream exon subsequently binds the splice acceptor site, joining the exons and excising the intron. A typical splice donor site has a sequence of or similar to GGGURAGU or AGGURNNG, in which R represents a purine and N represents any nucleotide. The cut site precedes the first GU (*i.e.*, GG/GURAGU or AG/GURNNG), which represent the 5'-terminal nucleotides of the excised intron.

[00064] Subject: As used herein, the term “subject” refers to a mammal. In some embodiments, a subject is non-human primate, or rodent. In some embodiments, a subject is a human. In some embodiments, a subject is a patient, *e.g.*, a human patient that has or is suspected of having a disease. In some embodiments, the subject is a human patient who has or is suspected of having a disease resulting from a mutated DMD gene sequence, *e.g.*, a mutation in an exon of a DMD gene sequence. In some embodiments, a subject has a dystrophinopathy, *e.g.*, Duchenne muscular dystrophy. In some embodiments, a subject is a patient that has a mutation of the DMD gene that is amenable to exon 45 skipping.

[00065] Transferrin receptor: As used herein, the term, “transferrin receptor” (also known as TFRC, CD71, p90, or TFR1) refers to an internalizing cell surface receptor that binds transferrin to facilitate iron uptake by endocytosis. In some embodiments, a transferrin receptor may be of human (NCBI Gene ID 7037), non-human primate (*e.g.*, NCBI Gene ID 711568 or NCBI Gene ID 102136007), or rodent (*e.g.*, NCBI Gene ID 22042) origin. In addition, multiple human transcript variants have been characterized that encoded different isoforms of the receptor (*e.g.*, as annotated under GenBank RefSeq Accession Numbers: NP_001121620.1, NP_003225.2, NP_001300894.1, and NP_001300895.1).

[00066] 2'-modified nucleoside: As used herein, the terms "2'-modified nucleoside" and "2'-modified ribonucleoside" are used interchangeably and refer to a nucleoside having a sugar moiety modified at the 2' position. In some embodiments, the 2'-modified nucleoside is a 2'-4' bicyclic nucleoside, where the 2' and 4' positions of the sugar are bridged (e.g., via a methylene, an ethylene, or a (S)-constrained ethyl bridge). In some embodiments, the 2'-modified nucleoside is a non-bicyclic 2'-modified nucleoside, e.g., where the 2' position of the sugar moiety is substituted. Non-limiting examples of 2'-modified nucleosides include: 2'-deoxy, 2'-fluoro (2'-F), 2'-O-methyl (2'-O-Me), 2'-O-methoxyethyl (2'-MOE), 2'-O-aminopropyl (2'-O-AP), 2'-O-dimethylaminoethyl (2'-O-DMAOE), 2'-O-dimethylaminopropyl (2'-O-DMAP), 2'-O-dimethylaminoethyloxyethyl (2'-O-DMAEOE), 2'-O-N-methylacetamido (2'-O-NMA), locked nucleic acid (LNA, methylene-bridged nucleic acid), ethylene-bridged nucleic acid (ENA), and (S)-constrained ethyl-bridged nucleic acid (cEt). In some embodiments, the 2'-modified nucleosides described herein are high-affinity modified nucleosides and oligonucleotides comprising the 2'-modified nucleosides have increased affinity to a target sequences, relative to an unmodified oligonucleotide. Examples of structures of 2'-modified nucleosides are provided below:



These examples are shown with phosphate groups, but any internucleoside linkages are contemplated between 2'-modified nucleosides.

II. Complexes

[00067] Provided herein are complexes that comprise a targeting agent, e.g. an antibody, covalently linked to a molecular payload. In some embodiments, a complex comprises a muscle-targeting antibody covalently linked to an oligonucleotide. A complex may comprise an

antibody that specifically binds a single antigenic site or that binds to at least two antigenic sites that may exist on the same or different antigens.

[00068] A complex may be used to modulate the activity or function of at least one gene, protein, and/or (e.g., and) nucleic acid. In some embodiments, the molecular payload present within a complex is responsible for the modulation of a gene, protein, and/or (e.g., and) nucleic acids. A molecular payload may be a small molecule, protein, nucleic acid, oligonucleotide, or any molecular entity capable of modulating the activity or function of a gene, protein, and/or (e.g., and) nucleic acid in a cell.

[00069] In some embodiments, a complex comprises a muscle-targeting agent, *e.g.*, an anti-transferrin receptor antibody, covalently linked to a molecular payload, *e.g.*, an antisense oligonucleotide that targets DMD to promote exon skipping, *e.g.*, in a transcript encoded from a mutated DMD allele. In some embodiments, the complex targets a DMD pre-mRNA to promote skipping of exon 45 in the DMD pre-mRNA.

A. Muscle-Targeting Agents

[00070] Some aspects of the disclosure provide muscle-targeting agents, *e.g.*, for delivering a molecular payload to a muscle cell. In some embodiments, such muscle-targeting agents are capable of binding to a muscle cell, *e.g.*, via specifically binding to an antigen on the muscle cell, and delivering an associated molecular payload to the muscle cell. In some embodiments, the molecular payload is bound (*e.g.*, covalently bound) to the muscle targeting agent and is internalized into the muscle cell upon binding of the muscle targeting agent to an antigen on the muscle cell, *e.g.*, via endocytosis. It should be appreciated that various types of muscle-targeting agents may be used in accordance with the disclosure, and that any muscle targets (*e.g.*, muscle surface proteins) can be targeted by any type of muscle-targeting agent described herein. For example, the muscle-targeting agent may comprise, or consist of, a small molecule, a nucleic acid (*e.g.*, DNA or RNA), a peptide (*e.g.*, an antibody), a lipid (*e.g.*, a microvesicle), or a sugar moiety (*e.g.*, a polysaccharide). Exemplary muscle-targeting agents are described in further detail herein, however, it should be appreciated that the exemplary muscle-targeting agents provided herein are not meant to be limiting.

[00071] Some aspects of the disclosure provide muscle-targeting agents that specifically bind to an antigen on muscle, such as skeletal muscle, smooth muscle, or cardiac muscle. In some embodiments, any of the muscle-targeting agents provided herein bind to (*e.g.*, specifically bind to) an antigen on a skeletal muscle cell, a smooth muscle cell, and/or (*e.g.*, and) a cardiac muscle cell.

[00072] By interacting with muscle-specific cell surface recognition elements (*e.g.*, cell membrane proteins), both tissue localization and selective uptake into muscle cells can be

achieved. In some embodiments, molecules that are substrates for muscle uptake transporters are useful for delivering a molecular payload into muscle tissue. Binding to muscle surface recognition elements followed by endocytosis can allow even large molecules such as antibodies to enter muscle cells. As another example molecular payloads conjugated to transferrin or anti-TfR1 antibodies can be taken up by muscle cells via binding to transferrin receptor, which may then be endocytosed, *e.g.*, via clathrin-mediated endocytosis.

[00073] The use of muscle-targeting agents may be useful for concentrating a molecular payload (*e.g.*, oligonucleotide) in muscle while reducing toxicity associated with effects in other tissues. In some embodiments, the muscle-targeting agent concentrates a bound molecular payload in muscle cells as compared to another cell type within a subject. In some embodiments, the muscle-targeting agent concentrates a bound molecular payload in muscle cells (*e.g.*, skeletal, smooth, or cardiac muscle cells) in an amount that is at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 30, 40, 50, 60, 70, 80, 90, or 100 times greater than an amount in non-muscle cells (*e.g.*, liver, neuronal, blood, or fat cells). In some embodiments, a toxicity of the molecular payload in a subject is reduced by at least 1%, 2%, 3%, 4%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 90%, or 95% when it is delivered to the subject when bound to the muscle-targeting agent.

[00074] In some embodiments, to achieve muscle selectivity, a muscle recognition element (*e.g.*, a muscle cell antigen) may be required. As one example, a muscle-targeting agent may be a small molecule that is a substrate for a muscle-specific uptake transporter. As another example, a muscle-targeting agent may be an antibody that enters a muscle cell via transporter-mediated endocytosis. As another example, a muscle targeting agent may be a ligand that binds to cell surface receptor on a muscle cell. It should be appreciated that while transporter-based approaches provide a direct path for cellular entry, receptor-based targeting may involve stimulated endocytosis to reach the desired site of action.

i. Muscle-Targeting Antibodies

[00075] In some embodiments, the muscle-targeting agent is an antibody. Generally, the high specificity of antibodies for their target antigen provides the potential for selectively targeting muscle cells (*e.g.*, skeletal, smooth, and/or (*e.g.*, and) cardiac muscle cells). This specificity may also limit off-target toxicity. Examples of antibodies that are capable of targeting a surface antigen of muscle cells have been reported and are within the scope of the disclosure. For example, antibodies that target the surface of muscle cells are described in Arahata K., et al. "Immunostaining of skeletal and cardiac muscle surface membrane with antibody against Duchenne muscular dystrophy peptide" *Nature* 1988; 333: 861-3; Song K.S., et al. "Expression of caveolin-3 in skeletal, cardiac, and smooth muscle cells. Caveolin-3 is a

component of the sarcolemma and co-fractionates with dystrophin and dystrophin-associated glycoproteins” *J Biol Chem* 1996; 271: 15160-5; and Weisbart R.H. et al., “Cell type specific targeted intracellular delivery into muscle of a monoclonal antibody that binds myosin IIb” *Mol Immunol.* 2003 Mar, 39(13):78309; the entire contents of each of which are incorporated herein by reference.

a. Anti-Transferrin Receptor (TfR) Antibodies

[00076] Some aspects of the disclosure are based on the recognition that agents binding to transferrin receptor, e.g., anti-transferrin-receptor antibodies, are capable of targeting muscle cell. Transferrin receptors are internalizing cell surface receptors that transport transferrin across the cellular membrane and participate in the regulation and homeostasis of intracellular iron levels. Some aspects of the disclosure provide transferrin receptor binding proteins, which are capable of binding to transferrin receptor. Accordingly, aspects of the disclosure provide binding proteins (e.g., antibodies) that bind to transferrin receptor. In some embodiments, binding proteins that bind to transferrin receptor are internalized, along with any bound molecular payload, into a muscle cell. As used herein, an antibody that binds to a transferrin receptor may be referred to interchangeably as an, transferrin receptor antibody, an anti-transferrin receptor antibody, or an anti-TfR1 antibody. Antibodies that bind, e.g. specifically bind, to a transferrin receptor may be internalized into the cell, e.g. through receptor-mediated endocytosis, upon binding to a transferrin receptor.

[00077] It should be appreciated that anti-TfR1 antibodies may be produced, synthesized, and/or (e.g., and) derivatized using several known methodologies, e.g. library design using phage display. Exemplary methodologies have been characterized in the art and are incorporated by reference (Díez, P. et al. “High-throughput phage-display screening in array format”, *Enzyme and microbial technology*, 2015, 79, 34-41.; Christoph M. H. and Stanley, J.R. “Antibody Phage Display: Technique and Applications” *J Invest Dermatol.* 2014, 134:2.; Engleman, Edgar (Ed.) “Human Hybridomas and Monoclonal Antibodies.” 1985, Springer.). In other embodiments, an anti-TfR1 antibody has been previously characterized or disclosed. Antibodies that specifically bind to transferrin receptor are known in the art (see, e.g. US Patent No. 4,364,934, filed 12/4/1979, “Monoclonal antibody to a human early thymocyte antigen and methods for preparing same”; US Patent No. 8,409,573, filed 6/14/2006, “Anti-CD71 monoclonal antibodies and uses thereof for treating malignant tumor cells”; US Patent No. 9,708,406, filed 5/20/2014, “Anti-transferrin receptor antibodies and methods of use”; US 9,611,323, filed 12/19/2014, “Low affinity blood brain barrier receptor antibodies and uses therefor”; WO 2015/098989, filed 12/24/2014, “Novel anti-Transferrin receptor antibody that passes through blood-brain barrier”; Schneider C. et al. “Structural features of the cell surface

receptor for transferrin that is recognized by the monoclonal antibody OKT9.” J Biol Chem. 1982, 257:14, 8516-8522.; Lee et al. “Targeting Rat Anti-Mouse Transferrin Receptor Monoclonal Antibodies through Blood-Brain Barrier in Mouse” 2000, J Pharmacol. Exp. Ther., 292: 1048-1052.).

[00078] In some embodiments, the anti-TfR1 antibody described herein binds to transferrin receptor with high specificity and affinity. In some embodiments, the anti-TfR1 antibody described herein specifically binds to any extracellular epitope of a transferrin receptor or an epitope that becomes exposed to an antibody. In some embodiments, anti-TfR1 antibodies provided herein bind specifically to transferrin receptor from human, non-human primates, mouse, rat, *etc.* In some embodiments, anti-TfR1 antibodies provided herein bind to human transferrin receptor. In some embodiments, the anti-TfR1 antibody described herein binds to an amino acid segment of a human or non-human primate transferrin receptor, as provided in SEQ ID NOs: 105-108. In some embodiments, the anti-TfR1 antibody described herein binds to an amino acid segment corresponding to amino acids 90-96 of a human transferrin receptor as set forth in SEQ ID NO: 105, which is not in the apical domain of the transferrin receptor.

[00079] In some embodiments, the anti-TfR1 antibodies described herein (e.g., Anti-TfR clone 8 in Table 2 below) bind an epitope in TfR1, wherein the epitope comprises residues in amino acids 214-241 and/or amino acids 354-381 of SEQ ID NO: 105. In some embodiments, the anti-TfR1 antibodies described herein bind an epitope comprising residues in amino acids 214-241 and amino acids 354-381 of SEQ ID NO: 105. In some embodiments, the anti-TfR1 antibodies described herein bind an epitope comprising one or more of residues Y222, T227, K231, H234, T367, S368, S370, T376, and S378 of human TfR1 as set forth in SEQ ID NO: 105. In some embodiments, the anti-TfR1 antibodies described herein bind an epitope comprising residues Y222, T227, K231, H234, T367, S368, S370, T376, and S378 of human TfR1 as set forth in SEQ ID NO: 105.

[00080] In some embodiments, the anti-TfR1 antibody described herein (e.g., 3M12 in Table 2 below and its variants) bind an epitope in TfR1, wherein the epitope comprises residues in amino acids 258-291 and/or amino acids 358-381 of SEQ ID NO: 105. In some embodiments, the anti-TfR1 antibodies (e.g., 3M12 in Table 2 below and its variants) described herein bind an epitope comprising residues in amino acids amino acids 258-291 and amino acids 358-381 of SEQ ID NO: 105. In some embodiments, the anti-TfR1 antibodies described herein (e.g., 3M12 in Table 2 below and its variants) bind an epitope comprising one or more of residues K261, S273, Y282, T362, S368, S370, and K371 of human TfR1 as set forth in SEQ ID NO: 105. In some embodiments, the anti-TfR1 antibodies described herein (e.g., 3M12 in Table

2 below and its variants) bind an epitope comprising residues K261, S273, Y282, T362, S368, S370, and K371 of human TfR1 as set forth in SEQ ID NO: 105.

[00081] An example human transferrin receptor amino acid sequence, corresponding to NCBI sequence NP_003225.2 (transferrin receptor protein 1 isoform 1, homo sapiens) is as follows:

MMDQARSASFNLFGGEPLSYTRFSLARQVDGDN SHVEMKLAVDEEENADNNTKANVT
KPKRCSGSICYGTIAVIVFFLIGFMIGYLG YCKGVEPKTECERLAGTESPVREEPGEDFPA
ARRLYWDDLKRKLSEKLDSTDFGTIKLLNENSYVPREAGSQKDENLALYVENQFREF
KLSKVWRDQHFVKIQVKDSAQNSVIIVDKNGRLVYLVENPGGYVAYS KAATVTGKLV
HANFGTKKDFEDLYTPVNGSIVIVRAGKITFAEKVANAESLNAIGVLIYMDQTKFPIVNA
ELSFFGHAHLGTGDPYTPGFPSFNHTQFPSSRSSGLPNIPVQTISR AAAEKLFGNMEGDCP
SDWKTDSTCRMVTSSEKNVKLTVSNVLKEIKILNIFGVIKGFVEPDHYVVVGAQRDAW
GPGAAGSGVGTALLLKL AQMFSDMVLKDG FQPSRSIIFASWSAGDFG SVGATEWLEGY
LSSLHLKAFTYINLDKAVLGTSNFKVSASPLLYTLIEKTMQNVKHPVTGQFLYQDSNWA
SKVEKLTLDNAAFPFLAYSGIPAVSFCFCEDTDYPYLGTTMDTYKELIERIPELNKVARA
AAEVAGQFVIKLTHDVELNLDYERYNSQLLSFVRDLNQYRADIKEMGLSLQWLYSARG
DFFRATSRLTTDFGNAEKTDRFVMKKLNDRVMRVEYHFLSPYVSPKESPFRHVFWSG
SHTLPALLENLKL RKQNNGAFNETLFRNQLALATWTIQGAANALSGDVWDIDNEF
(SEQ ID NO: 105).

[00082] An example non-human primate transferrin receptor amino acid sequence, corresponding to NCBI sequence NP_001244232.1 (transferrin receptor protein 1, Macaca mulatta) is as follows:

MMDQARSASFNLFGGEPLSYTRFSLARQVDGDN SHVEMKLG VDEEENTDNNTKPNGT
KPKRCGGNICYGTIAVIIFFLIGFMIGYLG YCKGVEPKTECERLAGTESPAREEPEEDFPA
APRLYWDDLKRKLSEKLDTTDFSTIKLLNENLYVPREAGSQKDENLALYIENQFREFK
LSKVWRDQHFVKIQVKDSAQNSVIIVDKNGGLVYLVENPGGYVAYS KAATVTGKLVH
ANFGTKKDFEDLDSPVNGSIVIVRAGKITFAEKVANAESLNAIGVLIYMDQTKFPIVKAD
LSFFFGHAHLGTGDPYTPGFPSFNHTQFPSSQSSGLPNIPVQTISR AAAEKLFGNMEGDCPS
DWKTDSTCKMVTSENKSVKLTVSNVLKETKILNIFGVIKGFVEPDHYVVVGAQRDAW
GPGAAGSSVGTALLLKL AQMFSDMVLKDG FQPSRSIIFASWSAGDFG SVGATEWLEGY
LSSLHLKAFTYINLDKAVLGTSNFKVSASPLLYTLIEKTMQDVKHPVTGRSLYQDSNWA
SKVEKLTLDNAAFPFLAYSGIPAVSFCFCEDTDYPYLGTTMDTYKELVERIPELNKVAR
AAAEVAGQFVIKLTHDTELNLDYERYNSQLLLFLRDLNQYRADVKEMGLSLQWLYSA
RGDFFRATSRLTTDFRNAEKRDKFVMKKLNDRVMRVEYYFLSPYVSPKESPFRHVFWSG
SGSHTLSALLESKLRRQNNSAFNETLFRNQLALATWTIQGAANALSGDVWDIDNEF

(SEQ ID NO: 106)

[00083] An example non-human primate transferrin receptor amino acid sequence, corresponding to NCBI sequence XP_005545315.1 (transferrin receptor protein 1, *Macaca fascicularis*) is as follows:

MMDQARSASFNLFGGEPLSYTRFSLARQVDGDNSHVEMKLGVDDEENTDNNTKANGT
KPKRCGGNICYGTIAVIFFLIGFMIGYLG YCKGVEPKTECERLAGTESPAREEPEEDFPA
APRLYWDDLKRKLSEKLDTTDFTSTIKLLNENLYVPREAGSQKDENLALYIENQFREFK
LSKVWRDQHFVKIQVKDSAQNSVIIVDKNGGLVYLVENPGGYVAYSKAATVTGKLVH
ANFGTKKDFEDLDSPVNGSIVIVRAGKITFAEKVANAESLNAIGVLIYMDQTKFPIVKAD
LSFFGHAHLGTGDPYTPGFPSFNHTQFPSPQSSGLPNIPVQTISRAAAEKLFGNMEGDCPS
DWKTDSTCKMVTSENKSVKLTVSNVLKETKILNIFGVIKGFVEPDHYVVVGAQRDAW
GPGAAKSSVGTALLLKL AQMFSDMVLKDGFPQRSIIFASWSAGDFGSVGATEWLEGY
LSSLHLKAFTYINLDKAVLGTSNFKVSASPLLYTLIEKTMQDVKHPVTGRSLYQDSNWA
SKVEKLTLDNAAFPFLAYSGIPAVSFCFCEDTDYPYLGT TMDTYKELVERIPELNKVAR
AAAEVAGQFVIKLTHTDELNLDYERYNSQLLLFLRDLNQYRADVKEMGLSLQWLYSA
RGDFFRATSRLTTDFRNAEKRDKFVMKKLNDRVMRVEYYFLSPYVSPKESPRHFVFWG
SGSHTLSALLESKLRRQNNSAFNETLFRNQLALATWTIQGAANALSGDVWDIDNEF
(SEQ ID NO: 107).

[00084] An example mouse transferrin receptor amino acid sequence, corresponding to NCBI sequence NP_001344227.1 (transferrin receptor protein 1, *mus musculus*) is as follows:

MMDQARSASFNLFGGEPLSYTRFSLARQVDGDNSHVEMKLAADDEENADNNMKASV
RKPKRFNGRLCFAAIALVIFFLIGFMISG YLG YCKRVEQKEECVKLAETEETDKSETMETE
DVPTSSRLYWADLKTLLSEKLN SIEFADTIKQLSQNTYTPREAGSQKDESLAYYIENQFH
EFKFSKVWRDEHYVKIQVKSSIGQNMVTIVQSNGNLDPVESPEGYVAFSKPTEVSGKLV
HANFGTKKDFEELSYSVNGSLVIVRAGEITFAEKVANAQSFNAIGVLIYMDKNKFPVVE
ADLALFGHAHLGTGDPYTPGFPSFNHTQFPSPQSSGLPNIPVQTISRAAAEKLF GKMEGS
CPARWNIDSSCKLELSQNQNVLKLVKNVLKERRILNIFGVIKGYEEPDRYVVVGAQRDA
LGAGVAAKSSVGTGLLLKL AQVFSDMISKDGFPRPSR IIFASWTAGDFGAVGATEWLEG
YLSSLHLKAFTYINLDKVVLGTSNFKVSASPLLYTLMGKIMQDVKHPVDGKSLYRDSN
WISKVEKLSFDNAAYPFLAYSGIPAVSFCFCEDADYPYLGT RLDTYEALTQKVPQLNQM
VRTAAEVAGQLIIKLTHDVELNLDYEMYSKLLSFMKDLNQFKTDIRDMGLSLQWLYS
ARGDYFRATSRLTTDFHNAEKTNR FVMREINDRIMKVEYHFLSPYVSPRESPRHFIFWG
SGSHTLSALVENLKL RQKNITAFNETLFRNQLALATWTIQGVANALSGDIWNIDNEF
(SEQ ID NO: 108)

[00085] In some embodiments, an anti-TfR1 antibody binds to an amino acid segment of the receptor as follows:

FVKIQVKDSAQNSVIIVDKNGRLVYLVENPGGYVAYSKAATVTGKLVHANFGTKKDFE
DLYTPVNGSIVIVRAGKITFAEKVANAESLNAIGVLIYMDQTKFPIVNAELSFFGHAHLG
TGDPYTPGFPSFNHTQFPPSRSSGLPNIPVQTISRAAAELFGNMEGDCPSDWKTDSTCR
MVTSESKNVKLTVSNVLKE (SEQ ID NO: 109) and does not inhibit the binding interactions between transferrin receptors and transferrin and/or (e.g., and) human hemochromatosis protein (also known as HFE). In some embodiments, the anti-TfR1 antibody described herein does not bind an epitope in SEQ ID NO: 109.

[00086] Appropriate methodologies may be used to obtain and/or (e.g., and) produce antibodies, antibody fragments, or antigen-binding agents, e.g., through the use of recombinant DNA protocols. In some embodiments, an antibody may also be produced through the generation of hybridomas (see, e.g., Kohler, G and Milstein, C. "Continuous cultures of fused cells secreting antibody of predefined specificity" *Nature*, 1975, 256: 495-497). The antigen-of-interest may be used as the immunogen in any form or entity, e.g., recombinant or a naturally occurring form or entity. Hybridomas are screened using standard methods, e.g. ELISA screening, to find at least one hybridoma that produces an antibody that targets a particular antigen. Antibodies may also be produced through screening of protein expression libraries that express antibodies, e.g., phage display libraries. Phage display library design may also be used, in some embodiments, (see, e.g. U.S. Patent No 5,223,409, filed 3/1/1991, "Directed evolution of novel binding proteins"; WO 1992/18619, filed 4/10/1992, "Heterodimeric receptor libraries using phagemids"; WO 1991/17271, filed 5/1/1991, "Recombinant library screening methods"; WO 1992/20791, filed 5/15/1992, "Methods for producing members of specific binding pairs"; WO 1992/15679, filed 2/28/1992, and "Improved epitope displaying phage"). In some embodiments, an antigen-of-interest may be used to immunize a non-human animal, e.g., a rodent or a goat. In some embodiments, an antibody is then obtained from the non-human animal, and may be optionally modified using a number of methodologies, e.g., using recombinant DNA techniques. Additional examples of antibody production and methodologies are known in the art (see, e.g. Harlow et al. "Antibodies: A Laboratory Manual", Cold Spring Harbor Laboratory, 1988.).

[00087] In some embodiments, an antibody is modified, e.g., modified via glycosylation, phosphorylation, sumoylation, and/or (e.g., and) methylation. In some embodiments, an antibody is a glycosylated antibody, which is conjugated to one or more sugar or carbohydrate molecules. In some embodiments, the one or more sugar or carbohydrate molecule are conjugated to the antibody via N-glycosylation, O-glycosylation, C-glycosylation, glypiation

(GPI anchor attachment), and/or (e.g., and) phosphoglycosylation. In some embodiments, the one or more sugar or carbohydrate molecules are monosaccharides, disaccharides, oligosaccharides, or glycans. In some embodiments, the one or more sugar or carbohydrate molecule is a branched oligosaccharide or a branched glycan. In some embodiments, the one or more sugar or carbohydrate molecule includes a mannose unit, a glucose unit, an N-acetylglucosamine unit, an N-acetylgalactosamine unit, a galactose unit, a fucose unit, or a phospholipid unit. In some embodiments, there are about 1-10, about 1-5, about 5-10, about 1-4, about 1-3, or about 2 sugar molecules. In some embodiments, a glycosylated antibody is fully or partially glycosylated. In some embodiments, an antibody is glycosylated by chemical reactions or by enzymatic means. In some embodiments, an antibody is glycosylated in vitro or inside a cell, which may optionally be deficient in an enzyme in the N- or O- glycosylation pathway, e.g. a glycosyltransferase. In some embodiments, an antibody is functionalized with sugar or carbohydrate molecules as described in International Patent Application Publication WO2014065661, published on May 1, 2014, entitled, "*Modified antibody, antibody-conjugate and process for the preparation thereof*".

[00088] In some embodiments, the anti-TfR1 antibody of the present disclosure comprises a VL domain and/or (e.g., and) a VH domain of any one of the anti-TfR1 antibodies selected from any one of Tables 2-7, and comprises a constant region comprising the amino acid sequences of the constant regions of an IgG, IgE, IgM, IgD, IgA or IgY immunoglobulin molecule, any class (e.g., IgG1, IgG2, IgG3, IgG4, IgA1 and IgA2), or any subclass (e.g., IgG2a and IgG2b) of immunoglobulin molecule. Non-limiting examples of human constant regions are described in the art, e.g., see Kabat E A et al., (1991) supra.

[00089] In some embodiments, agents binding to transferrin receptor, e.g., anti-TfR1 antibodies, are capable of targeting muscle cell and/or (e.g., and) mediate the transportation of an agent across the blood brain barrier. Transferrin receptors are internalizing cell surface receptors that transport transferrin across the cellular membrane and participate in the regulation and homeostasis of intracellular iron levels. Some aspects of the disclosure provide transferrin receptor binding proteins, which are capable of binding to transferrin receptor. Antibodies that bind, e.g. specifically bind, to a transferrin receptor may be internalized into the cell, e.g. through receptor-mediated endocytosis, upon binding to a transferrin receptor.

[00090] Provided herein, in some aspects, are humanized antibodies that bind to transferrin receptor with high specificity and affinity. In some embodiments, the humanized anti-TfR1 antibody described herein specifically binds to any extracellular epitope of a transferrin receptor or an epitope that becomes exposed to an antibody. In some embodiments, the humanized anti-TfR1 antibodies provided herein bind specifically to transferrin receptor

from human, non-human primates, mouse, rat, *etc.* In some embodiments, the humanized anti-TfR1 antibodies provided herein bind to human transferrin receptor. In some embodiments, the humanized anti-TfR1 antibody described herein binds to an amino acid segment of a human or non-human primate transferrin receptor, as provided in SEQ ID NOs: 105-108. In some embodiments, the humanized anti-TfR1 antibody described herein binds to an amino acid segment corresponding to amino acids 90-96 of a human transferrin receptor as set forth in SEQ ID NO: 105, which is not in the apical domain of the transferrin receptor. In some embodiments, the humanized anti-TfR1 antibodies described herein binds to TfR1 but does not bind to TfR2.

[00091] In some embodiments, an anti-TfR1 antibody specifically binds a TfR1 (e.g., a human or non-human primate TfR1) with binding affinity (e.g., as indicated by K_d) of at least about 10^{-4} M, 10^{-5} M, 10^{-6} M, 10^{-7} M, 10^{-8} M, 10^{-9} M, 10^{-10} M, 10^{-11} M, 10^{-12} M, 10^{-13} M, or less. In some embodiments, the anti-TfR1 antibodies described herein bind to TfR1 with a K_D of sub-nanomolar range. In some embodiments, the anti-TfR1 antibodies described herein selectively bind to transferrin receptor 1 (TfR1) but do not bind to transferrin receptor 2 (TfR2). In some embodiments, the anti-TfR1 antibodies described herein bind to human TfR1 and cyno TfR1 (e.g., with a K_d of 10^{-7} M, 10^{-8} M, 10^{-9} M, 10^{-10} M, 10^{-11} M, 10^{-12} M, 10^{-13} M, or less), but do not bind to a mouse TfR1. The affinity and binding kinetics of the anti-TfR1 antibody can be tested using any suitable method including but not limited to biosensor technology (e.g., OCTET or BIACORE). In some embodiments, binding of any one of the anti-TfR1 antibodies described herein does not compete with or inhibit transferrin binding to the TfR1. In some embodiments, binding of any one of the anti-TfR1 antibodies described herein does not compete with or inhibit HFE-beta-2-microglobulin binding to the TfR1.

[00092] Non-limiting examples of anti-TfR1 antibodies are provided in Table 2.

Table 2. Examples of Anti-TfR1 Antibodies

Ab	No. system	IMGT	Kabat	Chothia
3-A4	CDR-H1	GFNIKDDY (SEQ ID NO: 1)	DDYMY (SEQ ID NO: 7)	GFNIKDD (SEQ ID NO: 12)
	CDR-H2	IDPENGDT (SEQ ID NO: 2)	WIDPENGDT EYASKFQD (SEQ ID NO: 8)	ENG (SEQ ID NO: 13)
	CDR-H3	TLWLRRGLDY (SEQ ID NO: 3)	WLRRGLDY (SEQ ID NO: 9)	LRRGLD (SEQ ID NO: 14)
	CDR-L1	KSLLSNGYTY (SEQ ID NO: 4)	RSSKSLLSNGYTYLF (SEQ ID NO: 10)	SKSLLSNGYTY (SEQ ID NO: 15)
	CDR-L2	RMS (SEQ ID NO: 5)	RMSNLAS (SEQ ID NO: 11)	RMS (SEQ ID NO: 5)
	CDR-L3	MQHLEYPFT (SEQ ID NO: 6)	MQHLEYPFT (SEQ ID NO: 6)	HLEYPF (SEQ ID NO: 16)
	VH	EVQLQQSGAELVRPGASVKLSCTASGFNIKDDYMYWVKQRPEQGLEWIGWIDPENGDT EYASKFQDKATVTADTSSNTAYLQLSSLTSED TAVYYCTLWLRRGLDYWGQGTSVTVS (SEQ ID NO: 17)		

Ab	No. system	IMGT	Kabat	Chothia
	VL	DIVMTQAAPSVPTPGESVSISCRSSKSLHNSGYTYLFWFLQRPQGSPQLLIYRMSNLA SGVPDRFSGSGSGTAFTLRISRVEAEDVGVYYCMQHLEYPFTFGGGTKLEIK (SEQ ID NO: 18)		
3-A4 N54T*	CDR-H1	GFNIKDDY (SEQ ID NO: 1)	DDYMY (SEQ ID NO: 7)	GFNIKDD (SEQ ID NO: 12)
	CDR-H2	IDPETGDT (SEQ ID NO: 19)	WIDPETGDTEYASKFQD (SEQ ID NO: 20)	ETG (SEQ ID NO: 21)
	CDR-H3	TLWLRRGLDY (SEQ ID NO: 3)	WLRRGLDY (SEQ ID NO: 9)	LRRGLD (SEQ ID NO: 14)
	CDR-L1	KSLHNSGYTY (SEQ ID NO: 4)	RSSKSLHNSGYTYLF (SEQ ID NO: 10)	SKSLHNSGYTY (SEQ ID NO: 15)
	CDR-L2	RMS (SEQ ID NO: 5)	RMSNLAS (SEQ ID NO: 11)	RMS (SEQ ID NO: 5)
	CDR-L3	MQHLEYPFT (SEQ ID NO: 6)	MQHLEYPFT (SEQ ID NO: 6)	HLEYPF (SEQ ID NO: 16)
	VH	EVQLQQSGAELVRPGASVKLSCTASGFNIKDDYMYWVKQRPEQGLEWIGWIDPETGDT EYASKFQDKATVTADTSSNTAYLQLSSLTSEDTAIVYYCTLWLRRGLDYWGQGTSTVTS S (SEQ ID NO: 22)		
	VL	DIVMTQAAPSVPTPGESVSISCRSSKSLHNSGYTYLFWFLQRPQGSPQLLIYRMSNLA SGVPDRFSGSGSGTAFTLRISRVEAEDVGVYYCMQHLEYPFTFGGGTKLEIK (SEQ ID NO: 18)		
3-A4 N54S*	CDR-H1	GFNIKDDY (SEQ ID NO: 1)	DDYMY (SEQ ID NO: 7)	GFNIKDD (SEQ ID NO: 12)
	CDR-H2	IDPESGDT (SEQ ID NO: 23)	WIDPESGDTEYASKFQD (SEQ ID NO: 24)	ESG (SEQ ID NO: 25)
	CDR-H3	TLWLRRGLDY (SEQ ID NO: 3)	WLRRGLDY (SEQ ID NO: 9)	LRRGLD (SEQ ID NO: 14)
	CDR-L1	KSLHNSGYTY (SEQ ID NO: 4)	RSSKSLHNSGYTYLF (SEQ ID NO: 10)	SKSLHNSGYTY (SEQ ID NO: 15)
	CDR-L2	RMS (SEQ ID NO: 5)	RMSNLAS (SEQ ID NO: 11)	RMS (SEQ ID NO: 5)
	CDR-L3	MQHLEYPFT (SEQ ID NO: 6)	MQHLEYPFT (SEQ ID NO: 6)	HLEYPF (SEQ ID NO: 16)
	VH	EVQLQQSGAELVRPGASVKLSCTASGFNIKDDYMYWVKQRPEQGLEWIGWIDPESGDT EYASKFQDKATVTADTSSNTAYLQLSSLTSEDTAIVYYCTLWLRRGLDYWGQGTSTVTS S (SEQ ID NO: 26)		
	VL	DIVMTQAAPSVPTPGESVSISCRSSKSLHNSGYTYLFWFLQRPQGSPQLLIYRMSNLA SGVPDRFSGSGSGTAFTLRISRVEAEDVGVYYCMQHLEYPFTFGGGTKLEIK (SEQ ID NO: 18)		
3-M12	CDR-H1	GYSITSGYY (SEQ ID NO: 27)	SGYYWN (SEQ ID NO: 33)	GYSITSGY (SEQ ID NO: 38)
	CDR-H2	ITFDGAN (SEQ ID NO: 28)	YITFDGANNYNPSLKN (SEQ ID NO: 34)	FDG (SEQ ID NO: 39)
	CDR-H3	TRSSYDYDVL DY (SEQ ID NO: 29)	SSYDYDVL DY (SEQ ID NO: 35)	SYDYDVL D (SEQ ID NO: 40)
	CDR-L1	QDISNF (SEQ ID NO: 30)	RASQDISNFLN (SEQ ID NO: 36)	SQDISNF (SEQ ID NO: 41)
	CDR-L2	YTS (SEQ ID NO: 31)	YTSRLHS (SEQ ID NO: 37)	YTS (SEQ ID NO: 31)
	CDR-L3	QQGHTLPYT (SEQ ID NO: 32)	QQGHTLPYT (SEQ ID NO: 32)	GHTLPY (SEQ ID NO: 42)
	VH	DVQLQESGPGLVKPSQSLSLTCSVTGYSITSGYYWNWIRQFPGNKLEWMGYITFDGAN NYNPSLKNRISITRDTSKNQFFLKLTSVTEDTATYYCTRSSYDYDVL DYWGQGTTLTV SS (SEQ ID NO: 43)		
	VL	DIQMTQTSSLSASLGDRVTISCRASQDISNFLNWWYQRPDGTVKLLIYYTSRLHSGVPS RFSGSGSGTDFSLTVSNLEQEDIAATYFCQQGHTLPYTFGGGTKLEIK (SEQ ID NO: 44)		
5-H12	CDR-H1	GYSFTDYC (SEQ ID NO: 45)	DYCIN (SEQ ID NO: 51)	GYSFTDY (SEQ ID NO: 56)

Ab	No. system	IMGT	Kabat	Chothia
	CDR-H2	IYPGSGNT (SEQ ID NO: 46)	WIYPGSGNTRYSERFKG (SEQ ID NO: 52)	GSG (SEQ ID NO: 57)
	CDR-H3	AREDYYPYHGMDY (SEQ ID NO: 47)	EDYYPYHGMDY (SEQ ID NO: 53)	DYYPYHGMD (SEQ ID NO: 58)
	CDR-L1	ESVDGYDNSF (SEQ ID NO: 48)	RASESVDGYDNSFMH (SEQ ID NO: 54)	SESVDGYDNSF (SEQ ID NO: 59)
	CDR-L2	RAS (SEQ ID NO: 49)	RASNLES (SEQ ID NO: 55)	RAS (SEQ ID NO: 49)
	CDR-L3	QQSSEDPWT (SEQ ID NO: 50)	QQSSEDPWT (SEQ ID NO: 50)	SSSEDPW (SEQ ID NO: 60)
	VH	QIQLQQSGPELVRPGASVKISCKASGYSTDYCINWVNQRPGQGLEWIGWIYPGSGNTRYSERFKGKATLTVDTSNTAYMQLSSLTSEDSAVYFCAREDYYPYHGMDYWGQGTSTVTVSS (SEQ ID NO: 61)		
	VL	DIVLTQSPTSLAVSLGQRATISCRASESVDGYDNSFMHWYQQKPGQPPKLLIFRASNLES GIPARFSGSGSRDFTLTINPVEAADVATYYCQQSSEDPWTFGGGKLEIK (SEQ ID NO: 62)		
5-H12 C33Y*	CDR-H1	GYSFTDYY (SEQ ID NO: 63)	DYYIN (SEQ ID NO: 64)	GYSFTDY (SEQ ID NO: 56)
	CDR-H2	IYPGSGNT (SEQ ID NO: 46)	WIYPGSGNTRYSERFKG (SEQ ID NO: 52)	GSG (SEQ ID NO: 57)
	CDR-H3	AREDYYPYHGMDY (SEQ ID NO: 47)	EDYYPYHGMDY (SEQ ID NO: 53)	DYYPYHGMD (SEQ ID NO: 58)
	CDR-L1	ESVDGYDNSF (SEQ ID NO: 48)	RASESVDGYDNSFMH (SEQ ID NO: 54)	SESVDGYDNSF (SEQ ID NO: 59)
	CDR-L2	RAS (SEQ ID NO: 49)	RASNLES (SEQ ID NO: 55)	RAS (SEQ ID NO: 49)
	CDR-L3	QQSSEDPWT (SEQ ID NO: 50)	QQSSEDPWT (SEQ ID NO: 50)	SSSEDPW (SEQ ID NO: 60)
	VH	QIQLQQSGPELVRPGASVKISCKASGYSTDYINWVNQRPGQGLEWIGWIYPGSGNTRYSERFKGKATLTVDTSNTAYMQLSSLTSEDSAVYFCAREDYYPYHGMDYWGQGTSTVTVSS (SEQ ID NO: 65)		
5-H12 C33D*	CDR-H1	GYSFTDYD (SEQ ID NO: 66)	DYDIN (SEQ ID NO: 67)	GYSFTDY (SEQ ID NO: 56)
	CDR-H2	IYPGSGNT (SEQ ID NO: 46)	WIYPGSGNTRYSERFKG (SEQ ID NO: 52)	GSG (SEQ ID NO: 57)
	CDR-H3	AREDYYPYHGMDY (SEQ ID NO: 47)	EDYYPYHGMDY (SEQ ID NO: 53)	DYYPYHGMD (SEQ ID NO: 58)
	CDR-L1	ESVDGYDNSF (SEQ ID NO: 48)	RASESVDGYDNSFMH (SEQ ID NO: 54)	SESVDGYDNSF (SEQ ID NO: 59)
	CDR-L2	RAS (SEQ ID NO: 49)	RASNLES (SEQ ID NO: 55)	RAS (SEQ ID NO: 49)
	CDR-L3	QQSSEDPWT (SEQ ID NO: 50)	QQSSEDPWT (SEQ ID NO: 50)	SSSEDPW (SEQ ID NO: 60)
	VH	QIQLQQSGPELVRPGASVKISCKASGYSTDYDINWVNQRPGQGLEWIGWIYPGSGNTRYSERFKGKATLTVDTSNTAYMQLSSLTSEDSAVYFCAREDYYPYHGMDYWGQGTSTVTVSS (SEQ ID NO: 68)		
Anti-TfR clone 8	CDR-H1	GYSFTSYW (SEQ ID NO: 138)	SYWIG (SEQ ID NO: 144)	GYSFTSY (SEQ ID NO: 149)
	CDR-H2	IYPGDSDT (SEQ ID NO: 139)	IIYPGDSDTTRYSPSFQGG (SEQ ID NO: 145)	GDS (SEQ ID NO: 150)
	CDR-H3	ARFPYDSSGYYSFDY (SEQ ID NO: 140)	FPYDSSGYYSFDY (SEQ ID NO: 146)	PYDSSGYYSFD (SEQ ID NO: 151)

Ab	No. system	IMGT	Kabat	Chothia
	CDR-L1	QSISSY (SEQ ID NO: 141)	RASQSISSYLN (SEQ ID NO: 147)	SQSISSY (SEQ ID NO: 152)
	CDR-L2	AAS (SEQ ID NO: 142)	AASSLQS (SEQ ID NO: 148)	AAS (SEQ ID NO: 142)
	CDR-L3	QSYSTPLT (SEQ ID NO: 143)	QSYSTPLT (SEQ ID NO: 143)	SYSTPL (SEQ ID NO: 153)

* mutation positions are according to Kabat numbering of the respective VH sequences containing the mutations

[00093] In some embodiments, the anti-TfR1 antibody of the present disclosure is a humanized variant of any one of the anti-TfR1 antibodies provided in Table 2. In some embodiments, the anti-TfR1 antibody of the present disclosure comprises a CDR-H1, a CDR-H2, a CDR-H3, a CDR-L1, a CDR-L2, and a CDR-L3 that are the same as the CDR-H1, CDR-H2, and CDR-H3 in any one of the anti-TfR1 antibodies provided in Table 2, and comprises a humanized heavy chain variable region and/or (e.g., and) a humanized light chain variable region.

[00094] Examples of amino acid sequences of anti-TfR1 antibodies described herein are provided in Table 3.

Table 3. Variable Regions of Anti-TfR1 Antibodies

Antibody	Variable Region Amino Acid Sequence**
3A4 VH3 (N54T*)/Vκ4	V _H : EVQLVQSGSELKKPGASVKVCTASGFNIK DDYMYWVRQPPGKGLEWIGWIDP ETGDTEYASKFQDRVTVTADTSTNTAYMELSSLRSEDTAVYYCTLWLRRGLD YWGQGTLLTVSS (SEQ ID NO: 69)
	V _L : DIVMTQSPLSLPVTGPGEASISCR SSKSL LHSNGYTYLFWFQQRPGQSPRLLIYR MSNLASGV PDRFSGSGSGTDFTLKISRVEAEDVGVYYC MQHLEY PFTFGGGTK VEIK (SEQ ID NO: 70)
3A4 VH3 (N54S*)/Vκ4	V _H : EVQLVQSGSELKKPGASVKVCTASGFNIK DDYMYWVRQPPGKGLEWIGWIDP ESGDTEYASKFQDRVTVTADTSTNTAYMELSSLRSEDTAVYYCTLWLRRGLD YWGQGTLLTVSS (SEQ ID NO: 71)
	V _L : DIVMTQSPLSLPVTGPGEASISCR SSKSL LHSNGYTYLFWFQQRPGQSPRLLIYR MSNLASGV PDRFSGSGSGTDFTLKISRVEAEDVGVYYC MQHLEY PFTFGGGTK VEIK (SEQ ID NO: 70)
3A4 VH3/Vκ4	V _H : EVQLVQSGSELKKPGASVKVCTASGFNIK DDYMYWVRQPPGKGLEWIGWIDP ENGDTTEYASKFQDRVTVTADTSTNTAYMELSSLRSEDTAVYYCTLWLRRGLD YWGQGTLLTVSS (SEQ ID NO: 72)
	V _L : DIVMTQSPLSLPVTGPGEASISCR SSKSL LHSNGYTYLFWFQQRPGQSPRLLIYR MSNLASGV PDRFSGSGSGTDFTLKISRVEAEDVGVYYC MQHLEY PFTFGGGTK VEIK (SEQ ID NO: 70)
3M12 VH3/Vκ2	V _H : QVQLQESGPGLVKPSQTLSTCSVTGYSIT SGYYWNWIRQPPGKGLEWMGYITF DGANNYNPSLKNRVSISRDTSKNQFSLKLSVTAEDTATYYCTR SSYD YDVL LDY WGQGTLLTVSS (SEQ ID NO: 73)
	V _L : DIQMTQSPSSLSASVGDRTITCR ASQDIS NFLNWKQKPGQPVKLLIY YTSRLH SGVPSRFSGSGSGTDFTLTI SSLQPEDFATYFC QQGH TL PYT FGQGTKLEIK (SEQ ID NO: 74)

Antibody	Variable Region Amino Acid Sequence**
3M12 VH3/Vκ3	VH: QVQLQESGPGLVKPSQTLSTCSVTGYSTSGYYWNWIRQPPGKGLEWMGYITF DGANNYNPSLKNRVSISRDTSKNQFSLKLSSVTAEDTATYYCTRSSYDYDVL DY WGQGTITVTVSS (SEQ ID NO: 73)
	VL: DIQMTQSPSSLSASVGDRVITITCRASQDISNFLNWWYQQKPGQPVKLLIYYTSRLH SGVPSRFRSGSGGTDFLTITSLQPEDFATYYC QQGHTLPYTF GQGGTKLEIK (SEQ ID NO: 75)
3M12 VH4/Vκ2	VH: QVQLQESGPGLVKPSQTLSTCTVTGYSTSGYYWNWIRQPPGKGLEWIGYITFD GANNYNPSLKNRVSISRDTSKNQFSLKLSSVTAEDTATYYCTRSSYDYDVL DY W GQGTITVTVSS (SEQ ID NO: 76)
	VL: DIQMTQSPSSLSASVGDRVITITCRASQDISNFLNWWYQQKPGQPVKLLIYYTSRLH SGVPSRFRSGSGGTDFLTITSLQPEDFATYFC QQGHTLPYTF GQGGTKLEIK (SEQ ID NO: 74)
3M12 VH4/Vκ3	VH: QVQLQESGPGLVKPSQTLSTCTVTGYSTSGYYWNWIRQPPGKGLEWIGYITFD GANNYNPSLKNRVSISRDTSKNQFSLKLSSVTAEDTATYYCTRSSYDYDVL DY W GQGTITVTVSS (SEQ ID NO: 76)
	VL: DIQMTQSPSSLSASVGDRVITITCRASQDISNFLNWWYQQKPGQPVKLLIYYTSRLH SGVPSRFRSGSGGTDFLTITSLQPEDFATYYC QQGHTLPYTF GQGGTKLEIK (SEQ ID NO: 75)
5H12 VH5 (C33Y*)/Vκ3	VH: QVQLVQSGAEVKKPGASVKVSCKASGYST DYYIN WVRQAPGQGLEWMGW IY PGSGNTRYSERFKGRVTITRDTASTAYMELSSLRSED AVYYC ARE DY YPYH GMDYWGQGT LVTVSS (SEQ ID NO: 77)
	VL: DIVLTQSPDSLAVSLGERATINCRASE VDGYDNS FMHWYQQKPGQPPKLLIFR ASNLESGVPDRFSGSGSRDFTLTITSLQAEDVAVYYC QQSEDP WTFGQGTKL EIK (SEQ ID NO: 78)
5H12 VH5 (C33D*)/Vκ4	VH: QVQLVQSGAEVKKPGASVKVSCKASGYST DYDIN WVRQAPGQGLEWMGW IY PGSGNTRYSERFKGRVTITRDTASTAYMELSSLRSED AVYYC ARE DY YPYH GMDYWGQGT LVTVSS (SEQ ID NO: 79)
	VL: DIVMTQSPDSLAVSLGERATINCRASE VDGYDNS FMHWYQQKPGQPPKLLIFR ASNLESGVPDRFSGSGGTDFLTITSLQAEDVAVYYC QQSEDP WTFGQGTKL EIK (SEQ ID NO: 80)
5H12 VH5 (C33Y*)/Vκ4	VH: QVQLVQSGAEVKKPGASVKVSCKASGYST DYYIN WVRQAPGQGLEWMGW IY PGSGNTRYSERFKGRVTITRDTASTAYMELSSLRSED AVYYC ARE DY YPYH GMDYWGQGT LVTVSS (SEQ ID NO: 77)
	VL: DIVMTQSPDSLAVSLGERATINCRASE VDGYDNS FMHWYQQKPGQPPKLLIFR ASNLESGVPDRFSGSGGTDFLTITSLQAEDVAVYYC QQSEDP WTFGQGTKL EIK (SEQ ID NO: 80)
Anti-TfR clone 8	VH: QVQLVQSGAEVKKPGESLKISCKGSGYST SYWIG WVRQMPGKGLEWMG IIYP GDS DTRYSPSFQ Q VTISADKSISTAYLQWSSLKASDTAMYYCAR FPYDSSGY SFDYWGQGT LVTVSS (SEQ ID NO: 154)
	VL: DIQMTQSPSSLSASVGDRVITITCRASQ SISSYL NWWYQQKPGKAPKLLIYA AASSLQ SGVPSRFRSGSGGTDFLTITSLQPEDFATYYC QQSYSTPLT FGGGTKVEIK (SEQ ID NO: 155)

* mutation positions are according to Kabat numbering of the respective VH sequences containing the mutations

** CDRs according to the Kabat numbering system are bolded

[00095] In some embodiments, the anti-TfR1 antibody of the present disclosure comprises a VH comprising the CDR-H1, CDR-H2, and CDR-H3 of any one of the anti-TfR1 antibodies provided in Table 3 and comprises one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more) amino acid variations in the framework regions as compared with the respective VH provided in Table 3. Alternatively or in addition (e.g., in addition), the anti-TfR1 antibody of the present disclosure comprises a VL comprising the CDR-L1, CDR-L2, and CDR-L3 of any one of the anti-TfR1 antibodies provided in Table 3 and comprises one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more) amino acid variations in the framework regions as compared with the respective VL provided in Table 3. In some embodiments, the VH of the anti-TfR1 antibody is a humanized VH, and/or the VL of the anti-TfR1 antibody is a humanized VL.

[00096] In some embodiments, the anti-TfR1 antibody of the present disclosure comprises a VH comprising the CDR-H1, CDR-H2, and CDR-H3 of any one of the anti-TfR1 antibodies provided in Table 3 and comprising an amino acid sequence that is at least 70% (e.g., at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%) identical in the framework regions as compared with the respective VH provided in Table 3. Alternatively or in addition (e.g., in addition), the anti-TfR1 antibody of the present disclosure comprises a VL comprising the CDR-L1, CDR-L2, and CDR-L3 of any one of the anti-TfR1 antibodies provided in Table 3 and comprising an amino acid sequence that is at least 70% (e.g., at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99%) identical in the framework regions as compared with the respective VL provided in Table 3. In some embodiments, the VH of the anti-TfR1 antibody is a humanized VH, and/or the VL of the anti-TfR1 antibody is a humanized VL.

[00097] In some embodiments, the anti-TfR1 antibody of the present disclosure comprises a VH comprising the amino acid sequence of SEQ ID NO: 69 and a VL comprising the amino acid sequence of SEQ ID NO: 70.

[00098] In some embodiments, the anti-TfR1 antibody of the present disclosure comprises a VH comprising the amino acid sequence of SEQ ID NO: 71 and a VL comprising the amino acid sequence of SEQ ID NO: 70.

[00099] In some embodiments, the anti-TfR1 antibody of the present disclosure comprises a VH comprising the amino acid sequence of SEQ ID NO: 72 and a VL comprising the amino acid sequence of SEQ ID NO: 70.

[00100] In some embodiments, the anti-TfR1 antibody of the present disclosure comprises a VH comprising the amino acid sequence of SEQ ID NO: 73 and a VL comprising the amino acid sequence of SEQ ID NO: 74.

[000101] In some embodiments, the anti-TfR1 antibody of the present disclosure comprises a VH comprising the amino acid sequence of SEQ ID NO: 73 and a VL comprising the amino acid sequence of SEQ ID NO: 75.

[000102] In some embodiments, the anti-TfR1 antibody of the present disclosure comprises a VH comprising the amino acid sequence of SEQ ID NO: 76 and a VL comprising the amino acid sequence of SEQ ID NO: 74.

[000103] In some embodiments, the anti-TfR1 antibody of the present disclosure comprises a VH comprising the amino acid sequence of SEQ ID NO: 76 and a VL comprising the amino acid sequence of SEQ ID NO: 75.

[000104] In some embodiments, the anti-TfR1 antibody of the present disclosure comprises a VH comprising the amino acid sequence of SEQ ID NO: 77 and a VL comprising the amino acid sequence of SEQ ID NO: 78.

[000105] In some embodiments, the anti-TfR1 antibody of the present disclosure comprises a VH comprising the amino acid sequence of SEQ ID NO: 79 and a VL comprising the amino acid sequence of SEQ ID NO: 80.

[000106] In some embodiments, the anti-TfR1 antibody of the present disclosure comprises a VH comprising the amino acid sequence of SEQ ID NO: 77 and a VL comprising the amino acid sequence of SEQ ID NO: 80.

[000107] In some embodiments, the anti-TfR1 antibody of the present disclosure comprises a VH comprising the amino acid sequence of SEQ ID NO: 154 and a VL comprising the amino acid sequence of SEQ ID NO: 155.

[000108] In some embodiments, the anti-TfR1 antibody described herein is a full-length IgG, which can include a heavy constant region and a light constant region from a human antibody. In some embodiments, the heavy chain of any of the anti-TfR1 antibodies as described herein may comprise a heavy chain constant region (CH) or a portion thereof (e.g., CH1, CH2, CH3, or a combination thereof). The heavy chain constant region can be of any suitable origin, e.g., human, mouse, rat, or rabbit. In one specific example, the heavy chain constant region is from a human IgG (a gamma heavy chain), e.g., IgG1, IgG2, or IgG4. An example of a human IgG1 constant region is given below:

ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQS
SGLYSLSVSTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLG
GPSVFLFPPKPKDTLMISRTPEVTCVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREE
QYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLTP
PSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLYSKLT
VDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 81)

[000109] In some embodiments, the heavy chain of any of the anti-TfR1 antibodies described herein comprises a mutant human IgG1 constant region. For example, the introduction of LALA mutations (a mutant derived from mAb b12 that has been mutated to replace the lower hinge residues Leu234 Leu235 with Ala234 and Ala235) in the CH2 domain of human IgG1 is known to reduce Fcγ receptor binding (Bruhns, P., et al . (2009) and Xu, D. et al. (2000)). The mutant human IgG1 constant region is provided below (mutations bonded and underlined):

ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFCFSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 82)

[000110] In some embodiments, the light chain of any of the anti-TfR1 antibodies described herein may further comprise a light chain constant region (CL), which can be any CL known in the art. In some examples, the CL is a kappa light chain. In other examples, the CL is a lambda light chain. In some embodiments, the CL is a kappa light chain, the sequence of which is provided below:

RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDYSTYLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 83)

[000111] Other antibody heavy and light chain constant regions are well known in the art, e.g., those provided in the IMGT database (www.imgt.org) or at www.vbase2.org/vbstat.php, both of which are incorporated by reference herein.

[000112] In some embodiments, the anti-TfR1 antibody described herein comprises a heavy chain comprising any one of the VH as listed in Table 3 or any variants thereof and a heavy chain constant region that is at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identical to SEQ ID NO: 81 or SEQ ID NO: 82. In some embodiments, the anti-TfR1 antibody described herein comprises a heavy chain comprising any one of the VH as listed in Table 3 or any variants thereof and a heavy chain constant region that contains no more than 25 amino acid variations (e.g., no more than 25, 24, 23, 22, 21, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid variation) as compared with SEQ ID NO: 81 or SEQ ID NO: 82. In some embodiments, the anti-TfR1 antibody described herein comprises a heavy chain comprising any one of the VH as listed in Table 3 or any variants thereof and a heavy chain constant region as set forth in SEQ ID NO: 81. In some embodiments, the anti-TfR1

antibody described herein comprises heavy chain comprising any one of the VH as listed in Table 3 or any variants thereof and a heavy chain constant region as set forth in SEQ ID NO: 82.

[000113] In some embodiments, the anti-TfR1 antibody described herein comprises a light chain comprising any one of the VL as listed in Table 3 or any variants thereof and a light chain constant region that is at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identical to SEQ ID NO: 83. In some embodiments, the anti-TfR1 antibody described herein comprises a light chain comprising any one of the VL as listed in Table 3 or any variants thereof and a light chain constant region contains no more than 25 amino acid variations (e.g., no more than 25, 24, 23, 22, 21, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid variation) as compared with SEQ ID NO: 83. In some embodiments, the anti-TfR1 antibody described herein comprises a light chain comprising any one of the VL as listed in Table 3 or any variants thereof and a light chain constant region set forth in SEQ ID NO: 83.

[000114] Examples of IgG heavy chain and light chain amino acid sequences of the anti-TfR1 antibodies described are provided in Table 4 below.

Table 4. Heavy chain and light chain sequences of examples of anti-TfR1 IgGs

Antibody	IgG Heavy Chain/Light Chain Sequences**
3A4 VH3 (N54T*)/VK4	Heavy Chain (with wild type human IgG1 constant region) <u>EVQLVQSGSELKKPGASVKVSTASGFNIKDDYMYWVRQPPGKGLEWIGWIDPE</u> <u>TGDTEYASKFQDRVTVTADTSTNTAYMELSSLRSEDAVYYCTLWLRRLDYW</u> <u>GQGTLLTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGAL</u> TSGVHTFPAVLQSSGLYSLSSVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKS CDKTHTCPPCPAPPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVDVSHEDPEVKFN WYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALP APIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQ PENNYKTTTPVLDSGDSFFLYSKLTVDKSRWQQGNVFSCSVMEALHNHYTQKSL SLSPGK (SEQ ID NO: 84) Light Chain (with kappa light chain constant region) <u>DIVMTQSPLSLPVTPGEPASISCRSSKSLHSNGYTYLFWFQORPGQSPRLLIYRMS</u> <u>NLASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMOHLEYPTFTGGGTTKVEIK</u> RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQES VTEQDSKDSITYSLSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 85)
3A4 VH3 (N54S*)/VK4	Heavy Chain (with wild type human IgG1 constant region) <u>EVQLVQSGSELKKPGASVKVSTASGFNIKDDYMYWVRQPPGKGLEWIGWIDPE</u> <u>SGDTEYASKFQDRVTVTADTSTNTAYMELSSLRSEDAVYYCTLWLRRLDYW</u> <u>GQGTLLTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGAL</u> TSGVHTFPAVLQSSGLYSLSSVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKS CDKTHTCPPCPAPPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVDVSHEDPEVKFN WYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALP APIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQ PENNYKTTTPVLDSGDSFFLYSKLTVDKSRWQQGNVFSCSVMEALHNHYTQKSL SLSPGK (SEQ ID NO: 86) Light Chain (with kappa light chain constant region) <u>DIVMTQSPLSLPVTPGEPASISCRSSKSLHSNGYTYLFWFQORPGQSPRLLIYRMS</u> <u>NLASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMOHLEYPTFTGGGTTKVEIK</u> RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQES VTEQDSKDSITYSLSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 85)

Antibody	IgG Heavy Chain/Light Chain Sequences**
3A4 VH3/Vκ4	Heavy Chain (with wild type human IgG1 constant region) <u>EVQLVQSGSELKKGASVKVSTASGFNIKDDYMYWVRQPPGKGLEWIGWIDPE</u> <u>NGDTEYASKFQDRVTVTADTSTNTAYMELSSLRSEDAVYYCTLWLRRLDYW</u> <u>GQGTLLTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGAL</u> <u>TSGVHTFPAVLQSSGLYSLSSVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKS</u> <u>CDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVDVSHEDPEVKFN</u> <u>WYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALP</u> <u>APIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQ</u> <u>PENNYKTTTPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSL</u> <u>SLSPGK</u> (SEQ ID NO: 87) Light Chain (with kappa light chain constant region) <u>DIVMTQSPSLSPVTPGEPASISCRSSKSLHSNGYTYLFWFOORPGQSPRLLIYRMS</u> <u>NLASGVDPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMOHLEYPTFGGGTKVEIK</u> <u>RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQES</u> <u>VTEQDSKDYSLSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC</u> (SEQ ID NO: 85)
3M12 VH3/Vκ2	Heavy Chain (with wild type human IgG1 constant region) <u>QVQLQESGPGLVKPSQTLSTCSVTGYSTITSGYYWNWIROPPGKGLEWMGYITFD</u> <u>GANNYNPSLKNRVISIRDTSKNQFSLKLSSVTAEDTATYYCTRSSYDYDVLVDYWG</u> <u>QGTITVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALT</u> <u>SGVHTFPAVLQSSGLYSLSSVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSC</u> <u>DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVDVSHEDPEVKFN</u> <u>WYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALP</u> <u>APIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQ</u> <u>PENNYKTTTPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSL</u> <u>SLSPGK</u> (SEQ ID NO: 88) Light Chain (with kappa light chain constant region) <u>DIQMTQSPSSLSASVGDRVTTICRASQDISNFLNWIYQOKPGQPVKLLIYYTSRLHS</u> <u>GVPSRFSGSGSGTDFTLTISLQPEDFATYFCQOGHTLPYTFGQGTKEIKRTVAAP</u> <u>SVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSK</u> <u>DSTYLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC</u> (SEQ ID NO: 89)
3M12 VH3/Vκ3	Heavy Chain (with wild type human IgG1 constant region) <u>QVQLQESGPGLVKPSQTLSTCSVTGYSTITSGYYWNWIROPPGKGLEWMGYITFD</u> <u>GANNYNPSLKNRVISIRDTSKNQFSLKLSSVTAEDTATYYCTRSSYDYDVLVDYWG</u> <u>QGTITVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALT</u> <u>SGVHTFPAVLQSSGLYSLSSVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSC</u> <u>DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVDVSHEDPEVKFN</u> <u>WYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALP</u> <u>APIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQ</u> <u>PENNYKTTTPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSL</u> <u>SLSPGK</u> (SEQ ID NO: 88) Light Chain (with kappa light chain constant region) <u>DIQMTQSPSSLSASVGDRVTTICRASQDISNFLNWIYQOKPGQPVKLLIYYTSRLHS</u> <u>GVPSRFSGSGSGTDFTLTISLQPEDFATYYCQOGHTLPYTFGQGTKEIKRTVAA</u> <u>PSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDS</u> <u>KDSTYLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC</u> (SEQ ID NO: 90)
3M12 VH4/Vκ2	Heavy Chain (with wild type human IgG1 constant region) <u>QVQLQESGPGLVKPSQTLSTCTVTGYSTITSGYYWNWIROPPGKGLEWIGYITFDG</u> <u>ANNYNPSLKNRVISIRDTSKNQFSLKLSSVTAEDTATYYCTRSSYDYDVLVDYWGQ</u> <u>GTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALT</u> <u>GVHTFPAVLQSSGLYSLSSVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCD</u> <u>KTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVDVSHEDPEVKFNW</u> <u>YVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPA</u> <u>PIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQP</u> <u>ENNYKTTTPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSL</u> <u>LSPGK</u> (SEQ ID NO: 91)

Antibody	IgG Heavy Chain/Light Chain Sequences**
	Light Chain (with kappa light chain constant region) <u>DIOMTQSPSSLSASVGDRTTITCRASODISNFLNWWYQOKPGQPVKLLIYYTSRLHS</u> <u>GVPSRFSGSGSGTDFTLTISLQPEDFATYFCQOGHTLPYTFGQGTKEIKRTVAAP</u> <u>SVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSK</u> <u>DSTYLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC</u> (SEQ ID NO: 89)
3M12 VH4/Vκ3	Heavy Chain (with wild type human IgG1 constant region) <u>QVQLQESGPGLVKPSQTLSTCTVTGYSITSGYYWNWIRQPPGKGLEWIGYITFDG</u> <u>ANNYNPSLKNRVSISRDTSKNQFSLKLSSVTAEDTATYYCTRSSYDYDVLVDYWGQ</u> <u>GTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTS</u> <u>GVHTFPAVLQSSGLYSLSSVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCD</u> <u>KTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNW</u> <u>YVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPA</u> <u>PIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQP</u> <u>ENNYKTTTPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLS</u> <u>LSPGK</u> (SEQ ID NO: 91) Light Chain (with kappa light chain constant region) <u>DIOMTQSPSSLSASVGDRTTITCRASODISNFLNWWYQOKPGQPVKLLIYYTSRLHS</u> <u>GVPSRFSGSGSGTDFTLTISLQPEDFATYYCQOGHTLPYTFGQGTKEIKRTVAAP</u> <u>PSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDS</u> <u>KDSTYLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC</u> (SEQ ID NO: 90)
5H12 VH5 (C33Y*)/Vκ3	Heavy Chain (with wild type human IgG1 constant region) <u>QVQLVQSGAEVKKPGASVKVSCKASGYSTFDYYINWVROAPGQGLEWMGWIYP</u> <u>GSGNTRYSERFKGRVTITRDTASTAYMELSSLRSEDTAVYYCAREDDYYPYHGM</u> <u>DYWGQGLTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWN</u> <u>SGALTSGVHTFPAVLQSSGLYSLSSVTVPSSSLGTQTYICNVNHKPSNTKVDKKV</u> <u>EPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPE</u> <u>VKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSN</u> <u>KALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWE</u> <u>SNGQPENNYKTTTPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYT</u> <u>QKSLSLSPGK</u> (SEQ ID NO: 92) Light Chain (with kappa light chain constant region) <u>DIVLTQSPDSLAVSLGERATINCRASESDGYDNSFMHWYQOKPGQPPKLLIFRAS</u> <u>NLESGVPDRFSGSGSRTDFTLTISLQAEDVAVYYCQOSSEDPWTFGQGTKEIKR</u> <u>TVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVT</u> <u>EQDSKDSTYLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC</u> (SEQ ID NO: 93)
5H12 VH5 (C33D*)/Vκ4	Heavy Chain (with wild type human IgG1 constant region) <u>QVQLVQSGAEVKKPGASVKVSCKASGYSTFDYDINWVROAPGQGLEWMGWIYP</u> <u>GSGNTRYSERFKGRVTITRDTASTAYMELSSLRSEDTAVYYCAREDDYYPYHGM</u> <u>DYWGQGLTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWN</u> <u>SGALTSGVHTFPAVLQSSGLYSLSSVTVPSSSLGTQTYICNVNHKPSNTKVDKKV</u> <u>EPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPE</u> <u>VKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSN</u> <u>KALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWE</u> <u>SNGQPENNYKTTTPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYT</u> <u>QKSLSLSPGK</u> (SEQ ID NO: 94) Light Chain (with kappa light chain constant region) <u>DIVMTQSPDSLAVSLGERATINCRASESDGYDNSFMHWYQOKPGQPPKLLIFRA</u> <u>SNLESGVPDRFSGSGSGTDFTLTISLQAEDVAVYYCQOSSEDPWTFGQGTKEIKR</u> <u>RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQES</u> <u>VTEQDSKDSTYLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC</u> (SEQ ID NO: 95)

Antibody	IgG Heavy Chain/Light Chain Sequences**
5H12 VH5 (C33Y*)/Vκ4	Heavy Chain (with wild type human IgG1 constant region) <u>QVQLVQSGAEVKKPGASVKVSCKASGYST</u><u>DIYYINWVRQAPGQGLEWMGWIYP</u> <u>GSGNTRYSERFKGRVTITRDT</u>SASTAYMELSSLRSEDTAVYYCARE<u>DYYPYHGM</u> <u>DIWVGQGLTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWN</u> SGALTSGVHTFPAVLQSSGLYSLSSVTVPSSSLGTQTYICNVNHKPSNTKVDKKV EPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPE VKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSN KALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWE SNGQPENNYKTTTPVLDSGDSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYT QKSLSLSPGK (SEQ ID NO: 92) Light Chain (with kappa light chain constant region) DIVMTQSPDSLAVSLGERATIN<u>CRASESV</u><u>DGYDN</u><u>SFMH</u>WYQOKPGQPPKLL<u>IFRA</u> <u>SNLESGVPDRFSGSGSGTDFTLT</u>ISSLQAEDVAVYYC<u>QQSSEDPWTF</u><u>GQGTKLEIK</u> RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQES VTEQDSKDYSLSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 95)
Anti-TfR clone 8	VH: QVQLVQSGAEVKKPGESLKISCKGSGYST<u>SYWIGWVR</u>OMP<u>PGKGLEWMGI</u><u>IYPG</u> <u>DSDTRYSPSFOGQVTISADKSISTAYLOWSSLKASDTAMYYCAREFPYDSSGYYSE</u> <u>DIWVGQGLTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWN</u> SGALTSGVHTFPAVLQSSGLYSLSSVTVPSSSLGTQTYICNVNHKPSNTKVDKKV EPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPE VKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSN KALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWE SNGQPENNYKTTTPVLDSGDSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYT QKSLSLSPGK (SEQ ID NO: 156) VL: DIQMTQSPSSLSASVGDRVTT<u>CRASQSISSYL</u>NWYQOKPGKAPKLL<u>IYAASSLOS</u> GVPSRFSGSGSGTDFTLT<u>ISSLQPEDFATYYCQOQSYSTPL</u><u>TFGGG</u>TKVEIKRTVAAP SVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSK DSTYLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 157)

* mutation positions are according to Kabat numbering of the respective VH sequences containing the mutations

** CDRs according to the Kabat numbering system are bolded; VH/VL sequences underlined

[000115] In some embodiments, the anti-TfR1 antibody of the present disclosure comprises a heavy chain containing no more than 25 amino acid variations (e.g., no more than 25, 24, 23, 22, 21, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid variation) as compared with the heavy chain as set forth in any one of SEQ ID NOs: 84, 86, 87, 88, 91, 92, 94, and 156. Alternatively or in addition (e.g., in addition), the anti-TfR1 antibody of the present disclosure comprises a light chain containing no more than 25 amino acid variations (e.g., no more than 25, 24, 23, 22, 21, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid variation) as compared with the light chain as set forth in any one of SEQ ID NOs: 85, 89, 90, 93, 95, and 157.

[000116] In some embodiments, the anti-TfR1 antibody described herein comprises a heavy chain comprising an amino acid sequence that is at least 75% (e.g., 75%, 80%, 85%, 90%, 95%, 98%, or 99%) identical to any one of SEQ ID NOs: 84, 86, 87, 88, 91, 92, 94, and 156. Alternatively or in addition (e.g., in addition), the anti-TfR1 antibody described herein comprises a light chain comprising an amino acid sequence that is at least 75% (e.g., 75%, 80%,

85%, 90%, 95%, 98%, or 99%) identical to any one of SEQ ID NOs: 85, 89, 90, 93, 95, and 157.

In some embodiments, the anti-TfR1 antibody described herein comprises a heavy chain comprising the amino acid sequence of any one of SEQ ID NOs: 84, 86, 87, 88, 91, 92, 94, and 156. Alternatively or in addition (e.g., in addition), the anti-TfR1 antibody described herein comprises a light chain comprising the amino acid sequence of any one of SEQ ID NOs: 85, 89, 90, 93, 95 and 157.

[000117] In some embodiments, the anti-TfR1 antibody of the present disclosure comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 84 and a light chain comprising the amino acid sequence of SEQ ID NO: 85.

[000118] In some embodiments, the anti-TfR1 antibody of the present disclosure comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 86 and a light chain comprising the amino acid sequence of SEQ ID NO: 85.

[000119] In some embodiments, the anti-TfR1 antibody of the present disclosure comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 87 and a light chain comprising the amino acid sequence of SEQ ID NO: 85.

[000120] In some embodiments, the anti-TfR1 antibody of the present disclosure comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 88 and a light chain comprising the amino acid sequence of SEQ ID NO: 89.

[000121] In some embodiments, the anti-TfR1 antibody of the present disclosure comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 88 and a light chain comprising the amino acid sequence of SEQ ID NO: 90.

[000122] In some embodiments, the anti-TfR1 antibody of the present disclosure comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 91 and a light chain comprising the amino acid sequence of SEQ ID NO: 89.

[000123] In some embodiments, the anti-TfR1 antibody of the present disclosure comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 91 and a light chain comprising the amino acid sequence of SEQ ID NO: 90.

[000124] In some embodiments, the anti-TfR1 antibody of the present disclosure comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 92 and a light chain comprising the amino acid sequence of SEQ ID NO: 93.

[000125] In some embodiments, the anti-TfR1 antibody of the present disclosure comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 94 and a light chain comprising the amino acid sequence of SEQ ID NO: 95.

[000126] In some embodiments, the anti-TfR1 antibody of the present disclosure comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 92 and a light chain comprising the amino acid sequence of SEQ ID NO: 95.

[000127] In some embodiments, the anti-TfR1 antibody of the present disclosure comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 156 and a light chain comprising the amino acid sequence of SEQ ID NO: 157.

[000128] In some embodiments, the anti-TfR1 antibody is a Fab fragment, Fab' fragment, or F(ab')₂ fragment of an intact antibody (full-length antibody). Antigen binding fragment of an intact antibody (full-length antibody) can be prepared via routine methods (e.g., recombinantly or by digesting the heavy chain constant region of a full-length IgG using an enzyme such as papain). For example, F(ab')₂ fragments can be produced by pepsin or papain digestion of an antibody molecule, and Fab fragments that can be generated by reducing the disulfide bridges of F(ab')₂ fragments. In some embodiments, a heavy chain constant region in a Fab fragment of the anti-TfR1 antibody described herein comprises the amino acid sequence of:

ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSGLYSLSSVTVTPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHT (SEQ ID NO: 96)

[000129] In some embodiments, the anti-TfR1 antibody described herein comprises a heavy chain comprising any one of the VH as listed in Table 3 or any variants thereof and a heavy chain constant region that is at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identical to SEQ ID NO: 96. In some embodiments, the anti-TfR1 antibody described herein comprises a heavy chain comprising any one of the VH as listed in Table 3 or any variants thereof and a heavy chain constant region that contains no more than 25 amino acid variations (e.g., no more than 25, 24, 23, 22, 21, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid variation) as compared with SEQ ID NO: 96. In some embodiments, the anti-TfR1 antibody described herein comprises a heavy chain comprising any one of the VH as listed in Table 3 or any variants thereof and a heavy chain constant region as set forth in SEQ ID NO: 96.

[000130] In some embodiments, the anti-TfR1 antibody described herein comprises a light chain comprising any one of the VL as listed in Table 3 or any variants thereof and a light chain constant region that is at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identical to SEQ ID NO: 83. In some embodiments, the anti-TfR1 antibody described herein comprises a light chain comprising any one of the VL as listed in Table 3 or any variants thereof and a light chain constant region contains no more than 25 amino acid variations (e.g., no more than 25, 24, 23, 22, 21, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino

acid variation) as compared with SEQ ID NO: 83. In some embodiments, the anti-TfR1 antibody described herein comprises a light chain comprising any one of the VL as listed in Table 3 or any variants thereof and a light chain constant region set forth in SEQ ID NO: 83.

[000131] Examples of Fab heavy chain and light chain amino acid sequences of the anti-TfR1 antibodies described are provided in Table 5 below.

Table 5. Heavy chain and light chain sequences of examples of anti-TfR1 Fabs

Antibody	Fab Heavy Chain/Light Chain Sequences**
3A4 VH3 (N54T*)/Vκ4	Heavy Chain (with partial human IgG1 constant region) <u>EVQLVQSGSELKKGASVKVSTASGFNIKDDYMYWVRQPPGKGLEWIGWIDPE</u> <u>TGDTEYASKFQDRVTVTADTSTNTAYMELSSLRSED</u><u>AVYYCTLWLRRLDYLW</u> <u>GQGT</u><u>LVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEP</u><u>TVSWNSGAL</u> <u>TSGVHTFPAVLQSSGLYSLSSV</u><u>VPSSSLGTQTYICNVNHKPSNTKVDKKVEPKS</u> <u>CDKHT</u> (SEQ ID NO: 97) Light Chain (with kappa light chain constant region) <u>DIVMTQSP</u><u>SLPVTGPGEPAISCRSSKSL</u><u>LHSNGYTYLFWFQORPGQSPRLLIYRMS</u> <u>NLASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMOHLEYPFTFGGGTKVEIK</u> <u>RTVAAPS</u><u>VFIFPPSDEQLKSGTASV</u><u>VCLLN</u><u>NFY</u><u>PREAKVQWKVDNALQSGNSQES</u> <u>VTEQDSK</u><u>DSTYLSSTL</u><u>TL</u><u>SKADYE</u><u>YEHK</u><u>VYACEVTHQGLSSPVTKSFNRGEC</u> (SEQ ID NO: 85)
3A4 VH3 (N54S*)/Vκ4	Heavy Chain (with partial human IgG1 constant region) <u>EVQLVQSGSELKKGASVKVSTASGFNIKDDYMYWVRQPPGKGLEWIGWIDPE</u> <u>SGDTEYASKFQDRVTVTADTSTNTAYMELSSLRSED</u><u>AVYYCTLWLRRLDYLW</u> <u>GQGT</u><u>LVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEP</u><u>TVSWNSGAL</u> <u>TSGVHTFPAVLQSSGLYSLSSV</u><u>VPSSSLGTQTYICNVNHKPSNTKVDKKVEPKS</u> <u>CDKHT</u> (SEQ ID NO: 98) Light Chain (with kappa light chain constant region) <u>DIVMTQSP</u><u>SLPVTGPGEPAISCRSSKSL</u><u>LHSNGYTYLFWFQORPGQSPRLLIYRMS</u> <u>NLASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMOHLEYPFTFGGGTKVEIK</u> <u>RTVAAPS</u><u>VFIFPPSDEQLKSGTASV</u><u>VCLLN</u><u>NFY</u><u>PREAKVQWKVDNALQSGNSQES</u> <u>VTEQDSK</u><u>DSTYLSSTL</u><u>TL</u><u>SKADYE</u><u>YEHK</u><u>VYACEVTHQGLSSPVTKSFNRGEC</u> (SEQ ID NO: 85)
3A4 VH3/Vκ4	Heavy Chain (with partial human IgG1 constant region) <u>EVQLVQSGSELKKGASVKVSTASGFNIKDDYMYWVRQPPGKGLEWIGWIDPE</u> <u>NGDTEYASKFQDRVTVTADTSTNTAYMELSSLRSED</u><u>AVYYCTLWLRRLDYLW</u> <u>GQGT</u><u>LVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEP</u><u>TVSWNSGAL</u> <u>TSGVHTFPAVLQSSGLYSLSSV</u><u>VPSSSLGTQTYICNVNHKPSNTKVDKKVEPKS</u> <u>CDKHT</u> (SEQ ID NO: 99) Light Chain (with kappa light chain constant region) <u>DIVMTQSP</u><u>SLPVTGPGEPAISCRSSKSL</u><u>LHSNGYTYLFWFQORPGQSPRLLIYRMS</u> <u>NLASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMOHLEYPFTFGGGTKVEIK</u> <u>RTVAAPS</u><u>VFIFPPSDEQLKSGTASV</u><u>VCLLN</u><u>NFY</u><u>PREAKVQWKVDNALQSGNSQES</u> <u>VTEQDSK</u><u>DSTYLSSTL</u><u>TL</u><u>SKADYE</u><u>YEHK</u><u>VYACEVTHQGLSSPVTKSFNRGEC</u> (SEQ ID NO: 85)
3M12 VH3/Vκ2	Heavy Chain (with partial human IgG1 constant region) <u>QVQLQESGPGLVKPSQTLSTCSVTGYIS</u><u>SGYYWNWIRQPPGKGLEWMGYITFD</u> <u>GANNYNPSLKNRVSISRDTSKNOFSLKLS</u><u>SVTAEDTATYYCTR</u><u>SSYDYDVL</u><u>DYWG</u> <u>QGT</u><u>TVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEP</u><u>TVSWNSGALT</u> <u>SGVHTFPAVLQSSGLYSLSSV</u><u>VPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSC</u> <u>DKHT</u> (SEQ ID NO: 100) Light Chain (with kappa light chain constant region) <u>DIQMTQSP</u><u>SSLASVGDRTITCRASQDISN</u><u>FLN</u><u>WYQOKPGQPVKLLIYYTSRLHS</u> <u>GVPSR</u><u>FSGSGSGTDFTLT</u><u>ISSLOPEDFATYFCQOGHTLPYTFGQGT</u><u>KLEIKRTVAAP</u> <u>SVFIFPPSDEQLKSGTASV</u><u>VCLLN</u><u>NFY</u><u>PREAKVQWKVDNALQSGNSQESVTEQDSK</u> <u>DSTYLSSTL</u><u>TL</u><u>SKADYE</u><u>YEHK</u><u>VYACEVTHQGLSSPVTKSFNRGEC</u> (SEQ ID NO: 89)

Antibody	Fab Heavy Chain/Light Chain Sequences**
3M12 VH3/Vκ3	Heavy Chain (with partial human IgG1 constant region) <u>QVQLQESGPGLVKPSQTLSTCTVTGYSITSGYYWNWIRQPPGKGLEWMGYITFD</u> <u>GANNYNPSLKNRVVISRDTSKNQFSLKLSSVTAEDTATYYCTRSSYDYDVL DYWG</u> <u>QGTITVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALT</u> <u>SGVHTFPAVLQSSGLYSLSSVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSC</u> <u>DKTHT</u> (SEQ ID NO: 100)
	Light Chain (with kappa light chain constant region) <u>DIQMTQSPSSLSASVGDRVTTTCRASQDISNFLN WYQOKPGOPVKLLIYYTSRLHS</u> <u>GVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQOGHTLPYTFGQGT KLEIKRTVAA</u> <u>PSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDS</u> <u>KDSTYLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC</u> (SEQ ID NO: 90)
3M12 VH4/Vκ2	Heavy Chain (with partial human IgG1 constant region) <u>QVQLQESGPGLVKPSQTLSTCTVTGYSITSGYYWNWIRQPPGKGLEWIGYITFDG</u> <u>ANNYNPSLKNRVVISRDTSKNQFSLKLSSVTAEDTATYYCTRSSYDYDVL DYWGQ</u> <u>GTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALT</u> <u>SGVHTFPAVLQSSGLYSLSSVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCD</u> <u>KTHT</u> (SEQ ID NO: 101)
	Light Chain (with kappa light chain constant region) <u>DIQMTQSPSSLSASVGDRVTTTCRASQDISNFLN WYQOKPGOPVKLLIYYTSRLHS</u> <u>GVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQOGHTLPYTFGQGT KLEIKRTVAA</u> <u>PSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDS</u> <u>KDSTYLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC</u> (SEQ ID NO: 89)
3M12 VH4/Vκ3	Heavy Chain (with partial human IgG1 constant region) <u>QVQLQESGPGLVKPSQTLSTCTVTGYSITSGYYWNWIRQPPGKGLEWIGYITFDG</u> <u>ANNYNPSLKNRVVISRDTSKNQFSLKLSSVTAEDTATYYCTRSSYDYDVL DYWGQ</u> <u>GTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALT</u> <u>SGVHTFPAVLQSSGLYSLSSVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCD</u> <u>KTHT</u> (SEQ ID NO: 101)
	Light Chain (with kappa light chain constant region) <u>DIQMTQSPSSLSASVGDRVTTTCRASQDISNFLN WYQOKPGOPVKLLIYYTSRLHS</u> <u>GVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQOGHTLPYTFGQGT KLEIKRTVAA</u> <u>PSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDS</u> <u>KDSTYLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC</u> (SEQ ID NO: 90)
5H12 VH5 (C33Y*)/Vκ3	Heavy Chain (with partial human IgG1 constant region) <u>QVQLVQSGAEVKKPGASVKVSCKASGYSTFDYYINWVRQAPGQGLEWMGWIYP</u> <u>GSGNTRYSERFKGRVTITRDTASTAYMELSSLRSEDTAVYYCAREDYYPYHGM</u> <u>DYWGQGTLYTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWN</u> <u>SGALTSGVHTFPAVLQSSGLYSLSSVTVPSSSLGTQTYICNVNHKPSNTKVDKKV</u> <u>EPKSCDKTHT</u> (SEQ ID NO: 102)
	Light Chain (with kappa light chain constant region) <u>DIVLTQSPDSLAVSLGERATINCRASESDGYDNSFMHWYQOKPGOPPKLLIFRAS</u> <u>NLESGVPDRFSGSGSRDTFTLTISSLQAEDVAVYYCQOSSEDPWTFGQGT KLEIKR</u> <u>TVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESV</u> <u>EQDSKDSTYLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC</u> (SEQ ID NO: 93)
5H12 VH5 (C33D*)/Vκ4	Heavy Chain (with partial human IgG1 constant region) <u>QVQLVQSGAEVKKPGASVKVSCKASGYSTFDYDINWVRQAPGQGLEWMGWIYP</u> <u>GSGNTRYSERFKGRVTITRDTASTAYMELSSLRSEDTAVYYCAREDYYPYHGM</u> <u>DYWGQGTLYTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWN</u> <u>SGALTSGVHTFPAVLQSSGLYSLSSVTVPSSSLGTQTYICNVNHKPSNTKVDKKV</u> <u>EPKSCDKTHT</u> (SEQ ID NO: 103)
	Light Chain (with kappa light chain constant region) <u>DIVMTQSPDSLAVSLGERATINCRASESDGYDNSFMHWYQOKPGOPPKLLIFRA</u> <u>SNLESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQOSSEDPWTFGQGT KLEIK</u> <u>RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQES</u> <u>VTEQDSKDSTYLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC</u> (SEQ ID NO: 95)

Antibody	Fab Heavy Chain/Light Chain Sequences**
5H12 VH5 (C33Y*)/Vκ4	Heavy Chain (with partial human IgG1 constant region) <u>QVQLVQSGAEVKKPGASVKV</u><u>SC</u><u>ASGYST</u><u>DYYINWVRQAPGQGLEWMGWIYP</u> <u>GSGNTRYSERFKGRVTITRDT</u><u>SASTAYMELSSL</u><u>RSEDTAVYYCARE</u><u>DYYPYHGM</u> <u>DYWGQGT</u><u>LVTVSSASTKGPSVF</u><u>FLAPSSKSTSGGTAALGCLVKDYFPEP</u><u>VTVSWN</u> <u>SGALTSGVHTFPAVLQSSGLYSLSSV</u><u>TVPSSSLGTQTYICNVNHKPSNTKVDKKV</u> <u>EPKSCDKTHT</u> (SEQ ID NO: 102) Light Chain (with kappa light chain constant region) <u>DIVMTQSPDSLAVSLGERATIN</u><u>CRASESV</u><u>DGYDNS</u><u>FMH</u><u>WYQOKPGQPPKLLIFRA</u> <u>SNLESGVPDRFSGSGSGTDFTLTISS</u><u>LOAEDVAVYYC</u><u>QO</u><u>SS</u><u>EDPW</u><u>TFGQGTKLEIK</u> <u>RTVAAPSVFIFPPSDEQLKSGTASV</u><u>VCLLNNFY</u><u>PREAKVQWKVDNALQSGNSQES</u> <u>VTEQDSK</u><u>DSTYLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC</u> (SEQ ID NO: 95)
Anti-TfR clone 8 Version 1	VH: <u>QVQLVQSGAEVKKPGESLKISCKGSGYSFT</u><u>SYWIGWVRQMPGKGLEWMGIIYPG</u> <u>DS</u><u>DTRYSPS</u><u>FOGQ</u><u>VTISADKS</u><u>ISTAYLOWSSLKASDTAMYYCAR</u><u>FPYDSSGYYSF</u> <u>DYWGQGT</u><u>LVTVSSASTKGPSVF</u><u>FLAPSSKSTSGGTAALGCLVKDYFPEP</u><u>VTVSWN</u> <u>SGALTSGVHTFPAVLQSSGLYSLSSV</u><u>TVPSSSLGTQTYICNVNHKPSNTKVDKKV</u> <u>EPKSCDKTHTCP</u> (SEQ ID NO: 158) VL: <u>DIQMTQSPSSLSASVGDRVTTITCRASQ</u><u>SISSYL</u><u>NWYQOKPGKAPKLLIYAASS</u><u>LOS</u> <u>GVPSRFS</u><u>SGSGSGTDFTLTISSLOPEDFATYYC</u><u>QO</u><u>SYSTPL</u><u>TFGGG</u><u>TKVEIKRTVAAP</u> <u>SVFIFPPSDEQLKSGTASV</u><u>VCLLNNFY</u><u>PREAKVQWKVDNALQSGNSQESVTEQDSK</u> <u>DSTYLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC</u> (SEQ ID NO: 157)
Anti-TfR clone 8 Version 2	VH: <u>QVQLVQSGAEVKKPGESLKISCKGSGYSFT</u><u>SYWIGWVRQMPGKGLEWMGIIYPG</u> <u>DS</u><u>DTRYSPS</u><u>FOGQ</u><u>VTISADKS</u><u>ISTAYLOWSSLKASDTAMYYCAR</u><u>FPYDSSGYYSF</u> <u>DYWGQGT</u><u>LVTVSSASTKGPSVF</u><u>FLAPSSKSTSGGTAALGCLVKDYFPEP</u><u>VTVSWN</u> <u>SGALTSGVHTFPAVLQSSGLYSLSSV</u><u>TVPSSSLGTQTYICNVNHKPSNTKVDKKV</u> <u>EPKSCDKTHT</u> (SEQ ID NO: 159) VL: <u>DIQMTQSPSSLSASVGDRVTTITCRASQ</u><u>SISSYL</u><u>NWYQOKPGKAPKLLIYAASS</u><u>LOS</u> <u>GVPSRFS</u><u>SGSGSGTDFTLTISSLOPEDFATYYC</u><u>QO</u><u>SYSTPL</u><u>TFGGG</u><u>TKVEIKRTVAAP</u> <u>SVFIFPPSDEQLKSGTASV</u><u>VCLLNNFY</u><u>PREAKVQWKVDNALQSGNSQESVTEQDSK</u> <u>DSTYLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC</u> (SEQ ID NO: 157)

* mutation positions are according to Kabat numbering of the respective VH sequences containing the mutations

** CDRs according to the Kabat numbering system are bolded; VH/VL sequences underlined

[000132] In some embodiments, the anti-TfR1 antibody of the present disclosure comprises a heavy chain containing no more than 25 amino acid variations (e.g., no more than 25, 24, 23, 22, 21, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid variation) as compared with the heavy chain as set forth in any one of SEQ ID NOs: 97-103, 158 and 159. Alternatively or in addition (e.g., in addition), the anti-TfR1 antibody of the present disclosure comprises a light chain containing no more than 25 amino acid variations (e.g., no more than 25, 24, 23, 22, 21, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid variation) as compared with the light chain as set forth in any one of SEQ ID NOs: 85, 89, 90, 93, 95, and 157.

[000133] In some embodiments, the anti-TfR1 antibody described herein comprises a heavy chain comprising an amino acid sequence that is at least 75% (e.g., 75%, 80%, 85%, 90%, 95%, 98%, or 99%) identical to any one of SEQ ID NOs: 97-103, 158 and 159. Alternatively or

in addition (e.g., in addition), the anti-TfR1 antibody described herein comprises a light chain comprising an amino acid sequence that is at least 75% (e.g., 75%, 80%, 85%, 90%, 95%, 98%, or 99%) identical to any one of SEQ ID NOs: 85, 89, 90, 93, 95, and 157. In some embodiments, the anti-TfR1 antibody described herein comprises a heavy chain comprising the amino acid sequence of any one of SEQ ID NOs: 97-103, 158 and 159. Alternatively or in addition (e.g., in addition), the anti-TfR1 antibody described herein comprises a light chain comprising the amino acid sequence of any one of SEQ ID NOs: 85, 89, 90, 93, 95, and 157.

[000134] In some embodiments, the anti-TfR1 antibody of the present disclosure comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 97 and a light chain comprising the amino acid sequence of SEQ ID NO: 85.

[000135] In some embodiments, the anti-TfR1 antibody of the present disclosure comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 98 and a light chain comprising the amino acid sequence of SEQ ID NO: 85.

[000136] In some embodiments, the anti-TfR1 antibody of the present disclosure comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 99 and a light chain comprising the amino acid sequence of SEQ ID NO: 85.

[000137] In some embodiments, the anti-TfR1 antibody of the present disclosure comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 100 and a light chain comprising the amino acid sequence of SEQ ID NO: 89.

[000138] In some embodiments, the anti-TfR1 antibody of the present disclosure comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 100 and a light chain comprising the amino acid sequence of SEQ ID NO: 90.

[000139] In some embodiments, the anti-TfR1 antibody of the present disclosure comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 101 and a light chain comprising the amino acid sequence of SEQ ID NO: 89.

[000140] In some embodiments, the anti-TfR1 antibody of the present disclosure comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 101 and a light chain comprising the amino acid sequence of SEQ ID NO: 90.

[000141] In some embodiments, the anti-TfR1 antibody of the present disclosure comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 102 and a light chain comprising the amino acid sequence of SEQ ID NO: 93.

[000142] In some embodiments, the anti-TfR1 antibody of the present disclosure comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 103 and a light chain comprising the amino acid sequence of SEQ ID NO: 95.

[000143] In some embodiments, the anti-TfR1 antibody of the present disclosure comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 102 and a light chain comprising the amino acid sequence of SEQ ID NO: 95.

[000144] In some embodiments, the anti-TfR1 antibody of the present disclosure comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 158 and a light chain comprising the amino acid sequence of SEQ ID NO: 157.

[000145] In some embodiments, the anti-TfR1 antibody of the present disclosure comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 159 and a light chain comprising the amino acid sequence of SEQ ID NO: 157.

Other known anti-TfR1 antibodies

[000146] Any other appropriate anti-TfR1 antibodies known in the art may be used as the muscle-targeting agent in the complexes disclosed herein. Examples of known anti-TfR1 antibodies, including associated references and binding epitopes, are listed in Table 6. In some embodiments, the anti-TfR1 antibody comprises the complementarity determining regions (CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3) of any of the anti-TfR1 antibodies provided herein, e.g., anti-TfR1 antibodies listed in Table 6.

Table 6 – List of anti-TfR1 antibody clones, including associated references and binding epitope information.

Antibody Clone Name	Reference(s)	Epitope / Notes
OKT9	US Patent. No. 4,364,934, filed 12/4/1979, entitled “MONOCLONAL ANTIBODY TO A HUMAN EARLY THYMOCYTE ANTIGEN AND METHODS FOR PREPARING SAME” Schneider C. et al. “Structural features of the cell surface receptor for transferrin that is recognized by the monoclonal antibody OKT9.” J Biol Chem. 1982, 257:14, 8516-8522.	Apical domain of TfR1 (residues 305-366 of human TfR1 sequence XM_052730.3, available in GenBank)
(From JCR) Clone M11 Clone M23 Clone M27 Clone B84	- WO 2015/098989, filed 12/24/2014, “Novel anti-Transferrin receptor antibody that passes through blood-brain barrier” - US Patent No. 9,994,641, filed 12/24/2014, “Novel anti-Transferrin receptor antibody that passes through blood-brain barrier”	Apical domain (residues 230-244 and 326-347 of TfR1) and protease-like domain (residues 461-473)

Antibody Clone Name	Reference(s)	Epitope / Notes
(From Genentech) 7A4, 8A2, 15D2, 10D11, 7B10, 15G11, 16G5, 13C3, 16G4, 16F6, 7G7, 4C2, 1B12, and 13D4	- WO 2016/081643, filed 5/26/2016, entitled "ANTI-TRANSFERRIN RECEPTOR ANTIBODIES AND METHODS OF USE" - US Patent No. 9,708,406, filed 5/20/2014, "Anti-transferrin receptor antibodies and methods of use"	Apical domain and non-apical regions
(From Armagen) 8D3	- Lee et al. "Targeting Rat Anti-Mouse Transferrin Receptor Monoclonal Antibodies through Blood-Brain Barrier in Mouse" 2000, J Pharmacol. Exp. Ther., 292: 1048-1052. - US Patent App. 2010/077498, filed 9/11/2008, entitled "COMPOSITIONS AND METHODS FOR BLOOD-BRAIN BARRIER DELIVERY IN THE MOUSE"	
OX26	Haobam, B. et al. 2014. Rab17-mediated recycling endosomes contribute to autophagosome formation in response to Group A Streptococcus invasion. Cellular microbiology. 16: 1806-21.	
DF1513	Ortiz-Zapater E et al. Trafficking of the human transferrin receptor in plant cells: effects of tyrphostin A23 and brefeldin A. Plant J 48:757-70 (2006).	
1A1B2, 66IG10, MEM-189, JF0956, 29806, 1A1B2, TFRC/1818, 1E6, 66Ig10, TFRC/1059, Q1/71, 23D10, 13E4, TFRC/1149, ER-MP21, YTA74.4, BU54, 2B6, RI7 217	Commercially available anti-transferrin receptor antibodies.	Novus Biologicals 8100 Southpark Way, A-8 Littleton CO 80120
(From INSERM) BA120g	US Patent App. 2011/0311544A1, filed 6/15/2005, entitled "ANTI-CD71 MONOCLONAL ANTIBODIES AND USES THEREOF FOR TREATING MALIGNANT TUMOR CELLS"	Does not compete with OKT9
LUCA31	US Patent No. 7,572,895, filed 6/7/2004, entitled "TRANSFERRIN RECEPTOR ANTIBODIES"	"LUCA31 epitope"

comprises a heavy chain variable sequence or a light chain variable sequence that is at least 75% (e.g., 80%, 85%, 90%, 95%, 98%, or 99%) identical to the heavy chain variable sequence and/or any light chain variable sequence of any anti-TfR1 antibody, such as any one of the anti-TfR1 antibodies selected from Table 6. In some embodiments, the homologous heavy chain variable and/or (e.g., and) a light chain variable amino acid sequences do not vary within any of the CDR sequences provided herein. For example, in some embodiments, the degree of sequence variation (e.g., 75%, 80%, 85%, 90%, 95%, 98%, or 99%) may occur within a heavy chain variable and/or (e.g., and) a light chain variable sequence excluding any of the CDR sequences provided herein. In some embodiments, any of the anti-TfR1 antibodies provided herein comprise a heavy chain variable sequence and a light chain variable sequence that comprises a framework sequence that is at least 75%, 80%, 85%, 90%, 95%, 98%, or 99% identical to the framework sequence of any anti-TfR1 antibody, such as any one of the anti-TfR1 antibodies selected from Table 6.

[000150] An example of a transferrin receptor antibody that may be used in accordance with the present disclosure is described in International Application Publication WO 2016/081643, incorporated herein by reference. The amino acid sequences of this antibody are provided in Table 7.

Table 7. Heavy chain and light chain CDRs of an example of a known anti-TfR1 antibody

Sequence Type	Kabat	Chothia	Contact
CDR-H1	SYWMH (SEQ ID NO: 110)	GYTFTSY (SEQ ID NO: 116)	TSYWMH (SEQ ID NO: 118)
CDR-H2	EINPTNGRTNYIEKFKS (SEQ ID NO: 111)	NPTNGR (SEQ ID NO: 117)	WIGEINPTNGRTN (SEQ ID NO: 119)
CDR-H3	GTRAYHY (SEQ ID NO: 112)	GTRAYHY (SEQ ID NO: 112)	ARGTRA (SEQ ID NO: 120)
CDR-L1	RASDNLYSNLA (SEQ ID NO: 113)	RASDNLYSNLA (SEQ ID NO: 113)	YSNLAWY (SEQ ID NO: 121)
CDR-L2	DATNLAD (SEQ ID NO: 114)	DATNLAD (SEQ ID NO: 114)	LLVYDATNLA (SEQ ID NO: 122)
CDR-L3	QHFWGTPLT (SEQ ID NO: 115)	QHFWGTPLT (SEQ ID NO: 115)	QHFWGTPL (SEQ ID NO: 123)
Murine VH	QVQLQQPGAELVKPGASVKLSCKASGYTFTSYWMHWVKQRPGQGLEWIGEINPTNGRTNYIEKFKSKATLTVDKSSSTAYMQLSSLTSEDSAVYYCARGTRAYHYWGQGTSMVTVSS (SEQ ID NO: 124)		
Murine VL	DIQMTQSPASLSVSVGETVTITCRASDNLYSNLAWYQQKQKSPQLLVYDATNLADGVPSRFSGSGSGTQYSLKINSLQSEDFGTYYCQHFWGTPLTFGAGTKLELK (SEQ ID NO: 125)		
Humanized VH	EVQLVQSGAEVKKPGASVKVSKASGYTFTSYWMHWVRQAPGQRLEWIGEINPTNGRTNYIEKFKSRATLTVDKSASTAYMELSSLRSEDTAVYYCARGTRAYHYWGQGTSMVTVSS (SEQ ID NO: 128)		
Humanized VL	DIQMTQSPSSLSASVGDRTVTITCRASDNLYSNLAWYQQKPKSPKLLVYDATNLADGVPSRFSGSGSGTDYTLTISLQPEDFATYYCQHFWGTPLTFGQGTKVEIK (SEQ ID NO: 129)		

Sequence Type	Kabat	Chothia	Contact
HC of chimeric full-length IgG1	QVQLQQPGAELVKPGASVKLSCKASGYTFTSYWMHWVKQRPQGQLEWIGEINPTNGRTNYIEKFKSKATLTVDKSSSTAYMQLSSLTSEDSAVYYCARGTRAYHYWGQGTSTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSQVHTFPAVLQSSGLYSLSSVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVDVSHEDPEVKFNWYVDGVEVHNATKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFCFSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 132)		
LC of chimeric full-length IgG1	DIQMTQSPASLSVSVGETVTITCRASDNLYSNLAWYQQKQKSPQLLVYDATNLADGVPSRFSGSGSGTQYSLKINSLSQSEDFGTYYCQHFHWGTPLTFGAGTKLELKRVAAPSVEFPPSDEQLKSGTASVCLLNFFYPREKAKVQWKVDNALQSGNSQESVTEQDSKDSSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 133)		
HC of fully human full-length IgG1	EVQLVQSGAEVKKPGASVKVSCKASGYTFTSYWMHWVRQAPGQRLEWIGEINPTNGRTNYIEKFKSRATLTVDKSASTAYMELSSLRSEDTAVYYCARGTRAYHYWGQGTMTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVDVSHEDPEVKFNWYVDGVEVHNATKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFCFSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 134)		
LC of fully human full-length IgG1	DIQMTQSPSSLSASVGRVTITCRASDNLYSNLAWYQQKPKGKSPKLLVYDATNLADGVPSRFSGSGSGTDYTLTISSLQPEDFATYYCQHFHWGTPLTFGQGTKEIKRTVAAPSVEFPPSDEQLKSGTASVCLLNFFYPREKAKVQWKVDNALQSGNSQESVTEQDSKDSSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 135)		
HC of chimeric Fab	QVQLQQPGAELVKPGASVKLSCKASGYTFTSYWMHWVKQRPQGQLEWIGEINPTNGRTNYIEKFKSKATLTVDKSSSTAYMQLSSLTSEDSAVYYCARGTRAYHYWGQGTSTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSQVHTFPAVLQSSGLYSLSSVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTTCP (SEQ ID NO: 136)		
HC of fully human Fab	EVQLVQSGAEVKKPGASVKVSCKASGYTFTSYWMHWVRQAPGQRLEWIGEINPTNGRTNYIEKFKSRATLTVDKSASTAYMELSSLRSEDTAVYYCARGTRAYHYWGQGTMTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTTCP (SEQ ID NO: 137)		

[000151] In some embodiments, the anti-TfR1 antibody of the present disclosure comprises a CDR-H1, a CDR-H2, and a CDR-H3 that are the same as the CDR-H1, CDR-H2, and CDR-H3 shown in Table 7. Alternatively or in addition (e.g., in addition), the anti-TfR1 antibody of the present disclosure comprises a CDR-L1, a CDR-L2, and a CDR-L3 that are the same as the CDR-L1, CDR-L2, and CDR-L3 shown in Table 7.

[000152] In some embodiments, the anti-TfR1 antibody of the present disclosure comprises a CDR-L3, which contains no more than 3 amino acid variations (e.g., no more than 3, 2, or 1 amino acid variation) as compared with the CDR-L3 as shown in Table 7. In some embodiments, the anti-TfR1 antibody of the present disclosure comprises a CDR-L3 containing one amino acid variation as compared with the CDR-L3 as shown in Table 7. In some embodiments, the anti-TfR1 antibody of the present disclosure comprises a CDR-L3 of QHFAGTPLT (SEQ ID NO: 126) (according to the Kabat and Chothia definition system) or QHFAGTPL (SEQ ID NO: 127) (according to the Contact definition system). In some

embodiments, the anti-TfR1 antibody of the present disclosure comprises a CDR-H1, a CDR-H2, a CDR-H3, a CDR-L1 and a CDR-L2 that are the same as the CDR-H1, CDR-H2, and CDR-H3 shown in Table 7, and comprises a CDR-L3 of QHFAGTPLT (SEQ ID NO: 126) (according to the Kabat and Chothia definition system) or QHFAGTPL (SEQ ID NO: 127) (according to the Contact definition system).

[000153] In some embodiments, the anti-TfR1 antibody of the present disclosure comprises heavy chain CDRs that collectively are at least 80% (e.g., 80%, 85%, 90%, 95%, or 98%) identical to the heavy chain CDRs as shown in Table 7. Alternatively or in addition (e.g., in addition), the anti-TfR1 antibody of the present disclosure comprises light chain CDRs that collectively are at least 80% (e.g., 80%, 85%, 90%, 95%, or 98%) identical to the light chain CDRs as shown in Table 7.

[000154] In some embodiments, the anti-TfR1 antibody of the present disclosure comprises a VH comprising the amino acid sequence of SEQ ID NO: 124. Alternatively or in addition (e.g., in addition), the anti-TfR1 antibody of the present disclosure comprises a VL comprising the amino acid sequence of SEQ ID NO: 125.

[000155] In some embodiments, the anti-TfR1 antibody of the present disclosure comprises a VH comprising the amino acid sequence of SEQ ID NO: 128. Alternatively or in addition (e.g., in addition), the anti-TfR1 antibody of the present disclosure comprises a VL comprising the amino acid sequence of SEQ ID NO: 129.

[000156] In some embodiments, the anti-TfR1 antibody of the present disclosure comprises a VH containing no more than 25 amino acid variations (e.g., no more than 25, 24, 23, 22, 21, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid variation) as compared with the VH as set forth in SEQ ID NO: 128. Alternatively or in addition (e.g., in addition), the anti-TfR1 antibody of the present disclosure comprises a VL containing no more than 15 amino acid variations (e.g., no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid variation) as compared with the VL as set forth in SEQ ID NO: 129.

[000157] In some embodiments, the anti-TfR1 antibody of the present disclosure is a full-length IgG1 antibody, which can include a heavy constant region and a light constant region from a human antibody. In some embodiments, the heavy chain of any of the anti-TfR1 antibodies as described herein may comprises a heavy chain constant region (CH) or a portion thereof (e.g., CH1, CH2, CH3, or a combination thereof). The heavy chain constant region can of any suitable origin, e.g., human, mouse, rat, or rabbit. In one specific example, the heavy chain constant region is from a human IgG (a gamma heavy chain), e.g., IgG1, IgG2, or IgG4. An example of human IgG1 constant region is given below:

ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQS
SGLYSLSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLG
GPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREE
QYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLTP
PSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLT
VDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 81)

[000158] In some embodiments, the light chain of any of the anti-TfR1 antibodies described herein may further comprise a light chain constant region (CL), which can be any CL known in the art. In some examples, the CL is a kappa light chain. In other examples, the CL is a lambda light chain. In some embodiments, the CL is a kappa light chain, the sequence of which is provided below:

RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQ
DSKDSTYLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 83)

[000159] In some embodiments, the anti-TfR1 antibody described herein is a chimeric antibody that comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 132. Alternatively or in addition (e.g., in addition), the anti-TfR1 antibody described herein comprises a light chain comprising the amino acid sequence of SEQ ID NO: 133.

[000160] In some embodiments, the anti-TfR1 antibody described herein is a fully human antibody that comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 134. Alternatively or in addition (e.g., in addition), the anti-TfR1 antibody described herein comprises a light chain comprising the amino acid sequence of SEQ ID NO: 135.

[000161] In some embodiments, the anti-TfR1 antibody is an antigen binding fragment (Fab) of an intact antibody (full-length antibody). In some embodiments, the anti-TfR1 Fab described herein comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 136. Alternatively or in addition (e.g., in addition), the anti-TfR1 Fab described herein comprises a light chain comprising the amino acid sequence of SEQ ID NO: 133. In some embodiments, the anti-TfR1 Fab described herein comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 137. Alternatively or in addition (e.g., in addition), the anti-TfR1 Fab described herein comprises a light chain comprising the amino acid sequence of SEQ ID NO: 135.

[000162] The anti-TfR1 antibodies described herein can be in any antibody form, including, but not limited to, intact (i.e., full-length) antibodies, antigen-binding fragments thereof (such as Fab, Fab', F(ab')₂, Fv), single chain antibodies, bi-specific antibodies, or nanobodies. In some embodiments, the anti-TfR1 antibody described herein is an scFv. In some embodiments, the anti-TfR1 antibody described herein is an scFv-Fab (e.g., scFv fused to

a portion of a constant region). In some embodiments, the anti-TfR1 antibody described herein is an scFv fused to a constant region (e.g., human IgG1 constant region as set forth in SEQ ID NO: 81).

[000163] In some embodiments, conservative mutations can be introduced into antibody sequences (e.g., CDRs or framework sequences) at positions where the residues are not likely to be involved in interacting with a target antigen (e.g., transferrin receptor), for example, as determined based on a crystal structure. In some embodiments, one, two or more mutations (e.g., amino acid substitutions) are introduced into the Fc region of an anti-TfR1 antibody described herein (e.g., in a CH2 domain (residues 231-340 of human IgG1) and/or (e.g., and) CH3 domain (residues 341-447 of human IgG1) and/or (e.g., and) the hinge region, with numbering according to the Kabat numbering system (e.g., the EU index in Kabat)) to alter one or more functional properties of the antibody, such as serum half-life, complement fixation, Fc receptor binding and/or (e.g., and) antigen-dependent cellular cytotoxicity.

[000164] In some embodiments, one, two or more mutations (e.g., amino acid substitutions) are introduced into the hinge region of the Fc region (CH1 domain) such that the number of cysteine residues in the hinge region are altered (e.g., increased or decreased) as described in, e.g., U.S. Pat. No. 5,677,425. The number of cysteine residues in the hinge region of the CH1 domain can be altered to, e.g., facilitate assembly of the light and heavy chains, or to alter (e.g., increase or decrease) the stability of the antibody or to facilitate linker conjugation.

[000165] In some embodiments, one, two or more mutations (e.g., amino acid substitutions) are introduced into the Fc region of a muscle-targeting antibody described herein (e.g., in a CH2 domain (residues 231-340 of human IgG1) and/or (e.g., and) CH3 domain (residues 341-447 of human IgG1) and/or (e.g., and) the hinge region, with numbering according to the Kabat numbering system (e.g., the EU index in Kabat)) to increase or decrease the affinity of the antibody for an Fc receptor (e.g., an activated Fc receptor) on the surface of an effector cell. Mutations in the Fc region of an antibody that decrease or increase the affinity of an antibody for an Fc receptor and techniques for introducing such mutations into the Fc receptor or fragment thereof are known to one of skill in the art. Examples of mutations in the Fc receptor of an antibody that can be made to alter the affinity of the antibody for an Fc receptor are described in, e.g., Smith P et al., (2012) PNAS 109: 6181-6186, U.S. Pat. No. 6,737,056, and International Publication Nos. WO 02/060919; WO 98/23289; and WO 97/34631, which are incorporated herein by reference.

[000166] In some embodiments, one, two or more amino acid mutations (*i.e.*, substitutions, insertions or deletions) are introduced into an IgG constant domain, or FcRn-binding fragment thereof (preferably an Fc or hinge-Fc domain fragment) to alter (e.g., decrease or increase) half-

life of the antibody *in vivo*. See, e.g., International Publication Nos. WO 02/060919; WO 98/23289; and WO 97/34631; and U.S. Pat. Nos. 5,869,046, 6,121,022, 6,277,375 and 6,165,745 for examples of mutations that will alter (*e.g.*, decrease or increase) the half-life of an antibody *in vivo*.

[000167] In some embodiments, one, two or more amino acid mutations (*i.e.*, substitutions, insertions or deletions) are introduced into an IgG constant domain, or FcRn-binding fragment thereof (preferably an Fc or hinge-Fc domain fragment) to decrease the half-life of the anti-TfR1 antibody *in vivo*. In some embodiments, one, two or more amino acid mutations (*i.e.*, substitutions, insertions or deletions) are introduced into an IgG constant domain, or FcRn-binding fragment thereof (preferably an Fc or hinge-Fc domain fragment) to increase the half-life of the antibody *in vivo*. In some embodiments, the antibodies can have one or more amino acid mutations (*e.g.*, substitutions) in the second constant (CH2) domain (residues 231-340 of human IgG1) and/or (*e.g.*, and) the third constant (CH3) domain (residues 341-447 of human IgG1), with numbering according to the EU index in Kabat (Kabat E A et al., (1991) *supra*). In some embodiments, the constant region of the IgG1 of an antibody described herein comprises a methionine (M) to tyrosine (Y) substitution in position 252, a serine (S) to threonine (T) substitution in position 254, and a threonine (T) to glutamic acid (E) substitution in position 256, numbered according to the EU index as in Kabat. See U.S. Pat. No. 7,658,921, which is incorporated herein by reference. This type of mutant IgG, referred to as "YTE mutant" has been shown to display fourfold increased half-life as compared to wild-type versions of the same antibody (see Dall'Acqua W F et al., (2006) *J Biol Chem* 281: 23514-24). In some embodiments, an antibody comprises an IgG constant domain comprising one, two, three or more amino acid substitutions of amino acid residues at positions 251-257, 285-290, 308-314, 385-389, and 428-436, numbered according to the EU index as in Kabat.

[000168] In some embodiments, one, two or more amino acid substitutions are introduced into an IgG constant domain Fc region to alter the effector function(s) of the anti-TfR1 antibody. The effector ligand to which affinity is altered can be, for example, an Fc receptor or the C1 component of complement. This approach is described in further detail in U.S. Pat. Nos. 5,624,821 and 5,648,260. In some embodiments, the deletion or inactivation (through point mutations or other means) of a constant region domain can reduce Fc receptor binding of the circulating antibody thereby increasing tumor localization. See, e.g., U.S. Pat. Nos. 5,585,097 and 8,591,886 for a description of mutations that delete or inactivate the constant domain and thereby increase tumor localization. In some embodiments, one or more amino acid substitutions may be introduced into the Fc region of an antibody described herein to remove potential

glycosylation sites on Fc region, which may reduce Fc receptor binding (see, *e.g.*, Shields R L et al., (2001) J Biol Chem 276: 6591-604).

[000169] In some embodiments, one or more amino in the constant region of an anti-TfR1 antibody described herein can be replaced with a different amino acid residue such that the antibody has altered C1q binding and/or (*e.g.*, and) reduced or abolished complement dependent cytotoxicity (CDC). This approach is described in further detail in U.S. Pat. No. 6,194,551 (Idusogie et al). In some embodiments, one or more amino acid residues in the N-terminal region of the CH2 domain of an antibody described herein are altered to thereby alter the ability of the antibody to fix complement. This approach is described further in International Publication No. WO 94/29351. In some embodiments, the Fc region of an antibody described herein is modified to increase the ability of the antibody to mediate antibody dependent cellular cytotoxicity (ADCC) and/or (*e.g.*, and) to increase the affinity of the antibody for an Fcγ receptor. This approach is described further in International Publication No. WO 00/42072.

[000170] In some embodiments, the heavy and/or (*e.g.*, and) light chain variable domain(s) sequence(s) of the antibodies provided herein can be used to generate, for example, CDR-grafted, chimeric, humanized, or composite human antibodies or antigen-binding fragments, as described elsewhere herein. As understood by one of ordinary skill in the art, any variant, CDR-grafted, chimeric, humanized, or composite antibodies derived from any of the antibodies provided herein may be useful in the compositions and methods described herein and will maintain the ability to specifically bind transferrin receptor, such that the variant, CDR-grafted, chimeric, humanized, or composite antibody has at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95% or more binding to transferrin receptor relative to the original antibody from which it is derived.

[000171] In some embodiments, the antibodies provided herein comprise mutations that confer desirable properties to the antibodies. For example, to avoid potential complications due to Fab-arm exchange, which is known to occur with native IgG4 mAbs, the antibodies provided herein may comprise a stabilizing ‘Adair’ mutation (Angal S., et al., “A single amino acid substitution abolishes the heterogeneity of chimeric mouse/human (IgG4) antibody,” Mol Immunol 30, 105-108; 1993), where serine 228 (EU numbering; residue 241 Kabat numbering) is converted to proline resulting in an IgG1-like hinge sequence. Accordingly, any of the antibodies may include a stabilizing ‘Adair’ mutation.

[000172] In some embodiments, an antibody is modified, *e.g.*, modified via glycosylation, phosphorylation, sumoylation, and/or (*e.g.*, and) methylation. In some embodiments, an antibody is a glycosylated antibody, which is conjugated to one or more sugar or carbohydrate molecules. In some embodiments, the one or more sugar or carbohydrate molecule are

conjugated to the antibody via N-glycosylation, O-glycosylation, C-glycosylation, glypiation (GPI anchor attachment), and/or (e.g., and) phosphoglycosylation. In some embodiments, the one or more sugar or carbohydrate molecules are monosaccharides, disaccharides, oligosaccharides, or glycans. In some embodiments, the one or more sugar or carbohydrate molecule is a branched oligosaccharide or a branched glycan. In some embodiments, the one or more sugar or carbohydrate molecule includes a mannose unit, a glucose unit, an N-acetylglucosamine unit, an N-acetylgalactosamine unit, a galactose unit, a fucose unit, or a phospholipid unit. In some embodiments, there are about 1-10, about 1-5, about 5-10, about 1-4, about 1-3, or about 2 sugar molecules. In some embodiments, a glycosylated antibody is fully or partially glycosylated. In some embodiments, an antibody is glycosylated by chemical reactions or by enzymatic means. In some embodiments, an antibody is glycosylated in vitro or inside a cell, which may optionally be deficient in an enzyme in the N- or O- glycosylation pathway, e.g. a glycosyltransferase. In some embodiments, an antibody is functionalized with sugar or carbohydrate molecules as described in International Patent Application Publication WO2014065661, published on May 1, 2014, entitled, “*Modified antibody, antibody-conjugate and process for the preparation thereof*”.

[000173] In some embodiments, any one of the anti-TfR1 antibodies described herein may comprise a signal peptide in the heavy and/or (e.g., and) light chain sequence (e.g., a N-terminal signal peptide). In some embodiments, the anti-TfR1 antibody described herein comprises any one of the VH and VL sequences, any one of the IgG heavy chain and light chain sequences, or any one of the F(ab') heavy chain and light chain sequences described herein, and further comprises a signal peptide (e.g., a N-terminal signal peptide). In some embodiments, the signal peptide comprises the amino acid sequence of MGWSCILFLVATATGVHS (SEQ ID NO: 104).

[000174] In some embodiments, an antibody provided herein may have one or more post-translational modifications. In some embodiments, N-terminal cyclization, also called pyroglutamate formation (pyro-Glu), may occur in the antibody at N-terminal Glutamate (Glu) and/or Glutamine (Gln) residues during production. As such, it should be appreciated that an antibody specified as having a sequence comprising an N-terminal glutamate or glutamine residue encompasses antibodies that have undergone pyroglutamate formation resulting from a post-translational modification. In some embodiments, pyroglutamate formation occurs in a heavy chain sequence. In some embodiments, pyroglutamate formation occurs in a light chain sequence.

b. Other Muscle-Targeting Antibodies

[000175] In some embodiments, the muscle-targeting antibody is an antibody that specifically binds hemojuvelin, caveolin-3, Duchenne muscular dystrophy peptide, myosin IIb or CD63. In some embodiments, the muscle-targeting antibody is an antibody that specifically binds a myogenic precursor protein. Exemplary myogenic precursor proteins include, without limitation, ABCG2, M-Cadherin/Cadherin-15, Caveolin-1, CD34, FoxK1, Integrin alpha 7, Integrin alpha 7 beta 1, MYF-5, MyoD, Myogenin, NCAM-1/CD56, Pax3, Pax7, and Pax9. In some embodiments, the muscle-targeting antibody is an antibody that specifically binds a skeletal muscle protein. Exemplary skeletal muscle proteins include, without limitation, alpha-Sarcoglycan, beta-Sarcoglycan, Calpain Inhibitors, Creatine Kinase MM/CKMM, eIF5A, Enolase 2/Neuron-specific Enolase, epsilon-Sarcoglycan, FABP3/H-FABP, GDF-8/Myostatin, GDF-11/GDF-8, Integrin alpha 7, Integrin alpha 7 beta 1, Integrin beta 1/CD29, MCAM/CD146, MyoD, Myogenin, Myosin Light Chain Kinase Inhibitors, NCAM-1/CD56, and Troponin I. In some embodiments, the muscle-targeting antibody is an antibody that specifically binds a smooth muscle protein. Exemplary smooth muscle proteins include, without limitation, alpha-Smooth Muscle Actin, VE-Cadherin, Caldesmon/CALD1, Calponin 1, Desmin, Histamine H2 R, Motilin R/GPR38, Transgelin/TAGLN, and Vimentin. However, it should be appreciated that antibodies to additional targets are within the scope of this disclosure and the exemplary lists of targets provided herein are not meant to be limiting.

c. Antibody Features/Alterations

[000176] In some embodiments, conservative mutations can be introduced into antibody sequences (e.g., CDRs or framework sequences) at positions where the residues are not likely to be involved in interacting with a target antigen (e.g., transferrin receptor), for example, as determined based on a crystal structure. In some embodiments, one, two or more mutations (e.g., amino acid substitutions) are introduced into the Fc region of a muscle-targeting antibody described herein (e.g., in a CH2 domain (residues 231-340 of human IgG1) and/or (e.g., and) CH3 domain (residues 341-447 of human IgG1) and/or (e.g., and) the hinge region, with numbering according to the Kabat numbering system (e.g., the EU index in Kabat)) to alter one or more functional properties of the antibody, such as serum half-life, complement fixation, Fc receptor binding and/or (e.g., and) antigen-dependent cellular cytotoxicity.

[000177] In some embodiments, one, two or more mutations (e.g., amino acid substitutions) are introduced into the hinge region of the Fc region (CH1 domain) such that the number of cysteine residues in the hinge region are altered (e.g., increased or decreased) as described in, e.g., U.S. Pat. No. 5,677,425. The number of cysteine residues in the hinge region of the CH1 domain can be altered to, e.g., facilitate assembly of the light and heavy chains, or to alter (e.g., increase or decrease) the stability of the antibody or to facilitate linker conjugation.

[000178] In some embodiments, one, two or more mutations (*e.g.*, amino acid substitutions) are introduced into the Fc region of a muscle-targeting antibody described herein (*e.g.*, in a CH2 domain (residues 231-340 of human IgG1) and/or (*e.g.*, and) CH3 domain (residues 341-447 of human IgG1) and/or (*e.g.*, and) the hinge region, with numbering according to the Kabat numbering system (*e.g.*, the EU index in Kabat)) to increase or decrease the affinity of the antibody for an Fc receptor (*e.g.*, an activated Fc receptor) on the surface of an effector cell. Mutations in the Fc region of an antibody that decrease or increase the affinity of an antibody for an Fc receptor and techniques for introducing such mutations into the Fc receptor or fragment thereof are known to one of skill in the art. Examples of mutations in the Fc receptor of an antibody that can be made to alter the affinity of the antibody for an Fc receptor are described in, *e.g.*, Smith P et al., (2012) PNAS 109: 6181-6186, U.S. Pat. No. 6,737,056, and International Publication Nos. WO 02/060919; WO 98/23289; and WO 97/34631, which are incorporated herein by reference.

[000179] In some embodiments, one, two or more amino acid mutations (*i.e.*, substitutions, insertions or deletions) are introduced into an IgG constant domain, or FcRn-binding fragment thereof (preferably an Fc or hinge-Fc domain fragment) to alter (*e.g.*, decrease or increase) half-life of the antibody *in vivo*. See, *e.g.*, International Publication Nos. WO 02/060919; WO 98/23289; and WO 97/34631; and U.S. Pat. Nos. 5,869,046, 6,121,022, 6,277,375 and 6,165,745 for examples of mutations that will alter (*e.g.*, decrease or increase) the half-life of an antibody *in vivo*.

[000180] In some embodiments, one, two or more amino acid mutations (*i.e.*, substitutions, insertions or deletions) are introduced into an IgG constant domain, or FcRn-binding fragment thereof (preferably an Fc or hinge-Fc domain fragment) to decrease the half-life of the anti-transferrin receptor antibody *in vivo*. In some embodiments, one, two or more amino acid mutations (*i.e.*, substitutions, insertions or deletions) are introduced into an IgG constant domain, or FcRn-binding fragment thereof (preferably an Fc or hinge-Fc domain fragment) to increase the half-life of the antibody *in vivo*. In some embodiments, the antibodies can have one or more amino acid mutations (*e.g.*, substitutions) in the second constant (CH2) domain (residues 231-340 of human IgG1) and/or (*e.g.*, and) the third constant (CH3) domain (residues 341-447 of human IgG1), with numbering according to the EU index in Kabat (Kabat E A et al., (1991) *supra*). In some embodiments, the constant region of the IgG1 of an antibody described herein comprises a methionine (M) to tyrosine (Y) substitution in position 252, a serine (S) to threonine (T) substitution in position 254, and a threonine (T) to glutamic acid (E) substitution in position 256, numbered according to the EU index as in Kabat. See U.S. Pat. No. 7,658,921, which is incorporated herein by reference. This type of mutant IgG, referred to as "YTE mutant"

has been shown to display fourfold increased half-life as compared to wild-type versions of the same antibody (see Dall'Acqua W F et al., (2006) J Biol Chem 281: 23514-24). In some embodiments, an antibody comprises an IgG constant domain comprising one, two, three or more amino acid substitutions of amino acid residues at positions 251-257, 285-290, 308-314, 385-389, and 428-436, numbered according to the EU index as in Kabat.

[000181] In some embodiments, one, two or more amino acid substitutions are introduced into an IgG constant domain Fc region to alter the effector function(s) of the anti-transferrin receptor antibody. The effector ligand to which affinity is altered can be, for example, an Fc receptor or the C1 component of complement. This approach is described in further detail in U.S. Pat. Nos. 5,624,821 and 5,648,260. In some embodiments, the deletion or inactivation (through point mutations or other means) of a constant region domain can reduce Fc receptor binding of the circulating antibody thereby increasing tumor localization. See, e.g., U.S. Pat. Nos. 5,585,097 and 8,591,886 for a description of mutations that delete or inactivate the constant domain and thereby increase tumor localization. In some embodiments, one or more amino acid substitutions may be introduced into the Fc region of an antibody described herein to remove potential glycosylation sites on Fc region, which may reduce Fc receptor binding (see, e.g., Shields R L et al., (2001) J Biol Chem 276: 6591-604).

[000182] In some embodiments, one or more amino in the constant region of a muscle-targeting antibody described herein can be replaced with a different amino acid residue such that the antibody has altered C1q binding and/or (e.g., and) reduced or abolished complement dependent cytotoxicity (CDC). This approach is described in further detail in U.S. Pat. No. 6,194,551 (Idusogie et al). In some embodiments, one or more amino acid residues in the N-terminal region of the CH2 domain of an antibody described herein are altered to thereby alter the ability of the antibody to fix complement. This approach is described further in International Publication No. WO 94/29351. In some embodiments, the Fc region of an antibody described herein is modified to increase the ability of the antibody to mediate antibody dependent cellular cytotoxicity (ADCC) and/or (e.g., and) to increase the affinity of the antibody for an Fcγ receptor. This approach is described further in International Publication No. WO 00/42072.

[000183] In some embodiments, the heavy and/or (e.g., and) light chain variable domain(s) sequence(s) of the antibodies provided herein can be used to generate, for example, CDR-grafted, chimeric, humanized, or composite human antibodies or antigen-binding fragments, as described elsewhere herein. As understood by one of ordinary skill in the art, any variant, CDR-grafted, chimeric, humanized, or composite antibodies derived from any of the antibodies provided herein may be useful in the compositions and methods described herein and will maintain the ability to specifically bind transferrin receptor, such that the variant, CDR-grafted,

chimeric, humanized, or composite antibody has at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95% or more binding to transferrin receptor relative to the original antibody from which it is derived.

[000184] In some embodiments, the antibodies provided herein comprise mutations that confer desirable properties to the antibodies. For example, to avoid potential complications due to Fab-arm exchange, which is known to occur with native IgG4 mAbs, the antibodies provided herein may comprise a stabilizing ‘Adair’ mutation (Angal S., et al., “A single amino acid substitution abolishes the heterogeneity of chimeric mouse/human (IgG4) antibody,” *Mol Immunol* 30, 105-108; 1993), where serine 228 (EU numbering; residue 241 Kabat numbering) is converted to proline resulting in an IgG1-like hinge sequence. Accordingly, any of the antibodies may include a stabilizing ‘Adair’ mutation.

[000185] As provided herein, antibodies of this disclosure may optionally comprise constant regions or parts thereof. For example, a VL domain may be attached at its C-terminal end to a light chain constant domain like C κ or C λ . Similarly, a VH domain or portion thereof may be attached to all or part of a heavy chain like IgA, IgD, IgE, IgG, and IgM, and any isotype subclass. Antibodies may include suitable constant regions (see, for example, Kabat et al., *Sequences of Proteins of Immunological Interest*, No. 91-3242, National Institutes of Health Publications, Bethesda, Md. (1991)). Therefore, antibodies within the scope of this may disclosure include VH and VL domains, or an antigen binding portion thereof, combined with any suitable constant regions.

ii. Muscle-Targeting Peptides

[000186] Some aspects of the disclosure provide muscle-targeting peptides as muscle-targeting agents. Short peptide sequences (e.g., peptide sequences of 5-20 amino acids in length) that bind to specific cell types have been described. For example, cell-targeting peptides have been described in Vines e., et al., A. “Cell-penetrating and cell-targeting peptides in drug delivery” *Biochim Biophys Acta* 2008, 1786: 126-38; Jarver P., et al., “In vivo biodistribution and efficacy of peptide mediated delivery” *Trends Pharmacol Sci* 2010; 31: 528-35; Samoylova T.I., et al., “Elucidation of muscle-binding peptides by phage display screening” *Muscle Nerve* 1999; 22: 460-6; U.S. Patent No. 6,329,501, issued on December 11, 2001, entitled “METHODS AND COMPOSITIONS FOR TARGETING COMPOUNDS TO MUSCLE”; and Samoylov A.M., et al., “Recognition of cell-specific binding of phage display derived peptides using an acoustic wave sensor.” *Biomol Eng* 2002; 18: 269-72; the entire contents of each of which are incorporated herein by reference. By designing peptides to interact with specific cell surface antigens (e.g., receptors), selectivity for a desired tissue, e.g., muscle, can be achieved. Skeletal muscle-targeting has been investigated and a range of molecular payloads are able to be

delivered. These approaches may have high selectivity for muscle tissue without many of the practical disadvantages of a large antibody or viral particle. Accordingly, in some embodiments, the muscle-targeting agent is a muscle-targeting peptide that is from 4 to 50 amino acids in length. In some embodiments, the muscle-targeting peptide is 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 amino acids in length. Muscle-targeting peptides can be generated using any of several methods, such as phage display.

[000187] In some embodiments, a muscle-targeting peptide may bind to an internalizing cell surface receptor that is overexpressed or relatively highly expressed in muscle cells, e.g. a transferrin receptor, compared with certain other cells. In some embodiments, a muscle-targeting peptide may target, e.g., bind to, a transferrin receptor. In some embodiments, a peptide that targets a transferrin receptor may comprise a segment of a naturally occurring ligand, e.g., transferrin. In some embodiments, a peptide that targets a transferrin receptor is as described in US Patent No. 6,743,893, filed 11/30/2000, "RECEPTOR-MEDIATED UPTAKE OF PEPTIDES THAT BIND THE HUMAN TRANSFERRIN RECEPTOR". In some embodiments, a peptide that targets a transferrin receptor is as described in Kawamoto, M. et al, "A novel transferrin receptor-targeted hybrid peptide disintegrates cancer cell membrane to induce rapid killing of cancer cells." BMC Cancer. 2011 Aug 18;11:359. In some embodiments, a peptide that targets a transferrin receptor is as described in US Patent No. 8,399,653, filed 5/20/2011, "TRANSFERRIN/TRANSFERRIN RECEPTOR-MEDIATED SIRNA DELIVERY".

[000188] As discussed above, examples of muscle targeting peptides have been reported. For example, muscle-specific peptides were identified using phage display library presenting surface heptapeptides. As one example a peptide having the amino acid sequence ASSLNIA (SEQ ID NO: 975) bound to C2C12 murine myotubes *in vitro*, and bound to mouse muscle tissue *in vivo*. Accordingly, in some embodiments, the muscle-targeting agent comprises the amino acid sequence ASSLNIA (SEQ ID NO: 975). This peptide displayed improved specificity for binding to heart and skeletal muscle tissue after intravenous injection in mice with reduced binding to liver, kidney, and brain. Additional muscle-specific peptides have been identified using phage display. For example, a 12 amino acid peptide was identified by phage display library for muscle targeting in the context of treatment for Duchenne muscular dystrophy. See, Yoshida D., et al., "Targeting of salicylate to skin and muscle following topical injections in rats." *Int J Pharm* 2002; 231: 177-84; the entire contents of which are hereby incorporated by reference. Here, a 12 amino acid peptide having the sequence

SKTFNTHPQSTP (SEQ ID NO: 976) was identified and this muscle-targeting peptide showed improved binding to C2C12 cells relative to the ASSLNIA (SEQ ID NO: 975) peptide.

[000189] An additional method for identifying peptides selective for muscle (*e.g.*, skeletal muscle) over other cell types includes *in vitro* selection, which has been described in Ghosh D., et al., “Selection of muscle-binding peptides from context-specific peptide-presenting phage libraries for adenoviral vector targeting” *J Virol* 2005; 79: 13667-72; the entire contents of which are incorporated herein by reference. By pre-incubating a random 12-mer peptide phage display library with a mixture of non-muscle cell types, non-specific cell binders were selected out. Following rounds of selection the 12 amino acid peptide TARGEHKEEELI (SEQ ID NO: 977) appeared most frequently. Accordingly, in some embodiments, the muscle-targeting agent comprises the amino acid sequence TARGEHKEEELI (SEQ ID NO: 977).

[000190] A muscle-targeting agent may be an amino acid-containing molecule or peptide. A muscle-targeting peptide may correspond to a sequence of a protein that preferentially binds to a protein receptor found in muscle cells. In some embodiments, a muscle-targeting peptide contains a high propensity of hydrophobic amino acids, *e.g.* valine, such that the peptide preferentially targets muscle cells. In some embodiments, a muscle-targeting peptide has not been previously characterized or disclosed. These peptides may be conceived of, produced, synthesized, and/or (*e.g.*, and) derivatized using any of several methodologies, *e.g.* phage displayed peptide libraries, one-bead one-compound peptide libraries, or positional scanning synthetic peptide combinatorial libraries. Exemplary methodologies have been characterized in the art and are incorporated by reference (Gray, B.P. and Brown, K.C. “Combinatorial Peptide Libraries: Mining for Cell-Binding Peptides” *Chem Rev.* 2014, 114:2, 1020–1081.; Samoylova, T.I. and Smith, B.F. “Elucidation of muscle-binding peptides by phage display screening.” *Muscle Nerve*, 1999, 22:4. 460-6.). In some embodiments, a muscle-targeting peptide has been previously disclosed (see, *e.g.* Writer M.J. et al. “Targeted gene delivery to human airway epithelial cells with synthetic vectors incorporating novel targeting peptides selected by phage display.” *J. Drug Targeting*. 2004;12:185; Cai, D. “BDNF-mediated enhancement of inflammation and injury in the aging heart.” *Physiol Genomics*. 2006, 24:3, 191-7.; Zhang, L. “Molecular profiling of heart endothelial cells.” *Circulation*, 2005, 112:11, 1601-11.; McGuire, M.J. et al. “In vitro selection of a peptide with high selectivity for cardiomyocytes *in vivo*.” *J Mol Biol.* 2004, 342:1, 171-82.). Exemplary muscle-targeting peptides comprise an amino acid sequence of the following group: CQAQGQLVC (SEQ ID NO: 978), CSERSMNFC (SEQ ID NO: 979), CPKTRRVPC (SEQ ID NO: 980), WLSEAGPVVTVRALRGTSW (SEQ ID NO: 981), ASSLNIA (SEQ ID NO: 975), CMQHSMRVC (SEQ ID NO: 982), and DDTRHWG (SEQ ID NO: 983). In some embodiments, a muscle-targeting peptide may comprise about 2-25

amino acids, about 2-20 amino acids, about 2-15 amino acids, about 2-10 amino acids, or about 2-5 amino acids. Muscle-targeting peptides may comprise naturally-occurring amino acids, e.g. cysteine, alanine, or non-naturally-occurring or modified amino acids. Non-naturally occurring amino acids include β -amino acids, homo-amino acids, proline derivatives, 3-substituted alanine derivatives, linear core amino acids, N-methyl amino acids, and others known in the art. In some embodiments, a muscle-targeting peptide may be linear; in other embodiments, a muscle-targeting peptide may be cyclic, e.g. bicyclic (see, e.g. Silvana, M.G. et al. *Mol. Therapy*, 2018, 26:1, 132–147.).

iii. Muscle-Targeting Receptor Ligands

[000191] A muscle-targeting agent may be a ligand, e.g. a ligand that binds to a receptor protein. A muscle-targeting ligand may be a protein, e.g. transferrin, which binds to an internalizing cell surface receptor expressed by a muscle cell. Accordingly, in some embodiments, the muscle-targeting agent is transferrin, or a derivative thereof that binds to a transferrin receptor. A muscle-targeting ligand may alternatively be a small molecule, e.g. a lipophilic small molecule that preferentially targets muscle cells relative to other cell types. Exemplary lipophilic small molecules that may target muscle cells include compounds comprising cholesterol, cholesteryl, stearic acid, palmitic acid, oleic acid, oleyl, linolene, linoleic acid, myristic acid, sterols, dihydrotestosterone, testosterone derivatives, glycerine, alkyl chains, trityl groups, and alkoxy acids.

iv. Muscle-Targeting Aptamers

[000192] A muscle-targeting agent may be an aptamer, e.g. an RNA aptamer, which preferentially targets muscle cells relative to other cell types. In some embodiments, a muscle-targeting aptamer has not been previously characterized or disclosed. These aptamers may be conceived of, produced, synthesized, and/or (e.g., and) derivatized using any of several methodologies, e.g. Systematic Evolution of Ligands by Exponential Enrichment. Exemplary methodologies have been characterized in the art and are incorporated by reference (Yan, A.C. and Levy, M. “Aptamers and aptamer targeted delivery” *RNA biology*, 2009, 6:3, 316-20.; Germer, K. et al. “RNA aptamers and their therapeutic and diagnostic applications.” *Int. J. Biochem. Mol. Biol.* 2013; 4: 27–40.). In some embodiments, a muscle-targeting aptamer has been previously disclosed (see, e.g. Phillippou, S. et al. “Selection and Identification of Skeletal-Muscle-Targeted RNA Aptamers.” *Mol Ther Nucleic Acids*. 2018, 10:199-214.; Thiel, W.H. et al. “Smooth Muscle Cell-targeted RNA Aptamer Inhibits Neointimal Formation.” *Mol Ther*. 2016, 24:4, 779-87.). Exemplary muscle-targeting aptamers include the A01B RNA aptamer and RNA Apt 14. In some embodiments, an aptamer is a nucleic acid-based aptamer, an

oligonucleotide aptamer or a peptide aptamer. In some embodiments, an aptamer may be about 5-15 kDa, about 5-10 kDa, about 10-15 kDa, about 1-5 Da, about 1-3 kDa, or smaller.

v. Other Muscle-Targeting Agents

[000193] One strategy for targeting a muscle cell (e.g., a skeletal muscle cell) is to use a substrate of a muscle transporter protein, such as a transporter protein expressed on the sarcolemma. In some embodiments, the muscle-targeting agent is a substrate of an influx transporter that is specific to muscle tissue. In some embodiments, the influx transporter is specific to skeletal muscle tissue. Two main classes of transporters are expressed on the skeletal muscle sarcolemma, (1) the adenosine triphosphate (ATP) binding cassette (ABC) superfamily, which facilitate efflux from skeletal muscle tissue and (2) the solute carrier (SLC) superfamily, which can facilitate the influx of substrates into skeletal muscle. In some embodiments, the muscle-targeting agent is a substrate that binds to an ABC superfamily or an SLC superfamily of transporters. In some embodiments, the substrate that binds to the ABC or SLC superfamily of transporters is a naturally-occurring substrate. In some embodiments, the substrate that binds to the ABC or SLC superfamily of transporters is a non-naturally occurring substrate, for example, a synthetic derivative thereof that binds to the ABC or SLC superfamily of transporters.

[000194] In some embodiments, the muscle-targeting agent is any muscle targeting agent described herein (e.g., antibodies, nucleic acids, small molecules, peptides, aptamers, lipids, sugar moieties) that target SLC superfamily of transporters. In some embodiments, the muscle-targeting agent is a substrate of an SLC superfamily of transporters. SLC transporters are either equilibrative or use proton or sodium ion gradients created across the membrane to drive transport of substrates. Exemplary SLC transporters that have high skeletal muscle expression include, without limitation, the SATT transporter (ASCT1; SLC1A4), GLUT4 transporter (SLC2A4), GLUT7 transporter (GLUT7; SLC2A7), ATRC2 transporter (CAT-2; SLC7A2), LAT3 transporter (KIAA0245; SLC7A6), PHT1 transporter (PTR4; SLC15A4), OATP-J transporter (OATP5A1; SLC21A15), OCT3 transporter (EMT; SLC22A3), OCTN2 transporter (FLJ46769; SLC22A5), ENT transporters (ENT1; SLC29A1 and ENT2; SLC29A2), PAT2 transporter (SLC36A2), and SAT2 transporter (KIAA1382; SLC38A2). These transporters can facilitate the influx of substrates into skeletal muscle, providing opportunities for muscle targeting.

[000195] In some embodiments, the muscle-targeting agent is a substrate of an equilibrative nucleoside transporter 2 (ENT2) transporter. Relative to other transporters, ENT2 has one of the highest mRNA expressions in skeletal muscle. While human ENT2 (hENT2) is expressed in most body organs such as brain, heart, placenta, thymus, pancreas, prostate, and kidney, it is especially abundant in skeletal muscle. Human ENT2 facilitates the uptake of its

substrates depending on their concentration gradient. ENT2 plays a role in maintaining nucleoside homeostasis by transporting a wide range of purine and pyrimidine nucleobases. The hENT2 transporter has a low affinity for all nucleosides (adenosine, guanosine, uridine, thymidine, and cytidine) except for inosine. Accordingly, in some embodiments, the muscle-targeting agent is an ENT2 substrate. Exemplary ENT2 substrates include, without limitation, inosine, 2',3'-dideoxyinosine, and calofarabine. In some embodiments, any of the muscle-targeting agents provided herein are associated with a molecular payload (e.g., oligonucleotide payload). In some embodiments, the muscle-targeting agent is covalently linked to the molecular payload. In some embodiments, the muscle-targeting agent is non-covalently linked to the molecular payload.

[000196] In some embodiments, the muscle-targeting agent is a substrate of an organic cation/carnitine transporter (OCTN2), which is a sodium ion-dependent, high affinity carnitine transporter. In some embodiments, the muscle-targeting agent is carnitine, mildronate, acetylcarnitine, or any derivative thereof that binds to OCTN2. In some embodiments, the carnitine, mildronate, acetylcarnitine, or derivative thereof is covalently linked to the molecular payload (e.g., oligonucleotide payload).

[000197] A muscle-targeting agent may be a protein that exists in at least one soluble form that targets muscle cells. In some embodiments, a muscle-targeting protein may be hemojuvelin (also known as repulsive guidance molecule C or hemochromatosis type 2 protein), a protein involved in iron overload and homeostasis. In some embodiments, hemojuvelin may be full length or a fragment, or a mutant with at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98% or at least 99% sequence identity to a functional hemojuvelin protein. In some embodiments, a hemojuvelin mutant may be a soluble fragment, may lack a N-terminal signaling, and/or (e.g., and) lack a C-terminal anchoring domain. In some embodiments, hemojuvelin may be annotated under GenBank RefSeq Accession Numbers NM_001316767.1, NM_145277.4, NM_202004.3, NM_213652.3, or NM_213653.3. It should be appreciated that a hemojuvelin may be of human, non-human primate, or rodent origin.

B. Molecular Payloads

[000198] Some aspects of the disclosure provide molecular payloads, e.g., for modulating a biological outcome, e.g., the transcription of a DNA sequence, the splicing and processing of a RNA sequence, the expression of a protein, or the activity of a protein. In some embodiments, a molecular payload is linked to, or otherwise associated with a muscle-targeting agent. In some embodiments, such molecular payloads are capable of targeting to a muscle cell, e.g., via specifically binding to a nucleic acid or protein in the muscle cell following delivery to the

muscle cell by an associated muscle-targeting agent. It should be appreciated that various types of molecular payloads may be used in accordance with the disclosure. For example, the molecular payload may comprise, or consist of, an oligonucleotide (e.g., antisense oligonucleotide), a peptide (e.g., a peptide that binds a nucleic acid or protein associated with disease in a muscle cell), a protein (e.g., a protein that binds a nucleic acid or protein associated with disease in a muscle cell), or a small molecule (e.g., a small molecule that modulates the function of a nucleic acid or protein associated with disease in a muscle cell). In some embodiments, the molecular payload is an oligonucleotide that comprises a strand having a region of complementarity to a mutated DMD allele. Exemplary molecular payloads are described in further detail herein, however, it should be appreciated that the exemplary molecular payloads provided herein are not meant to be limiting.

i. Oligonucleotides

[000199] Aspects of the disclosure relate to oligonucleotides configured to modulate (e.g., increase) expression of dystrophin, e.g., from a DMD allele. In some embodiments, oligonucleotides provided herein are configured to alter splicing of DMD pre-mRNA to promote expression of dystrophin protein (e.g., a functional truncated dystrophin protein). In some embodiments, oligonucleotides provided herein are configured to promote skipping of one or more exons in DMD, e.g., in a mutated DMD allele, in order to restore the reading frame. In some embodiments, the oligonucleotides allow for functional dystrophin protein expression (e.g., as described in Lee T, Awano H, Yagi M, et al. 2'-O-Methyl RNA/Ethylene-Bridged Nucleic Acid Chimera Antisense Oligonucleotides to Induce Dystrophin Exon 45 Skipping. *Genes*. 2017;8(2):67 and Watanabe N, Nagata T, Satou Y, et al. NS-065/NCNP-01: an antisense oligonucleotide for potential treatment of exon 53 skipping in Duchenne muscular dystrophy. *Mol Ther Nucleic Acids*. 2018;13:442-449). In some embodiments, oligonucleotides provided are configured to promote skipping of exon 45 to produce a shorter but functional version of dystrophin (e.g., containing an in-frame deletion). In some embodiments, oligonucleotides are provided that promote exon 45 skipping (e.g., which may be relevant in a substantial number of patients, including, for example, patients amenable to exon 44 skipping, such as those having deletions in DMD exons 7-44, 12-44, 18-44, 44, 46, 46-47, 46-48, 46-49, 46-51, 46-53, 46-55, 46-57, 46-59, 46-60, 46-67, 46-69, 46-75, or 46-79).

[000200] Table 8 provides non-limiting examples of sequences of oligonucleotides that are useful for targeting DMD, e.g., for exon skipping, and for target sequences within DMD. In some embodiments, an oligonucleotide may comprise any antisense sequence provided in Table 8 or a sequence complementary to a target sequence provided in Table 8.

Table 8. Oligonucleotide sequences for targeting DMD.

SEQ ID NO	Target sequence [†] (5' to 3')	SEQ ID NO	Antisense Sequence [†] (5' to 3')	SEQ ID NO	Antisense Sequence [†] (5' to 3')	Target Site
160	CUUUGCCAGUACA ACUGCAUGUGGU	400	ACCACAUGCAGUU GUACUGGCAAAG	640	ACCACATGCAGTT GTACTGGCAAAG	Intron 44
161	UUGCCAGUACAAC UGCAUGUGGUA	401	UACCACAUGCAGU UGUACUGGCAA	641	TACCACATGCAGT TGTACTGGCAA	Intron 44
162	UUGCCAGUACAAC UGCAUGUGGUAG	402	CUACCACAUGCAG UUGUACUGGCAA	642	CTACCACATGCAG TTGTACTGGCAA	Intron 44
163	UGCCAGUACAACU GCAUGUGGU	403	ACCACAUGCAGUU GUACUGGCA	643	ACCACATGCAGTT GTACTGGCA	Intron 44
164	UGCCAGUACAACU GCAUGUGGUA	404	UACCACAUGCAGU UGUACUGGCA	644	TACCACATGCAGT TGTACTGGCA	Intron 44
165	UGCCAGUACAACU GCAUGUGGUAG	405	CUACCACAUGCAG UUGUACUGGCA	645	CTACCACATGCAG TTGTACTGGCA	Intron 44
166	UGCCAGUACAACU GCAUGUGGUAGC	406	GCUACCACAUGC GUUGUACUGGCA	646	GCTACCACATGCA GTTGTACTGGCA	Intron 44
167	GCCAGUACAACUG CAUGUGGU	407	ACCACAUGCAGUU GUACUGGC	647	ACCACATGCAGTT GTACTGGC	Intron 44
168	GCCAGUACAACUG CAUGUGGUA	408	UACCACAUGCAGU UGUACUGGC	648	TACCACATGCAGT TGTACTGGC	Intron 44
169	GCCAGUACAACUG CAUGUGGUAG	409	CUACCACAUGCAG UUGUACUGGC	649	CTACCACATGCAG TTGTACTGGC	Intron 44
170	GCCAGUACAACUG CAUGUGGUAGC	410	GCUACCACAUGC GUUGUACUGGC	650	GCTACCACATGCA GTTGTACTGGC	Intron 44
171	GCCAGUACAACUG CAUGUGGUAGCA	411	UGCUACCACAUGC AGUUGUACUGGC	651	TGCTACCACATGC AGTTGTACTGGC	Intron 44
172	CCAGUACAACUGC AUGUGGUAG	412	CUACCACAUGCAG UUGUACUGG	652	CTACCACATGCAG TTGTACTGG	Intron 44
173	CCAGUACAACUGC AUGUGGUAGC	413	GCUACCACAUGC GUUGUACUGG	653	GCTACCACATGCA GTTGTACTGG	Intron 44
174	CCAGUACAACUGC AUGUGGUAGCA	414	UGCUACCACAUGC AGUUGUACUGG	654	TGCTACCACATGC AGTTGTACTGG	Intron 44
175	CAGUACAACUGCA UGUGGUAGC	415	GCUACCACAUGC GUUGUACUG	655	GCTACCACATGCA GTTGTACTG	Intron 44
176	CAGUACAACUGCA UGUGGUAGCA	416	UGCUACCACAUGC AGUUGUACUG	656	TGCTACCACATGC AGTTGTACTG	Intron 44
177	AGUACAACUGCAU GUGGUAGC	417	GCUACCACAUGC GUUGUACU	657	GCTACCACATGCA GTTGTACT	Intron 44
178	AGUACAACUGCAU GUGGUAGCA	418	UGCUACCACAUGC AGUUGUACU	658	TGCTACCACATGC AGTTGTACT	Intron 44
179	GUACAACUGCAUG UGGUAGCAC	419	GUGCUACCACAUG CAGUUGUAC	659	GTGCTACCACATG CAGTTGTAC	Intron 44
180	GUACAACUGCAUG UGGUAGCACA	420	UGUGCUACCACAU GCAGUUGUAC	660	TGTGCTACCACAT GCAGTTGTAC	Intron 44
181	AUAAAAAGACAUG GGGCUUCA	421	UGAAGCCCCAUGU CUUUUUUAU	661	TGAAGCCCCATGT CTTTTAT	Intron 44
182	UCUUACAGGAACU CCAGGAUGGCA	422	GCCAUCCUGGAGU UCCUGUAAGA	662	GCCATCCTGGAGT TCCTGTAAGA	Intron 44/exon 45 junction
183	UCUUACAGGAACU CCAGGAUGGCA	423	UGCCAUCCUGGAG UCCUGUAAGA	663	TGCCATCCTGGAG TTCCTGTAAGA	Intron 44/exon 45 junction
184	UCUUACAGGAACU CCAGGAUGGCAU	424	AUGCCAUCCUGGA GUCCUGUAAGA	664	ATGCCATCCTGGA GTTCTGTAAGA	Intron 44/exon 45 junction
185	CUUACAGGAACUC CAGGAUGGCA	425	UGCCAUCCUGGAG UCCUGUAAG	665	TGCCATCCTGGAG TTCCTGTAAG	Intron 44/exon 45 junction
186	CUUACAGGAACUC CAGGAUGGCAU	426	AUGCCAUCCUGGA GUCCUGUAAG	666	ATGCCATCCTGGA GTTCTGTAAG	Intron 44/exon 45 junction
187	CUUACAGGAACUC CAGGAUGGCAU	427	AAUGCCAUCCUGG AGUCCUGUAAG	667	AATGCCATCCTGG AGTTCTGTAAG	Intron 44/exon 45 junction

188	UACAGGAACUCCA GGAUGGC	428	GCCAUCCUGGAGU UCCUGUA	668	GCCATCCTGGAGT TCCTGTA	Intron 44/exon 45 junction
189	UACAGGAACUCCA GGAUGGCA	429	UGCCAUCCUGGAG UCCUGUA	669	TGCCATCCTGGAG TTCCTGTA	Intron 44/exon 45 junction
190	UACAGGAACUCCA GGAUGGCAU	430	AUGCCAUCCUGGA GUUCCUGUA	670	ATGCCATCCTGGA GTTCTGTA	Intron 44/exon 45 junction
191	UACAGGAACUCCA GGAUGGCAUU	431	AAUGCCAUCCUGG AGUUCCUGUA	671	AATGCCATCCTGG AGTTCCTGTA	Intron 44/exon 45 junction
192	UACAGGAACUCCA GGAUGGCAUUGG	432	CCAAUGCCAUCCU GGAGUUCCUGUA	672	CCAATGCCATCCT GGAGTTCCTGTA	Intron 44/exon 45 junction
193	ACAGGAACUCCAG GAUGGCA	433	UGCCAUCCUGGAG UCCUGU	673	TGCCATCCTGGAG TTCCTGT	Intron 44/exon 45 junction
194	ACAGGAACUCCAG GAUGGCAU	434	AUGCCAUCCUGGA GUUCCUGU	674	ATGCCATCCTGGA GTTCTGT	Intron 44/exon 45 junction
195	ACAGGAACUCCAG GAUGGCAUU	435	AAUGCCAUCCUGG AGUUCCUGU	675	AATGCCATCCTGG AGTTCCTGT	Intron 44/exon 45 junction
196	ACAGGAACUCCAG GAUGGCAUUGG	436	CCAAUGCCAUCCU GGAGUUCCUGU	676	CCAATGCCATCCT GGAGTTCCTGT	Intron 44/exon 45 junction
197	ACAGGAACUCCAG GAUGGCAUUGGG	437	CCCAAUGCCAUCC UGGAGUUCCUGU	677	CCCAATGCCATCC TGGAGTTCCTGT	Intron 44/exon 45 junction
198	CAGGAACUCCAGG AUGGCAU	438	AUGCCAUCCUGGA GUUCCUG	678	ATGCCATCCTGGA GTTCTGT	Intron 44/exon 45 junction
199	CAGGAACUCCAGG AUGGCAUU	439	AAUGCCAUCCUGG AGUUCCUG	679	AATGCCATCCTGG AGTTCCTGT	Intron 44/exon 45 junction
200	CAGGAACUCCAGG AUGGCAUUGG	440	CCAAUGCCAUCCU GGAGUUCCUG	680	CCAATGCCATCCT GGAGTTCCTGT	Intron 44/exon 45 junction
201	CAGGAACUCCAGG AUGGCAUUGGG	441	CCCAAUGCCAUCC UGGAGUUCCUG	681	CCCAATGCCATCC TGGAGTTCCTGT	Intron 44/exon 45 junction
202	CAGGAACUCCAGG AUGGCAUUGGGC	442	GCCCAAUGCCAUC CUGGAGUUCCUG	682	GCCCAATGCCATC CTGGAGTTCCTGT	Intron 44/exon 45 junction
203	AGGAACUCCAGGA UGGCAUU	443	AAUGCCAUCCUGG AGUUCCU	683	AATGCCATCCTGG AGTTCCT	Intron 44/exon 45 junction
204	AGGAACUCCAGGA UGGCAUUGG	444	CCAAUGCCAUCCU GGAGUUCCU	684	CCAATGCCATCCT GGAGTTCCT	Intron 44/exon 45 junction
205	AGGAACUCCAGGA UGGCAUUGGG	445	CCCAAUGCCAUCC UGGAGUUCCU	685	CCCAATGCCATCC TGGAGTTCCT	Intron 44/exon 45 junction
206	AGGAACUCCAGGA UGGCAUUGGGC	446	GCCCAAUGCCAUC CUGGAGUUCCU	686	GCCCAATGCCATC CTGGAGTTCCT	Intron 44/exon 45 junction
207	AGGAACUCCAGGA UGGCAUUGGGCA	447	UGCCCAAUGCCA CCUGGAGUUCCU	687	TGCCCAATGCCAT CCTGGAGTTCCT	Intron 44/exon 45 junction
208	GGAACUCCAGGAU GGCAUUGG	448	CCAAUGCCAUCCU GGAGUUC	688	CCAATGCCATCCT GGAGTTC	Intron 44/exon 45 junction
209	GGAACUCCAGGAU GGCAUUGGG	449	CCCAAUGCCAUCC UGGAGUUC	689	CCCAATGCCATCC TGGAGTTC	Intron 44/exon 45 junction
210	GGAACUCCAGGAU GGCAUUGGGCA	450	UGCCCAAUGCCA CCUGGAGUUC	690	TGCCCAATGCCAT CCTGGAGTTC	Intron 44/exon 45 junction
211	GGAACUCCAGGAU GGCAUUGGGCAG	451	CUGCCCAAUGCCA UCCUGGAGUUC	691	CTGCCCAATGCCA TCCTGGAGTTC	Intron 44/exon 45 junction
212	GAACUCCAGGAUG GCAUUGG	452	CCAAUGCCAUCCU GGAGUUC	692	CCAATGCCATCCT GGAGTTC	Exon 45
213	GAACUCCAGGAUG GCAUUGGG	453	CCCAAUGCCAUCC UGGAGUUC	693	CCCAATGCCATCC TGGAGTTC	Exon 45
214	GAACUCCAGGAUG GCAUUGGGC	454	GCCCAAUGCCAUC CUGGAGUUC	694	GCCCAATGCCATC CTGGAGTTC	Exon 45
215	GAACUCCAGGAUG GCAUUGGGCA	455	UGCCCAAUGCCA CCUGGAGUUC	695	TGCCCAATGCCAT CCTGGAGTTC	Exon 45
216	GAACUCCAGGAUG GCAUUGGGCAG	456	CUGCCCAAUGCCA UCCUGGAGUUC	696	CTGCCCAATGCCA TCCTGGAGTTC	Exon 45
217	GAACUCCAGGAUG GCAUUGGGCAGC	457	GCUGCCCAAUGCC AUCCUGGAGUUC	697	GCTGCCCAATGCC ATCCTGGAGTTC	Exon 45

218	AACUCCAGGAUGG CAUUGGG	458	CCCAAUGCCAUC UGGAGUU	698	CCCAATGCCATCC TGGAGTT	Exon 45
219	AACUCCAGGAUGG CAUUGGGC	459	GCCCAAUGCCAUC CUGGAGUU	699	GCCCAATGCCATC CTGGAGTT	Exon 45
220	AACUCCAGGAUGG CAUUGGGCA	460	UGCCCAAUGCCAU CCUGGAGUU	700	TGCCCAATGCCAT CCTGGAGTT	Exon 45
221	AACUCCAGGAUGG CAUUGGGCAG	461	CUGCCCAAUGCCA UCCUGGAGUU	701	CTGCCCAATGCCA TCCTGGAGTT	Exon 45
222	AACUCCAGGAUGG CAUUGGGCAGC	462	GCUGCCCAAUGCC AUCCUGGAGUU	702	GCTGCCCAATGCC ATCCTGGAGTT	Exon 45
223	ACUCCAGGAUGGC AUUGGGC	463	GCCCAAUGCCAUC CUGGAGU	703	GCCCAATGCCATC CTGGAGT	Exon 45
224	ACUCCAGGAUGGC AUUGGGCA	464	UGCCCAAUGCCAU CCUGGAGU	704	TGCCCAATGCCAT CCTGGAGT	Exon 45
225	ACUCCAGGAUGGC AUUGGGCAG	465	CUGCCCAAUGCCA UCCUGGAGU	705	CTGCCCAATGCCA TCCTGGAGT	Exon 45
226	CUCCAGGAUGGCA UUGGGCA	466	UGCCCAAUGCCAU CCUGGAG	706	TGCCCAATGCCAT CCTGGAG	Exon 45
227	CAGAACAUUGAAU GCAACUGGGGA	467	UCCCCAGUUGCAU UCAUGUUCUG	707	TCCCCAGTTGCAT TCAATGTTCTG	Exon 45
228	AGAACAUUGAAUG CAACUGGGGA	468	UCCCCAGUUGCAU UCAUGUUCU	708	TCCCCAGTTGCAT TCAATGTTCT	Exon 45
229	AGAACAUUGAAUG CAACUGGGGAAG	469	CUUCCCCAGUUGC AUUCAUUGUUCU	709	CTTCCCCAGTTGC ATTCAATGTTCT	Exon 45
230	GAACAUUGAAUGC AACUGGGGAAGA	470	UCUCCCCAGUUG CAUUCAUUGUUC	710	TCTTCCCCAGTTG CATTCAATGTTT	Exon 45
231	CAUUGAAUGCAAC UGGGGAAGAAAU	471	AUUUCUCCCCAG UUGCAUUCAAUG	711	ATTTCTTCCCCAG TTGCATTCAATG	Exon 45
232	AUUGAAUGCAACU GGGGAAGAAAU	472	AUUUCUCCCCAG UUGCAUUCAAU	712	ATTTCTTCCCCAG TTGCATTCAAT	Exon 45
233	AUUGAAUGCAACU GGGGAAGAAUA	473	UAUUUCUCCCCA GUUGCAUUCAAU	713	TATTTCTTCCCCA GTTGCATTCAAT	Exon 45
234	UUGAAUGCAACUG GGGAAGAAAU	474	AUUUCUCCCCAG UUGCAUUCAA	714	ATTTCTTCCCCAG TTGCATTCAA	Exon 45
235	UUGAAUGCAACUG GGGAAGAAUA	475	UAUUUCUCCCCA GUUGCAUUCAA	715	TATTTCTTCCCCA GTTGCATTCAA	Exon 45
236	UUGAAUGCAACUG GGGAAGAAUAA	476	UUAUUUCUCCCC AGUUGCAUUCAA	716	TTATTTCTTCCCC AGTTGCATTCAA	Exon 45
237	UGAAUGCAACUGG GGAAGAA	477	UUCUCCCCAGUU GCAUUCA	717	TTCTTCCCCAGTT GCATTCA	Exon 45
238	UGAAUGCAACUGG GGAAGAAAU	478	AUUUCUCCCCAG UUGCAUUCA	718	ATTTCTTCCCCAG TTGCATTCA	Exon 45
239	UGAAUGCAACUGG GGAAGAAUA	479	UAUUUCUCCCCA GUUGCAUUC	719	TATTTCTTCCCCA GTTGCATTCA	Exon 45
240	UGAAUGCAACUGG GGAAGAAUAA	480	UUAUUUCUCCCC AGUUGCAUUC	720	TTATTTCTTCCCC AGTTGCATTCA	Exon 45
241	GAAUGCAACUGGG GAAGAAAU	481	AUUUCUCCCCAG UUGCAUUC	721	ATTTCTTCCCCAG TTGCATT	Exon 45
242	GAAUGCAACUGGG GAAGAAUA	482	UAUUUCUCCCCA GUUGCAUUC	722	TATTTCTTCCCCA GTTGCATT	Exon 45
243	GAAUGCAACUGGG GAAGAAUAA	483	UUAUUUCUCCCC AGUUGCAUUC	723	TTATTTCTTCCCC AGTTGCATT	Exon 45
244	AAUGCAACUGGGG AAGAAUA	484	UAUUUCUCCCCA GUUGCAU	724	TATTTCTTCCCCA GTTGCATT	Exon 45
245	AUGCAACUGGGGA AGAAUA	485	UAUUUCUCCCCA GUUGCAU	725	TATTTCTTCCCCA GTTGCAT	Exon 45
246	AUGCAACUGGGGA AGAAUAA	486	UUAUUUCUCCCC AGUUGCAU	726	TTATTTCTTCCCC AGTTGCAT	Exon 45
247	AUGCAACUGGGGA AGAAUAU	487	AUAUUUCUCCCC CAGUUGCAU	727	ATTATTTCTTCCC CAGTTGCAT	Exon 45
248	AAUUCAGCAAUCC UCAAAAAAAGA	488	UCUGUUUUUGAGG AUUGCUGAAU	728	TCTGTTTTTGAGG ATTGCTGAATT	Exon 45

249	AAUUCAGCAAUCC UCAAAACAGAU	489	AUCUGUUUUUGAG GAUUGCUGAAU	729	ATCTGTTTTTGAG GATTGCTGAATT	Exon 45
250	AUUCAGCAAUCCU CAAAACAG	490	CUGUUUUUGAGGA UUGCUGAAU	730	CTGTTTTTGAGGA TTGCTGAAT	Exon 45
251	AUUCAGCAAUCCU CAAAACAGA	491	UCUGUUUUUGAGG AUUGCUGAAU	731	TCTGTTTTTGAGG ATTGCTGAAT	Exon 45
252	AUUCAGCAAUCCU CAAAACAGAU	492	AUCUGUUUUUGAG GAUUGCUGAAU	732	ATCTGTTTTTGAG GATTGCTGAAT	Exon 45
253	AUUCAGCAAUCCU CAAAACAGAU	493	CAUCUGUUUUUGA GGAUUGCUGAAU	733	CATCTGTTTTTGA GGATTGCTGAAT	Exon 45
254	UUCAGCAAUCCUC AAAAACAGA	494	UCUGUUUUUGAGG AUUGCUGAA	734	TCTGTTTTTGAGG ATTGCTGAA	Exon 45
255	UUCAGCAAUCCUC AAAAACAGAU	495	AUCUGUUUUUGAG GAUUGCUGAA	735	ATCTGTTTTTGAG GATTGCTGAA	Exon 45
256	UUCAGCAAUCCUC AAAAACAGAU	496	CAUCUGUUUUUGA GGAUUGCUGAA	736	CATCTGTTTTTGA GGATTGCTGAA	Exon 45
257	UCAGCAAUCCUCA AAAACAG	497	CUGUUUUUGAGGA UUGCUGA	737	CTGTTTTTGAGGA TTGCTGA	Exon 45
258	UCAGCAAUCCUCA AAAACAGA	498	UCUGUUUUUGAGG AUUGCUGA	738	TCTGTTTTTGAGG ATTGCTGA	Exon 45
259	UCAGCAAUCCUCA AAAACAGAU	499	AUCUGUUUUUGAG GAUUGCUGA	739	ATCTGTTTTTGAG GATTGCTGA	Exon 45
260	UCAGCAAUCCUCA AAAACAGAU	500	CAUCUGUUUUUGA GGAUUGCUGA	740	CATCTGTTTTTGA GGATTGCTGA	Exon 45
261	CAGCAAUCCUCA AAACAGA	501	UCUGUUUUUGAGG AUUGCUG	741	TCTGTTTTTGAGG ATTGCTG	Exon 45
262	CAGCAAUCCUCA AAACAGAU	502	AUCUGUUUUUGAG GAUUGCUG	742	ATCTGTTTTTGAG GATTGCTG	Exon 45
263	CAGCAAUCCUCA AAACAGAU	503	CAUCUGUUUUUGA GGAUUGCUG	743	CATCTGTTTTTGA GGATTGCTG	Exon 45
264	AGCAAUCCUCA AACAGAU	504	AUCUGUUUUUGAG GAUUGCUG	744	ATCTGTTTTTGAG GATTGCT	Exon 45
265	AGCAAUCCUCA AACAGAU	505	CAUCUGUUUUUGA GGAUUGCUG	745	CATCTGTTTTTGA GGATTGCT	Exon 45
266	GCAAUCCUCA ACAGAU	506	GCAUCUGUUUUUG AGGAUUGC	746	GCACTGTTTTTGA AGGATTGC	Exon 45
267	GCAAUCCUCA ACAGAU	507	GGCAUCUGUUUU GAGGAUUGC	747	GGCATCTGTTTT GAGGATTGC	Exon 45
268	GCAAUCCUCA ACAGAU	508	UGGCAUCUGUUUU UGAGGAUUGC	748	TGGCATCTGTTTT TGAGGATTGC	Exon 45
269	CAAUCCUCA CAGAU	509	GGCAUCUGUUUU GAGGAUUG	749	GGCATCTGTTTT GAGGATTG	Exon 45
270	CAAUCCUCA CAGAU	510	UGGCAUCUGUUUU UGAGGAUUG	750	TGGCATCTGTTTT TGAGGATTG	Exon 45
271	CAAUCCUCA CAGAU	511	UACUGGCAUCUGU UUUUGAGGAUUG	751	TACTGGCATCTGT TTTTGAGGATTG	Exon 45
272	AAUCCUCA AGAUGCC	512	GGCAUCUGUUUU GAGGAUUG	752	GGCATCTGTTTT GAGGATT	Exon 45
273	AAUCCUCA AGAUGCC	513	UGGCAUCUGUUUU UGAGGAUUG	753	TGGCATCTGTTTT TGAGGATT	Exon 45
274	AAUCCUCA AGAUGCC	514	UACUGGCAUCUGU UUUUGAGGAUUG	754	TACTGGCATCTGT TTTTGAGGATT	Exon 45
275	AAUCCUCA AGAUGCC	515	AUACUGGCAUCUG UUUUUGAGGAUUG	755	ATACTGGCATCTG TTTTTGAGGATT	Exon 45
276	AUCCUCA GAUGCCA	516	UGGCAUCUGUUUU UGAGGAUUG	756	TGGCATCTGTTTT TGAGGAT	Exon 45
277	AUCCUCA GAUGCCA	517	UACUGGCAUCUGU UUUUUGAGGAUUG	757	TACTGGCATCTGT TTTTGAGGAT	Exon 45
278	AUCCUCA GAUGCCA	518	AUACUGGCAUCUG UUUUUGAGGAUUG	758	ATACTGGCATCTG TTTTTGAGGAT	Exon 45
279	AUCCUCA GAUGCCA	519	AAUACUGGCAUCU GUUUUGAGGAUUG	759	AATACTGGCATCT GTTTTTGAGGAT	Exon 45

280	UCCUCAAAAAACAG AUGCCAGUA	520	UACUGGCAUCUGU UUUUGAGGA	760	TACTGGCATCTGT TTTTGAGGA	Exon 45
281	UCCUCAAAAAACAG AUGCCAGUAU	521	AUACUGGCAUCUG UUUUUGAGGA	761	ATACTGGCATCTG TTTTTGAGGA	Exon 45
282	UCCUCAAAAAACAG AUGCCAGUAU	522	AAUACUGGCAUCU GUUUUUGAGGA	762	AATACTGGCATCT GTTTTTGAGGA	Exon 45
283	CCUCAAAAAACAGA UGCCAGUA	523	UACUGGCAUCUGU UUUUGAGG	763	TACTGGCATCTGT TTTTGAGG	Exon 45
284	CCUCAAAAAACAGA UGCCAGUAU	524	AUACUGGCAUCUG UUUUUGAGG	764	ATACTGGCATCTG TTTTTGAGG	Exon 45
285	CCUCAAAAAACAGA UGCCAGUAU	525	AAUACUGGCAUCU GUUUUUGAGG	765	AATACTGGCATCT GTTTTTGAGG	Exon 45
286	CCUCAAAAAACAGA UGCCAGUAUUCU	526	AGAAUACUGGCAU CUGUUUUUGAGG	766	AGAATACTGGCAT CTGTTTTTGAGG	Exon 45
287	CUCAAAAAACAGAU GCCAGUA	527	UACUGGCAUCUGU UUUUGAG	767	TACTGGCATCTGT TTTTGAG	Exon 45
288	CUCAAAAAACAGAU GCCAGUAU	528	AUACUGGCAUCUG UUUUUGAG	768	ATACTGGCATCTG TTTTTGAG	Exon 45
289	CUCAAAAAACAGAU GCCAGUAU	529	AAUACUGGCAUCU GUUUUUGAG	769	AATACTGGCATCT GTTTTTGAG	Exon 45
290	CUCAAAAAACAGAU GCCAGUAUUCU	530	AGAAUACUGGCAU CUGUUUUUGAG	770	AGAATACTGGCAT CTGTTTTTGAG	Exon 45
291	CUCAAAAAACAGAU GCCAGUAUUCUA	531	UAGAAUACUGGCA UCUGUUUUUGAG	771	TAGAATACTGGCA TCTGTTTTTGAG	Exon 45
292	UCAAAAAACAGAU CCAGUAU	532	AUACUGGCAUCUG UUUUUGA	772	ATACTGGCATCTG TTTTGA	Exon 45
293	UCAAAAAACAGAU CCAGUAU	533	AAUACUGGCAUCU GUUUUUGA	773	AATACTGGCATCT GTTTTGA	Exon 45
294	UCAAAAAACAGAU CCAGUAUUCU	534	AGAAUACUGGCAU CUGUUUUUGA	774	AGAATACTGGCAT CTGTTTTGA	Exon 45
295	UCAAAAAACAGAU CCAGUAUUCUA	535	UAGAAUACUGGCA UCUGUUUUUGA	775	TAGAATACTGGCA TCTGTTTTGA	Exon 45
296	UCAAAAAACAGAU CCAGUAUUCUAC	536	GUAGAAUACUGGC AUCUGUUUUUGA	776	GTAGAATACTGGC ATCTGTTTTGA	Exon 45
297	CAAAAAACAGAU CAGUAUUCU	537	AGAAUACUGGCAU CUGUUUUUG	777	AGAATACTGGCAT CTGTTTTG	Exon 45
298	CAAAAAACAGAU CAGUAUUCUA	538	UAGAAUACUGGCA UCUGUUUUUG	778	TAGAATACTGGCA TCTGTTTTG	Exon 45
299	CAAAAAACAGAU CAGUAUUCUAC	539	GUAGAAUACUGGC AUCUGUUUUUG	779	GTAGAATACTGGC ATCTGTTTTG	Exon 45
300	CAAAAAACAGAU CAGUAUUCUACA	540	UGUAGAAUACUGG CAUCUGUUUUUG	780	TGTAGAATACTGG CATCTGTTTTG	Exon 45
301	AAAAACAGAU AGUAUUCUAC	541	GUAGAAUACUGGC AUCUGUUUUU	781	GTAGAATACTGGC ATCTGTTTTT	Exon 45
302	AAAAACAGAU AGUAUUCUACA	542	UGUAGAAUACUGG CAUCUGUUUUU	782	TGTAGAATACTGG CATCTGTTTTT	Exon 45
303	AAAAACAGAU AGUAUUCUACAG	543	CUGUAGAAUACUG GCAUCUGUUUUU	783	CTGTAGAATACTG GCATCTGTTTTT	Exon 45
304	AAAACAGAU GUUUCUAC	544	GUAGAAUACUGGC AUCUGUUUU	784	GTAGAATACTGGC ATCTGTTTTT	Exon 45
305	AAAACAGAU GUUUCUACA	545	UGUAGAAUACUGG CAUCUGUUUU	785	TGTAGAATACTGG CATCTGTTTTT	Exon 45
306	AAAACAGAU GUUUCUACAG	546	CUGUAGAAUACUG GCAUCUGUUUU	786	CTGTAGAATACTG GCATCTGTTTTT	Exon 45
307	AAAACAGAU GUUUCUACAGG	547	CCUGUAGAAUACU GGCAUCUGUUUU	787	CCTGTAGAATACT GGCATCTGTTTTT	Exon 45
308	AAACAGAU UAUUCUAC	548	GUAGAAUACUGGC AUCUGUUU	788	GTAGAATACTGGC ATCTGTTT	Exon 45
309	AAACAGAU UAUUCUACA	549	UGUAGAAUACUGG CAUCUGUUU	789	TGTAGAATACTGG CATCTGTTT	Exon 45
310	AAACAGAU UAUUCUACAG	550	CUGUAGAAUACUG GCAUCUGUUU	790	CTGTAGAATACTG GCATCTGTTT	Exon 45

311	AAACAGAUGCCAG UAUUCUACAGG	551	CCUGUAGAAUACU GGCAUCUGUUU	791	CCTGTAGAATACT GGCATCTGTTT	Exon 45
312	AAACAGAUGCCAG UAUUCUACAGGA	552	UCCUGUAGAAUAC UGGCAUCUGUUU	792	TCCTGTAGAATAC TGGCATCTGTTT	Exon 45
313	AACAGAUGCCAGU AUUCUAC	553	GUAGAAUACUGGC AUCUGUU	793	GTAGAATACTGGC ATCTGTT	Exon 45
314	AACAGAUGCCAGU AUUCUACA	554	UGUAGAAUACUGG CAUCUGUU	794	TGTAGAATACTGG CATCTGTT	Exon 45
315	AACAGAUGCCAGU AUUCUACAG	555	CUGUAGAAUACUG GCAUCUGUU	795	CTGTAGAATACTG GCATCTGTT	Exon 45
316	AACAGAUGCCAGU AUUCUACAGG	556	CCUGUAGAAUACU GGCAUCUGUU	796	CCTGTAGAATACT GGCATCTGTT	Exon 45
317	AACAGAUGCCAGU AUUCUACAGGA	557	UCCUGUAGAAUAC UGGCAUCUGUU	797	TCCTGTAGAATAC TGGCATCTGTT	Exon 45
318	AACAGAUGCCAGU AUUCUACAGGAA	558	UCCUGUAGAAUA CUGGCAUCUGUU	798	TTCCTGTAGAATA CTGGCATCTGTT	Exon 45
319	ACAGAUGCCAGUA UUCUACA	559	UGUAGAAUACUGG CAUCUGU	799	TGTAGAATACTGG CATCTGT	Exon 45
320	ACAGAUGCCAGUA UUCUACAG	560	CUGUAGAAUACUG GCAUCUGU	800	CTGTAGAATACTG GCATCTGT	Exon 45
321	ACAGAUGCCAGUA UUCUACAGG	561	CCUGUAGAAUACU GGCAUCUGU	801	CCTGTAGAATACT GGCATCTGT	Exon 45
322	ACAGAUGCCAGUA UUCUACAGGA	562	UCCUGUAGAAUAC UGGCAUCUGU	802	TCCTGTAGAATAC TGGCATCTGT	Exon 45
323	ACAGAUGCCAGUA UUCUACAGGAA	563	UCCUGUAGAAUA CUGGCAUCUGU	803	TTCCTGTAGAATA CTGGCATCTGT	Exon 45
324	CAGAUGCCAGUAU UCUACAGGA	564	UCCUGUAGAAUAC UGGCAUCUG	804	TCCTGTAGAATAC TGGCATCTG	Exon 45
325	CAGAUGCCAGUAU UCUACAGGAA	565	UCCUGUAGAAUA CUGGCAUCUG	805	TTCCTGTAGAATA CTGGCATCTG	Exon 45
326	CAGAUGCCAGUAU UCUACAGGAAAA	566	UUUCCUGUAGAA UACUGGCAUCUG	806	TTTTCTGTAGAA TACTGGCATCTG	Exon 45
327	AGAUGCCAGUAUU CUACAGGAA	567	UCCUGUAGAAUA CUGGCAUCU	807	TTCCTGTAGAATA CTGGCATCT	Exon 45
328	AGAUGCCAGUAUU CUACAGGAAAA	568	UUUCCUGUAGAA UACUGGCAUCU	808	TTTTCTGTAGAA TACTGGCATCT	Exon 45
329	AGAUGCCAGUAUU CUACAGGAAAA	569	UUUUCCUGUAGA AUACUGGCAUCU	809	TTTTCTGTAGAA TACTGGCATCT	Exon 45
330	GAUGCCAGUAUUC UACAGGAAAA	570	UUUUCCUGUAGAA UACUGGCAUC	810	TTTTCTGTAGAA TACTGGCATC	Exon 45
331	GAUGCCAGUAUUC UACAGGAAAA	571	UUUUCCUGUAGAA AUACUGGCAUC	811	TTTTCTGTAGAA TACTGGCATC	Exon 45
332	GAUGCCAGUAUUC UACAGGAAAAAU	572	AUUUUCCUGUAG AAUACUGGCAUC	812	ATTTTCTGTAG AATACTGGCATC	Exon 45
333	CAGAAAAAGAGG UAGGGCGACA	573	UGUCGCCCUACCU CUUUUUUCUG	813	TGTCGCCCTACCT CTTTTTTCTG	Exon 45/intron 45 junction
334	CAGAAAAAGAGG UAGGGCGACAG	574	CUGUCGCCCUACC UCUUUUUCUG	814	CTGTCGCCCTACC TCTTTTTTCTG	Exon 45/intron 45 junction
335	CAGAAAAAGAGG UAGGGCGACAGA	575	UCUGUCGCCCUAC CUCUUUUUCUG	815	TCTGTCGCCCTAC CTTTTTTTCTG	Exon 45/intron 45 junction
336	AGAAAAAGAGGU AGGGCGACA	576	UGUCGCCCUACCU CUUUUUUCU	816	TGTCGCCCTACCT CTTTTTTCT	Exon 45/intron 45 junction
337	AGAAAAAGAGGU AGGGCGACAG	577	CUGUCGCCCUACC UCUUUUUCU	817	CTGTCGCCCTACC TCTTTTTTCT	Exon 45/intron 45 junction
338	AGAAAAAGAGGU AGGGCGACAGA	578	UCUGUCGCCCUAC CUCUUUUUCU	818	TCTGTCGCCCTAC CTTTTTTTCT	Exon 45/intron 45 junction
339	AGAAAAAGAGGU AGGGCGACAGAU	579	AUCUGUCGCCCUA CCUCUUUUUCU	819	ATCTGTCGCCCTA CCTTTTTTTCT	Exon 45/intron 45 junction
340	GAAAAAGAGGUA GGGCGACA	580	UGUCGCCCUACCU CUUUUUUC	820	TGTCGCCCTACCT CTTTTTTC	Exon 45/intron 45 junction
341	GAAAAAGAGGUA GGGCGACAG	581	CUGUCGCCCUACC UCUUUUUC	821	CTGTCGCCCTACC TCTTTTTTC	Exon 45/intron 45 junction

342	GAAAAAGAGGUA GGGCGACAGA	582	UCUGUCGCCCUAC CUCUUUUUUC	822	TCTGTCGCCCTAC CTCTTTTTTC	Exon 45/intron 45 junction
343	GAAAAAGAGGUA GGGCGACAGAU	583	AUCUGUCGCCCUA CCUCUUUUUUC	823	ATCTGTCGCCCTA CCTCTTTTTTC	Exon 45/intron 45 junction
344	GAAAAAGAGGUA GGGCGACAGAUC	584	GAUCUGUCGCCCU ACCUCUUUUUUC	824	GATCTGTCGCCCT ACCTCTTTTTTC	Exon 45/intron 45 junction
345	AAAAAAGAGGUAG GGCGACA	585	UGUCGCCCUACCU CUUUUUU	825	TGTCGCCCTACCT CTTTTTT	Exon 45/intron 45 junction
346	AAAAAAGAGGUAG GGCGACAG	586	CUGUCGCCCUACC UCUUUUUU	826	CTGTCGCCCTACC TCTTTTTT	Exon 45/intron 45 junction
347	AAAAAAGAGGUAG GGCGACAGA	587	UCUGUCGCCCUAC CUCUUUUUU	827	TCTGTCGCCCTAC CTCTTTTTT	Exon 45/intron 45 junction
348	AAAAAAGAGGUAG GGCGACAGAU	588	AUCUGUCGCCCUA CCUCUUUUUU	828	ATCTGTCGCCCTA CCTCTTTTTT	Exon 45/intron 45 junction
349	AAAAAAGAGGUAG GGCGACAGAUC	589	GAUCUGUCGCCCU ACCUCUUUUUU	829	GATCTGTCGCCCT ACCTCTTTTTT	Exon 45/intron 45 junction
350	AAAAAAGAGGUAG GGCGACAGAUCU	590	AGAUCUGUCGCCC UACCUCUUUUUU	830	AGATCTGTCGCCC TACCTCTTTTTT	Exon 45/intron 45 junction
351	AAAAAGAGGUAGG GCGACAG	591	CUGUCGCCCUACC UCUUUUU	831	CTGTCGCCCTACC TCTTTTT	Exon 45/intron 45 junction
352	AAAAAGAGGUAGG GCGACAGA	592	UCUGUCGCCCUAC CUCUUUUU	832	TCTGTCGCCCTAC CTCTTTTT	Exon 45/intron 45 junction
353	AAAAAGAGGUAGG GCGACAGAU	593	AUCUGUCGCCCUA CCUCUUUUU	833	ATCTGTCGCCCTA CCTCTTTTT	Exon 45/intron 45 junction
354	AAAAAGAGGUAGG GCGACAGAUC	594	GAUCUGUCGCCCU ACCUCUUUUU	834	GATCTGTCGCCCT ACCTCTTTTT	Exon 45/intron 45 junction
355	AAAAAGAGGUAGG GCGACAGAUCU	595	AGAUCUGUCGCCC UACCUCUUUUU	835	AGATCTGTCGCCC TACCTCTTTTT	Exon 45/intron 45 junction
356	AAAAGAGGUAGGG CGACAGA	596	UCUGUCGCCCUAC CUCUUUU	836	TCTGTCGCCCTAC CTCTTTT	Exon 45/intron 45 junction
357	AAAAGAGGUAGGG CGACAGAU	597	AUCUGUCGCCCUA CCUCUUUU	837	ATCTGTCGCCCTA CCTCTTTT	Exon 45/intron 45 junction
358	AAAAGAGGUAGGG CGACAGAUC	598	GAUCUGUCGCCCU ACCUCUUUU	838	GATCTGTCGCCCT ACCTCTTTT	Exon 45/intron 45 junction
359	AAAAGAGGUAGGG CGACAGAUCU	599	AGAUCUGUCGCCC UACCUCUUUU	839	AGATCTGTCGCCC TACCTCTTTT	Exon 45/intron 45 junction
360	AAAGAGGUAGGGC GACAGAU	600	AUCUGUCGCCCUA CCUCUUU	840	ATCTGTCGCCCTA CCTCTTT	Exon 45/intron 45 junction
361	AAAGAGGUAGGGC GACAGAUC	601	GAUCUGUCGCCCU ACCUCUUU	841	GATCTGTCGCCCT ACCTCTTT	Exon 45/intron 45 junction
362	AAAGAGGUAGGGC GACAGAUCU	602	AGAUCUGUCGCCC UACCUCUUU	842	AGATCTGTCGCCC TACCTCTT	Exon 45/intron 45 junction
363	AAGAGGUAGGGCG ACAGAUC	603	GAUCUGUCGCCCU ACCUCUU	843	GATCTGTCGCCCT ACCTCTT	Exon 45/intron 45 junction
364	AAGAGGUAGGGCG ACAGAUCU	604	AGAUCUGUCGCCC UACCUCU	844	AGATCTGTCGCCC TACCTCT	Exon 45/intron 45 junction
365	AGAGGUAGGGCGA CAGAUCU	605	AGAUCUGUCGCCC UACCUCU	845	AGATCTGTCGCCC TACCTCT	Exon 45/intron 45 junction
366	AGAGGUAGGGCGA CAGAUCUAAUAG	606	CUAUUAGAUCUGU CGCCCUACCUCU	846	CTATTAGATCTGT CGCCCTACCTCT	Exon 45/intron 45 junction
367	GAGGUAGGGCGAC AGAUCUAAUAG	607	CUAUUAGAUCUGU CGCCCUACCUC	847	CTATTAGATCTGT CGCCCTACCTC	Exon 45/intron 45 junction
368	GAGGUAGGGCGAC AGAUCUAAUAGG	608	CUAUUAGAUCUG UCGCCCUACCUC	848	CCTATTAGATCTG TCGCCCTACCTC	Exon 45/intron 45 junction
369	AGGUAGGGCGACA GAUCUAAUAG	609	CUAUUAGAUCUGU CGCCCUACCUC	849	CTATTAGATCTGT CGCCCTACCT	Exon 45/intron 45 junction
370	AGGUAGGGCGACA GAUCUAAUAGG	610	CUAUUAGAUCUG UCGCCCUACCUC	850	CCTATTAGATCTG TCGCCCTACCT	Exon 45/intron 45 junction
371	AGGUAGGGCGACA GAUCUAAUAGGA	611	UCCUAUAGAUCU GUCGCCCUACCUC	851	TCCTATTAGATCT GTCGCCCTACCT	Exon 45/intron 45 junction

372	GGUAGGGCGACAG AUCUAAUAG	612	CUAUUAGAUCUGU CGCCCUACC	852	CTATTAGATCTGT CGCCCTACC	Exon 45/intron 45 junction
373	GGUAGGGCGACAG AUCUAAUAGG	613	CCUAUUAGAUCUG UCGCCCUACC	853	CCTATTAGATCTG TCGCCCTACC	Exon 45/intron 45 junction
374	GGUAGGGCGACAG AUCUAAUAGGA	614	UCCUAUUAGAUCU GUCGCCCUACC	854	TCCTATTAGATCT GTCGCCCTACC	Exon 45/intron 45 junction
375	GGUAGGGCGACAG AUCUAAUAGGAA	615	UCCUAUUAGAUC UGUCGCCCUACC	855	TTCCTATTAGATC TGTCGCCCTACC	Exon 45/intron 45 junction
376	GUAGGGCGACAGA UCUAAUAG	616	CUAUUAGAUCUGU CGCCCUAC	856	CTATTAGATCTGT CGCCCTAC	Intron 45
377	GUAGGGCGACAGA UCUAAUAGG	617	CCUAUUAGAUCUG UCGCCCUAC	857	CCTATTAGATCTG TCGCCCTAC	Intron 45
378	GUAGGGCGACAGA UCUAAUAGGA	618	UCCUAUUAGAUCU GUCGCCCUAC	858	TCCTATTAGATCT GTCGCCCTAC	Intron 45
379	GUAGGGCGACAGA UCUAAUAGGAA	619	UCCUAUUAGAUC UGUCGCCCUAC	859	TTCCTATTAGATC TGTCGCCCTAC	Intron 45
380	GUAGGGCGACAGA UCUAAUAGGAAU	620	AUCCUAUUAGAU CUGUCGCCCUAC	860	ATTCTATTAGAT CTGTGCCCTAC	Intron 45
381	UAGGGCGACAGAU CUAAUAGGA	621	UCCUAUUAGAUCU GUCGCCCUA	861	TCCTATTAGATCT GTCGCCCTA	Intron 45
382	UAGGGCGACAGAU CUAAUAGGAA	622	UCCUAUUAGAUC UGUCGCCCUA	862	TTCCTATTAGATC TGTCGCCCTA	Intron 45
383	UAGGGCGACAGAU CUAAUAGGAAU	623	AUCCUAUUAGAU CUGUCGCCCUA	863	ATTCTATTAGAT CTGTGCCCTA	Intron 45
384	AGGGCGACAGAU UAAUAGGA	624	UCCUAUUAGAUCU GUCGCCCU	864	TCCTATTAGATCT GTCGCCCT	Intron 45
385	AGGGCGACAGAU UAAUAGGAA	625	UCCUAUUAGAUC UGUCGCCCU	865	TTCCTATTAGATC TGTCGCCCT	Intron 45
386	AGGGCGACAGAU UAAUAGGAAU	626	AUCCUAUUAGAU CUGUCGCCCU	866	ATTCTATTAGAT CTGTGCCCT	Intron 45
387	GGGCGACAGAU AAUAGGA	627	UCCUAUUAGAUCU GUCGCC	867	TCCTATTAGATCT GTCGCC	Intron 45
388	GGGCGACAGAU AAUAGGAA	628	UCCUAUUAGAUC UGUCGCC	868	TTCCTATTAGATC TGTCGCC	Intron 45
389	GGGCGACAGAU AAUAGGAAU	629	AUCCUAUUAGAU CUGUCGCC	869	ATTCTATTAGAT CTGTGCC	Intron 45
390	AGAUUAUAGCAG GGUGAAAG	630	CUUUCACCCUGCU UAUAAUCU	870	CTTTCACCCTGCT TATAATCT	Intron 45
391	AGAUUAUAGCAG GGUGAAAGG	631	CCUUCACCCUGC UUAUAAUCU	871	CCTTTCACCCTGC TTATAATCT	Intron 45
392	AGAUUAUAGCAG GGUGAAAGGC	632	GCCUUCACCCUG CUUAUAAUCU	872	GCCTTTCACCCTG CTTATAATCT	Intron 45
393	AGAUUAUAGCAG GGUGAAAGGCA	633	UGCCUUCACCCU GCUUAUAAUCU	873	TGCCTTTCACCCT GCTTATAATCT	Intron 45
394	AGAUUAUAGCAG GGUGAAAGGCAC	634	GUGCCUUCACCC UGC UUAUAAUCU	874	GTGCCTTTCACCC TGCTTATAATCT	Intron 45
395	GAUUAUAAGCAGG GUGAAAG	635	CUUUCACCCUGCU UAUAAUC	875	CTTTCACCCTGCT TATAATC	Intron 45
396	GAUUAUAAGCAGG GUGAAAGG	636	CCUUCACCCUGC UUAUAAUC	876	CCTTTCACCCTGC TTATAATC	Intron 45
397	GAUUAUAAGCAGG GUGAAAGGC	637	GCCUUCACCCUG CUUAUAAUC	877	GCCTTTCACCCTG CTTATAATC	Intron 45
398	GAUUAUAAGCAGG GUGAAAGGCA	638	UGCCUUCACCCU GCUUAUAAUC	878	TGCCTTTCACCCT GCTTATAATC	Intron 45
399	GAUUAUAAGCAGG GUGAAAGGCAC	639	GUGCCUUCACCC UGC UUAUAAUC	879	GTGCCTTTCACCC TGCTTATAATC	Intron 45

† Each thymine base (T) in any one of the oligonucleotides and/or target sequences provided in Table 8 may independently and optionally be replaced with a uracil base (U), and/or each U may independently and optionally be replaced with a T. Target sequences listed in Table 8 contain U's, but binding of a DMD-targeting oligonucleotide to RNA and/or DNA is contemplated.

[000201] In some embodiments, an oligonucleotide useful for targeting DMD (*e.g.*, for exon skipping) targets a region of a DMD sequence. In some embodiments, an oligonucleotide useful for targeting DMD (*e.g.*, for exon skipping) targets a region of a DMD RNA (*e.g.*, the Dp427m transcript of SEQ ID NO: 130). In some embodiments, an oligonucleotide useful for targeting DMD (*e.g.*, for exon skipping) comprises a region of complementarity to a DMD RNA (*e.g.*, the Dp427m transcript of SEQ ID NO: 130). In some embodiments, an oligonucleotide useful for targeting DMD (*e.g.*, for exon skipping) comprises a region of complementarity to an exon of a DMD RNA (*e.g.*, SEQ ID NO: 131, 954, or 972). In some embodiments, an oligonucleotide useful for targeting DMD (*e.g.*, for exon skipping) comprises a region of complementarity to an intron of a DMD RNA (*e.g.*, SEQ ID NO: 958 or 967). In some embodiments, an oligonucleotide useful for targeting DMD (*e.g.*, for exon skipping) comprises a region of complementarity to a portion of a DMD sequence (*e.g.*, a sequence provided by any one of SEQ ID NOs: 955-957, 959-966, 968-971, and 973). Examples of DMD sequences are provided below. Each of the DMD sequences provided below include thymine nucleotides (T's), but it should be understood that each sequence can represent a DNA sequence or an RNA sequence in which any or all of the T's would be replaced with uracil nucleotides (U's).

[000202] *Homo sapiens* dystrophin (DMD), transcript variant Dp427m, mRNA (NCBI Reference Sequence: NM_004006.2)

TCTTGGCATCAGTTACTGTGTTGACTCACTCAGTGTGGGATCACTCACTTTCCCCTACAGGACTCAGATCTGGGAGGCAATTACCTTCGGAGAAAAACGAATAGGAAAACTGAAGTGTACTTTTTTTAAAGCTGCTGAAGTTTGTGGTTTCTCATTGTTTTAAGCCTACTGGAGCAATAAAGTTGAAGAACTTTACCAGGTTTTTTTATCGCTGCCTTGATATACACTTTTCAAATGCTTTGGTGGGAAGAAGTAGAGGACTGTTATGAAAGAGAAGATGTTCAAAGAAAACATTCAAAAATGGGTAAATGCACAAATTTCTAAGTTTGGGAAGCAGCATATTGAGAACCCTTCAGTGACCTACAGGATGGGAGGCGCCTCTAGACCTCCTCGAAGGCCTGACAGGGCAAAAAGTCCAAAAGAAAAAGGATCCACAAGAGTTCATGCTGAACAATGTCAACAAGGCCTGCGGGTTTTGCAGAACATAATGTTGATTTAGTGAATATTGGAAGTACTGACATCGTAGATGGAATCATAAACTGACTCTTGGTTTGATTGGAATATAATCCTCCACTGGCAGGTCAAAAATGTAATGAAAAATATCATGGCTGGATTGCAACAACCAACAGTGAAAAGATTCTCTGAGCTGGGTCCGACAATCAACTCGTAATTATCCACAGGTTAATGTAATCAACTTACCACCAGCTGGTCTGATGGCCTGGCTTTGAATGCTCTCATCCATAGTCATAGGCCAGACCTATTTGACTGGAATAGTGTGGTTTGCCAGCAGTCAGCCACACAACGACTGGAACATGCATTCAACATCGCCAGATATCAATTAGGCATAGAGAACTACTCGATCCTGAAGATGTTGATACCACCTATCCAGATAAGAAGTCATCTTAATGTACATCACATCACTCTTCCAAGTTTTTGCTCAACAAGTGAGCATGAAGCCATCCAGGAAGTGAAAAATGTTGCCAAGGCCACCTAAAGTGACTAAAGAAGAACATTTTTCAGTTACATCATCAAATGCACTATTCTCAACAGATCACGGTCAGTCTAGCACAGGGATATGAGAGAACTTCTTCCCCTAAGCCTCGATTCAAGAGCTATGCCTACACACAGGCTGCTTATGTCAACACCTCTGACCCTACACGGAGCCCATTTCTTTCACAGCATTTGGAAGCTCCTGAAGACAAGTCATTTGGCAGTTTATTGATGGAGAGTGAAGTAAACCTGGACCGTTATCAAACAGCTTTAGAAGAAGTATTATCGTGGCTTCTTCTGCTGAGGACACATTGCAAGCACAAGGAGAGATTTCTAATGATGTGGAAGTGGTGAAGACCAGTTTCATATCATGAGGGGTACATGATGATTTGACAGCCCATCAGGGCCGGTTGGTAATATTCTACAATTGGGAAGTAAGCTGATTGGAACAGGAAAAATTATCAGAAGATGAAGAACTGAAGTACAAGAGCAGATGAATCTCCTAAATTCAAGATGGGAAATGCCTCAGGGTAGCTAGCATGGAACAAAGCAATTTACATAGAGTTTTAATGGATCTCCAGAATCAGAACTGAAGAGTTGAATGACTGGCTAACAAAAACAGAAGAAAGAACAAAGGAAATGGAGGAAGAGCCTCTTGGACCTGATCTTGAAAGACCTAAACGCCAAGTACAACAACATAAGGTGCTTCAAGAAGATCTAGAACAAGAACAAGTCAGGGTCAATTCTCTCACTCACATGGTGGTGGTAGTTGATGAATCTAGTGGAGATACGCACTGCTGCTTTGGAAGAACAACCTTAAGGTATTGGGAGATCGATGGGCAACATCTGTAGATGGACAGAAGACCGCTGGGTTCTTTACAAGACATCCTTCTCAAATGGCAACGCTTACTGAAGAACAGTGCCTTTTTAGTGATGGCTTTTTCAGAAAAAGAAGATGCAGTGAACAAGATTACACAACCTGGCTTTAAAGATCAAATGAAATGTTATCAAGTCTTCAAAAAGTGGCCGTTTTAAAGCGGATCTAGAAAAAGAAAAAGCAATCCATGGGCAAACTGTATCACTCAAACAAGATCTTCTTTCAACACTGAAGAAATAAGTCAGTGACCCAGAAGACGGAAGCATGGCTGGATAACTTTGCCCGGTGTTGGGATAATTTAGTCCAAAAACTTGAAAAGAGTACAGCACAGATTTTACAGGCTGTCAACCACCTCAGCCATCACTAACACAGACAAGTGAATGGAACAGTAACACTACGGTGACACAAGGGAACAGATCCTGGTAAAGCATGCTCAAGAGGAACCTTCCACCACCCTCCCCAAAAGAGGCAGATTA

CTGTGGATTCTGAAATTAGGAAAAGGTTGGATGTTGATATAACTGAACTTCACAGCTGGATTACTCGCTCAGAAGCT
GTGTTGCAGAGTCCTGAATTTGCAATCTTTCCGAAGGAAGGCAACTTCTCAGACTTAAAAGAAAAAGTCAATGCCAT
AGAGCGAGAAAAAGCTGAGAAGTTTCAGAAAACTGCAAGATGCCAGCAGATCAGCTCAGGCCCTGGTGAACAGATGG
TGAATGAGGGTGTTAATGCAGATAGCATCAAACAAGCCTCAGAACAACCTGAACAGCCGGTGGATCGAATTTCTGCCAG
TTGCTAAGTGAGAGACTTAACTGGCTGGAGTATCAGAACAAATCATCGCTTTCTATAATCAGCTACAACAATTGGA
GCAGATGACAACTACTGCTGAAAACTGGTTGAAAAATCCAACCCACCACCCATCAGAGCCAACAGCAATTAAGAGTC
AGTTAAAAATTTGTAAGGATGAAGTCAACCGGCTATCAGGTCTTCAACCTCAAATTGAACGATTAAAAATTCAAAGC
ATAGCCCTGAAAGAGAAAGGACAAGGACCCATGTTCTGGATGCAGACTTTGTGGCCTTTACAAATCATTTTAAAGCA
AGTCTTTTCTGATGTGCAGGCCAGAGAGAAAGAGCTACAGACAATTTTGTACACTTTGCCACCAATGCGCTATCAGG
AGACCATGAGTGCCATCAGGACATGGGTCCAGCAGTCAGAAACCAAACCTCTCCATACCTCAACTTAGTGTACCCGAC
TATGAAATCATGGAGCAGAGACTCGGGGAATTGCAGGCTTTACAAAGTTCTCTGCAAGAGCAACAAAGTGGCCTATA
CTATCTCAGCACCCTGTGAAAGAGATGTGGAAGAAAGCGCCCTCTGAAATTAGCCGGAATATCAATCAGAAATTTG
AAGAAATTGAGGGACGCTGGAAGAAGCTCTCTCCAGCTGGTTGAGCATTGTCAAAGCTAGAGGAGCAAAATGAAT
AACTCCGAAAAATTCAGAAATCACATACAAACCCCTGAAGAAATGGATGGCTGAAGTTGATGTTTTTCTGAAGGAGGA
ATGGCCTGCCCTTGGGGATTTCAGAAATTTAAAAAAGCAGCTGAAACAGTGCAGACTTTTAGTCAGTGATATTCAGA
CAATTCAGCCCAGTCTAAACAGTGTCAATGAAGTGGGCAGAGATAAAGAAATGAAGCAGAGCCAGAGTTTGCTTCG
AGATGGCTAAATGAAGTAGAATTTAACTTAAACCACTGAAAACATTTCTGGCGAGCTGAGGAAATCTCTGAGGT
CTTGAAGGGAGGTTTGGAGAAAACTGTAAAGCCTCCAGAAAGATCTATCAGAGATGCACGAATGGATGACACAAGCTG
AAGAAGAGTATCTTGAGAGAGATTTTGAATATAAACTCCAGATGAATTACAGAAAGCAGTTGAAGAGATGAAGAGA
GCTAAAGAAGAGGCCCAACAAAAAGAAGCGAAAGTGAACTCCTTACTGAGTCTGTAAATAGTGTATAGCTCAAGC
TCCACCTGTAGCACAAGAGGCCCTTAAAAAAGGAACCTTGAACTCTAACCCACCACTACCAGTGCTCTGCACTAGGC
TGAATGGGAAATGCAAGACTTTGGAAGAAGTTTGGGCATGTTGGCATGAGTTATTGTCTATCTGGAGAAAGCAAA
AAGTGGCTAAATGAAGTAGAATTTAACTTAAACCACTGAAAACATTTCTGGCGAGCTGAGGAAATCTCTGAGGT
GCTAGATTCACTTGAAAATTTGATGCGACATTTCAGAGGATAACCCAAATCAGATTTCGCATATTGGCACAGACCTTAA
CAGATGGCGGAGTCATGGATGAGCTAATCAATGAGGAACCTTGAGACATTTAATTCTCGTTGGAGGGAACCTACATGAA
GAGGCTGTAAAGAGGCAAAAGTTGCTTGAAACAGAGCATCCAGTCTGCCAGGAGACTGAAAAATCCTTACACTTAAT
CCAGGAGTCCCTCACATTCATTGACAAGCAGTTGGCAGCTTATATTGCAGACAAGGTGGACGCAGCTCAAATGCCTC
AGGAAGCCAGAAAAATCCAATCTGATTTGACAAGTCATGAGATCAGTTTAGAAGAAATGAAGAAACATAATCAGGGG
AAGGAGCTGCCCAAGAGTCCCTGTCTCAGATTGATGTTGCACAGAAAAAATTACAAGATGTCTCCATGAAGTTTCG
ATTATTCCAGAAACCAGCCAATTTTGAAGCAGCTCTACAAGAAAGTAAGATGATTTTAGATGAAGTGAAGATGCACT
TGCTGCAATTGGAACAAAGAGTGTGGAACAGGAAGTAGTACAGTCACAGCTAAATCATTGTGTGAACCTGTATATAA
AGTCTGAGTGAAGTGAAGTCTGAAGTGGAAATGGTGATAAAGACTGGACGTCAGATTGTACAGAAAAAGCAGACGGA
AAATCCCAAAGAACTTGATGAAAGAGTAACAGCTTTGAAATTCATTATAATGAGCTGGGAGCAAAGGTAACAGAAA
GAAAGCAACAGTTGGAGAAATGCTTGAAATGTCCCGTAAGATGCGAAAGGAAATGAATGTCTTGACAGAAATGGCTG
GCAGCTACAGATATGGAATTGACAAAGAGATCAGCAGTTGAAGGAATGCCTAGTAATTTGGATTCTGAAGTTGCGCTG
GGGAAAGGCTACTCAAAAAGAGATTGAGAAACAGAAGTGCACCTGAAGAGTATCAGAGAGGTAGGAGAGGCCCTTGA
AAACAGTTTTTGGCAAGAAGGAGACGTTGGTGAAGATAAACTCAGTCTTCTGAATAGTAAGTGGATAGCTGTACC
TCCCAGCAGAGAGAGTGGTTAAATCTTTGTGGAATACCAGAAACACATGGAACCTTTTACCAGAAATGTGGACCA
CATCACAAGTGGATCATTCAGGCTGACACACTTTTGGATGAATCAGAGAAAAAGAAACCCAGCAAAAAGAGACG
TGCTTAAGCGTTTAAAGGCAGAACTGAATGACATACGCCCAAAGGTGGACTCTACAGTGACCAAGCAGCAAACTTG
ATGGCAAAACCGCGGTGACCACTGCAGGAATTAGTAGAGGCCCAAATCTCAGAGCTCAACCATGATTGTCAGCCAT
TTCACACAGAAATTAAGACTGGAAGGCCCTCCATTCTTTGAAGGAATGGAGCAGTTTAACTCAGATATACAAAAAT
TGCTTGAACCACTGGAGGCTGAAATTCAGCAGGGGGTGAATCTGAAAGAGGAAGACTTCAATAAAGATATGAATGAA
GACAATGAGGTACTGTAAAGAATTTGTGCAAGAGGAGACAACCTACAACAAAGAATCAGAGATGAGAGAAAGCG
AGAGGAAATAAAGATAAAACAGCAGCTGTTACAGACAAAACATAATGCTCTCAAGGATTTGAGGTCTCAAAGAAGAA
AAAAGGCTCTAGAAATTTCTCATCAGTGGTATCAGTACAAGAGGCAGGCTGATGATCTCCTGAAATGCTTGGATGAC
ATTGAAAAAAATTAGCCAGCCTACCTGAGCCAGAGATGAAAGGAAAAATAAAGGAAATTTGATCGGGAATTCAGAA
GAAGAAAGAGGAGCTGAATGCAGTGCCTAGGCAAGCTGAGGGCTTGTCTGAGGATGGGGCCGCAATGGCAGTGGAGC
CACTCAGATCCAGCTCAGCAAGCGCTGGCGGGAATTTGAGAGCAAAATTTGCTCAGTTTCAAGACTCACTTTGCA
CAAATTCACACTGTCCGTGAAGAAACGATGATGGTGTGACTGAAGACATGCCTTTGGAAATTTCTTATGTGCCTTC
TACTTATTTGACTGAAATCACTCATGTCTCACAAGGCCCTATTAGAAGTGAACAACCTTCTCAATGTCTCCTGACCTCT
GTGCTAAGGATCTCTTTAAGCAAGAGGATCTCTGAAAGAATATAAAGATAGTCTACAAACAAAGCTCA
GGTCCGATTGACATTATTATAGCAAGAAGACAGCAGCATTGCAAAAGTGCAACGCCTGTGGAAGGGTGAAGCTACA
GGAAGCTCTCTCCAGCTTGATTTCCAATGGGAAAAAGTTAACAAAATGTACAAGGACCGACAAGGGCGATTTGACA
GATCTGTTGAGAAATGGCGGCGTTTTTCATTATGATATAAAGATATTTAATCAGTGGCTAACAGAAGCTGAACAGTTT
CTCAGAAAGACACAAATTCCTGAGAATTTGGGAACATGCTAAATACAAATGGTATCTTAAGGAACTCCAGGATGGCAT
TGGGCAGCGGCAAACTGTTGTCAGAACATTGAATGCAACTGGGGAAGAAATAATTAGCAATCCTCAAAACAGATG
CCAGTATTTACAGGAAAAATTTGGGAAGCCTGAATCTCGGTTGGCAGGAGGTCTGCAAAACAGCTGTACAGACAGAAAA
AAGAGGCTAGAAGAACAAAAAGAATATCTTGTCAGAAATTTCAAAGAGATTTAAATGAATTTGTTTTATGTTGGAGGA
AGCAGATAACATTGCTAGTATCCCACTTGAACCTGGAAAAAGAGCAGCAACTAAAAGAAAAGCTTGAGCAAGTCAAGT
TACTGGTGAAGAGTTGCCCTGCGCCAGGGAATTTCAAACAATTAATGAAACTGGAGGACCCGTGCTTGTAAAGT
GCTCCCATAGCCAGAGAGCAAGATAAACTTGAAAAATAAGCTCAAGCAGACAAATCTCCAGTGGATAAAGGTTTC
CAGAGCTTTACCTGAGAAACAAGGAGAAATTAAGCTCAATAAAGACCTTGGGCAGCTTGAAGAAAAAGCTTGAAG
ACCTTGAAGAGCAGTTAAATCATCTGCTGCTGTGTTTATCTCCTATTAGGAATCAGTTGGAATTTATAACCAACCA

AACCAAGAAGGACCATTTGACGTTTCAGGAACTGAAATAGCAGTTCAAGCTAAACAACCGGATGTGGAAGAGATTTT
GTCTAAAGGGCAGCATTTGTACAAGGAAAAACCAGCCACTCAGCCAGTGAAGAGGAAGTTAGAAGATCTGAGCTCTG
AGTGGAAGGCGGTAAACCGTTTACTTCAAGAGCTGAGGGCAAAGCAGCCTGACCTAGCTCCTGGACTGACCCTATT
GGAGCCTCTCCTACTCAGACTGTTACTCTGGTGACACAACCTGTGGTTACTAAGGAACTGCCATCTCCAACTAGA
AATGCCATCTTCTTGATGTTGGAGGTACCTGCTCTGGCAGATTTCAACCGGGCTTGGACAGAACTTACCAGCTGGC
TTTCTCTGCTTGATCAAGTTATAAAATCACAGAGGGTGATGGTGGGTGACCTTGAGGATATCAACGAGATGATCATC
AAGCAGAAGGCAACAATGCAGGATTTGGAACAGAGGCGTCCCCAGTTGGAAGAACTCATTACCCTGCCCAAATTT
GAAAAACAAGACCAGCAATCAAGAGGCTAGAACAAATCATTACGGATCGAATTGAAAGAATTCAGAATCAGTGGGATG
AAGTACAAGAACACCTTCAGAACCAGGAGCAACAGTTGAATGAAATGTTAAAGGATTCAACACAATGGCTGGAAGCT
AAGGAAGAAGCTGAGCAGGTCTTAGGACAGGCCAGAGCCAAGCTTGAGTCATGGAAGGAGGGTCCCTATACAGTAGA
TGCAATCCAAAAGAAAATCACAGAAACCAAGCAGTTGGCCAAAGACCTCCGCCAGTGGCAGACAAATGTAGATGTGG
CAAATGACTTGGCCCTGAACTTCTCCGGGATTATTCTGCAGATGATACCAGAAAAGTCCACATGATAACAGAGAAT
ATCAATGCCTCTTGGAGAAGCATTCTAAAAAGGGTGAGTGAGCGAGAGGCTGCTTTGGAAGAACTCATAGATTACT
GCAACAGTTCCCCCTGGACCTGGAAAAGTTTCTTGCTGGCTTACAGAAGCTGAAACAACCTGCCAATGTCTACAGG
ATGCTACCCGTAAGGAAAGGCTCCTAGAGACTCCAAGGGAGTAAAGAGCTGATGAAACAATGGCAAGACCTCCAA
GGTGAATTTGAAGCTCACACAGATGTTTATCACAACTGGATGAAAACAGCCAAAAATCCTGAGATCCCTGGAAGG
TTCCGATGATGCAGAGAAAAATAGATGAGACCTTTGAAAGACTCCAGGAACCTCAAGAGGCCAGGATGAGCTGGAC
TCAACATTAGGTCCCATTGGAAGCCAGTTCTGACCAGTGGAAGCGTCTGCACCTTTCTCTGCAGGAACCTCTGGTG
TGGCTACAGCTGAAAGATGATGAATTAAGCCGGCAGGCACCTATTGGAGGCGACTTCCAGCAGTTTCAAGAGCAGAA
CGATGTACATAGGGCCTTCAAGAGGGAATTGAAAACCTGTAATCATGAGTACTCTTGAGACTGTACGAA
TATTTCTGACAGAGCAGCCTTTGGAAGGACTAGAGAACTCTACCAGGAGCCCAGAGAGCTGCCTCCTGAGGAGAGA
GCCCAGAATGTCACCTCGGCTTCTACGAAAGCAGGCTGAGGAGGTCAATACTGAGTGGGAAAAATGAACCTGCACCTC
CGCTGACTGGCAGAGAAAAATAGATGAGACCTTTGAAAGACTCCAGGAACCTCAAGAGGCCAGGATGAGCTGGAC
TCAAGCTGCGCCAAGCTGAGGTGATCAAGGGATCCTGGCAGCCCGTGGGCGATCTCCTCATTGACTCTCTCCAAGAT
CACCTCGAGAAAGTCAAGGCACCTTCGAGGAGAAATTGCGCCTCTGAAAGAGAACGTGAGCCACGTCAATGACCTTGC
TCGCCAGCTTACCCTTTGGGCATTACGCTCTCACCCTATAACCTCAGCACTCTGGAAGACCTGAACACCAGATGGA
AGCTTCTGCAGGTGGCCGTCGAGGACCGAGTCAGGCAGCTGCATGAAGCCCACAGGGACTTTGGTCCAGCATCTCAG
CACTTTCTTTCCACGCTCTGTCAGGGTCCCTGGGAGAGAGCCATCTGCCAAACAAAGTGCCTTACTATATCAACCA
CGAGCGTCAAAACAACCTTGTGGGACCATCCAAAATGACAGAGCTTACCAGTCTTTAGCTGACCTGAATAATGTCA
GATTCTCAGCTTATAGGACTGCCATGAACTCCGAAGACTGCAGAAGGCCCTTTGCTTGGATCTCTTGAGCCTGTCA
GCTGCATGTGATGCCTTGGACCAGCACAACTCAAGCAAAATGACCAGCCCATGGATATCCTGCAGATTATTAATTG
TTTGACCACTATTTATGACCGCCTGGAGCAAGAGCACAACAATTTGGTCAACGTCCTCTCTGCGTGATATGTGTC
TGAAGTGGCTGCTGAATGTTTATGATACGGGACGAACAGGGAGGATCCGTGTCCTGTCTTTTAAACTGGCATCATT
TCCCTGTGTAAAGCACATTTGGAAGACAAGTACAGATACCTTTTCAAGCAAGTGGCAAGTTCAACAGGATTTTGTGA
CCAGCGCAGGCTGGGCCTCCTCTGCATGATTCTATCCAAATTCAGAGACTGCTTTAGAGGGGGACAACATGGAACCTTGGGG
GCAGTAACATTGAGCCAAGTGTCCGGAGCTGCTTCCAATTTGCTAATAATAAGCCAGAGATCGAAGCGGCCCTCTTC
CTAGACTGGATGAGACTGGAACCCAGTCCATGGTGTGGCTGCCCTCCTGCACAGAGTGGCTGCTGCAGAACTGC
CAAGCATCAGGCCAAATGTAACATCTGCAAGAGTGTCCAATCATTGGATTACAGGTACAGGAGTCTAAAGCACTTTA
ATTATGACATCTGCCAAAGCTGCTTTTTTCTGGTCGAGTTGCAAAAGGCCATAAAATGCACTATCCCATGGTGGAA
TATTGCACTCCGACTACATCAGGAGAAGATGTTTCGAGACTTTGCCAAGGTACTAAAAACAATTTTGAACCAAAAG
GTATTTTGGCAAGCATCCCGAATGGGCTACCTGCCAGTGCAGACTGTCTTAGAGGGGGACAACATGGAACCTTCCCG
TTACTCTGATCAACTTCTGGCCAGTAGATTCTGCGCCTGCCTCGTCCCTCAGCTTTCACACGATGATACTCATTCA
CGCATTGAACATTATGCTAGCAGGCTAGCAGAAATGGAACAGCAATGGATCTTATCTAAATGATAGCATCTCTCC
TAATGAGAGCATAGATGATGAACATTTGTTAATCCAGCATTACTGCCAAAGTTTGAACAGGACTCCCCCTGAGCC
AGCCTCGTAGTCTCTGCCAGATCTTGATTTCCTTAGAGAGTGAGGAAAGAGGGGAGCTAGAGAGAATCCTAGCAGAT
CTTGAGGAAGAAAAACAGGAATCTGCAAGCAGAATATGACCGTCTAAAGCAGCAGCAGCAACATAAAGGCTTGGCCC
ACTGCGCTCCCTCCTGAAATGATGCCCACTCTCCCCAGAGTCCCGGGATGCTGAGTCAATTGCTGAGGCCAAGC
TACTGCGTCAACACAAAGGCCGCTTGGAAAGCCAGGATGCAAACTCTGGAAGACCACAATAAACAGCTGGAGTCACAG
TTACACAGGCTAAGGCAGCTGCTGGAGCAACCCAGGCAGAGGCCAAAGTGAATGGCACAACGGTGTCTCTCTCTC
TACCTCTCTACAGAGGTCCGACAGCAGTCAGCCTATGCTGCTCCGAGTGTTGGCAGTCAAACCTCGGACTCCATGG
GTGAGGAAGATCTTCTCAGTCTCTCCAGGACACAAGCAGGAGGTAGAGGAGGTGATGGAGCAACTCAACAACTCC
TTCCCTAGATTCTTATAAAAAAGTTGTTTATAAAAAACCCCTAAAAACAAAAACACACACACACACATAC
ACACACACACACAAAACTTTGAGGCAGCGCATTGTTTTGCATCCTTTTGGCGTGATATCCATATGAAATTCATGGCT
TTTTCTTTTTTGCATATTAAGATAAGACTTCTCTACCACCACACCAATGACTACTACACACTGCTCATTGTAG
AACTGTGCTGAGTGGGGCAGGCTTGAGTTTTTCAATTCATATATCTATATGTCTATAAGTATATAAATACTATAGT
TATATAGATAAAGAGATACGAATTTCTATAGACTGACTTTTTCCATTTTTTAAATGTTTCATGTTCACATCCTAATAGA
AAGAAATTACTTCTAGTCAGTCATCCAGGCTTACCTGCTTGGTCTAGAATGGATTTTTCCCGAGCCGGAAGCCAGG
AGGAACTACACCACACTAAAACATTGTCTACAGCTCCAGATGTTTCTCATTTTTAAACAACCTTCCACTGACACGA

AAGTAAAGTAAAGTATTGGATTTTTTTAAAGGGAACATGTGAATGAATACACAGGACTTATTATATCAGAGTGAGTA
ATCGGTTGGTTGGTTGATTGATTGATTGATTGATACATTCAGCTTCTGCTGCTAGCAATGCCACGATTTAGATTTA
ATGATGCTTCAGTGGAATCAATCAGAAGGTATTCTGACCTTGTGAACATCAGAAGGTATTTTTAACTCCCAAGCA
GTAGCAGGACGATGATAGGGCTGGAGGGCTATGGATTCCCAGCCCATCCCTGTGAAGGAGTAGGCCACTCTTTAAGT
GAAGGATTGGATGATTGTTTCATAATACATAAAGTTCTCTGTAATTACAATAAATTATTATGCCCTCTTCTCACAGT
CAAAAGGAACCTGGGTGGTTGGTTTTTGTGCTTTTTTAGATTTATTGTCCCATGTGGGATGAGTTTTTAAATGCCA
CAAGACATAATTTAAATAAATAAACTTTGGGAAAAGGTGTAACACAGTAGCCCCATCACATTTGTGATACTGACAG
GTATCAACCCAGAAGCCCATGAAGTGTGTTCCATCCTTTGCATTTCTCTGCGAGTAGTTCCACACAGGTTTGTAAAG
TAAGTAAGAAAGAAGGCAATTTGATTCAAATGTTACAAAAAACCTTCTTGGTGGATTAGACAGGTTAAATATATA
AACAAACAACAAAAATTGCTCAAAAAAGAGGAGAAAAGCTCAAGAGGAAAAGCTAAGGACTGGTAGGAAAAAGCTT
TACTCTTTTCATGCCATTTTATTTCTTTTTGATTTTTAAATCATTCAATAGATACCACCGTGTGACCTATAATT
TTGCAAACTCTGTTACCTCTGACATCAAGTGTAATTAGCTTTTGGAGAGTGGGCTGACATCAAGTGTAATTAGCTTTT
GGAGAGTGGGTTTTGTCCATTATTAATAATTAATTAATTAACATCAAAACACGGCTTCTCATGCTATTTCTACCTCAC
TTTGGTTTTGGGGTGTCTGATAATTGTGCACACCTGAGTTCACAGCTTCACCACTTGTCCATTGCGTTATTTTCT
TTTTCTTTTATAATTTCTTTCTTTTCTTCATAATTTTCAAAAGAAAACCCAAAGCTCTAAGGTAACAAATTACCAA
ATTACATGAAGATTGGTTTTGTCTTGCAATTTTTCTTTATGTGACGCTGGACCTTTCTTTACCCAAGGATTT
TTAAACTCAGATTTAAACAAGGGTTACTTTACATCCTACTAAGAAGTTTAAAGTAAGTAAGTTTCATTTCAAAAT
CAGAGGTAAATAGAGTGCATAAATAATTTGTTTTTAATCTTTTTGTTTTCTTTTAGACACATTAGCTCTGGAGTGA
GTCTGTCTATAATTTGAACAAAAATTGAGAGCTTTATTGCTGCATTTTAAGCATAATTAATTTGGACATTATTTCTG
TGTGTGTTCTTTATAACCACCAAGTATTAACTGTAAATCATAATGTAAGTGAAGCATAAACATCACATGGCATGT
TTTGTCTGTTTTCAGGTACTGAGTTCTTACTTGAGTATCATAATATATTGTGTTTTAACACCAACACTGTAACAT
TTACGAATTATTTTTTAACTTCAGTTTACTGCAATTTTCAACATATCAGACTTCACCAATATATGCCCTTACT
ATTGTATTATAGTACTGCTTTACTGTGTATCTCAATAAAGCACGCAGTTATGTTAC (SEQ ID NO: 130)

[000203] *Homo sapiens* dystrophin (DMD), transcript variant Dp427m, exon 44
(nucleotide positions 6535-6682 of NCBI Reference Sequence: NM_004006.2; nucleotide
positions 1127547-1127694 of NCBI Reference Sequence: NG_012232.1)

GCGATTTGACAGATCTGTTGAGAAATGGCGGCGTTTTTCATTATGATATAAAGATATTTAATCAGTGGCTAACAGAAG
CTGAACAGTTTCTCAGAAAGACACAAATTCCTGAGAATTGGGAACATGCTAAATACAAATGGTATCTTAAG (SEQ ID
NO: 954)

[000204] *Homo sapiens* dystrophin (DMD), exon 44 target sequence 1 (nucleotide
positions 1127547-1127601 of NCBI Reference Sequence: NG_012232.1)

GCGATTTGACAGATCTGTTGAGAAATGGCGGCGTTTTTCATTATGATATAAAGATA (SEQ ID NO: 955)

[000205] *Homo sapiens* dystrophin (DMD), exon 44 target sequence 2 (nucleotide
positions 1127595-1127643 of NCBI Reference Sequence: NG_012232.1)

AAAGATATTTAATCAGTGGCTAACAGAAGCTGAACAGTTTCTCAGAAAG (SEQ ID NO: 956)

[000206] *Homo sapiens* dystrophin (DMD) exon 44/intron 44 junction (nucleotide
positions 1127665-1127724 of NCBI Reference Sequence: NG_012232.1)

GAACATGCTAAATACAAATGGTATCTTAAGGTAAGTCTTTGATTTGTTTTTCGAAATTG (SEQ ID NO: 957)

[000207] *Homo sapiens* dystrophin (DMD), intron 44 (nucleotide positions 1127695-
1376095 of NCBI Reference Sequence: NG_012232.1)

GTAAGTCTTTGATTTGTTTTTCGAAATTGTATTTATCTTCAGCACATCTGGACTCTTTAACTTCTTAAAGATCAGG
TTCTGAAGGGTGATGGAAATTACTTTTACTGTTGTTGTCATCATTTATATTACTAGAAAGAAAATTATCATAATGAT
AATATTAGAGCACGGTGCTATGGACTTTTTGTGTCAGGATGAGAGAGTTGCTTGGACGGAGCTGGTTTTATCTGATA
AACTGCAAAATATAATTGAATCTGTGACAGAGGGAAGCATCGTAACAGCAAGGTGTTTTGTGGCTTTGGGGCAGTGT
GTATTTTCGGCTTTATGTTGGAACCTTTCCAGAAGGAGAACTTGTGGCATACTTAGCTAAATGAAGTTGCTAGAAAT
ATCCATCATGATAAAATTACAGTTCTGTTTTCTTAAAGACAATTTTGTAGTGCTGTAGCAATATTTCTATATATTCT
ATTGACAAAATGCCTTCTGAAATAGTCCAGAGGCCAAACAATGCAGAGTTAATTGTTGGTACTTATTGACATTTTA
TGGTTTTATGTTAATAGGGAAACAGCATATGGATGATAACCAGTGTGTAGTTTAAATTTCAACTTGTGGTGTCTTTGA

ATATGCAGGTAAGATAGATTAGATTGTCCAGGATATAAATTTGGTTGCTAAATTACATAGTTTAGGCATAAGAAACA
CTGTGTTTATTACACGAAGACTTAATTATTTTTGCATCTTTTTTAGCTCAAATTGTTCATGTTGCAATAGTCAATCA
AGTGGATTTGAATTGTAGCCAATTTTTAATGCCAGAAAATACTGATTAAGACAGATGAGGGCAAAAAACACCCAGTA
GTTTATTAAATACTTTAGATATTTCAAATGCTGGATTACAAAAGCAGTATCACATTTGACTTTACAAGTCTTCAT
TCTCAAATATGTTTCCATAGTAAATATGCCCTTTAATATTAAGGAGTTAAGCATTAAACACCTATTTATATGATAA
GCTATTTAAACACAGAAAATATTTTTAAACCTTGTGTAAATATATGTGTATCAATCAAACCTGCATGCACACCAGC
GTTGGCATTGTATAGAGAGGAAATGTATGGATTCCCAATCTGCTTTAATATAGAAGATACATTTAAAAATAGCAC
TGAAGTGAATTTTGGGCTAATGTAGCATAATGGGGTTTCTGCCTGAGAGGCAGAAACATATTAGAGTTATATAAAAT
GTTTTGGGGTAGATATAGAAACCCTTGCATTTTCAATGATATCCAACCCAAGGTAGTTATATATTTCAATTTATA
TTTTATTATCAAATTAGTACTTATTGTGAAAAAATCAAGTAACATAGAAATTTGTAAAGTACCTCCATTTCTACTC
TTTGGAGGATAGTTGTTTCAGTATGAATTTTGTACATATTTTCAGGCTGGGTTTCTTGGAAAGCCATTGTAAATGGGA
GATTTGTATGTAGAAGGTTAACTAGGGAGTACTTTTACGATGAAGCAATTTGTTTTGTATGTAACCTGGTGTAGTTTT
CTTCATGTTTTCTGTTCTTGAAGTCAGTTAAGCTCTTGAATCTGTGCATTTAACATTTTCATCAAATTTAGAAACCTT
TCAACCATTTTTTAAAAAAATGGAACCTCAATTGTACATTTATTAGGCTCCTTAAAGTGCCCCACTACTCACTGA
TGTTATGTTTCATTGTCTGTTTGGTCTCTCTTTTCTCTGTAATTTGTTTTATATAATCTCTATTGTCAAATTGACTAA
TCTTTTCAAAGTCTAATCTATGGCTAATCCCATGTAGTATATATTTTAAACATCAGACATTTTCATCTCTTAGAAG
TAAAAATTTGGGCTTTTTTATTTCTTCCATGTGTCTCAACATGTTTCAGTCTTTTACTTCTGATATATAGATA
CAGATATAATAACTGTTAGAATATTTCTCTACTAATTTTATCATCTGTGTCTATTCTGGGTTAATTTAAATTTGAT
TTATTTTTCTCTCATTAAGTGTGTTGTTTAACTGCTCTTTGGATGACTGGTAATTTTGGACTATATGCCAGACAT
TGTGAATTTTAACTTAGCGCGTGCTTGATCTTCAAATAAATTTCAAATATATTGAAATAAATATTCTCAAACCTCGT
TCTGGAACACAGTTAATTCACCTTGAAACAATTTGATCTTTTGAGAATCTTCTTTTATGCTTTGTTATGACCAGAA
CAGTGTAAGTTTAGGGCTACTTTTTCCCACTACTGAGGCAAAACCTTCTGAGTACTCTCTGATGTCCTGTGAA
TGATAAAATTTTCACTGGGCTCGTGGGAACAGGTGGTATTACTAGCCACGTGTGAGCTCTGTGATTGTTTCTCTT
TAATTTCTTTGTGAAGTTCTTCTTAGCTTTGAGTGGTTTTCTTGCATACATGAAGTATCAAGACTCAGATGAAG
AATAAAATAAAGCTTTCTACAAATCTCCAAAATTTCTCTGTGTATATATCACCTCTCTGGTATTTTGGCCTGTGAT
CACTAGTCAGCTTGGGCTGCTGAAACTCTCAGCTTCATCTTTTAAACAAAAGCCTCTGGCAAGGATCACTGTCCTT
CAATGTCTGATGTTCAATGTGTTGAAAACCGTTGTAGCATATATTTTGTCTTTTTTTTTTTTTTTTTTTTAAAGT
GTTTCAGGTGTTTCAGGCAGGAGATTAAGTTCAGCTCCTTTACTCCAACCTTGAAAACAAGTCCAAAACAACCTATT
TTGATGTAATTTGATCTTTTAAATACATTAACTTACACAATTTTGTGAATATATCATAATTTTAAATTTTTCAGAGAA
TGCTAATGGTCTCTATTCTTGACAGTGTGGTTTAGTTGAAACTGATGAACATTTTATCAAACTTTTCCCTCAA
TTGGATACTTTTTTTTTTTTGGATGGAATTTTGTCTTTGTCAACCAGGCTGGAGTGGCATGATCTCAGCTCACTGC
AACCTCTGCCTCCAGGCTTCAAGCAATTTCTCTGCCTTAGCCTCCCGAGTAGCTGGGATTACAGGTGCCACCCCA
CACCTGGCTAATTTTTGTATTTTAGTAGAGACGAGATTTACCATGTTGGTCAAGGCTGGTCTAGATCTCCGACCTC
AGGTGGTCTGCCTGTCTCAGCTCTCCAAAGTGTCTGGGATTGCAGACGTGAGCCACCATGCCTGGCCAACCTGGATAAT
TTTAAAGAACCATTTTATTTAGTCTATTTTCTCAATCTATAGATGAGATAAGAAAAATCATTTAGATGTGCCAA
GGAAAAATTTCTTTCAGAAAAGAGCTGTGAATGATATCACAACCCCCCAACAGTTAAGGTATTTCTTTCTGGTTA
TTTTATGTCCAAAATCATGCATATGAACATGTGCACACACATGAGCGTGCACACACACATGAATACATATACACGCA
CATAATGTACCTTAGGTTATCTTTCCATTCTGAGTAATATCGTAAAATGGGTAAAATCAACCCCGTAAGATACCTT
CATCGATAAGGCAAAATCAAAGCTTTGGTAATTTCTGCTATCTTGGCCTTTGTTGATTGACTAATAATGAATAAGAGA
ATGAGTTTCAATATTTACTATGAAATTTTGTAGAAGACAGGATGTAGACAGTGGCTGTTAGCAGGCAATTTGTTGG
CATGAGCCAGTAAATGGTTACTGTGAAAAAAATCAACCAAGCAGCCCATATATTAAACAAACACAGCAGAACGCT
TGGAGTCTGAAGCCTCATATGTACAATTTTCACTAAAGAAATAACTTTTAGATATGAAATAAACAAATAGATATATG
TTGTAAACTTTGCTCTATGATTTTGTATCAAATTCATCATATTTTTTCACTTTAAAGAAGAGAATTTAGTGTCTT
AACTGAGACTTAGTGTTATCATTTCAAATATACTGACTGCCAATAGCAGTAGAAAGATAATCTGGTTCATGCAACT
CTATTTTTTTCTCTGTGCAAGTAAAGACAAAATTAAGTACATGAATTAGTGCTTTTTGAAGATATTCAGAGC
AATATACCATGCCACTATGGAACCTCTCTAAATAATCCCATTTTTTACCTGAGAAAAATTTGATCATGTTAT
ATGCCACTCAAATGGTTTATTAATTCGTTGAATGATATCAGCATCTCTTAATGCATTCACTAAACAAGCAGTAAT
TGAGTGCATATACAAAGTTTATCATCCACCAAAACAGTGACAATCCACATGAGGCTCTAATAGAAGTTTAGAAAGG
GGGTTAAGTGGTTAAATGCTGGACTCAGAAAGATTGGATTCAAATCCAGGTCCTTTAGCTTAATAGTTGTAGAATC
TTGTGAAAATATCTTAATCTTTTCATGTCTCTGATTTCTCTTCTTAAATGGAATATAAATGAGATGTGTATAA
AGCCACTTTGGAATAGCATTTTGCACAAAATAATTACTTAATGAATGAAGCCCTATTATAACTAATCACTCTTTAT
AAGTGATTAGTTATCATATCAATACAACTAAGACTTATTACTGAATTTATCGTCTCTAAACATCCACATGCAGAAA
ACCAACCTGGAATTTTCAAAAACCTTATTTTTATGTAGTATAATTTCTTCTCAAAGCATAAGGGCTCTTGGATTAG
GAATTGAGGAAAAATCCAATTCAGCCAAACGCATCTGTTTCAGATAGCTGACACTTCTGCCTACTCATTTCTAGCT
AACAAGAAGAAATGTTAATGGGAGTTTTCAAAGGAAAAGCTGAACACCATGAAGGAAAGTGACACAAATAATGTAG
CTCATATATTGACAGGGTGAATTTGTGTGCTTTCAAGTCCCTTCAGTGAAAATAGGAAAGTAGAAATTATAAAATGC
CCTAACATTTAAAGCTAGCATGTTCTTGGAGACTAGGAAAAATAAGTTTTAAACATGGGCTATGATAGAATGAGA
TGGAAAATGTTGTAGTTGGCAGTAGAAACAATAACATACCATTAGATTAAGTATTTAAACCATGAAATATTTT
TATTAATGGAATGGCATCTGTTTTATGAAATAATGCTGCTGAATGAACCATATTAATAATGACCAGTATTTCTGTC
AGAACGTTGTGCGACACATACAAGCCTGAGACCCTAAAATCTTAAGGTATTTCCATTTGAAATCGACCTTAAGACATT
AACAGTAGTGTATTGTTTATGATGAAATTTTTAGGCTTTAAATCAACAAATGTTAAGCAGACATGGGGAGCGAAAC
ACCAGTGTGTTATTCTGACATGAATAAACTGCTGTTTTAGGGAAAAAATATAGTCTTGTTAAGGTAAAGCTAATTG
GTTTTCTGGTATCTTTTGAATGTTAGTGTGTTTTACTGCTCCATAACCTATGTTATATGGTAAATGTGCAATATAT
TTATATATGTTGCTGTAAAGAAATGTAATAAAAACTGTTTACTTTGTGATATGAAAGTAAAAATTTATTTCATTGTC

ATTGAGCATACAGAAGTAAATATGGATTACATATGTCATATTTTAAATGTTACATGGTCCCACCATCAAATGTTGAA
AAACTTATAGTTTAAACGTCATATTTCTATTGAAGAAAAATACACTCCCTTTTCTCAAATGTGAAATGTCCAGAGAGAA
TGGAAAATTACATATAAAGCATGTAGTTATAGCATGGTGACCCTGCTGTGATCTCTCAGATGAGGAACAAAAGGGAG
AAAGAAAGAGCACACTGGTGCTTTGGAGTTGAGAGAAGGCAAAAAAGAGTACAAAAATGTCAAAGCCAAGTTTAGC
TGCTCTTCAGCTCTCCCTTTAGCTGCTCTTCAGCTTTACCTTACCATGGTTATTAGTGATTGAAGAAAATTTCAAAG
CACTTTTTAAAGGACCAATTTCTGAAGAGTTTAGATTACAGAGACAAATGGAGTTGGAGTGACTCTGCTCAAAAG
TTTGAGACAAGCGAGTCCATGAAAAGACCGTCTCTCTTAAATGGAAATACCCAGGTTTTCTCATTCTTCTCGCCTT
GCTTTCAGCACTCGCAGCCCAGAAAGCCCTTATCTAACAGGTACTGCCGTTGAAAGGTCATTGACTTGTACAAAAAT
GATGAGTGCTGAATAGATGTGCATAGGTCAGTACAGTATCTGCTACAGAGAATGAGTTTTCGTATTTTTATTAGGA
TACACCTAACATGGCAATCTACTGCCTCAAAGAACTCTATAGGAGGTAAGTGAATTTATATTAATACAGATTGAATT
AAAGATAATCTAGAAAAAGGCATATGATGTAAAAAATCAGACACAAGTATATTTCTGTATAGTCAGTTTTTACA
TTGTGATTTTACCAGCTGGCTGCTGAGTTTGACGGCTTCTTAACAGCCACACTGCTGAGATTCAAATGCTGATAGAA
ACTTTGATGGAAAAATCACTGGAGTAAATATTTCTACCATCTGTTGCCCTTCACTGGGACCCTAACGTTAAGAATAA
TTCATACCATTGCTTGTCTTTATATTTCCCGAGCAGTAATAAAATTTTATAAGATTTTGTGTTTGTGGTCACAAAGC
TATCCTGGTTTTCTGTAAC TAGAAGACATACACTAGCATAAAGGGAATCAGCCGGAATAATTTACTGCTAAGAGAAATTTG
TCTCTAGTCACTTACTTTAAGGTTACAGCAATGTGTAAGTGTGGGAATACATTTTAAAAAGAGCTTTTCAAAGTTAT
TAGCTGGTAGTCTGCTTAACTTCTTAACTCTGCTCACTTGCTGAAACTGTAGTATGTGTTTTCTATGTTTATTAT
TACCTTTTTATTGCTGCTTGAAACTCTCTGCACTTTTTTGCCCTTATCCATCTTTTCAAGAGTAGTAATAAACC
AATTTACTGGGAGTGTGGTACCAGGCAGAAATTCGAGAGGGGCTTTCAATCCTTGCCCATCAAGTGATCTTTTCA
AAATAAGTATATTAATAATTGGATAATTTTCAAGTGGCTTGTATTAGACTTCCGTTGTCCAGCATGGCATGTTTAA
GAAGATGACAGATTTTATACATTATTGGAAAGAAGCAAGAACAAAAAACATAACTTACTGTAGTAACCACGGTAA
AGAAGTGTAAAAATGCAGGATAAACATGTCTATCCCTAAGGGATTCCCATTTCTAGAGCATGAAATTATCAAGAGAG
TAAGAGACTACAAAAAATGAGAAGAAATGCTGATTGCAAAATTCAAAATAGAAAAAATCAAACAAAACGCGCACCAT
CATTTCTGGAAGCAATGAGAAGCAGAAATGTCTATTTAATGAAATGTAAGATTAAAGTTAATAGAAGTAATTTTCATG
AAATAATATTTTGAAGGACGATGTTCCAGCCATATTGATCTTCGTGTTTTCTTTTACATCCCTTCTTACTGTTC
CTAGAATGCTTGTCTTACCTTTAAATTTGCTTTTTCTCTTACCAGAGGGCTCTACCCTATCTCCAGTTTCTCACCA
TGTCCTAATCTACTCCCTCTCAGAATTTTTGTACACTTCCCTTTATATATATTTGTGCTCTAATTTTATATTCACAG
ATATGCTTTTTGTAACCTCCCTTCTTAAAGAAAGCACACAGTACGCACACATGCACACACAAAAATGAACTCT
TCTGGGAGATCTGCTTAACTTTCTTCAACTCTGCTCACTTGCTGAAACTGTAGTATGTGTTTTCTATGTTTATTAT
CTTTTCCATTAGAATGAACATATTTTGGGTACTTGGTCTTTCTCGATCACCATAATACCTCGGTACGTAGAAAAAT
GATTCATATATTGAAATGTAATATTCAGTAGAACGAATAATACATAAAATAAATTTAAAAATGATACTTTTATTGT
ATTACCTGAGACAAATGATCCCAAGTTTGTCTTGTCTTTTATAGCCAAAACATTCTCTCTTACATTGAGCTTCCCT
TCACCTCTTCTGTGTACAGAGCACTTAAATTTTACATTGCCTGATACTTTAACAATATGATGGCCCTGTTCTCTT
ACCCATTGGAGCATATGTTAAATACCAGAACCCATGTAAACAACATATATTGTGATCCTACTGTGTGCAAGCAGAT
ACTGCTTGCTGCTAGGAATACAGAGCTGACTAAGAGCTCCTTTTTCTTTATGAGCTCACAGTCTCATGAGTTCAAC
GTCTTAAGGCACAACGTCTAAAGCAAAGGGCAGTAAGTAAACACTCCAGAAAGTACTGGATCTGGCCTAGGACAAAT
GGTGGGTTGTTTTTCCAGCTGTTATTTTTCTGCCCCCTAATTGACAGTCTCCATTACACCTCTGGGATACCTAGT
CTGACTTGGGAAAACCTGACTTTGGGAATCAGAGGCAGTCTCTCTTGCTTATATATGAGGAACCTAATGGATACTT
ACTGTCAATTAGAGAACTCTGCTTCTAGCCTGGCTCCTTTTGTAAGAAGGTTGAGTCCCCTTGAGAGCCCTGCAGA
ACATAACCATTTGCATGTAATGAACAGTTTGTAACTTTGAGATTGATGTGCAATTTCTATTTGACAAGGGAAAA
CAATTAGGATTAACCGTGGTGTATATCCAGAAATACCAACGTTGTTTCCACACTCTAAGTGTGTTGGGTCAATTAT
ATGAGATTCAATTTTGTCTGTTGTACCCAGTTTGCATTACCATTACGTCTTAATTTATTATACCTATTAAAA
GTTTTTTTGGTAATTTGTTCTTATTGCTACTCAGGCATTAATATGTCTGCAGGCTGTGAAATGAATAAATTTAATG
TGGCAGCATAGTTCTCAAAATCCTGGCTTACAACATAGTACAGGCTTGTATTGTAATCCTAGTTAACATGGAT
TTATTTGAAAAATCCAATTTTACTGCTAATCTTAAATAACACATTTTTCAAACATTTTATCCTTGAATTTCTATTTT
TTATAATTTATGGCTGTTGTATGTATTTACAAAAGGACAATGTGTGACTTTTTAAATACTAGTAATGGATTGCTGAA
ACAACCTGTAACCTTAAACAATGCAATTGTTAAAAAATAAAGTGTGACGCTGCTTAATGGAGGCTTATGAACAT
ATGATTAAAGATATATGCTATAATAAGCAAATTCACCTCACTGATAGTTTATAGGAACCTTTCAAATTTAATCTCATAA
CCAGTGCTATCCTTCAAAGAAATGGTCAGGGCAATTTAACGAGTACATGACCACGCAAGATAATTTCAATTGAAGAGTG
GCTGAACTGTTGAAATATTTCTAGTCTCCTTGGGATATCATTAAGAGCAGAAATTTTGAATGGAATTGTAATGAT
GTTTCAGAAAAGATAAGTAGGTAACCTCTTAATACGTTTTGTGCTGCTGTAACAAAGTACCTAAGACTAGGTAATA
TTTGTAAATGAACAAAATGTATTGGCTCAGAGTTCTGGAGACTAGGAAGTCTAACATTAAGGTGTGAGGCTTATGCG
AGGGCCTACTTGATATGTCATCACATGATGGACGATTAGAGGGCAAGAAAGATCAAAGGGGGCTGAACTCCCACTT
TTATAAGGGAACCAAACCCACTCGTGAGGGTGGAGCCCTCAATCCTTAATCACCTCCTAAAGCTCCACCCCTTAAT
ACTGTACAAATGGCAATTAATTTCAACATCAGTTTTTGAGGGGAAAAACATTGAAACCATAGTAGTGATACTGACTA
CTACCACACAGGGCTTGGGAGGCTACCCTAGCTGTTGCACCCAAGAGATGAATCTTCTAATGTGATTACCTTTATCA
TTTTTTTACTTTATTAATAACTTTTTATTTTACATGTATACTTTTGTCTACCCACCATTTCATGTCTGACCCTG
CTACTACTATGTCTAGCATACATTCATACCTTTAAACCAAGCAAGGGTGGAGTTCCATCTTTTAAAAACTA
AACAGGCATTTTGGACAACACATTCTTGGAATGGAATCTGGACAACATTTATCAAACATGGTAGGGAAGGTTCTCA
CTCTGCATTATCAAACGACAGCCAGATATCACTGTTACAGAAACGAAATCAGATGGAAATTTTAAACAAATTTGT
TTAAACTATTTTCTTAGAGAGACTTCCCTCCACTGCCAGAGATCTTGAATAGCCTCTGGTCAGTCATCTGGAAGCAAT
TCTTCACATAATTCATGAACCTTGGCTTCCACTTTAGGAAGAGAACCACCTTTTTCTATACTTGCTTGCAATTTTGTCT
TTAATGCTTCTACAGAACTAGGTCCTTTGGGTGTTTTAGGAGTTTTCTTGTGTTTTGAAGGATCTTGTCTTTTGT
ATCTTGGTGTGACGGTTTTGAGTCTTTCCATTCCGATTTTGACTTTTGTGCATTTTGGCTGGAGTATCTCATATA

[illegible]

CCAGGAGGTAATCTAAATATGGCCTCCTTGTGGGGGGGGGGGGGGTGTGTAATTGTCATATAAAATAGTCTCACCC
TTAAAGGAAAAACACAGATGGTGGTAATGATGTAGTCATAATGTACATCTCCACAGTGGTGGAAACAAAATATCCACA
GTTTTGCTTTCCCGAGTTTCAGTGACCCATGGTCAACTGCTGTCTGAAAATAGGTGACTACAATAACAATAAGATATT
TTAAGAGAGAGAAAGAAAGATCACATTACATGATTTTCATTACAATGTATTGTTATAATTGTTCTATTTTTATTCA
TGATTTTAAATCTCTTAACTGCGCCAAATTTATAAATTAATAATTTATCACAAGTACATATAGTTTATATAGGGCTCA
GTACTATCTGCAGTTTCAGACATCCACTGGGAGTCTTGGAAATGTATCCCCACAGATAAGGGGTAAACCACTGTATC
CTATTTGTGTGAATGCTACAGGTGTTGTGAGCTCATAACAATATGACATCAACACTGAACTAATCCAGGATTTGGTA
GTGAGAGTGTATTTTGAAGGAGTGAGACGTGGTGCCTCATCCAAGCAGAGAAAATAATTTGAAATTTGCCTGAC
AATAAAATACAATGTGAGGTCTCTCTTTAGAGCTGCAAAGTCCAATTGAGTCCCCCTAGCCACATAAGATACTG
AGCTCTTAAATGCGGCTAGTACTAATTGAGATGGGCACTGAGTATAACACACATGCCAGGGTTTGAATACTTAGAA
CCAAAAGGAAGTAAATGCTCATTATTGCATGTTAAATTTATGGTTTTATTATAGTTGATTAATAAATATATATA
TTAAATGACTTCATTTTGTCTTTTAAATGTGGCTATGAAAATTTCAAATTATATATGTGTGTGATTACATATGT
GTGTTTTACATATGTAACGTGATGTTACATGTGAAATTGATTGTTACATGTGACATGTAAAACACGTTACCTAACAC
GTGCATATGTATGCAACACATATGTAACGTGTTACATATATAACACGTTACATATGTATTGTTACATGTGTGCTTGC
ATTACACACATGCATAATATGAAATTACATGTAATTTCAAATTACATGTGTATATTTTGAATAATACAAATTACGTA
TTTTGTATTTTTGTCTTTACAAAGTCAAATTTACCTATTTAATAAAGCATCATGAGTTTTTTATAACTAGTAACT
TTGAGACTTTTGTAGGAGAATAAATAAGCTTATTATTAAGCACTGATTGGAAAAGTGAGCTTGCTGATAGTCCGAG
GAAAAAGGACTAGAGATCACCTTTCTCCAGCTCCGCTCCTCTCCCAACCTTTTTCTTTCCATTCTCTCATCCCA
ATTCAAAGTGCAGAGTTTACAGTTGGTGTGCTGATTTAGAAAACAGATATATAAACAGCCTTAAATTTTCTCCAGG
CTTTTACAATGAAAAGAAGTTCAATATCAAAAGTAACAATATAATCTGTGGAAAGGTATAGGGGGCTATGTTTTGA
GGTAGAACTATAGGTGCTCCTGGCCAAGCATGGTGGTTCAAGCCTGTAATCCAGCACTTTGGGAAGCTGGGGCGA
GAGTATTGCTTGAGCCCAGAAGTTTGAAGTCTAGCCTGGCCTACAGGGTGAACCTCCACCTCTACTAAAAATACACAC
ACACACACACACACACACACACACACACACACACACACACACACACACACACACACACACACACACACACACAC
CTACTCAGGAGGCTGAGGCGGGAAGATTGCTTGAACCTGGGAGACAGAGTTGTCAGTGAGCTGAGATAGCACCCTG
CACTCCGACCTGGGTGACAGAGTAAGACTGTCTCAAAAAAAAAAGAAAAGAAAAGTATAGGCACTCCTTATATG
CAGCTGCTCACACCCCTCCTCCTTCACACCCCTCCCCCTTCACACCCCTCCCCCTCCCCAAAATTTGCAAGGGGAA
AAATGTGTGTAATTGGCAGTATTTAGTGGCGTGCAACCGTGAGTCATCAGACTGCACATCCTCACTTCTGCTAGTGG
CTCAGTACCCCAACAGCACTCAGTGAACCTAACTCATTTCAAAGGTGAAAACAAGTGAGTTTGGCCACCGGAGGTG
TTCAAACCTGTCAGTGTGAGCAAAATGTGGAGGGTGTCTGTAGTTTGTTCAGTTGATATTTGTGCTCCACCCCT
TAGCTGAACCTACTAATTATTAATATCTGTCTTGATGGTGCCTCAGGAGAAAAGCTTCTCAAAGGGAATCAATGTTCAA
ATTATAGTAGGTATCTTGGCCATGGAAGTTATTGAATTTAGCCAATACTTGCTACTCTTTCATTATAGTGTGAGA
ATGCAGTGTAATGAACCTGACTCTCACTGTCTGACTTGCCCTTTCTCATCGCATTCACAATAAGCACGTCAATACGT
ATACACATTTTCATATTTCTAAAGTTTACTTTATTTCTTATTGTACATCGCTGTGCTGTGATGGAAGAGAAAAGGA
AAAACACTATTGATTGCAAACTGTTTTATCTTTGGTGGCTTAGATTTTTTTTGTATGATATGAACGTCTTGCCATA
CCTAAGGCAACACAGCAAGCTAAATAGATTTCATATAGCATGTATTTTTTCCAATTAAATGTTTAAATTTTGTGAG
TATACTGGGGACATTTTGAATAATGGAGAAAAGTACAAAGAAAATTCATAATTTCTACCACCTATCAGCACAGTGAAA
TTTTATGAAGAAACATAATTTTCATGTAAATCATAGTGAACCTCACGGTAGGTTTTATTTAATACAGTAATTGGAGAG
CTGGTAGGAAGACAAAACCTGGTTCAAAAGAGAATACAGAAAACAAATGCTTCTATAATGAGTGAATTTTTAAAAAG
TATTTCTGGAATAAGATTAGTGAATAAGATACTAACTCGTTGATACCCTACAGCCTTTGGGGTTATATCCTCTACTG
GGTAAAAAGTCATTTACATCATATCAGTTTTCTAAATTTGCATTGAACCTTCATAGCGTTGTAACATGTGTGGGCC
AAATTAATAGTAAACAGTAAGAGTTGCTTTACTCTGAAAATATTGAAAGCTCTTGTGAGGGTGTGAGGAGTTTGTAG
AAAACAACGCTACCATTATTTTGAACACACACGATCATCTTTTGTCTTACTTCTAAGTTTGGGATAATTTTCTTA
AATTATCTTATTATCTTATCCATTTTCTTAATTTCTTAACCTTTTAAATGTTTCTCTAGGCACCTTTTATTGATTT
TTGGAATATAGTTGATATGTGCTGAATTTTATCATCCAGTTTTAATTCTACTGAAAAATCTAAAAGATGTTTCATCA
ACTACTATATTTCAAATGCATACATCCCCCTTTCATGCTAAAGAACTGTATGGGAAACACAGTCTGACATTTTCAGG
ACCTGGTATCATTTAAAGTCTTGACACTGTTAAATTTAAACAACGCTTTTTTAAATCAAAGGATACAAAAGGGCT
GTGTTGGTCAGAGGATACAAAATTTTCAGTTAGATAGGAGACATAAGTTTCATGAGATCTTTGTACGACATGTGACT
ATAATTAATAATAATATGTTTTCGAAAATTACTAAGAGAGTCGATTTTAAAGTGTCTCACCGCAAAAAAATAGTATG
TGAGGTAATGCATATGTTAATTAGCTCATTTTAGCTAGTCCACATTTTCAATACAATGTGTTGTATAATACGTGAT
ATATACAACCTATATTTTCCAATTTCCAATAAGTAAAAATAAATGTAAATTTTGAATAAATAAATGTGAAGAAC
ATCCAACTTTTCATATGAACCATGAGATATTTCTGTGTTAAAGATTAAATGTCCAATAAATTTTGTATGTTAACAGA
AACAAAATAGTTTAAATTTTAAATACATATTTGCATATTTGACCCCTGAAGTTCACTGTCTAAGTAGAACAC
AACTATATCTTAAAGTCAAAAATGCTGAAATTTCTCCCAAAATCCCAAAGCTCATGAAAACATAAACAGAAAATTTCC
AAATAATTCTACAGGGAAAATAAGACACACTATTTGATCTGATCAAAACAACGGGATGATTATGGTTAATAATGAGTT
ACTTGTACATTTAAAAATAACTAAAGGAGTGTGATTGGATTGTTTGAACACAAAGGAGAAATGCTTGAAGGGATGG
ATACCCCGTTCTCCATGATGTGATTATTACCCATTGCTGCTGTGTCAAAACATCTCATGTACCCTACAAATATAT
ACTCCTACGATGTACCCACAAAAATAAAAATAAAAAAGAGAGGGACCCGAAGATAAGCTAATATTTAAGTCTCATCAT
ACTTATTAAGATAAGCAATACATACCCGAAGTAATAGCAATTTAAACCAGATGTTGGGGGAGGGTTCTCAACTGTTT
ATTAATAATCAAAGTCACCTGTCTTGTTTTTTCTTTTGTTTTTTGTTTTTTTTTTTTTTTTTTTTTTGTGATGGAGTCTCG
CTCTGTCAACCCAGGCTGGAGTACAGTGGCGGATCTTGGCTCACTGCAAGCTCTGCTCCCGGGTTTACGCCATTCT
TCTGCTCAGCTCCCGAGTAGCTGGTACTACAGGCGCTGGCTACCACGCCCCGCTAATTTTTTTGTATTTTTTAGT
AGAGACGGGGTTTACCGTGTAGCCAGGATGGTCTCGATCTCCTGACCTCGTGATCTGCCACCTTGGCCTCCCAA
AGTGTCTGGGATTACAGGCGTGAGCCACCGTGCCAGGCCACCTGTCTTGTTTTATCATGATCCCGAGAGTATATATGT
ATGTGTACAGCTCATCTAAACCTTTTTCTTTCAACATGATCAATAGATTGAACATTGGAGATATTTTATAAGAAAT

AATGAAGACAACCTCAATCAGCACATATATATATTAATGTGGAATCTATAATGATTGCGAAGCCTGAAGCAAACCTAA
ATATTCAGTAATAGGTTCTTTTTTCCATGGTATATCCATTTGAATATATAACATAAATGCCTTACATTTGTTTTAA
CTATTTAAGGTTTATGTTGTAGTGTGATGAAATGGCTGGCAAAAGTCAGAAACTCAGGAAAGTTTCAGGCTTATAT
CTGGAGCCTGGTTTTCTTTCTTCAAGGTAGAACCTCTGTGAAGTGAAAAATTTTTTTATATCTGGAGCAATAATGT
AGAAGCTTAAATGTATTATCCAAGTTGTCATAAGCCTATTATTTCTTTACATTACTGAAGTGAAAGACAGCATTAA
GGCTAAATGCCATACTTGGCTATAATTTATATTGTTTGAAGACTGGAAATGAGCCTGAAATGTACATTTTTTTCCAAA
ATAGTTCATGTAATATTTGAAACCTGACAAGTAACCTGATGATTTTCATGGAATACCATCAAATATAAATGTGAAGTT
TTAAAGACACAGGGAAATACTCAGAATAAACCCCTAACCCACAGGCCAGCAGAAGAACTAGACTTGAGAAAAATGAAT
GGGAAGATAGATAGTAACAAATGACTTCTTTGGCAGCCTTATATATGCTTAGTCTTATAGACTGTTTTATGGATGCT
CTGCACCTCTATTTCCAGCAAGTATGGCATTGGAACAGGACCACAGAGACAAACTATGAGTTTCACATTTCCACAA
CTGCACAGATAGAAAGAGGGAACAACAGAATACTCCCTTTCTTCTTGAACAATAACTTCTGTTGAAGCTCATGGC
TTCTTTTTCAGCTGTTTTCTGCTAGCTCCTCCTCCGCCTTTGACCTCTAAGGCAATGCTCTTCAAAAATTTCAAGACTG
CTTTCTAATTGAAACAAAACCTTATAAGCACATTTCTTCCCACAAAATGTACATTTATTTGTAAATCATATATGAATA
TGACTAAGCATGTAAACGTATGTGAAAAATAGAAATCAATAAATATAAATGCAAACACAAATAGAACATTACAGTT
TTCTTTTGTGTCCAGTGAGTTGTTCCAAATTCCTCGGAGGTAGGTATGTACAGTTTGAGACTATACCTTCAATCC
TAGGGTTTCTGGTTTCGCTCTCCTCCTAGGTGATAGCATCCATTTCTACGGACTTAAGTGCATCTTTAGTTGAATA
ACTCCTCTATTTTCCATCCCATATTTCTTGATTCCAAACCTGCTTGTTTACCTGAGCATGACCAATAGTAACTATT
GGCTGCCGCACATGCAGCTTTGACATTTTATTTAAATCTTTCCCTTCCCAGCCCTCATCTATTTACAGTAGTA
TCTTCTTCTTATCTACTTGATTGGTAAGCAGAGTCCACATGATTCCATCATTTATCTCCATTTTATATCTAATCTA
TAAGCAAGTAATGCAATGCAACTTCTGTCTCCAAAAATTTATTTTGAATTTGCCTTCTCTTCCCTGTCATCTCCCC
ATCTTAGGCCAGGTACCTCTGCCCCTCTTGCCAGATTAGGTACATTTCTCTTACTACTGTTGTTATTCTCTTCCCTAT
TCAATCTTACACCGCAGCAAAAATGGATCTTCTCAAAATGTGAGCTAGATAAAGGCATTTCTGTGCTTAAGGCCCTCA
TGGATTTATCTTATTAGGATGAACACCCAACCTCTTTATTTATGGCTTAGAATACAATGAATTAACAACATAATGAAT
ATATTATATTTCTATCTTTACCATTTTCTTCTTAAGTCAACCTTTCTCAATCCATATAGGATAATCATATTAGTGCT
TCCTCACTTTCTAAAACATCTCAGGGCCTTTGCACGTGTTTCTCTGTCTTAGACCCAGAATGCTCTTCTTTTCTC
TTGTGTAGCTAGGTGCTTCTTTCCATTACGTATCAGATGAAATGCAGTCATTCCCTCCTCCTTCCCTCCTACCT
CACAAAAAGTTGATGCCTCTGTTAAACCATGAATGGAATTTTACTCGGCAGTGAATAGAGGAAAAACCAATGGTAAA
AGCAACCATATGAATGAATGAATGTCAAAAATATTATGCTGAGCCAAAAGTCATAGACACAAATATGGGTATTTACA
TGAAGTTAAAGCACAGCAAAAACCTCAATTACGGTAATAGAAATTAAGAAAGTGGTTACCTCTGGGTGAGGGTTGGAAT
GAGTGGACAGAGGCATTAGTGACTTTTTCGGGGTAATGGAATGTTGTCTATTTTGTTCAGGTGGTGAATACATAGA
TACATTCATTTGTCAAAACACATCCATCCAAACACTTAGACTTTTGCATTTTATTATATGCAAAATATGCCTCAACT
GAAAAAAGTTGTTTTCAAATATATCAACAGTTGAAATCTTTTAAAGATTTGATTCAAATGAGATTAATTTCTGT
ATCCATCATTTGATGTATGATAGTTTGTATGTAGTTAAGGTATTGGAGATAATTGAAAGTTATACTCACAAGAAGG
CTGCATAATATGAAGTTTATCTGCCTTGATCTTTAATAGCTTTTCGCGATTTCAACTTCTTCACAGCTCTGTAAAG
GCAGTGTGGCATGTTGAAGCAAGCATGTGTTTTAGAGTAAACACAGAGCTGGTATACAACCCCATGTCTACCAATTAT
CAATGATGTGGGTATGTTGCTGGATCTCAATAATCTTCCACTGTGAAATGGAATGTAACACCTGACTCACAACGCAA
AGGTATTTACCTTATGTAATATAATTCCTGCGATCCTGGGACCTCCCTTAATCCCATCCACAGATGCCAGGTTAAAG
ACCCCATCAGAGACTAGAACAGTTGGGATGTCAAAATGAATAAATATTAATCGAAGGGCCTATTGTGATTGAACAC
CACGCAGTAGGCATCTCTAATACCTACCGTCTCCCTCCTTTTTGGGGGAAACATTCTAAATGTGCAAAAAATAAAG
GGTATTTGCTTTCTGGCACTTGGGATCGATTTATTAGGATATGTTAGCAGAACAGCAAAGGTGAAACACTAAAAG
CACCATCAATACACAGGCAGAGGTGAAGCCATAAAGCCTTTATTTTAAATTAATGCACAATATATAAGAGGTATG
TTAGAATGAACGTCCAATCCCTGAAAGGATATACGAAAGACATTCATAAAATTACATGGGCATGTTTTCTTAATGTT
CAAAATATTGTTTTAATTAGTGTATTATGAGTTTATTCATGTGTCTGTGTGTTGTTATATTAATCTTTTCTTGCA
TTGCTATAAAGAAATACCTGAGACTGGGTAATGGATGAGAAAAGACACTTACTTGGCTCACAGTTCTGCAGGCTGTA
CCGGAAGCATAGCAGCATCTCCTTCTGTGGAGGCTTCGGGAAGCTTCCAGTCGTGGCAGAAGGCAGAACGGGAGCAG
GCATTTACCTGGCTAGAGCAGGAGCAAGAGAGACAGAATGAAGTACCACACAGTGTAAACAGCCAGATCTCAGAG
AACTCACTCATCATCATGAGGATGGCACCAGAGGATGGTGTTAAACCATTTCATGAGAAATCCACACATGATCCA
GTCACCTCCCACAGGCCCCACCTCCAACACTGGGAATTACATTTCAAGATGAGATTTGGGCGGGGACACATATCCA
AATGATATCCATGTTTAAATCAGAAAAATAAAGTTAAACAGTAACAGTGATTTTACTTTGTAGACCTTTGCTAATGGC
TGAAATCTAGCTCCATTCCGAGAACAGCTGCGGTACACATTTTGAAGATAGTTGATTAATATGAAAGAAGCCTTA
TCTGTAGTCTTTAAGGCCATTATGGTTTACATATATGAGTAAATATTCCAAAGTAGCCATGCCAGTTAATCATATATC
CAGATCTAAAGGCCACTGGGCGACAAAAGTAAAGATACATAGCAATTGTTACTTTATATCAGCATTAATCTTTGTA
TATTTTAAATGGATATTTGCATTTGAGGATATCCACTTAAGAGTTAGGTACATGGCTCTTACATTTAAGTAACATTT
ACTTAAATTTCTGGCTGCAGCAATTCACATAGGTAGAAATGAAGTCTGAATTGAGTTGGGGGCTTTGTCAGTGCTC
TCTCTGTTTCATGGCTATTTTGACAATGCTGAGAGATGTGGTTAGCCATTCTTTTTCATTTTCATTTGGCAACCTAG
AGAGCAATTAAGCCTTCTCCCTTAACATAGATGTATGTTTTACTCATTTCTGGATCTTTATGGCTGACTTTGAATCC
TAGCCTGTGGTAGAAAGCATGGTGTGAGAAGGAACATGAGTTAAGACTATGCATACTTGGCTTTGAGTCTTGGGTA
TCATACCTCCCTCATAGAGTGAAGGAACAGGGATCTTCTTGAGGCCAGACCCGGCATCCATGTTAAGAAATACCT
GTGCAATTTTGCTTCTGATATTTAAGGTGAAAATGCATGTTTGGGTCATTGTGAGGATTATGTGAGATGTTACTTT
TAAATATAGCCCCCTTATTATATGCTCTCATAGTTTTCAGGCAACACTTGTCTGATTTGTAACCTCAGTTTTAACTG
TAATGTTTCCATCAATGTCCCTCTTACCTGGTACAGGGGCTCTTCATATTCTTGGATTACAAATCTGTGAATGCAAC
CATGCATCAAAAATATTCAGAAAAACAATGAATGCCTACCTCTGTACTGATGATTTATAGGTGTTTTCTTGTCTATT
ATTCCCTAAACAGTACAATGAATAAGTATTTATATAGCAATTACATTGTATTAAAGTATTATAAGTAATCTAGAGAT
GTTTTAAAGTATATAGGAGATGTGTGTAGGTTGTATGGAATAGTATGTCATTTTATATGTCATTGAACATTTGT

GGATTTGCTATCCGTGGGGATCCTGGAACCAATCCCCCATGGATACTGAGGGACAATTGTATTATAAGCAGCAAGAG
GGAAAGGAATCTGTCTATTTTGCCCAAAATCGTGTTCCCGGGACCTAGCATAGCTCCTGGCAAAGAGTATACAACAA
ATATGCATTGAGGAGAGAAACAGAGGGAACCATATCCCTTATTCTCGCTGTTCCCTTCATGTAATGAATAAACAGTC
AAATCTTACAAGAGATTTTAAACCAGTCAGAGAAAAGTTGGAAGTTAGTTAGTTGTTTCATACATTGAGAAGCCTCGA
CGCTGTGTCATCTAGGTAATGAAAGATCTAGGGAAGTTTAGCAGGGAGAAGAAGAGAGATGATAGTTGTCTTCAAAT
GTTTGAAGGACTGTTACGGACACAAAAATTTAAACTTGTGCTGAATAATTTCCAAGAGGTACACAGTCTCTCGATAGA
AGCTAAAGTGGGGGTGACATTTGACTCAACAAAAAGCCATCTAAATATCAGAACTTTCAAAAGCAGGAAGTGGTGC
CTCAATTAATAGTGTGTTTTCTAGCACTTATGATACCTGATCATAGGCAAGATAATGAAAAATTGGGACCTGGGAGT
TATACATGGGAATTTGTTTATCAGTTGGGTGATTAGGAGAGGTGGCCTTAAAGTCTGTTGTGTTCTAAGAGTCTGT
GATTCTGAGTCTTATTTCCCAACAAGAGAGGTACAGAGCAGAAGATGGGATTGGGAGAAATAGGATAAAGATACCAG
GAAATCCTAAAGGTAAGAAAAGGAAGGCAGACCTGAAGCTAACTCTATCTTCAGGTGCTTGCCTAGAGCCAGCCCT
ACCTACTTAGAGAAATGTTGAAGAGCCAGTTAAACATCTTTAACACGGATGTAAAACAAAACCTATCAAAACCTGAAG
ATTTGCAATGTTCTAACCTACTCGTCAGTTGGGCTTTTTTACAAATACTTCAGTAAATAGGCATAAAATTTATTTTT
TAATGATAGAAAATATCTCTTAAAGAACTTATAACTGTGGATAAAAGCACCACCATAAAAATCTTGTGGTGAATAT
ATATATATATATATATATATATATATATATAAAATTTTAAATATGGTTAGCTAGAATATGACGACAATGTTTATGAA
ACACAGAGACTCTTGACAAGTCCCATGTATACACTATAAACTTTAAGTTATCCACTATTCACCTACTAAGCTTATA
CTTATTAGTGTCTGTCTGCTTATGCGGAAGCAGGCGGTATAGCATTGCACAAAACATATGTGGTCTCT
GATGGAGTTTTTTCAGTCTAGTGGTGAAGCAGTGAATGGGTGTACAGATGTTAAATAATTGTACAATTAGTTGCATG
TGTAACGTCAAAAGTTCAGAAGATGACAATTGATCTACGGCAATGTTTCTCAATCTCTGACGTTTTGAGCCAAATAC
ATCTTTGTTGTGGTGGACTGCCCTGTCCACTATAGGATGTTTGGCATCACAACCTGACCTCTGCCATTAGATGCCAA
TAGTACTCTCTCTTTAATCACAATTTGTCCCAGACATTTCCAAATGTCCCTTGGGGAGCAAAATCATCCCTAGTT
GAAAACTCAGTGGTCTAGGGGGAGGTCTTTATGAGGAAGTAACATCTAAGAAAGCTGGTATGTTTACATATAGCTACA
GTCTATTACACATGTATACATATGTAACAAGCCTGCAATGTTGTGCACATGTACCCTAGAACCTTAAAGTATAAATAAAA
AAAAATGTAACAAAACAATACAGTATGATAAGTGCTATGGGACCAAAGATGAAAGGGTTCTACTGCACAGTTATGAAC
TCATAGTTAGGCTTTTGGGTCAAAATTTTGTCTGAAGATATTTGCCACCCACGTGACCTTTGGCAGGTGACTTAGCT
TATTCATGCCTCAGTTTTATCCAATGTGAAATGGGGCTGGAAAGTCCCATGTACTTCTTAATAACTTTGCGGAAATA
ATATGTGGTTATATAGGAAAAAATCCTAGAAGTATGCCTGCTGCGTAGTAAAAGGAAGGAGAAGGATAAA
GAGAAATCTGCATTTTTCTCTGTAATGGGGCAGATAGTAAATATTTAAGTTTTGTGGCCCAATAGTCTCTGTCT
ACATTTACTTGATTCTGCGAGTTGTGGCATTTGGAAGCAGCTATGGACAATACTTAAATTAGTAGGTGTGCTGTGCTT
TCAATAAAATTTTATAAATACAAAGTTTGCAAAACAAAGTTGTTTTTTTTTTTTTGTAGTTTGTGACACCCTAGT
AAAGAAGCACCATTGTCAACGTTAAAAATTATCAAATTTTATTTTTCAAAGTTTTCAAATTTGCTTTGCTTGGTCT
AGCTCATGAAATAAGTCAAAAGTAGCAAGACCTCCACCTCTAAAATAATAATAGTAATGATAACCTCAAAAGGAAAG
AAGAAATATTTTTAAAGAAGAAAAATTTATGTTAAATAGGATTATTTGTGCAGAGAAAACCTAGGAGACTCAATTTTA
AAATCTGTGAAATAATTTTAAAAATACTTTATGAATAGATACATAATAGCTTTTATTCATATTAATGACTATAAATG
CAAAATGGAAATTTTCATTACACTGATGACAATGTATAAATTAAGGAGGAATAAAAAATTTAGTACCTTATAGTCTCGTAA
AAAGCATAAAAAATATACATAAGAAAAAGCAAAATTTGACTACGTAGGATTGTTTTAGGATTTAAGATTTATTTGCAT
TAACTTGCAATACCAGCCAAGTTAACATTTGAATTTAATACAGTTATAATCAGAATGCTTTTGATGTGTTTGGGG
CAATATAATTTCAAAGGAAATAGGCAATGATGTAATTTAAAGTTTATATAGAAGGAAATTTGTGTGCGTGTATGTGTG
TGTATAAATTTGAAACAATTTTATTAATAAGCATATTATGGCAGCAACATACACTTCCAGATTTCTACTATACTTTG
AAGTAATTTGATCAAAACCACAGTGTGCTGGCATAAGGCTAGAGAAATGGGTTAGTGGTTTACAAGTGAGAGTCCA
GGAAACATCCAAATAAGATTGGATATTTTAGTTCTGTGTGGATAGCCTATTTCACTTAATAAATAGTGTCTCGTAA
TTGACTATTCATGTACCTATAAGTTTAACTATAGACCAAAAAACGCCCTACTAGATTAAGGAGCTAACTAGAAATA
TAAATTCATATAAACAATAAAGGAAAGTGTAGGACTTTATAAGCTTCATGGGAGACAGATTTTTGGTAAAGTCAGGAA
GCCTGGAAGACTTAAACATAAAATTTGGCAGACTGAATTAAGTATAGTTTAAAGCTTCCATAGAGCAAAATAAATC
ATAAACCAAGTTTTAAATATATAATGGATTTAGAGAAGGTATTTACAAAAATATATGACTAATGGAGGTTAATAAT
AACAAATGTGAAGAAGGATATGAAATGGCATTCTTACATAAAGGTCAAACAAATGACCTATAAGCATAATAAATCAT
ATTAATCTCCACTAGTAATAACTACACACATCTACATAATATAGATGTTACGCCCTGCATTTGATTTACTTTATCTGT
CTTTTGGCAGAATCTTTGTCACCAGATAAAAAATTTCTATATCATTACCAGAAAGGTATATTATTATAATGTTTATT
ATGTTGCAGTTGTAAAAGAAATAACAGCTTTTCAATTGTTTACAAATCCTATAGAACATTTACTGAAATACATTTAC
ATTTTGTGGCAAACTTGGATTTAAATACCGTGTTCTGTGCTTTGTTTTATGCCGTTTTCCCATCTTTTCTCCAGGAAT
TTGATTGTGCTTCATTGAAAGCTAAAAAGAAAAAATAAATTTCTGGTTTTGGTTTTAAAGAAATTAGGTTAGGGGT
AAAAAGTCTGCTTGTCTTCTGTAAAAAATAAAAAACAAGTTTTCTTGTCTTGGAGGCTTTATATTAAATGGAT
TTTTAATTCATAGACAGCATATTGTGATGAAATTTCCCATGAGCTTCACATTTTGTCTTCAATAGCAGAACTAACT
TGGTTGCAGTTACTGCCCTTCTGAGAACAGTGTTCTGGAATAATTTTGACATACATATGTATCTCTTTTTAAACAT
GTGTTAATCTTTTCATAAAGAAAGTTTTCCAGCTGTGTACCTGTGACTCCAACCTTCTGGGGGACAGGGATATG
AGATGTTGGAAGGGAATGGCTTGAAGAAATAAAGTGCAAAAGACGTAATGCTTTCTGTGGTAGAAATGTATTCAGT
GACCTGTAATGACCTTCCCTACTCTTGTCCCTTCATTTTTCCACAAAGTATGGTCTGGGCAATTATAAAAAATTGACAT
TTGCAGTGGGCTCTTCTGTAAAAAGATGCTCAATCAGAAATGATTTATTTAGAAAAAGAGATGATATAAACATATAT
ATCCCTGTCTCGGAAGTGTGAAGGTTGAAAAGCAAGGAGATGATCTTCAAAGTGTCTAAAATATTGATTTGTAACA
TCGTTTTATGAAAGTGCTTCAGATTATTTTTTCTTGGATGGCCCTTATGCTTTGGTCAAGTTGATGCTAAAAATCT
GAACTTCTTTATTTTAAAAAACTTTTAATTTTGAAGGAAAGTTCACGGTGTGTCTAATTTCTTTTAGATAGT
CATTAATGTAAATGTAAGAGTCATTCTGAGAACCACATCTGCTGATATGTTCCGTTAAATTACAAGTTCTATGTGTA
TTTGCTTTGCTTTTCATACATGAATCTTCTTACTCTCTTCCCACTGCCAGAAATTGCCCCACTCAACGTTTCATA
AAAGGTCCATTTCAATCGCTATATTTATTTTCAAGAGCAGAGATATCATATATTTCAATTTTAGTTACTTTCCAATA

TCAAGCTAATAACTCACACAAATAAATCAAACCTACAGCAAAACAGCAATCTAGCATTCAACAAAACCTCCCCAATGC
ACATATTTTCAAGCTGTAGATATGTATCATCCACCATGCTGAAATAATGTACATGTTCAAATCAAATGGAAAACCTAGA
ATCAAAATTTGTTGATTACTTCTTATCAGGGCATTITTTATATATTTAAGAAAAATACAAATTAATCATTTTCAGGAA
GCAATCCTTCTGGCTAAGATTTTTTTAGCATAATGCTTAAAGTTAATTGTTGATCTTTATCTATAAAATTCAAAGGTG
GACTAAAAATGCAGAATCAATCAGGTAGTCCATTTTGCATCAGGTGAAATATATAAAGCATAAAACAGCGAGTTACA
TTTCTTAACAAAATTTGAATTACAGTGAGTAAAGTGACAGGACAAATGCATTAAGAAAAGATGGACTGAAATGGATA
GAGTAGAATATATGCATCTATAAAACACAGTCATATATAATACACTCATTTTTTTTTCTTACGAGTGTGAGATTAATG
GAAGAAAACAATAATAACAAAACAGTGTGATGTGTCAGATTTACCTTTTAATTAATAAAATTTATTCACCTCAG
AGGGGAATTTTCTTTCTTGGGTTAGCTCAATCATGTGAGATCTTGTTCATTTAAAGGTCAGTTTACTTGCCTTCTG
AGGTTTTTGTGTTGGGAAAAAGAAAAGAAAATAGATTTTCATTGGTATCCTGGGTAGAAATTAATTGTTTATCATTCA
TTTTAAGATCTCCGAGAGGCAGAAAAAGGGGAACCTGTCAACCCCTTTTGTCTTCTGGATCTCAAATGAAGGGATA
CATTTCTGTACATGAATGTGGAATTAAGACCATGTGCAACATGATAAAACAACACAAATTTGGGGGTGTCTCTGTG
CTATACATTATTGAATTTTTCCATGCTATACACTTTTTGGATGTGCTGTGCTATTATTACAGTTTTTTTTAAATAAA
AGTTTTTGTAGACTAAATTTGCCCTCTCTACTTTGCATCGTTTTTGAACAAAGGATTTTCAAGACTGATAAGCTCAAA
TGTATCATTTATTGTATTCAAGTAGCATTCAATTTTTCTTTAGAAGTATAATTTGTAGATATTTTAACACAGAAAAAC
TTGCAACACTGCTCATGATAGGCATTATTATATATTTTTTGAAGACTATATGGATAATGATTCTAAGTTTACTT
TTCCGTTTTTGTCTTCACTTTAGAATTAAGCAGAGATAAATCCATATTCTTGGGGCGATGTTTGGACAACTGAT
TCTCTTTAAAGATCTTTGTGTGAGTGAAGGTGCAGCCAGACTGGGAGTTATTGTGAAGAAACAGATTTCAGGAAGGT
TGAGAAACTTGCTAAGGCTAATCAGATAGTTACTGGCAATGTTGTTTCTAAATCACTGTTTGGCTCCCTCATTCAA
TGAATCTACACTATGTGGGACTGCCTCTTGTCTCTGACATCTTTTGTCTGCTGAAATAAATGAACCTCAAAGCCTAGAA
GGTAGAAAAGAGGGAGTTGAGAATTATATTCAGGCACAAATACCAATAAGGCTATTGCCCCCAGAACTGCAACTTCT
CTTGGTTTTAACAGATAACTATTTAGCTGTGAGGTACAATGAGGAAGTGGACACACAAGTTATCAGGAGATTCTGAT
GTGCCAGTTTTATATTTCTTGTACAGGTAATGATTGCAAAATTTCTTAAACAGCTGTCTCAGTGGAGTAACCTG
GGAGTACATGAAGGCATTCCAAGGAGTAGGCACAGATAGTTTTAAGGGAATTTATTTCTAGATCTTCTACTTTATTT
TGTACTCTTCTGAAAACGAATTGCCTGAAAAAAGACATCTGTAGTCAAGACCTCAGGCT
GTTTCTCTTTCTAACCCTTGCCCTTTCTAACCCTTCTCCCAATTTAAGAAAAAAGCCTTATATTTTCATCCAAC
TCTGATCTTACTAAGGCTTCAAACAAAAGAAGCATGAATGACTTTTCATGACAGGGCAACATAGCTTTTTGCAAGAA
AGTGGTTGCTAACTCTTTGCTTTCAACTGAACCCGAAGAGAAGACCTGATAAGTTGTCAGCCGATAGATCATTAAAA
ATACGTTTTTGGTAAGCAATCATCATGTACTTTTAGCATATGCCATAGCAGGAGCACAATGATTAAAGCAATGCTACT
ATAATACAATTCCTTCCGTTTCTTTCTACTCACCTATTGTAATAAGATTTTTCATCATTTACATCTATACAGACAAA
AATTAGGGATAGAATTGATGCTGAAGCCTTTCCAATTGTAGAATTAATTTATATTTCTTCTGAAGGTGTATAAATGT
TAAATACCCATCCATCTTATTAAGAGATGTATTTTCAATAAAATTTATTTTTATGTTTATCAATTTTATAATATA
CATATATTGTTTTGGTCAATTGCACGTTAATAATTGTAACAATACCTCAATTGAAAAGGTTTGTTTTTTACATTTAG
GACTTACAGTAACAGAAAAAAACACTCATTTGTGTATACATACTGTTAAGAAAAGTATACTAGGTGATCAATAAGA
TTTTTTTCAGGCATAAACATATATCTTAGTTTTAAGATATCGATATTTACAATGTCCCTCAAATTTATATTTTTCAG
TCATTTAAGAAATGAAAAGTACATTTTGAATGCGGATTTTAAATCTGCAAGGGTTGACTCATTTTTTCAAGAGTCTTTT
TAGGGGATACAGAAGCAAGAATGTTTGGAGTTCCCTGATCAGTATCTTTAAGAGAAGGTATTTGTTGGTAGTTCCCTA
GCAAAATTCACAGCCTGATGCTACTTAAAGATAATAGTAATTTTAAATAATGCTTCTGATAAAAAACATTCA
TGCACACTCAGTTTAAAAAGATATTTAAACATTTGTAGTTGTAGTTTGGGAACCTCATGATACAAGTACAGTCTGTAA
ATGAAGCTCTTAGTTTGCAAATATCAGAGATAAGCTATTAATGCGAAAATTGAAATTTGCCCTGATATATGCATAA
ATTAGTGTCTCATCTCCATCTTGTGTCAGTATGATTTTTTAGATTCTCTCTATGTATACATACATATATATATATA
TATTTATATATATATATATATTTGTGTAGCTGTGCTATGTGTATTTGGACTAATGGGTCAAAGGACAGTACTAACC
CAATTCAATAATTAAAGAAAACATAATTTGAGAATTAGCTTTATGGTAATTGTTTGACTTAAATGAGTAGATCAGA
GAAGAATAAGGGCTTTCCCTTATTTAAACAAGCTTCATTTTTTTATCCAAACATTACTTAGCTGATTAAGCTTCAC
TTGTTTTATTTCTTCAAAGCATTCAATTCAGGTGGGTACTGAGTAACTGAAATATCACACCAGGGAACCTTCAACACC
ATCCAAGCTTAAAGGCTTCACTTGTTTCAGTGTGGCATTTAGTGAATGTCTAGGCTACTGATAATATTGTGAGTAA
GTTGGCAGGGATCATAAGAAATGATAAAATACAGTTCTTGAATAATGTTATGGTTTGAGGAAAAGATCTATGTTTGA
ATTAGACTGACTTGGATTCAAACCTCTGGCTGTACCTTTGGGACAAGGTGTTTCAGAAAACCTAGCCTATGTTTTTTT
CTGCAAAATGATCCTCTTTTCCAGGATTCTGTAGAGATTCAAAGATATGTGAATGTTTAGAAAAAGAATAGACTTT
TGATCATTTGTTAATTCCTTACTTTCCCAATTAGACTTGTAAAGACTGGGAAGAAAGCTACACAAAAGATTGAACAA
ATTATAGCTGACAGACCATAGCAAAAGATACAGGGCAAAACCTTAAAGGGGAAAACCTACACATTAATTTTAAAC
CATTAAATAGCATACTTTTGTGATATTAACAAAACCTCAAAATTAAGATAAAGTAAATTAATTTTAAATGCTG
TTTTTTCTGTTTACTGATGTTTTTCAATTTGCTTCAATTTATTTGGAAGATATAAAATGTGTTAGACACTGTTAGG
TGCTGAGTGTATAAAAAATCTTATTAATACAATTTAAACACGCACACACATATATATGTTTATAACAATTGATGCC
ATGTATGTACTGTTTATATGCTTATATCTTCCACAGACCTGGGGGGAGGGGATGTAGAGTCTTACCAGAACCA
TAGGAATCTTCTCACATCAACATTTCTTTTGAAGTTTGTTCATGAGGCACCATCCAGATAATACTACCATCTGCAA
TGTGGCTTGAGAAGATGTTAGATTTTTTTATACATAATAAGGCTGTAAAGTATTTCTGTATTTAGGTAGAGGTA
TGTAATACAATATGTATATATAAAATTACATATCCAATAAAATCTGGTGTAAATAAGGACTAGCTTCTATGATAATAT
AGTCTAAAGGCTTTTCAATTTGGTGTATAGAAAATTATGTGAAATATGTTTCTGGAGTAGAATTATTCGCATTTTCAG
CTCTCTGACAGTGAAGAAAAGCTAGAGGGAGAGGTGAACAAGAGAGGGAGCATAATGGACAAAGCTTTGCTGGAAG
CCAAACCACCACTTCATATGCAATCTGACAGGCCTCCCATTTTAGGTGTGCTGTCTATTGAAGCTTTTCAGCTGCAC
CTTGCTGTGGCTAGGCTATTTTCAAAGATTAAATGCGAAAACCTGGAAATTAATGCAACTTAATTTCCCAATTTAA
TTTCCATTATTTTGAAGTAAAGATTAAAGAAATGTATAATTGCAATTTCTGGTGAAGAGGTAATTATAGGAA
AGGTGGGATGATTTCAAGTGGGGGATATAGCTTACTGCAGCAGAGAGGAATCTAAGCTATCATTTCTTTTGAATTG

GTCTGGAAATATGTTTTACATGGAAATATACTATATTTTTAGGAATTTTCCTTGTCATATTACTGTATCCTTTTCT
GTTAGAATATAAATTCTGAATTCCTATTCCACTGTAGATCTGCCTCCGATTATATTAGCTCTTCTGAAGTTATCAA
AAAAAATAGATATACAATATTCCATATATGTCAAAGCAATTATTTTTAGGTTAAGTAATAAACCAATGACCTTTA
ACCCGGTAATATTCTGGGTTGTTTCATAAAAAAACTATATTAGGTAATAATGTCCTTTCCACTTAAGCAACTGAAAAA
ATACACAATACTTAACATTTGGTTAATTAAATACCTACTCCAGACAAAAGGATTTTCTGTTTTCAAGTTATCTTAGC
AAGCTGAGCAGGAAGCAATGATATATCCAATCAGAATATCCATGGAAGCTCTGCTACAGTTTTCAAAAAGTTCTCATC
AGGCAGCTTTTAAATGCCTACTCTGAAAATGGTCCAGGTTAAAGAACAACAGCTTCCTCGTCAGATAGCAGTATTG
CTTGCCCATGTTTCTTCTAGCACAAAAAGTACCTGCTCTTCTCTGAGTACCTACATTCTAAGGACTATGGCTTAC
ATAAACAGCATGGGTTGGGGCAATTTCCAGCACACTGCTCACTCTCGAAAACGTATGATGCAGGTGAGAGTAATGT
TTTTGTTTGAATCTGCTTTCACTCGTGGGAAGATGAACTACTTGCAAAGATCTGTACTTTAGCTATTATGAGTAACA
AAAGACTCCTAAAATATTGCACACATTGTGGGATGGAGAACCATCATCTGGGATTGATGGATCCTATGGTTTGG
CTTTGTGTCCCAACCAATCTCATTTTGAATTGTAATCCCAACAATCCCAACATGTCAAGGGAGAGAGACCAGGTG
GAGGTAACGAATCATGGGAGCAATTTCTCCCATGCTGTTCTCTGATAGTGAGTGAGTTCTCACAAGATCTGATTG
TTTTATAAGGGCTCTTCTGCTTCACTGGGCATTTCTTCTGCCACCTGTGAAGAAGGTGGCTTGCTCCTTCTCAC
CTTATGCCACGATGGTAAGTTTCTGAGGCCCTCCCAAGCCATGCTGAACTGTGTGTCAATTAACCTCTTTCTTTTA
TAAATTAACCACTCTCAGGCAGTTCTTTATAGCAGTATGAAAAAGGACTAATAGAGACGTGCTCTCAGAAGTCACA
GTGATCTTGAAGCACTTAGTCTCCATCAGACATCAATCGAGAAAAAATCATTAAAAATCACATTTTATTTGATGTAT
CTCTCTGTAATGGGAAAGGTTTTACTTTGAGCACTAAAACCTGCCAGAATTCTCAATTTTCTAACAGTGTGTTAA
TAAACACCTACTCATTTAGTATCCAAACCAGGTCTGTATTTCTCAATTAGAGCTCACCAGGCTTTCATCATAAAGTA
GAGCTTCAAAATGTCTGCAATCCCACTCCTATCAAAAACCTAGAAGGAGGTAATATTTAGAGTAATACTATAACCA
GATGACCACATCTAAGAACTGCTGACCTACGATGTAACCTTCTGTCCATTTTTCCCTTTGGAAAGTCTAGGATCT
TTTCTTATACCAGCAAGTTACAAGCCTGGACTACATAACTTGCTTTCCGCAGAAGAAAACACCATGAGTTCTGTGTT
TCATATTAAGCACTTAGTCTCCATCAGACATCAATCGAGAAAAAATCATTAAAAATCACATTTTATTTGATGTAT
ATTTCTCAATAATCCTATGTATTAGTTCATTTTCTACTGCTATGAAGAAATACCAAGACTGGGTAATTTATAAGT
AAAAAGAGGCTTAATGGACTCACAGTCTCATGACTAGGGAGGCTCACAAATCATGGTGGAAGGTGAAGGGGTAGC
AAAGGCATGGCTTACATGGTGGCAGGCAGAGCGTGTGCAGGAAAAATGCCCTTTATAAAACCATCAGATCTCCTGA
GACTTATTCAGTGCCTAAGGACAGCACAAAGTATTTAGCTCCCTCAGCACAGAACCATCCCGTGATTCAATTACCT
CCCACCAGTCACTCCCATGACACATGGGGATTATGGGAGCTACAATTCAAGATGAGATTTGGATGGGGACACAGCC
AAACCATATCATCCTATTTGGATGATCAATATTATCAAGGTATGCTCCCTGAGGGGGCTCTTTTACCATTATAA
CTCCAGGACAAAAGTTTTATTCTTTGTAAGGACAGTGTATTCTTATGGTCTTATTTCTCCTAAGATCCAGACA
CCAAAATGGCCATCTATCATTGACTTAACTCCTGAATTTTGCTTAGAGTAACAGATTTAGTGAATCTAAATATTTTC
TGCTGTGGAATGTTAATTATACATGTTCAAGTTACCTTTGATTGATGTGACAGTTTGTGCCAAAACACACTCATT
ATCAGAACTCAGATCATTATGTTGGCTCTGTGTTTCGTTACTAAAGGAAGAAAAACAGTTTCTCAAAAAGAAAAATC
TGATACCTAGGAAGACCAATTATACCTCACTCTTTTCTTATCTCATCACCACATCCAATATTATAAAGAACTTACA
AAGTAAAAAGAAAGGTGTTCTGTAGATGTAGCGCCTGGCTTGATGGTAGCTTAAATGAACACAGCTAAAAATATTT
TATGGCTAGTGTCCAAAACAGTCTGGCACCAGACAAAAATAAGAATATTTAAATATATTTTAGAGTTACTTTAAGA
GGAAGGGAGAGAGAGATGTAGGCAGGAGGAGGAGGAGCAGGAGGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG
GAGAGAGAGAGAGAAATCTGGGGTTTCTATGGAAGGGCTAAGAATATGTAGAAAACAGTTTACAAAGAAATATGGTCC
AAGAATCGTGTGTACACACACACACACACACACACACACACACACACACACACACACACACACACACACACACAC
AGAAGATCTGTCATTTGTCCCAACATGGATGGACCTGGAGGACCTTATGCTAAATGAAATAAGCCAGACCAAGAAAG
AAAAATATTGTATGATCTCACTTATATATGGAATCTTTTTTAAAAAAGGTCAAATATATACAGATAGTGAATTAA
CAGTGGTTACCAGGGTCAGGGTAGTTGTGAGGAAATGGGGCAATGTAGGTGATAGGATACAAATGATTAAAAATATAT
TAATATATTTAAAGATATAATATACATCATGAGGACTACAGTTAATAATAGTGTGATTCAAGATTTTGTATAAATG
AATAGATTATAGCTGTTCTTGCCACAGAGTGAAAAATGGGTAAGTGTGAAATGATAGATATGATAATGTTCTCCACA
ATGGTAACATTTTACACTATATATATAAATATCTATGCATCTTACACCATTATGTGGTATCCCTTAAATATATACA
ATAAAATTTATTTTACAAACACATATTAGGAATGCATTTCTGATTTTTTAACAATAGTTAACCTCATTAATATATTT
CACACTATCATTTCTAGTGTACATGAAAAGTAGTTTGTGACATTAGTTGTAAAAAAGGTCAAATATATACAGATAGTGA
TTTTGGGTCAGAGAATGTTCTGGCCATAAGGTAGGTTTCTGCTTGCCCTACTAGATATCTTAACTTCGATTTCTGAA
CATCCCATCACTTCAGAATCTCTCAATCCTTTCTAACATCCGCAACATTGTTTTCTTTCTGCAATTTCTTATATTGA
CTGATGGATTATATAATTCATTTCTCTGAAAAACCTGCGAGTTATCATATATCCCTATCCATTCTGGCTCTTTATTG
CCCAATCTCACTACCAAAATCCTGTGACACAGCCTTCTGAAATATTTCTCAAAGCATTATATAATCTGGCTCTCATCAA
CATTTTCAACCTCTGTTTTATCATTCCACTATTTCTAGCATTTTTCATTTTACCTTACCATCACTCATCCAA
CAAAATAAGTATTTAGCTCCCTCAGTAATTAGTATTATTATTATTATAACTAGATGCTGAGCATAACAGAAGTGA
ACATGACAGACATAATCCCAGCAGGGATGTCAGACTTTATGCAAGTAATCAACCATGATGAATCTCATGAGATTCTG
AGAGAGAGAGAGAGAGATTGAGAGAGAGAGAGAAAGGGGAACCACTGGTGTCCGAGTTAGAAATTTGAATTAGTATC
TGGGTCACCAAAAGCTTCTGTGAAGAAGTGATATAGACTTGGCCACACAAAACCTACCGTGAAGGTGGTGAAATTTT
TCTATGCAGAGTACCACATTTAAAGAGCTAAGCCTGAGAGTGTGAGAGATAAAGGAACGAAAGAATGTGACAGCAG
ATTATGTTTTGAAGAAAGATGTTCAAGAGACCAAGCTTAAAGAGGAGATGGGGCTAGAACCTGGAGGGTCTTCGGGT
CCTGTTGGGAGTTTTTCTCTGCCAGAAAGGGCTTTGTACAGTGGTTGTGAGGAAAGAGTCATGATTAGAGCTTTGA
TTCAGAGACTTCTTTGCTGAAGTGTGGAGAATGGTTCAGAGAGAAGCAAACTGAATGGACAAAAGAGGTTATTAT
TGTAATCTTGCAAGAAGCGATGGTGGTCTTGACTAAAATAGTTCTAGTGAGAATGTGACAACAAACCTGAGAAAAA
TACAGGAGACGTAATTGACGGGGGTAGTGTAAAGTTGAACGATTGCAGAGTTGAATTTGAGGAAAGTGTATATAT
CATTTCCAGTTTCTGATGTCATACACCTCTGGAGATAACACTGCCATTTCTTTTGAATGGGAAAAATAAAGTGAT
CAGTAAGTACGTATTGGATAAAAATAATGAATGTTTAAATGCATAAGGGGAGAGGAAAGAGTTGCAGAGAAAAGAGAG

TAAACGTATTTTGGATGTGTTAATTTTGGAGATACCTTTGAAAAATCCAAGTGAGGGGTGGGTAGTCAGAGAAATGA
ATGTGGATGTCAGGACGAAAGGTGACCGTGATGAACGTATGTCTTCTCTAAGCACGTTATACAGCTTCATGTCAC
AAGTGACTCACTTCATGTCAAGTGACTCACAAGGTCACTTGTGACAAGCATTTCCTGGTGGTTCATCCCTAACC
TCCCTTTCTATACTCAGCTAAAAATGTCACCTACAATACTTCTTCTTGACTCCACCGTCCCCACTTTACTGATATGA
ATACATTTTAAATAAATGATATAATAATGCTTAGTTTGTAAACCTAATGTTCCCTCAAGTGGTATAATTATCTGATTT
GTATGTGATCATCAACCCCAACCATATTAGGAGCACCTTGAAGGTAGAAGATTTAGGTTTCATGCTTAACACCACATCT
GGACCACTGTGGATTTAACTTTCTACAATGATTGTATTCTTAATATATTGGGTGCCACTATATTCCAAGTAATAT
CCTGCACACTACGTACAAGGAAGCATAGGTCCCCTGTGCTCATGAACTGTAATTTTAGTAAGCAGGGATAGGATAC
AAACTGAGAAAGGAAAACAATTTAGAAAGTGGGAAATATTATGCACAGAATTAATAAAAAAGAGAAAAATCTTGAAA
AAGTCTTCAATACCTCACTTGAAGGTGATTTTGAAGAAGAACTGATGGACAACTAGAGTCAGCCATGTAATGATG
TAGGGGCAAAGCATTCCGGGCACAAGGGACAGCTTATGCAAAGACCTTAAAAATGAACCTAGCTTGTATGTTGGAGA
AGGATAAAGAGAATAAGGTATCTATAAGGTAATTAGGAAGAGGATGAGTTATTTAGTCCCTTAGTCTTTGAAGCAC
ATTATCTCATACTTCAATTGAGTTTATTCTTAGTGTCATTCTTCTGGATGCAATATTTGAGATAAATGCTTTAATGA
ACGTTACCTCCCTCCGTAGTAATGCCTGAGTGTACAAAAACTTTTTTGTGTTACATACGTAGCCATCTAATGGAA
ACATAAAATAGGAATCAAAAGTTGAGTTTCATGTACAAAAGGTAAGGACTGTACATGTGGTCATAACAACCTTCAAAA
GCACCTGAAGGTAACCTTTAAGGAAGATACAAAGGCTAGGAAATATCTAGGATCCATGAAGACAGACTTACTTAAGG
TCATAGTGTGTCAGAGTTGGTTCCCGCGGTGGGTGCTGCTGCTGACTTCAAGAACACGCCACGGACCTCT
GCGGTGACTGTTACAGCTCTTAAAGGTGGCACGAACCCAAACAGCGAGCAGCAGCAAGATTTATTGTGAAGAGCAAA
AGAACAAAGCTTCCACAACGTGGAAGGGGACCCAAGCAGGTTGCCGCTGCTGGCTTGGGTGGCCAGCTTTTTATTCCC
TTACTGTCCCTCCCATGTTCCATTTCTGTCTATCAGAGTGCCCTTTTTTCAATCCTCCCCAGATTGGCTACTTT
TAGAATCCTACTGATTGGTGCAATTTTACAGAGCGCTGATTGGTGCGTTTTACAATCCTCTTGTGAAGACGGGAAGGTT
CCTGATTGGTGCGTTTTACAATCCTCTTGTAAAGACAGAAAGTTCCCAAGTCCCCACTCGACCCAGAAAGTCCAGC
TGGCCTCACCTCTCAATAGCATTAAAGATATAGTTTTACAGAGCATATGAATCAAAACTTACATTTGCCAATTTTA
TTTGCTTGTGTTATGTGTTTCCAACATGTCTTGTCTTAGGGCCAAATGTTCCCTAGAGAATAACTATTCCAACATATC
TTAGTTGCTGTATTTTTATGCAACCTTCAACTCTCCATACTAAAATGTCTCCAGAATAGAAAAATAATCTTTTCAA
GTTTCAAAAGAGGCTCTCTATATATTCCCTTAAAGTACCAGGCAGACATATTCTAGGTTTCTAACATTGCGTGT
TGCCAGGAAGTATATCCAACCATCACAGTTATTCTGTAAACCAAGCACACTTATTGGAGTGCTTCTGCTTCTGTT
CTTGCTTGAATTTGGAAGCTCCTTCCAGGAAAAAAAAAAAAATATCTATAGAAGGGGAAAAAGTAATTTTACTTTGA
AAATAAAATATACGTGAGCAATAGTTTTATTCTGTTTTTAATTTACCATAGCTTCCAAAGACACATGTTTTATAG
TAGGGGTTAGCAAGTGTTTTCTGTAATGTAAACGTAAAGGGCCAGAGAGTAAATATTTTAGGCTTTGTTTTCTATAC
TCTGTTGCACTATTCAACTCTGCTGTGTAAGTGTGAAGCAGTCATAGACAATAGAGAAATGAAGATGTGTCATTG
TGATCCAATAAACTTTTATTACAAAAATGGCAATGGCTAGTTACGGCTTGAGGGCTGCAGTTGTCAGACTCTCAC
TTCAGAGCTAACAGTTGTTGTCAGGAGTCACTTGTTTTTGGAAACCTACAATGAGGTACTATAACACCAAAAAGAGT
TATCCCTTCTTTTTCTCTCACTTTTTGAATTAAGAGAATAGAAATGTAGTTAATGATAATGTCCAACCAAG
TGTAATTATACCTGTTAGAAACACAGCTGGAAGCCTGTGTGCCAGTCTTATTTCTCCTGTGATCCTCATTTTCAG
AGGTTGAAGTCATAAGTTTGCCATGTCTACTTTCTGACAGGGGAATTATAATAATGTGGAGTCACCTTTTGTGTTG
ACTTTGACAATGCTTCATTGACTTACTACCAATTTTCTAATTTTTATGAAGACTTTTTGCCGAAATGTAGACTCAG
TCTTCTCTCTGTCTACTCTTTCTATAACAATTAACAATGAACCTATTTACCTTTTAAACATCTTTTTAAAAATTT
CTATACACCTTGAAAAATGTAATACAAAGTAATGCTGCATCATGTATATTGCCTTATTCACACATAGCCTCTTATGG
TATATCATATAAAAAATGGAACAATACAGCAACAGGTTGAATGAACAGTAATCAGGTAACAGGAAAAATGAGATGCTT
TAATATTTCACTTAAAAACTCAATTTCTTAAAGCATACATATAAATATTTGGAAGTATAGTTTGAAGAAAAATATCT
TTAAAAATATTTAATTGATTAGTCTTATTTATAAGATAATTTTTTAGGAGGCTGGTTGCGGTGGCTCACACCTGTAAT
CCCAGCACTTTGGGAGGCCGAGGTGGGCAGATCATGAGGTGAGGAAATCGAGACCATCCTGGCTAACACGGTGAAC
TCCGTCTCTACTAAAAATACAAAAATAGCCGTGCATGGCAGCGCATGCCTGTAATCCCAGCTACTCGGGAGGCTGA
GGCAGGAGAATCACTTGAACCTGGGAGGCCGAGGTTGCAAGTGAGCCGAGATCGCGCCACTGCACTCCAGCCTGGTGA
CAGAGCTAGACTCCGTCTCAATAATAATCATAATCATAATAATTTTTTAGGAAGCATCAGAAATATATAAGAAAA
AGATTATTTTCTTAATTGCTTTACTAAAAACACCTCTATGATTTTTTCAGTAAAACTTGATTTCTGTCTATGTGTGA
GTGTGATCTGCCTCTCTTGGGATACTACTGTACTCATGAGGAGTGATTTTTTTTCCAACGACCTCTTTGTCACGTC
AACAGGTACACAGGAATAGTGTACCCTAAAAAGCCACCTGCCACATGTGCTGAAAATGTAAAAGTACACACATACAC
ACACACACACACACACACACACACACACACACACACACACACACACACACACACACACACACACACACACACAC
TTTTTTTTTAATTTAGCAGTTAATGTCCTTAAAAACAAATCCTTATACTGCAACAAATACTTAGCCAGTACTTCTGA
TACCTCCAACTGTGGTGATTCCAAGTACCTCTATGATCTTTGATTTGATCCACAGCTTTTCCAGTTATCTGCAA
ATACCTTCAAGTTTTATCTCATTTCTCAGTGCAACTCATTAATAATTTTTCAGCTGAATTCATTTTATAAACATGT
TGTGAATGTCCTCTTTATATAAGCAAGGTTGTAAGGAAGTGGCCACATAAACAGAAAAATGAATAACATATGGTTTC
TGGCCTTAGTGATCTCATGTGTGAGTTAGGCATATGGGCAAAATCAGAACACTATAGAGTATAAGTCTAAAAATGGTA
GTATTTTATAATAGAGGATGAAGAGGGTGCTGTGGGATCATAGGTGACAGATATAACTCCCGTTGTGGGACTTGAGA
AAGGCTTCAGAGCTGGAACATTTAGTTGCTATTGAACACAAAAATAAGACTCACTGTTGAGAGAAGGGAGAGGGAG
GGCAATTTCAATCAAAATTAAGATTCTGTGGCATATTCGGAACCTGATGTTTTTAAAAAGAGTAATGTTTATTACATTC
CTCTACATAAATATATTTCTATGTAATATGAATGACAAATATTTAACACAAAAATGCCTTATAACATTTGAATGAAA
TCCATCATATGACCTGTTATCTATTTCCATTTCTTTTTGCTCATATCATTATGAACAATGACCTGATAAATTTTTT
ATAAGACTTTTGTGAATTAGTAAAGGATTATTAAGTTTAGAATGAACAAAGCTGACCAATCATTCAGGCAAAATTTGA
CCGTTTTGTTGTCGCTTTTCTTATTTCTGAAACCATAACAATCCCTGAAATGAATAAGTACATATTTGATAACTTCC
TAAATTAAGGCTCAAAACACTGGTAATCTACTGGGCTTTTCAATTTGTTCTTCTATTGTCTAATCCTATCTATATTT
CTTTATATGAGCTATGAAAAATTAGATTATTAAGTTGCTCTTTATCTTAATAGAGAAGATGTTTTTCTATGACA

TTAAGAGGAATTTGATTTTTTCTTTAATGATCTACTTTTAAATTTTGGTAGAGTAGCATTGATAAGATCAATATTAC
ACATTGTTAAGTATGCATTACATGTTGATAAGATAAAATATTACACTTAAATATGTTTATCAAAATGTATGAATGATA
AAAACGAATTCGAAATGTATGGGAAAGATCTTGAATAAAGGTCTATGTACATTTCAAGGATGTCTACATATGCAAA
TTATCATAATATAATAACTATTGAATATGATTATCTTCACATACTTTCTTTATTTTTTCATCTCTTAGATGAAATTGG
GTATTGTTTTCTTATAGCTGGAACAAAGCATTACAGAGAATTCTTAGTGTGATTTCATTGAAACTCACTGTTATATG
AGTTCAACAAAGTTTAAATTAGTCCATGACTTAATCATCCTTTATAAATCCTATCACTAGTATTCGGTAAGGACAAA
GTCAATTAATAAATTAGCAACAGAAGCATTAAAAGAAGGATTAATAAATACAAAATAAGGGATGTGATATCTTTACG
TATTGCTGAGATGTTAGTGCTAAGGAAAACTTCCCTGTTTCATAATGTGAGGTGGGAAAAAGAAGAACTATTATTGT
ATATTTCTCTCTCTAAAACCTGCCTATCTGACTGTGTTTTCTGTGTCAGCCGTATTAACAGATGTTTAAATTTACT
CACTTTAGTATATAAGGCATCATAATGTATGAACTATTTCAAAGGCCCTATGATGGCTAATTAATAAAAAATATATT
AAATATTAGCTGGACAAAATAAAATATGTATTAATTTTGGAAAAAGTAGATCAAGGTTTTGTCAGATCTTTTCATATC
AATATATTCTTTGCTGAATAAGCTTTTATTGTTTACCAATATTACTAGTTTTTATAGAGATGTAGATATCACCACAG
TATGACTAATTTTATAGGGACACAGATAGATAGATGTTATTTTATTCCAATCTTATTTTTACATATAACAGGTATAA
ATATGCGCTTGAAAGGAGTATATCACTTAGGAGTCAGTCAGAAAAGTAAAGATCTTCTAGTCTAATACAGTGGTTCT
CAGCCAGGGGTGATTCTGCTGCACGCTGAGGGATAAATTTGGCAATTTCTGGAGACATTTTTGGTGTGACAAATTGCA
GGAGTGTTACTGGTATTCATTGTTGGTAGAGACAGAGATATTGGTAGACACTGTACAGGACACAGGAAAGTCTCTTACA
ACAAAGAATTTATCTCCAAAATAGAAATGACGTAAGTTGGGATTACAGGCATGAGCCACACACCTGGCCCACTCTTTCTTT
AGGAACTAGTTACGAAAGTATAGAGACATTTAACAAGCTGAACAAAGGATAGTGAGATGGCTCAGAGATTAGCAACT
GTGGCATGAAGCCACTACTACGTTTAGGTAAAAATAAGCTACCATTATTCTTTATAGTAATAATAATAAATATTATT
ATTATTATTATTGAGATGGAGTTTCGCTCTGTTGCCCGGGTTGGAGTACAATGGTACAATCTCGACTCACTTCAAC
CTCTGCCTCCAGATTCAAGCGATTCTCTGCCTCAGCCTCCTGAATAGCTGGGATTACAGGTGTGCACCACCCCTC
CCAGTTAATTTTTGTATTTTTGGTAGAAACGGGGTTTACCATTGTTGGTCAGGCTGGTCTCGAACTCCTGACCTCA
GATGATCCATCCACCTCAGCCTCCCAAAGTGCTGGGATTACAGGCATGAGCCACACACCTGGCCCACTCTTTCTTT
TTTAATTATTGAGAAATATAAAAAATATGTCAAAAGTAACAGGTGTGGTGGAGTTACAGCATGCACATAATGGGATAC
AGCCCATTTATCTAATCTCAGATGGAACTAGAAAAAAGAGAAGATCTTTGCTAAAGCACAGATTATGTGGAAAAAT
CATTTAGAAAAATAGCTTATCACAACATTAAATTTAAATCCTTTAGCTGATCATTTTTCTTGTCTATTTTTCTTTT
AAAAATTGAGAAGACAGTGAGTTTTTTTTCTTTATTGTCTATTCTTGATGTCAAAAAATAATATGCACATTATAAGT
GGGAAAAAGATAAGTCGAAATGAAATGAAACAATGCGAGGAAAAAATGTCAACACTCTTCAATTAGAAAAAT
GACCCCATTTCTCTCCAAATAGAAATGACGTAAGTTAGGATGAGGAACTTTCTCTTCCATGGCAACTCTAGAGAA
GGGGTAGATGGCATGGGATTGTGGACAGATGGACACAGAAAGAGGCTCATTATTGTTATTGTTAAACTTTTACT
TCTAGTAATAGTGACACCTCCTTCAGCATTTCTTTATCAATTGTCAATATTTTTTGGATCACCAGCATCACCTTCTA
TATGTATGTCTAGAAACCTCCTGTTATGAATTTACACTTCTCAGAGTCAAGACAGAAATGCTGTGAATTGGGCGATA
AATAAAATACCCCTTTTATTGCCTTGCTTTGTCTCTTAAAGAAAGATGCCTGTTGGGGGACTATGAGAATGCTTT
GTGCTTCTGGACCTCAAGGGACAAATCTATAATAAAATATATGCATAGTGATGAGAAATATATATAATGCAAGTTTG
TAGAGATCAGTTAACTTATCTTGTCTAGGCAATTTATTTCTAAACAATGATTTCAATCATTAACATAATATTAGCCC
ATTCTATACCTCCATTTTTGTCAAATCCCTGTACCTTCAAGGACTTGGCCATCCCATAGGCTGCTCTGCTTTTAAAT
AGAGGAAGATGCTGTAACCTTGGTACCATTGCCAGTTATGAATTTATCCATTAATGAACATTGCATTTAAGGCATA
GGTTTATCTCCTTCTCCAGGTATGAACCTGCAGGATTCCTACCTGAAGCTTAAGGAGAAATAAATCCACCTGGGACA
ATCAAGGACAGATCAACCAATCAGCTCAAAGCAGGTGTGAATTACACAGTTTATTTGAGTGACAAGGTAGCTAAAGC
AGGGATAATAAAAGAAGGGAGTGGGTTGATGTGGACAGACGAACATATGGCTTTAGGAAATTTGGTAGGGACTGAAAC
ATATTTTGTGTAATTTATGTGGGTCTAATAGCTTTTGAAACTTGTTTACAAGACCTGTGTAAAGTGGTACTGGCATAT
TCATGCATGAGAAAACATCAAGGGAAACTTAATAGTTCAAGGAGGTGACAAAGAAGAGAGGAACCAATTATTTTCA
CTAGCCGTCAAAGCAAGAAAAATAATCAGCTTGAGCCCTTCGGGGAAAAGATAGGTTAAATATTAAGTAACAGTTTG
TTATTATTCCAAAGTGTCTTAAAGTTGCTCCCATCTTTCTGTTTCTCTGAGGGAATTTAGTTTTTTTTGTGG
TTTTTTTTTTTTTTTTTATAACTGTCATTGGTCAGAGCTTGATTTGATGCCAGTCAAAATTTTTTAAAGAGATTA
TGAAACTGCTTAAACTCTTCCAAAGGAAGATGGGTGCTTTAAACATGTGTTTCAAGAGGAAGAGCATAAGAGCA
TTATATGGTAAGGCTGAAAGCAGATATCAGCGTTTAGGGCCATGAAGAGGTAGAGCTCACATTGGTAGGATCATTTG
ACTAGAATTCAGAGATCAAAATTGTATGTTAGTCTAGCATTTGGGGAGGACTTGTAGCTAGTATCTTCATTCTAGCT
TGGGAGCCTAGGAATCAGGTTAGGCATCTTGCACAGGAATGGGCCGATGGGCTAAAATCTCCTTGAGAGAGATGATT
AATCCAGGACAAACCAAGCAGTCATGCCAATGAATTACTTTAACAGGCTACTTCATATCTCTATCCTTTGGGCAGCA
CGGTCTTCTAGAGATGGGGCAGGCCAGGCTGCAGTTGAGATTTCTATAAACTAAGGTCAAAAAGATGCAGCAGTGAA
GAAGTCATGCTTATCTTGTATAAAATCATGTTTTCTTTTAAATGAAAATGTACATTTAAACCAATTTTAAACT
AAATATTGACCTTAAATTTCCAACCAAAAAATGCTACATAAGTGGTATTTATTTTTGAATTTCCCTCATGCTCCTCC
CACTGTGGGGACAAGGAGTGGTGGTGGAGAGAGATCTTTAGCAAACCTGTGAGTAGAGAATTAGAAGGTAATGGG
AGGAAGGTAAAGGAAAAACATCATAGATGGATAGGCTCACAAACATTAAAGGCCTTCGTGCCTGTCCTTCATGCCTA
TTCATCCCTCTCCAGTATGTGAATCAATGTACTTGTAAATATTCATTACCTCACATATTTAGCATTAACCGTGTA
TCAGGGACGTTGTTAGACCGTTGGTTTACGATGATGTGTAAGAAATATCATTTGTAACCTCAGACTAAGTGAAGTGCTC
AATATAATAAGATGTAATGTTATGGAACACTAAGTCTGTGCTGAAGACTTATCTCCTTTAATCCATAAACCAATCTG
GTGGGTAGTCTCAATGATCATCTCCAAGTCACAGTTGAGGAAATTAAGGCTTCAAGAAGTTAAGAACTGGACCAAC
ATCACAAGGTAGCATCAGAGTGACAGTTTGATTTCAAAGTGTACTTGACTTCAAGGCCACATTTCTTGCACGTT
TAATATTGCCCTTCTCAGGTAAATATACCATTAATGTGATACAACCTTAAGCATTGAATTACTTACAACGTGCAG
AGTTAAACCAGCATTATTTACACTATACTTCAGCTCGTTTATAAGTGAACATTTATTTTGTGGACTAACCTATGAA
ATGTAACCACATTGAATTCCTCTGTTAGGTACAGGTTTGGTGATTCCAGGGAATAGAGTATGACTGAATGCACAGGT
AGGGGTGAAGTGAACCCGGTCAGAAAAATTAGAGAGCATCGAGCAGATCATTAAAGCAGCTGTCTTTCAAATGTGCAG

[illegible]

AACCCGTCATCTAGGTTTTAAGCCCCACATGCATTAGGTATTTGTCCTAATGCTCTCCCTCACCTTTTCCCTGTGTC
CACATTGTTTTCTTTCTTTTGAAGCCTCTCATTCACTAGGTTTTCAATCCTGCCTTGCTAGTGTTCTAACTCTAAGG
CCTAGGCAAGTTATTTACCGAACTTAGCCTCAGTGTCTCATCTGCAAAATGGATAGTTTTATGATATCTTCAGCC
CTTAAAGTCAATGGTTCTGACAGCTAGGGTGTACTATCTTCTGGATATCAGTCATCTCAAGCAAGCCCTCCTTTTT
TGGACCTTCTTTTCACACACTTCACATACCTTAGAGAACATAATACACATCCTCTTTACTCAGGGCTTATCTTTAT
AACAGGCTTCCCTAATTCAATTAACCTCACTTTTCAAAAATATTAGTGACTACTGTGATGTAAATAAAATTTGCATTTT
ATAGGGGTCTTAGTAACCCAGAAGGGAGTGGGAAAAATTAATATATATTGAGAGTTTATTAAGTGCTAGGTACTGTA
AATATTTTCTTGATTTTAACTCCTCCGAGTAATTCTACAACAAAGATATTATCATTGCTATTATGTAAATAAAAGAAC
AAAGTAGAAAGAAACCCACGGTCTTGTATAAGCTCCCTAGTTGGTGGGTATTGAAGGGAGTATTCAATCTTGGT
AGCTTCTGAGTTTTTGTCTCTCAGGGAATCTGCCAGATGTCCAGGGCACCTGCCAAACCCCTATGAGGCTATAAGAA
AACCATTAAAGGTCTTAGATTACCCAGCTTTTGGGAGTTAGAATTCTGAATGAAATTTAGTTTCCCTGCAGCTACA
AAGGAATTGAGTTAGGGAAGTGATGACTTTATCTTTAGCTACATTGGTTATTTTCTTATAATAATCCTGGCTTGGT
AGATTAGAGGCAGCCCGAGTAACCCAGAATCGCTAAATAGAAGTGCGAGCTCATTGCCCGCTGTCTTCACTATGT
TTGCATATAGGAAGCAAGAATAAAACAAGCATAAAATAGGCTAACTAGCTTGTGAGAGCTCTTCACACCAAGTCTTT
GTGAGTTCCATAAGACACTGACTATTATTAAGACAGAGACTCCACATAAGTAGGAATTTATGTTTTCTTTT
CAGTCACCAAGGACAATCCTCTGCATAGGTTAGCAAAAAATGGTACTGATCCTATAATCTCTAATATTAAAGTTTA
GATTTGGCAAGCTTAGCTATCTTATGTTGTTTATTGTTTCAAAAAACAATATTGATTGGTATCTGTACTATAAGTCTA
CTGTGGGTCAAATCCAATACAGCAAATACCATTGCAATAACAATTTACAAAACCTACATCAAAAAACCTTTCATG
TTTGAGCCAACAGCCTGATAGTGCTAAGGACTTTGAGTACAGTATGCTAGAAGATTCTTAACAGTTATTTGTCTGG
ACAACAAAGGTTGACTCCATTAACACATAGCCATCAGTGTGGGATTATTTCCAAATCAAGCTTTTGGAAAAGTCAA
ATGAAAGTTTGCAAGCAGGTGGGGCATGGTGGTTTATGCTGTAATCTCAGCACTTTGGGATGCTGAGGCAGGCGGA
TCACCTGAGGTGAGGAGTTCGAGACCAGCCTGGCCAACGTGGTAAACCCCCATCTCTACTAAAAATACAAAAATTA
GCTGGCTTTTGTGGTGCATGCTTGTAAATCCCAGCTACTCAGGAGCCTGAGGCACGAGAATCAGTTGAACCTCGGAGG
CAGAGGTTGCAGTGAGCCGGGATCATGCCACTGCACTCCAGCCACATGACAGAGTGAGACCTGTCTTCAAAAAAG
CAAAAAACAACACGCAACAAAAAACCAGTGGAAATGCAATAAATGTTTATTGAATGAATACTGAA
TAGGGAGTTTCACTAATCCACTCAAAATAGTGTGAATTTCCAGCTCTAAGGTCAATGCTTGGCATATATATCCTG
AAGGAATGAATGGACACAGAGTAATTTTTTTTCTAAATGCAATTCAATTATGTCACTTCCCTTCTTAAATCCTT
CAGTAGCTTCCCGTAGCCTCCAGCATATTATTTGAATAGTGCTTCTCAAACCTTGATGTGCATCAGAATCACCTGG
GGATTTCTTAATTAACGTATGCTGATTAGTGGTCTGGGGTATTGTCTGAGATTCTGCAATTTCTAGCAAGTGCTC
AGGGTTATAGCAATGATTTTGGCCTGCAGACCATACTTTGGGTAGCAAGACATAAGCCACTTAACTTGACATAAAA
GACTGTTTAGACCTTAGTTTCTCTCTCGCTCTTTCCCATTTTGGAGCTTTTGTCCGGTTTATGTTTTTCCCTGAA
AATACCGTGATCTTACATTGTCTGTCTGGATGCTGAATTTCCCTAATCTGGGCTCCATGTAGTTTTAGGTTTGA
CATCACAACCACAAAAGATTTCCCTTCTCCCTTAATCTTGGTTAATGTCACTCTCATGTATTATACTGTTAATGA
AGCATTGAGGACATAAACTTATCAAAATTTTATCACAATCAATGATGGCACCAGTGATAACATCCAAATGCCTGG
GTGAGTAAATAAGAGGAGAAATAGGGGACTTGTGTTAAACTAAGTTTGCAGAGAAAAATGTACTGTATTATAATTAA
ATTGGATGTTTATTTGTTATGACAAAAAGGAGCTAGAGTCTTTTAAATCCACCCCTTGGCACCAGTCTTATCTCCT
TGTAACATACGTTTGAATCCCATGTCTATTTCTCCATATGGGAAATTTAGCTCCCTAAACATCACCAATACAACC
TGTTGATAAGACAAAGTTAAATTTATGCTTACTATGGTAAGAAAGACCACAGCCTGGACAAAGCTTTGGTAGTATT
TCATAAGGAGAAAGGTGAGGTTGGAATTCATTGGGAGTATGAAGCTTGGTTAAGATTGGTCTTTCACTGTGGGGG
ACAATTAGGATTGGGTAAGGATCATGGTATTACAACCTAGTTTGGTGGAAACAGCAGTGAAGATTTCTAGCCAAG
AGGCTCAGAGACTATTAAGGTGTGAACCTTATTGATGTTTTTGTGTAAGAGTTGATGGGAGTTTGGGGAAGTTACT
TTAGTGAACAGTCAAATTTTGCCTGGCCAAGAGTTATCTGTAATAGGAAAGTTATGCTAATGAAGACAATGGAAA
GGTAAACCATGTTAATGTGACAGCCAGCTATGTGAGCATAAGGGGTAGGTAGCTTTGGTCCCTCATGTCCAACTG
TTGTAGTGGTAAGTGATCTTCACTCTCACATAGATTGAAAGCTTCTGAGGACAGGGCAATGCTTTGTAACTTT
AAAAATCTATGCTCTGCACATCACCTGCCGTAGACAAGCATCTAGTAATTGACGGTTGGGTAGATACTGAGGGAAA
ACATGACCAAAATAAAATGGCAATAGGACACAAATCTACTATTGGAAGAATAACAGTGTTTCCACTGATAT
TTGCTACACACAGTGGGGTCCACAGAGCAGCAGTACCATTGGGAGCTTATTGGAAATGGAGACTCTCAGGCACCAC
CGCAGGTCCAATGAATTAACCTCTGCTTTTTTAAAGGTCATTGTATTCAATTATTATTTTTTCTTTTTCTTTAC
TTTCGATGATTTTTCTTTATTTGTTTTGAGATGGGGTCTTGCTATTTTGCCGAGTCTGGTCACAACTCCTGAGC
TCAAATGATCTCTCCACCTCAGCCTCCTAAGTAGCTGGGATCACAGATGTGAGCCACCACACCTGGCTTGTATCACA
TTAAATTTTGGAGAGCAGTGCTTTAATATCTATTCCATCTCACTCACTTGATGAGGTATTATTAATCCCACTATGCT
ATGTGGAAGTTGAAGAGGAAAGTTTAAATGATCTTGTCAAGGTCAAACAGCTTACAGGTATGTAGGCGAAGGATCA
CGATTATTTATAAATAAAAGTTCCCTTCTTCTTCAAGTTGTAATAATCTGCAGTTAGAGAGTCGGGAAGAAGATCA
AAACTGCATACATTTGCTCTGCCAAGCCTGATAACTAGTTCCAGAATTACAGAAATGGTGTGAAATAGCACTCA
AGTACCAGGCTCTATCAAAATTAATCTATCCATAAGGCAACTGCCAATTATTTTTAGAGAAAAATGTAGACTGAA
AAGATAGACAAATCCAAGTAGCAACTCCTGTAATAATATGCCCATAGGAGCAATCTTGAAGATATAAATATTGGTA
TGTTTCTCCTTCATTTATCATTTATCTGATCATTTGACAAGTATTTATTGAATGCCTGTAAAGGGTGTAGATATATG
TGGTGAAGCTGCAGGTGTAAGTAGGCTTTCTGAGGATATGCATGAAGTTGATGTTCAATACTGGAGATGTGTGTA
TACAGACTGAGGATTCCTTCAGTGGATATTAAGAAGTGGAGTAATAGGCAGTAAAGAATACACTAGTCAGTTGTGGT

93

CTTTAAATTTGAACATATTTTGTACCTGGAGGGAACATTGTAATGTAGCCCATATGTGGTATGCATCCTGAAGAAAA
CCTGAAATTATAGAGGAAGTTATCCTGCCTTCTTTCTTCTGTTGAATGAGTTAAAAATATATTAACAATTTGCCTTTC
ACTTTGTATTTATCATTTTGTATCTTTGCATATTTACATATACATTCATGTGTACAAGGGCATATATACTCACAGGT
CAGGGCTATTTAAACAGCTATTTATTTGAATATGCCAGGGAATCTCCAAGATATAAAGAAGCAGTTATTAGATAC
TATGTCAGTATAGAATTAACAGCCATCTTTTAAAGATGGAAGAGAAAAATTAATTAATTACATACAATTTCTAACCT
CAAGACATTTTCTTTCTGGAGACAAGGAATACTGAGGTGCTCACGATAGTGAAGACTCAACAAGACCCTAATAAAAT
AGATGAGGATAAGTAAACTACAATAGCCAATAAAAAACAACAAATAAACCATGTTTCGTGGCATGTTGGTGA
GTATCTCTGTAATATCTGTCAATAAGGGTCTCTGTAGATTTGGAGTAATGTTTCAGGAACCTACCTGTACTAGAGAAGA
CAGTGGAGAGGACTCCAGTGGCTAAATTTCTGCTGCCTTTGCTTCCAGAAATGTAATAATAAGGAGGTATTGTGGCA
TTTCTTGGAAAGCAGTAGTCTTGTTCATGGTCTGACTGTATAAGAATGCCTAGAGAAACATAACCTCAGCTGACTAA
ACTCCCTTGATGATTGTCACTTTGTCACTGAACCTCTGACCATACCTTTTGCCCTCAGAGGCAAAAGACGGGTAGGA
AGTGATCTCCTCATCTGGTTTTTAAACAAGTATATAACTAGAGAAGTGGATTATCTCTAAACCCACTCTTGTCCCT
GGAAAAAGGGGAGTCACTCTATCCGTTTTCTAGCCAATTTATGTATACTCTTAGTTTGAGAGCATGAGAAGGAAAAAC
TATTTTCTTTTCTTACCTTGGCTGGGTTTTTAAGAATTTATTTTTAGTTTAATCAAATAATATTTTAAAGGTAGT
AAGCCTCTCATAAGCAGTTTGATCTGTTCTAAAATAACTTCAATTTTTCTTTTTTAAACTTTCTTTTATCTTACAC
ACAAAGTATAATAGTAATATGTACTACTAGAACAAATGAAACAGGATGGAGTCACATAGAGAAATATATCATATTC
TCCCTATCCCTCCCTTAAATATTAACATTTAGGTGCTGTGCTTCTCCATTAATTTTCAAGCAATAAGGCCCTAAT
TTCTTCCAAGAGTGAGGAGTAGCAGCACGGTAGTTTGACCTGATATAGCTCTCTTTCCCTAGCCTTTTGCTTAAAGT
GCTTTCTAGGGGCTGACTTTACTTACCTAAAGATGTTTCAAGCAAGGGCTCACATTTTGGTAGCAGAAGACACTT
ACTGATTGCTCTCACTAATAATTTTGAAAGGAATGTCAAAATCTGGGAGGATCATGAAAGAAATATCAGAAATTTCC
TTTCAGCTGCCATTCTCCTTAATACTGTTATCAATAAATTCAGCATCTCATATGTGATAGCAAAAAAGGTGCTGCC
TTTGTCTTGATCCTGAGGTTCTTACCTAATACCATTGGTAGCAATAAAGATGGTGAGAAAAATGCTTCTTCTATGG
TGTTCAGGTCTGAACGAGCACCCCTCACCTCCACAGACGGTGGCAGGTATTCAAGCATTTTACAGACTTTGGAGTTA
AATATAGCAGTGTTATTCTAATTTAGGTATGCCACCACCAGCGGCACCGCAACTGCAATAGGAAAAATGATTGGCA
ATGCCAGCTATCTGATGTTTTCATGTGCCAGGTGCTGTGAGTTCTTACAGTATTACATTTCCATCCTCACACAAGA
GAGTGCCAGTGAGTGTTGCTGTGTGCCAGTGCCAGGCTAAGGGCTTTGAACACATTACCCTGTTTTATCCTCATAA
CTTTCCACGTTATTTTTATTCTGAATGAAGAAACAAGTTCTCTGTAGAGATGCTGTCATTGATCCACTCATATCCT
TTCACATCCGTTTAAACATTTTCCCTGCTGTGCTTTTACTCCCAACAACTAGCTCCCTAATCGCTCTGTTGGAGGGTG
GCCTTGAGGCTGCCAGAGCCTATTTGGTCTGTGTAAGAGAGAGATGGATCTATCCTGGAATTTATGTCCTCTGTGT
TGGAAGCCCTTAATCAATGACTGCTGGTTGCAGACACATAAATACGTGAGCTTTCTTGTTCCTCAACTGAGAAATTC
AGAAGTGTGAATGGCACTGCCACCCTGGGCTTTTATGCCATATATGTGTTTGGTCTGTTTCCCTTCCCAATCTCACT
TCATTTTCCCTTACCAGTGTTTCTTGAAACACATCCCATTAGATCATTTTTTGATGAAGCTTCATCTCAGAACCTC
CATTTAGGGAACCCAACTAAGATATTCTCTAAAATAGAACTTTATTGATAAAGTTTCCAACTGTCTTAGTAGAT
GGCAATATAAGACCAAGCCAAATCTTTCTGGGTCCAAATCCCTGTCTTTAATTAATAGACTCCATTACAACACAT
TCTTCAATCTTTAGTCAGCAAAACACTTACCACGTGCCATTTTTATGGCATATTATATTTATACCATAGTTAGGATAT
TATGGTTTATGAATATTTTATATCTGTACACCTGAAATTTCTATTGACCTCTCTGGGCCACAGTTTTGCATCTGTAAA
ATCAGCACAAATATGCTACTTATCTCATAGAGTAGACTTAAAAACGAATGAAATGATATATGCCAAGTGTGAGAAT
CACAATTGGCAATTACTCATGCTCATTAATATTAGCTGTTTTTATGAGTATTGTTTCATTTTCGGTGCATAATATC
CTATGCAAAGAACAAAAGGTATTGGTATAGGCATTGAAACTTGAAGCATAGAAGAAAAAGTTAATTAACCGGTGCCC
CACTAGATGCCTCTAACTGCTGGCTCCGTGTATCCCTTTAGCCTTGGCTCGTCACGAGAAAACCTTGGAGACATTT
TGCTGGACTCAGCATCAATTTAAGAAAGATGAATGACATTTTTCTTGAAATGTATTTCAGTCATAGCTGCTTTTT
CTACTTTTATATTTTGGAGTTCTTAGAAAAAATTAAGGACTCCTTTTTTAAAGAAAAATGGTATAAAAGAAAAATGCA
TATCACTTTGTCACTTTATTATTGTAACCTCATCAAAGTATTCAAGTAAAGACAGTAGCCAAGTGAACCTCTTCTTG
TAATGCTCGGAAACCATTTTAGCAATGGTAAATTTGCTGCAATTTATATTGTCAAATTCATGATTTGACTTATTT
TAGAAAAGTTATTAACCTCTGAAGAGAATGCTTCAGAAGCATTTAAATGAGTACAAGTTATCACCAGTGATATACAT
AAATTTCAATTTCAAAATATACTTCTAGAACTGTACTTAGTATAGTATTTGTACAAGGATTAATTTCTTATTT
CATTTTGTAGGAATTTATTTATGAATGTCTATGGCTTCCAGTGTAAAGCAGACTTAGAGCATCATCTTTTACAATA
ATCTTTTTTTTTTTAATCAAAGGGGAGATATTCTGGTAAAAACAAAACAAAACAAAACAAATAGTTTATTCTGCATTT
TTATTAAGTCCCTCTGTAAGTCATCCCTGAAATGGGATATGTAGAGTCTTATATTTATTTATTTCTCAGAAGCTTAT
TGGAGGTGATATGAAGGATTTTAAAGACCTACTAACTAACAAAACACAATTTAAATTAATTTTCAAAATACCTTA
ACAAATCTTATTCTCCTTATTTTCAAATCTTTAACAATGTTTTCTTATTACTAACATAATATCTTCTGATGAGT
CATAATAATATACAAAATGACAGTCTAAGTAACTTAACTGATTAATTGAGTCTTCTAAATGATAGGCTTATGGC
ACTATTACTTCTATATGAGAAATGAGGAAGTAGAGGTATAAATAAGAAATTTTTTGGCCGGGTGCGGTGGCTCACGC
CTGTAATCCCAGCACTTTGGGAGGCCGAGGCGGGCTGATCACGAGGTCAGGAGATCGAGACCATCCTGGCGAACACG
GTGAAACCCCGTCTCTACTAAAAATATAAAAAATTAGCCTGGCGTGGTAGTGGGTGCCTGTAGTCCAGCTACTCGG
GAGGCTGAGGCAGGAGAAATGGCGTGAACCCGGGAGGTGGAGGTTGCAGTGAGCCGAGATCGCGCCACTGCACTCCAG
CCTGGGTGACAGAGCGAGACTCCATCTCAAAAAAAGAAAAAGAAATTTTTTGTAGTGATACAGTTAGA
AAATGGCAAAATGGGAATTCAGACCCAAACAGTAAGCATCAAGGATACCTTTCTTATCAGTATGCTAATATGAAAC
CTAAGCATACTAGAAAATCTAAGTGCCAGTTGGAACCCAGAATTAACATTTTGGTGTGTAACCTTCTGGCTGCTTTT
TCTATGCTAACAAACATATATGACATACAAAATACACACATACACAAATTCCTGTTCACTACTTCTTTTATGTTAA
CATCACAATGTACCGTACACAGCTGTATTATTTTATATTTGATTTTATATTTTTCTAAAGTCAGTGATTTGTCAA
ATATCAACTTATCTATTTAATAGGAATATGGGATGATCTTTGCTTATACATACATACATATGTATATAAAAAACAAA
TCAAGTATTTTAAAGCGTTTACCAGAAGTCATATGTCAATCAGTAAAGTATATAATTTTTTGTGCGCAATGACATATA
TCATAAAACGCTACCTATCATAGAATGAAATGAAACACAGCAATATTGGGACACCTATTCTCAAGCAACAGCTTT

GTGATTTATTAGCTATCTCACATGAAATAACTCATTAACTTGGTATTCCAAGCAGCAAAAGAAGGATCAGTTAGGTC
ACTTGCAAAATAATACAAAGCTAGGTTTAGGGGTGGGTGCGCTTGGTGGGATGTAGATGAAACCATATGGGCCCTT
GAGTTTATAATTGCTGGGATCTGCATGGTGGGTATATGGATGTTTATTACAGTATGCTAGTGAGTTAAGAAAAGA
GGAATTATTATTGACTTACATCATAGAGTTTATGCAAAAATTAAACGATAATTTATTTTAACTCTAGAGGTATAG
GTACCATCATGAAGGGACCCACAGAAGTATGTAGCCAGTAATTATTGGAGCTGGAACAGATACTCTGCTGTCAGTT
GTTCTGGTTTTGTGGTCATTGTTCTTGCCCTTGCAAGTTACCAACTCTAAGACCTTGGGCAATACTTTAAGTCTTGG
TTGTCTCATCTGTAATAATGGGGAGAGCAGTAAGTGTCTTAAAGGTTTATTCTCATGTTATATGACTTACGGTATGTA
AAACATCTGCGTTTACACATAGAGGTGCTTAATGGATGATTGCTCTCATTATTAGGCTACATCTAATCTATGAA
TTTAAAACTGTATAGAAATATGTGACAGATTCTTTAAGAGCCAAATACCAACTACAGTGAAAAATACTTAACACTT
GCTGAGCTCTTAGTATGTGTCAGGCTTAACTACCTTAATGCTCATAGCAATCCTATAAGATAGGTACTCTTGTATC
CTATTTTATATCTTCTAAATTTGAAGCAAGGGAAGTTAAATAATAGGACAAAGATCATACGCTATCTCAATCATATAT
ACCCATCTGGCTGTCTACCTGTCTCCTTCCATCCATCCATCCACTTATTCATCTACCCATCCATCCACTCAGTTACT
TCTCTCTCTCCACCATCCCTTTCCCTTTCCCTCTCCCTCTCCCTGTCTCTGTCACTCTCCTTTACTTATCTATCTA
TCGATGGATCGGTTTATCTATCATCTATCTATCTCTATCATCTATGTATAGTTGTTAATAACACTAACATTTTATAA
ATTACAAGACTGAAAAATGTTTTATTAACTTATGGTAACAAAAGACCACATTGTGAATAAAAAAAGCAGTAAACAC
AGGTCTCTGCACATGAAAGAGATGTCCTAAACAGGAAGAGATGTCCTAAACAGTAGGGATACATAGTATCATACA
ATCAAAACATCTGTCAGCCCTATAAACTTACAAAGCAATATAGTATTGAGGTGAACCTTATCTTTCTACTATTACACATTT
TGAGGTTACTATTTTTATTTTTCTCATTTTACAGGTTAAATTTAATATGGCTTCCAATAAAAAATTAGTATGGTTAA
TAAATATCTTGACGTCTTGTCTCTATAATCCTACCGATAGTTTACAGTAATTAGTAAAATAAAATAATAGGAAAAAT
ACCTTTGATAC TAGTATTAAATTATAATCATATCATTAGGTAATTTCAATTTGTGATTTTCAAGAATCTGTAATATG
GTAGCTTCTTCTACTGACATGTTTGAATTCATTTTAAAGGCTTATAATTCACAAGTAATCTATATATTATCTAAAAAT
GTAAATGCACATTCACATGGAGATAATAAATTAGCGTGAAATGGCTGTATTTTGTCTCTATAATTTTAAACATACA
GGAAATCAGCTGTTGTCTCAAAAATCAAGGAAATATAGTATTGAGGTGAACCTTATCTTTCTACTATTACACATTT
TAATATAGTTCTCTCACAGTGCAACAGAGCAAGAAGCTTTAGACACATTTGCTGCTGCAAGGAGCATGCTGTGCTG
AACTTAAACACCTTCCCTTTCAAACCTCCTTGGGACTGTTTTTTTCCAAGAGACTTCAAATGCACTAAATTTAGCAT
CCGTTGGAGGCACACCCAGGCATATTATAGTGAAAGCCCCAATAACTGAATGTGTACCACATTCACAATGTTTAT
GTGTGTATATGCCTTATCTATGATGTATTGCAAATTACAAAAATTTGTGTTATTATTACAGTAACAAAAACACTTCC
AGCAAAATTTTAAACAGTGATCTCTTTTGAATAACTTACATACATGTGTGATGGGTCTTAACTTTGTCACTTTTAT
GTTTCCATCATGTTGTTTTAGCCAGTGAGGGTTTTGTTGGTTTTTCATTTATGATTATATATACCTTCAAAAAATAGAT
TTCAAAGTGTGAATTTGATTGATTGATTGACTGATTTCATTGAGACGGTGTTCCTCTTGTGCCCAGGCTGGGGTG
CAATGGTGCATCTCGGCTCACCACAACCTCTACCACCCAGGTTCAAGCGATTCTCCTGCCTCAGCCTCCCTAGTAG
CTGGGATTACAGATGTGCACCACCACGCTGGCTAATTTTTGTATTTTTAGTAGAGACAGGGGTTCCACCATGTTGG
CCAGGCTGGTCTCGAACTCCTGACCTCAGGTGATCCACCTCCTCAGCTTCCCAAAGCACTGGAATTCAGACGTGA
GCCACCGCGCCAGCCGTGAATTTTTATTTTTGAAAGACAAGAATGTCCTTGCCTAATTGCATAATAGTTTAAACAT
ATGAAGACTAAATATAGCTTTTAGCCATGACAATTTTTATTATTATGTTTTTCATTTTAAATTTTCAAAAGATCCT
CATCAGTGACTCTTTTTGGTCTTCTTTATAAGCGTATTTTAAACAGGACATAATAAAGATAAATCCCAACTTTTT
AAAGTTGTATCCGTATGTATTACTTTAAAGTGCTATTATAAACAAGATTAGAGGCAACTTTTATTCAATCAGATT
TTAAGTAATTTTACCAAAAAATATGGCCTTGATAATGTCTCTGTAACAGGTTCTCTGTAATATACATGCTGAGGATTG
GTTTGTCTTTGCTTTTGATACTATTTTAAATTAGAAAAGTAATGGGGAATCCAGACCCTTCTCATTTAATAATCCAGA
GAAAAATCAGTCCATGTTCTAATAGTTTAAATTTTTCTACTAAACCCATGTGAGAATCCATATGAGTGGAATGGAG
AGGAGTTCCAGCTTCAAAGTTGGCAGATTGAGATGATTCTATGGCAACAGAAATGTGCTTGAGGGAATCAGTTGCG
GCATCTTCTATAATTTGTGTACCTAGATTTTGCCTTAGGAATTTCTAGATTTCCATAGAACATTGTGACCTCAAATG
CTTTATCTTAAATAAGAAATAAAGCAGATTAGAAGAATTATTTGCCTACAGTTTGTGGGAGATGGGCAAGTCTTAA
GAGTTTATTAGGTACCCAGAACGAAACATATTTCTTGGGCCTCATAATCACATTGAAATACAAGGATTTAGTTATA
CACAGTGACAGTTAGTGAATGACAGTCTTCAGTATCTAGTAGACAGTAAACATATAAAGATGTATTTGTGGCCGGG
CACGGTGGCTCAGCCTGTAATCCCAGCACTTTGGGAGGCCAGGCGGGCGGATCACGAGGTACAGGAGCCGAGACC
ATCCTGGCTAACACGGTGAAACCTCGTCTACTAAAAAATACAAAAAATAAATTTAGCCATGCGTGGTGGCGGG
CGCCTGTGGTCCCAGCTACTCGGGAGGTTAAGGCAGGAGAATGGCGTGAACCCGGGAGGCGGAGCTTGCAGTGAGCA
GAGGTACAGGCCACTGCATCTCAGCCTGGGCGACAGAGGGAGACTCCATCTCAAAAAGAAAAAATAAATGTATT
TTTACTTTTTAACTACAGCGAGAGACCTGGCAGCCTACAGCATACAATTAGTGTTCATTATTTAGATTGCATGGATT
TAATGTGAGGGGTCAATTAATCTGTCTAACCAGTGAGCCTAGCCTTGTCTCAATACTGCCTGCCTAGTGAGGGTGAA
CTGTGCTGGAAATAATATTACAGGATTATCTGCAGATTTTTTTTTTAAATGAGTGGTTAAGTCTTCAATGTTCTGTGAA
AATTCAGAGTAATAAATTTATATGAAGTTGTGTAACAGGTAAAGGATAGTTTCTTTTACACGGGTAAAGATTAAACA
TGAGGAGGAAAACTTTAGCAATGGCATTTAATTCATTCAATATATTTATATTGAGCTCCTTTAAAAATACAGGGCC
TTGTGGTGGTGTCTGAGGACAGAAACAAAACCAAGTAATACATGAACATAACCTTGATTTTCATGATCTAGTAGACC
TATAAAAGTTGTGATATCTGATGAAAAGAAAATGGTAAAGATATTCCAAACAGTGTATGCAATCCAGAGATAGGA
TGGAGGGGCTCTACCTGAAGGATGATGATAAGAAAACCGTGTGAGTGAAGGGTGATTTGTGGAATTCAGATAAAAT
ATCAGTCTTGAATGCTAGTGAATACTCAATGATTGACTAGATCCCATGGACAGTAATTTCTTCAATTATGACGATG
CTAGTGTTTTATGACTATACTATCATTCTCCATGCCAGGCACCTTTGCCATTTGGTAAATGTATAGTGTGCTATTCTA
ACAAGCATGCACAGAGCTTTTACTTTAATGTATCCATGAGTTTATTGGGGTTTCAAGATTTAGGTAAGCTTTGCAAGG
TCGTAGCATGGAGTAAATATCTGAAATTCAGACCCATATCTAACTAAGTTCAAAGACTGTACAGATATTTCTCCTC
CTTTGTGCAGAGAAGGATAGGAATGGTTCCATATTATCATGGACTTAGTCAGATGTTTTAAAAATTATAATGTCTGT
GTTAATGAAGAAGGGATGATATTCAAGTGCATATTTCTTAAACGTTACTTTGCTTAAATGCTCTCGACTTTTCTGTGAGA
TGGATAGTGTAGATAAAATCCCCAAGGGGACTCAGCAAGTGCAAGTAAAAACAATGAAACTTTTAAAGCCCTTTGTCAA

96

97

98

AGATCCATTCTAATTTGTGCAGAGGCGACTTGTTGTTTTAAGGCAAGAAGGAGGGAGAAGGAGTGGGGTTTCATT
GAGTTAGAGAAAGTAAAAAGTACAAAGGGCTGGACAGTGTAATGTGATTAGGCCAGCTGTGTTAGCTGGAAGTTAT
TGAAGTTAGGATTCTATCTTCCACAGAGAACAGGAGACAGAGGACTTATCCTTCTTGATGATGTCATTTGAAAAGA
ATGGCTTTTCAGGTCCTTGAGTGAGAGACACTTCTGATTTCCAAGAGCTACATGTTTACAATTGTAAGCCCTTTTGAG
TAAATGTTCTAAGAAACGGAGGTAAGAGTCCATCAACAGATGTGTGTTGGCTAGAACAAACATTAAATTTTCTGG
CAGCACTGAGCTTTCTCAAGCAGGCACTTAAGGGAAGGCTAGGGTCATCCTAGGGACATGGCCTTCTGGGGCTAGAA
ACCATACTAGAGTTTAGTCAAGTCTTAGTGCAAGGGTTTGGACAGAGTTGTTAAGTGCTGAGAGTTCTGTATTTCTC
ACTGTCACAAAGGAAGATCAGAAGCTCCTGATACTTTTTTCATCAGTACAATTGAATATATAAAATCCTATACACAAA
AATAAACTAAGCTTATACAGCATATTGGTCAAGGAATGTTGCTGGCCTTATTAATTAGATAGCCAGTTAAAGAA
GAATTTTTTAATATAATTAATGTTAAAGTAGGATGATAGTATATAAAACGTGTCTACTGTCTGAATACAACTAAA
CTGTTTGGTTTAGCATTTACCTCAAGATCTCTTAATATCCCCCAAAGGGTCCCTAAACCACAACTTATCTTTGTGC
TCATGAAGTAGAGAAAGAGACAGTTAATAGACATTTCTAGCTGATAGACTGTTGTAGAGCAGAGAACGCTCTGTGTTT
TTGAAAATTAACATATGAATTTGCCCTCTTCCCTATTAAGGAAGAAGAGTTTCTTAATTGTGCGAACACATCAA
GTGAACATTCAATTAGATTTTGTGACCCAGGGTATAACATCTGGTTAAGGTTACATATTTCAAAGGAACAAAAC
ACTAGAACTCTTGGTTTTAAATCTCATGGCTGGAGGATAATTTGCAGCAGAGATTTATCTGGCAAGCATACAGAAT
TGCTGAGACTGTTCTAAAGATGTAAGTGTTGGGTGTTTGTGTCGTGAAAATAGCTGTTTACATCTATTAAGTGGATAC
CGATGGTTGAAGTGCCCTCTATGTCAGTTTTTACCAATCAACTTTTGCCCTCACTGTGTGACCACTTTTACCTA
ATCAACTTGGACTGCTAATGTCTTTTCCCTGGCACCACTATCTGTCTCTTTTGCAAAGCACAGAAAACGGCATGCAT
GATTGTAGTTTATAAAACACATGTACCAATGTGGTCTACAGCTTCTGTTGAGTTGAGAGGGTCAGTTTCTGTAATC
TCTTCTGGCAGAGAGTCAAGAACAGCTTCACTTTTCCCTCTGCTACCTCTCTACCCGTAAGTGTGAACCCATCACTTT
GCTAACACTCAGGAAGGGGATTACACAAAATAGAGCAGGAGCCCTCTGACCTGAATATGCATCTGAGCCCTAGCCAT
AGAGCTTCTGATTCACTAGATCTGGGATGGGGCTAAATATTTGCATTTTAAAGTGATAAGTGATGCTGATGCTGC
TGTTCCAGGACCAATTTAAGAAATATCGATAAAGGTGGAGAATTAACCTGCAGCTCAGAAGACCTGAGTTGTTG
CCCCAGCTTGACTTTTACAATCTAGCAAAATGGATAAAACTCGCAGGACTTCAGTTCTCTTCTACACAGTGAGTG
GTTAGATTGGCTTTGTAATTTAAATTAACAGGGTTTGATTCTGATTCACTACACAAGGTTCCAAAGAAGGAATGA
TATCTCTTTTCACTTTTCTGCTTCTGTCCCTAGGTAATCTATCTATGTTCTGATTAACTAATACTAATG
TTTCTGCAAAGCTTCTAATATTTACATCTCCAGCCCTGAAACTCTCATTTGAATGCTAGTCTTATATACATACCCCC
CTGCCATTTGACATCTCCACTTAAATGTATCAGAGGCAACTCAGACTCAACAAGGACCAACTGAATGTTGACCT
TGCTCTTCAAACCGATACACATCCAGTTCTCTCCATCCCAAGTGAATGACACTATCCAGTTAAGCAAGCTCAAGT
TGGATTTTTTTTCTCTACTCTTCTCTACTGTCCGTCAACTACCATTATTAATCTGTACCTGGTCTCTACTGATTTA
ACCTTCTCAATATCTCTACAGTTTTTCTTTATGCCCATTAGTATCCTAGTGCAAGCTACCATCGTCTCTCATTGGAA
TTAACACAGTAACCCCCCTACCCACCAGACTGTTCTGCCTACAGATAGTGTGATTTTAAATAATATAAATCTAGCC
TTGGCTAGATTTCTCTTCAAAGGTTACATTAATTTAGCCTTAAATGGTGCAAAGCTTTGCATAGTCTGTCT
CTTTGCTATGTTGGCAGTATTTTTACTATCCCTCTCATCTGCTCATTCTCTGTACTCCAACCTACATACTTTGTT
TTTTTTTTTTTTTCTCTAACTACAGTGCTGTAATCTCTTTTCTTTTGACAGTACTATCCGTTTGTGTCAGG
GAATCTGCTCACTGTCTCCACCCACTCCACACACTCACGTTTTCTGCCCCGTCTTACCGGTCTTGATCGGTTGTCAC
TTGCTCAGGAAGGTTTTCCCTGGTCACCCCTCCACAAATTGAATTAAGTCTCTTGCTGCATGCTGTCTTAGTGCTC
TTATTTTTCTCTCTCATCTTAATTCAGTTTGTAATTACATGTTATTTGTGTGAGGATTTGATTATTATCTGTGT
CACCCACTAGATATTGGGCATTCTTTACTTACTCACCCTGAATTCATAGAACCACAGTAATTGTACACAACAAATA
TTCAAGAGAAATTTATTGAATTGATGAATGAAAAGTTGTACCTTAACATGTTCTGACATGTATCCAAAAAGAGCT
CCCCTTTGGGGTCTATTAGGACTTTGGACCTTAGGTAACGTAACCCCTAGTTTCGCTCAGGTTTAAACAGTAGAAAGT
AATTGGGTCTCTTTTGCATGTGGCTTTTCTAAGGGCTAACCTGTCTTCGGAATGAGTCAATACAGCAGAGCTGTTG
AAAGCAGACTCTAGCTTCGGAACAACGTTGGTCCGAATCATGGTTCCGTCACTTTCTTAGCTGTGTGATTTAGAATAAA
TTAATGTTTTTAAAGCTTTGATTTCTCTCTTAATCTGGAGATGCTAATAAAGCCAACCTCGTAGAGGTATTGCGA
TGAGTAAATAAGCATAATTTGCTGTAAACACCTTGAGATTGCCTGTTGTATGCTAACTAATCAATAAATGAAGCT
CTTAACATCTATTATAGATATTTCCAGCATTAGTATACATATCAGGCATGTGGTAGAAGCTCAATATAAAGTTTT
GTTAAATTGAATAGATTCCATATATGGTATTTCTACAGCATTATGCTCCTTATTTAAGTGCTCTTAAGTATTTTTTA
AGTATCACCTCACAAAAGACAGATGTTTAATTCATTACACATGTGAATTGTTTTAGATAGAAAATAAAATAAAAAAT
TCAAACATTGAAATCAATAGTGACCTTACCTTAGGATTACACCATAAAATTTCTACCAATCGAGAATAAAGTGAC
AGTCTATTTCTTTCTAATACTTTTAAACGAACAAATGTTTATTGAACACTTACTACTTCTAATCTATGACAGACAT
AAAGATGAATAAAGCATGCCACAATGTTTAAAGGAGCTCACTATATCATAAGAAAGCGGATTACACAGACAACCTCT
ATAAGATAAAAGTGTAATTTAGGCTGGCTGTGAAACGTAAGGATTATAGGTATAGTTAAGAGTGGAATTTTAT
ACTTCGAGGATTTTCACTTACCTTTATATTCTTTGTCTAACCTTTTCACTGTTTCTCTTTCTTTCAGAAAACAGAGCACCTT
TTTCTGACACATTCACTTTCCCTATGGAGTAGAGCAGTTGTTTTCAAAGTGTTGGGTCCAGATCAGCATCACGGG
GATGGTTAGAAATGCCCATTTGAGCCTCACAAACAGACCTACTGAAACAGAAATCTTGGAGAGTGAGCCCGCAG
ATCTGTGATCAAGCCCTGTAGGCAATTCTAACGCACACTCAAGTTAAAGAACCACGGGAAGAAAGGTCCATCCTGTA
ACAAGACAGATTTTTTCTATTAGCATCAATTTTGATCATTTATATATATATATATATATATATATATATATATAT
ATATGATGCTCACAAAACCATTCACCTTACTAGGTTTGTAGTATTCCTTCCCTTCCGTATTCTGATTGCTGATGTAT
ACAAGATGAACACACATTTACCTGAGACAAGGTAAGACTACACATGTCTCATTTGGGGACCAGAGGCTGTAATCTTA
CTCAAGGTCAAAGCGTCTTCACTGCTTTTCTTCACTGCTTTTCAAAGTAAATTTCCATGTAGGTGTCACTTTGTTT
TCTTTTTGTGTTTGAAGAACCGATTAAAGGGGTGAAGTCTGGCTAAACTTAGTGTGAGGACATTACTTAGATAAAAA
TTATTTTAATTTATCTTGTAATGTTCAATGTGAGAAGAAAAGTCTTATGAGTAGTGATTCTTAAATAACAACAA
TTTAAAACTACCCTGAAGTCTGTGAGAGTAGTTTTGCCTCATTTGTCTAGATAAGAGAAAAAGGTTACATTAG
GGATTGCAATTTGTCTGCCAAGTGACGTTTATTTATTCAGAAACATTTAGAGAGGAATGTGTGAGTTCTGTTGCAG

100

CCTGTAGGCAGGCTTCCTCTCTGATTTGGGAGAGTACAAATTGCGACAAGGTTAAATCATAGCCTGGGAATTTGACC
TAAAATTCACCTCTTCTCCCATATGCATTATGAACCTTCTGCTGGTTTTTAAAAGAAGCTACTTAATGTCAGCTCGA
AGAGGTTGGAGGGGTTAAAAACATGAGCATGGCAGTAAGAAGATTATGAAGGATCTGAGAAGATTATGACTTGAT
CAGATGGTATTTTGTCTAGCTAGCCACATTTGTGAAGACTTGAAAACCTAGGGAGGCTTGCTCTTCTAAGAGGGGGCAC
TGCTGGGACCTGGATTCTGTGGAACCGTATTAGTAGAATAAACAATAACCTTTGCTTGATCAAAATGAACCTTCTATT
CTCATGTGTCTTTTGACATATTTTTATTAATCATATCACTGGGACCTCCTTGCTGAAAAGATATCTCCGTTCCCATTT
CTGATGACTCCCACTAGGAGTGAGATCAAATGAAGATGGCATGGACCATTTCTCCATGTGACAGCTCTCTGTGGTT
GCCTTTTAACACTTCTAATGCCCTTTCTCTTAAGAATTCCCATTTGTCGTCTGGCACTGGTGTGTGATCAATAAAA
ATGTAATGGAGTGAGGCTTAGAAACATGAGGAAATTTACTCAAGCTATCCATTTATGATGTGTCCATTTGTGTGT
CAGGGAAGAAAACTTTTCACTCCCCCTTAGGTTTCACTTGGGGGGCTGCAAATTAACCTGACGACAGATAGA
TTGGCAATGAGAAAGACAAAGTTTATTCAGAGAAGTATGTGGGAGCTCACAGAAAACATAGCTCAATGAAGTTAGAA
TTTGGGGCTTATGTACTATTTTAAACAAGGGTTTTGAAAAGAAGAGTGTTAGAATTTCAAGCCACAAAGTTGGTGGGA
AATATGAAAGAACTAATGAAAGGTAATGTTTGTGTTTGTAGTAAAGTCTGTTTATGTAATTTTCTTTTCCAGCGACAA
CTTCTCATCTCTGGTGACAGGAGTCACTTTTACCCCTGGTGCAAGAACTTTCTTAAAGGAGGATTTAAACAGT
TGAATTTATTTTCAAGAACTCTTTGCTTTTAGGCAGATAGGGGGAGTACAGAAAAAGCCCTTCCCGTATCTGTTGATCC
TCAAATGGCTTTAGCTCAAAACAATTTTACATCAGATGGCATAATGTAGATCTCTTCAATGTGTTTCATTTATTTCC
ACAGATATTTGTGAAGTACATGATATATGCCAGGTACTTGGGATACAGAATACATAAGTATGAGATACCTGATCTGTA
GAACTTACACTCTAGTAGTGAGCTAGAGAATAAATGATATTATTTATATATGCATACACATATGATTTTCAAGATAGT
GATCCATATTTGAAATAAAGCTGGTTAAGGGAATAGAAAATGATATTGAAGGTGGACTTGTTTATGATTGGGTGGATT
GGCATGGCTTCTTAGGGGGCAGTATTTGAGCAGATATGAGAGCAGATATTTCTCAATTTGGGCAAAAACATTCCAG
GCAGAGGAAACAAGGGCAAGGGCACTGAGTTCAAAAGAGACTTGACCTAGCCAACAAATAGCAAGGATTCAGTGTA
AGAGAAGGTGGGGAAGGAAGGAGGTGCAAGTATAGGCAAGGGCAAGATCACACGGGATCTTGCAGGCGGTGATAAAA
GAATTTAACTCTTTTATAAATTTTGACAGGACATCATTTGAAGAATTTAGAAAAATAGAGTGGAGATACCTGATCTGCT
TTCTTCAAAGAGTTTCACTCATCTATTGCTGAGTAGAGTTAGACTGAAATGGAAGCAATAGTGAATACAGGGAGATAG
CACAGGAAGCCACGTTACTAGTCCACATCAGAGGTGGTTTCAAGTACTAGGGTGGAGTGGTGGGGTCACTTAGAGAGCTG
GTATTTAGGATACATTTTAAAGACAAAGCTGACAGGATTTGCTGTGATGAATTAGATGTAAAGTATGAGAATAATTG
AGAATTTATTTCTAAGTTCTTTGCTGGGGAAAAAGTGGAGGAGGAAAAAGTTAGGGTACAAGGTGTGATGAAATCAAGA
GTCTCTCTTATTATCAGAGTCTCATTAGATATCCAAGTGGAAATGCTGGAAGAAAGTTGGGTAGATCAGTCTGAAG
CTGAAGACAGATACCTGTGACTGGAATAATAACGTAAGAGTTGGCCGGACACAGTGGCTCACTCTATAATCCAGCA
CTTTGGGAGGCCAGGATAGGAGAATTACTTGAGCCCAGGAGTCCAAGACCAGCCTGGGTAACACAGCGAGACCTCGC
CTCTACACACACACACGCGCGCAAAAATTAATCGGGTGTGGTGGCACATGCCTGTAGTCCCAGATACTCAGGAGGCC
GAGGCTGAAGGATCACTTGAGCCTGGGAAGTCAAGGCTGCAGTGAGCCGTGATCACACCGCTGCACTCCAGCCTGGG
CAACAGAGTGAGACCCGTGCTCAAAATAAATAAATAAATGTGGCAGTCATAGGCCCTTAGATGGTTTTTAAAGA
CATGGGACTGGATGAAGTCTTCTAGGAGGAGAGTTTGGGAAAAGAGCCGAGAAATGACTGCACCTTTCAAAACAGG
AGGAAGAAAAAATACTCAAAGGAGACAAAAGCAACTTCTGTGATTATAGAGAAAAACAGGCAAGTGGGATGAAG
AAAGTCTTTCATGATAGAATCAAAACAGTGTCAAATGTTGAAAATACAATTAGACAAACACAAAAGAATAGACCAT
TGGGTTTTGCAATATGGAGCTCATACTTGACCTTGATAAAAGACATTTTCACTGGAAGCATGCATCAAAAACCTATT
TGTGGTAGGTTAAATGTAGTAGGAGGTGAGGATATACAGACAGTGGCTTTCACTGTGCAGATACTGCTGCTCATGC
ACTAATTAAGACATTTGTTGAGTATCTACTATGTTGTATCCATTGCTAAATAGTAACAGCTGGGTTTTAGTCAGGT
AGAACAGCATCAAAATCATTATAGTATCCCAAGATAGGTACAGTAAATCTGTGAAGGAATCAGAGTAGTCTCTTCT
CCAACAGAGCGCTAAGACCCAGCTTCACGGAGAAGGTGGTAGATTAGCTCATCTGGGAGGCTGAGTAGAAGCTTGTC
TTATAGAGGGAGAACATCAGAAGTGTGGACAACAGCTTGAATAACCTTGAAAGGACAAAAGAGGACGGTCTGCCCTG
GAAATATTAAGAAGTCTCACATGATTAGACACAAGATATTAGGGGAAAGGCATAAGGTGAATTGAGTCAATGAGGTC
AAAGAGAAGCTAGCTGGAGGAACAGGCGATCATAAAATGAGTAAAGTATATATTCAAAGATTCTTTTGAAGGGC
TACACAGGATGGATAAGGGGAGAGAGAGGTTGAGGCACAGAGACAAATTGAAAGGTGCAATCATAACCAGAGACA
TGAAAACCCATAGAAATCTGATGTAGATTATGTGCTCCCAAGGTTGAACAATTAAGTACGCTTTTCAAGTTGTTATG
CCCATGATATTAACATATTTTATAACTGCAATAAGTGTGAAGCTAAAGATAAATACAAACAATGTAATTTCTTATTC
TGTGAGAAAATGTTGTAGCTGGAAGTTAAACATGTTTCTTAGCTAAAGAAAAATATTGTGTGATCTGGATTACTTAA
TGTTATAATTTAGCAACAAAATGTTGACATTGAGCCTTGCAATAATCAAAAAGTAGTCTATTCAATAACCACATTCT
CAGAAAAAAAACAAGAAATATTAGAAACAATGATAAATTATCGTAGTAATTTAATTCAGTATTCTATTGTTTTATT
TGGATTTAGGAAAGGCAGAAATGTTGAAATATTAATATATATCCCTGTAATAATATAATTTGTGTCTGAGAGGTAGA
AATGAGGCGATGAGGCTCAAAGTTTGATAATGAACCTTCAAAGCTATAACTATGATCAGGAATTAATAATGGACATA
AATTCCTAGAAATCGTCAGGAGTTGCTTGTGAAATCGGAAAGGAAAGGATATACACAAAAATAAAGAACAGCCAATG
CTCTCAAAGGAGTCTAATTTTTATAATAGTCTTCTGTGTTAGAGCTGAACCTTCTGGTTTTAGAAGGACACTCTGTT
GCCTGGAATAGGGCATGGAAGGATCAGAGTCAATGTCATCTTCATTCTTCCCATGAACGAAATCGAGGCCCT
GAAAAGTCACTGTGTTTGTGTATTTTATTGCAACTAAGATGTGCATTTTAAATTGATACATAATAATTGTACAT
ATTTGTGGGATACATGTGATATTTGATGCATGCATACCATGTGTAATTATCAATAAGGATATTTCTGTATCCGTC
ACCTCAAACATTTTACCATTGCTTTGTGTGGGAACATTTTACGTTATTTTATTATAGCTATTTTGAATAACAAAAAG
ATTGTCAATTAATATAGTACCCCTACTGGATGCACCTGTTTTTAAATTTTCTGAAAACAGATACGTCTCATAGGTG
ATGGTGTACAGCTGTGCATTAGTTATTATTGCCTGTGCAAGGTGCAACGTAACCTATTCAATTTGTTGTCAATTAAT
TAAATAGTTACATTTATTTATATGCGTTATTATACTAATAAACACAATATTGAGATAGTTGAGCTCTAGTTTTGAC
TCTGCTGTTAACTAGCTGCGTTACTTTAATTTACTTAACTAATTTGGCTTTCAAATTCCTGATAAGTAAATTAACA
CATGAGTTTCTCTGTATAATAGCCTGAGAAATCGGTGAAACACATGAATTCAGATGTTGATGCTATTTAATAGCG
GGATTCCAGATATCTACTTGCCATTATGGGAGGGAGAGAGGAGGTGGACTGGAGGCTGTGATTTCCCTAGGAGGTTG

TTAAATTGGCCAGGTGAGGAAAGCTGAGACAGACCATAAATATGAAGCATGATACCTAGCCCTCAGTGTGAAAGA
AAATCAAATCTCATCTTTGTGGTCTAAATATCAGTATGATACAATCCTCTGTGTAGACATATCCTCTGCCCTATTGT
TTCTTTTCTAAAGCTAAAGCCCAGGTGTGATCACATCCCTCCGTTATTTACAAATTTCTGATGATGATATTCTTC
TAATATCTACATTCTTTACCATTACCATGATGTCCAAAACCTATTATAATCTATTTCGTCTCCAAGTGCCATGTTGTG
GTCACCCCTATGCACCCCTCTAAACCCACCATATGACCTTCCCGCTGCTACTTGAATACAGTTGGCCCTCTACCTCGTT
GTGTCTTTGTCATTGCCTATTAAATTGCCTTTCCATTCTCAAATCACTCTTTTCGCTGGACCAGCAACATCAGCACC
TCTGGGAATTCATTAGAAATATAGATCCTCAGGCCTCATCTCAGACCTGCTTGATCAGAAACATTGGAGAGTGGAGA
TGAGCAGCCTGTATTTTTATCAGCCCTCTAGGTAATTTGATGCACACTAAAGTTTGAGAACCCTGGTCTAGAGCAT
TCTTCTTTAACTCTCTTTCTAAAAATTATTAGAATGAATTCGAGGGACGGGATCTCCTTGAAAGCCAAGAACATTTCT
TTGTCTCTTTCTGACTTCAGGGCGTAGTACACTTTTTGGCCCATAAATTAAGCTCGATAAATGCATTCTATGCCAA
TAAATCAGCTAAATCAAATATATTATTCATGCCCTTGAGGTATCTGAAATTTGTTTGAGAAATGTAATATATACTAT
AGAGTAACAAGAGATAAATTTATTGCCATAGATAATAAAACAATATCCTCTGTATAATAAATCCTAGCCTCTGCTCA
ATGGGCAAAAACGGGACTGGGGTTTCAGATTTTAAAAAGATTATTGGTAATTAATCACCTGGAGAAGCACTTGCTG
CAGAGATGGGACTTGAAGCATCATAATAAAGCTGTTGTTTATTATGATTCGGTCAGAGCTGATGGAATCAGAGGATT
GTGTGAGGTATGGAAAGTGGTTGACATTGAATTCAGGCTGCACAGTTGGGACTTGATATGATAACCAAAAAGAAAAG
AATGTCTGGGGTGGTAGCAAGCTCTAAATTTAGACAATCTAGGCTTATCCTAAGGAGAATATAGATACAGATAACTG
AAGTTTAAAGCTATTAGCCAGCTCCTCATCCTATAAATGCTATTACCTGGGAAAAGAGGCAGAAAATATACCTCTCT
CATAATACTTTTGGGCAATAACATTATAAAACCAAAAGAATGACATGGCTTATCTCTGTAACAAAGTGGCTCATTGTT
CTTTATTCTACTGTTATCCTTAAGAAAAAATTTTAGTAAATTTGTTATGCTATACTCAACTTCAAGAAGGGATAGC
GCTTATAAAAAAATTGTTTAAAGAAACAGGCCTATTTCTCTTTGGGAGAAGCCACGGAGAAACGAAAAGAATGGAAC
GTGTGTTTCTGCCAGATGGCAATAAATGTAGGGTAAATTTCTGTCTTTTAAACTGTATTTTTTCCATCCCTCTG
TATATACACATATCCTAGGACTGTTATAAAATGCTGCATGCGTATGTGAAAATGGAACCTTATTGGGCTGTTTGATG
GACCTTTAAAAATATATTGTTGGTTTGGGTACATACAAATGCTATGCAATATAATCCGCAATTATTCTTATGTAAACA
ATGGATAAACTGTTTCACAGTCCAGACATTTATTTGGTCACTGTTTGTAGAATGTCTATTTTATTACTTCTGAATT
TGTATTCCAGAGATCTGCCTTCAATGTTGGATACTTCCACTGTAATATTCTAGGAGATGCTCACTTTCTTTTTCAGC
ATCTGACACAGTACCATCTGCCTCCTCTTTCTTGCCACAAGTAATAACAATTTTATAAAGGAGGATCACATTACAG
AATTATAGGTGGTAAACTTTCTACCACCAGATTTACCCAAGAACCTGAAACACATTTTTTCAAAGGAAATAGAATG
TCCTTCTTGACTACATCGGAATTTTGCTTGACGATTTATGCTTTTTTTTTCCCTAGTGTAGCTAGCCATGTGG
AAGTGAAGCCATTAGCCAGCTCCTCATCCTATAAATGCTATTACCTGGGAAAAGAGGCAGAAAATATACCTCTCTCT
CCAGTTAGAGTCTAAAGGAAGAGAACAATATGGGTAGTTGTGTTTACCACAAATTGATAGAACTCCTTTATTTTAAA
TGCTAAAACCAATAAATTGTTTATATGACTTCAACATTGACTATCACACACTGTTGCATGATAACAGAGTGAAAC
TACCTCTATTGGATTTAAGTGGGGAATCTATGTCTCATCTCATTCTTTTTTACTGTGGAACCTAGTTGATTCCAG
GATCAGCCTTAGCTCCAACCTTGCCACACTTTGAGTTTGGTTTTTCACTTGCAATGTGCACAGGAACTTCTATAGGA
TAAATCGAGGAAGATTTTACTCTGCAACGTGTTGCAGAATTAACATTTAAAGTGGCAAAACCTTCGTGTGTAGGTT
GTCTCCCCAGAGAATGTAAAAATGAATTGAAGGCAGCACCTAAATAGGTAAACGACAGCCAAATCAAAACAAGAACAAT
GAAATTTGACTGGCAAAATCAAATTGAAATGTATAACGCTGAATCTCAGAATATAGGAGGATGCATAGAACTAAG
CTGTACTATTATAAAGTCATAGCCATTGAAAAATAATGACTGGTTAATTTGGTTTTCTTTACCTCATGGATGTGAA
TGTTTAGATTTTGATGTTGGTGTTATTTGACGTGTGTTTGTCAAGAAGTTGCCTTAGTCGGCTCGCATTTAGGATAA
AAAAAATATTTTAAAGAAATGTTTAAAGAGATTATGTTGGAGACATTAGAAAACAAATAATTATGCAGAGGGCAGGACT
ATCAAAATATAATAGAAAAATTACACCGCTCTTTTATGATTTCCCTCTTTTGGCATTTAACACAAAACCTTTATGAT
TACACACACCGCACTCCAGAAATGCTTAAAGGAAGATGAGAGGAAAATTCATAGAAAGTGCAGGCAATTTCTGTG
AGGACAGCAGAATGATCACTTCATCTCTGTATTTTTTTTTTTTCAAATTTCTGTATCTGTACAATGTCTTTTCCAGC
TCTAATATTCTGTGATTTGGTAATTTCCGCACTCAGATTTCTTTAATGAATTTTGATGATATTACCTATTTTTAT
ACCAGATATTACCTGGCTCTAATTTCTTTTACCCTAGGAAATAAAAGTATCGGGTGAATTTCCCATTTTCTTATG
TTATTGATACAGGTCTCTGTTGGATATCCCCACGATTAACCTTCCCTGCAGCATGTTTCGATGGTGGCTTAAAGAAGAA
ACCATGTATCAGAGCCCTTGCTCTATATAGACTTTTAGATAAAGAGAAATACATATCACAGAATTATTCTGGGCGCA
TAGAGTCTCTAAATGCAAAAAAATAATTGATTGATGCTGTTGATTCTTCTCAGATAGATTAGTGTAGAGAGAGAG
CATTCCAAAACCTGAGCAGAAGAAACACAGTCTGAATCAAATAACATGAAATTTTAGCTAACAAAGTAAATAACACTT
TTTTCAGAATATGCAATAATATTGGTTTATTATGAAAAATGTATAGGCTGATAGATGAGCATAGAGAAAAAATTAT
AAATATCTTCTTTAATATCACTTTCCCGAGCAACCACTTTTAACATTTTGATACATTTTCATGTTCAAACATTTCC
TAATAGTCTTTTTCTGTTATATAAATATGAATTTTAAACATTCGTATGTTTATGAAAAGGCAATAAGATACTGCT
CTTTTATAACAGGCTTTTCTGAATTTTCAACATGCAATGCTATGCTTACATGCTCCTTGTTGTTTCTTAACATAAAAA
ACCTCACGTTATTTTAAAAAACCATCTTAAACATAATTATCCATTAAAGAGAAGAGGTTGGGGTAGAGAGTTTCAGACT
ATCAATATCAAAGTTATATTTTCTGTAAGTATTTTAAATTTTAAAGTGTAGCTATAGGTATATGATTATAAAACCAAT
AGCAGAGAAAAGATACCACCTTTGAATATAGTTTTCTTGGTTCCATGAAAATGGCCTCCTTTCTTTTGGCAGTCC
CTCAGTATCATTAACCTATTTTTCTGTAAATGCCATCATTGTATCACATGCTCCTCAGGAAAAGGCACTTTTCTCTTT
TAAGCTAGTGTGTTGTTCTTCTAATTTTATGGCAATTTAACGAGTAACAATCCTGTTTCTATAAAATACGTGTTCC
TAATTAATCTATTGCAATTTCTATCCATGAGAATTTAGATGACTTTCTTTGTGAAGAGAAATCTCTGTAGCATGAGATT
TTCTTTGCTCTTAAATTTCACTTTTTCACATTTTAAATGACCTGATAGTATTTTGTGATTTTGTGCTGATTTTTT
TTAACCAATCTTACCTTGTGAAACATGTAAGTTGTTTCTAATATTTGCAATGATCAAAATGTGGATCCAACCTTCACT
AAAGCGTTAAGAATCTAAACAACAAACAAGAAAGAGTTGGCTGTCATCTTGCTGGACCACCCCGTGAGTTACT
ATTTTCTTGTTTCCGGTCAAGTTCATCCTAAATCATTTCAGTACACAAAATGTTTTTAAAGTTTGGGACAGGGGG
TAGAGAATGTCAATATTCTCCTCAAGGCAGTCATATGAGCAATTGAGTATCATGTGGAATAGTTGTACTGTAAAGT
TATGGGGCATCAAACCCAGTCAATATGTTTCTGGAATTTGAAAAGTCCCTGGACATTCTAATGATACTGTTGTTTCA

TTTGACCTACTGTTACCACTACTTTTGATCTGTCAACACTGCCGTAATGGTTAATTTTGTGCATCAACTTGACTGG
GCTACAAGGTGCCAGATATTTGGTCAAACATTATTCTGGGTGATTCTGTGCAAGTGTATCAGATGAGATTAAACAT
TTAAATTTGGTAGACTGAGTAAAGTAGATTGCCCTTCCCTAATGTGAGCAGACTTCATGTAATTAATTAAGGCCCTGAA
TAGAAGAAAAACACTGACCTCCCTGAGCAAAAGGGAATCGTTCTGCCGACTGCCTTCAAACCTGGGACATGGGCT
TTTTCTGCCTTCAGACTTTAACACAATATTAGCTGTCTTGTATCTCAAGTCTGCTCTACTTCGATTGGAACATAC
ACTATCAGCTCTCTCGGGTCTCCAGCTTGCTTGTTCACCTGTATACCTTGGGAGTTGTCTAGTCTCCATAGTTGCCCT
CCATAATTGCATGAGCCAATTTCTTACCACATACAAACACACACAGAGACACACACACACACACACACACACACA
CACACATATAATTATATATGTGTGTGTATACATATTCTTATTCTTTTGTCTCTAAGGAACCTTAATATACTC
CTTATTACTCTTTCTACTGCCTTAGAGATCTTCAAGGCCAAGAGCGTAATCCTCCATCCTGGCTCTTTTTCTTAATC
ATTAATGATCAACTCATAGCCATTTAGCTCAACTAAAAATAATTTGTTTCATGAAGCTTTACACTCCCACATACTGAG
GAACGTGGTACCTAAGATCAAACAGTCACCTGCCTCATCAAATGCATTCTCTTCAACCCCATACAAATGTCCCCAGA
TGGAACTCACACCATAAAAAATATTAGATCCCATTTGACTTTTCTGTCTTCTCAAGGATCATTTGCAGAGCTTGAAAAAG
ATGGCTCCTCCCTTTGCCTAAGCAGGTTAACTTGGTGTAAAAGTACATGTAAGATTGGCACAAAGGAAAAATAAATC
AGTTTTGCCTGGGTCTTAAGAAACATTTCCCTCTGCCTCATGGTAATTGTACCTGCCAGTTGATTGCATTACTCAAG
TGGAGACCATGAAGTGAAGTGGTAGAACAAAGAAATCCCTATAATTTTATTAGTATGGTGAAGAAATACAGATAT
GTAGAGAAATGACTGGGATTAGATGGAGCAAAACATAATTCGAGATCCTGATACAAATGTACTTCTGGCTCAAGG
GAGGGAGCAGAACATTTCCCTGTCTAGGGAATAATAATGCTGATAAAAAATGCAGATATGAGAAATTTCTGGTTA
GAAGCTGAAGTGGATTCTTATGGTCCCTACTCAGACAGCCTCTCCTTCAGATGAAGAACTGAAGCACAGAAAGCT
CATCCTAGTGTTCATATTGAAAAACCCATTCAAGTCTATTTTAATAACCTGTTACCAAAATGAGGGAAATAATTT
AACTTTAATGTTTCACTTTGCATTACCCTTTTCTGACTAGACTTCTATCCTTTTCTTGAGTTGAGCTCATTAACTA
CTATGAATTTATGGTTATGGGTAGAGGTTAATTTTATACCTGTCCATCTTCTGGCATCTTATTACACTAAAAATCA
TTTTTAAATGGCTTCATTTTAAAAAATATTATTTTCAGTTGCACATTTTAAAGACACATCATTATGTACTACAGAAT
ATGCATTTTATACTCTCCTTTATTAATTTTATTATTTTCCAGGTAGACCAATCAAATGAATCAGAAATTTCTGGTTA
GATCTATTAGACAGCATAAGTATGTTTTTCATCATTTAAATTAAGTGAAGAACACAATTTTACTTTAAAGTGTGTGAC
GTTTCCAGCCTTTATAAAGTCAACACTTAATCACATCTGAAATTTGCAGGAAAAAATTTGAAAGCCTTCAATTATT
AACATTATTTTCGGGAGAAAAAGCCACTTTGCCGAGAACTTTCACTTTTCTCTCGTAATTAAGTCTGATACAAAT
ATTCATTATGGTGAAGTTTAAACATAATAGAGTCTAGCTACTTCCACAAAAATACTATTCAATGAGTTTCTACATTG
ACATCTAAGTACCTTGTAAATTAATGTTGTACACGATCCTTTTATTATATGCTGGATTATCAAAATGACTTATTAG
CAGTATAAAGACACAAAGTTCTGAAATGTAATTTATAGCCATGAAAAGGAACTGAGCTTTGTGTGACAGTTAAATTT
GAAGAGATCAGGTGATTATTATGAAGCATGAATAATAATGCATATTTAACTCACGTTTTTGTTTAAATCATTAAATAT
GATTGTTTTAGAAGAAAGTCTACCTCTATCATATGGGCAATAAAATGTGTATAAGAGCAAACATTGTGTATGTGAA
ATAACTCAAATTAAGACAGTTTTCACATTAATTTCTACAGTTTTTAAATTTAAATCATTAAATGTATCACACAT
AGCTTTATTCAATTTAAGCTATAAATGTTACAATTTCTGTTTAAAGCTGTTAATATAAGCTTTGTAAGAGCAATTTCTG
TATAAATATAAGAAATGTCTATTATTCTAATAGCTACCATTTATTTAGTGCTTGTGTAGTGCAAAAGTACTGCACTG
AGATCTTTTGATATGTTCTTTAATGTTACAATTTTACCTGAGGCATTTCTGTTTCTGCTGGAAATATGGTCTCTCT
GAATTGAACAAGGGAGGCATTTTGGTTGTTATGATGAAAGGTGGACACTGCTGGCACTAACGTGTGTGTGGTAAAGCG
ACTAGACTCTTCATGATGCGTAAACAGTGTTCCTCATACCCCTGCACATTCAAATAGAGGAAAACCTTGTTTATAG
TTAATTTCCCTTAGAATGTAATCCATTAAACATATAAACACAAAGCGTGTGTTTGTGTGGATGTTTTTACTGGAGC
AGGGAGACAGGAGAGGAAATGCAGTTTTGATAGTTGCTGAATTTTTCAAGAATGCAGCAATTATAGAACAATTTCTA
GAAGTTTCCTAGGAGCTCTTTCCATAGCAGAAAACTAGGACTTAATAGCCTTGGGACTCATGGTACTTGTAGTGTTC
CATACAACCTCACCTATATTAGGGGACATTTGAAAAATTTCTACATTAAAGGGGATTCTTAACATAGGCGCAAGTGTC
TGGCATCTTCAATAGGTCTTCTGGTGTGGCCATGAAAACATTACACGTTTCAAAGTATTTTAAAAATAAAATAAAAC
ATATATTGTTGTGTTATGAATTATTTTCTTTCTTTTTTATATGATGGTTAGATCACTGTGCAGACAAGTTTATGAGA
TCTATTCAATTTCAATTTAGGGTGGTAAATGAGGGTGTACTAAATGTTGGTTCTAAAAAGGGAGACATTGGGTATTA
CAGAATTCAGAACAGCTCTAAGCCCTGTGCACATTTAGCATTAGAGGACACAGGCAAACTGCGCTCCAGTCTGGC
AGCTTCTTCACTATGATATGATGTTGGTGGGTGCTTTACCTCTCTAGTTTTTACTTTTTTCTAAGCTAGGGC
TATTCTATAGTTCTTTATCATGTGTTACTGTGAAGTAGCAAGACCTGACATAATTAGAGCAGATAAAATGTCTCAA
CAAATATTGCTTATCAGAAGGATTATGTATTACCTCCCGAAATACATCAAAATATATTTTCCAATTCAAAGAATAT
GTAGTACAAAAATCATGCCTAAATTAACAGAGTTGCAGTAGCCCAAGGAGAGAAGATAATCATTATTGATTTCTTCT
TCCTTTTTTGCTAAGCAGTTCTCTGTCTCTGCCTCCTCAGTTGTTGTCCATCCCCTCCCTCCCTCCCTGAA
CTCTGAGGGGTTTGTCTGCCGTGGCCGTTCTGTAGTCATTGTCTGTCCAATGATGAAAACAAAAATACTGCAACAGA
ACACTATGCCCTTAGCTTACCTCCTTTCTTCTGCTAAATGACACTCAATCCTATTCTTTTGTCTTAAAGGATATC
CTAAATGAATAGCCACTGGGGGAAAAAGGTTATATAAGATTGTGCACTGTGTGAAACTGATGCAACCAGATCAAT
GATGTGAATTTCTCTTAACTATTTACTGGGATCTAGAAACAGGTCTCTCAACTTAGCAGTGTTCAGAAATATAATAG
GCCTTCCTTATACATACATCTGAAGCCATCTGAGTCAGGAAGAGTCGTGGTCTGATAAATATTTTGAAACTTGCA
TTTGTCTTATTAAGCAAACCTGTTTATTAATAGTGTGCCTTATTTTTTAAAGCAAAACATTTATAAACAGTAGTCAT
TACAGGCATTCAGTGTACGGAGTGATCAATTGTTAGACCTTTAGGAATCGATTGTTTCGTGGAGCTTCGGCTTATA
ATTGAAATGTACATCAGAAAGGAGTGTAAGACATAGCTTCAGGAGAGGCCATTTATGCGCTTTTGTTCAGACTAAGT
ATAGAGTCATCATGTGAAGAAAGATTCTTCTCTTAGTAAAAATCCTTTAATGGTTGGAATAACACTTGATATTTAAT
ATTTCTTTCTACTTTATATCCACATTTATTCAAGTGCTAACGCGTGTGGGGCAGCAATGAAGCACTTTATTCCAACA
TTATAGTTCTCATATCTGCGTATGATTATTTTCAATTATCGTTAGCATATATATAATGATGACTTTTAAAGTACAC
TGTATTATATTCACTGGAATAATGATTAGCTATTAATAATTTGAACACTATCCAGGAAATTACTGAACATGTCTTAC
AAGATAAACCTCGTATGATATTGTCTCCAAATAACAGTGCTAACCAAGAAGAGTGCTACCAAGTTCAAAAGTAATCA
CAGGGAGTAACCTAAATGCAGCTCCGTTGGGTAAAAATAGTTTCTTAAATTTATGTTCCCTAAGTTTGAGATCG

ATTTCTACAAGGGGATAAAATGTTTTTATAAAATTCTCAGTGATAAGTCATGTGATTAAAGAACCCCAACTTTTTTTTC
CAAAGACATTTGCATCTCTGATCAAAATAACAAGATCCAGTCTTAGTTATAAAATGGGGAATTTTCATCAAAATAAG
GAGCTACTCGTTGCATAAGAAGACTAGTACAACCTTAAAGCCAATTTAATTTCAATGAATGCATGATCAGCTCCATTG
CCAATTGAGTGTTTTTCTTATTCATCAGAAGATGGGTTCATCATCGTGTTCATATCAACTGTTCTCAAACCATATT
GCCCATTTAAATAAATATAGATTTGTCTCGAAATTTCAAATTCATGTCATATTTCAAAATAGCCTATGGTCCTATT
TATTACTTTTAAATATTATAGATATAAATTTTTTATTCTAAAGTAACTGTGTTATACAACCAAAATTTTCATTATAAA
TATGTGACTTTTTAAATAAGTAAATGACTTATTTAAGTAAAGTCATTAAATTTTCCAGTCTGTCTTCATCCACCT
GATCTTTGAATGAGTTAGGAACAATACAGGAACTAATACAACTTAATTTTGATTACAAAAGATGAAATCATTCTG
TTATTTATTCAACACACTATGTGTCAATAAAATCTTATACTGTGAAAGAATTCGTCTAAGTCCATTTGCTGTGCTT
GTAACAGAATACTGAAATGGGTAATTTACAAAGAAAAGGAGTTTACTTCTTACAGTTACGGAGGCTGAGAAGTCC
AAGGTTGAGGGGCCACATCTGGTCAGAGCCTTCTCCCATCCAAGTACTAACCAAGTCTGAACCTTACTTAGCTTCCAA
GATCAGATAAGAGTGGGCGCGTTTTAGGCTGGTGTGGCTGTAGACTTGTAGAGCCTTTTTGCTCATGGGGACACAGC
AGAGCCCTGAGGCAGTGCAGGACATTACATGGCAAGAAGGCTGAGTATTCTAATGTGTTTCATGTCTCTCTCTCTGT
CTTATAAAATCATGAATCCTACTCCCATGATAACCCATTAACCTATTAATTTATGAATGGATGAATCCATTACATAAG
GGCAGAGCCCTCATGATGCAATCACCTCTTAAAGGCACAATCTCCCGGTGCTGCCACGTTGGGGATTAAAGTTCCAA
CACATGAAATTTGGGGGACACATTTAACTATAGCAAAATGTAATAAAATGTTATATAGAACAATGTTCTTACTG
ATTATAATTTGTTATATTGGTAAAGTGTAAAGTCTTCTCCATATTAACCAAGGATATATTTTACGTTTATTAATAGTTTAA
TTTACAATTCATATGAATAACATCTGGTAAAGTTCTTTTCAAGAAATGGGAAAATTAGAAATGTTTAGAAGAAAA
TAATTCATAAATATTAAGTTCAAACCTGGATTTCATAGTTTATGTGAAATTTCTGGGAACCAATTGCAAGGGGAGAAAA
TAGTTACAATAGCAATGGTGAAGATGAGAATAAGAGCAGGTATCAACGTTAATTGAGGGTGTGTTATAGTTCTAATC
GTGCTATGCCCACTACATGACTTTTCCCTGTGTGAGGTTTCCGAGCTTCTTCGTAGTAATCCTAAATGAGCTGGAG
AGAGGCTAGGGTAACTTACTCAGCTCATAGAGCCATAGAGTAGTAAAACCTGTATTGAACTCTGGCCTGTCTGAC
ATCATTCTGTGGTCTTTTTAAACCACCCTGCTTCTCCATATTAACCACTCCAAATCTAGGTGAAAAGAAGAAAACTCA
GAACATGTTCTGCAACAAAAATATAACAAAATATAATGTATATAAACACTTATACATAATATCTACTAATATCTTTACT
ATGAAAAGACTCTGATACGAACATTTTACATAATTCATGCAGAAGTGTAAATCACATTGTCTGTGATGAGCTGTGTA
TGTATCTGATAAAATTTCTGGCAACCAGACATCAACTCGTAGGCATAGATCTGTAACACTAAATATTTGCCTCGAGAA
ACTTAAAGAAATAAAGACAAATGAATGAATAGGAACATGGAACCTGAGTACAAGATAAAATCCTCTAAAGCAATCGA
TGTACTTGTCTGCTGCGTTATTTGTTCTAAGCAAAAGAAGCATGGCGAAGGGAGATGTGAAGCTAAAAACAGAATGCTT
AGAAGGAGATGATAGCAGGAGGGAAGCAAGATGCGACCAAGCTCCCAAAAGGCGGGCTTTGAACAAAACAAAAACAGA
AAGCTAAGCCTTTGACGGATGCACGGGATGCAAGAACTTTAGTCAGGAAAGAGGAGGCGAAGAAAAACCTCCAAA
GAAAAGGTGAACAATATTTAATAGGCAAATGACAGATAGCAAGAGATATATACCATGCTATGTTTTCTCATTGCA
GCTGAAGACAACTGGGGTATTTATGCTTTGAAAAAGCGTAAATCTAAAAACAAATGTGGAGAGAAGACGATGA
AAACACGTGTTAATACAGAAAACATGGCTCCAAGGCTTTAAACTTCTTGTGAGATAAATGCATTTACATTTCCGT
AGTAGCTAATATATATATATACATATATATATATCTGGGAAAATAATACACAGTGATTTCTTTCTTTTTT
TCATCTACTTATGTGAGAAAAAAGTAGGCTATCTGAAAGCTTTTTCAGTTAAATGAGGAAGAAAGTTAGGTGATCTTG
TAAATAATATATATGTTCAAGATAATGTAAGGCCCTTGTGTAGTTTTCAAACCTTATCTTTAATAGCAGTTTCTTCT
GGGGATGGGGTAGTTCAAAGTTGAAATGTTAGAAAGATGTTAACTTTTTTCTTTTTTACTTCTCCCTTTCAGGATG
GAATTAACAAATTTGATTACAAATAGATCTCAGAGAGAGGCAAATGCATTGAATCCAGAAGTAACATAAAATTAGAT
CATGTTTAGTTATGCCCGAGGTACATGGTGATAAAATGAGGATAAACTGAAATGTCTGTGAGCCAGATTAGTTT
ATTTTATGCCAGTCCTAGGAAAAAGACACATCATGGTAGGATACATCCTTTTTTTTTTAAATTACTTTTAAAGTTT
AGGGTACATGTGCACAGTGTGCAAGTTAGTTACATATGTATACCTGTGCCATGTTGGAGTGTGCACCCATTAACTC
TTCATTTAACATTAGGTATATCTCCTAATGCTGTCCCTCCCCCTCCCCCACCACACAGTTCCAGGGTGTGA
TGTTCCCTTCTCTGTGTCCATGTGTTCTCATTGTTCCATTCCACCTAAGAGTGAGAACATGCGCTGTTTGGTTTTT
TGTCCTTGCGATAGTTTACTGAGAATGATGATTCCAGTTTCATCCATGTCCCTACAAAGGACATGAACTCATCATT
TTTTCTGGCTGCATAGTATTCCATGGTGTATATGTGCCACATTTTCTTAATCCAGTCTATCATTGTTGGACATTTGG
GTTGGTTCCAAGTCTTTGCTATTGTGAATAGAGCCGCAATAAACATATGTGTGCAGTGTCTTTATAGCAGCATGAT
TTATAGTCCCTTTGGGTATATACCCAGTAATGGGATGCTGGGTCAAATGGTATTTCTAGTTCTAGGCCCTTGAGGAA
TCGCCACACTGCCTTCCACAATGAACAGACACTTCTCAAAAGAAGACATTTATGCAGCCAAAAACACATGAAAAAA
TGCTCACCATCACTGGCCATCAGAGACATGCAAATCAAACCACAATGAGATACCATCTCACACCAGTTAGAATGGC
AATCATTTAAAGTCAAGGAAACAACAGGTGCTGGAGAGGATGGGGAGAAATAGGAACACTTTTACACTGTTGGTGGG
ATTGTAACATAGTACATTTCTAACATCAATTTATCTCTAAAGCAATGTTTCATAGGGCACACTGTGAAGGCATAGATT
TGCGTACAAAATTTAAAGGCCATAAGCCCTCAACATGCAGACAGTATACTCAGAGACTATTTGAAAGATGAGATT
CTGGAACTTTTTAAATGACCCCAATCATTAGCAATGATTAATAATTAATATTCAACATTCTATATTTACCAAGGCAATA
AAGTAGACTAATCTATTTTAAAGGGTTTTAAATGAAGAGATGAAACAAACCAATGATTTTGATTAAACTTCAT
GAAAACATAAGTTGCATTAATCAGGTGATTTGTTTTATGAGCATTCTGATTGAAGTGATCATATTTAGCCCCGGGA
GAATAAGAGAAGGTAAAGTATGGGTATGGCACTGAATTTACTGAGATGATTATATTGTTTGAAGTAAAGAACTTGTA
TTAAGAAACAAGTATGTGCCAAACATTGTGCTAGGAGCAAGCAATGCTAAAATTACATGGGTAGAAAGAGAGAATGA
AATATCTAGAAATGAGTTAGAAACATCAGTTTTTCCAAATGAGGAGCCCTGACTTCACATGAAATTTCTCATTTTCAA
ACAAGGTAGTTTATGAAAACCTGGACTATTAGCAAGACAGGGTGGGCATGCCATCAGTATAGTACCTGGTGTAAACT
AGAAATTTTAAATCATTGTGCTTTTCAATTTATAATCAGTAAAATCCAAGGTAGGACAACTTTTACTTTTTCTGTAT
AATGGACTGATATTTGAATTATACCCAACTTTAATTTTTGCCAGAAATTATGCTTTATTGTTTCTCTAAAAATGGTA
CTATAGATCTTTATTTATTTCTATATATTTATATGATTTTTACATATATGTGCATTTACATGTATATACATCCATAA
ACTATATACATATATACATAAAATTACAAATATGTGTACCTACGTACATATATATGCATATATCAGCAGAAATACAG
GCACATTTTCAATACCCCTTTTTGATTTTTTCTTGAAGAGCATAGCATCTGAATTTATTATGGATTTATTTTTAA

TTTATGGTCATGTTCTTTGAGTGCTTTTGGTGTTTATCTGGTTGCCCCAACTCGCTAGCATTGTAAAGAAGATGTG
CAAAGCCTGAATCTAGACTGACTTTTCATATTGACTTTATTAGTCAAAAAAGTAGATGAAAATGTAACAGTCCGTGT
TAAAAATGGGAATAAGACAGATGTTCAAGCCCTAGCTTCAGCAGTTTTATAGCTGAGATTTACTGGAAGAAAACATTT
TCTGAACTGTAAAAACATGCAAAATGCCTACGTGACAGACTTCATTAACATTATTAAATGCTATGATATAGTAAAAGA
ATTTGTAACTGTCAAGTGCTTTGTCAACATTAGGAATTTAGTTATTATAGGTATTTCCATATACATGTTGTATTTA
GAATTCCTTTAATTTTATCTTAGGGTTGATTTGTATTTTAACTAAGTCACTTTATATATCTGGTCCCATATACA
AGTATACTTTTCTTAGGATAAGAAAGTGATCTTTATATATGTTTATCAACCCAAATGCCCATCAGTGATGGACTGG
ATAAAGAAAAGGTGGCACATACACACCATGGAATACTATGAATCCATAAAAAAGAACGAGTTCATGTCTTTGAAGG
GACATGGATAAAGCTGGAAGCCATCATCTCAGCAAACTAACACAGGAATGAAAAACAGACACCGCATTTTCTCAC
TCATAATTGGGAGTTGAGCAATGAGAACACATGGACACCGGGAGGGGAACATCACACACCGAGGCCTGTCCGAGGT
GGGGGGCAAGGGAGGGAGAGCATTAGGACAAATACCTAATGTCATGCGGGGCTTAAACCTAAATGACGGGTTTATA
GGTGACGCAAAACCATATGGCACATGTGTACCTATGTAACAAATCTGCACGTTCTGCACATGTTTCCAGAACTTAA
AATTTAAAAAACTTTAAAAAAGAAGTGTAGATACTGATCCAAAAAAATGTTTCATTAATGGGGGTTAAATGATTAT
TTCTAAGTAGACTACTCTTGAACCTTGAATCTTTAAGAATTTTCTTTGCTATTGAAGCCATTCAAACCTCTATTTTA
TTAAAGCTGTGCTTATTCTAGTAGATTTTAAACAGTAATACCTGAATACATTAGAAATATGCAAACTCTGCATTACAT
ATGGCATCTGCAGAGCAGAGGAGTTTGGTCATCTGGACTCATGCTAAAGTCTCCGAAAAATCCGCTTGTCTTAAATGA
TGTTGACTCGCTATAGCTATATAGCTTATATAGCTTAAAGTGAATGATGATGGCTAATACCCCTTCTATCTGTTA
GATGCACTCAGAACCTCACCTACCTGGGTCTCAGCTCTCCAGTGAAATCTCTACTTTAAGTTTATTTTCTAACATG
GTAAGAGCCTTCAGTTTATGTTATGCTCAGGCCCGTCACTGTGAATAAAATATTAGAAATGGACTTTTTTTTTTGT
ATTTTTTAAATGGATCCCTTGAACCTTTAAAAAAATTTATTTTATTTGAGCTTTCTACTGTTATCAGAGTGTCTCTAA
GCATGGCCTCCCGTTTTTGTGTTAATATAATTTCTTACGTTATTCAAATAGTAACCATTTATTTTCTCATGGCTA
GAATCTGGAACCTATTAGGAAATCACTGAGCATAATTGAATGGCTGTTTATTTGAAGAGCTATGTCAAGGCAGCAT
AGAGTTGTATTTCTTGCAGGGGCTCTGGAGTCAAAGAGCCTGGGTTCAAACCTTGGCTCCACCACTTTCTATCTGT
GGGGCATTGGGCGTGTTACATTTGTGAACTTTTGTCTCCATTTGTAAAGTGAGGTTTGGGGGATGATTAAACCA
GATAACTCATGTGAAATATTAAATGGAATGTATTTGGTAGGGGATTATTTATTTTAAATTTGGATTGCACATGAC
ACATGTCAGGGATCATGTATGCATTTTGGATAGAAAGATGGCTAAGATATCATGCCTGACTCTTAAAAACTTACCT
AATGGTAAATGACGAGTTAATGGGTGCAGCACACCAACATGGCACATGTATACGTGTGTAACCTGACATGTTGT
GCACATGAACCTTAAACCTTAAAGTATAATAAAAAAAAAAACTTATAATCAACTGTAGTAGAAAGAGATCTGAATGG
CTTGCCATTTAGCTAGGCACATGGTATATGTGCTTAAATTCATACTAGCAGCCACTACAGTTGTATGATTAATAATG
AGCTTCCAACCTGCACAGAATGCTTTTAAATCCATAGAAAATCAAATCAGAAACAAGTTTTTGTAAAATTAATGTGAAA
GGAGCAACAATTAAATGCAAGATTGACATTTATTTTCTAAATTTGGTTCTATTTTCTTTCACATTTACAAAATTTAT
AAGAAAATTTCTTTATTTCTATGTGATATAAAGAAGTGAATGTACTTTGATGTGAATTATTGTTGCCAGTGCTGTTT
AACTTTTATCCATAATTTACTAAGCACCTACATTTAGACAAAGGCATTATCCATCCCTTTGGGGAGGATTTTCTAGATG
ATTCATACACAGACCTGGTCTCGAGGAATTTAAGATTTTCTTTGGGGAGGGAATAAGGACTTTAACCAACTCAAGA
GTACTTAGAGAAATTTCTGAAAATAAATTTATCAATGAAAACCTTGTATATTAAAAAGAAACTGTCATTTCTGACTTCC
ACAAATCTAGGCTTGAACCTATGGATAACGAGATATTTCTATTACTCTCACTCACGTCAATTTTACAAAAGTGAAAA
GGTACATTTTAACTAGTGAAAGAATAGAGGAAATGGAAGTAGCTCGAGGCAGTGGACGATGATTCAAAAAGACAGGG
CCCTATTATTTGATCAAGTTATGCAACGACTCTGGGCTGTTTCTTACCTCTGGAAGGAGGAATAATCTCCAAGCC
CTTTCAGACTCTTTTGGTAATTCACCTCCAGCACATCTTCTAAATGCCAGCATTAACTGTCTCTGATTTGTCTCAT
GTTTTTCTAGCCCCATGCTCTCTGTTTCGCCATTTACCCTCATGCAAGGTACAAATTACACCCATCATCACAAAGACA
CTTGCTCAAGTCCCATTTGCCCTTGAAGACCTGCCACACCTACTCTCTCAAAAACCATCATTTTCTGAAAGTCCCTA
TACAGCTCATTGTTATTTACAGTGTACTGCCACAAGCCACTAAGCATCGTTTTTGTGAATACATGACTTACAGACTT
AGCTTGAGTAAAGATACTTGAATGAACACCATTTCTTGGCTATCTTCTTATTTTGTATGTACCTTTCAGGCCTATG
AATTTTAGTATAATAGATAACCAATAATTATTTCTTGGTTCTTCTTGCACATCTGAATAACCTATGCAAGTGAT
AGAATGTTTTTCTATAAGGAGGTCTTACACTGGAGATTGTGTATTTCTTAATGCTGTTGAAGGAAGAGATGTGTATC
TAAAAATAATAGACTCTAACAAACATTAAATTTATATTCTATTATCTGTTTTTGTGATTGAGATATCTCACAAAAAT
AACTAAACATTTTGGCATTATTGATATTACATATTTGCCATGAATATTTGTAAATGAAGAAAAATATATATACATCA
GTAATTATCTTGGCAAACCTTCAATTATGCAATATTGTTACATAGATTACATATCTAAGTGAACACTGGAGTTTTTA
ACAATATTGTGTGTTTCAATAATGTTTTATTTATTATTTGCCACTAATCTTATTGCCATTTCAAGAACTATGTATAAG
TTGTTCTAAAACTATTAAAGTATAGGTGACCATGGTCACTACTGCTACTTTTGGTAAAGGCCAAATATGTGAAGAC
TTTTTAATGTGTTTAAACAAACGTTGAAGTTTTTAACTGTTTAAACATCAGTAGGACTCTTGGAAATATTTCCTAAG
AGAGTAAATTTTCAACTTGCAAAGCATGATTAACCTTGTGAATTATAAACCATCTCTTGTAGTTATGTAGCATTTT
TGTTAATGAGCAAGAACCATTGTGGTTCTTTTTTACATTTCTTAAATAATTTCTCCGTAACCTCATTGATATCTCC
AGTAAATTTAGATAAGCTTTTTTTTTTAAAGGAGGGTTAAATGACATTTTAACTAATTTTTCTTGTAGTTATAC
AGAGTTGAACATCTGAGGGTTTTATTGACAGTCATAAAAAATTTGTATTTTCTGTGAAATATAGAGAATTTAATT
CATTATCATATTATTAATCTGTGGGCCATTGTCTTAATCTAGAGGCACAAGCTGTTTTTATCCCACTGAAATAGA
GGAATCAAAGTATGTTCTTGTCAAAGCACAAAAGTGACATACTACATAGTATGCTTCTTGAGTAGTCGTAATCT
CATGTGTTAAATTACATCCCAAAGATTTTCAATGTTTTTATGACTTTAATAATTTATGGTAATTTCTAATCTGGCCT
TTGTTGACCTGTCTTGTCTTTTTAAATTTTTAGTTTTTTCGACAAAATAATTAACATATTTTAAATAATCTTCCAAAGGT
GTTTAAATGGCATTGTATAGAGATAGCTGAAGGCTTTTGGCTTCTGTGTTGTAAACACTTTCTTAATAAAACATG
AATTGCTACAGATGATCCAGCAATCCCACTACTGGGCATTTATCCAAAGAAAAGGAAATCAGTATCTTTGAAGAGA
TAGCTTTGTTCCCATGTTTACTGCAGCACTTTTCACTAGCCATGATATGGAATCAACCTAAACGTCCATCAGTGG
ATGAATTGAAAAGAAAATGTGGTATGAAACAGAAATGTGCTTTAATTTATATTAAACACACTCATATTTCTTCTCA
GCTGTTAAGTATTGAGTTATAGATTTTAAAGAATTTATGTGAAGACTAAAGTGACTATTAAAGTAAGAAATTTATTT

TTTCCATTATATTTAACTTATTTTCATACTTTAATGTTAGCGCCAATGAGCAAGACTATTGAATACAAAACTAATTA
AGTAGTGGTGATAGTACAGTATATAAGGGAGAACATTCTTTTAGAAAAGGAACAATAACAGGGAGCAATAGAAAACAT
GAATGAGTGTAAGGTCACCTAGTGTTAAACAGCTAAAATATAGTACAAATAAGTTGCGTTTTAATAGTGATTTTAT
ATAATTACACCTTGATGTTTTATTTGTTACAAGAATTGTCCAGGAAGATTTCTCTAAAGACCAAAGGCACCTCTCCC
CTAAATAACTCCAAAGCCAGTCCTGTGTTTCTATAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAGTGAAAATAA
CGTGATGAACATTTTTGAGGAAGTATAAAACCAAATACTCCACTGCATAGCTGTTCTGCAGGTATTGTATTGATA
TATTACATTATTCAGCTTTGGAGTCTCCACATCCAATGTTACATCATCACTCTAAATTAAACATGTATAGATAAATG
AAATAAATGAGATAGCATATGAAAATCTCATAGCCCAGCCCCTGCACTATTTAAAAATAGAAATACCAAAGAATTGTA
TTCCCTCATCTGAAAGCTATTTAGTGGTGGTGTTCAAATAAAAAATCCATCTACTGCTGTTGCTTCCATTGTATCTT
TTTCTCTGCGGTACTGAAAGAGAAAGAGACCCAGAAGGGGCTTGTCTGAAGTGTCCTCTTTTAAGCTGTTGCTGC
TTTAAGCACAGGGTGGACAAATGTAATAGGAGTTTCATAAAGGTGGAATAAACACGCGGATTACGGTGTGGGTGAAT
ACTTTTCAGATGTTTAAACCAGGAGCTCTGCTGTCATGCTGGGAGTTGCCATGCCTCTTCTAGATTGAGGCACATTATC
ATGCACAACCTAACTCCAAGAAATCTTTTAAACCACTGGAAATTGAACCCAGAACATGTCTCTAAGCCAGCCTTTTC
ATCTTGACACCGAATCATAGCATGAGCCAGTCTGTGAGGGATGCTGCTGCTCTCTAGGCCAAATTTTAAATGTTGAAA
TAATGAATCATGTTTTCTTGAAAACCATGTACACCAAAGAAAAGTTAGTCATTTTATAGATGATGAATATTAACATT
TTCTTAGACAATCTGATAAATTATCAGATCTCACTTTTGGCTCTTTTAAAGACAGTTATGCCTCAGAAATATTAATA
AACCCCCAAGCCCTTATACCTAGTATGTTCACTATGATGAGAAATTCTTGAAGTTCTGTAATCAAACTGTTATCACTG
TTATTTCCCTTACTTTTCAATTTTATTAGTATGTGAATAATATTTTTAAAAATTCTAGTGTATGCTTGTATATATTTTA
ACAACATGACTTTTAATTAATGTCTTGATAACATTTCTCTAGTGTATGTTTTTCAGTAACATGATTATTAACGTGTA
CTTTAAAAACCTGTGGATTAGATGGGACCATTTTAAATGTTTTTAAACCTGGAAATCTGATGGCTTTAGGTTAGT
TCAAGCTATAGATCACCTGTGGAGAATGGAAGTCCAAAAAATAAGCTGTAGCAGCCCTTTGAGTATTTCTAAA
ATAGGGAGTTTATCCAGAGCATTGGTTTTCTAAAGCTTCCATTATTTATGATGTTGAGCTTTTCAGGATTTAGCTACA
ATATTTACTCAACATCTAAAGCATGCTTTTATCAGTCTAGTGTATTTATATCTTTTATAATCAAACTGTTATCACTG
AAAAAATATATAAGTTTCTATGTATCTGGAAGAATTCTCTGGTGTCTTCTAGATATGGATTTTGATGTGTGGAATA
AGAATTCAATTCAGGATAACAGAGATGTTGCTCTGAAAAAATCGAAGAAAATCAGCTTTTCTTAAACATTCTGTC
AAAGCTCCTGACTATTAGTTATCAGCAGTGTGTTGCCAAAGGTGCTTCTCTTCTCTTTTAAAAAATCATCT
GCTGCTGCTACGCCGCAAGTGTGTTCCCGCTGTGCCGTGAGAAGATGTGTGGCATAAAAAAATGGGCATGGCCTGAGT
TAAAGTGCTACATTTAAGCCAGAGCTGGCTTATTTATAGTTGTCTAATCATAGGAAAATGACAGAGCATGCTTTT
CTCTTGCAATATCCGTTTGTGAAAAATTAACACATGAGCAGAGCTTTCAGAGAGGTTGACTGGCCTCTCAGACAGCA
CCTCATAGGATGGCCTGTGTTGAAGCATCTCCTTTAACCAGGGTCTGTCCCTCAGCATTGGGTTGGCTCACCTAGAT
TGGATTGTCCAGCAGAAAAAACCACAAATTCAGAATCATATCCAAACCGGAATACTCTTTCACTTACATTAC
TTGTACTACCTTTTCAGAACTGGATACCTGAGTGTGTGAGGGTAACTTAGAACTTATCTCATGGTTAGAAGTTTT
AGAATTAGAGAGCGATGATCATGAAACGGACTTCATGATCAGAAGCAATGGAGCAAGGAATGAGATGTCTTTGAGGA
GTATTTCCCTGAGGCTGTGGATAACGCTGACGAATAATCCCCACCTTAAAGTGGGTGACCACTCTAGTAGCTGTA
AGGTGGGAGGTTCTTTCTCAGAGATAAATCTGTGCTCTTCACTTGGCCATTTCCAGGTTTTCATGTAGGTAGAA
GAAACACCTGTAATCTGAAGACACTCTTCCTTCAGCTTTGTTAGTGACAGGGATTTAAATATGTCTTTACACATTT
TCCTTAGATAGTTAAATTTCACTTTTCTGTTTGTGTTTTCTCTGAAGGTATTCTAACTCCCTCCTAATGGACTTCT
AGAGCTTTCTAATTTCTATGCAATTTCTGTGATTGTTGTTCTGGTAACTTTGAAGGTAATCTCTGATTCAACTTCTTG
GAGATTCTATCATGTCTCTGTTTATTAACCTTTATGTTACTCATGGTTTCTTGATGAGGACTCATTAACATAAT
GTAAGTAGAAAATTATTAACACATAAATTTACTACGGGTGTTGTTATTTCTGATAGTAGCTAGCTGTAAGATTCCAA
TTGTTCTTCAATCTTTGCTCAGTGATCTGTGTAGTCTTGACTACTTCAAATAACTTCCTAGAAGGATTAGGGA
TTTAATAATCTCTTAATAGGAACACTTAAACACACTGCTGGTGGGAACGTAAATTAGTTCGGTCGTTGAAAGCAGTGT
GGTGATTTCTCAAATAACTTACAAAAGAATTACCATTTGACCCAGCAATCCCATTATTGGGCATATACCCAGAGGAA
TAGAAATCATTTACCATAAAGACATATGCACGTTGTGTATGTTTCATTGCAACACTACTCACAATAGCAAAGACATG
GATTCAACTTAAATGCCTATCAATGAACAGACTGAATAAAGAAAATGTGGTACATATACACCATGGAATACTATGTG
GCCATGAAAAAGAATGAGATCATGTCTTTGAGCGCATGAGTGGAGCCAGTGGCCATTATCCTTAGCAAACCTTAT
ATGGAAACAGAAAAACCAATACTGCGTGTCTCAGCTTATAAATGGAAGCTAAATGATGAGAACATATGGACACAAAG
AGGGGAATAACACACACTGGGGCTACTGGAGGGTGGAAACACAAGTGGAGGGAGAAGATCAGGAAAAATAATTATTG
GGTACTATGTTTAGTACCTGCGTGAGAAAATAATCTTTACACCAAACCCCGCAAATGCAGTTCACCTGTATAGCA
AACCTGCACGTGTACCCCTGAACCTAATTTAAAAGTTATAAAATAAACGTATCTTATTTTCAGTACAATACACCACA
GAGTAGAAGGGTTAAAGAGATTGCTTCTGAGGAGGTGAGATGGGGGTAAAGACAGCACAAGAGCATTTTGGGGGGT
GATGAAGCTGTTCTGTGCTTGCCCTGCGATGATGAGCTACACGACTAAGCCCTTGTGAGAACTCAGAGAATTTACTT
CAAAAGGAGCGGATTTTACTACACATCAATTCCAATAACAAATACTTTGTCTTTAAGCAAAGGGATACCTAAATATA
GCGTATTGAATGGATCTCCAGAAAAACACATTTTTCAGTTCATGTTTCAGCCTAGGCCTCATCTCATCCAGGAAACC
TTGTCTTGCTTGCCCTTACATACATGTGGCAATCAGTAGTTTCTTTTAGGGCTCGGACTGAACACTCAATGAACCTC
AATCTTAGCGCTTGTCGTAGCAGATTGACATGGTTTATTTATATGTGTCATTCTCTGTAGTAAAGGAAAGGATCAA
GGCCATTCACTTTTGTAGTGATTGTGCATGGCAGTATTTGGCACATAGTAGATTATTAATTAATGAACCTTCTGTTT
CACACACACACACACACACACTTCCAGACTATTTTCAGTCTATTTTCAATTTAATATTGCTTTAGTCTTCCAAAGC
CCCTCTGCCTCAACACCAACCCCTTCTATCTCATTATTCATCAGCTTTTCTCCTATTACGAACTACTTAGGAAAGCC
CACTTATTTAGCTTATGATGGCAAAAATAAATATTTGTACTTTTTTTTTTTTTTTTAGTCATCGCTTCATAGAACAG
CCTCTGTCTCTGCTTATGCCATGTCTGAATATATGCTGGAGGTAAAAGAGTTCCTGGTTGAGAGCTTCAATTTGA
GAAACTATCTGAGATTACTTTCCAGGTTCCACCGTGGAACTGTCTGACCTTGAACAAATGACCTCGAACAAGTGGC
TGAAATCTCTTCTATTTTCGTCAACTGTAAAATGGGGGAAACCATGTCTATCTCATGGGGTTCATGTGAAGGTTAAG
AAATTGCTTATTCAGTGTTTAGCACAGTGCTGATGATAAAGCTCCTAGGAATATTAGCTGTTATTGTATTTC

TTAAAGAAGCCCATAGCTCTATATGCCCTTTTCATTATATGTTTTAGTAGCCCAATTTAACATATGGATAAAATATTT
TTAAGTTAAATGATTTGCTAATGGATTGTGAACGAGTGGCAGACACCCATATTATAGACGAAGGTCAAGTCCATAA
CATACAGTACATTTCCCCACTTTTCATTTCCCATTTACCAAAATTCATTATTCTCCTGAGAAACTCATTATAGAATTCA
TGTCAGATTTCATCTGTGTGTTCCACGAGTGCCTTATATCCAGAAATAACACTGAGTCATTGTCTAGATGTAGCAGA
GGTGAATCCTCCAAAGAGAAGCCTCAGAGTGGCCAGGTTTGCCAAGTATAGGGATGCCTTGATTACTGGCCTTACT
CTTTATGCTCGTGAATTCCTAAGTTTTATTCCTCCTGTAGTCATAGATTGGCTTTTAAGCTACAAGCTGAAGAGAGA
GAAAACCTCTTCCACCTCGTTGGAATATGTCTCTTCAATCCATTTGAGCCAATTTAGGACATGAGACTGCTCTTAGT
CTAGAACCAGTCATCAGGAGAATTCCAGGTCTGATTGACTCGGACTAGCGGGTCAATATCAGGGCAAAAATTTCCAAC
GCACAACACGATGTATCAGTAAGGAGAACCTCAAAATTATTTCTTAACGTCCAGATCATGTTCTATTTTTATATAT
CTATTTTCTCACATAAGTCATTAATAATGATGTACCTGTGCGGGTCCCTTAAATGATACTCAAAGATCTTGAATTATAG
GCTAATAACTAATTAATAAGCTGCAGAAATTAACATTTCTGTACGTTTATGTAGCATTTTCCACATGTACTTCA
GAGGCTTGAGAAAAGACCTGAAATAATGACTGAATAACAGCTTTTACTCACTTAATTTCAAATTTGTTAATTTCTCT
GGGAAATACCGTCAACATCCATTTTATTATTTTTCTCAATTACATGTACGTTTCTACATCAGTGGATAAGTTAAGGA
GAAGAATTCCTCATGATAATTTTTCTGCTCGAAAATTTGAATCAATTTTTTATTTTACATTATACTCTTTCTCT
AGTCATTAGAAAGGGAGTGGTGGTTAAGATAGGCAAGAATGCTTTATAAGGATACTACTCTCGTTTCAATTCCTAAC
ATCAAAAACCTTAACAGTGTGTAGACTATAAAATAAAATATCTAGGGATCAGAGCATTGTGCTGAACCTTTCAGGTT
TTTTAGTCAATAATATATATGACGTGTTACAGAAATTTGTGTCACAAAGTACTTTGGAGCTCAGGCCCTTTAA
GTTGGTTTTGTACTTTTTCTTTTTCTCGGAAGACTTTTTTGTCTATTTACCTGGAAGTGTCTTTTTTGGTA
CTGTGAATTAATAATGAGACCAATCTACTAGGCAGGAAAAACCTTAATTAGATTGTTGACACAGACAAATAAGAATG
TCAATTAGCATCTACTGTACATGCCTCTCCAGACTGCTTCTAGGATGAGTGGCTCAAGCAGTACATCATCTTTA
TACTCTAAAGCATCAAGGAACTTGGAGTGACAATTCATATCATGAACACATCCACAGTGATGATGATTGTGCTTC
TTCCCCCCCCACCAACAACAAAGGATGAATGCCAATTAATGTATTGAGTTTTTGGCGTCAAAGGCTGGATCACTGT
GCAATGAGGGTAATCATCTCTGACCAGACAGGCCATACCAATCCATATGTGTGAATTAAGATAATATGCGTGAAACA
CCTTACTCTGGATGTGGTTCATAGCAGTAGCAAAAAGATGAAAACATGGTATGCTAACATTTTAGAGATCTGTACT
CTATTTTAAATAATTTTATAAAAGTGCATATACAATAAAAGTGCACGTATCACAAGTATATGCCTCAAAATCTAAA
GCCAGTCATGTAATCAGCATCCACTTCAAGAAAGAAACAAAACAGTACCCCTGGTTCCTCTTTGCAATCATTAGTC
TCCCAAGAGTAATCACCGATCTGATCTGTGACAGCATAGATTGGTTTTGCCCTACTATATTTTTGCTGAATTATACA
ATATATGCTCTTTAATGTCTGGCTTCTTAGTGCAATTGTATTTGTGTATCAGCTATTCTCTTGTGTGATGTTATTA
CAATCATTTTATGGGCTGCATAATATTCCATAGGGTAAATATAACAGTTTTATTGATAACTTAGCTATGCAAAATAG
TGCTGTTGCAGACATATATTCTATTACATGTCTTTTGGTATAAGAATTTACACATTTACATGGGTGTATACCCAGA
ACTGAGATTGCTAAATATTGGGGCACATTGTATACATTTTGATTTAGTAGATAAGATATTGCCAGATATCGTAAATG
CACAGTTTGATAAAATATAGAGATTTTATCTTTTTCTAGAGAAAAGCCATCAATATCAGTGTATGTGTATATATAC
GCGTGTGTATATATACGTATATATATACGCGTGTGTATATATACGTATATATACACACATATATATACGTATATATG
TGTATATATATACGTATATATATACACATATATACATATATGTGTGTGTGTATATATATATATGAACAACCTCAGAA
GCAGAAAGATACCCCATGTTCTCACTTATAAGTGAAAGACAAATAATGTATAAACATGTACACATGGACATAGAGTG
TGTAGTGATAAGCATTGGAGACTGAAGTGTGGGGGTGTGCAAGGGAATCAGTGATAAAATTAATGGCTACAATGTACA
TAATTTGGGTGATGGATACACTAAAAATCCAAAGTTACCACATATCCAACATACTACATAATAAAATTGCACTTGT
ACCCCTTACATTCATACAAATAAAAAATTTATTTAAATAAAAAATAATATGTGTATATGTATGCATACATACATATGC
ATATACATATGTGTTTGTGTGTGTATATACTTACACTTAAATAAGCATGGATGCTGCAATGAATGCTCAATTT
ACAAGGGTTGTCCATCCAACTTGTGGCAAGTATCTCACCTCTCAAGTTGTTTTCTTTTTCTTCATATATTTCTTG
CTTTTGTCTAGGAAGGAATAATTTGGCTTGCCCTTTCAGAGTGTACAGTCAGCATGATAACCCAAACACTTAAGACA
CGTGCTAACCCATGTGGATCCCTTGAGAGAAGGAAAACAGTGGTCTTTTACTGGGCAGATAGAGCCCGGGGCCAGG
TTTCGTGGCTTGAAGATTTAGCTTCTCTGCGCTCTCAGCTCAGTGCCTCTGGAAGCAATTTACAACCTTGTGAGGC
CATACTCAAAGGCCCTGTTATTAATTCGCCGCTTCCGAGACCCATTTAGAGGATCTCAATTGCTCTCAGAGTGA
ATTTACTGTTTCTGAATCCGTAATCCCAATAGCAGGTCTGTTGCTCTCATTAGATAGCTTAAAGTTAGAGTCGGCA
GTGTAATTTGGCACTGAGTACTAAGTATCCAATGCTTATGTGGAAAATATGTTCCCTATTGCAACAACCTGATATT
CATATTCAATTTGGCACCATCATCTATCTATAAAGCAGTACTACTTGTGTTTATTAAAGTTTATCCCAATAATTA
TTTTAGTAATAATGCTTGAAAAATAGGCCCTTGGTCATTTGCATGTCTGTATATGGCATATCTGAGTCTTTGTATGTA
TTAGAAAGATCACTCGTTTTGACTTGATGGTTTAATAAAAGATGTCCCTCACTTTGGGCAGAGACATTTGAAAAAGG
CACTCCAACACAGGGACCTAAGAGGTGAATGAGATGCAGCTCTGAATCAGGTCACACGGCCTCAGGAAGGAAACATCT
TGGTTTTACATCCCTCACTTCTCGATGTCATGTGCAATGACAAATGACCCCTCAACACACACAGGCACATACA
CAACACACACTCACTCACTGATTTGCTCTTCTTCCCTGACTAAGTCTTCTTACTAATCAAGCTCTAAGACT
TTTTTACTTTACCTAAGGTGAGTGTGTGAGGATTTGAGGTTTCAATATTAATAATTCAGAAACATTTAAAGTTCATTTT
AAATATTAGTAAAAAAAATCTTGACAAAATACAATTATAGACAAAAAGAAAATTCAGAATATTTGGAATTTAAGGT
TGAGGTTACAGCCCTATTTATGAAATATTAGAAGAAAATGCTGGAGAGAATAAAGCAGGTTTATGAGTCTGATAGA
AAGCATAACCAGATGATTATGCATATATTTGCATATGCAAAGCTTTCTAGGCAATCTGAACATTTAAACCTACAAAT
GTGGCTGCGATGAACAGCCACAGAAGAGCAGGCTAGAACAGAAGAGGAGGCTAGAACAGAAGAGCAGGCAGAGTTG
TAAATGAAATGTTAATTTTCAATGGTTGATCTCCCAAGTACTGGAACAGATTTGTGCTGTTTTCAAGGTTTTGGTTC
AAAGAATCCAGTAGTGATTGAATGTTTTGTGGCACTTCCCTGTTATTTTGTGTTGTAAGCTACCTCAATCCATGA
AGTGGCTATGAGCCCTTATACAACACTGTTGATTTTTTTTTCTTATCTACGCAAAAGATTTTTGATTACAGGGCCA
GGCATGGTGGCTCAGCCTGTAATCCCAGCACTTTGGGAGGCCGAGGCAGGCGGATCATGAGGTCAGGAGATAGAGA
CCATCCTGGCTAACACGGTGAAAACCCACCTCTACTACAAATACAAAAAATCAGCCGGGCGTAGTGGCATGTGCCGG
TAGTCCCAGTACTCGGGAGGCTGAGGCAGGAGAATCACTTGAACCCGGTAGCCGAGATCTGCCACTCCACTCCAG
CCTGGGCGACAGAGCCAGACTCCATCTCAAAAAAGAAAAAAGATTTTTATTACAGTGGCTATCAGACTC

ATTAAATAGAAGCCTTAGGTTAAGTTCACGGGTTGCTAGTTGGAAGCCTCCATGGACTATGTTTCAAAAATAATAGA
AAGGAGTTATGCAGGACTTCTTGAAATGTTATTTAAAAAGTCAGAATAGGCTTTCTATTACTTGTCTGAGGTCAAAT
ACATGTAGTGTCTTCTGACCATTTCATCCAGGGTGTAGCTAGGACAATAAGAGGTGCTTAAAAATTATTAGATTGA
GTAAATGAGAAAGCCCTTAGAAACATAGGAACAGAATGACCCTTGCTTTGGATCTAATATTGACTCCCACGCCATAA
TCCCTTTGGAGAACTCCTTTATTTTCTCTCCATCAAGAGCAGGTATAAATTAACACCAATTAAAGGGGCCATCT
AGCTCAGCTGAAGCTTTTCATCACACATGTAGGGGAGGTATGGTTGGGAGGGATCTTTTATCCTTTAGGTCTCAAT
TTACATAGGACTTTTGAATAATCAAATAGCCCCAAGAGCTGATCTTAGGACTAGTTGTAATTGAGACTATTTCTCC
ATGGGGTAGAAAAATCTAGTTGTAGGAAAAGTGAAGTAGATGTATGTTAACCTCAAAGGCTGTTTTTACAAAGG
ATGTTAAAGCATCATCTTTGCTCAGAAAGGGAGCAATAAACAAATGAGTGGAATAACAAAAGGAAATAATGGCCA
GGTGCAAGTGCCTCACACTAGTAATCCCAACACTGGGGGGCTGTGGTGAAGGATCGCTTGAGGCTAGCAGTTCAAGA
CCAGCTGAGTAAAAATAGGCTCATCTCTACAAAATAGATAGATAGATAGATAGATAGATAGATAGATAGATAGATA
GATAGCCGGGCGAGGTAGTGTGCCCCCTGAGCCCCAGCTACTCAGGAGGCTGAGATGGGAGAAATCGTTTGAGCCCAT
GAGGTCAAGTCTATGGTGAGCTGTGCTCCCTCCTGCCACTGCACTCCAGCCTGGGTGACAGAGTGAGATCCTGTCTC
GAAAACAAAAGGCATACTTTTTAGATGTAATGGAATAGAGTACTTCCAAACCTGGCTGCCTGCTGGAGTTGTATTGG
AAGAGGTTGCACGACTTCAGTGAGATGGCCTAGATGCCTGCTCAGCAGTCATCTAGTTAAAGCAACTAAGAACATG
TAATATGAACTGCAAAAAGAGATCGTGTACGTAAATCACTCTGGGCTCCTCAGATAGAGTAATAAACACAACCTCC
TGACAGCCAAATAAAAAGAGAAATAATACAGCCCTTGACTTCTTGGTTGCTTTGACATACTAAGTAGGTTGACAG
GTTGGGTTCTCTGGGAAACAGACTCTAAACATTTTTATTTTTACTTTATTTGTTGTTATTATTATTATTATTATTATTA
TTTTAGACAGAATTTTGCTCTCGTTGTCCATGTTGGAGTGTAATGGCACAATCTCGTCTCACTGTAATTTCCGCCTT
ATGGGTTCAAGTGATTCTTCTGCCTCAAACCTCCCAAGTATCTGGGATTACAGGCAAGTACTACACGCCTGGCTAAT
TTTGATTTTTTAGTAGAGACGGGGTTTCATCATGTTGGTCAGGCTGGTCTCAAACACCCGACCTCAGGTGATCCACC
CACTTCTGCCTCCCAAAGTGCTGGGATTACAGGCGTGAGCCACTACGCCCCGCCAGACTCTAAAAATAAGTTTAATA
TGCAGAATACTTATCAGGGGAATGCCACTGGACCAATACATATTTCAAGAGAGGGCTAGAAGCAGGATTGGACAGAA
AGAGAAGTTGAGCTGTAATGCAGGCCCAATAACAGCCTTAGTGTTAAGCAGGCTGAGAGATTGAGCAGTTAATGAGA
CAGTCAACCCAAACAGTTTTATAGGCATCAAAAGTATGATCAGCATGGTGTCAGTTTCTGTGTCACTTGTCCACACA
GTATGATACCAAAATTAAGAGACCAGATGACATGCACACAAGCAGTGTGCACTCTGTTGTTGAGAAGCCAATTTTC
GTCATGCAATTAAGCAGTTTTATACCTCTGCAGCTGTACTTTAAGGGGAGCTGAGATGGAACATCATATGTCTCACCA
TAACCAAGAAAGGCAGATGAGAAATGTTCTATCGCCACCTCCCACAAGGTAAGGGACTTCCCTAAAGATACAGAGGTG
GGTGGAATATTGCTTGGTAGACTTCCCTCAAGACTGCCTATCTTCCCATGTTGGAAGGATCAGAGCAGTTTGTCT
AAGACGTGGGTCAATCTGCAGTTGAACTTTGTGTATGTGGCCTATGTGGATACTTATAATATCATTGGGCACCTCCA
TAGAGCTGTTTCCCAATTGACCAACATATGGGAAGCTTCAGAGCTTCGAATGACCCTTCAGAGTAGTCTGTGAGAAC
AGTGAGCCTTACTACTCCTGCATTAATCAGTCATTGGATGATAGCCTTCTCAGAAATAAGTCATGACCTTGTGCAAG
GGGGCTCTTCATGGCTGGGACCACCCCTAAAACCTGAGAGCTGAAGGCTGTCTGCCACCAGCCCTTCCACCTGCTGGG
ACAAGTTCTTTATTGAAGGGAAATCTGAGTAGTTTCATCAGCGTCCATCACAGTAGTCAAGCCGTTCACTTCTCTCTC
TTATGACCAACATTGTGCTTATTGTTATGTAATCCCTTTCCAGAACATTTTAGGTTAAGTTTTAAAAATAATGCATAT
AAATAGACAATTCAAATACTGGGGAAGAAAGCTTGCACTTATATTGTTATAGAAATGTGCACACTTAAAGAGCTGA
TTTCTTCTGGGTATTTACATAACTTTATTTAAAAATCCATCCATTTTTAATTAGCTGTTTTTAATATGCAGTTAGCT
AAGATATTATAAGCCATATATTAGGCTAATGGACATTTAAACAGCTTAGTTAAGTTCTTTTAATGGAAATGCTGACAA
ACCTTTGTCTGTAATTATAGCAACACTGTGATTACAGAAGGAGGTGCCTCTCCTTGTGTTTGCAGCCCTAAATTC
CATGTGGCTATAAGTAACAAAGTCCATTATTAGATAAACACAAGTCATACTTGGCATTACTTGCATTACTCGTCTCC
TTGCTTTATTTGAATCATTTTTTAAAGTTGTAATAATGTTTTTCAAACCTCAGAATAGTGGCAGTTAATAATATGAT
TCCTCTTATATTATGAGATTTTAAAAAATAGTTCACCAGTTTCTGGTGGCCTCTATACCCATTGGCAAGTCTAGCC
ATTGTGAATTAAGTAAACAATCTTTATGAAATTTTTTAATCCTTAAACCCTATAAGTTTTTATTCATCATGTGAG
GTCACCTGTCAAAGGGTTTAAACATTCAGAATTCAACAAAAGTTTATCAAACACCTATTACAGGACGTGCAATTTTGG
GCGCACTGGGATTTACAGCAATTAACAATCAAGATATGATTTGTATCGACATGGATATTACATTCTCTCACAGGAGAC
AGAAAACAAAATAACTAGAAAATATACATAAAGAGACTTTAAATAGGGGTAAATTAACAGATTGTGACAGGATGACC
ACTTTGGTTTCAAGATATCTAGGACATTTTTTCTTTTTTCTTCCCTCCCTCCCTCTTTCTTTTTTTCTTTTTCTT
TTTTCTTTCTTTTTCTTTTTCTTTTTCTTTCTGCTTTTCGGAGTCTTGCTCTGTTGCCAGGCTGGAGCGCAGTGGTGCAA
TCTCAGCTCACTGCAACCTCTGCCTCCCATGTTCAAGCTTTTCTGTGTGCTCCGCTCCCAAATAACTGGGACTAGA
GGCATGCACCACCAGGCCAGCTGATTTTTGTATTTTTTAGTAGAGATGGGGTTTGACCATGTTGCCAGGCTGGTCT
CAAACCTTGACACTCAAGCGATCCACCCGCTCAGCCTCCCAAGATGTGGGATTTACAGGCGTGACCCACCAGGCC
CAAGCTAAGGATTTTTTTCTGAGCCATGTTATTTTAAACAGATCTGAATGACAGAAGAGGGGAGCTTCTGATG
TAGGGGAAGAAAAATATGTTCTTCTACCTTCTAGGCTGCCAGCTGGAGTCTTACAAAGTTAGAGTGACAAAAGA
CAGATTAACAAGAGGAAAAGCCTAGAAGTTTATTAATAATTCAGTGACATACACCTGGTAGAACTCAGTGATGA
GTAACCTCAAAGGGGTGGTTAGAATGTTGGGTTTATATAGCATCTGAACAAAGAACAGTAACTTTAGAGAAATGAC
AAAACAAAGAAAAAGGGGTTTAGGTATTTAGGGTTGCCAAACTGTAGGAAGGTAAATATATGGGAGAAACATGGAG
TATAGTTTGTATTGCAAGTCTATCTTGAGATCACTTTTCGTATTCTTCATGGCCATAACAATTTCCAGGAGAG
AGGGCTTATAGCAGTTATCTTCTCAGAGTTTCTGCTTTTTATTAGACAAGGGAAGCAGCTGGGAAGCTTCTTTT
TGCTTATATTGATTCTTACTTGCTCTAACTAAAAGTAATCTTTATGTCAAAGTGCCATATTTTGGAGTGGTATATA
TTGATCTCCTATAATAACAATCAAAAGGAACAGTATTTCTAGGCAGGAGTACCATAATGCATAGTGTGTTGGTGAAA
GACAAGTTAAACATATTCATGGGGCAACACAACAATAAGCCAATATGGCTAAGACATTGAGGATGAGTGAGTTGGAG
AAGTAGGCAATGGCCAGCTCATATAAAGACTTGTTCGTTTTTATAAATGTTTAGATTATTTATGTAATTATGGTGGC
AAGTGATTGGAGAGTATTAGCTTCACTTTGACTGGCTTATCGAAAACGGAATGTAGGGGGTGAAGTGGAATAAAAA
GACCAGTCATTAATTGAGTAGTCCGTGTGAGAGATGATAGTGGCTTGACAAAGGACGATTGTACTGGAGAGATTGAA

109

AGGCAAGAGAATAATCCTGGAGAATTTCTCAAGGCATCTTGAACCTCTTTGATTTATTGCTCACATATAGTAATTTG
CCAAATGACGCCCTAGTGAACCTGAAAGAAATTAATGCCCCGTCTTAAGTCACTTTACCGAGGGACTGAAAACCTGCA
GCATTTTGCCAATTAGAGGAGGAAACAATCTACCTTGCAAGTCAAGGAGTACTGGATAAAGGAGCTAAGAGTGTTC
TTTTTTTCCCTTCTTACTTTAAAAATCCCAATTCATCCCATGTCTTTCTTAAAGGCTAAGTGAAGTAGTAAGTACG
TTTTTGCAACATACGAATTTAGCAGACTGGCCTTGTGTTTATTTTTGGCCGGAACCATTAACCTTATTTCCAACCTT
CTCCTTTATTTGTTGGTTGATAATGGGCTAATTTTGAATCTTTACTGTCAAAAGAACATTAAGAGAAGCAGCCCTGC
CTGCATCGCAGGCTATGTCTGTCTTTGCCGAGTATTAAACACTAAAAAAAATTAAGAAAATACTAACAAAATGAC
AAAGCATTAAAGAAAATAAACTAGATGTTAAAGGAAATGAGAAAATAGGAAAGGATGCTGTACCTGGAGTGATTTTT
TTTCCCCAGGCTACCTAAGATGATCAAAAAAGAGCTAATTTCTCTTAGGTTTCTATTAAGGAATTACTAGAATATCG
GGCACACCAGGAACTTTATCAGTGGACCTGTCTGAACCAAATTTCTTAATGTATATATGATAATTTGTTACCAC
ATCCCAGATTTATTTACAGGAATTAATAATATTTTGAACACTGACAGGGGAAAATGGGTAAAGCATTGATAGATAC
TACAATCTGTACTTGAACCTGCACTCAAGGAATTCGTTAGTCAAGAAAAGAACACATGACTGTGGGCCCTCTGGGT
TTTGGAACCTCTTTTGTAAGCATTTTTTTTTTTTTCCCAATAGAAGATATTATTTTTGAAAAGGTTAAATAAAAAAT
CTTTGTTCACTATATAGTTTCTCCTAAGGAGTAAATTAATTTATATAAAATATTGCAATATAAATAACAATTTTAA
AATCTCAAAAGAGCAGTGTTTTAAAAATAATGTAGAAACATTAAGAAATGACTTCAAAATGATAAGAATGTCATTGGA
GAGCAAAGGTTTTTAATATTACATATCGTGGCAGTATATCAGCACCCAACCGCTCAAGATACAGAGTTCTTTACA
AAAATCAACAGAGAAATGTGCCACCTGTTCATATAATTTAATAATAAGCCAGGCAGGCAATTAAGTCACTTT
CACAAATAATGAGCAAGCCCATGGTAATATAATTCATTACATAAGATTTATCTCATGGAATTTCTTAGACTGTGCT
TTGAAATTTAAATAATTTCTGATAAATGCCAACAGAAATAGAGAAATCAATTCAGAGCAATTACTAACACGTTGCATT
ACCTTTCTAACATTAATATTCTCTTCTACATATCATTGAAGAGAAAATGAGGATGGAAAATAAAAAGATCAGGTA
ATATATTTGCTTTCTCATCTAGGGTTGTTATGATCTTCAAGATGAAGTTTTATTTTTTACTCCTAGCAAAATGATATT
CTTTTTTATTTTAGTTTTTATTTTTATTTTTCTGTAAATTAATGGGGTACAGGTGGTATTTGGTTACATGAGTAA
GTTCTTTTTTTTGATATTTCTGAGATTTTTTTTTTATTTTACTTTAAGTTTTAGGGTACATGTGCAACAGTGCAGG
TTTGTTACGTATGTATACATGTGCCATGTTGGTGTGCTGCACCCATTAACTCGTCATTTAGCATTAGGTATATCTCC
TAATGCTATCCCTCCCCCTCCCCCACCACACAACAGGCCCGGTGTGTGATGTTCCCTTCTGTGTCCATGTGT
TCTCATTTGTTCAATTTCCACCTATGAGCGAGAACATGCGGTGTTTGGTTTTTTGTCCTTGCGATAGTTTGCTGAGAA
AACCACGAGGTACCATCTCACGCCAGTTAGAATGGCGATCATTAAAAATCAGGAAACAACAGGTGCTGGTGAGGATG
TGGAGAAACAGGAACACTTTTACACTGTTGGTGGGACTGTAACTAGTTCAACCATTGTGGAAGTCAGTGTGGCGAT
TCTCAGGCATCTAGAACTAGAATTACCATTTGACCCAGCCATCCCATTAAGTGGGTATATACCCAAAGATTATAAA
TCATGCTGTCTGTAAGACACATGCACATGTATGTTTATTGCGGCACTATTACAAATAGCAAAGACTTGAACCAACC
CAAATGTCCGACAATGATAGACTGGATTAAGAAAATGTGGCACATATACCCATGGAATACTGTGCGACCCATAAAAA
AGGATGAGTTCACGTCTTTGTAGGGACATGGATGAAGCTGGAACCATCATTCTCAGCAAACATTGCAATGAGTA
AGTTCTTTAGTGGTAATTTGTGAGATCCTGGTGCACCCATCACACGAGTAGTATACACTGCACCATATATGTTATCT
TTTGTCCTCGGCACCCCTTTTCTACCCCCCAAGTCTCAAAGGCCATTTGTATCATTCTTATGCCTTTGCACTCTCA
TAGCTTAGCTAGCTGACGATATCAGTGAGAACATATGCTGTTTGGTTTTTCCATTCTGAGTTACTTCACTTAACATGATA
GTCTCCAATCGCATCCAGGTCATTGCAAAATGCTGTTAATTCATTCTTTTTATGGCTGAGTAGTATTCATATATATA
TATATAGACACACGTACATACATATGTATATATACCGCAGTTTCTTTATCTACTTGTGCGATTGATGGGCATTTGGGT
TGATACTTGCACACACATGTTTATAGCAGCATAAATCACAATTGCAAGTGATATTCTCAGGAAGCATGATGTAAGTG
ACAGAGACTTACTTTGTAGACTGCACTCATTCACTTGTCTCTGAATGTGCTCTAGGCAGCCTGAGTTTCTACTATG
TCAGTGTTACATAGATGAGAAACCCCATGGGTGGTTTCCACAGAGGCTGCAATACTATTTTTGATACCAAAAATCTG
TTTGGTTTTTGGTATGCCCCATATGGAAACTGAAGTGTGATACTCTTTGTGATCCCTCTGTGATCCCTCTGATGAAC
ATGGTTACCTTCTCAGCAGTTTGTAGCGGGGTGGGGAGAGCGCCTGCTTCTAGCCATCCGATTGGCCTGAATCAT
CAAAAATGCTATCATGAACAGGTTCTGTTTATCTGCTCCAGATTACCCCATCATGTTCTAGAGTGCTGGTTTCAT
GCTTGAATCTAGATCAAGCTGCTTTCTCCTCCCTGCTGTACTCCCTGTGGCTACCTACAGTCTGCTGTGCTGACAGA
TAATCTAAACCAATAGCACCTAATTAGCCTATTTGCTCATGTGTTTTTCCATCGTGGTATAATGTCTCTCTTGTCAT
ATTTAGGGTGAAAATGTAGCAACACGTTGCTGATGTTTAAATTTCTGGAATGCAGGTAATGAATGTTTGTGTTTGTCTTA
TCCAAGTCTTCCCATCAGATGTCAAATATAGAAGAACAGTGTTTCAGAGGTCCTAAATTTAAATTTGGAGTGAGAAAT
CACAGCGCCCTGAACTCAGGCAAAATGCACTCTGACAAGTCAACCAGATATTCACAGATGGTCTGGAGGATTTGAA
GCCTAATTTGGTGAAATAAAATTAATGAGTGAAATTTGTATGCAGTCATTAATCTATCACCATACTTAAATGCTTC
ATTGAAATTTCTTTTACTGCTTCAAATGAAAAAGATCAAACTATGTTATAGAAAAGCATTCAAAACCTTACATAA
CATAGATAAAACTTTGGTTGGAGACTTACAGAATTTCTCTGCTGCTTCGAGAAAAGTTACAGTGGCCACAAATCTATT
GCTATTAGAATATTTTATTGTATTCAACACTCAATTTTACCATAATTATGTATATGAGAAAAATTTTTTACCTATA
AAATAATTATTATTACCTTTTAAAAATCTGACATTCTTCTTTTTTCTAAAGAAACATATTTAGATTTAGCTTTTAT
TTTATTTTTTGTGTTGATACATAGAGATTGTACATATTTCTAAGATTCTAGTGATATTTTGATACAAGCGTATAATGT
GTAATGATCAAATCAGGGTAATTGGGATATCCACCATCTGAAACACTTATCATTCTTCTTTTCAATGCCATCATAC
CAAAAGGAAGTAAATAGAATTTCAAATATAAGGACAGCCATGATTTTACATACATGCCTACGATTCCACCACAAACC
ATAATTACGTCCCCCAAACCTTTTAAACATTTAGATCTTTGTCCAGGATTTTTCATGATAAGGATTTGGGCTATGACT
CTGTTACAGAAGGGCCAAATGACTAAAAATGTCTCTGAAACAATATTGATTGCAAAATTTCTACCCAGTGTGTCAGGTCA
ATATGTTCCAATTCGGAATTTATAACATTGTATCTCTACTCCAAACCATCCAATCTCACCTACCTCACTTCCATAT
TATGGTGGGTGATCTCAGATTATATTTAAGCTCATGGTTACTTGTCAAGTAGATATGGAGTTTAGCCTAACTTTTGA
AATTTATGCTGAGATTACCTTCTCATTATAGAATTAAGTAGGCAGTTTCCAAGTTTAGATTTAGCAGGCAGTTTTT
TTCAAATCACTTAAAGTTATATTTTTTTTAGGGCATTGAACAGGTTTGAAATCTTACCAAGATGTCATGTACACATA
GACCAATAGAACAGAATAGAGAACACATAAAATAAACTGCACAGCTACAGCCAAGTGTTCGTCGACAAAGTCAACAA
AAAAATAAGCATTGGGAAATGGATTAAAGATTTAAATGTAAAGCTTCAAGCTATAAGAATCCTAGAATAAAATCTGG

GAATACCATTCTGGACATTGGCTTGGGAAAGAATTTTGGACTAAGTCCTTAAAAGCAATTGCAAAAAAAAAAAAA
AAAAAAAAATGACAAGCAAGGACTTACTAAAAATAAGAGCTTCTGCATGGCAAAATAATGATCAACAGAGTAAACAG
ACAAACACCAAATGGGAGAAAACTTTTGCAGTTATGCATCTGACGGTGGTGTAAATATCCAGAATCTATGAGGAACC
TAAACAATTGAACAAACAAAAATCATAAAACATCATTTAAAAAATGGGCAAAAGACATGAACAGACATTTCTCAAAA
GAAGATATACACGCAGCCAATAAACATGAAAAATGCGTCACATCACTCATCATCAGAGAAATGCAAAATCAAAACCGC
AAGGAGATACCATCTCACACCCGTCAGACTGGCTTTTGTAAAAAGTCAAAAGACACCCAATGCTGGCAAGGCCGAG
AGACAAGGGGATGCTTATACACTGTTGTTGGGAATGTTAATTAGTTCAGCCACTGTAGAAAGCAGTTTGGACATTTT
TCAAAGAACTTAAAAATAGAACTATCATTTGACCCATCAATCCCATTACTGAGTAGATATCCAAAAGAAAACAAATGG
TTCTACCAAAAAGACACATGCACACTCACATGTTTGTACAGCACTATGCACAATAGCAAAGTAATGGGATCAACATAG
GTGTCCGTCACAGTTGGATTGGATAAAGTAAATGTTGTACACATACACCATAAAATACTATACAGCCACGAAAAAGAA
GAAAATCATATCCTTTGACGCAACATAGATGCAGCTAGAGGCCATTATCCTAAGCAAATTAACATAAGAACAGAAAA
CCAAATACTATATGTACTCAGTTATGAGTTGGAGCTAAATGTTAGGTACTTATAGAATTGAAGATGGCAACAGTAGA
AACTAGGGACTAATAGAAGGGGAAAGGAAAGGGGGAGACAAGGGTTGAAAAGCTGCCTATTGTGTACTATGCTTACT
ACCTGGTTAATGGGATCATTGTATCCCAAACCTCAGCATCACGCCATATATCCAGGTAACAAACCTGAACATGTAC
CCTCTGGATCTTAAAAGTTGAAAAAAAAGATGTATATAAATATTCGTGGTCACTAAAAGTATCTAATGTATTATA
CATAAAAATAAAAAATGGGTGAATTGGAAGTGTATTCTTTGTATCAAGTCATGTCGGAGATCCTATTCTGCTTTGAT
CACAGTGTGAATCTTTTGCATTTTTTGTACCAGTCTTCTTTATTTATTGAACATAAATCTTCTCAGCACCCAAAT
TCTGTACAGAAAGATAAAAAACATTCTTTGTCCATGTGTCTGAAAATTTTTAACCTATTTTTCTAATGTTTTAAGTGAG
AAGAGCATGTTAATACTGAAATTGTAAGCAGTAGACTGAAAAATCATCCCAATCCATGGGTTATATATTGAATTGCT
TTTAACTGTATTACTAAATATTAAGCTTAATTTATTTTATTTCTACATATCCCCATTTCCACTATAGGTGATTGT
TGAATTTAGGAACTTCCTTCTCTCATCCATTTTTATATTAAACTCAGACTTTCTAAAACAATATTTCTATCCATCC
ATCGTTGGTAACTATGTACTGACATGTTTGTGTCATCCGAAAAATGTAGCATTAGTTTGTGCGCAGAGAATAAT
CCAGTCACCATATGATGAGCTGATTTTATTTATTCGTAAGTGTGTTTATTATTATTAATCTCTCAGCACCCAAAT
ATAGGGGACTTAATGATACCTACAAGTAAAAACGGAAGACAAAAACGCCCTGCTCTCTACAGAGGTTAAATGTTTT
TGCAACAGGGCTCTAGATCTCAGCTGTGAAAGTAGGGACGAGATGAGGCTAGGCATGCAGTGTGAGTATAATAA
ATAATCAACATGTGAGCATCTAATGCAGGTGTGCAAAACAAAATGTACACATGGGTAGTCAGGTAACAGAAAAGCA
TGAAGTAGTAAGGGCTATCTATGCAAGAGGTTCCAAGCTGACTATATACTGAAATATTTAAACACTATGTGGGGCAA
ATAAAATGGACATTAGAACAGTTCGATGGTCAGTTGGGGACTTCTGCTCTTTCTCCAGTCTCTGAACATATCTTAA
AGCCACAATCATCTATTTTTATTTATTTGTTATACATTTATTTATAAGCCAGCACCCCTGTGATTAAAGTTCTGTGA
AATGCTGAGTTGGAAGATCGATGGATGGGGGAAATTTAGTGCAGAGGTTTGGCCAGGTTCAAAATCCTTTATA
AAATATTAATACATGGAACAAATATTGAACAATTAACCCTGATAAGTTAATCAATCTGATTCAAAGTACACCTGT
GAAGAGGGACATGGCAAGAAAAATATTACAGTAAGAACTAGAAACATTCCTTCATGGCTGCTTGATATGGATATGTC
ATGTTTAAAGAAATCTCTTTAGACTGTTGAGATTTTTTCTTGACAAAGAAGATTCACGTGTCAGGAAAGAAAG
AGGTACTGTGAAATTTGTTATTGAAAACATGCACATACTTTTGTGAGAATGAGTTAAAGAGTGAACAAAATGTGCT
ATTACTTACGTGTGTGCTGTTTTAATTCAAGATTAATAATTTAAGTCCACAGACAAGACCCTTTTATATGAAT
ATTATTTTTCTGCTTTATTGCTCAATTTTATTACCATTTCAAAACACCCGTTGCTTTCTATGGCCAAAGATGTTT
AGCACTTTTCATGTTTATCTCTGTACAGTCCAAAATACAACACTTACTTTACACATACACAAACATCCAATGTAT
TTTGTTTTCTGTCAAGTAAAGACAATGTCTGTGTTATTAAGTTAAATGTCACTTCAAATACAGGATATGTTGATAT
TAGAATGTTCAACTTTATTTCTCATTTAAGCAAATTACAGTGTGAAGAATGTAAGTGCAGCAATTTATAAAAAATCA
TATCACATTCAATTATGAGAGCAAACCTGTTTTGTAGACTTGAAGTAACTTCAATTAATCTTGGAGTTATCATTTC
AAAATTTCTAAACAGAGAGAAATACGGAGTGAATAATGGTAGGTTTGGGTAAGCTGCTTCCAGGAAAAGAAAGCA
ATTATATATGTTACATAGCACTGACAAGGAGAAACAAAACCTTTGGACGGCAAAGAAGTGCATTAGTCTTTTTGAC
ATGTTCTGTGTTGTTGTTTATTACGTAGACAATCAGTCAACTTCTCAAGTTTGATATCCTTGAATCATTTGAAA
TTTAAATTTTAAATGAAAATTCATTAATTCAGGCAAGGAAAGTATTCTAATTGCTTTTGAGAATCAGACTATGA
AAGAATTTCTTTGGCAAACCTGCACTGCTTTTCTCTTTTATCATTGGTTGCTTCGTAGGTACTTAATTGAAGTCTCT
CTGATTATCAGCACGGCTGACATCAGTTCCTCCATGCATTTTAAACAGTAGGCCAGATGTTTAAAGGATCAGCTG
AAGCATCGATGAGTGTGCTAGGGTGAATAATAAAATTTTCAATATCTACAAGAAGCAAATAAAAGCATAAGCATTTT
CCCCCATATCTCTGAAGGAGAAGATGAATGCCTAAGCAACATTTTAAAGATGGGTTGAGTGTGGCCTGTGGGAAAA
TTGGGTAGAAAACCTGTAGTTAGCTAATGTATATACGTGTTGCTCTTTAGCTCACCATATACCCACACACATGGGC
ATGCATGCATACAGACAGACACATACATAACACACAACAAACAGGAAATTCAGATATACTGAAGAAATGTATTAAAG
GGATTACTAAGTTTGTAAATAAAATCCTTTAAGATGCTGAGAAACAATGGAAGAGAGTAGGACATGATGGCTCA
TACTTTCTGTAATTTTACTTTAAACGTTTGCCAAAGTTTAAATTAATGTAGATGTTTTGTGAGTATGATTAAATGAT
CTAACAGTTTGAATAAATTAGGCATTTTATCACCTAGAAAGCCAGAAACCCAGCATGCAAAAATTTCTGGTATGTC
TGCATTTTACACTTAGATATAACAGAGAAATGACAAGTAGTCAAGTGGATAGAGAAACGAATGATTCTTCACACATG
CACACACACATAGAAATTGCTTTTTTAATAGTATTTAATGTAACACATTTATGCATAATTTCTCCATAGTGTATAT
CTTATAGTGAATATGTATGAATAGTCTCTAACATTAGTGGTTTTATAGATTAAACATAATTAAGGCTTTATATATT
AAAGAGTCAATTGGTGACATTCTAATATAAACATGTTTATCTCATATACATTGAAATATTAGATAATTCATTCGTTG
AGAATAAATCGAATGAGTCAAAACCTTTAACCTCCACTTTGAGCTTGTAAATAGTATCCACTGAAAATTTCCATGAA
AATTTTTAAGTCATTTCTATTTATATATTCAAGTCCAAACATCTCACAAAGTTTAAATGTAACTCAAGAATATAATT
TCTGTATTCTACAATTGGAAGCATCCATCATATCAGATGAAGTTATATAGTTTGTGAAATTTTGCAAACCTTTCTGTT
TAGTAAATCTTAATGTCAAACATTTTAACTCCAGGTGTCTTTCTTTTCAGTTTAAATATCCGCGATCTTTGTATA
CTCGTTGAATGGATTCTCAATAAGTAACCCACAAATATATATACATACTATGTACCTACAAAAATAATAAAAGTA
AAGAAATCGACACTTATCCATACCTGTCCCATAGTAATAAGCTATTTCATAAGTATATTTGAAAGATATGAGAATCAT
AAAAGTTCGTGTTTGCACCCTTTTGTGCGTGGAATCCTAAGCTTTGCATTTTGTGGATCTAGACTTTTTGGAGTGTGG

112

113

ATGGAAGATCTCTGACAGAGGGAACAAAGGCATAGTGACAAAAGTCAAGGGCATATTTAGGACTGGAGAGTGGTATG
TGTGGCTTGAGAGTGGGCGAGAAAAACAACAATGCCTCTGTAATAGGAAAGTAGACAGAGGCATGACATTAAGAGC
TTTGCCAGCTGTGCTAAAAGTAGTGAACAAGAGCTAACAAAGTGAAGAAATGTACCTTTTCTGATGTGTATCATTCC
CTTATTCATATACTTCTTGAGGGGGAAATTCATTCTGTGTTGATCTAGTAACTACTACAGGACCAAAATGATAAAAA
GAAGTATAGGAAAGAATGTTTCAGCATACTTTACGAGATAACTTCCTTGTAGCTATTCTCCATAGTATTTTGAGCAT
CACAAAGCAATGAGCTGAAACTGTCTAAGCCAAAATTGACTTGTCTATCTGTTAGGGATGCTTAGATGAGAATTCTAC
ATTTGAGAGCTTCTTAGATTCAATTGACCACTATGTCCCATTTCTAAGATCCATGAATGCGTGACCTAACTATTACACC
TTCTTTTAGTCTGATTGTCAATTTTGTATTTCAATTGTGCAAGTTTCTAAAACATTTTAGGAAGATAAATCTAGC
AGTGGTGTGGGAATAGACAAGAGAGAAGGGGAAAGACTCTTCAGGAACTAACTCACAATTTATGAGTATTCTTTA
TTGCCCAAGTCTTCCCAAAGTCTTTCATCAAGAAAGAGGCATTGCAACTCTCCTTTTATAGTTTGTTTTATTCTGG
AGCAGTGATGTTTGGTGGAGTTGTTCCCTCAGTGCGTAATTAAGGGCCATGACAATTACAGTTCATCTCCTGCTG
CTCAAGGTACTGCAGATATTTGGATCTACTACTCTCATTTTCCAATTAATGTCAGCTTTAGATTTCCTTCAGTA
TGCTATGTTATAAAATTTGATTATCGTTGTGCCACCTTCCCACCTTAATTTCAAGCAGGTTTCTCGATTACCTGACT
AACTAATGAATCTGACTAACCCAATATCTGTGGACAGTAGTGTGATGTTACTGATTTTGTATGATTAGTCAAGT
CATATTCATGCCACGTTTTCATATAGTACCATAAAGGATATTCTTCTCGTGGTCTTTTCTTTTATTCTGAACATAC
AATGAGAAGACCGGTAAAGTGGGCTAGGAAATTAAGAAAAATACAAATGGCAAAAAATATGGGTCACCTCGAAGTCT
AGAATTAAACATCAATAAAAGTAGGCCATTTTGTAGTTTCTAAATTTATTTATTTAAACATTTCTTTAAATTTACAT
AACTATACTTTTGAAGTGTTCATCCATGTGTTAAGATTCAATTTGGGGTCAAGAACTAAATTTTCATATCCCTGGG
AGTGGAACCTAAGTAAAAAATAATTTATGGACCTTGGTTAATAGCTAGAGGAGCAAGAGTGTATCTTTATGTGAC
TTAAGTCTATGTGAAAAGTGAACCTTAAGATTAATTTATGGGGGAATTTACTTACTCAGGTTCTATGCCTAGATGG
TCTGCCCACTAAGAAAACCTTATTTTCTGTTTACTCCATCCTATTTTTCATCTTTTATCTGCAGTTGAGAAAAAG
CATATATTTCTACCAATACGAAAATCTCTGGGAACATATTTTCTACATTTCCCAATTTACTTCAAAAAGTAACT
TAGGTTATTTTATGATCTCCATTACAATGGACAGGTGGCTTATTGAATGTTGTCTGTGAATACAAAGATCCAGAG
TTTAAAGAACAAAGGTGTACTTGCATCTCCCACTTAGGGTTTGCTTGTGGTGGAGAGAGAATCTAGTTTGCTTAAAG
GATGACAGTGCAGTGCCCAAAATATCTGATATCATTAAAAGTCTCATATTTGTCTTTCGTAACCTTCTCTAGGGCTG
TCGATGACAGGAGACCTTAACTCCTATGCCTTGATTATGTGAATAAGCACATGAAAATATTTTAGTTATCTTAGTT
CACTTTTAACTAAGTTTCAATTATCACTAGATTCTAAATATCATCATTGAGCCGTTCTTAAGGAACTGATTTTCTA
CATATTCATTCACCTTACCTATATCTAGTGTGCTACTATTTGCCAAGAAAAATTTACTCTCTTAATTCAGCATTC
ATATACTTTAAGCATCATAAAAAGTAGGCCATTTTGTAGTTTCTAAATTTATTTATTTAAACATTTCTTTAAATTTACAT
TCTATCATTACACTATATTTCAACACTACAGTAAGCAGCCTATTTTGTGATTTTTCCTTATATAAAATACATAATTG
AAATTAATAATGAAGTTACCAAGAGCCATTTTCACTCTGGGGAATGCACATTTATAAATTTATGGGGTTATTTTCT
TCATCAGCTTTTCATATTATTAACCTTTGTCTTTCATAATTACAGAGATGACTAGACACAGAAGGGAATTTAACATT
TGGTGTGCATTTGTCTAACCTATACCTTATGTGTAGAAAATACATTTCCATTTGAAAAAAATCAGTAATTTGGGGT
TGATCAAGAGGGCAGCCTGAAAGTCGGGTGATGTGACTCACACCTGTAATCCCAGCATTTTGGAGGCCAAGGTGGG
ATTATCGATTGAGCCAGGAGTTCAAAACCAGCCTGGGCAACACAGTGAGAGCCTGTCTCTATTAGGGGGAAAAAA
AAAAAGAGGAAGTTAGCCTGAGGCAATGTAAATGAAATACATATTTCAAGGATATTTATACATGATTACGTTATT
CATATAAGATGTGCCAGAGAAGACTATAGGTACGTTATTTTACACTATTTTGTAGGATTTTAAAGAAATCAATGT
GTTTTTATTTTCAAGTTAAGTAACTTACCTAATTTACTTCTCATGGACACAAAAGTTTTTAAAGATAGGATC
AAAAAGCCCATGTTGAAGCATTTTGAAGTGGATGAAAAACATCTATTATCTTTAAAAATTTTATGATATTACTGAT
TGTAATAGACTCCCTTTTAAAGAAATCATTCCTTATAGAACATAAGGTTTACATTTACAATCAACAATTTCTATCCT
TACTACAATAAAGGCACATATAAAAGTACAGTTGCATATTTAGCAGGTTTAAATGTACATTTTAAATGTAGAAATCA
ATTCAATTCCTTTCAATTTATCAGCATTATTACAGTGATTTCAAATTAAGCATAGGTAACCTTTGATATAGATAAATGAT
GTACACAGCAGTTAAATTTTATTTTCAATTATGTAGTAATTTGTATAACCTAGGCAGTATAATTTGTAACTTTGTAT
TTTATTATTATGCTTCTCCCACTTGGCATAAGCACACACTTCTTAAAGCATAATTTTCTATAGACTTAATAACTC
CCTAAAAACCTGTTTTGGACCCCTATACTATTTGATATAGGCAGAAAAAAACATAATCCATGCTCAAATTTGAAAA
ATGACTGGTCAATTTGGTATAATACTAAAGGTAATAAATCAAGAGTCTATGAACATTTCCGACCTGCACATTT
GTTTTATTAAATGCATAATTGTCTTTAGTGTGTTCTATTTGTTTATACTCTACTGATTTTAAATTAATAATACCAA
AATACGTTTATTAAAAAAGTGTGAGAACTAAGTTGTTAAATATACTTAACTAGGAAAGTAACGTTTAAACGAGAT
AATTTATAGAGAAATGTGGTGTATTGCCAATTAGATGTCAAGATACAATACAACCTGATAATGAAAAAGTAGCATTTT
CTTAGGGATGGAATACAGTGAAGGAACACCCAGTAAGAATACAAAAATTAAGTAAAAAAATCTTCTTCTCTGAA
AAACCAAGTGCCCTTCAAGTGCAGAACCTCATCCAATAATGTTAGGTATCACTAAAGCCTGATACCTTCAATTTT
CTGATCAATTAAGGCATGATTTTGTAGTCTTATACATAGAGGTAAGAGCTATAAAAAACCTTAATGCTATCTG
ATGTGAAGTGTGGATCACTTTGACCCATCACTTCTACGTCTACATCTTGGATAAATTTCCATTGTTGTATAGATTG
TACAGGTTTAAATGGTGCCTTTGTGGAGGGGGCTCGCTTATAGAAAATGGAGACTCTGAAGGGATAAGGAATAAATGT
ATCACTTCAGGTCTTTTATTGAAATTGGGGTCCAGAGAGCCTTTTGTATCAGACTTGTCAAACCATTTCCATTTA
GTAATTATATATGCACTAGCACTTATTCCTACTTACCTCACCTCTTTATGCCCATTTCTTGTAGTTGCGGTATATGC
ATGAATAATTTATTGCAACCCCTTACCAACAATGGAATAAAACTTCCATTCTGAAAGCTTTCCATACCTCATTTTCCAAT
AGCAATAAGGTTTATTTTAAACGAGCTATTACAAATGTACGAGTCAAGTGAACATAGTATTCCTTTGTGAAGAACTC
CAAGTGATGCATGCTGTTGTCTCAAATCTCAATTAGACCTTGCTTTGAGGTCCCTTCAATTGCCAGTCATCTGTTCT
CCTTCCCTGACTTGAGTATTTCTCCAGATATAGATAAATACATTTTCCCACTCTGTGTTCCAAGAACTGACAGTGG
CTTTCATTCATTTGTTTGTGTTGTTTCTTCTCGTTCTCAAGTATCCCGCAGTCTACTGTTCTTCCCTCCATT
CGTTTGTCTTTCAGAGTTTCAAAATCCAGCATAGGTACTTCTTCTAAAATGTCTTACCCTTCACATACACACCA
CTTGAGACCCCATCAGCCTCTGTCCACACAGTTTGGTTACATTCATAGACTATTTTATACATCAAAATATTTGAAA
ATTTTAGGGTAAATCTCAGTAGTCATTTTGTCTTATTCAACCAATACTAGTCAATCAGCCTGTGCCAGGTT

TTGTTGCAGGTACCAGGTATCCATCCATAAAGAAAAACAACGTCCCTTTGTTGTGGAATTTACATTTTAGCAGGGGAG
GCAAAGAACCCAATAAATATGATAAAATATCAGATTAAAGTACGATGAAAAAATCATCAGGGTAAAGGAAAAAGG
GAAGCAGTATTTTAGCAAGAGTGGTGAAGAGAGGAGGCTGAGAGTGTGACATCTGAGCAGAGACCTAAATCAAGTCA
AGGAATGAAACATGCTACTATCTAAAGAAATGAGTCAGGATAAGGAACTAGTAAGAGCCGAGGCCCAGAGATGTGAA
TATGCTGTTCCAGGAACAGCAAAGAGACTGGTTGATATGATGTGAAAAATGAGAAGAAACCTTATGATATGTGTCAA
GAGAAAAAATTTTAAAGCATGCTTGGGAACGGAGGCCCTCCAGATGAAAAAATACACAGTTCAAATCTTGT
TTCATGCATTTAGTTTGCCTTGGCAATCTTGGGCAAAATGTTAAATTTCTGTACGTTTTATCTTCTCATTTTTTAAAA
TAGGCACAAGGACATCTACTTAATAGGTTTATTGTGAGGAGTAAATGAGATGATATATCTAGGATGCCTGGCATTAT
ATCATACTTAATAATACTGAATAAATAATAGTTATGTCTATTATTTCTTATCGTTTTTATTATTATTCAA
TGCACAGACCTGTTTATAAGATAATGATAAATATTAGTGGCAGAACTGAAGATGTTATAAATTATTAGGAGCGGG
ACCCTCAGTTCAATGTATCTGTTTTAATATAGTCAGCAAAAGTGTGAAGATACCAACAATTAAATTTCAATGCATT
CTTCCATTTCTAGTTTATAAACTGATGAACCTACAGAAATGTCAATGTATGAATTGCATACCTATTCTTAACAAA
CAGATTTGCAAAATTATGTGTAATAATAGCCCTCAGCCTTCCAATTTGTTATTGTATATTTTCAATGGAATACATAA
TCTGTAAATTTTGTGTTTTAATGATATGTGAACTGCCTAAAGTAGAGTCTTGGCACTACTTCACTTTTGTCTCCA
GAGATAGTGGATAAAAGTGTCAATAATGAACACTCTATATTCTAATCAGGCAAGGGACAGGAACAGAGTGG
TCACAAAATACCACAAAATTAAAGCACATTCCAAATTAATATATATGTTTTTATTACAGATAATGTTTGTCTAGACT
CTTTCTAATTTATCTGCAAGATTTTGGGAATGTTTTTAAATTTTAAATTTTACACACCTGTGTTACTAGGCATGCT
CAAACTATTGTTAAACTAAATCTTCTCATCTCTAATAATAAGATGTGAACCTATCTTGGGAAGGTGGTTATTAGG
ATGGGAGAGATAATGTATTTTCAATCAAGTAAAAATATTTCTCTGTTTCTATCTTTCTCTTTCTCTGTCTATCTATT
ATCATCTATATCCAGGTATCTATGCACCTATGTAGACTAGCATTCAATGAACCATAGATATTATTAGTAGTAGAATT
GTTACTAATATTAATAAAGAGTATTTAAGAAGAAACATGTCTTAAAGCATAAGGTCAATTTACTCTCATGTTT
TTTGGCATATGAAGCCTAAAAAGTGTCAATTTCAAGAGAGTATTAATAAAGATTGTGATACTGAAAGGTTCTGTCT
TGAAATTTTGTGTGGTCTTACAAATATATAAACTCTAAGCAATTTTCAGTGAGCCAATTACTGACTAGGCATATGTCT
TATGACTCTTTTGTCTAGTATGTAAAAAACAAGAGTAGAGACATCATAAAATATAGTAGATGGGCACTAGGGA
ATTACGCAAAATAATTTGTAGATTTAATGTGAACCAAAACATCTGTTCAGTCAATTTCCACAGGTCATGTGGCA
AAGAGTATGAGTTCCAGACTGAGGAGAGGAAAGGTTGTCTTCCACAGGGAATAAACTGAGTGAATAAACATAA
TTTTTCTTCTTAAGCATTATTTAAACAAAAAAATGCCATTAATCTATCTTTCTGCTCTCTTATCAATGCTCC
CTTCCCTTTACCACCTGTTTCAAACCTCAAGCCTTGGGATTTTATTTTGGCTTTTGCCTTAATGTAACATAAAATG
AGAGCATCACAATAATGAAGCTCATCAATAATTTTAGCAGCATTTCCTCTGTTTTTAACTTTCTTTTGGAAACGT
AGATTTTCAAAATTTAAGGGCCCAAAATATGAAATGCAATTATAATAGGCCATTTGTTTCAATCAGCTTGATAAACTTG
AATAATAGTATTGAACTTTTAATGCAAAAAGAACAAAACAAAATAGAATCTCCACGAAGAACTTTTCAATGTTT
GCATTTCTGTGTGAGGAGAGGGTAATGAATGTGGGAACCTTAATGGAATCCATGTTCTTCCAGTGATGACAAGGGT
CAAAATGGAGAAAAATGGTCACTTTCTACCCAGTACATTATATTAGTTCTATGTGGACAACATAACATAGCTGATG
CTGGTTTTCAGGCCATAAATGTAGGTATGTATTTTCTACTATTTATAAGGCAAAATTTCTATTTGTTTAAATGATTT
CTATATAGGTAGATTATCTGTCTTTAGGATTAATAACGACCTGTAGACCAAGAGACTTTCTAATGTCCACCTTAGA
GTATATGGCTTTTACTGTTACAGTTTCCATTTCTTTGCTTGCCCTTTGAGAGAAGGAAAGGAGACATTTGGGATA
CATACATCAATGAGGAGCTATTAATGAATAAATGAATGAAATTGTGAGTCAATTTATCCACATGATCATCAATTGCC
AATAATTTTATCACCTCTGTGGGATTAAGTAGAGGTAAACAGTTTGAATAATTTGATTTTTTGAAGCATTATAAATGT
TCAAATATATCACTCTGGTAACTAAGGGAAAGTGTATTATTTCTTATGCTTAGTCTATTTTGGTTTTGCTTTTT
AATTTAAATGAACACTTATATCAAAGAGCTTGCAGGATTATAATTTGAATTTTGAAGCAAGATCATTTTCTTAA
CATCAACAAAGAGTAGATACAATAGGAATAAAATCGGCAGAAAAACAAGAGTATCAAGGACAGCGGGAGGGTGG
GTCTGTGTTAGCATGTATTGCTATGAAGAAATAGCCGAGACTGGGTAATGTATTTTAAAAAGAGCTTTAATCGATT
CATGATTCTGCAGGTTGTACAGGAAGCAGGACACCAGCATCTACTCAGCTTCTGGGGAGGCCCTCCGGGAGCTTTTAC
TCATAGTGGAGATGAAACAGGAGTAAGCATGTACATGGCCAGAGCAGAAGCCAGGGGGAGGTGCCACACATTTA
AAAAAATAAATAAACAAGATCGCTCAAGAACCTCAGCTGCTATCATGAGGACAGCATCAAGCTGTGAGGGATCCA
CCTCCGTGACTCAACATCTCACACAGGCCCAAGTCAACACTTGGCATTATATTCAACAAGAAAAAAGTTTAA
ATTGGCTGATGGTTCTGCAAGCTGTACAGGAAGTGTGCGCAGGCAATTTGCTTGGCTCTTGGGGAGGCCCTCAGGGAG
TTTTTGTCTCATGGCAGAAGGTGATGCCACACACTTTAAAAAACCAGATCTCATGAAACTCACTCACTACACT
GAGGACAATAACAAACCATGAGGGATCTGTCCCATGACCCAAAAACCTCCCGCAGGCCCCACCACCAACATTGGG
AATTATATTTCCACTTGAGATTTGAGTGGCGGCAATATCCAACTATATCAGGGCTCATGTCCAGTTATATGTCAA
CATGCCGTGATTGAAACATCCTGTCCAAATCACTGCCCTGTGCATAATACTTATATTTTCTTTATTGAATACGAAC
ACAAGAGATTAAATAATAGCATTTTCTACTTTTAAACAGTGGGACCATATTAACATTGGAATAGTAGATAA
CGATAGTAATAAATATGATATAGGCTGGGTGCGGAGGCTCACGCCTGTAATCCAGCACTTTGGGAGGCCAAGGCGG
GCGGATCATGATGTGAGGAGATCGAGACCATCTGGCTAACACAGTGAAACCCGCTCTCTACTAAAAATACAAAAA
ATTAGCTGGGCATGGTGGCAGGCACCTGTAGTCTCAGTACTTGGGAGGCTGAGGAGGAGAAATGGCGTGAACCTGG
GATGCAGAGCTTGAGTGAGCCGAGATCGTGCCACTGCACTCCAACCTGGGCGACAGAGCGAGACTTCATCTCAAAA
AAAAAATTAATAAATAAATAAATAAATAAATAACGATAAAAGGATATGTGTAGGTTTTTTTTTAAATAGGCTGTAA
CATTAATAGGCATTGTGATTTTCAAGGATATCATCAAACTCCTGTGCTTAAGACATCCCTATTGTAAGGAAGGC
TTAAGTTAACTTCTCATGAGCCACAATTTTCTGATTATATGTTTGGTGTGTGTAATAGCCACCTCAGTGATGATTT
GATTAGCCTGGACCTTACATAATCATTTGAAGTATACCATGTTCTTTATATACTTCTTTAGTGTTGAAAGCTCAA
AATTAAGCAAAATAGTCCCTTGATAATGTTTAGATTCTTAACATTTGCTTTCTAAAGCTGGCAAACTACTCTCTCC
CAGTGTCTGAAGTTAAATAACATGTTGCTTAGTGAGGACTTTAATGTTGCCATGCCATAGGAAGACCTTATTCGAA
ATCCCTTACCTGGGAGAAATGTCAGATTATTACCCCAACTTGTTTAACTTTTAGGATTTTAAAGGTGTTTACA
TTGTATTAGAACAAAATACTATTGAGAAACATTTCTAGAAAAAATATCTTTCCAAATTAATAACAGTGGTATGT

AATGTAGGAGTCTGATTATAATGATTAATAACATGGGCTTTGGGCATACTGCCTAGGTGAACTCCTGGTTTATTG
CATCACTATTAGTATAACCTATGGGAGTTAACCTACGTAAGCCTCAGTTAATTTTTCTCTCAAATTGATCTAATAAT
CGTCTCTCATAGGCTTGTTTTGATAGATATTTCAAGTGTATATAATACTTAGGACAGTGCCTGATATCAGTAAGTC
TCCTTATATGCTATTTTTCTTTCTATTTTAATTATTTATGCAAGAGAACTATTATGCTTTAACTCAATTAATAA
AATGCCTTTGTATTTATTCATGTCAAAGGAAATATGCAAGTATTGCATTCACCTCCTAGGTGCCTTTTTGAATTGAG
CTTTGCATGGTTAGTTTTGTATAAAAGGTTCAAGTAACTTTCTCATAAATGATTTTTTATTGAACATATGGAATCCATT
AAGTGTTAGCAAAAGTCACTATCCACTGAGCTGTGTCCAGGGGCTGACAGTTATGTCTATCTCTTGCAAAAAATAAC
ACATACATAAATGCACTAAGACGTATATTACCTGTCTCATCTCTTAGAGCATTTCATTTTTCTTTAAGTTTTTT
CTTTCAATGGGTTTTTTATCTTTGTGAGTACATGGTAGGTGTATATGTCAACGGGTACATGAGGAAGGTGTATATA
TTGATGGGGTACAAGAGAGGTTTTAACACAAGCATTCAATATGAATAGTCACATCATGGAGAATGGGTTATCTATC
CCTTCAAGCATTGTGTCTTTGTATTACAAACATTCTAATTATACCTCTGTTAGTTATTTTTAAATGTACCAATTAAGTT
ATTACTGACTATAGCAACCTATTGTGTATGAACAGTAGATCTTATTCTTATTTTTCTAACATCTTAGAACATTT
CCACAAACACTACCTGCTTGTAAATATACCTATTCTAATCTTCATATAATCAATTACTTTTTCTCTAGAAATGTA
CTATGACACATCCATGGGGAATGTAGTAATCTAATTAAGACTATTTCCTCTCATTTTATATTAAAGAAATGTGC
TCTATCAATTTATTTACTTGTACAGCCGTAGGCAACCTCTAAATATTTAAAGTTCTTAAAGTCAGATATTTCACT
TAATATTGTGATTATATAGTTGATTTTGTGAAACATGTTTCATCTACCAGAAATAAATATACACACACATTTGATATG
GTTAGGCTTTCTGTCCCCACTCAAATCTATTTTGAATATCCCGTGTGTCAAGGGAGACACAGGTGGAGGC
AATTGGATCTTGAGGGTGGTTTTGCCCATGCTGTTCTCCTGATAGTGAATCATGAGATCAGATGGTTTTATAAGGG
CTCTTCCCCCTTCCCTCCTCACTCATTCTCCTTCTTGCCACCTTGTAAAGGAGGTGCCTTGCTTTCTACTATGCCCT
TCTACTATGCCCTTCACCTTCTACTATGATTGTAAGTTTCTGAGGTCTCCCCAGCCATGCTGAACATATGAGTCAA
TTAAATCCCTTTCTTTTATAAATTACCCAGTCTCAGGCAGTTCTTTATTGCACATATATGTGTGTGTATGTGTATGT
GTGTGTGTGTATATGTATGTATATATGTATACATATGTGTGTGTATATATGTGTATATATGTATATATATGTATA
CATATGTGTGTATATGTATGTATATATGTATACATATGTGTGTGTATATATGTGTATATATGTATATATATATAT
ATATATATATATATATATATATGAACAGAGAGAGAGAGAGAGAGGGAGGAAGGGAGAGAGGGAGGGAAGCATGGAGA
AAGAGAGAGTAATAGCCTAAATAGAAATAAACTAGCTCCAAGTACAGGTTTCGTCAACACTCTCTATCATACCCCC
ACCAAAGTTAATGTTAACCACTTGGAGCCGTGTTCTTCTTAGTTGTGGAGTACTTAGCAAAATTTAAATCTAAT
TATGCCTAATTCAACGACAGTGCTAATTTGAAAGTGTTAGAACTGAAGACCTATAATAATATGAGAGTTACAAAA
CATAAATAGTGAGACAATGATGAATGTAGTGGATGCATGTACGAGGGCTATCATTGACAGTAGAGATGATGCTCAA
GGACAGACAATGAGTCTTTCAATGTGTGGAGAATGTGCTGCTGTACAGTGATGTACAGGAAGAAACAAAACTGA
GGAAGTATCAGTAAACAAAACTCAAACATATGAGTATACAGCTAGAATAAAAGCAACAGTACTAGATGACAATAA
GCCCAATGTTAACTCAGAAAGCAGAAGGTTTTAAGAAATTTGGGGAATACTGTGGCTGATGATACTTATGTCTCAAG
CCACAGATGCCATATGGGCTCTGCGCCAGTTGAATCGGCACCACCTGGCAGTAAGTGGGCAGTCCACGACTGCCA
GGACATCCCTTCCAACACTTGTGGAGATCACCAGGAAGGGGGAGAGACCTGCCTTGACAGATTTTCAATGTGGGCG
AAACAGGTCTATTTGAGAAAAGATGTTCAATAGAACATATGTGCAAGGAAGAAGAGATGATGCTTAGTTCTAA
GCTCCAAAGAGCTGGCTTACACTCCAACCTGGGGAAAAATGCATCCGGGAAATGCAAGATTAATGTCTTAGCCAT
TCTTTTGAATGGATGGACATGACCCCTTTCTACTTGAAGACAGAAAAACATAACCATATTGATTTTCAGGTTTTCTTCA
TTGGTTTTCCATTTAGGATTGTTCTTCCCCATCTTCTTTCTGTGTAGGCATCCCAGTTCCCAAGTGTTCATGAAGCAC
GTATGGCCTTCAGGGGATGTGTCTGTATACATTGTTATCTTATGGATGCACGGTTTTGTCTGCACCTTGGTTCTGAA
TGCTTTTACTCTTGAGCATCTGCCCATGGGTCCCTTCTCAAGGCCTCAATTTCTTGAGTTTAACTGCATGGCCC
ATGCAGCTTTTCAGTTAAGCATCTCTTGCTATGACCAACTCTTTTCTCAGTCAACTCCCACACTCTTTTCAGGGAC
AGGAAAAATGTAGCCACTTGTCTGGCTGCACTCTGAGGCCTCAAGAAATTTAGTGAATCTGCCTTTGCCCTTCTGCT
GATGAAATACTGCCACATCAGGCCCTCTTTCGAAACCTACAAGCATCTAATTTTCTTGCTTCTTCCCCAACTTTT
TTTTTGACTCCCCCATCCAGAGAGTTCTTATGTCTACTGTACTAGGAAAACTCATTCTTAAGGTATGGTTTTCA
AATCATTCTCTGGTCTGGACTTTAGCTACGGTTTTAAATGAAGAAACAACCCAGAGCCAAAATATAATGAACTATT
TCCTTCTTCCACAGAGTGGAACTGCTTTGGGGTTAAAGGGCCAGTGAACCAATAGAAAAGGATCTCAGGGAACAC
AGATTGAAGAGAGAGAAGAAAAATATGAAGGCATTTGGTTCTCTTTTGAAGTTAAATCTAGTGGGGATTGTAA
GCACACACACATATACACACACACGCTTACACACACACACAGGATGAAGTTATGAAGGATTTTGTCACTCCAACGACC
TTGAATTTGATTATCTAGGTCAGTTGTTACCAAAGTGAATGTACATGCCCAATAATATGCGTGCTAAACAGTTGGG
GTAGTGAGAAAAAATACTTTTTATTTATCTTGTCTCTAGAAATTAATATTTTGATTGTATATTTATAGTGTATGT
GATGTGTAAGTTGTGTCTACAAAATACTGTCAATGTAATTTAAATTAACATATGTCTGTGAATATATATTTATATA
GGGTATCATGCTTAAATGTGTTTACTTCTGAGGTACATGAACATTTTTCCCCAGGCACAGAAAGACAATAACGACA
TGATGTCACTTAAATGTGCAATGTGAAGAAAGTTGAATTCATAGAGATGTAGAGTAGAATCTGTTTAAACAGGCGCT
TGGGAGGTGGAGTGAGGGAATAGAGAGTTACTGTTCAAAGATTACAAAGTTTCACTAGACAGAGGGAATACATTTT
GAGATCTATTTAGGAACATTTTGGAGCCCTCACTCTAAGTAATAGGAAATCATTACTTTAGTTAACATATTTGAAT
ATGAGTTGTGATGTTCTATATCGTTTATTTGGATTCTACTAACCCACACCTAGATTTTTATGGCATTACCTTTTAC
TCACTGTGAATATCTACTCATAGACAGATGCCCTGGGAACTTGGACTTGAGGCACCCAAGAACTGAGACAGTGAGA
TTTGGGGGCACAAGGATCTATGGATAAGTTCACTTTAGTGATGATAAAATCAATTTGGCATGTTTCACGGACAGTGT
GCATTTTAGAAAGGGTAAAGACTTGGAAACGGGATATTTTGAAGCCAAAGTGTTCCTAAATAAATAGCTGTATATTT
GAAGCAAATAATTGATTTTTTGTCTCTTTGTGCCCTCGCCTGTAAATGGGAGAAATGTATTCCTTTCTCATCCTT
CTCATGAGGCCATTGAGAGTATCTAATGAGATCAGACTGTGACATAGCATAATAATTCTCATTTCTTGAAGGCCTAT
TATACACTTTGCAAGCACTGTATGTGTTTCTACTTCTTGTGTCGTTTTTCTGGAATAAATATCCCCCTCC
TTTACATTGGATTGCCATTATTACCCCTGTAAGGAAGGCTTCATGGTTCTCATTTTCATCTGAGAAAATTTAGGCTC
AGAGAAGATCAGTAACCTTATCTAAACACACACATACACACAGACATATCTATGCCATTATTCTTAACCTAGTT
TCTCTATTCAAGGATTATCTGCTGTCTGCTTCTGATTATAATCTGTGTAAGCTGATCCAAGTGACACGATTAC

AGGGAAATTGTAAGCCCTTTGAGAGCAGAGACTACCTATTGATATCTACATTTTAAAAATTTGATTTTAGCCAACCTG
TTTATATGCAATGACTAACAGGTTAGTTTGAAGTTGCAATAAATATTCCAAATCCTAGACTAAGTAAATTTATTAATG
TAATGATTTAACTTGATTTTTCATTGGCATGTTTCCCTGAAGTCGTCATGCAAAATTGAAAAAAGATATAG
TGTGTGATTCTAGATTGAAATTCAGGAATCCTCCAGGGTTACCTTGTGCTTTCCAAATAGTTTCAGATTGCTTAGT
CTGACCAACAAGGTCCTTGACACTTGGAACTCTGTCTATCCCTCTAATTGACTTTGTCCCTGATGACCTCGCCAGA
GATACTCTTCACCCAGCTATACTGTGTGCTAGAGTTTCTCTGATATCCCATGCTATTGTTTCTTTGTTCTCTTC
ATAAGGTACCATTTCCACCCGCCAATCCTGTTTTCTGATGGACTTTGTTTACCTTACAAGATCATTGCTAAT
GTATTTATTTTGAAGAATAAAAGTGTAGGAAAGGTCACGGGACAAAGCTGTACACCAGACCTTTCCAGACGAACCT
AGTGTATAATCTCCCTAGTCCAACATCATGGCTTAAGGCAGTCGATAGATCCGCTTAATGTCCTTTTGAGTTTTCT
TACTATTATTATATAGAGGATTTATTTTGTCTGAATTCCTCCCTAGATTGCCCCAGAGCAATGACTATTTACAG
TTTATTCCTCTTTGTATCTTTATGTTAAAGCCAGACCTTGGCACATATTCTAGCTGATTGAAGACGTTTGTGTGAA
TGACCAAGTGATTGAACAAATGACCATGTGCTCTGCCACAGTCGCGTCAGTTCTACTTTGGTTTGGTTATGTGTTG
CCACATTAAAGTTGTAGCCTGGGAAGTTGAGTTGTGAGATGTCTGCAGAACATGAAAAATTGGAATAATGAGGTTAT
TTCTAAATTTGCTATAATTTAAAAATAAATAGTGGTTTATTCATATATGAATATACACTGGAAACAAAGAATTTCTA
GAATACTGGAGATTCAATGATAACATCATTGAAATTAATAAATAATAGGATTATGCTAGTTACTTTCTAATTTACT
AGAAATTTGACCGTGTGTCATGGCAGTATAATGAGTATCATGGGATAGTTACAAAAAGTGGTGCTTAGTGAGTTTCTG
TGGAAATCTCGGTACCAATAAAACGGAGGATTTCCAGAAATCGATATTCTCAAAGCTTAGTGCTACACTGGTTA
GTTACACTTTGTGTGCTTTTCGTTTGAATCAATGGAAGGAGGCTATAACTGAAAAATTATTGTTTTAGTGATTATAT
CTTTAATAATAAGAGTTTTAAGAATCTATCATTAGAAATAATTATTCCTCAATTTGTAATTTCTCAACATTTGAACAA
ATAAATGCTCTGTGTCTATCAGTTAATCTTGCCCATGAAGATTTAATAAAGCACGCTAGTTTTTACAAATGTGATTT
TAGAGATGGTCATTACTTGGTAAAAATATTTTGTGTTAACACTTCCATGAATATGTTCTGTGGGAATATACTGCCCTC
ACATTGCTTGTCTATGAAGACATGATTTTTCACATCATCTATCAGTATTTTGAGAAAGAGATTGATCCCATATTTCT
ATGAGCATTTGAACATTTCTAGTATTTTGTGTTAATCATTAAAAACAACCTTTGAAGTCTATGTGCTACACTGGTTA
TTTCCCTCTTGACTTTTCTTTACAGATAACCCCTCTATCATAAACCAACCTATCTATATTGTTGTCTCCACATCATGT
TGCCAGCCCTGCTTTAACACACTGCACATTGACTTCTAGCAGCAAGGCTCATGGGAGGTACTCTCATCAAGGACAC
TGATGGTCTCATGTTGCTAAATTTGGTGGGTCCTCTACAGTCTTTATCCTAGTTCACCTTATATGGACCACTGTC
AACTCTGTTCTGCTTAAACACTCTGTTTCTTATATGACTCTACACTCTTAACTCCTTTGTGAATTCCTCATC
TGCCCTTCCATTAAGTATTGACGACATCCTTCATAGTTTGTATCTAGGACCTCTTTTCTCTTACTTGACATTATGT
GGTAATCTTGTCTTTGAACGCAATTACCATTTCTATGTTGATGACCTTAAAGCTATAAATCCAGCCCAATCATTT
TTCTGAGGAAGCTACAAGAATACACAAATGTCTAATAGATCTCTATTTAGATGTCCCTCAGGTGCTTCAAGCTTAAA
ATACTCACCTGAGCTCATCACCTCATCTATAAATTTGCTTCTCCTCCCTGGCTCCCTGATTTATTTAATATGACCA
CCATCCACTTAGTTGAATAAAGCAGAAGCTGGACACCATCTATACCTCCAATTAATCACTAAGTTTTGTTGTTAAA
TACGTTCTTACATTTTCTCTCTAGAATGTCTATTTTCCCCATCTTTACACCCAAAACCAAAAGTCAGATGACCCTG
ATCTCCTGCTTAGATTTCAAAACACTAICTCTTGCTAGACTCTGGAATTTTCACTTGTCTCTCTCCAATCTATTT
CTACACCTTAGACTCTGGAATTTCACTCTGTGCTTCCACTCTCAATCTATTTCTACACAAAAGCTAGAGTAATTTTAA
AAAAACAAAATCTGAATGTGTTTCAATTTTCTGCTTAAAGCCTTCAGTAATCTTATTTGTTCTTCCAGGGATAGAGT
AACAACTTTTACAGCTTAGTTTATTAGCTAGTTCTTTAACACAAAGGACTCTCTCACTTGTCTACTCCCCCTAACAC
ACTTCGCCCTAACCTTTTGCCATTCTCCTCTTCCCTTTTCTCTCCAGATGGACTTAAGTCCTTTTCAGATTCTTAAA
TGTTTCTTCTCCAGTCTCTTACATCTCTTTTCTTGTAACTCTAAAACTACTTAGCTTACGCAAGGAAAAAGGTC
TGTACAATTTCCGGAATCAGCGATCCTAACGTTCCCTGTTGTTTTTCTGTTGGGACATGAATTCATTACAGTGCC
TCTAAACATCACCACCCCTGCCATCTCTCCATCTCTTCTTCTTCTGAGCTTATCCATCTTGAAGACTTACAT
ATTTTTTTTCTACCAGGAAATCATTACTAGCCTTATTATCCCCTGTCCAAACCAATAAGTCTGATTAGGTATCTGT
ATATATTTAATATTACTATATGTGTTTTTCTAACACTCTAGTAGAGGAGAAGGTGATTTCTTTCTGTTTTTTAGAA
GCCTGTATTTCTGCTATTTATAGCTCTTAAAGGAATCTCATGCAATTCCTACTAGAATGTAAGTTACGGTAGGATAA
GAACTGGATCAGTCATATCACACATCCACATATAGGACCTAGCACCATATCTAACACACAGCAGGTACTCAATACAT
TTCTTTCCCAATAACTAAAGAGTTTAAACAAACCAAAATGATTAAATGAGAAGTAAGTGTTTTGGTAATTTCTGTG
TCCTTACTAGAGTCTAAATTTGAGTGATTTTATATCTCATGTTTATCTACTCCCTTTCCCAACCCCAATTTCTTTT
TTTAAATTTTTTAAATCAAAATATGCCTTAAACCTTCAGGATCAGTTGAGTAAATGATGCTTTTGTGCTCTTTTGCA
AAATAATTGTATTTTCAAGATTTTGTATTTAGATATTATAACACACCTAAATAATAGCTTTAGCTTAAAGATGAAGT
GCTTCTTAAACTCCCTAAGATGGGTTGGACTATGGATATGAACATGGACAATATCACATTAATTTGTGTACACAGTT
CTAACACAGGGTCTGGCATATAAGAACAAGTCAGTAAATAGTTGAAATGGAATTTGAAATTTAAGTAGCAAAATAA
AGTATTTTGGACCTACAAAGCAAGAAATCACATTTTCTTTTGTGTCAGATTCCCTAGGAAATTAATTTTATTTAG
TATTTAAGGATGTTAAATATTTATTTTATGTTCTATTTACTAGGCTTCTTTTTATGAAAATTAATTTGGTGAATAAG
CGTACATATCTTCTTTACCAGAACATTTACATTTTGGGCAGTAACGCTGGCTTTTGTAAAAAGCAAAATATGTG
TGAAATTTATGTTTGTGATTTCATGCAATTACATTTCCATTTTAAATCTTCTTTGAAATACTCTATTTTGGACA
CCATGAAACTGTATTAGATCTTAGTATGTTAGCAATGTTTTGAGTTTTAGAGCCATAATTATTTAATGACCACTT
TCAGCATATACGTTTTCTACAGGAAAAATAATCTCAAGAACATGAAAAGTGAATCTATATTTGGGTTTCAAAATG
ATACATTTTGTAGCTAAATATCATAGTTTAAATTTCTAGTGAAATAATAGTGTTGTAATTTTATGAAGAGACTCAGT
GTTTAAAAATTTAGACTCTATAGTCAAGTTTATGTTTATAGGACATAGGTTATTCAATTACATTTAAAAATAATTAAT
TTAGAAAATGTGATCAATGTAACAAATTTTACCTGTTCTTTTCTAAAGCTAAATTTGTTGTTTGAAGTGTCTTCT
AAAATGCTAATGAACATCAATTTAATTTGTTGAGCTTAGAGTTAGAACTTAATTTATATTGCCAGAAATAAAGAAAC
AAATGGATCCCAAAAGATTCACACATTAGAAATGTATGCCAGGGAATGCTTTTGAATGTGTTCAAGTCATGGCTTC
TAACTCGTAACTTATAACTTGTGTTATGTCTGGCTTCATTCCTTAAAGAAAAGGAATAATAATGCCTTCGGAGAGC
ATCCCAGCTGTAAGAGCTATGCATTGGTGTCTAAAAAGCTTCTCACTCTCATACCATCTGGTCTGGGAATTTAA

118

AATAAGGCAATTCTCTGGGCTTCAGTATGTTCAAAACAGAGCATTAAATATTATTATAGACTTTTGATGATTTACACAA
TTTTAGCTTTTTGGCAAGACATATTTACTAGTACTAAGTAAAAGCACGTTGACTTTCTAAAATGAAAATGTGTATGT
GAGGATGAAGAAAAAGAAAGTGTTTTGTGTTGATAATATAGCATTATAACACTGCACAAAAAATGGTATATGCA
GAGACTTCCATCACTTGCTTATGATGCCGCTTGGGATCTCATTAAATAAGACACTTCCTCAGACACTTCCTTTGTGT
TCAATAAATTTCAATTTCTCTCTTTCTTTCAGTTCACTTCAAGAAGGACGGCAGCAACTTTCTTGTGGCAAACCTG
ACAAATGTTTTTTAGTGTCTGATTATACTCGAGCATTCTGTAGCAAAATGCTGTGGGTGAAAATGCCTTCCTTTCTAA
GGGAATTTAGCTTCTGTAGTACCAGAATCTCCTTGTGAATGAACATGTACTGCCTAAGTCTTAGTAATCCCTCCTT
TTTGAGCCCATTTCTGGCATCTCTCCCTTTAATATTCTCCTCAAAAAGTTGGATTTTCTCTGGACTTTTCATATTACA
GACTTTCTCTTGGTTCATCTCATCCATTCCGTGATTCCAACACTACATTTTCCCTCCATCCTGGCATCTTCTTTCTTCC
AGACTTGTATATGAACACTGCTTCCATTATACACTTGACCAACCTTTAATTTCTATAAGATCAAAAACCTCAGCTCA
CAAGCTTTCCCTACCATTGAGCGGGGTTCTTCTTTTGTCTTTTGTTCAGACAATGGCACCACCACTACTCGAGTA
AGGCACGTTTCAATTTATCAGTCTCTACCAATCTACAATAAACTCTCTTGAATTTATCCACTTGTTCATTGAAACA
GTCATTTCTTTACCTGGGTAGCCTGCACCTTCTACCTGCATTGATTGAGCAGTCTCTTACCAGTGGCTCTCCCTCC
CTCTCTGCTCTCTTCTTGTCTCTTCAATTTATTCTTACTCTTCATAGTGACTTTTATTAAATGCAAAATATGACCT
TATAACTCCCTTGCTTAAAGACCCACTCATGTTTGTCTTTGTATCCATAACTTCCGGCCTAGGGCTTAACGCATAGC
AGGTGCTCAGTAAATCTGTGGTAGATGAAAGAACAAGTTGTATAAATACTGAATGGTCTGATGTGCTCTTTGTGTG
TCAAGAAGGACATTTTGCAGTACGATACATCCCTTTAGTAGGCATTGACAGCATTCGCATTTATTCATTGAAACA
AAGAGAAGATGGATGTATTGATTCTGTATTTCAAATGACATAACTTTTGTGAAATAAGAGGCTGCCACGGTAATCTG
AGGGATCTCTCAAGTTCAAGGGACTCCACAGTGTCTTTGTGTAAGGTAACAGGCTAAAGGGTTCAGTCTTAACTTTT
TTAAGACTGTAGTTTCAAGGTTCCCTATGGTGGGGCTATAACCTGAATTACATCCCTTTTCAATTCATGCTGATAATG
AGAATAACAAACAGGGGTATTAGGAAAGAATCCAGGTTTGATGCAGGGAAAAATAAAAAACACTGATAATCTCTA
GTGTCCCAACTTCAAGAATTCCTTTCTTTTACACCAAGCTTTTTTCTCTGCCAGGACTTACTTTGTCTTCTAC
ATGTTTAAAGGAGAAAAATGAGTTAACAGAAGGGGAGGTACAGCATTTCTATTTTACTTAGATGCTAGAGAACAGGAT
GAAAGGTATGAAAAATATGAAAGTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT
CTCTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGT
ATGTTGTGGCAGAGACAAGTGTACATCAAAATTCGTGGTCCCTCTTTCATAGTATAGAGTCTTGTCTAGGATCCAGC
TGCAAGCCAGCAACTACATTTCCAGCCCCACTGGCATCTAGTTAGAGCCATGTGACTAGTTGTGACCAATTGAATG
TGAGTGGGAGTTATGTTGCAGGCATACCTTTCCATCTTCTTACTTCCCATTTGCTAACCTTATGGAAAAGAGTCCC
AAAGACTAGGAGATGAAAAAGCCTAAAATGGAAGGAGTACAGAGTCCCTGAATTACTGGGTAGAGAAAAGCTTTTG
CAGATGGGAATGCCCATTTTGTAGTATTCTTTCTTTTCTTAAAGCCACTAAAATTTGTGGGATCTCTTTGTTATAGCTA
CTGGCATTAACTCTTACGTATACATACAGCTATGTGTACAAAGAGGAATAGATACATTTTTTAATCGTTGAAAGG
GGAGAAAGAAACATATTTAGGAGGAAAAATAATTTAGTCTCTACAATTGAAAAGTGTTTATGAATAATATTTGTTT
TGGCAGCATATTAATCTCAGGCAGCTGAACTACATTAATTTTCAATTTCTCTATATATGTTTTTGTCTTCAGGGTTT
AGTAACACTGATATATAACAGTTTCTTTCTTTTAAATTTCCAAATTTAAATGTCTAAGTTTGCCTTCTAGGCAGAAAT
TAAGTCCCATTGTGGAATGAGATTGGATCAACACTTCAACCAAGATCATTTTAGTTCTTTGTAATCTTAAATGAAATA
AGCTAATAAAGCATTAATTTAGCATGTTGTAAACTTTCGTGAAGTTTAAATATGCTTCTAAGTGGCAGCTCTTAGCT
TATTATCTCTAAAGCTAAAGTCAAAATAAATGTCTCAGTTGATGAAATGGAGATGAGGCAACATTTTATCAAAATTA
ACAAAATATTTTATATCTGAATTATAAAGTCCAGATTATCTAGTAATTATCATATAAATGTATTTAACCAGACATGC
ATTTTTCTCTAATCAGTAGCCCTGGAGTCTTTGGACCACAAATGTGCCTTATCTCAAAATGCTTTAACTGTGACATTT
TGCTTTAGACTAGCTCGACTACTTCTACAGAAATTATACACTTCATTCACATTCATCCAGATGAAAAAATACATGT
AGAAATGATCATATAAAGTAACATTTGTTTAGGATTTTACAGAGTTTACGAAGGGTTTTTCTATTCACTTTCTCACTTG
TTCTTCATGTAAACTGGTTTGGTGGACAACCTGTCATTATCCCTGTTACCTGGAGCCCCTGGGTCTTAGGGAGACTTC
TTGACTTCTCAAGGTCATGAAGGTGCTAACTCTGACCGTGTTTTTATTCCTACTGTGCCACACTTCTCAGGTAAAAA
TCATATTGCAGACACTTTAAGAGAAGTACTTAAGAAAATAAATTCCTCCAGAGAATTACATTTAAGTTGTTTCATTA
ACTGCAGTGCATAAAGAAAGGAAAAGTGTCCCAAAACCCATGTAGTATTTTGTCTATTGCTTATGGTAATATTCTGCA
CACCTAATATTGTGCAGATAATTTTCCATGTAACAAAATGTCTTAAATCAGCAATGTCCAATAAATCTTTGTGTGAT
GATAAAAATGTTCTGTCTGTGTCTGTGCTGCAATACACAGCCACTAGATACACATGACTACTGAGCAATGGTAATATG
GCCAGGGACACTAAGGAATAAATTTTTATTTAATATTAAATAACGTTTAAATTTCAAAGCCGCATGCGGCTAGTG
GTTGTCTCATGATACTGCAGTTATAGAAAATTAGAATTACCTCTTTAAATACTAAACCTATTTTTAATAGTAGGAT
TTTTAAATTTAAATAGTTCTAAGTGCTTTTAAAGTGATACGAAGTCAAATGCAAGATTTCTGTTTTAATAGTACTCTC
AACCAGAGACAATCTTCATGCATCCTTATACATGTTCTTTGTTGCCCTTATTTAGTTTTATTTTAACTTAAATGAG
CTCTGTTCTACTTGTATATTGACTTTGCTTACAGAGAACCAAGTATAGTGGAAAGAAACACACATGAGGACTGAG
GCTACCAACCAGGTTCAACTAAATGCACTCTGATTTTAAATGTAGTATTGGGATCCCTGTTGCAATTTATTGAAGAAG
AAAAAACTTTGCAACCAAAAAAGATATTTGAAAGCAACTGTTCTTCTTGGACACATGATCCCTCATAAGTGGGGCT
TCTGTCTTTTTCAGAGACTTAATTTCTGTTCATATTCTTTTCAGCAATAGTAATAATGATGATGGCGATGATGATAAT
AATCATGATGATGCCTAAGTGTGTAGTAATGCTTCTTCTGAGCCAGACGTTAGTCAAATTAATTTCTCTACATTA
TTCAGGCAATCATCAACAATCCCACAGGACAGGTTTATTATTATACTTATTAGCTAGCAAAATGATATAACTAG
GTTAAGTTTACTTGGCCAAAGTCTATCTGCAAGACAGTGCTCTAGTGTCCCTGCTTCTGACCATGATGTTATGCTGC
CTATCCTAGAGCTTTTCTCTTCTAAATAGTAAATAATATATTCTTTGTTTGTTCATACCTTTTTTTTTTTTTTTTT
TTTTTTGAGAGGGAGTTTCGCTCTTTTCGCCAGGCTGGAGTGAGGTGGCGCAATCTCAGCTGACTGTAACCTCTGCC
CCCACCAGGTTTCGAGTGATTCCCTGCTCAGCCTCCGAAGTACCTGGGATAATAGGTGCCACCACCACATGCCTGGC
TAATTTTTGTGTTTTTTCAGTAGAGACAGGGCTTACCAGTGTGACCAGGCTGGTCTCGAGTTCTCAGCTCTGGCAGT
CCGCCCGCTTGGCCTCCACAGTGCTGGGATTACATGCATGAGCCACTACACCCGGCCCATACATAAATATTTTAA
GCGAAGTACACATGCATGATCATACACTTTTAAATAATTTCAATTTAACTGTTTCCAAAGAATGTTAGTATGAGGTTT

TCTTTTTTCTTTTTATAATTTCAACTTTTATTTTAGATTTCAGCGGGTACATGTTCCCTGGATATAGTGCATGATGA
TGAGGTTTGTATATGAATGATCCCACCACCCAGGTAGCGAGCATGGTAACCACTAGTTCTTCAACCCTTGCTGTT
CCCTTCTCCTCCTTCTTCTCTGTAGTCCCCAGTGTCTATTGTTCCCTGTCTTTATGTCCATGTGCACTCAATGTTTAG
CTCCCACTTTTAAAGCGAGAACATGCAGTACTCGTTGTCTGTTCCCTGCGTTAACGTGCTTAGGATAGTGGCCTCCAA
TGATCCATGTTGTTGCACAGGCCATGATTTTGTAGTTTTTATGGCTGTGTAGTATTCCATGGTGTATACGCGCCA
CATTTCTTTATCCTGTCCACCATTAAATGGGCACCTAGTTGATTGCATGTCTTTGCCATTGTGAATAGTGTGTGATG
TTATATGTACTTTTTGGTATATTCAAAGAGAAATGCTATTTTCTCTTGACATATTATGTCAATTTAACATATTTA
TGTCCCTTTTCTTTTTAGGAGCACCATTCTCTTCTTTAACATTATAAATAAAATATTTTTTGTCTTTCTGTTTTTG
TAAGTGCAGTTTATTGACAGAGTGAGACATACACGTCGATATTGTGACTAGCTGCATGTCTTCTATTATTTAGAGG
TCTCACTCAAATGTAGATTATCAAATTCGTTAGTGAAGAGGGTAGAACAGCAGAACTAATGCTGGTTTTCTTCTCT
AGCATTTATTGATGATAAACTAAGATGATAATACCCCCAGGTCTTAGATACCTGCAGTAGGACAGGCACCTACAT
TTAATGCTCCTAGGAATCCTTCAAAGTGATAGCATAGTTATTATACAGTAATTGAGAAAAGTGTGTTTCTAAGTTA
GAAATTTTTCCGAAGTTGCAAAGAAAGTGAATGGAAGAATTATACCAAGTTCTGGCCGGGCGCAGTAGCTCATGCC
GTAATCTCAGCGCTTCAGGAGGCCGAGGCGGGCGGATCATGAGGTCAAGAGATTGAGACCATCCTGGCCAACATGGT
GAGACCCCGCTCTTTACTAAAAATAGTAAATTAGCTGGGCGTGGTGGCACGCACCTGTAATCTCAGCTACTCGGGAG
GCTGAGGTAGGAGAATCACTTGAACCCGGGAGGCGGAGTTTGCAGTGAGCCGAGATCGTGCCATTGCATCCAGCCT
GGCGCACAAGAGCAAAACCTCGTCTCAGAAAGAAAAAAGAGGATTATACCGAGTTCTCTGAGTTCTCTTAATTATT
CCAAGCCCAACAAATCCTTTTTTGCAATATATGACATTGTTTCCCTGTTTGCATTCCCCATTCTGTGTATCACACA
TCCTGTGGCCTGATCAAAATTCATTTTCAGATTCTGAATTTATTTTCCATTGAATCTATATAAACTATAAAGACAGA
AGATATATGTATGTGTGTATACCCACGTTTCTCTTCCAGTGTCAACTGATAAAAAATAGATTTCAAAGTCTCAATAAC
CTTTAATTCCTTTTTCTCTTAAAAATCTTTAGAACTTGTACATGACATTCTGACTCTAGCAGATTTTAGAAAAACA
GAGAGGCCATTAGATATTCATACCTTACTATTTCAGATGAAGTATTCAATGCTAAATATGTAATTTATCTGCTTTGC
AAATGTATGGTCAGATTGAGTTCCACAAAGGAGAGATAATTTTTTAATATAGGCATTCTGTAGCTTCCCTAAATTATT
GAATTAGTTTAGAGCAAAATCCTTAAATGTATCGTTGCTATGCTCAAATTTTGTATACCTTGCCACGTAGGCTATA
TTAAGATTTTCATTGAATTTTGGTTTCTTCTCAGTGATAATTCATATATCAACTCACCCTCAGATTTGCCTTTGG
GAAAAATCCAGGCCCTTTTTCTGATTTTTAGAGCAGATTTAAAAAAGTGATTCTGTATATGTGTTGAAATTAACCA
CATCTCATTGCTTTTGAATGATTGAGGTAATGTATACCTACTACTTTAAAAAATGACTTACTTAGAAGGTGTCCA
TAGTTTTATAAGTTCCATTGAACCTGGTTTATATTGTATTTAGAAAGGAAAACCTACTCCTTTTATCCTTAAGGGTGAA
AACCTGGATTTTATATACAAATTAACACATATTTATTTTTTATTATGAAATATATACAAATATAAACCTTTACAGGG
AGTGTTTAAAGTGGTGTGTTCCAATGGAATATAATGTGAGTCAAATACGTAGTTTCAATTTTCTACTAGCCATAT
TAGAAAAAGAAACAGAGAAATTAATGTAATAGGATACTTTATTTAGCCTAGTATATCCAAATCACAATATTTAAAT
ATGTAATCAATATAAAAAATTAATAATTATGTATTTAACCTTTTTCTTTAGTAAGTCTCTGAAATCTAGTGTATATT
TACATTTATGGCACATTGCAATTTGCATTAGTCACATTTGAATTGTTCAATAGCCACAGGTGGCTAATGGCTACCGT
GTTGGACAGCACAGGTTTAAAGAATAATGAACATCTGTGTTCCAACTTCTGAGTTTCAAATAAGAAGAACACCA
TCAGTATTTTGGGAGAAGCTCCCTATGTTACCCCTTGCTAATCACCTTCTCTCCCCCAGAGCCAAAAGTAAACCAT
ATCTTGAATTTCTAGTAAACAATGCTCATTTTTTAAAAAACGTATGTTCAACACCTGTATTTGTATCTTTAAAGAGT
AGCTAGTTTTAGTTTGCCTGGATTTGAACCTTATATTAAGGGAACCAACCCATCTCTAATCTTCTCTGTGAATCTTT
TTCTCTCAATACTATGTTTTACATATTTACGTTTCATCAATGTGCAACTCATTGTATGTATATAACACAATGTATATA
TTTTACATGCGTATGGACATTTGGGTTGTTTTATGTTTTTGTTCATCACAACCAACACACATGTGTTCTTGTA
TATGTTTTATAGTGCATGTTTAAAAATTTCTCAACAGTATTCGCTAGTAGTATTGTCAGGTCTAGGGTATGCACAC
ATAAATAGAAATGATTGATTAGCTGCAATTTGTAGTGCACACATATTGCTATGTAAAGTGATCCATGTTTAAAGACT
TAACTGAATTTAAAAATATTTTATTGGAGCCAATCTAAATGAGCTAAGGGTTTGTATTGTTTACATAAGCAAAGAT
TACACTTACTGGGTCAATTCGGTTGATTAACTTTGGATATATAAAATATATAGCTAGTTGTTAAATAGATATAATTA
TTAATTGGCATTACTTTTTGTTGTATATAAAAAATTTCAAATATCCATGACTTAAGCAAGGTAACACCCACTGGGT
GGCTTAAGCAACAGAAATGATTTCTTGCACTTCCGGAAGTTGAACGTCTAAGATTAAGGTGATGACAGGGTTGGTT
TCTGGTGAGTCTCTCCCTATGGCTTGAGATAGCCGCTTCTCCTTCATGACCTTCTCTCTGTGTATGTGCATCCC
TTGTAGCTGTTTCTTCTTTTATGAGGACATTAGACTTTATGGATTAAAGGTCTTACCCATATGAATCAATTTAACCTT
AATTACCCCTTTAAAGGCCCTACCTCCACTTGCAGGGGTTAAACTTCAACATATGAATGGGGTTGAGGAGACCTAC
TTCAGTCCATAACAGTTTCTATATTCTGAAGATGGTCTTTAATTAACATAACAGTTAATGTTACTTTACTGGGAATG
TCTTTTGGATGGGGGAATAAGCTGATGATATGAGAAGGGTTGGTGAATTTCTCATAAGTGTGAAATTTGTTGGGCCG
GCCAGCATGATTTTCAATCAAAATACGCTTTGGGACAAGTAGGTTGAATCACTACGAGAGGTTTAAAGAAAGCAAG
GTTGGATTGCAATTTTAAATGAAAGAAAGACAGGCTTTGTTGATGTGCCAGCAAGACTTATGGCTTTAACG
TAGATAGTAAGGCAGCAGATTCAATCCACTGATCGTGATCTACTAGTGAATTTCAAAGCCTTATGCAATAGAACTAC
AAACCCCTTCTTGCACCTTGCAGGTGGATCCATAGGCAAAATGAACATTTGCAAAAAAGCCGCTATGTTTCAGA
ATTTGTGCTAGGGCTTTAATATCTATAATTTCTCCAAATCCTCACATTTAAGAATTAATTCAACTTAGCCCCATGA
ATAGGGTGAAATTTCTGAGATTTAACAACTAAAATAAGTTATCTGAAGACAGACAAATAGAAAGAGTTGAGATATT
CTATTTGAATGTAAATTTTCAAAAAGTAGAATGACAGCGTCAGGAATTACAGTCTCAGTGTGAAACACAAGACTTA
GGAACAAATTTCTGTCATGTAATTTCTGAGATGGGACAAAGTACAGCATACGTAAGGAAGTTTGAACAAATAA
GATAATTTTACGAGCTTTGAAACATGTGTAAGAAAGATACGAATAAAAGTATAATCACATTTGACTAAAACATG
AATACCTTAAACTGAAAGCACTGAGATTATCATTATATAATTTGAATATTTTAAACCACAATGCTTTGGGAGTG
CACTGTAATATTTAGAAATTTGAATTTTAACTTACTGGCTTAAAAAGTAATGTACTTTGTTTTAAATTCAAAGATTA
TCTTGTAATTCAGTTCGATCTATTGAAAAATTTATAAAATTCGGCAAGAAGCCAAAGAAGCAATATGTAGCTC
AAGATAATTAATTTTCAATGTTTGGCTTTAGAAATATATTGTCGTGACATAGTACATGGTAATCTAGTGAGCCAG
ACAAGTAGTTTTCTTTTTGTCAAAGGAACAATTTGATGCGTGTTCAAGTTGCTTAAATAAAATTTTGTATGTGC

TTTCTCATCACAAGAGAACAATATGATTTTTGAAATTATTTTTACTTTTATAAAAGAAAAAAGCCCTCACAGAG
AAAAAGAAAAAATGATGATGCTTTGAAAAACAAAGTTAATACAGCTTTACATATATTTGACCTACATCAGGGTT
AATATTTTTCAAGGTGAAACATTAGATGCTGGAACCTTGCAAAAACAGGCAATCCTCCTTTAGATGAAACGGACACTC
TAAGGGTTAATTCATTCACTGAGACCTATTGTGAAGTAAGCCCTACAGAGACTGAAAAAGTTAAATGCAACTCACAA
AAGTTGCTAGAAGAGTCATGATGTTAAAAATAAATAAGTACACAATGTATGCTGCAAGTATACTTAGAGCCATGCTA
GGTGCGGTTGAGAAGTTCAATACAGGTCCAAGATAATAGCTGCTTCTCCTATAGAACATGCTTCTCATTTGGAGGGA
TAAGACCTGTGTCTATGAAACAGGCGTAATTACATAGCTCTGGAATAATATGCCGAAATAAATGAGACAGTAAGT
GTTATTGTACTATAAAGAATGAAGAAATCATGATGAGAAGTAACAGTTAATGAATGTTTTCTAGAAAGAGTAGGATC
TGAATTGGCCTTAGGTTGTAAGCAGAGTTATAGATAGAGTAGTGGTATGTCAGAGTCACTCTGGGTGCTTAAACAT
ACAAATCCCCAAGTCTCACCCAAATGTGCTTCAGATGAAAGGAAAAACAAATGACTTGAGCTCCCCCGCAAGAA
CACGGGTGGTATATTGAGCAGCCAAGGAGTGACCAGAGTGGCAGGCCATGTTGAGGGACAAAAGAGGCAATTAGA
ATATGATTAAATACAAATTTACAGTGGGATGAGTTGTTAGCCTGAGGAGCTTGAATGTGAACCTCTGTGCAAAAAGGA
GTCATTAAATACTTTTGA AAAAGGTGGGATGGGAAGAAAATGACATTCTCAAGACAATTAGATCGAACAGTATTAAG
CATGCTGACTTATTAAGTTATGCACCTTGAGAGGGTGGAAATGAGGGAAGGGTCTTTATCTGGAGTAAGACAGGAA
GAAGCTAAGCTGTAATTTCTACTGGACTGTAAATTATGTGCAGATATATTATCTGTCATGTTCTGGGCGCATTTCTC
AGTACATAGCACTTGAACAGGTACTCGATAAATTGTCAAATGGATGCATGGAGTGATTTCCATGCAAAATCTAATA
TTGTATAGTATTAGAAGGGGAAAAAGCATGGCATTTGCTAGCAGAAAATGTCATTTGGTATTGATTTGCAAAAATGCAAC
TTTCAACAGTTTGCAAGCCATCCACTCAAACATTCTGTCACTTTTCCAATAATTTTGAAGGATGTTCTTTTACTTTC
TACCTTATTACACAATGAGTTGAGTAAGATAAAGAAGTCATGTGCAACAAAACAGAGGGAGATTTTCTGAAAGGCAC
TACACCAGGAAGTTGTTGTACTCTTGCTTCATCTTGCCATCTTGATATACTTCTGGCGCTACCTCCAGGCCAGTTC
CTCGTTACATATGTCATTTACTTCCCACATGCTAGACTCACCGAGTTAATCATTTTGTCTGCAGTTAACACATTTTAG
CAGAGTGTAGGTTTATGGGTGAGAAGGAAATCAATGATGTTTCAATACAGGGTCTTTTCCATCCCCCTTATTTCC
ACTTAGAAGTGTCTCTCAAGTCTTAATTTGCCTCTAACTTTTTTCCAGCTTACATTTCTTTTCTGAAAAATGCAAC
GACGATGCCAATGTTTGTGACCTGAAATACATTGTAAAAACATTCAATACTTTGAGCAGAGCTTCCAACTCCCA
TTTGCTCTTTTATCTCCCTTACCTTGCCCTTTTTTGAAGGCAATGTGATATTTAATCCGTTTCTATTGATGCTTC
AAAATTATTGAAAACTGGTAATTGTATTTTCCCTTTACTTATCAGTTGCTAGTTGACAATGAGTGTTTGCCCAAA
CAATAACCAATCAAAAGGTAAAAAGGAGATTCCAGACATATCTGAGAAGAAATCTTTGGAAGAAGCCCGTAAATGG
AATGGGAATTCAAAACAAAGCCGTTTCCAAAAGAAATACTAAATGGTCTCTAAATGCAAAAGGATTGCTCCCCAAGCA
TTTTATGGGAGCATAAAAAGCTCCCAACACATTTTATGACAATACTTCTACTCAATGACTTCTGTGTTGACATATT
TGTTGCACTCGACGTTAGTATTTACAGCTTCTTATCCCAAATATTTACTTAACTGAAGCCCTGATGTTTTTAAAAAC
TTTTCATCTGTGTTTAAACAGCCATTTTACAGAACTTATTTGTTTCATCAGGCAGATATTTACTGAGAAGTTGCAA
GTGCCATATATCTAAAAATGCTGATGATAAACTGTGAACACAATAGATTCTCATGGTGCTTATGGTCAGGGCTAG
CACACACACTTGTGAAATGATCACTGATGATCAAAGGCATAAACTACATTTGGAAGAAATACCGAGGGATCCAGA
AGTATCTTGGAAACACTAGCAAGTATAGCAGATGGTGGGATGGTGCTTCAAAGAACTTCTTGTGGAAGATGTTACG
TATGATCCTTCTCTGTGCCAGGCAGCTGTAGGAAGTCTGGAGAGAAAAAGATGTGCTAGATACCGCCTCTGTCTTA
TGTCCTTGTGCTTTGTGGGGAGGTGAGTAGGATAATCCAGTTCTCATGCAGTGAATGAGTACCATGACGGAAATG
CACTCCAAGAACTAGGCAGCATGACCAGAGATAGGACATTTGAGAAAGACTTCACTCGGGTGGTACTATCTTAGTCT
GGGTGCTAAATAGATGTGATAGATGAGTAAGGGTGACCCGGAAGCAGGAGGGAAGGGGAGGGCTTTCAGAACAA
AAGTGCGAGGACATTAAGGTGAAATAGAGTATAATAGTATTTCCAGATCCTTGGGATGTTCTCCATTAGGCTAAAA
CAAAGGTGTTTTCTCTTCTTAAAGATTTATGACTGCGATTTGCATAACAGAAGGTCATTTAATAGACCTCTAACT
GAAGGAATTTCTGAATTAATCACAACATATCTTCCATGGCCAGAGAAACCATTTGCCTCCTTATGTGCGACATTACTA
ACAGCACCAGCACCTGTGCTCAGGCCAGCGGGAGGGTGGGTGTTGCTGCCTAGGTAATGCTCACCAACTGATGTC
CTGCCATGAGTAGTTTTGCCAAGTTCCACAAAAAACTTAGTGTTCTATCAGCATCTAATGAGAATTACAGTCATT
AGTTAAATAAAGAAGTATTAGATAAGGAGCAGAAATGAACAACACACAATCCATCAGCTTGGTGAATGGTATCAGAT
GGTTTCTGGGTGCTGGGCAGCTGTGCATCCAAGTAGACAGGGAGAATATATATGTCCTTTGCCTTATGTACTTGTTT
CTCTAATCCAAAGGCAGCAATCCGTGGAAGTGTGATGATAAGGTGTTTAGTGGTGAAAATGCTTGAAAGCCAG
TAGATTATTTAAGTGATGTTTTTAAAAATGCAGATGGAGATAAGTACTTTTTATCTAGAGTAGTGTTCTCAAAGG
GAGGTCCCGGATCAGCAGCGTTAGCATCACTTGGGAAGTTAGACCTGCATGGGCCCCATTCCAGATCTCACTTGAA
AACTCTAGGGGGTGTAGCCCGGCAGTCTTTGTTGTGACCAGCTCTCCAGGGGGTCTGACACTCCAAATGTTCAAGT
TTCAGAACGCTACTCACAGGCCATCATGCTCGGCATCACCTGAAAGCTTGTTAGAACTAGAAAGTCTTGCCCCACC
CCAAGCTCAATAAATCAGAGTTTTTGGGAGTAGGGCCAAGAACTGTGGGTAAACAAGGTCTCCAAGTGATTCTTA
TTCAATGCTAAAAATTGAAAAGCGTCGATCGAATTTCCATGGCTTGTCTCAGCTTTGATTGCGTATCTGAATCTGGGGAG
ACAGTTGAGCTATTTCCGGGCCAGATCACATCTAGACCAATTGAATCAGAATCTATGGAGGCAGGACCCAGACATCA
GTATTTTAAAAATATTTCTTGAATGATCCCAGAGTGATAGCTAAGGTTGAGAAACACTGTTCTAGGATTAAAGGATTAA
TGTGTTTGAGAGTATGTTAAGATCTTAGGCAATCACAAGGGTGTTAAGAACTACCATCTTCGCAAAAGGAGAATGT
GCCTCAGATATTTCTGGTACTGCTTTGATTTTACCTTCAGTAGTCTTACCTATTTTGAGTATGCTTAGTAGTACTAAT
ATGAGGCTTATTACTAATATGTTAAAAATTTGTCTTTTAAATAGTGGGTCTAAACGTTTTAATCTTTAATCTCTGAC
CCAAGTAGAAGCTTTTCTAAACATTTTCAATAAGTCTCCACCTTGCTTCTGACCTTCACTTATGTTCTTCCAGGGT
TCTTCGTGTGTTACTAGTAATAGTAATGGCAAGTGTATTATGAACACTTACTATGTGAAGATTCTAACTGGCTTTTA
ATAATCACATCAGCTCTGGGAGGTAGAAGGTAGGGATCCTCCTTGCTTATCAGGTGAGAAAAGTGTACTATAGAGAA
GTTAGCAACTTTTCCAGGTCATAATATGTGACAGCTAAAGGGAGCATAATGGTTGGAATAAAATAAATCTACTCTA
GTTGTACCGAAGGCTCATATTTGTCTCACGTACTTGATTTGGTTCGAGGCCCAAGGGGTCAATTTCCAATGCTTGGAT
TCCTGGATATGTAGAGTTGATTAAAAATGCTAAAAACCTATTATGTATCATACAATCATACATATCACCTAAAGTA
TTATGGAATGAATCTGTATTATTAAGGAAAAAGGCTGTGTGAAGAACAAGTGAACCTTCATTTAATTGAAATT

AAATAACATGCATCATACACTAAAAGTGCACGTTATGACCCCATGAATTACTTCAGGTGGCTTTGATTTCATGTTACA
TACACTAACAAATATAGAAGAGTGATATAATGCTTCTTAATTACTACTAATGGAAGTTTACTATTAACTGCTTCT
TATGTAAGAATGTAAATGTTTTCTGAAATATCAGAACTTTTCATTAGGAAGCACTTTTAAAAATAGCAAACTGATA
TGCATATGATTTCCATATACATTAATTTGAACCTTGTAATGATGTTATAAATTATAGAAACCAAGGGGATGTTCAA
ATTAGATATTTGTCTAAATAAATCATGTATGGATTGAACAAATACTCATTGAGAAATAAATGTATTCCTTTTCTTTT
AATTATCTAGGATTCCTTGTATCTCTTCAGAAAGCAAAATGCTTCTGTCCGTTTATTTCCAGTTAAACATTCCT
CAGATTATGTAATAAGTTAACTTCCAATCCTCTTATTTCTGTTTATCTCACCCTCTTCTAATTTAGACGTGATCA
ATATCTTATCTTTTGCATTTCATAGACATCAGGATCCAGAATAATTGAGTGAGCTCAAAACAACAATGGCAAGAAT
GATGTTTTTCAGAAACTCAGCAATCATTGCTTTAATAAATATTCATTGCCTACCAACTATAAGCAAAGTATTGGCTA
GGCCATGTGGGGTATACAAAAATGTATTAATATGGCTCATTCTCCCTAAGAACCTACACCTATTAGACAAAGTACA
TGCATAAAAAATTATAATGTATAATAGAAAATAAATACAAGCCCTAGAATGCACAGTTGAAGTACGATTTGCATTAT
TATAAAAAGAAAGATGAATTGGCTGGGCACGGTGGCTCACGCCTGTAATCCCAGCACTTTGGGAGGCAAGATGGG
AGATCACGAGGTTCAGGAGTTCGAGACCATCCTGGCCAACTGTTGAACTCTATCTCTACTAAATATACAAAAATTA
GCCGGGTTTGGTGGTATGCACCTGTAATCCCAGCTACTTAGCAGGCTGAGGCAGGAGAATTGTTGAACCTGGGAGG
TGGAGGTTGCAGTGAGCCAGATCTGGCCATTGCACTCCAGCCTGGGCAACAGCAAGATTCCATCTCAAAAAA
AAAGGAAAGAAAGAAAGATTAATTTCTGTTAGCTAGAAATCAAGGAAGGCTTCATGGAGAAAAAATATTTCAACA
CACACTTGACCTAGCAGTGGGATCAGGCTGATGTTAGGCTTGAAGCTATGTACAATTCAGAATTATGAGGAGAAGAAATTT
AGTATATATATGAAGAGCAGTAGAGAACTAACAAAGTGGAATAGACTCAATTTACAATACTTGCCTGCCTGGAGTA
CTCTATACGTTGACTGTAAGTTGCAGTTTACTCAGAACATCCCCTTTCTACTTGTATTATCCTATGTAATCATTTA
TTGGGCCTCCTTTTGTCTCTAAAAATATCCTTGTGTTGGATAATAGATTATCACTCTGTTTCTTAAATGAACCTGCCTG
TGCTCTATCCCAGTAAAAGGGTGCATTGGGGCCTTCGTAACCTGCCTCCACTACATGGTTGATTGAAACCAGAGCTT
GGCATTAGAAGTTAGCTGAACAATCAGATTTCTATTCTTGGAAAACCAAGAATTCAGAATAGATACAGAAGCTG
TATAGCTTTAATAACATGACAGAGTTGTAGCCTTGAAGCTATGTACAATTCAGAATTATGAGGAGAAGAAATTTGA
AGAAACAGTAGCAGCCGGGTAAATGCAGAAACAAATGAGGGAGACACCTAGGGGGTGACTGAGGCACAATAATGGAA
GAGAAGTGCAAGTGAATTTGCTTGAACCTTACTGATGAGATTTCTACTGTTGCCTTGAATCCAGGACCACCTATATG
TTCATTCTTTGTATGCTCAGAGTTATGACAGATGCTGTTATTGAATCCCCAGAGACTCCCTTATCGTCTCACCTC
AAACCTTACAATAATCCCTTCTATCTTTCTATCCATCCAAGCTGGCTTAAGTAAAGTCTATGATCCATATTCCTAGT
AAACAGAGAAGGAAAGAGACTGAAGGCAAAGGCCCAATTAGTAGGCTATTGCAATATTTTCAGGGAAAGGCAATG
GCCATCACATTGTTGTCCAGGAATGAGAATAGAAATGAAAGAAGATAATGAAAGTTGAAAGGACTGGGGGGCTTG
ACAACCTGTTTAGACTTGAGGAGTCAGATAAAATAGGAAGCCAAAGATAATTCAGAATATTTTGATTTTGATTTTCAT
CACCAAATAAGATAGTAGTACTATGAAGAAAAATGGTTAAAAACAATAATAAAGAGAACTCCTCCAAATAGT
ACCAAGGGAGGGAGTTTAAATAGAGGAAATTAATCCGTAGGTGATGAGAGTCCCTGAGAAGCCAAACGAGAAAAAGATC
AAAACAACCCAGGGATTGGCAGTCGCAGGAAGCTGTTCTCACTTATGGCTGGGGCTTTAAGCACAAGGTGACATGAG
ATTTCAGAATTTGAAGTCGTCTGGAGGCAGCTAGGATCAGGTGGGGCTGTCTGTTCGGCAGGACCTGCAACCACA
GGAGGAGGATGCGTCAAGCAGAAAGTTGGAACACAAGAGGGGATTAGCCATAAGCCACAAAAATACCTTCCAGAGCA
GAGAGAAGGAGAAATACCTGAATTCCTGATTTTCCCTGCCATTTAGTTCCTGCTATTGCCACACATTGACGTATT
CCATCCAGAGAAGTCCATTGGCATATGAGTCTGGGAAATGTAGTTCCAGGGGGACATGATCTTAAGGGAATAGAC
AATGACTGGTGCAACAACGACCTGTGTGAGGCAGGAGGGAAAAACAGGAATAATATAGTTTTTCTCTAGATCCCT
TCATGCACAAGATGCAAAAGAAATGTGTTGGCTTAATGAGCCATTCTGGGTGGCCCTGTAGGTGGCTGTCTACGA
ATAAGATTTTGTAGACAAAACAGAGATGACTTCAAATGTCACAAGAAAAGTATCAGACAGGAATTAATATTGACTTGA
TCTGTACAGGCGTCAATGATTTGCATTAAAGCCAAAGATCTTCAATTGTTAATGTCTGGGAAATTCCTCAGAGCATTA
CGACTACTTGTGTGGATTAGTGTAAACGGATTCCCCCACTAACATTAGGAAATCATGTCAAGCACAGAGTGCCTATG
TAAGAGTGGTTGTGTCTATTCACTACATTCTTGGACTAATAACACACTTAGCCTTCTGAAATGCCAACATGTACA
AAACCAGATTGGGGTTTTTGTAGTTGTTTATGGAACATCATTTATTGGGTAGCTCCTGTAGAAGCAAGATACAGAAA
CTCTAATTAGGAATAAGACAGTCCCTGTACTTCAAAGAGCTCTCAGGGGAGGCACACAAGTAAACAAGCAATTATTA
TCATACGTTAGGATAATACCGTCAATGGTGATAACCATGAGTGATAGCCAAACACATGGAAGAGGTACCCAAGTCTA
ACTTGGGGTAGTCAGAGACTGCTTTTCAAGGATATCCAGTAAGTGTAGCTAAGACATGATACGTATTTCTAGGAGG
GAAATTTTCAAGGCAAGGTGGAGATTGTGCAGTGACGCCAGAGCCTGGATTATTTTGGTGACTGCTAGTATTTTCAG
AATGACTTCAGCAAAAGTTGTAGAGAAGATAGAAGACAACAAAGTATAAGCAGAGGCCAGATAATGAGGACCTGGAA
CAGTGGTTTTGCTGGTAAATGTTTAAACAAGAGGCTCTTGGCGGGGAGAGAGAGTGTCTGATTTGCAGCATTGTCAAA
TTTTGTTGCACAAATGCTCCAGCATAGCCAATTTCAAAGCTACCAGTGTGACGTCAATTGAATGCCAGAATTGGAAGAA
ACGGGCAGTAGCACAAGCATTGTATAGTTATTTTCAATCCAGATATAATAGATAAAATATCCAGATGGTATTTAAAT
AGATATGGATGCAAAATTTAAATATATGTACATTATGTGCTTCAATGTTACTGAATGCGCACACATTCATTATCCA
TTCATTACGTGTTAATTTAAACAACATTCTGAGCCTCTGCTCTGTGCCAAACGCAGTTCCTAGCTGCTGGAATTAC
AGCACTGAAAAAATTTGTCTCACTGAGGTAAGACAAACATTATTATGCCATTTTACAGCTGAGAAATTAAG
ACATATGAGGATTAAGCAGTATAGTTAAATACACAAATTTGGTACATGAAGGAATCAAAGAGGAAATCAGCTCTCAG
ATTTTAAATCCAGGGACGCTTCTGTCTATACCATACTACCTACCTAGTTGAGCTGGATTTTATCATGGTTTCCCTA
TTTTTATCACCATGTGGTTGGATAAGTAAATAAATATATGTGACCTTTCAAATAAATTTGGGTCAATTTTCTTGG
AGCTCATCTGGTGTGAACTTAAATACTGCAATTAATAATGATTATAATACCCCTGGAACCTCTGTAGCAACCTCTTT
TGAAGAACCTCAAGGAGCCTCTAAATGTATCAAACCTAAGTTCTTCAAGTGAATTAGTTATCATCTGAGAGTAATATA
GACTTTTAAATATGCATTAATTGTATTAAACCTTTTCAGGCCATAGACTTAAGTGTCTTTCTTCCAAATAAAAAATA
GTAATCTCTGTCCATTTTCTTTAGAGAATAATGAAGTAATTTTCAATTGAATATGTAGTCAACATAATTACTTCAATT
CAATCGTGAAGGATTTTAAAAATATTTATGTCTACTAACTTAAAGACATGCATAGATTTCAAGAACCTTAAAAATGC
ATATTGCCCTTTTGGCCTATGCCTCATAAAACAAAAATTATGATAACGTTGTGTGTACAGAAAAACGCAGTATTGT

AAATGAAGGGTGCTTCAAAGGCCATGAACCTGGAAAGCAACTTATTTACAGAGACCCCCAGCAATAGCAGCTAAAAGA
TTGACTGACTCCCTTTATTTTCAGTTATCCTTCAGACACTTTTGACCTCTTCCTGTGCCTTTCTAGTCATGTGCAAT
CTTGTGGATATCTCTTCCTTCCTCTTGTTATTTTCTATTTCTCTGTTTCTATTTGTTTCTAAAAATAATCATGTTT
GAATATAGGATTAGCTTCCTTCCCATCTCCCCATTACCAATCTCTCACTATACCGCTATGTTATTAATCTTCCTGAG
AAATATATCAGGTTTACATTACATTAGTTACCAGCTCAAAACGTATCAGTGGCTTTCTAGTCCTCACAGGCTCAAGTTA
ATCTGCATATTTCTGACTTTCATATTTCTGGGTTTCATGCAAACCTTTTCAACTTTCCCTCTTATACCTACTTAGGAGGAC
CCTCAGGTTCCATCATGCTCATGTTTCAAGCCAGAAGTTCTCCTGCCTCTTCCTCTATGTAGACTCCACATAGACTA
TGATATCCTGCTTCTCTTTAATCCTCCATCTTCAGCTCACAGCCCACTCCTCTGTGAACAGTTAAATGATTCTCC
CACCTCTTACCTCCTATAGCACTTATTTTTCATGCAGCATTTTGTAGACTTAATTAAATCTACAGTTTAAAAAATG
TTTTTCTACCACAGTCTCTTATTCATACTAAAACCTTCAAGTCTATCCATTTTGCTTATACAACCACACCGTTAGGT
CTTTTAGGTTCCAAGAATACAAGAGAATGGCAAAGCACGTTGTTTACATCCACACATACTGTGTAATCAGGTAATT
TTTTTAAATCCTATGATCCTCAATTACCTCAGCTGTAATAATAGGTACTACTCATACTGCAGAACCTTGTGTGGAATT
AAATAAATGAGTGTATTAAAAATGCTCAACAAGATTGGCACAAAATCGGTACTCAGTAAATGCTAATCATTATTCC
CTTTCTCTTCAAAGCTCCACAATTCTGTATTTCATATACCCCTCTTTATATCATTGCAAAAATGTATCCTATTCCAA
CTCTTTCCACCTAGCCTCAACATTTACAAACACTCCTGGTGGGAAGGGAAAGCTTTTGAGGAGAGCACATCTATACT
CATTTACTTCTCAGGGATGCAAGCTGCCCTGCTTACTGAGGGCATATGTTTCATAGTCACACCGGAGGCCACTGTCCC
CTTATCCTCTCAAAATGGGCAGTAGCAAAATCATCTTCTGAGTAGTAAAGACCTGCTCTAAATTTTCACATGCTACA
GATAATTTCTTTTTTAGTAAGTGTTATCTTACATATATGCCAAAATATCACCATTATATGGAACACTAGCTGAAAGA
AAAATTATTAGTAGTCTTAATTTTCTAGCTAACATAAAATCTCTCCATTTTCATCATCCATTAGATTAAAGACTT
TACTGTTAGCTGAATATTACAGAGACTTTATCTGATTTTAAAAATTATGAGGTTCAATATGTTAAGACTTCAAGGG
TGAGCTGTTTGTGTCATTTATAATGCGTGACTAGACAGTAAGTAAAGGATTGTTGACTTTACAAGATTCTCC
CCACCACGTCCTCCCAACCTGTGCTGCTGTGTTTGGCTGAAATCTTTACTTCTAGTCAATCTTTGGACCTAAA
GCTTACCAGCTTTTAGCATCCTTTAAGATTGACGTGTTCTGAGGAGACCAATAGATGCTAAACCAAATTTTCGTATGC
ACTTGGCAATATAGGATAATAACAACCATACTCCCTGCAATTGTTTCTTAACACAGATGTAACCAAATTACCACAAGC
TGGGTGGCTTAATAGACATTATTCTCTCACAATCTGGAAGCTAGGTGTCCAAAATCAAGGTCAATTATCCCTCTG
AAGGCTCTGGGAAGAATTCTTCTTGGCTCTTCCAGCTTCTGGTAGCCCCAGGTGTTCTTGATTTCAAGCAGCAC
AAGTTCAACATCTGCTCCTGACCTCACATAACCCCTCTCTTTGTGTGCTTTCTGTGTCCACTCTTTCTTTATTAT
TATTATTATTATTATTATTATTATTATTACTTTAAGTTTATAGGTACATGTGCACAATGTGCAGGTAGTTAGTTACAT
ATGTATGCTATGTGCCATGCTGGTGTGCTGCACCCATTAGCTCATCATTTAGCATTAGGTATATCTCCTAATGCTATC
CCTCCCCCTCTCCCCCACCCACAGTCCCCAGAGTGTGATGTTCCCATTCCTGTGTCCATGTGTTCTCATTGT
TCAATTTCCACCTGTGAGTGAGAGTATGCAGTGTGTTGTTTGTCTTGTGATAGTTTACTGAGAATGATGATTT
CCAATTTTCATCCATGTCTCTACAAAGAACATGAACCTCATCATTTTTTATGGCTGCATAGTATCCATGGTGTATAT
GTGCCACATTTTCTTAATCCAGTCTATCATTTGTTGGACATTTGGGTTGGTTCCAAGTCTTTGCTATTGTGAATAGTG
CCGCAAAAGGACACCACTCTTTGGATTAGAGCCCACCCTAAATTCATGGTGATGTCAATTTGAAATCTTAACTAA
TTACATCTTCAAAGACCCCTATTTCCAAATCTGGTGACATTCAAGGTTTCAGGGACATGTGACTATTCCGGGAAACT
ATTTCATCCACCACATCCCCCTTGAAATTTCTGGAATATGTAGTAATAAAGGCTTCTGATAAATTAGTGTGGAAGT
ATTCACGGTTATAAATTACTAAAAAGTCTCACTGTGAGCTCTTAATCAAAGGCCCTATAAAACATTTATTTGCTTG
ATTAAACTACACATCCGATATTTTGGTTTGGATTATTATTATTTTATAGACTTGAATAACTATTTTATGTGAAA
TAGATTCCATAACTGAAGCAGCATACCTCTCAATTTCCCAACATTTATTTATTTATTTTGTCTTCACACTACTTA
ATAACTGAGGAAAAATCATTAGACCAAAGTTTACCTTGGTTGACACCATCCAGACAGCTACAGGAAATAACAATGG
AACTAAATCTCTAAGAAAAAGAGTCTTTTCATGTGAAATATTGCGAGAGTTGATTCTAGATATATAGCTGTTGGAAGA
ATGGATACTATTACATAGATATGGCAGAGTGGTATCCAGCACCTTTCAACAAAGATCTTTTCAGAGTCAGTCTTATTA
TGCTGAGGAATTTACCCAGGGCTTAGGTGCTTTTACTGACAATCTAACCACCTGCACCCACCCACCGTCTAAAGC
TAAAGTTTATTTGGAAGACTTAGGAAATCAGTCTTCGGAATGTTTCTGAGACTGGTACACCCACCACTTCATTAAAGT
GCTTCACTTCACTTCATTAGACAAGAAGTAAATACCTGTGAGGAAATATTTATAGTACCATGTATATGGGTATCT
TATTTAATACTACTTAATGATGGTACTACAAGTTATATAAAATGGAGAAATAAGTCATCAAGTTTGACAATAATGAT
ATTTGATATTATCATTATCTTTTTTATTTCGTTCCCAAGGAAGTACTCTGTTATTGTTTGAAGAAATGATATTGAT
ATAATAAAGAAGGAAAGGTGGTAATATTCTTTATTTTGTATCTTTATACCCAGCTCTTTACCAATCTCCCC
ATCTCTGTAGTTCTCCTCTGGTGTCCCAGGCAGTGAACCTATTCCAGTGGTTAGGGAACATCTCATTGAGTAAGTT
ACATCAACATTTCTTCACATTTTCAGGACAACAGGAACAGTGCCAAATCCTAGCCCATTTGTTCAACTCTCAAGCTTA
TTATCTTAATAAACATCCATCCCAAGAAAGAAATTCATCAAGATCAGAGAGGAATACGTATAATTTTATAGTACA
GTATTTAAATGAAACAGCTTTTGGCCCGCTGGTCTCAGTGGGCTCAAGGGGAAATTCAGGATCTGTAGTACTCT
CACACCAAGTTTAATAAAGGGTGTCTTATAAAAAGCTAATTTCTTGTGTTAAATTGCTTTTTTAAAGTAATCTTGCT
GTTGCAAGAGACCCATTTCATAGCGCTGACACTGGGAGCCATGTTGGAAGGCTAGATATGCTCTGGGAGATAAGGTA
AGATCCAGGTGGAATCTTCTTTACAGAATGACAATGTATATAGCTAATATTGCTCTTGGAGCTAGTTTGCATGC
AGTTGCTGGTATGGCACTGCTCAGCAGCTGCTGCAGATAAGAATGAGTGATGATGCCCTAGATTTTAAATGGAACCT
TTAGAGTGTCATGCAGCAGTGGGGTGCAGTCTTCAGCAAGAAAAACGAGCTGACTTGCAGGCATGAGAGATCATCAA
GAAAGATAAAGAAATAGGACATCCACTCTAGGTTAGGCAAGGCTTTTATAGAGGATATTATGGAATGAGCAAGAAC
AATTTAATTTTTTATAATGCCACTCCATTTAACTTTAAATAACAAGGTCAAGGTACTGTGTTTTTATTAATGATTAAA
GATTTGGAGCACTCTTTCTGTTGAAACATACTGCATCTGTTTGGCAGAAAAAAGTGACAAAGAATAAACTGGG
ATCAGAGAACAACAAAAACATATTCTGTCACTTGCCTAACACAAGTTAAAAAGCAAAGGAAAAAGAGACAACCTCTGA
TGGACATGTTTCATCCTTATCCCAACAGAGGATTTATTACCTAAGGTCTTATTTTCAAGTTACTTTGATCCAG
GATGGTAACATAAAATGTACATTTTAAAAATAAATGGAAGTATAAGATCAATAAAAAACCATATCTGTGGATAAAA
CAGCAGATTCAATCTTGTGGCTGAAAGTTTGCTTTAAACCAACATTTGGTAACATTTCACTCTGTAATTTATTA

AGACATACTGTTATTATAAACTATCTCAGTTTGCATCTTGTGGTTCTGTCAAAATTTATCCTGCTAATTCTCAA
CTTGTAATATCTCTGATATACATGATTAATCTATTTTAGGAATAAAACAAAACTACCTTTATCTTACGCATTCTCA
GGAAGTGTTTTTAGATGTAAAGTAGGGGTAATTGTAGTATAGTGGAAGGATTTTGAACCTTGAAGCCAGAACATATG
TCTCTGCCAAAACTAGGTGTGTGACCTTAAATAAGTTACTTAGCTTCTGAATCTTAGTTTGTTTAGCTTTTTTCT
ATAAAGTGGCACACCTATCCACATCACAGTTTGTGTGCAAAATTAATAAAATACTATATTAGAAAGAACTTTTA
GAAAGAAATTTATAAACTGAAATGTACTATACAAGTTTAAATCATTCTCATTATTTTCTTACCTAAAAATTTTGACC
TTATTTTCTTAGCAAATGGCTGAATCTGTAAAATTTAACCCACGCGAGCATCTGGATTCAAGAGAACTACGGTCA
TTTCTTTATACAGAATACTAATTATACACATATAGCAAAACACAAGTTTTTCCAACTACTCTGTGTTTTTAAAGAT
TCAGTGTGGGCAGAAGGAATTTTATCAACTATGTTAGGGGAAAAAGTCTGAAGAAATGAAAATAATGAGAAAAAGC
ACTGTTGATTTAAGTGCAGGAACATAAACTTCAAGGCAAAATGTGAGGCCAACTGAGTTTATATATATCCTCACAAA
ATGATTTAGTTAATTTAAAACTTTTCTAATAAGCAACACAGGTAATCCCAAATTTCTATCTTTTATAGCTCTAAGAG
TCCCCATAATTTATTAGCAATTATTTACCACCCACTTATTATAAGAAAAGCCCTGGGATAAGCTTTGAGAAAGAAC
TAACAAAAACAAAACCTTGATTGTTTGTCTCTAAAAAGCTGGGTCTAAAAATAGGCAAGGTAAGATTTTGTTTTGAGGA
GCCCGTATTTTCCAGCACTGTCCATTGTAACATTAAAAATAGTTTGGCAAAATCCTCACTCTGTGGGTGTATTGCGCT
AGGGTGCTAAAATTGCTTAAAACTTTTGTATTTGGCTAACTAAAAATCACTGAATAGTAAACAGTAGCATTAGAGAT
GGCAGAGACATTAGGTGTCTAGCAGTTCAACTGCTTACCTAGCAGACAAAGACATTAAGTTCCATTCTTAAATTT
AACTATCTGGTTGAGGATACACAGTAGCAGAGCTAAATCAAGAACCTCTTGGGGTAGAGTTTTGTTTATAGCTATTA
CTTTGTTTTGGAATTAATAAACAGTGCCTGTTTGTCTAAGTTAAATGAAAATATGCTCTGAAGGAGAAAAACAGCTAT
AAAAATAGACTTAACTTCCAACTATGGATCACAATAAACTAAAGAAATAATTTCTGTAGCAATAAACTCCAACACT
TTCCATAGGACCAGAAAGGCTTGAGAAAGAGGAGAAACAAAAAATGCTTGGGGCTTACCATATATATGGAGAAAGC
TAAATGAATAAACAGTTGAAAGACAGCGAGTTATACTAGTAACAATATTACTGATATCGGAGCTCTCACTTATAAA
TTGTATATTATGATCATAGTGACTAGGTACTTTATATCTGCTTTCTCATTCTTCTCACCATTAAATTCACATGTAGG
ACAGATTACCTTCTTGTCTTCTATCCAGAGGCTTAGAGCTCAGGCCCTCATCGAAGACAGACAGAGCTATCATCTCTT
ATTCTAAAAAAAACCTAAGACCCAGACATAGCTGTGCTACTTATAGACTAGAATGTGAGAGAAAAAGACAAGCTTT
CATCATGGGCTTAACAACTGAAACACTTCTTCAATTTTGTAGATTGAGAACTTAGCTAATGCTAGGTGTAAAGATG
ATATGCTACCTTCATAACCTTGGTGAGGAGAAATTAGCATTCTCTCAGTCTCTAGAAGGAGGATGACCATGAAGGTC
TTCATTCTCTTGAGAAGATAATCAAATGCTTCACTGCCCTGTTAACGGTTTTACTCAATATTCACCAAGAAAAGTAGA
TGGGATTAATTTTGCAGACACTTATACGGGTAATTTATCTGTATAGCAGAGACATACCTTTAGTGCATAAATGTT
CCCTTTGTGCTCTTTGTAAATAAACATCACCATAGAGAACAAACACGAAGTAATGACATTGAATTAAGAGACACCATA
GAGGCAACAGCGACTGGAATTTGTGAAAGTAAAAGGATAGTGCAACAGTTGTGCGTTGCATTCTGCTCTGAAGATT
AACAAGCTGGGTGAGGCTTTGACCATCATGATGAGCAGGAGATTTTTCTAATGGAATCCCAATCAAGTTCTGCT
GCACCCAGAAAGGAACGGCTTACAGAAATCTTACATTCTTTGCACATACCAAATTGCTTGGCATATTCTATCACAA
GGTTTACTTTCCAGGGAATGTGATCAAGAAATCATGATCCTAATTCCTAGTTAACCCCTCAAAGTTTCTCAGAACAGT
CAGTGCATCACTGTCAACTTTTGTGCAATGTGGAATCAGAATTGGTCACACGTTTTTCCGGCCACTGTTTTAGATT
CATATAATATTAGTGAATCATGTGAGCTGGTATAGCCATGAATTTATACTTCATGAATAGGCACTCAATAAATAG
TGGATTAATATCGACCGATTGATTTTTACCTCCAATAATTTCAAAAAATATCATTGAAGACAAGGTTGTTGAAGCTGT
CACTTTTCTTGTGTAACCTTTGTTGTGCCAGGAGGAACAGATGGTAAATCAAAAGTGATTAGAGAATCAGTGGGGT
GGGGGTGAGATTGGAGGGGAGAGGCTTCCCAGTGAGACCCGCTAGCGTCTTCCCTGAGCAGTATGTTAACCCAAGA
CAATTTTAGAAATCTGTGCCCTAAGTTGCTTGACATCCAAAGCACACTTGATGCATCCTACATTTCTAAATATTTT
TATTGTTGTTTTCTCGGTAGTAATCATCTGGTTTAGTCACTCTAAAAGTCAAGGATGAAATTTTAAATGCAAAATAA
AGTGCCTACTTTCTCTCTTCCAATTTTGTGTTTATTGAGGTATAATTTACATGCACAAAAAAATCGCCTTTT
TAAAGTGTACAGTTTGATGAGTTTTGACAAACATATGCAGTCTTACAACCACGTCGGTGATCAGAATAGGAAATATT
TTTATCACTTCAAAAAGTTTCTTGTACTCCGTTGCAGTCAGTCTCTGCCCCACCCAGCCCTGGAAACCACTG
ATAGGTAAAAGCACTTTTAACTGTAAAGGTATTTAATGTATGGCAGTGTGAGTGGTAATAATAACAAGATTTATTCA
TTGGTTCACTGTATTTTTGAGCACTTATATGTGCCCCGTTGTATGCAACCCATTATGCTCAACCCCTGCCCTCCTCAC
CAGGGATAAACTAGTGGCAGAGATAGACAAAGAAGCCGCTCTCTATACCCCTATCTTATAGAACATTCTTCAATG
TTAGAAATGCAGTATAATGTGGCCATTGAGAACCTTGAAGTTGCTTAGTGGAATGAAGAAGTGAAGTTTTAACTTT
ATTTAATTTCAATTAATTTAAATTTATATAGCCACATGTGGCTAATGACTATCCCACTGGAAAGTACAGCTTCTATA
CAATATGATAATATGATACATTATAACGCAGGAGTTTAACCAAGTGCTAAAGCTTTACTATCACCAGGGTCACTGGT
GTTATGTGAAAGAAAACCTTACAATAGAAAAATAATCCTTTAAATAGTCACAGACCTGAGAAAGTTTCTTCTCAA
GGGAACACACATTGGCTCATTCAAAGGAGGTTAAAACTAGCAATTTAAGGTAATTTCAATGAAGCTTTCTTCTGGATT
TCTCATGCTTATGTATACATAAAATAGGCAATTTTCGATGGGACCTAATAAAATCACTGTTTTTATTGTAACATTTT
AACAAAATTTATCAACAGCATTGCATTTATGTTCAACCTATTTGTTCTGAGAAAGACAACGATTAAGTAGAAGTCAT
CAAAGTTACCAGAACAATTTTGTCTTATGTTTTAGAAGGCATTGAAGGTGTTTTAAATGTACACTTATAGAGTCA
GAGTACTATGCAACTGTGGCCCTTATAGTTTATCCGTATGCATCTAAAGCCATTGTTACATCTGTTTCTAATTTGTG
CATGGATTGTCCAAGATACACAATGGAAATTCATTTTATTTATCAATTTGAAGAGGTTTCACCCATGTGGTCACT
ATGATCACTATGGAGTCACATTAATTTAGAAAGTCTCCAGAAGTTGCAGTATTTATTTAAATTTCACTTTTCTTCA
GAGGAACAAATTTCTCCATTTCTGGATTCTGAATCTCATATAGCCATAAGGTTGTTGTAAGAAATTTGACAGCTAATAGG
AACACATCTGGGGAGAGACCAGTTGAAAAGTAACTTGGTTCTGAGTGAAATATACAGAGACAGTTTCTACTTCAG
GTGGTGTGCTAATGAAGCTATCATGGTAATTTTAGCCATATGATCCCTAAACGACTTCAGAACCACCTTTTCATCC
ACTAAGAACCACCTTCAACCCTGCCACGTTCACTACCACAGTATAATATGGAACACCCTCTGGAATTCAGTAAGTA
ACTTCTTAACTCATTGGCTATAGAGCTTTGCCTTTGTAATTTCTTCTTTTGCAGTAAAAGAGATTGTTTCAAAGT
AATCCAATTAGTCCCTAGGCATGTCTAGAAAGGTAGAGTCAACAACAGTAAGGTAATAGTCTTTATAAGATATGTAA
GAAATTATCAGTCATTTACTTTAAATAATTTGTACACTTTTCTTTTATATGGTTCTTCTATGTTGAAGCCAGTGG

TCATCCAGTGATTAAGATTAGCCAAACTCAAAGGCTAAAACATAAATTCAAATGGTATTATTTTGCTTTAATTTTAT
GCAATGCTATGATTTTAAATTTTCATGAAAGTTTCGTATGGCATTGCTATCAATTTAGTCAGGATAAATTTCCCGTG
AAATAATCCACAATTTTCACTGTACGTTGGGTACAGGTAAGGAAACACCCTTAAGAGCTTATCCAGTTATTAGCTG
GTATTATAAATTTCAAGTAATTCATGTTCAATTAATAACAGTTACTTTAAATGGGAAAGTATGAGTCAAGAGTTA
GTACAAAGGAGAATCTTAAAGATGAACATCAAAGAATCTTACTATTGATTTGTTGGTGCCTTTGCTTGCCTTCTC
CAAATTGACTTGACGTTTTTAAATTTGTACTGATAATCATCAGAGTCAAATCTGCTTTTAGGCAAAAAGTATCCGCTA
GTTATTTCCCTACTATGAAAGTGATGAGATGAATTGATCATGTCTCCAGTGTATGGATGGATGTCTTTGAGGAAGAC
CTACTGACCTTATGTTTATCTTCTGTGTCAGCATGGTGTGACTATGTGGAGAGACAGTGTCTATTTGCTAAATACTTTGT
TTTTCAAATAAAAAGATTTACAGATTATGCATTGTAGAATTTATAAGTATTCTTTTATGTCTTTGAATGTGCCAAT
ACAATTTTTATGAAGTTGGAACATTTTATCTATTTTAAATGAAATTGTAAGCCTTCTGTGAATCTTTTATTAATTT
TATTCTGAAGAAAATCTGACCAGTTAGGGAATCAGGTCAGGTTACGACGTGATCCCAGTGGAAAGCTGAAGTGT
GGACTGTGATTTTAAATAGGGAAGAGGTACTGAAGTGTGTTTTTATTTTGTGTTACAAATCAGCCTTTCTACTAT
TATGTACTCCCATCCTTCTATCTTTTTCTCCACCAGAACGTATTAACAGGCATGCATATAATTAATGCTTTTCTTGA
GATAATATTAAATTAACCTCATCTGTGAGCCGCTCTGGGCTAAAAGTACACAGTCAATCTGGGTAACATTGAGT
TGATGTAAATATGCCACACATACTGACAATGCTTACCATTTATTGTGTGAATGAAAAGCAGTGTAAATATTGTTT
TTCTACTAGGGAAGCTCCACATTTTAACTAACTTTGACCGTATTTCTAAAATGCCAGAGCATCTGGAATTTGTTAA
GGAATGATAGTTTTTGTGTTTTTAACTGTTAGGTAATCCTGAACCTATGGAGCCATCCATGCTGAAAATACTGAGTAAATGA
GTTTCTTCTCTTTATTTTAAATGTGATAAAATGTAGTTTTTGTCTGAGGCTGACAAAACAGTGGTAGACTACACTAAC
TCTGCGTTTTGCTGGGTTTTAATCTTACCCTCTCAAGGCATGGAATGGGAGCTCACTTCAGACCCAGCCATGCTTCACT
GTCCACTGCTTCTCATGGATATAGTGTGAACATTAATAGATGAATTCATAAAGTGCTTTAAGCTCTTTGGAGAA
AGATACTCGCTGCATAATATTCTTAACTCCCATACGCTCTTATGATATAAACCATTCTGCCAGGAAATCCTTTTTA
GGGATTACTACTTAAATGAAATTTTCAATTTAAAGCAGGAAGAATATACATCTACTGACAGACGAAAATGTGCT
TAAGGCGACTGCTTTTAAATAGGCAGAAATCCTGAACCTATGGAGCCATCCATGCTGAAAATACTGAGTAAATGA
AAACTGGTAGCAAATTTGGAATATTAATCATCACATTAAGTTGCAAGAAAAAATAACAAGCCACATGCCCTTTA
AAAAACGTGCACAAATCTTTATTCTAGAAATATATAACTTTAGGCCTAAAAAAGTACAAAAAGTAAATTTTAT
GGCTCTGAAAATATCCTTAAATTTACTCAGGTGACAACATTAGTGTTTAAAGAGTGTAGTTTTCAATCTTAGCTACAA
GTTGGAATTACTCTGGAAGCTCTAAAAAACAACAAAAAATAGAGATGCCTAGTTCACCTGCAGAAAT
TCTGATTTGATTTTTCTGGTGCGAGACCTGAGAATAGGAATTTTTTAAAGCTTCCCTAGTGATTCTAGTGTGCCAC
CTAGGTTGCCCTTAAGGTAAACCTCATATTATGCAGAACCTAGCAATCACCATCCTGATTTTATAGACGAAGATCAT
AAGACCCAAGAGGGCAAATTTGATTTATTCAAGATTGAATATACAAATGATAGAAGATTCACATAAGATGCAGTATAC
AGAGTGGCTTTGTGGATTCTTGCCAATGCAGGCAGCAGAATTTCTTTAGGGTTCACCCAGTTCAGGCACCTCTTTGC
AGCAGCACTTGACTAAGGTTCTTCTGATTGGATCATTATATGGGCAAAAAGAAAAAGCTTAATTGAAAAGAGCTGAA
CCCACATTGTGGAATGGAAGATATACAGTTTACACGTTATAAATGATTAATATTTCATGAAAGCATACTGCCCTTTCC
TCTTCCCTTCCCATAGATGACATCATTGCATTGGTGTAGTTAGGTTGGTGGTTTTCTGTTGTTGATCTTGGTTCTGA
CACAGTTTCATCACTTATTATCTGGCTTATTATCTACTTCTACATTCATTGTTTCACTCACTCAATTAATTAATCAAC
ATGGTTTTTTATTGTTTTGGACCGTTATATGCCTGCAACGCTACGTAAGGCTGAGGATATTACAATGAACAGGAAAC
AACCTGAAGTTTAAAGGTATCAAGCCTTTGAGTTACTGTCTTTTATCATAGCTGATATAAATGAAGCCCCACTTT
TTTTGTTTTCAATTACTGAAAATTCAGTGCTAAAAAATGTGGATTTTTATTCACTAGATAAAGTACTACAATTAG
GTTTCCACTGACCTTGGCTGTTTTTGTTCCTAGTTGCCATTACATAAATCTGTGCCACTCACAACCTAGGAAGGGTG
TAACATTCTCTGTAATAGTTTGCTTTTGAATAGTGTGGATTCTACTGTCCCTCGCAGTTTGGAAATATGACC
ACTGAATAATCAGTGTTTTGGAGACTAAATAGTGTGCTGCAAAATTCCTCAAATTAACCTACTGTCTTTCCCTGTG
ATGTATCTCATATTCACTATGATTACCTGAGAAGAAAGATATTGTTGAGAACCCTTTACCTACTCGAAGTTTTG
GTATTTCAAAGATTCACTATTATGTGATGTTGATTACATTAGCACTAATACTATTGGCAGAATTTCAATTCAGTTA
TTTTCTTTTTTCCAATTTCTCTCATGCTATGTGTTGTCCCTTCGAGCTATAAAGCCATGGCCGATTTCATGGGT
GCTTTTGTAAAGCGTTTCAGCAGTCACGTTTGTAGATTTTTGAATGGGACTTAGAGCCCTTTTTTGTCTTTATGTA
TTTCTATTCTCAGCAAAAGGAAATGCAGACATGCAAGAAATAGTGATCAAATGTCCTGTGACTATTGTGGGTGT
CATTAATGGTATAGGAGAAATAGAAAATAGTTGCAAGATGCATTAAACAAATAAACGAGGCTTTGAGATTACCA
TGAATGTGGCCCTTCTATGAAAAGTAGTTAACATCCAACCTGCAAGTTGTACTGGATCAGTTTGACTTTAACCTTT
AGCTAATATGAAAATATGGAATTGTGTGGTGGTGCTCAAAAAAGAAAACCTCATTTTTCTTAATTATCATCAATTA
ACATGTACTGACTACCCATGAGGGAAGTTAATTTGCTCTTGAGTGGAACAGTTATTTGCCCTATTATTTCTCCCT
TGCTTATTTCCCTCTCCCTCCCTCCCTTTCCATTCAAAAGAAAAATAGATAAAGCAATTTCTGATTAGCCAG
TGAAAGCCTCTACATAAAAATTTCCAAAGATGTGCCATAAATATCCACAAAATGTAAAACCTTTCTAATTTTGGTTT
GCATTTTTCTTTTTCTTATTATAAAGGTAATAAGTGCTCATTATAGAATTTGAAAAATATAGGAAGTTGCACGGAAG
ACGAATAAATCAGCCATAATCCTACAAACCTATTGACACTTGTACATATGTTTGTATCTCTAATGCATTCTATTAT
GATAATGCATCTTTTCAACCAATAGAGTAATCACTGGTGACTTTCAAATTTGCCTACTCATTTTTCACTCTGTGGAC
TTACTTTTACTACCTCTTGCCCTTTTTTCAGTAAATGAATAAATTTAAGTAAGTAAATACAAATGTAATAACTTATG
CGCTCAAGCACACAGATACACACAGAGAGAAATTTGGAACCTCGGAAATGCCATCCTCTCCCTAGGGCCGCAAGTGAG
TTGATAAGCACGTAAAGGAAGGATAATCAGGGGAGCCTTCTCGTATTGCCAGATGGCTCAAAAATTCGTATCTCTAC
CAACAACCTATTGAGCTTTGAAGAAATATCCATGACCCCTTTGAATCTTTCAGTTTCTTTTCGCGTTCACTTTGAG
AACCAAGTGACAAGTGAATTTCTGACTTGGTCTTTTAAACCTGTAGCGCAGTTCCATTGAGATTTTGTGGGCACA
AGATTGCAATGAAGAGATCAACAGGGAGAAATTCATTTCCCTATATATGTGCGATTAATCCGGAGTGCTAAGGGCAG
ATATAAAGCAGGTGCCTACTCTGTATAACTTGAATAAAAACCTTTCCAAAGGCTGATGATCCTCAAGTCTTGTTT
TGCAATGACTGATGTATAACTTCAGGCCAATTTTTCTCCAGTTAGTCTGTGTCACTGGGAGTCCCATTTCTCGGG
AGCAGCCCCATGCTTTGTGAGGTGCGGAGCCACAGAAGGTTAATGCGAAAAGAAGGCCTCTTGCCAGACTGTTTTT

CAGATGATACGTAGGGTTATTAGTTTTGAGCTCCTTAAAGAGATTTTTCTCACCTGTCCTACCAACTTATGTTTTATT
CATTGGTGTAGAGGGTTTTAGTGGCGGAAGTAAATATTTAGCGGGGAAGGGACAGCGTTTCATGGGAATTTTGCCCT
AACTTAATTTTGTATCTTTAGCTCATTCTAGTCACTTTGTGTTTTGTCAACTGAATTTGTTTTGCATACAA
AGGCACAAAATGTTTGCTTCAGACCTGTCACTCTTATTTTTAGCATGGTTAGACAAAACTGAGATGCTTTAATGT
CTAACTTATCCAGTTTAAAGTGTGCAAAATCTCCAGGCAATGTCATGGGCAACTAAGGGATAAAATCAGAGATTT
AAAGGTGCCAGGTTTTCCACGCTTCTAACAGTTGGCGTTTTGGGTGTATAACAATCCCTCAGCTTCTTCTTTAGTTT
ATGGAGTCTTTGTGGAGGGAATAGCAGGTTTTTAGCTAAAATTATCATGCTGTGAGTTGGGTCTCTAGTGCATCCTG
AAGAGCTTGCATTATTTACAGAGGCTGGGCTATCATTTTAAATCCTGATGCTTCAATGCCCGTTATCATTCTTGACA
AACTCTTCCAGCCCGTGGTCTGTTTTCTCTGTTTGTCTCCATTTACTTTTCTGAGCAACCAGCTGAGCAAAAGATTT
ACATAACTTTTTGTTTAAACAAACCCCTGTACAGTTCACTCTTTCAGCCAGTATGTAAACACTTTTGAGACACAGTTAC
ATTTTCTATTTTAGTCCAGATTCTGTTTATTTTGCTACATTTTTTGTGCCACATTTTTGTCTTTGTTAAGTCTCT
TACAGATTCACATGAAAAACCGAAGCCGTGGCTGCTCAAAAGTCATTAATAATGAGATTTTTAGCTACTGTTCTG
CTTGTAATTTCTTCAATTTACATAATACAGTCTCAAAAGGCCACAGAGAATTCAGCCTCGCTTATCTCTGTGTGCA
GATGATGGCTTCTAGCCTTACCCAATCCAGTGCAGCTTGCTTGCCATCCAGGAGTCAATTTGTTTCCATCTGACA
TTAGCGTATTAAGAGATTGGAGATCAACAAGCAACATGTTCTTGTAGAAAGGTAATCAAGGTTTAGAGCCTGTGT
GTCATGAGACTCTAGCATTGAAACCGCTAAGGGGTTGACCACCATTTGCCAAGCACCTGTTTAAAGATTTCTTCC
TATGATAAGGACCTAAAGTGATTAGCATATGATAAGACCAATAAGATTATTTTTACCTTGGTAAAGAATTTTAAATT
TCAAATCTTAAATTACCATCTTTTCTTTTACCCAGGGTCTTCTTTCTACCTCTACGACACATTTAATTACCTATATTC
CCCAACCTGTACCATAATTAATTTTGAATGGAAGTTTTATAGGGTAATTTATTGGAAGGATGGCCTTGAGTGTCAAT
ATGTTCAATGAATGCCCTATTTTGACAAAGAGATGACTAAATGTTATTGAAATCTTTTAAATCCACCACGCTTCTGC
TTAGATGTAATGCAATCTGTTCTTTACATTTGTGATTGAATTGAACCTTGAAGTACCGCCATATTGATTCCTTC
TGCAATAAAATATAATTACATTTCCCTAAACTTTCTACACTCTCCCAAGAGATTGGCTGGCTTTGTATTGTAGATT
TTTGGTGATCACAGAGGACAATGCATTATCATAAGACCAATAAGATTATTTTTACCTTGGTAAAGAATTTTAAATT
ATTTCTAGTTTCATTTTCAATTTATATCCATCTCTTCTCACCTCTGCTCTACAAAAGTATATATGACTATATAAATT
GAAAAAATATCAAGTGCAAAATTACAGAAATAAATAATTAGGTTATTTTAGTGGAGGAAGGTTTGTGTGGGTGGA
GGAGGAGAGGAGTGAGCCAAAGAAAACGAGGGACCATACGTGATCATATTTTGCAGCTATTTTAAATTGTTTGTGT
ATATACTTTAAATATTATAAAATAAAATTTTAAAGTCAATGCATATTTGGAGCCAATGATGAGGGATAACTTCAGA
AACGTGATCATCATCTAGTGTCTTTCATAGTCTTTCAACATTTCCAGATAGTTTAAATGGCCTGCTCATGGAGGC
AATGCCCTAATTTTAAACATATCTCTTCCAACTCTGATTTCTTGGCTTCCTAACATTAAATGCTTCAAGCTTCTTT
CACCATAATTCTTATCAAGAGGATAAGCCAGTTTATTCTTAAAGAAAACCTAGCTACACAAAACCGTAAGTCATT
CCAACATAAATCCTTCACTATCCTCTCTATAGATTTGGTTTTGATTCTCTCTGCTGAAATTCACCTTCTTTCTT
CAGCTATCCACACGCTTACCCTCTAACTTCCCTCAGGAGTGTCTATTAGCTCCATTACAGTGACCACAGTAATAT
AGTAATCCCTGCTGTTCTCACTCTCCACTTCTTACACTGCGTTTTAAGTCTCTTCATATTTCTTATCACCTTGTA
TCATGATCGGTTTTCTTAGTTGTTTTATTTATGTTGCCTTCATAAATCCATGAGAGCTCACTGCCGTATCTTTAG
AACATGGAACAGTGCTTGGAAACATAAATGGGCATTCCCTTAAATAGCTGTAGAATAAACTTTCAAAATCAACAATAATG
TATTTGCCAAATCCATTGGCTTCTCTGCCATTTTATCTTGTTCATAATCACTGCGATATTTCCCTTCTTTTTTTTT
TTTTTTAAAGTCTGTAACCTTTAGCTTCTGTAATATCTTAGTTTTTTATTTCTCTCATGTGTCAAATCATCAGT
TGAGGCTTATGTTTTCTTCTCTCACTCTGACCTACCTTTGTTTACATCTCATCTTCTGGCTTTGGCTATCTGT
TTTTTATCTCTGTTCCAACCTGTATTTCTAGCCCTACTACCTGGACATGACATGTGGATATCTCCGTATGACCCGAG
TTCCATATGACTTTGCAAAATTCATCCCTGCTCTCCCTCCAAAGTCATCCCAACAATTGACTTCCGTGTTCCCTTCCA
ACCTATTAAGGTTCAAACCCACTTTTGGCTCCTCTTTCAGGCTACACTTTTCTCTCTCAGTCTTTTTTTTTTCTC
AAGTTCTTAGATAAAAGTCATAGTACCTTACGTTGTAATTGCCACTGGTCTGGTCTTTCTGCCGTGCTTTCTTTTCCA
TTTGTAATCACATTATCCATTCCAATCCATTTATAACTGTGATCAGCCATAAAAATAACATTTATCATATCGTTT
GTCTCCTTAAACCTGTAGTAGATCCCTCTATTTACAAGATCTGGTATAAAATCACCTTCCGTATTTCAATGCC
TGTTTTAATATAATCTCAATATTATGCGTCATAAATCCCTCTGTGTTCTTGCACTTTTTATTTCTTATACATCTCAT
CAACATGTCTTATCAACTCTCAAACTGTATTGGTTTTTCAGGAAAACCTATAAATATTCTTTTGTAGACCTTTT
GTTTGTATCTTTGAAGATCTCTCTCTGAACCTACAATATTTGTCTGTATAATCAATTTGGAATTCATCAGGTATT
GAAATATGACATGTCTTCTATTGTCTTGAACATTAATTAACCTTTATTTGACTTTTTATATGCTTACATCTTGTTT
CCTCACGGAGTGTTAACCTACTAGAAAGTAATAGTTTAACTTATATTTATTTTAAATTCAGATTTAGTAGCATACTT
TACACGTGGTAGGATGTGTAACCTGCTTACACCTTGCTTACGTGAGTTATTAATGTTTTCGTATATTTAATCTGAGG
ATGTACTAGCAATGTAAACTGTACCGCATGAAATTGAGTAATTGAACATTTGTTTTAAATGTGTGCTTAACTT
ATTGTACCATTTTCTCATAATCAGCTCAAGTTAACTTTGTGGTTGTACGTATTATTTCTTGTGAAATGCCAACAA
ACTTAGAGCAAGGAAAATAACAGGTATAATCATACTATAAAGGCAACCTTAACTAGCATAGTCTCTTAGCTCATA
TGGTAACCTACAATAATGTACAGTGACAAAGAGAATATTGTACTTTCTTAGCACACACTTTCCTACTACTCTACTGTT
GTGGATAAAAAACAGACATACTTTAGGAGAACTATGTTATTTCCAAATAATGCCTTAAAGGTTACTCCAGGAAAAGG
CATTTACATAAACTATCTAGGAAAAGAACCTTTTAAATAATATAAAGAGCTCACCCAAAAGGACTGAAGTGTTTAGT
TGAAAAAAGTAAAAATGTGGAAGACTTTGAAAAATAGTTTCTTGCAAGTATATTTTCATCGCTTCCACTTACGTTAT
GAAGACATTAAGCGTAGTTTATCAAAAACCTATTTTGTACATGTCTTCTAATGACAGAACTAATGTCAACATGATT
TCATCATTTGAGAAATGCGTAAAGAAACCTTTGTACAGTTTTTCTATGAATGTTCCCTAAGATTAAAGCAAAATTC
CAACACGAATTAGGCACTCCGAAAGGAGGAGGGGAGGGGAGGCAAGTGCTGCAAACTTCTGTTGGGTACTAT
GTTCACTATCTGGGTGATGGAATCAACAGAAGCCCAACCTCAGCATCACGAGTATACCTTGTAAACAAACCAACA
CATGTACCCCTGAGTCTACATTAATAAATAGAGATTAATAAAGGAAATCAGTATATAATCTAATAAATACCTCTCAA
GCTTCTCATTTTTTAAATAAATTTTAGATTATTTTATGGAATAAATAGGCTCTTCATTGTATATAAGTTCAAT
TTCTGAGTTGCAAAAATCCTCTCTTTATGTTTTTCCCGTATTAGCATGTTTTCTCTGTTTTTCCCACTCAA

127

TCCTCTCTCTCCAGTGTATAGCTTGCAAGCAAGTGCATGTGAAATAAAATTAAAGCCTTGTTTGTGTTTTTTTCATC
ATGTGAGTACAAGACTTTTTCAATAAAAAATGAATTACTTTTGAACATATTTGTTTGGACAACAAACAGAGAAAAGAT
CTATTTGATTGATAGTGGACAGAATTTTCATTAAGTTCAACAGCAGAAAATACCACAATTGCATCATTCACCTTCGTG
TATCAAAAGAAAACAGAAAATTAGATGTGATGAACCTACACAAATGTTCACTATGCATACCTTACCCATTAAATAC
ATTATCAAGAATCATGTCAGCATGACATTCTAATATAGCAGCTTTACAAAAACATGTAATCTAATCTAGGGATGCTG
TTGTCTCTTTAAATCAGCTTCAAACATATTTCTGGGTGATATTTCTCATTCTTTTTTGATCCACATTGTTTATTC
CATAATGATTATATTTAACTGAAGATAACAGCATTATCAAAGTGAAAGACAAAATAGATGTTTAAATAGGAAAGTGAG
TATCGAATCATCTTTTTTCTACCAAAAACATCTATAATTATGAAGTATTTGGTTAATTATTTTCAACAATAATTTAAA
AGTGTACAACCTTGCCGATTTTTTTGTACTTTCTACTTTTCATGTCTCGCATATATCTCTTTAATATCTAAGTATTTG
AGTCAGAAAAGAGCCAGTACCGAATAATGGGAATCTCACTGAAATGTGATAACAATCTGGGGCCTGGTCTGGGACC
TTTATCTGCAGGACAACCTTGACAAAATATTTAGACCCCAATTCCTCGTCTTTACCCTAGGAATAATAACACATTTT
CTGACCTCATACTTCACGTGGATCTCAAATGGAACAAATCATCTGATAGCACTTTATGAAGTATATGAAGCAATAA
ATTATCACAATAAGATAATTGCAATTATTTCTTTGGCATAGTATTAGTGATGTCTTTATCTGTCTGACAAAATCAACA
TTTCTGTATGGTAACCTGCTTTCTTTGTTTAAACAGAAAGATCATGCCAGAAAAGATGAGTAGGTAGATACCTTAACCT
GTTGTTCTCTGAATCTGGAATGTATTGCAGATGTCCAGACTGATCTTTGTTCTTTTTTTCTTTACAAATTTCTTTT
CACATTGACAGTGTGATATTTCTTTAAATGTGCAATACATAGCTAACCTTATTTGTTTGTGTTTACTAATTTAAAA
TCTAAACTGCTTCAAAAATACCTTTCGACATTTTCTGGATATTGATACAGTCTAAATCTCTTTTCGGAAGACTCCCT
GTAGTATGTAAACAAAATTTCAAACATAAAATGAAATATTGAGTTTTGTATTAAAGCCAAGGATGAGGAAAAAAG
TAAGTATATATGGAAGAAAGAAATGGTATTGAATGGGAGTTTTGATGGAGCATGTTGACATCATGATAATACCTATTAT
CTTTATATTTCTGAATGTGCAACAAAATTAGAGCAATTTTCCCTTATTTCCCTACAATACGCTGTCTTAATTAATTC
TAAGCTTTCTGTATTTCACTAGTAATCTGTATTTTGCAAAAGGCAGCATGTTTATAAGATATCAAGTAACTAAAGTT
TATGGAACCTTGAACAGCATTTTAAACAACATTTCTCCCTAGATAGTTTATGGTAGACATGAATTTATTTCAAACTA
GTATGTAGAAAAATACCATTAACAAAAGCTGTAAGTTTATTTAGAGGAGCTGAATAATGTTACTTTGAGAAAGATA
AAATGTTATTTATGATTTTTTGGTATCTTTTACCCACTATATATGGCCATATCTCTGAAAACTTTAGTAATATGTAC
TAATGCAAAATATGGTAGTAAATATGTCTACAGGTGCTGATACCATAGTAGATAAAGTATGATAACTTTATTTTAAA
ATATCATATTTAAATAATTAATATACAGTACTGGGAAGACTATTTATCTATTCTCTCACTCTGAATAAAAAAAT
CCAGAAAAAATACCTTGTTTTGGTAAGATTATATCAATTTATTTCCCAATGGGTAGAGGGTTATTTTTTCTGTAT
CATAAACGTATGTCTCTTATTATAAAAAATCCACTAAAAGTGATAGAAGAAAACCAAAAGATAAATGTAACAATG
ATGCCATTTTCCAAAATACCTTTCGACATTTTCTGGATATTGATACAGTCTAAATCTCTTTTCGGAAGACTCCCT
CCTGTGTAGTTTCCCAACTACTCTGCAATCTTATTTCTCTGTGTTCTGTAGAAAGGAGACCCATTGTCAC
CATGTCAAATAACACAAAATGGTGCACGTATAAGATCATTGTCTCTGTCCATTATTTGCCAGAGGACCTCAAACCTT
TTCAGGTGGTGGGCAACTGGATGTCTGTCTCTCTGTACAACAGAACACAATTCATTATTTATATGGTTATTTCA
TTTTAAGAAAATTTAACTTTTATTAGCTGGAAAAAAGAAAGTGGTTTTTAAGTTGTTTGAAGATGTGAAATTCAA
TTTTCTACTGCAAAAGAGATTCAACTGCAACACAGGCACACATGTCTGGTGTAAAGACGAGTTGTCTACAAACC
CAAAATTAGCTGCCTCCACGTGTCTTTTGTAAACAGTGTGTTGTTTGTCTCTTGTTCCTATTCAGAAATGCTCTTT
AGCAGGAATTGATGGAACACAGTGCAGTGACCTCTTCTGTCTTTAAAAATCGAGATGACATTTGCCCATCTGCAG
TGTTAACATAGTTCTCAAAGACCACTGACAGTGGGTAGGACTGTATTGCGCAAGTTCTCTCATTTCCCTAGAATA
TAATTGGTCCAGGGCCAGAGATTTTAGCTCATTTAGAGCAGCAAGGTGCTCTTTAAAATTCCTCACCTATTTTGG
GCTTCATTTCCCTTATACGGTTATGCCTTTTCCAGTCTGATGAACATTCTCCTTGACAGAGCAGACAAGCAAAAGGA
GCTGCACATGCTGCTTTCTGTGTCGTCTCTATCCCTAACCTTCTCCCTTCTGCCCAATCAGTGAACCTTCGTCTT
TCTGGTTCTTCTTCTCCTCCAAATGGAAGTAAAAAGGCCCTGAATGTTGTCTTTTACCATTATCACGAGCCTCAATTCAT
TCCAAGCTCAGCTTTTCTCACTGTTTATACAGTCTATATTGTTCTTCTAATATTTGCCCTCAGTTCTCTGTCCCT
CGTTTCTTCCCATGTTTCATACTCTATTAGAATCTGAGCACCTTTGAGGTTGTCCATACAGTGGCACACATCTTTGTT
TTATACTCACTGGGATGATTGCCATTATATTGTCAAATTTTATTCTAAAGAGCTTTTACAGCTTTCTTGAGCCA
TTTTCTCTTGAAATTCAGATCGTTGAATCTCTACGCTTTTCTCTTCTAATCTAATAAACATACACCCCCACATAC
ACAGTGTGTTCTCTGAAAGACAGATGCCACTTGACTCGTCTTATAGATTGTCTAAATGATCATTTGTGTGGGGAT
AAAAGGGTGAATTGTATAATATCCCTGATGGTTTACGAGTCTGTTCTGTATAACCTGATTCATTTCTGACTCT
TTTAAATCTGTCTGCAATGACTGAGGTTTGGCAATCAGCCTATTTCAAGTTAGTTGTTTCTTGCAATAAGAGGGT
CCATATGTACTGTGTGAAGTAAGAGAGAGAAAGTACTTAGATTGCTGGATGCCCTGATTGTTAGCATGGCTAAGGT
ATTGTGTAAGTAAGGAGAGCAGTTAAAAATGATATTGTTTTATTTCTTAATTGAGGTAAATTTTATATAAGATGA
AACAGACTTATTTGGGAGAGGAGGAAGAGTTGTTCTTACATAACATTTCAACCTGTCATATTTAGTTGAGAACTTC
AATCTGTCAAGATATTTGTATAAATTTCAAGATTCTGACATTAATATATTTTCCAGCTTTTCTACTGGGTGTGAC
AGTAACTTATACTGTGGCAGGTGTATAAGTTAGTAAAGATATTAATGCTCAATCTGTTAACTTTTGTGAAGTGGTC
CCACTGATAAAGTGACACCTCAATAAAAAATAAAATTTCCATTACCTCAGAAAGCTTTTTCATGCTACCTTCCAGTCA
ATTCCCAGCCCCAATAGGCACCTATTCTTCTGATTTATATCACCATAGATTAGTTTGTCTTTTTAAAAATTTGTAT
AAATGAAATCATACAAAATGTACTATTTTGATCAGCATACTACTTTTGAGATTCAATCCATGTAAGTGTATCAGCTGT
TCATTCCTTTATTGATGATTAATATTTCTATTGTATAGATATACCACAATTTATTTATCTATTCTCTTTTGTATGGAC
ATTGAGGTGGTTTCTAGTTTGTGCTGTATGAATAAGATGCTGTGGACATTTGTGTACAAGCCATTTGTGAGCATA
TGTTTTCATTTAGTTTGAAGTAACTCTGTAGAAGTGAATGGCTGGGTGAAATGTTTAAATTTATGAGATATTGTCAA
ACAGCACCTAAACAGTTTTCTAAAGTGGTTGTGCCATTTTGCAATGCCACCAGTGATGATGGAGAGTTCCAGTTACT
CTACATCTTTGTCAATATTTGGTCTTGTGAGTCATTTTAAATTTTGTATCTTACAGAATATGAGGTATATTGTTG
TGGTTTTAACTTATATCTCTGATTACTAGCACTATTAAGCATCTTTTCATGGATTTATTGGACATTCATATAGAT
TATGTGTGTTGAAGATTATTACCTTTATGATTATTGGGTGAAATAGTATCATTTTGAGGTCAATTCATATAACTTGA
AGACTGGGAATGACAGACATTTTCTGTTTTGTCTTTTCTTTTACTTTTATCTGAAGAGTCTACTAGAATGCAGT

GTGCTGCCTGAGCAGCAGGGCATTAGCTTTGTAAAAGCTCTGTTCCCTTGGCAACCCACCCTAATATGAAGTGCA
GAACATTTGAATTGCTTTTGACCAGCTTCAGCATCAGCACTATTTTTTTTTTTTGTAGACCCCTAGTAGGTATTTA
AAAGTACAGAAATAGAATTTAATCATGCTTTTTACCAGTGTGCTATGCTCTTAGAGATTCTTTCAACGTGCATAAA
AATTCTGCAGTTTACCACATACCAGTAAAAGAACTCAGTCACTCATTTAGCCATTTAGTAAAAAGAACAAATTA
CTGATGAGCATAGTGGAGACCTCAAAGGTAAAGAAGACAATGTCCCTGAAATAAAGACAATCATAATTTTCAATCA
AAATAATGAAATTTAGGCTGGGCATGGTGGCTCATGCCTATGATCCTAGCACTTTGGAAGGCTAAGGTGGGAGGATT
GTTTGAGGCCAGGAGTTCAAGACCAGCCTCAGCAAAAAAGTGAGACCCTGTCTCCACAAAAAATTTTAAAAATTAT
CTGGGTGTGGTGGTATGCACCGGTGGTCTCAGCTACTCAAGAGGCTGAGGTGGAGGATCACCAGAGCTCAGGGGTTG
GAGACTACAGTGAGCTATGATTGTACCCTGCACCTCAAACCTTGCATGACAGAATGAGTCCTTGTCTCTAATAATAAC
AAAAATTAATTTTATAGACTGTGAAAAACCATTATGTAGATACAGTTCAAGTACAGTATGATTTTATAGGATAGAT
AACTTTTGTCTGAAAATGTATTTCCCAATTTATAGGATAGATAAATTTTGTCTGAAAATGTATTCCAATAGAGTTAG
TATTTGGGGCAGACCTTTTATCCATTTAACCAACATGTTTTGAGCACTGCCAGGTAGCAACACGTTACTAGGCACTAG
AGTGAGAAAAAGATTACAGTTCTCTGCTCTCATGGATCTCATGGTCTAGTCAACTGGAATGAAAGGATTACATAAGTAG
AGGTAAAGACACACATGATGGAGGATGGAGAATAGTCAAAGGTCTGGAGAATGACCAGGACGTCACTGTGAGTTGTC
TAATTGCACTGAAGCATGGATGAAGAATTGGAAGTCAATTGTAAGAAGCCTAAAAAGGTATCTCTCAGGGATGCTAT
GAGGTTCTGAATGTTATGTACGCTATTTGGGCTTCAACAGGCAGGCACTGAGTATTCAGTATAAATTTTGGAGCAGG
GAATCCACCAGAGAATATGCATCTGGAGGATTAATTGATAAGAAAGTAAACCTATAGTTTTCACCCTCTTTTACAAATA
GAGATGAAACAGTTAGGAGGGTGTATTATAACATAGGTGAAGTGAATGAATAACCAGGCTGGAGGAAAAGCAATA
ACGATGGAATCAACCGGGCAAGAAGTATAACAATTAGGATCAGTAAAATAGAATTTGGATTGGAGGAATGAAAAAA
AAGGGACAAAACAAAGTTGAACCTGCTGGTATCCATCTGGAATAACAGATGTCATTCAAATAAATAATGTAATGAA
TATAAGAAACCAGTTTTAGGAGTGAAGTGGATGTTGGCTTGAATAATTTTCTTTGAGGTTTTCAGTCAAATGAAAAG
GTCCTGAAATGCTACGTGGTAGCCTAAGAAGGAAGCGTTCTTAGAGAGAAAAAATAGAAAAAGATTTACATTTGAT
AATTTAATCTTTTCTTATACAAGCTAAATTGATAAGAAAGTAAACCTATAGTTTTCACCCTCTTTTACAAATA
TCCCTAACCTTTTAGATATTCACATGAATAATTGAGAAAAATCTAACAGATGACTTGCTTATGTCATTTGTCTGCTT
TATCCTTAGGTTCTCTGGCTTATATATTGTTCAATAAAATACAGATCATTGATATTGTACAATGTACTGATAATGG
GGAGTGAATCCATGCTTGTGCATTCTTTTTTTTTTTTTTTTGGATTGTCAGAGGGCGTGCCAGTCAACAAGAGAG
GCACAATTGTTTTATCATCACCTCTTCTCATCTAATTCATGAAGGAGAGTAGTATTACCATACAACAGATAATGA
GTTGAAAAACAAGAACTAACCTCAGAACTTAAGGCTTGGGGAAAAATAAAAGAGTAATTTGTGTTAATGCCTGT
ATAACTTGGCAAGAGGACATATAAGGCTTAGTGATGCCAACATGTGCTTAGATGTGGATTGTTAGTGTCTCTT
GGGGGTTCTGTAATCTAAGCTAAATGCTCAAAATCAATTAATTGATGTTAGACACAGAGATCTGCTTTGATCCCTCT
TTATCGTATTTCTAGGCCTTCCATTCTCAAGAGCCTGAGAAACGACAGCTTTCCTTAATAACTTGTTATTTGTGGT
AGGAGATGAACTTTGATAAAAAACACAATTATTTTTAAATGTCTCTTTTCACTCTAGGCTGTTGTATGATTTCAA
AAAGTTACTTTTGACCCTTTCCAGAATGAGAAAGCAATCAAGAAGATTATAATATCTTGCTTAGTTTTCTGCTCAAT
TTATCAACAAATATTTCTTAAGCAATTATTAAGCTGAGCAGTGCTCAGCGCTGTACTTGGTGATATAGGAAATGGGG
AAAAGACTGTCTTTAAGGCCTTTATAATAGTAATTACCTCAACTTGCTGTTTTCTTTCCCTTACCATTTCGCCAAAT
TCATTGATCTATCTTGTTCTCAAAGCAATCGCCATAGTTATATTGTAACACAGCATTTTCTAGGGTGTCCCCATTAA
GTTGAGAGTGTGACAAGAAAAATACAAGCTTATTTATCATTGTAAAACCTTGAGACACCTAGTAGTTACCCTAAATTA
AATATTTGTTGGAGTCAGTCACACTAAAGAGAACACTTACTGCATTGAACAATTTACCTACATTAGACAGCATTTAA
AGACTATGCCACAGCAAAGGCCATGGAATCTTGTGAACACAGAATAGAAGTGTATTAAGGAACAAGCTTAATCTT
GTTCTCTTAAAGCACAACTTTCTCAAAACATATTTTGAAATCACCTTTGACCATTTTTTTTAACTAATAGGTGGG
TGGGAGTTAGGTTAGGAAAACACAAGCAGCTTCATCAAAACGATATTCTATTTTCTTCAAATTTGTGGGGAATCATA
CGGCCTCTCAATTTTCTACATTATGCTAATTATGATATTAATCTCTCTGCCAGCAAATGAAAATAATACATATTAGA
TGTAGCAAATGTCAATAATGACAAAATTAGTCATCATGCAGATACTCAGGGATTCCCAAATATGTTTGGATTATGA
TTGCTAGCTTTGAGTTTGCCAGAATCGTTTCAATAAAAAATAAGGGACTCAAACACATTTGGAGCAAACTCACATC
ATAAATTTTAGACATAGCTCTGCCAATAATGCTCTCAGTTATATTTTCAGTCCTAATATTTCTCTGAGTTCCAGAC
CAGTATCTTCACTGTCTGATTGATACTCTCTCTTCACTTCTGTCTCCAATGCATTAAGTCCCTGTGATTTACTTT
CCAAATGCCACTTTGGTTCCATGCACCTTCTCCATTTCTGCCACTGACTCCTCCTCAATCCAAGGACCATCTTTCC
TCACTTTAACTACCATGATATCTCTGCTTGGTCTCTTACTTCTATTCCCGGGCTCCTCCAATCCATTATCCTCC
AGCAGAGAATGATGACTAGCACCTTCCACAGTGTCTGGCTAATAGGAGGTATCCAATCAATAATTGACTTACAGAGT
GAAAATATAGGCATGGCAATACCAGTAGAGAACTACAGGGTTTTAGAACCAATGACATTAGATACTTCCATCAAAAT
ATTTACAGTGTATAATCAAGTTGACTTGCACATTTGTCTATTTTGA AAAACAATTTGTGGCTTTTTCTATATGC
ACACATATATGATCACCCTCTACCCGCAATGCTTTTGAAGAAGTATTTATGTGGTCTCAAATCTGATATGATA
CCTCTAGAGAGAAGAGAAATTAGAAATTTTAAATGACCTATGCTTCTTTTGAATATCACGTCCTGAGACAGTGTT
TTTTGAGTTACGTGCAATATGTTCCACGATGAAACATTTAATGTGTTTCAAGGCATGCTAGTAATCATGTAGAAAGA
ATTTTATGCCTGAAGTCACATGTTCTATAACCAGGATCACTTAATAAGAAAACAAGTACAGCTGTGGACAAGATGCC
TTTTTATCAGGGAAAGGCCAATTTGTTTTCTTTGCAATCTAAGTAAATGGAGAGAAAAACACAGCCCTTAAATGTT
TTCTATTTGTCTGAAGTTCTCATGAATGAGTTAGAAGGCAGAGGATTAATAAATCCTTGAACGTAGAGAGAGC
TAACATTTATTTAGCAAACTAAACCTATTTCGTTTGCAGAGTTCTGTTCTGTACTTTGTAAACAACAGTTTCTTT
AAAAACAAGAGCCACCAATTCAAATGCCTTTACAGAATGATTGAATGCTTTTATGCCACCTAAAGGCATTCAAATC
ATTAATCAAACAAAGTTCTAACGCCAAAACATGTCTGGGACCAGATTTAAATGTAGCCCTCAGTTTCAGAGGGCAA
AACTTAACATATTTATATTTTCTCACTTTAGGTAACACTGTATTGAATCTCTGCTTGAATTTGAGGAGCAGTGTA
TTTTTTCTTTTTGGCCCAGGGCAGCATTTCTTGAAGAGAAAGAAAAACAACCCAGATACCCCTACAAAACATGTA
GTACTTAAAGCTCTTTATGATGAATTAATTTGGTATACACATTAATAGCAGTGATAATAACAAATCTATATATATA
TATATAATTGATATGAATAAGATAAATACATCAAAAGGAAATTTCAATACAATTTGATATTAGGTAAATGTCCCAT

130

TCACATGTTTACTAGAGCACATCTCATGGGCATTCAAGAGAGTATGGCCAGGACAGCTTGTGAATAGTTCAGTAACT
 GTGCATAGTTTTATATTCATTGTGAGGCACCGTGTCCCGGTTTGTGATTTACAGAGTATTTTAATTGCTAACTGT
 ATGCTACCAAATTTCCAGTATTCGAAAATAATTTTCTTGAATGTAGAAAAAGAAAAAGCCAGAAATGTATGTG
 AAACGAGAGTCTAAGGGAGCTTTACCTCAGTCTCAGAAAACATGCATTCCTTCCTTCATTTAGGAAGCATGTACTGG
 GGTCTACTGTGAGCTTGTATTTGTGTCAAGGAGTAGGAGAATACAAAAATATTAGAGAATATGAATCACATCTATTA
 GGAGAGTTTTCTACATACGCACATTATTCTGTCTAGTGACATAAGGATTTGAGTCATTCAGATTTAAATACGGTAGGT
 ACCTCAAGTTCTCAGATATTATTTCAATTTCTAAGGTTCTGATTTAGTTAATATGTTATTTTAATGGCCTTACAAAT
 TCTAGATTATCTTTTTTAAAAAGTTAAATAGAACGTAATTGCCATTTTTATTTAATGGTAAAAAGCATTTTTGTTTT
 TGTGTGACTTGGTTGTAATATTCTCCTTTTCAATTGAGCTATTTTTCTGATACTTACTCTTAAAAATTCATTTCAG
 GAAAAAAGTAAACAATATTTAAGCTTGACAATCATAAAAAATGCTCTGGTGACTATAGATTATTTTAAAAATTTATTAC
 TGTAGCTTAGGGATATCTTGATGGGATGCTCCTGAAAGCAATTAATCTCAGTTTTTGTGGCTTCTAATGCAAAAT
 ACATTGACGCAGACAGAATTTGAAATGAATTTCTTCTAATATAGCAATTAATTTTATTTAAATATCTCTAGAGTTT
 TTTTTTAATACTGTGACTAACCTATGTTTGTCTTTTTTACCTCTCGTATCCACGATCACTAAGAAACCCAAATACT
 TTGTTTCATGTTTAAATTTTACAACATTTTCATAGACTATTAACATGGAACATCCTTGTGGGGACAAGAAATCGAATT
 TGCTCTTGAAAGGTTTCCAACTAATTGATTTGTAGGACATTATAACATCCTCTAGCTGACAAGCTTACAAAAATAA
 AAACCTGGAGCTAACCGAGAGGGTGCTTTTTTCCCTGACACATAAAAGGTGTCTTTCTGTCTTGTATCCTTTGGATAT
 GGCATGTCTAGTTTCATAGGGAAATTTTACATGGAGCTTTTGTATTCTTTCTTTGCCAGTACAACATGCATGTGGT
 AGCACACTGTTTAATCTTTTCTCAAATAAAAAAGACATGGGGCTTCATTTTTGTTTTGCCTTTTTGGTATCTTACAG
 (SEQ ID NO: 958)

[000208] *Homo sapiens* dystrophin (DMD), intron 44 target sequence 1 (nucleotide
 positions 1127695-1127744 of NCBI Reference Sequence: NG_012232.1)

GTAAGTCTTTGATTTGTTTTTTCGAAATGTATTTATCTTCAGCACATCT (SEQ ID NO: 959)

[000209] *Homo sapiens* dystrophin (DMD), intron 44 target sequence 2 (nucleotide
 positions 1375846-1376095 of NCBI Reference Sequence: NG_012232.1)

TGACAAGCTTACAAAAATAAAAACTGGAGCTAACCGAGAGGGTGCTTTTTTCCCTGACACATAAAAGGTGTCTTTCT
 GTCTTGATCCTTTGGATATGGGCATGTCTAGTTTCATAGGGAAATTTTACATGGAGCTTTTGATTTCTTTCTTTG
 CCAGTACAACATGCATGTGGTAGCACACTGTTAATCTTTTCTCAAATAAAAAAGACATGGGGCTTCATTTTTGTTTTG
 CCTTTTGGTATCTTACAG (SEQ ID NO: 960)

[000210] *Homo sapiens* dystrophin (DMD), intron 44 target sequence 3 (nucleotide
 positions 1375985-1376035 of NCBI Reference Sequence: NG_012232.1)

GTATTTCTTTCTTTGCCAGTACAACATGCATGTGGTAGCACACTGTTTAATC (SEQ ID NO: 961)

[000211] *Homo sapiens* dystrophin (DMD), intron 44 target sequence 4 (nucleotide
 positions 1376035-1376075 of NCBI Reference Sequence: NG_012232.1)

CTTTTCTCAAATAAAAAAGACATGGGGCTTCATTTTTGTTTT (SEQ ID NO: 962)

[000212] *Homo sapiens* dystrophin (DMD) intron 44/exon 45 junction (nucleotide
 positions 1376066-1376125 of NCBI Reference Sequence: NG_012232.1)

TTTTTGTGTTTGCTTTTTTGGTATCTTACAGGAACCTCCAGGATGGCATTGGGCAGCGGCAA (SEQ ID NO: 963)

[000213] *Homo sapiens* dystrophin (DMD), transcript variant Dp427m, exon 45
 (nucleotide positions 6683-6858 of NCBI Reference Sequence: NM_004006.2; nucleotide
 positions 1376096-1376271 of NCBI Reference Sequence: NG_012232.1)

GAACTCCAGGATGGCATTGGGCAGCGGCAAACTGTTGTGACAACATTGAATGCAACTGGGGAAGAAATAATTCAGCA
 ATCCTCAAAAACAGATGCCAGTATTCTACAGGAAAAATTTGGGAAGCCTGAATCTGCGGTGGCAGGAGGTCTGCAAAAC
 AGCTGTCTAGACAGAAAAAGAG (SEQ ID NO: 131)

[000214] *Homo sapiens* dystrophin (DMD), exon 45 target sequence 1 (nucleotide positions 1376124-1376176 of NCBI Reference Sequence: NG_012232.1)

AAACTGTTGTGTCAGAACATTGAATGCAACTGGGGAAGAAATAATTCAGCAATCC (SEQ ID NO: 964)

[000215] *Homo sapiens* dystrophin (DMD), exon 45 target sequence 2 (nucleotide positions 1376154-1376220 of NCBI Reference Sequence: NG_012232.1)

GGGAAGAAATAATTCAGCAATCCTCAAAAACAGATGCCAGTATTCTACAGGAAAAATTGGGAAGCCT (SEQ ID NO: 965)

[000216] *Homo sapiens* dystrophin (DMD) exon 45/intron 45 junction (nucleotide positions 1376242-1376301 of NCBI Reference Sequence: NG_012232.1)

CTGCAAACAGCTGTCAGACAGAAAAAGAGGTAGGGCGACAGATCTAATAGGAATGAAAA (SEQ ID NO: 966)

[000217] *Homo sapiens* dystrophin (DMD), intron 45 (nucleotide positions 1376272-1412382 of NCBI Reference Sequence: NG_012232.1)

GTAGGGCGACAGATCTAATAGGAATGAAAACATTTTAGCAGACTTTTAAAGCTTTCTTTAGAAGAATATTTTCATGAG
AGATTATAAGCAGGGTGAAAGGCACCTAAACATTAAAGAACCTATCAACCATTAATCAACAGCAGTAAAGAAATTTTT
ATTTCTTTTTTTCATATACTAAAATATATACTTGTGGCTAGTTAGTGGTTTTCTGCTATTTTAACTTGAAGTTTGC
TTTAAAAATCACCCATGATTGCTTAAAGGTGAATATCTCAATATATTTAACTTCAACAAGCTGAATCTCAGTTGT
TTTTCAAGAAGATTTTAGAAAGCAATTATAAATGATTGTTTTGTAGGAAAGACAGATCTTTGCTTAGTTTTAAAAAT
AGCTATGAATATGACTATGAAGCTAAAAAAGTGATAGTGTCACTTACCTCTAGTTTACCACATTTGTGAATACAT
TCTTGAAGGGGAACCTTGAGCCAAAGAGGTACAAGTTAATGGGGAAAAACAAACCTCAAAAAGGTTACTGTCAAATT
CAATCATCATTTAAATTTCCCTTGGAATGTATTGAAGGCACAGAAAGCCAAATGCGTGCTGCTGCAGTTGGAAAGCC
TAGAGAGTTTATAAATGGGATTTTGTATTATGCTTCCAGTTGTTGATGTTAATGTGCTTGTTCGTAAAGGAAGAC
TTGGCCTTTATTTACCAAATGAGACTATTGTTATGAACAATGAAACTTCGTTCTTTTGCCAAGCTCTTGCATCCCA
CCCATCATCCACATAATAGGTGGATTTTAATATTTCAGGAAGCTAGAACAACTCATTGATGAATATCTTTTCGTTAAGA
TGTATTAAGAAGATTTTGAATATTATGTCAGTTGCTTTGCCACCTCCTCTTTCCCTCTTTATTCATGTTACAT
TATTCAGAAAGTAGATACAATTCATATTTGTACAAAAATAAACACATTAGTTGACCTAAACACACACACACACAC
ACACACACACACACACACACACACACACACACACACACACACACACACACACACACACACACACACACACACAC
GATATTTTGAATAATTAAGTCTTGGTTTTGAAAATCTTCTTGATTATAGATAGATAAAAATAAAGAACTAACTTTGT
AGTTAACTACTTCTTAGGTAAGTCATATACTTTTTTCCAGATTGAAATTCTTCTTAAATCATACAAGTATTTT
ATTATTTAGATAACTGATGTGCTTATACTATGAACAGGTATAAACCTGTATAATGTCATTTCTGAACTAGGCTCAAT
CTAATCCAAATTAAGATGGTAAGAAATGAGAAAAATAAAAAATGAATACCATACTATAAATATATATACGGAG
AGAATCATAAAGTGGATTAAATCGACTGGAAGATTATTTTCTATAAATATATAAAGTATTGTTTCCCTATTGTTAAT
GTCTTACTCATATAGTATTGAATAGAGTGATTAACTATCCCTCTGATAACTCTAATTCACCTGAATTTTCAAAAT
CTTGTTATCTGTTATTGGGCTCTAAAGGCACATTATAATTTATAACAAAGATGTAGCAATATGCCTGTTTCACCAA
ATAAGCTCTAAATTTTAGATCTTTCTAATTTTATAAGAAAGTGGTATATGCTGACTCTGTTGTGAAATAGTATACA
AATTTTAAAGTTAATTACAGCTAGGGATTTGGCTGTAATTAGGAAAAAATTTTCCCATTTAAACATGTTGACCTACA
TTAAATATTGCACTTCAGTGCTTTAAAAAGTCAAGTTACAGTTCCTTGAGTTTTTTTTTAAAGCTGAGCTTTTAAAG
TTGCTATTTTACGCTACATTTTAAAAATAAATGTTTAAACATTTTAAATTTCCACTGAGACCCTTTTGTGGCATA
TTCTCAGGATTTTATATCACTTAAATTTTATGAAATGTAAAAATGTAATAAATATAAGTACTGGTTCTACCAAT
ATACTCATAGCTATTTCTAAGCATCCAGTAGCAATCAAGTAAAAATTAATAAATAATATTTTATGAATAATATGT
TAACCTAACAAATTAATTATAGAAGGGCTGAATCACGAACCTATTGCTAATCAATAGTGTACTCTCAGTGCAACGCA
AGCAGATGTTAGAAGGGAATAGAAGTTATTTATTGCACCGGTGAAAAATATATAAGATGCCTATTCAACTTAACAAC
AGTAGTCTTCGTTTGAATGGACTTTAAGTACAGCGGTAGAAATATTTAACATTTTGTAGTCCAGGGACATCAATG
AAAGAAAGTGATAAATTCAGCTAGATGCTATATGGAGCCCTGTAGTTGCAAACTTTAAGTCTTCTGAAATTTT
AAGATATTAGAAATAGGAAAAAATCTCAAAAGTTCAAATAATAGTGGACATCCAAGAAGGTTAGTCTATGTTGGA
AGCAATGAAGTGTGAAATGTAGTCAGTTAGCGATGCAGTTTAAAGATAGACAATTCCTACAGCTTCAATTATGTAA
CAGAAGAAGTGGATACATCTATAGGCTTAAGCATGATAAATAATGAGTTTAAATGATGGCGTAGCCACCAAACTGTCT
TTGTACACGAAGGAGGTGCAATAAAAACCTATCATCGGCTGTAAGGGGAAGTCATAGGTTGATACAAAGCAAGCCT
GTGTACAAGTCTTTAAGCAAGCGTCCATGAATAGCAAGGGCGCCATGCTCTTCACTGGAGAAGAAAATTACCTATT
TGCTTTTAACTCTAAGTGAATTAAGCATTCCTTTTCAATTTGAAAGTAGGCAAAAAAATCACAGTAGTACAA
TCAGTACCTATGAAGTCACAGATATGTACACATCTCATTACAGTTATAATAAATATATCAAAATATCATTATGCTT
ATCACTACTTCAAACTGCAGTACTTATTATATGTGCTACAGGGTCTTATTGTTGGGCTTTAAACATTATTCTGAG
GAATGTCAGGCTTCAACAGATTGCCAAAGAGTCCAAGGCATAAAAAAATGATCCTAGCCAGCTGTCTGTTTATCTG
CCGAGAATCTCATCTAATTTACTATGTTTTCAGTCATTTAATGTGCAGTCACTATCTTCATACACTCCTTTTCTT

CTGGAGTATTCTAGGAGAAGACATACCAGTCGAGGGGTTCTGGGGAGCCAGGCCTTCAAGCAATGGATTGCTGACAA
CATAATGAAGAGGATTTTACTTAGAATAATGTCAGTTGATAAAAGTTTGAATGGGAGACGGAAGCAAGGCAGTGGGA
AGTGGAAATTCCTAAATTGAGGAACCTCTGAATCATAATCCTTAGCAATAATAATTAAGATTTCAAACATTATAATT
CTTTCTCTTTTAGACAAGTCTGATATTGCTTATCCCATATCACAGATAAGGCAATTATTCTACTAATATGCATTAA
GGAATAGTGGTTTTAATTTAAGTGTTACCTTAATGAAAATAATTTGAATTTTTCTCTCCCAAGTCTTTTTGTGA
AAAAATTTCAAACATATAGAAAAATGAAACAATTGCAAAACATATGCCCATTTTACACTGTTTTCTCCCCCTAAATT
CTTAGAGTCAACAATTGTTAACATTTTGCCATATATGCTTTTTTCTCTCGCTTTCTCTACCCCTTTCTGTATCTC
TCATATATAGGGCATCACACACACACACACACACACACTTTTTAACATTTTGCAAATAAGTTATAAAT
ACCATTATATTTTACCCCTAAATAATTCAGCATGTGTCGCTTTGAAATACAGACATGCCATATATAACCATGCCTGT
TTATTATGCTCTCCTCCAAATTAATATAAATCTGCATTATTGTTAATATCCATTCCATATTCATATTTCTTAATA
GTTCAAAAATGCTCTTTTATATTTTGCAGGGAGTTAGTACCAATATCTTATCATGGCTCATGCATTACATTTGGTTA
TTATTATTTTTCATCCTTTCTTAGTCTAAATAGCCCTTCCACATTTTTTTTACCAGATATTGAAATTTGAAATGGTCC
AGGACGCTAGCCTCAAAAAATGTCTCATCTTTTCAAGGATTTGTTTTATTTTTTTTCCCTGTATGGGATGATTTAACTT
GTTCTGTAGTCTCTGAATTTCTAGTAACTGGAAGTTAGGTCTAAATAAGACTTCAAGAGATGCATGTCAAACATGT
TTGGCGAGAATACTTCATATGAGATGCTGTGATTTTGTATTACGTCACATCAGGAGGTGCATCATATGAAGTAGTC
TCACTAAATGCTGCAAAGTTTTATTACTTGCTTCAGGTGGTGACTGACAGATCTTGCAATATAATGTCACATTTTTT
CTTCGCAATTAATAATCATCTAATGGCTTTAGTATCATGATGATCCTTCCCTAACTCAGTTATTACACTGGGGC
TTGCAAAATGGAGGTTTTCTAATCTGACATGATCTTAACATTTACCAGCTGGCTTTCTTCTGTTTGAAAAA
AAAAAAGGTTTTCTCTATATTTATGTCAAAATGGACTCATAAATTTTTATTATTCAATATATTATTATGAAT
TACAGTTATTATCTTGGCCAGAGCTTCTGCTCAATTTGTCCAGGCTCACCTTGACTTTGCCTATCCAGATTTA
GAATTACCCATTTTTTCAAGGAACCTCTGGTTACTTTTAGAGGTGAATAGTACGTAGAAACGTACATCTGGGTAGTA
GCCCCCTTCTCAATGGAATGTGTGCACCTTTCTGGCAAGCAGTCCCAAAGGAGATAATATTTTTCAGATTACCTTGGAA
ATGATTTCTTGACAAATCTCTTTCAGAATACATGGAAGTTAAAGTAAGTCTAGACATGTTAAAAAGCCCTTTCTGTG
TGAGACTTCATGTACGGTCATTAAGTTACTACTCTTTAAACCTCTCTACTTCTGAATTTCTTAAACCAAAATGTACT
AGTATATAATCTATGCTGGTTTGCCATGCAAATTAATGGTGTAATAAGATAATGGGAGGCATTTCGTAATGTACTT
AAAGGAAGAAATATTGTTTAAAGACCTTAGCTCATTGTTTGCATGCAAATACAGCTGTTGATTAGAAATGAGCCT
TATCTAATTCATTAAGTAGGCCTGGTTGGTCTCTCTTGAAGTCTCCATTAGCAATTCATATTGCTCTATGCGC
TTCCTTGTAAGACAACCTGTTGTCTCTTAAAGTTTTCTTTAACTTTGGCTTCTTACAAATTCAGACCCACCCCAACC
AAATAGCTTTCAACCAAAATAGCTTTTTCAGCATCTTATTTCCTACAAATTAAGCGAATATTTTAACTCAAAATG
GCTCTTTACAGTGTGTGCAATATGTTAAATGTACCCAGTATATCCGTGTGAACCAAGTGTACAAAGCCTGCTCACACA
TTCACATTTTGGCCCCAGGATCTGTCCCGTCCGCTTGCTCTGTACTCAAACCTTCTTTTTTCTCATTGCCAGTTTA
GACCTTGACTCTCCATCCAGCCAGAGTTTGGAACCTGAGTACCCACAGGCTGAATCCTGAATGCATGCAGTATTTT
TGCATAGCCACTGTTTTTAAATAATTGACAACCTTTAAAAAATTGAGAGACCTCATTTTTTAAAAAATATGGATTTCT
TGTCTTCTTTTGAATAATTAGATCTGGCTACTAGGCACTATTACTATATTTTCTTGGCACCATCACCTACAACCT
GAGTAACAGATGTTTTCAATTTTCTTGCTACTCAAAGTTGGTCTCTGCTCCAGAGCACAGACATCACCTGGGAGTTGC
TAAGAAATGCAGAATCTAATAAATAACAGTCAAGCTTTTAAATAAGATTTCCAAGTTTCCAAGTGATTTCATGGGCAC
ATTAAAGTTTGAGAAGCATTGCCTGGGGTAAGCAAGCTTTGCTCTCAGTTTGCAGCACCTGTCCCACTTTGCTCATT
TATATTAATTGCTTTTCCATAGATATTTGATTTTATAGTACCTCATGCAGACCTTTGTATGATGATGACGGTTAGGG
TGGTGATGGAAGTGATGGTGATAACACTTAATATTGCCATGCACTGTTCCAAGTGTTTTACGTAGCTCAATACTTAT
AACAACTCTATGAAATAGTTGCTATTCTCCTTTTAAATTTTACAGGAGGGCAACGAAGGCACAGACTGATAAACTCT
TTGCCCAAGATTGCACAGCCAGCAAGTATTTGAACCAAGGATGCAGTCCCGCAGTGTGCTCCCGAGTCTTTACTCTA
GATCAGATTTTGCATTATTTATCCAGTTTTGTCCATCAGGATTCTCTGGTATACACTTGCAATTTCTTCTTACCAA
CCTTCTCCTTACCTTTGATGGCCACACGTAGTAGCAAAAGAATTGAACATAGAATCTGTTCTGACCTATCTTTCCAA
CCCTGTTTTTATAATTTCCACTATTTCTGTTTATGCTGAAGCTTTGAATGACCTGAAGTTTTCTGTTCTTCAGCT
TTTGCAAAAAAAAAAAAAACAAGAACAAAAACAAGACAAAAAAAAAAAAAACCGCTTCTTTGGTTGAATTTCTCT
TTCCCTTATTTTTTTTCCAAAATCTTACACATCCCTTAAAGACTCATCTTAACTGCTATTACCTCAATGAATTTGTG
ACCTGCTCTTCTCAACATAAGCAGTTTTATTCTCTTAAAGTTTTCTTGCCCTTTTATAACACTCATGTAATATTG
TATGTATATATCATGTATCATACCTATTTACATATGCTTTTCCCCAGCAAGATTAAGCTTTCATGAGGGCAGAGG
ACTCTCTTATTGTTATCTCTATAACCCACAGTACTTACCAGAAAGCCTGATATATTGTAGATGGCCAGTAAGTACTT
TCTTAATTTAAATCGTAAGAATTTTATTCACATTGAGATTAACTGAAGATTTAAATCTTTTACACTTGACATTATTA
TATAGATTAATAATAGATCTAAAGAGCCAGACCAATTTTCTGTTTTATCATGTTATCATTATTCATTTTATAGGT
TTGCAATTTAGAAATGACCTTGATCCCTTCTAGTCTTAAAAAAATGGAAGGAGTTTGGTTAAATTTTATAGCT
ATTCTTCAGAAATTTAGTACATTTAAGAGACAAGTAACTTCAATTTTATTAGCTAGTTATGGCAAAAAGCAGCTCTTT
GATTCAAACATTTGTACATTTGTTTTATCTACTCTCACTGTATCTCAACTAATACCTTTTAAAGTGAATTAAGCAGG
AATTAGCCCTGAAACTGAATGTTTTAGCCTCATCTACATATAGCCACAAGATGTTTATAGATGCAATCCATATCACC
AAAGAGCTATTTTTAGATTGATCAGAGAGAATCATACAGATATTATTATTACAGGTGTCAATGGAAAAGCTGGTCT
CTTCCCATCTGTTCTCTGATGACTCTTGAAGGCTTTCAAGGGCATTCTAATTTCTTCATCAAAAAGCATGAAAAA
TCAGTTTCATAGTTTATGTTTATGTCATATTTTATTTTTTCAACTTGGCTAGTTCTAGTGAACACAGACTAGCTGG
CACCATAATGTTGTTGCAATTTGGCTGGTAATGATGATACCACTGTGTGGAGATATACAAGTGAATGTACTTTATTTG
TGGCCTTCCATGAACTTTATGTGCTGGGAAAGTAGGAGTTAGGGAGAGTTTGTAGGGAACGTGATCTCTGGGATG
GGTCTTAAAGGATGAGAAGAGGCAATGAAGAGTAAATGGACATGCCAGAGAGAAAAAGTGACAGGAGCAAAATCAC
TGAAGCAAGAAAAATGGCTACATTGAAGGACTATACACAGTTCAAGTATAAAAAAGGCTCTGTTAAGCAAGCACCAT
TGACTTACCCTAACTCTTCATTTTCTACATATAAACTGCCCAATTTCCACTCCAAACCTATTGATGGATATTAGTA
ACCTATTGATGTTTTTGAAGGTGTTCAAGTATCCTTTCTGGTACCATGTACCTTGGCTCCCAACCTTTGAGAGTAT

GTTCCTCAAGAGGCAACAGTCTGTGGTTCTGACCTGGCTATGCAAGTTATTCTTATTATTAAAAATTGTCCTATTTA
ATTAATATCATGAAACTAATGAAATAGAAATGAAAAAGATAAGAGAATTGTGGTTCTATGAATACTAAATTGAAT
GCTTTGGAAGACTTGATAAGGTGATTAGAAAAAAGGCCAGATGCGGTGGCTCACACCTATAATCCCAGCA
CTTTGGGAGGCCGAGATGGGTGGATCACCTGAGGTGAGGATTCGAGACCAGCTGGCCAACATGGCGAAACCACAT
CGCTACTAAGAAAAATACAACTTAGCCAGACGTGGGCTGTAGTCCCAGCTACATGGGAGTCTGAGGTGGGAGAGT
TGCTCGAACCCGGGAGGCGAGGTTGCAGTGAGACAAGATCATGCCATTGCACTCCAGCTGGGTGACAGAGTGAGG
AAAAAAAAAAAAAAAAAAAAACCACGGTGTGTTGAATTAGATGTAGGTAAGACAACGTGTTAAGATTGGGTATGA
GGGATAGAATCCCCAAAAATGGAGGTATTTGCATTGAGATTATTTTCAGCATCTCCAAATCTGACTGTAATTCAA
AGAAACCAACTAAAAGTCACAGATTATGAAATGTAGAAGTGTGTTATGCAAAAAGTAATATGCTTAACTTCAACCT
GTGGGCTTTTACTCCAGGAAAAGTCTCGGACCCCATACCAATGAGAAGTAAATGAGTGACCCTGTATATTCTAA
GAAAAATAAATGTTTGAAGATGTGTAAACACATTATATAATCCCTCCAATTTTACAATATTTTCCAAAAACCGC
CTATCCACTTACCCTAATCAAGTTTGATAAGGGGACTTCTTTTATATGTAGGAAGGCTGAAAAATGACGCCATGAC
AAATGAAATTGTCAAGATGGACCAGGTGATGGAAGATTGAAATCTCAAAGAATTTTCCAGGGTAGAATATAAGG
ATGTTGGGACGTTTTTATATGCTTTAGATTGTCATCCTCATATGTCCCTTTGACAGTTGAGCTCAGAGTGAAAAAA
GAGAGTGAAACTAGTGGCAGGGTGACTCAAGTTAGAGACAATGAGTAAGCAGAATAGAACTTTAAAAACCTGACAGA
TTCAAGAAATACTTGATGAAAGTGAACAATTTAGTCGTTAAGTAGATGGGATGATGAGGGGAATGAAGGGACAATT
CTAGGATGATGGGTATCTTTTCCAGGTTTTTGTCTGGGGGACAGTGGCTGCATGGAAGGCTGTTAGTCAGGAATA
CAAAGGAGAGTAAGTGAATGGAAGAGGAAAGCAAAATCAGACATACAGAGCTCAACTTGGGATATAATAGTCTTAAG
GAGCTCTTGGAACATTGAAAAATAAGGTGATCAGAAAACACGCATTTGAATAGGTAAGTCTGAACATCAGGAGGAAGA
CAAGGGCTGAAGACACTGAGCCATTTTGTGTCAATGTAGAGATGGTGGCAATCTCCATTGAACTAAGTCTCTCA
ATAAGGTACCTTTCTCAAGTCATTAATTTGCTAACCAGTAAACAAACCAGAATTTCCAGAGTACACATTAACCATTA
AGCACTGCTGTGGAAGGAGGTTTCAAGGTGTCAGGAAGCCAACGTGGCAGATGAGCACTAGTGGTGACAAATGAACCA
AAGTGATATGGGTATCTTTATGGGGCCACAGAGTACCATTGTAACATATCACAAATCAGAAGGCTTGACAAACAAA
ATATTGGGGATAAATCAGGGAAAACCTACCACAACATACAGGAAAATAAGTTCAAAGATTTTATCCTACAGATTGCA
GATAAGAAATGAGCCCTTTTATTTGGGGCACCTAGGGAAGAGTAGATGCCCATATGTATATTTAAAGTATGAAT
ACAGCATTTTATTTGAATATACTGCAAAATGGTCAATACAAGGGTAGCTACAGAGCCATAACATGAAAAGGAAACACA
AAGAAATACATGCCCCAGTCAGACTCCTTACTTGGGTTGCTGTAAATTTCTCTCTCCCTTTAAGGTTATTGCATTTAA
AGTCTATCTGTTGATTGGACCCAACAGCAGCTGCACCAAGACTGTACCATTTTTAAAAAAAAAAAAAAAAAAAA
ACAGGCCAAAATGGCATTCTGCATTTATTTTCTTGGTGGCTGAAGAACTTGAATTGTCTACCCCTCAAAGCTTCTCT
TTGAGACACATTTTATAATTAGAAACACTTATTTACAAAGTTCTTTTATGTTAGAATCACAAATCATAACACTCCA
AAAAAGGAATACACTATCCTCAGGTGAGTGTCTTACCTTTGTTTACAAAAGAAAACCCAAAGTCTAAGAGAAAAAT
GTGTTGATCATTTTATTGATTCCTTACCTTGGTTTTAATATAGTTAATGGATGTCTTAGATATGTATAATAAGTCTAT
TATCATGTTCCCTTTAAATTTCTCTTTTGTGTTTACTAATTATATGTTGTCTAGTGTGACCATTAATATAAGTCTAA
ATTTATTATAATGTGATTTTTTCTACAAAGGTTAATTTGAATTAATAATTTTATTTATCTCTCTACTATGATA
AATGTTTTTTAAAAATCGTTTTGTAAAAATGAAAGTACTATATTTGTGTAAAGCTGCCAATCTAACAAATTTATCATTTACC
ATTATGATGGTGAATGTATAACAATCCTTATATTTCAGCAGAAAGCCTTATCTCTCATTTTCAGAGGAATCTTGCCCCG
GTTAATTATTCTGTCTCTTGAATGCACACAAACACAAGCATATCTTTACCCTTTTTCTGCTGCCTCACTATCCCTGA
TCAGGTGAATGTTTTTAGCTCCTAGATTACAATATAAATATATTCAGACATTCTTTCCAAATGCATTCAATCCACT
GTACTTGTCTAGAGTTCATAGCTGTGAATAACAGAACCAGTTTTTGTTGATAGAAGCGGAAACGGACTTTAGGAGAA
AGATACAGACCTGTTCCCATTCCTAAACAAAGGGATAGAAAACCAGCTCAAAATGGGCAGAACTCAAAAAGAGGCT
CAGCTCCAAGAACTATAGTCCAAATCATACCTAGATTGGATCTCGAACTCTTGACTCAAGCGATCCACTCATCTT
AGCCTCCCACAGTGTCTGGGATTACAGGCATGTGCCACGACGTCTGGCCCCATACACTAGATGTAACAGTTGCCATG
CACCCTCTACCCTGCAGACACTGGGTGAAGAATGTCTTACTGGAAGAATTTCTAGATAGTGCCTTATAATT
CTGTCACTCATTCAGATTCAAAAAGTGAACCTCCCATCAGATTCCATTTGTATTTGGGGATTTTGTTCGACATA
ATCAGGGCATTTCAGATTCTGGGCAACCAAGTTAACAATGTCTCTTACTTCCCTTTCTTGTGTTATTATCCCATTT
GAATCTCTTCATAGTTAGTCACTGTTTACTTAAACACACATTTCTATTATCACATTTCCCTCTCTCTTTGTCT
GTTTGTCTTTTGAATTCAGAAACCATGCTCAGAAACCATATTGCCAATAACAACAATGATTTCTTGATGTTAAATCCAC
TGGACATATCTTAGTCTTATTATCCGTAGGCCATGTGCCATTAACCTGAACACTTTCCGTATTAGCACTTGGTCTAT
CTTATCTTCCAAGTCACTAATCTTATCTGAATTTATTTTACCTCTCTATGTAATTCCTTACTATATTGATGACACT
CCTTGCTTTTACCTGCCCCCTTACATCCTGATGTTTCTCTAGGACATGTTCTGAACCTCCCTTCTTCTCATTTCTATAC
GGTTTCCCTGATTGTTATCCATAGCAACAAATGTAGCTTTTCACTGTATCAATTAGAATAATATCTAGGGAGATTAAA
AAAGATTATATAGACTGAAACAAAGTAGAAATATGATTTCTCTTCTGTAAGAAGGAATCTGCCAGTAGGTCCGA
GGTTGGTATCATTTGCTCTATGATGTTGAAGATCCAGATCCCTTCTGTCTCACAGATCTGCCATCCTTTGGTGAGGTC
CTTACACTCATGGATCAAGATGACTATCAGCTCTCTATCTATCACAACTGCTTTTTCAAAGGCTGCAAGGTGTAGGAA
GTGGACAAAAAAGGGATACCTCTACCCTTTTAAAGGGACTTCATGGAAGATCTACACAACACTTTAGCTTGTATGTC
ATTGGCCAGAAATTTATTTCTCATGACAATGCCAACTGCAATGGGCATTCAAAATGTAGTGAATGGATCATGGGCTA
AGCAGCTAAGCAGTCTCTACCAAGTCACCGATTTTCAATTTATGGCCTAAGTCTAATATTTGGCCCAATATATAGTT
TCAGATTAGACCTACATATGTAGCTTCAATGGACCAATTTCTCTCTATGTCTCAAAGCCATCTCAAAGTCAGTAT
ATCCAAACTCAACATGTTATATTTCTCTCCCAAAATCTACTGTGGGTGATATCACTATCTATTTCATGTACCCAAAC
TATAAATTTGGAAGTTACAAGAGCTAGTATTAATGACACTAAGTTTTGTGCATTTACTCTATGAACAGGACTTTGAT
AAGAGTTTTTACAAATGTTTCCCACTTAATGTGCGCAATATCTCAGTTATAGAGATTTTATACGTCATCATCTCACC
TGACTCTTCGAGATCATAAGCAAAGCATGGCAGCATTTTATGTCCATTTTACAAATACCACATTAAGCACAAAGAA
AAAAACAAGATATATGTCCAAGGCTAACCAAGTTATAGAAGGATCGAGAACTAAAAGTCAGTGATTTAGACCCAGAT
CTGTGCCTTTTCCCTTATTGTTACATATGACCATATCTAGCTATGTGAACAAAGCAGCTAATAGTGACGACAGGGTA

GAACAAATAAGAAAGTGAATATTCCCCACTACATTTATGATTATTTGCCAGTTTAAACAGCTTCAAGCCTGTGTCTTC
TCAGATATGTGCTTCTCTTATGTCTAAGGAAAAGTACTATATTTGATATGCTTTTATGAACCTTCTTTTTTGAGAT
GGGGTTCTGGCTCTGTCACTCAGGCTGGAATGCAGTGGCATGATCACAGTTCAGTGCAGCCTTGATCTCCCAGGTTC
AAGCGATCCTCCAACCTCAGCCTCCTGAGTAGCTGGGACCACAGACACGGGCTACTACACCCAGCTATTTCTTTTTT
TTTTTTTTTTTTTTGGTAGAGGCAGGATTTCACTGTGTGCCCCACCTGGTCTCAAACCTCCTGAGGTCAAGTGATCCA
CCCACCTCAGCCTCCCAAAGTGCAGGGATTACAGGCATGAGCCAATGTGATTGGCCTGAATTTTTTAAATTTAATTT
TATTGAGGTAAATATACCTCTATATAAATAAAAGTAAATATACCTTTACCATTTTTAAGTATACAGTTCAGTGGTA
ATAAGTAAATTTATGTTATTTTTCCCCTTTGTCCCCTCTCCCTACTCCTATTTCTGATCTCTGGTAACCCAAAGGT
AGTGTCTACTTTCATGAGATCCATGTTTTTAGCTCCCACATGTGAGTGACAACACATAATATTTGTCTTTCTGTGCC
TGGTTTACCTTACTTAAATAATTACCTCCAGTTCTATCCACGTTGCTGCAAATGACAGGATTTACCCCTTTGTATG
GCTGAATAATATCCCATGGTGTCATATATATATACATTTTCTTTATCCATTTCCTATAAAATTTTAAATGGTGT
GGAATTTGGAGAATACTTAAAGGAAAAATGACGATTGTGTAAAGGAAAGTATCTACAAAAGCAAGGTTTATCTACCC
CATAAAGATAACAAGAGAATCTGTGAATGTGGATACGGTTTCTGGAGTGTTCAGAGGTTGAAAGATTGTGAAGAAC
TGGATGGGTATAAAAAAAGTGAGGAGGAGAAGAAATGAAAGTTCGGAATGTTCTGTAAATTGTAGATGAGTTCCC
TATATTAATTTTTAAATGTAATTTGAGATTATAATTTTTTTTGATGATCTATTTTTGTCTGGGCTGATTCTCTGTTG
GTGTAACCTCTTAAACGAATATGGGTCACGTGGGACCTGGATTTTTATTAGAATTACATGTGCGAATCAAATTTCTAAC
TTTATGAGCCATATAATGATTGTTTTTTTAAATGATTGTTTTTAAATGATTGTTTTTAAATGATTGTTTTTCTCTCTG
ACTTATTTGGTGTTTTTCTTGCTAATTAGCCTTTATACTAGGCAGTAGTAAATCAGAGTACTTGGACTTCAGGTTGGC
CATTACATAAACCTGGCACTAAATGCTGGGTAATAATCACCTATCTTCCACCTGTGTTTATTACCTTTGGAAGTA
TGTAACATGGTATCTTTGCGTTTATATTTTTAATTTGTCTTTTTTCTCTTGCACCAGCTACTTAAATTATCTGAGC
TTCCTTTTACTAATCCAAAAATAAGATAATAGTACATATTTATAGAGATGTTGTAAGAGTAAGAGGTAATGTAAT
AAATTTGGCTAGCTCTATGCCAGCACATGAGTAGGTGCTTAGAAGTTAGTGTCTGGGTACATGACTTCTGGGGATGA
TAAAGTGAGTAGCTCGATAAATCTCCCCAAGAATCAGTAAATGGGACACACTGGAGAAAACATCTTATGACCTGG
ATATCAACCAACGGCATATGCTAAATTAAGGATGATTATTTATAAAAAAGTACTAACTTTGTATATGAACAATATG
AATTTGTGGTGTATTTGCCTGTATTGCCCCCAGTCCCCACTCCCAGCTTGGTCAAGCATAATAGTTCTATCAAGGTA
GAACAAGCCATGGAATAAAGCAGCTTCATCACCACAGGACTGATTTTATTTGAAGCAGAAGTTAAAACTCCATGT
CCAGAAGCATTGTGAGTAACGGTGGAGACCTAGGCGGCAAAACAAAAGGCAGAAATAGCAACTCAGCTGGCCTAAAGT
TGCAGTCTTGATTGGAACAAGTAACTGACTGGCAGACTGGCCAGAAATTTAATTTAACCAGCATATCTGCAAAATGA
GGCAGCCGTAATAGCCTCAGTAAGGACTCCTTGTTGCTCCTTTCATGAAAACCTTAAATGTGCTGCATGTTGAATA
TACCCTTTAACACATATAAAGAACCTTTAGCAAACTTGAAGTCTTACTGGCTTGAGGTATTTAAGATCAACTGCT
GGCCAACTATTGACTAATGCAAAATTAAGCTATGCTTACCTCTAGGAACTAGGCATACAGTTTGTCTGTTGTTTG
ACAGAGAAAGAAATATCAACAGCCACACACTGTGGGGAAACAGATTCCACAGATTTTATCTAGGCAAGTTATTTAAAC
TTCAATTTAAAAAACGCTGGGCATAAGAAGGAACATCAGAATTTGGGGCTCCTTTAATATGTTATTTAAATGTCAA
ATTTTCAAGAAAAATTTACGATACGTTCAACTGTGACCCATTCTCATGGGAAAAGCAGTCAACAAAAGTTGTCTCT
GAATTTGGCCAGGTATTGGCAGATAGAGACTTAAAGGCTCCTACTATAAATACCTTCAAAACACTGAAGAAAAGCAT
GTTTAAATAATTAAATGAAAGTATGGTAACAATAACTACAAATAGAGAATCTCAACTAAAAGATACACACTATATAA
AAGAACCAATGAAAATTTAGAAATTTGAAAGTAGAATAACCAAAATTTAAAAAATCACTAATGGGGCTCAAGAGC
AGATAGTAAGACAGAAAAAATAAATCAGTAAATTTGAAAATAGATAAATAAATATCCAACTGAAATGTCAG
AGGTAACACAGTATAAAAAACGAACATGAGTCATAGCTTTGTGTCAAAACATTGAGCATATCAATGTAGATGTTACA
AGAGTTCCAGAAAAAAGAGAATGTTGTTAAAGAGGCAGAAAAATTTTGAAGAAATAATGGCCAAACACTTCACA
AATACGGTTAAGCTCAACAAACCCCAATAGAAATAAACACGAAGAGATCAATACCCTAAACATAAGAGTCAAACTA
TTGAAATAGTTTCATTTGAAATTTATTGAAAGACAAATGGGAAAGTCTTTAAACAAACAGAAAAAATGACTCCTCA
TGTACAGGGATCATATGATTGATAGTTAATTTCTCATATAAACAATAGAGGCCAGAGGTATTGAAATGACATATTC
AGAGTTCTCAGAGAACACAAATTTGCCAACCAAGAATTCCGCATAAAACAAAACCTATCCTTCAAAATATAGGTAAA
ATAAATATATTACCAAGTTGAGAATGAGAATATTTCTGTAGCTGACCTGACTTACAAGAAAAAATAAATAAAGT
CATTAGGCTGAAAAGAAGTATATTAGTAAGTCACTGAAACCAATGAAGAGATAAAGAAATCACAGAACTGATAAATA
TGATAGATACATATAAAAGACTGTACAAATATAGATATGTTTTTTCTTTTAACTTCTTTAAAGACCTAAGATT
GCATAAAATTTATAACATTGTGTTATTGTGTTTATAAGCAGGAGGAGCAAAATGGAGCTTAGCAGAGAAAAATATC
TAAATTTTACTGTGTTAAATTTAGTTTGAACCTAAGTAAATTTATGATCAATTAAGATGCATATGTAATCTTTAGAGCA
AGCACTAAGAAAAATAATAGTTAAACCAAAATTTAAATTTACACACTAAAAATAACTAACAAGACAGTGCAGTAAA
GGAGAAACCGGAACAAAAAGACATGAATAAGATGTGAAAAATACAAATATGGCAGATGAAATTGCAATAAAGCTT
GAGAATTTCCATTAAAAAATCTGAAATTTGAAATGCTTAAATGTGAAACTTTCTGAAGTTAAGATAATAAACC
AAGTGGAAAAATTTACACCTGACCTGTAATGAGTCACAGTCAAAACACAGCCAAAACCTTTGTTTCATGCAAAAAAT
ATTTAAGATACTTTATAAAATTTACCTCCAGGTTATATGTATAAGATATCTATTAAGATATATATATATACATATATA
TATATATACATATATATATATATACACATATATATATATATATATATATATATATATATATATATATATATATAT
TCCATCTCTCAAGATATTAGGTATATGCAAAATATTACAAAATCTAAAGAAATCCAAAATCCAAAACACTTCCAATCC
CAAGCATTTTGGATATGGGATACTCAACCTACATATCAATAGTTATAGTAAATGGGAGTGAACCTAAGCATTTCCAAT
ATAGGCAGAGATTTTACAGACAGGATTATTTAAATATATCAACCATAGTTTGTGTTTAAAGAGAAATGTATTAGAGCCAA
AACCATATAATTTCAAAGAAAAAGAGGTACTATGCAAAATGTTTACATATAAAAAATGAAGTGACAATACTAATGT
CAGACAAAATAGACTTTTATGACAAAATATGTAACAAGAGAAAAAGACATTTTTAATTATATAAGGGGTCAATTAAGC
AGAAAAATATAACAATTATAAACGTATATAATTAATAGGAAAGTCCCAAAATCTATGATGCAGAAATTGACAGAAATTC
AAAGGAGAACTAGACAATTCAACAATTATTATTGGAGACTTCAAACCTACTCTCAATAGCTGGCAGGCCAATTAGA
CAGAAAAATAGCAACAATATAGAAGAATTCACCAACACTATCAACCAGCTTGACCTAACTAACATTTATAGGAGACG
CCACCAATGAAAGCAGAATACATATTATTTAAAGTGCACATGAAATTTTCTCTGGGATAGATTCTATGCTAGGTC

AAAAACAAATCTCAATACACTCAACAGGCTTGAATTCATAAAAAATTATGTTCTCTTAATATGTCAGAATTAATTTG
GAATTCACAGAAGGAAATTTGGAAGATATCAAAATATTTTGAAATCAACAACCTCTAAATCCATTGGTTAAAAAC
TAAATCACATAGGAAATTATAAAATATTTTGAAGTGAATAAAAAATAAAGCACACATGTCAAGATTTATAGGATGT
AACTAAAGCAGTGCTTACAGGGAACTTCTAGTTTTAAATACCTATTTTAGAAAAAGATAAAATCTTAAATCATT
ACTCAAGCTTTTCGCCATAAGAACTAGAAAAAGAAGAACACAGTAAGCTCGAAGGAAGCATAAGGAAGGAAATAACG
GGGGTTAGAGCAGAAGTCAATAAAATAGAAGAAGAAAGAAAAATCAATGAAACCATACATTAATCTTTTGAAAAAT
ATTTTTTACATGGAGAAGCTTTAGCTAGACTGACCAAAAAAAAAAAGAAATTACCAAAATCATAAAGGAAAAAGGGGTA
ATTACTACCAACCCTACAGAAATTAGAAAGACTAGAATGTAATAACATGAACAACATTGTCAACAATTTCTGCAAAA
CATATTAATGAAAAAATCTTAGAAAGACATAAATTAACAAAACCTGATTCAAGAAAAAATAGACATATGAATAGA
CCTAACACAAACACAGAACTGAATTAGTAATTTAAATTTTCCAACAAAAAACCAGGTCCAGGAGAAAGATAGG
AATCCGAGGCATCCACAGTATAGAAGAAGAAATGAACTCTCTTTATTACAGACATAACAATCCTGTATGTAGAAA
AATCTGATATCCACAAAATAACTGCTAGATCTGATAAGTTCATGAAGCTTGCAAGATAATCAATATACAAGATAAA
TTACATTCTGTGTACTAGCAATAAAAAATTGAAAATGATACTAAGAAAAATAATTTCAATCTTTGTAGCATAAAATA
GATTAAATGGTCATAAATTTGAAAATATAAGTACTAAACCTGTACTCTGAAAACCTGAATACATTGCTGAGAGAAAT
TAAAAATCTAAATAAATGGGACCATATCCATGTTTCATGAATTGGAAGACTCAATACTGATAAGGTAGTGATTCTCC
CCAATCTGTTCTATAGATTTAATGCAATCTCCATCGACATCTTAGCAGATGTTGGCACAATTTGAAAAATTCGACAA
TCTTGGCACAATTTGAAAAATTGATCCCAAAATTTATATATAGCAATTCAAATGTACCAATGACCAATCAATGATTA
GAAAAAGAAGAAAAAGTTAGAGGACTTTGAAATCAGGACATTACCTGATTTCAAATCTTGATGTAAATCTGCAATG
ATGAAGACAGTGTGGTACTGTCTATAAGGACAGGCTTATAGATCACCTGTAGGTTTAGGAAACAAACCTATTTCATATT
TTTTTCTTAAATCTACTAAGTGCCTCTAATGTTGACAATGGAAGAGACTCGATAGTCCAGCAATAAACTCTTATA
TTTATGGTCAATCAATATATGACAAAGGTGACAAGATAATCCAATAGAAGAAAAAGCTTATTATTGGGTAGCTTATTG
TTAGTGACAGAAACAGAGCTGATTGTTAATACAACCTCAACAGGAAAAAGGCAATAAATCTGATTTTAAATATTT
AAATATATATTTCTCCAAAGAAGACATAGAAATGGCCAACAGGTATGTGAAAAGGTGCTCAGCATCAATGATTA
GGGAAATGCAATCAAAACCTCTGTGAGATGAACACTATCATCTCACCCCTGTTAGGATGGCTACTATAAAAAACAAA
CCAAAAACAAGAGATAAGAAATGTTGTTGAGGATGTGAGGAAATCGGAACGCTAGTACACCATAGGTGGTAAATGGAA
AAATGATGCAGCTGCTATAGAACACAGTAGAAAGGTTCTTGAAAAAGTTAAAAATAGAACTACCATATGATCCAGCA
ACCTCACTCCTGGGTATATATCCCAAAGAAATTAACCAGAAATCTCAAAAAGATATCTGCACTCTCATCTTCTCTGA
AGCATTATTCACAGTAGCCAAGATATCAATACAGCATAGCTGTGCATGGAAGAAATGCATGGATAAGAAAAATGTGGT
GTATTCATACAGGGAATATTTATTTGGCCCTAAAAGGGAAGGACGCTCTGCCATATTTGACAATATGTATGAACCTGG
AAGGCATTATGCTAAGTGAAATAAGCCAGTCACCAAAGGGCAAATACTGAATGATTCCATTTATATGAGGTGTCTGA
GACAGTCAAACTCGTAGAACAGAGAGTAGAATGATAGTAACCAGGGGCTGGGCGAAGGGGGAACCTGGGAGTTGCTG
TTCAATGAGTATAAAGTTTCAGTTATATAATGTAATAAGTTCTAAGATCTGCTGTACAACATAGTGCCTGTACTG
TGCACCTAAATTATTATTAAGAGGATATGTCTTAAGTGTCTTACCATAAGAAGAAGAAGAAGAGAGAAGGAGAA
AGTGAAGAAGAAGAAAGAAAAATGAAGGGGGCATGAGCAAACCTTTGGAGTTGATGCATATACTTGGTTACCTTGA
TTATGGGGATGGTTTCATGGTTGTATGCTTATATCCCAATTCATCACATTGTATACAGATGCTCCTCACCTTAGGAT
GGGATTGTGCTCTGATAAACCCATCATAAATTGAAAATGTTATGAGTCAAAAGTACATTTTCAATTAATGATATTTT
CAACTTACAGTGAGTATATCCAGATATAACCCCATCCTCAGTCCAGGATTATACTAAATGTGTATCGCTTTTGCACC
ATGGTGAACCTCAAAATTTGAAGTCAAACCATCGTAGTCAGTCGGGGAAGATCTGTTTGTAAATATGGACCCATCG
TGTACACCTTAAATACTTAAATAAGCTGTTAAATGAAAATTAAGTTGACTGGGCACATGGCTCATGCCTGTCTATC
TCAGTGCTTTGGGAGGCCAAGGCAAGAGGATTGCTTGAGGCCAGGAGTTCAAGACCAGCTTGGGCACATAGCAACAT
TCCATCTCTACATAAAAAATTAATAATGTAGCCGACTGTGGTGATGCAAGCCTGTAGTCTCGGAGGCTGA
GTTGGGAGAATTTCTTGAGCCAGGAGTTGGAGGTTACAGTGAGCTATAATCATGCTACCACACCCAGGAGACCCCT
GTCTCAAAATAAATAAATAGAAGCTTTAAAAAATATTGGTATCTCAGTGTTCCCTCATTATCCACTGTATTTAAGGTT
TAGCTACTTGTGCTTGATGCTTGACAAGGTAATCTTACTTTTCTCCTGATATTGGTATGATGCAAAATTTACTATAT
ATATGACACAAATTTATATATGCAATATTTTCTCGTTAATGGCCTTTTATTTTACTCTCATTTTCATTATGCTTTGC
CTTTAAGTCATATAGCAAAATAAATTATGTGGCAATTTCTTAGCACTATTAATTCAGGAGAAATGGGAACAGAATTC
TCTCATAGATTTCAGCTGGAAAGGTAATGATGGTCAGCTCCCAAGTGGAGAAAAAATAAACTCCTTCAGTTTTCGT
AAACATACAGAGAAATTTTCTCCTAAGTGCTATGTCTGCTGTATGCTCTATTGATCTGAGAACCAGAAAAACAC
ATATTTTAGTTTACACTGCCTTGACTCTATTGTACATGGCTAGGTCTGTTTAAAAAAGAAATCCTTGAAGATACCCCT
TTGGATTCTAGTATTTTAAACGGATGCTTAGCTAAGTGAAGTGGTCTACTTCAAGGATCAAAACCAATCTTGAGTA
ATCTGTTAGGTAGACTCCCTAAGTTTCACTGTACCTTGTACCAATTTTAAATGAATTTAGTAAATGACATGGATGT
AAAATAAATAATACATAAAATAAAGTTTCATGCAGAACTCAATTTTAAATGCCCAGGTAATGATAGATATTACCTG
TCCATTTCTCTGGACTTAGCTCCTGCAACTCTCCATTTTCTCTCTAAACCTTTAGCCACACTGAATTCCTAGTTTCA
ATTCTCTGACTCGCTAAGTATTTCTTCTACCTTGATAAAAGCTAATTCCTTTGTCTTGTACCATCTGTATTCGGC
TGATATTGACATAGTTTTAGGGCTCAATTTCAATGTTACTTACTCAGAGGGACTCACTGTTACAACCACCACAGCC
TTTTCAATCTAAGTAAGATCCACTGCTCTTCTTAGAAACAGGTTATATTCCAATGACTGTAAGTGCTTTTGTCTT
AGAACATATGTCTCCATTTCAAAGACCGATAGATATTTCAGTTAAGCCCTTTGAGAAAAATATAAATGTTGAGGACCT
TGATTATTATGTTATTATGCTTCTTCTATGTTTCCAGGACTCTCAACAAATTTGCTTTGCTTTGTTACTCA
TGGCACATAATGAGATTAATAATGTTTGAAGAACATTTCAAAAATACACACAGAGGAGACACATCTTAGTCTAAAGT
TAGACATGATACCAAAAACTATAAATACTATAGCTGACCAGTGACCCCATTTTATTCATGGAAAGTAAATTTGATGC
ATATTTGCCTTTAGGAGCAACATACCTATGAAAGTCTGAAAGTGAAAGTTTGTAAGAAAGGAGTACTCTCCTAACA
ATCTTAATTTTTTCTATATATATGATGGTTTGCATTAAACTCTTTTGTATGATTAGTGGTTAATGTTGATGTCA
CCCATGACACCATAAGCTACGTGTATGGACTGGCTCTGTTTGTTCCTCCTGAATATCCAGCAAAAAATAGTATAGT
GCCTGGCCCTTGGTAGATGTGTAATAAATGTTTGGTGAATGCATAGCTACACTTCAATGCTTATCGCATTTTAAATCC

137

TTAACATACGGATTTCAAAATCACTGTGCTCTTGTACATAAGAATGAAAAAGAACAAAGGAATATTACATATGTGGTG
GTGGTTATTGGAGGTGGGGTTATGAGCCAGGCTTCATATTCATGAGCATCACTTTTGCTCACACTCCATTGGCTCGA
ACTCAGTCATGTAGCCAAACTAATGGCAAGGGAGACTGGGAAATGACAGCTAGCTGCACAATTAAGAGAAATGAGTA
GACTTGTCTAATGAGCAGCTAGCCAGTCCCTACCACGAGGACTTTGCTCAAATGTCTCCTTCTCCATGGAACCTTCT
ATGATCACCTTTATAAAATCACAACCTGCTCCCCATCTCCCCCTCAATATTTCCATCCCTTTTCCATGCTTCATTTT
TTCCCTCTGTAAACACTTACTGTATCACAATCTATAGATTTTATTTCTTATCTTGTCTTACTGTCTGCCTCCCCCTCC
TCCCAATCGGATGTAAGGTCCATGAGGCAGGGATTGCTGCCGATATTCACGGCCATATCAATGGACACTAGTAGACC
CTCAATAAATGGCTGTTGCATTGTGATTACATATATGCTTCACCTAGAAGTAGTCTCATCTGGTGGCACATTTACTC
ATAGATTGACATTAATTCTCTATTGTTTTTCCCCAGCAAAATTTGTCAAGGTAGTTTGTCTAGTAGGGAGAAATAAA
GTTGTCTAGGTGGCTCATCAAAAGTTCAATTTTGAGTACTCCTCCTGTGTACTCATAATGTTTTATAAACTTTTAT
CTATGTAAGCAAGCTTGGCTTAGACACAATCTAGGATTAAGAGAAAGCTCTGTATCCATATTTCCCTTTTGTGT
ACCTCCTTTTATGTTCTCTACCATTTTTTTTGTAGTGTGTTAGTGAAGCACTAGGCTAAATCTTGGGTTTCTGCAAA
AAAACTTTAATCCTCACAACACTCTAAAATGTTTTATTGTTCTAATTTTAAGACGAGGAACTGAGGGCTAAAGAGA
TTAAGGAACCTGCCCCGTGTTACGCTACTCAGCTGATACTGGCAGCATTTAGATTGGACTTACTTTCCATACAGAT
ATTCGCATTGCTAACCTTCAGGTTTTTCCCTCATCGTTTTTCCACATCTACTCAAAAGTTGCTAATCATTTCTCTAAT
AGTGAGGCATAAATGACTGAGAAATCTTGATATATTTCCCCCTCAGGAGCACTTCATTCCGACAAGACACAACTT
TAGGGAAAATGAACAAATGCTACTTGTACAACTCAAGCAACCAAGGTATGGTAGACATGTTTCCCTTAAAAATAA
AGTTGATGCTTGGGTTCTGATTCTGATAATGACCTACGGAGGGTATGGCCTGAGGAGGTTACTAGGTGTGTGTAGAA
ATCAATGTTTTGTTTTGGTTTTCCCTCGGGAAGGGTCAACTTATACTGAATCCTTCTGAAGTTTCTCAAATTACAA
GATGGTCATTTATTTTACTTCAATCAAAACAACAAAGTACTGTCCGGGAAAGATGTATTGCCCTGACTTATTCTCAA
TTTATGCTTATTTTGGAGGCTTGTAGAAGTAAACCTGATAGAGGAGGGCAAAAACACACACACAGACACACACAC
ACTGGGAGAAAAATAATTTAACACAGTTTAGGGATTGACTTTGGTTGTATGACATCACAATTGCAAGAGTTGGATGC
CATTGTAACCAAGCTATGGAAAGAATACTGTTAAAAGTAACTCATTAAAGTGGTTACATGGTGTAGCTTAGGACATA
TGGCACAGAAAAAGATAAAGCTGTCTTTACATAACATAAACTGTATTCTGTTATGTAAATGTGTGCTTGTGGCTT
GCAGTAAAATTCCTAGTGAAACATTACCTCTAGATTGAGCAGTACTATACCTCAGGCCACATGGATGTAAGTAAAGA
TGATGCCCTCTGGAAAACCTGAGTTAGGCAACAACAAGTGCATCCATGAGGATGCAAAATTTCAATGTTGAAGGTGCC
GTGAAGAATTTGAACAAAATTTGTTGCATGAAATATGAATGAAGAAGTGTGATCTAATGACATAATATTTTGTACTAT
ATAATTTTAAAGTAGTACACACAATCAATTAATGAATTAACATTATATGTAAACAGGTGATCATTGTATCTCCAT
TTTCTAAAGTTTCTATGTTTAAAGGTGATCAAAAACCTTGGAGAGAGGGACTTCTCATTGGAAAAATGGATAGTCA
CTTTGGGTATGTGATGTATCAATCTCTAGAACCTCAGTTTCTTTCATTGAAAGCATATAAAAGGCAATCCAAAGGATG
TATGGAATATTTAAAGATTCCACTGTGAACTATCTAGCACTTTACCTGAAACACTTGTAGATCCCCTCACCAAAA
TCATGCCATGTGATTTGGCAGTCTATTCTCTTAGCGTAAGAGTAGCCCGACAGAAAATGTTCTAATGAAGTTAATG
TTAAATTCATTGAATTTAGCAACACATGAGTAGCGCTTCTTCTGATTATGCAAACTCTCTCACCATCGTAATACGT
GCTTCTTTTAAATTCATTGGGAACATTTGTAATGTAAATGGTAAACAGAGCCAATATTTCAAACAGAAGCCATTCTTT
CTAAAAAAGCTAAATGTCTAAATGTATTGAAATGCTTCTAAAAGTAAAATATTAGCACTTATTGTCAGATGGGT
ATGTTAAATATCTCACTCATTATTATTACTACCCTTGTCTGAATAAATCCTCCCATAGCATTAAAGCAAGTAGGTA
AACAAAGAAATAACACTTTCATGTGATGAATGCCAATATGAAGCACGTTTAAACTGTCTGTCAAGAGACAAGCCTGG
AAATGCTAACTGTGTTTTCTTTGCTTTTTGCAATCATCTGAATACATAAATTCAAATTCAGCTTTTAAACTTCAA
ATCGAGGCTTTTGAAATTCAGAAAACACATGCGCTTGGAAAAGCAGATTATAACAAGGTCCCAACGGGATTTGTG
ACCATCTTTTTTATATTTCAAAGTATAAAAAAACTAGATAAGAAATGACTACCAATGTTTTCATATTTAAAAGA
TGCTGTTTTTTTAAAAAATTAATCAGTGGAAAAAAGTTTTCCACAAATATCGTGTAAAAAGAAAGACAGCAAAAA
GCTTAGCCAAAGCTTTTACTGTTTAAAGTATGATTTATTCTGAGAGTTCTTAAAGAGTTTTCTAAATAGTATATGGT
TAATATCCATAAAATCATATGCAAGATGCTGTCTTTCAAATTTGATGCTGAAGGTTAATTATAAAATGTACTTAATTA
TTTATAGTGTCCCATTTAGTCCCAGATACTCTGTGTCCAAGAACACTGTAAATACAGAAAGTTTAGCAGAATTATAT
TGGAAAGGCAGTAATTTTCAAAATTAACCTATTGATATAATGCAATCCCATTAAAAATTTTTCAGCGAGAATTGT
TTTATAATTTGACTGAATGATACATTACATAAGTTAGAATAACTAAAGTGGGAGAGCGGGTTAACCTACCAGAAAT
AAACATATTTTAAAGCTGCAATAATTTGACATAGTGCATTAAGTGTACAAAAATCTACAGTAGATCAACAAGCAGAAA
CTTAAATATCATGAAGAAAGCACCATAAATCAATTCAGAAGAGATGGTGTGGGGGAAAAAATATCAGTTTCTGAA
AACTCTTCAAGGTTAGAAACAACACTATATAAATTTAAGATGGATTAAATATTTGGTTGTTCTTTTTTAACAAATG
AAAGAGTAAAGGATCAAGAATAAATGAGAATATCTGAACAATGGTAAAAATGGCCACAATTTTAAAGGATACATCAAT
GAACATAATATCAAAGAAATAAACTGTTAAATTTTATTAGAAAAAACTACTAAAAGGCAAAAGGAAGCTGGGAA
GTAGCTCAATTAATTAATGTTTTCAGATAATGTGAAAAAGACTCTTAAAAATAGGAAAAACAGGAAATGAGCAAC
CAGACATTGCCGATAATTGACAGTGGAACTAAATAAATGACAAACATGTACACACATACAACATTTTCACTTTTCC
TATTAGTAGAATACTTAAAAATATCTATGGCAAGCTTTTTTATTGTTTTTATTGGTATATCAATTATAATGCTCAATAG
TGGCAAAAGTGTAGTGAGACAAGTATTTGTAACTGTTGGTGGGAGTTTACGAGTGTCTGAGTACCAACCTTGACA
GAAATTCACAATGTGTATCTAAATCCTTAGGATTCCCATTGTTAACTTTTCTATTCTCATTCCAGCAGATACATGAT
TCAAAATGTATAAAATAAATGTGTTTTATTGTAGGGTTATTCTATTATAATAAAAAATGAAAGCAAAACAAATTCCTAAT
AACCAATAAATGGTGAAATATAGGGTACCCTATATATCTTATTACTAGGATCTTAAAAATCAAGTTTTTAAAGCG
TAATTAATGACCTACAGAGACACATAGTAGAATAATAAATGAAGAAAAATAAGCATACAATATAGGGTTTGAACCCAG
TAATACATATAAATCTCACTATGATGAATAAGCACAACTCTCTCTCTGTACTGGATATTCTTGATAGAAAAAA
TATGCTAGTAAATAATTTGAGACATATTTGAAAAGAGGGGAGTGTGTTGATTTAGAAATTTCTAAACTTGAGGGTTAT
TATTATTTTTTTGGTTTGATATTACTTTTTCTCTGCTCCTTAAATTTTGTGTTGTTGGGGGGTTTGGGGTTTTCTTT
TCCTTAAACGTGTCTGCTTCTAGATGAAAGTTGAAAATGTTTAAAGCCTTGCCAATGTGTCTAGGTTTTTCAAATG
TAATCAGATTTTAGCAAGATTTTACTTAACTAAAAGTATTTCAGAACACTGTGCAAAATCATCTGGAGTCAAAATAGTA

ATGGAGGCAATGATTTGCAGAGTAGAAACAGAGAGAGAGAAAAAGATGAGATAGACCCCTCAAATCTAGACCCAAGG
AATTAAATCTGCTTGAACATTTAAACAAATAAAGGATGCCTGTACTATACTAGACGTTTTCTTCTCCACAATTGA
TTCTAAGGTGAGAATCTGAGGGGAAATGGTGCTGTTCCACATTCTAAAACAAACGCCAGCAATCGAGACCAGCCAC
TTCCCATAGGGTTTACTCTAAAGCAACAGGGATTATTATCTCTATTCCAAGCAATTTCCAATCTCTCTGTACTCC
GTGTCCCAGGCAAGATTAAAAAGACTCAGGTAGGAAGGGGTAGTAAGCTTTGTGGGGAGTGCAGTTTGTGGTAAGGG
ACAGTTCCCTTCTCTTTCATCTCTCTGAGTCAGAAGTAGAGACTTCGAGAGAATCACTGAGAGTAAGTATGTAGACTC
CAAGAAGGAAAAAGCATCCTCTCACTTCAATGAATGTTTGAATCTGCAGACCTCCTTCCAGGTCTGTGTAGCTTT
TGGAGAGGCCAGAAGAGCACCGTAGGCATTCCTTTGGCTTTCCATGGCCAAGCACATAGAGTAGAAGAAGAGGAGGA
ACCGTAAGGTTAACCATAACATAAGAAATCAACAAAAGGCTTTGAAATTGACTTTTCCTATTTTTCAATTTAAATAAG
AGAGAATTGTCAATGATTAAAAATTCATAAAACGAAGAAAGAATGGACTCAGAAAAATAGCAAACATGAAATGTTAATT
ATTAGTTCAAAGTTAGTTTACCGTGTCTTCTCTGCCAACTGATTGCTAATGACTAAAGTCCTTATTTCCAGCTTTC
CTCTCTCCCCGAGCTCCAGATCTCTTGATTTATTAACATAGTAGTTTCCCCAAAATATATGAGACAACAAAATATAC
TCTCAGCTGAAGTAAATAGCATTTCATCTTCCAGTCAGATAAGGCAGAAGTACTTCTAGATCAGATGTTATATTTCGG
GATAGGTTAAAAACAGACCTGTCTCCAGTGTCCAGGAATGAACAGTGGATGTGCTTATTTCTATTGCATGCGGTG
TATCAAAATATCTCACGTACCTACAAGTACATACACTTACTATGTCCCTACAAAAATTAACAAATAAATCATAA
ACATTTGTAAAAATAAGCGAATAAATGTATAAATGAATTTAAAGAGAATAGACAGAGGGGAGAATGTAACTTTACG
TGTCAGAACAGACTTTGAACAGGCTCTATCATATAGGAAAACTGAATGAATATATGCAAGCATAAGTCCAATAA
CCAGATTCTGATTTACAGAAATGATCGCACTGTAGTTCTCTCAAGGCCCTGTCTTTGAACAGGCTGTGTCTTATTC
TGCAACATGCTGATCTATCTTCATGCTTCAAGACTCAGATCATTATCTTCTCTGGGATGTCTCCCAAGCACTGCCCC
AGAAATAACTTCTCTCTCTATAATACCTAATCATAATCCTTGGCTTACATGCTTGTCTTCTCTATTGACTATGAAA
TCCTCAAGACAAGGTATATAACGTATATATCTTTAATCCTAATGCCCAATTGAGCTCTTAGAAGGTAGTAAGCTCCC
AATACACATTTGTTAATTTGAAGCAAAAAAAAAAAAAATAGCTAATCATTCAAAAACTGAATTATCACAATGTCCA
TCTAAAGTACTATATTTACACAATTAATGTCTATACAGCCAGGTTAATGAACAGACTAAAATTTATGCAACATGGA
TTATCGTAAACATAATTTGAATGAAAAAGGCGAGACACAAAGGAGTATAAAGCCATACAAATCCATTTTTCATAATA
TTCAGTACCGGCAAAATAATCAAAGTTGACAGGGTACTGGTTATACTTGGAGGCAGTGAAGTGCAGGAGGATAAGAGG
AGATTTCTGAGATTCTGATAATATCTATTTCTTCTGTGTTGTACAGTGTGTTCAATTTTTAAACACTATTGGG
CTATACAGTTAAATTTGTGCAAGTGTCTGTACGTATATTACACTTCAGTTAAAGCTTCCATGGAAGCTACACATAGT
TCCCAAAAGACAACAAAACAAAAATTTCAATTATTTAAGCACAAACAATTTGTTTCAGCTGTCTTACAATCGAA
TATGTAAGAAATAAATTTATGGCTAATTAGCATAGAGTTATATGCATTTTCATAAATTAACAACTTCCACGAGTACAACA
TATGTTAAGTATTTTAAATCAGTTTTTCTCTTCTCAAATAAGGTTGTGAGTCATAATTCGGAAAAACAGTTTAGCA
TGTAATAATTTAGTGTTTTATTTTAAACCAAGCTGAAGCCACATAAAGCAGAACTGCTCAACTGAGCCCTATCCAAA
TCCTTGACCCACAGAATAAGAAGCAGATAAAATGGCTGCTACTTAAACAAAACAAAACCTTGTTTATATTTTGTGTC
CTCTCATTTTCCATAAGTATACTTTAATTAACATTTTAAACCTTGTAACTTTAGGTTATATACTTACTTTAGTTGG
TTCTCAACCAGGGACAATTTTGTCCCCACCCCAACCCCCAGCATATTTGGCAGTGCCTTGAACATATTTGGTTG
TCACAGCTCAGGGGCGAGGTGTTACTACTGGTATCCAGTGTGTTTCAACAGGCCAGGGATACGTAAATACCCCTACA
ATGCAGAGGATAGCTGCTCACAGCAAAGAATTTTCCAAACCTAAATGTTAGTAATGCTAAAGTTGAGAAACCTTGCT
CAGATATAATGACATAATGTTGTTAGAAATTTTATTTTATTCATTTTAAATGTATGTATGTATGTATGTATGTACGTA
CGTATGTATGTATGTTTGTGAGATGGAGTCTTTCTCTGTTGCCCGGGGTGGAGTGCAGTGGCAGCATCTCGGCTTAC
TGCAGCCTCTGCTTCCACGTTCAAGTGATTCTCTGCTCAGCCTCCCTAGTAGCTGGGATTACAGGCGCCTGCCA
CCAAACCTGGCAAATTTTGTATTTTGTAGTAGACGGGTTTACCATATTTGCCAGGCTGGTGCAGAACTCCTGA
CCTCAAGTGTATCCGCCACATCGCCCTCCCTAAGCGCTAGGGTTACAGGCATGAGCCACTGCGCCTGGCCAGGAATT
TTTGAATCAGAATTTTCTTGTTCGATTTTAAATCTCTTATCATTTAGAGATTCTTGAAATATTGAAATTACTTTGTT
CAAAGTGAATGAATTTTCTTAAATTATGTATGGTTAACATCTTTTAAATTGCTTATTTTAAATTGCCATGTTTGTG
TCCAGTTTGCATTAACAAATAGTTTGAAGACTATGTTGGAATAAATAACAATTTTATCTCTTTCTCCAG
(SEQ ID NO: 967)

[000218] *Homo sapiens* dystrophin (DMD), intron 45 target sequence 1 (nucleotide positions 1376272-1376321 of NCBI Reference Sequence: NG_012232.1)

GTAGGGCGACAGATCTAATAGGAATGAAAACATTTTAGCAGACTTTTAA (SEQ ID NO: 968)

[000219] *Homo sapiens* dystrophin (DMD), intron 45 target sequence 2 (nucleotide positions 1376339-1376383 of NCBI Reference Sequence: NG_012232.1)

ATTTCTATGAGAGATTATAAGCAGGGTGAAAGGCACTAACATTAA (SEQ ID NO: 969)

[000220] *Homo sapiens* dystrophin (DMD), intron 45 target sequence 3 (nucleotide positions 1412133-1412382 of NCBI Reference Sequence: NG_012232.1)

CACTGCGCCTGGCCAGGAATTTTGAATCAGAATTTTCTTGTTTCGATTTTAAATCTTATCATTTAGAGATTCTTG
AAATATTGAAATTACTTTGTTCAAAGTGAATGAATTTCTTAAATTATGTATGGTTAACATCTTTTAAATTGCTTAT

TTTTAAATTGCCATGTTTGTGTCCAGTTTGCATTAAACAAATAGTTTGAGAACTATGTTGGAAAAAATAACAAT
TTTATTCTTCTTCTCCAG (SEQ ID NO: 970)

[000221] *Homo sapiens* dystrophin (DMD) intron 45/exon 46 junction (nucleotide positions 1412353-1412412 of NCBI Reference Sequence: NG_012232.1)

AAAATAACAATTTTATTCTTCTTCTCCAGGCTAGAAGAACAAAAGAATATCTTGTTCAGA (SEQ ID NO: 971)

[000222] *Homo sapiens* dystrophin (DMD), transcript variant Dp427m, exon 46 (nucleotide positions 6859-7006 of NCBI Reference Sequence: NM_004006.2; nucleotide positions 1412383-1412530 of NCBI Reference Sequence: NG_012232.1)

GCTAGAAGAACAAAAGAATATCTTGTTCAGAATTTCAAAGAGATTTAAATGAATTTGTTTTATGGTTGGAGGAAGCAG
ATAACATTGCTAGTATCCCACTTGAACCTGGAAAAGAGCAGCAACTAAAAGAAAAGCTTGAGCAAGTCAAG (SEQ ID NO: 972)

[000223] *Homo sapiens* dystrophin (DMD), exon 46 target sequence 1 (nucleotide positions 1412383-1412432 of NCBI Reference Sequence: NG_012232.1)

GCTAGAAGAACAAAAGAATATCTTGTTCAGAATTTCAAAGAGATTTAAATG (SEQ ID NO: 973)

[000224] In some embodiments, an oligonucleotide useful for targeting DMD (*e.g.*, for exon skipping) targets a splicing feature in a DMD sequence (*e.g.*, a DMD pre-mRNA). In some embodiments, a splicing feature in a DMD sequence is an exonic splicing enhancer (ESE), a branch point, a splice donor site, or a splice acceptor site in a DMD sequence. In some embodiments, an ESE is in exon 45 of a DMD sequence (*e.g.*, a DMD pre-mRNA). In some embodiments, a branch point is in intron 44 or intron 45 of a DMD sequence (*e.g.*, a DMD pre-mRNA). In some embodiments, a splice donor site is across the junction of exon 44 and intron 44, in intron 44, across the junction of exon 45 and intron 45, or in intron 45 of a DMD sequence (*e.g.*, a DMD pre-mRNA). In some embodiments, a splice acceptor site is in intron 44, across the junction of intron 44 and exon 45, in intron 45, or across the junction of intron 45 and exon 46 of a DMD sequence (*e.g.*, a DMD pre-mRNA). In some embodiments, the oligonucleotide useful for targeting DMD promotes skipping of exon 45, such as by targeting a splicing feature (*e.g.*, an ESE, a branch point, a splice donor site, or a splice acceptor site) in a DMD sequence (*e.g.*, a DMD pre-mRNA). Examples of ESEs, branch points, splice donor sites, and splice acceptor sites are provided in Table 9.

[000225] In some embodiments, an oligonucleotide useful for targeting DMD (*e.g.*, for exon skipping) targets an exonic splicing enhancer (ESE) in a DMD sequence. In some embodiments, an oligonucleotide useful for targeting DMD (*e.g.*, for exon skipping) targets an ESE in DMD exon 45 (*e.g.*, an ESE listed in Table 9).

[000226] In some embodiments, an oligonucleotide useful for targeting DMD (*e.g.*, for exon skipping, such as for skipping exon 45) comprises a region of complementarity to a target sequence comprising one or more full or partial ESEs of a DMD transcript (*e.g.*, one or more

full or partial ESEs listed in Table 9). In some embodiments, the oligonucleotide comprises a region of complementarity to a target sequence comprising one or more full or partial ESEs of DMD exon 45. In some embodiments, the oligonucleotide comprises a region of complementarity to a target sequence comprising one or more full or partial ESEs as set forth in any one of SEQ ID NOs: 885-912. In some embodiments, the oligonucleotide comprises a region of complementarity to a target sequence comprising at least 4 (e.g., 4, 5, 6, 7, or 8) consecutive nucleotides of an ESE as set forth in any one of SEQ ID NOs: 885-912. In some embodiments, the oligonucleotide comprises at least 4 (e.g., 4, 5, 6, 7, or 8) consecutive nucleotides of an ESE antisense sequence as set forth in any one of SEQ ID NOs: 922-949.

[000227] In some embodiments, the oligonucleotide comprises a region of complementarity to a target sequence comprising at least 6 (e.g., 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or more) nucleotides of one or more ESEs (e.g., 2, 3, 4, or more adjacent ESEs) of DMD exon 45. In some embodiments, the oligonucleotide comprises a region of complementarity to a target sequence comprising at least 6 (e.g., 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or more) nucleotides of one or more ESEs (e.g., 2, 3, 4, or more adjacent ESEs) as set forth in any one of SEQ ID NOs: 885-912. In some embodiments, the oligonucleotide comprises at least 6 (e.g., 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or more) nucleotides of one or more ESE antisense sequences (e.g., antisense sequences of 2, 3, 4, or more adjacent ESEs) as set forth in any one of SEQ ID NOs: 922-949.

[000228] In some embodiments, an oligonucleotide useful for targeting DMD (*e.g.*, for exon skipping, such as for skipping exon 45) is 18-35 nucleotides in length, and comprises a region of complementarity to a target sequence comprising at least 4 (e.g., 4, 5, 6, 7, or 8) consecutive nucleotides of an ESE as set forth in any one of SEQ ID NOs: 885-912. In some embodiments, an oligonucleotide useful for targeting DMD (*e.g.*, for exon skipping, such as for skipping exon 45) is 20-30 (e.g., 20, 25, 30) nucleotides in length, and comprises a region of complementarity to a target sequence comprising at least 4 (e.g., 4, 5, 6, 7, or 8) consecutive nucleotides of an ESE as set forth in any one of SEQ ID NOs: 885-912. In some embodiments, an oligonucleotide useful for targeting DMD (*e.g.*, for exon skipping, such as for skipping exon 45) is 20-25 (*i.e.*, 20, 21, 22, 23, 24, or 25) nucleotides in length, and comprises a region of complementarity to a target sequence comprising at least 4 (e.g., 4, 5, 6, 7, or 8) consecutive nucleotides of an ESE as set forth in any one of SEQ ID NOs: 885-912. In some embodiments, an oligonucleotide useful for targeting DMD (*e.g.*, for exon skipping) is 30 nucleotides in length, and comprises a region of complementarity to a target sequence comprising at least 4 (e.g., 4, 5, 6, 7, or 8) consecutive nucleotides of an ESE as set forth in any one of SEQ ID NOs: 885-912.

[000229] In some embodiments, an oligonucleotide useful for targeting DMD (*e.g.*, for exon skipping) targets a branch point in a DMD sequence. In some embodiments, an oligonucleotide useful for targeting DMD (*e.g.*, for exon skipping) targets a branch point in DMD intron 44 or intron 45 (*e.g.*, a branch point listed in Table 9).

[000230] In some embodiments, an oligonucleotide useful for targeting DMD (*e.g.*, for exon skipping, such as for skipping exon 45) comprises a region of complementarity to a target sequence comprising a full or partial branch point of a DMD transcript (*e.g.*, a full or partial branch point listed in Table 9). In some embodiments, the oligonucleotide comprises a region of complementarity to a target sequence comprising a full or partial branch point of DMD intron 44 or intron 45. In some embodiments, the oligonucleotide comprises a region of complementarity to a target sequence comprising a full or partial branch point as set forth in any one of SEQ ID NOs: 881, 882, and 914. In some embodiments, the oligonucleotide comprises a region of complementarity to a target sequence comprising at least 4 (*e.g.*, 4, 5, 6, or 7) consecutive nucleotides of a branch point as set forth in any one of SEQ ID NOs: 881, 882, and 914. In some embodiments, the oligonucleotide comprises at least 4 (*e.g.*, 4, 5, 6, or 7) consecutive nucleotides of a branch point antisense sequence as set forth in any one of SEQ ID NO: 918, 919, and 951.

[000231] In some embodiments, an oligonucleotide useful for targeting DMD (*e.g.*, for exon skipping, such as for skipping exon 45) is 18-35 nucleotides in length, and comprises a region of complementarity to a target sequence comprising at least 4 (*e.g.*, 4, 5, 6, or 7) consecutive nucleotides of a branch point as set forth in any one of SEQ ID NOs: 881, 882, and 914. In some embodiments, an oligonucleotide useful for targeting DMD (*e.g.*, for exon skipping, such as for skipping exon 45) is 20-30 (*e.g.*, 20, 25, 30) nucleotides in length, and comprises a region of complementarity to a target sequence comprising at least 4 (*e.g.*, 4, 5, 6, or 7) consecutive nucleotides of a branch point as set forth in any one of SEQ ID NOs: 881, 882, and 914. In some embodiments, an oligonucleotide useful for targeting DMD (*e.g.*, for exon skipping, such as for skipping exon 45) is 20-25 (*i.e.*, 20, 21, 22, 23, 24, or 25) nucleotides in length, and comprises a region of complementarity to a target sequence comprising at least 4 (*e.g.*, 4, 5, 6, or 7) consecutive nucleotides of a branch point as set forth in any one of SEQ ID NOs: 881, 882, and 914. In some embodiments, an oligonucleotide useful for targeting DMD (*e.g.*, for exon skipping) is 30 nucleotides in length, and comprises a region of complementarity to a target sequence comprising at least 4 (*e.g.*, 4, 5, 6, or 7) consecutive nucleotides of a branch point as set forth in any one of SEQ ID NOs: 881, 882, and 914.

[000232] In some embodiments, an oligonucleotide useful for targeting DMD (*e.g.*, for exon skipping) targets a splice donor site in a DMD sequence. In some embodiments, an

oligonucleotide useful for targeting DMD (*e.g.*, for exon skipping) targets a splice donor site across the junction of exon 44 and intron 44, in intron 44, across the junction of exon 45 and intron 45, or in intron 45 (*e.g.*, a splice donor site listed in Table 9).

[000233] In some embodiments, an oligonucleotide useful for targeting DMD (*e.g.*, for exon skipping, such as for skipping exon 45) comprises a region of complementarity to a target sequence comprising a full or partial splice donor site of a DMD transcript (*e.g.*, a full or partial splice donor site listed in Table 9). In some embodiments, the oligonucleotide comprises a region of complementarity to a target sequence comprising a full or partial splice donor site across the junction of exon 44 and intron 44, in intron 44, across the junction of exon 45 and intron 45, or in intron 45 of DMD. In some embodiments, the oligonucleotide comprises a region of complementarity to a target sequence comprising a full or partial splice donor site as set forth in SEQ ID NO: 880 or 913. In some embodiments, the oligonucleotide comprises a region of complementarity to a target sequence comprising at least 4 (*e.g.*, 4, 5, 6, or 7) consecutive nucleotides of a splice donor site as set forth in SEQ ID NO: 880 or 913. In some embodiments, the oligonucleotide comprises at least 4 (*e.g.*, 4, 5, 6, or 7) consecutive nucleotides of a splice donor site antisense sequence as set forth in SEQ ID NO: 917 or 950.

[000234] In some embodiments, an oligonucleotide useful for targeting DMD (*e.g.*, for exon skipping, such as for skipping exon 45) is 18-35 nucleotides in length, and comprises a region of complementarity to a target sequence comprising at least 4 (*e.g.*, 4, 5, 6, or 7) consecutive nucleotides of a splice donor site as set forth in SEQ ID NO: 880 or 913. In some embodiments, an oligonucleotide useful for targeting DMD (*e.g.*, for exon skipping, such as for skipping exon 45) is 20-30 (*e.g.*, 20, 25, 30) nucleotides in length, and comprises a region of complementarity to a target sequence comprising at least 4 (*e.g.*, 4, 5, 6, or 7) consecutive nucleotides of a splice donor site as set forth in SEQ ID NO: 880 or 913. In some embodiments, an oligonucleotide useful for targeting DMD (*e.g.*, for exon skipping, such as for skipping exon 45) is 20-25 (*i.e.*, 20, 21, 22, 23, 24, or 25) nucleotides in length, and comprises a region of complementarity to a target sequence comprising at least 4 (*e.g.*, 4, 5, 6, or 7) consecutive nucleotides of a splice donor site as set forth in SEQ ID NO: 880 or 913. In some embodiments, an oligonucleotide useful for targeting DMD (*e.g.*, for exon skipping) is 30 nucleotides in length, and comprises a region of complementarity to a target sequence comprising at least 4 (*e.g.*, 4, 5, 6, or 7) consecutive nucleotides of a splice donor site as set forth in SEQ ID NO: 880 or 913.

[000235] In some embodiments, an oligonucleotide useful for targeting DMD (*e.g.*, for exon skipping) targets a splice acceptor site in a DMD sequence. In some embodiments, an oligonucleotide useful for targeting DMD (*e.g.*, for exon skipping) targets a splice acceptor site

in intron 44, across the junction of intron 44 and exon 45, in intron 45, or across the junction of intron 45 and exon 46 (e.g., a splice acceptor site listed in Table 9).

[000236] In some embodiments, an oligonucleotide useful for targeting DMD (e.g., for exon skipping, such as for skipping exon 45) comprises a region of complementarity to a target sequence comprising a full or partial splice acceptor site of a DMD transcript (e.g., a full or partial splice acceptor site listed in Table 9). In some embodiments, the oligonucleotide comprises a region of complementarity to a target sequence comprising a full or partial splice acceptor site in intron 44, across the junction of intron 44 and exon 45, in intron 45, or across the junction of intron 45 and exon 46 of DMD. In some embodiments, the oligonucleotide comprises a region of complementarity to a target sequence comprising a full or partial splice acceptor site as set forth in any one of SEQ ID NOs: 883, 884, 915, and 916. In some embodiments, the oligonucleotide comprises a region of complementarity to a target sequence comprising at least 4 (e.g., 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, or 16) consecutive nucleotides of a splice acceptor site as set forth in any one of SEQ ID NOs: 883, 884, 915, and 916. In some embodiments, the oligonucleotide comprises at least 4 (e.g., 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, or 16) consecutive nucleotides of a splice acceptor site antisense sequence as set forth in any one of SEQ ID NOs: 920, 921, 952, and 953.

[000237] In some embodiments, an oligonucleotide useful for targeting DMD (e.g., for exon skipping, such as for skipping exon 45) is 18-35 nucleotides in length, and comprises a region of complementarity to a target sequence comprising at least 4 (e.g., 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, or 16) consecutive nucleotides of a splice acceptor site as set forth in any one of SEQ ID NOs: 883, 884, 915, and 916. In some embodiments, an oligonucleotide useful for targeting DMD (e.g., for exon skipping, such as for skipping exon 45) is 20-30 (e.g., 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, or 16) nucleotides in length, and comprises a region of complementarity to a target sequence comprising at least 4 (e.g., 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, or 16) consecutive nucleotides of a splice acceptor site as set forth in any one of SEQ ID NOs: 883, 884, 915, and 916. In some embodiments, an oligonucleotide useful for targeting DMD (e.g., for exon skipping, such as for skipping exon 45) is 20-25 (i.e., 20, 21, 22, 23, 24, or 25) nucleotides in length, and comprises a region of complementarity to a target sequence comprising at least 4 (e.g., 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, or 16) consecutive nucleotides of a splice acceptor site as set forth in any one of SEQ ID NOs: 883, 884, 915, and 916. In some embodiments, an oligonucleotide useful for targeting DMD (e.g., for exon skipping) is 30 nucleotides in length, and comprises a region of complementarity to a target sequence comprising at least 4 (e.g., 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, or 16) consecutive nucleotides of a splice acceptor site as set forth in any one of SEQ ID NOs: 883, 884, 915, and 916.

[000238] In some embodiments, an oligonucleotide useful for targeting DMD (*e.g.*, for exon skipping) comprises a region of complementarity to a junction of an exon and an intron of a DMD RNA (*e.g.*, any one of the exon/intron junctions provided by SEQ ID NOs: 957, 963, 966, and 971). In some embodiments, an oligonucleotide useful for targeting DMD (*e.g.*, for exon skipping) comprises a region of complementarity to at least 10 (*e.g.*, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, or more) consecutive nucleosides of a junction of an exon and an intron of a DMD RNA (*e.g.*, any one of the exon/intron junctions provided by SEQ ID NOs: 957, 963, 966, and 971). In some embodiments, an oligonucleotide useful for targeting DMD (*e.g.*, for exon skipping) is complementary to any one of SEQ ID NOs: 957, 963, 966, and 971.

[000239] In some embodiments, an oligonucleotide useful for targeting DMD (*e.g.*, for exon skipping) comprises a region of complementarity to a target sequence of a DMD RNA (*e.g.*, a target sequence provided by any one of SEQ ID NOs: 955, 956, 959-962, 964, 965, 968-970, and 973). In some embodiments, an oligonucleotide useful for targeting DMD (*e.g.*, for exon skipping) comprises a region of complementarity to at least 10 (*e.g.*, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, or more) consecutive nucleosides of a target sequence of a DMD RNA (*e.g.*, a target sequence provided by any one of SEQ ID NOs: 955, 956, 959-962, 964, 965, 968-970, and 973). In some embodiments, an oligonucleotide useful for targeting DMD (*e.g.*, for exon skipping) is complementary to any one of SEQ ID NOs: 955, 956, 959-962, 964, 965, 968-970, and 973.

Table 9. Example target sequence motifs

Location in DMD	Type	SEQ ID NO:	Motif Sequence [†]	SEQ ID NO:	Motif Antisense Sequence [†]
Across exon 44/intron 45 junction	Splice Donor	880	AGGTAAG	917	CTTACCT
Intron 44	Branch Point	881	CCCTGAC	918	GTCAGGG
Intron 44	Branch Point	882	GTCAG	919	CTGAC
Intron 44	Splice Acceptor	883	ATCTTACAG	920	CTGTAAGAT
Exon 45	Splice Acceptor	884	AACTCCAGG	921	CCTGGAGTT
Exon 45	ESE	885	GAAGTCCA	922	TGGAGTTC
Exon 45	ESE	886	AACTCCAG	923	CTGGAGTT
Exon 45	ESE	887	CTCCAGG	924	CCTGGAG
Exon 45	ESE	888	CAGCGGC	925	GCCGCTG
Exon 45	ESE	889	AGCGGC	926	GCCGCT
Exon 45	ESE	890	TCAGAAC	927	GTTCTGA
Exon 45	ESE	891	GAACATTG	928	CAATGTTC
Exon 45	ESE	892	TGAATGC	929	GCATTCA
Exon 45	ESE	893	GAATGCAA	930	TGTCATTG
Exon 45	ESE	894	TGCAAC	931	GTTGCA
Exon 45	ESE	895	CAACTGG	932	CCAGTTG
Exon 45	ESE	896	CTGGGGA	933	TCCCCAG
Exon 45	ESE	897	ATTCAGC	934	GCTGAAT
Exon 45	ESE	898	TGCCAGTA	935	TACTGGCA

Location in DMD	Type	SEQ ID NO:	Motif Sequence [†]	SEQ ID NO:	Motif Antisense Sequence [†]
Exon 45	ESE	899	GTATTCTA	936	TAGAATAC
Exon 45	ESE	900	CTACAGG	937	CCTGTAG
Exon 45	ESE	901	TACAGGA	938	TCCTGTA
Exon 45	ESE	902	TGAATC	939	GATTCA
Exon 45	ESE	903	CTGCGGT	940	ACCGCAG
Exon 45	ESE	904	TGCGGT	941	ACCGCA
Exon 45	ESE	905	CGGTGGC	942	GCCACCG
Exon 45	ESE	906	TGGCAGG	943	CCTGCCA
Exon 45	ESE	907	GGCAGGA	944	TCCTGCC
Exon 45	ESE	908	AGGAGGT	945	ACCTCCT
Exon 45	ESE	909	GGTCTGCA	946	TGCAGACC
Exon 45	ESE	910	GTCTGCAA	947	TTGCAGAC
Exon 45	ESE	911	CAGCTGT	948	ACAGCTG
Exon 45	ESE	912	CAGACAG	949	CTGTCTG
Across exon 45/intron 45 junction	Splice Donor	913	AGGTAGG	950	CCTACCT
Intron 45	Branch Point	914	CATTAAC	951	GTTAATG
Across intron 45/exon 46 junction	Splice Acceptor	915	TTCTCCAGG	952	CCTGGAGAA
Across intron 45/exon 46 junction	Splice Acceptor	916	TTCTTCTTTCTCC AGG	953	CCTGGAGAAA GAAGAA

[†] Each thymine base (T) in any one of the sequences provided in Table 9 may independently and optionally be replaced with a uracil base (U). Motif sequences and antisense sequences listed in Table 9 contain T's, but binding of a motif sequence in RNA and/or DNA is contemplated.

[000240] In some embodiments, any one of the oligonucleotides useful for targeting DMD (e.g., for exon skipping) is a phosphorodiamidate morpholino oligomer (PMO).

[000241] In some embodiments, the oligonucleotide may have region of complementarity to a mutant DMD allele, for example, a DMD allele with at least one mutation in any of exons 1-79 of DMD in humans that leads to a frameshift and improper RNA splicing/processing.

[000242] In some embodiments, any one of the oligonucleotides can be in salt form, e.g., as sodium, potassium, or magnesium salts.

[000243] In some embodiments, the 5' or 3' nucleoside (e.g., terminal nucleoside) of any one of the oligonucleotides described herein is conjugated to an amine group, optionally via a spacer. In some embodiments, the spacer comprises an aliphatic moiety. In some embodiments, the spacer comprises a polyethylene glycol moiety. In some embodiments, a phosphodiester linkage is present between the spacer and the 5' or 3' nucleoside of the oligonucleotide. In some embodiments, the 5' or 3' nucleoside (e.g., terminal nucleoside) of any of the oligonucleotides described herein is conjugated to a spacer that is a substituted or unsubstituted aliphatic, substituted or unsubstituted heteroaliphatic, substituted or unsubstituted carbocyclylene, substituted or unsubstituted heterocyclylene, substituted or unsubstituted arylene, substituted or unsubstituted heteroarylene, -O-, -N(R^A)-, -S-, -C(=O)-, -C(=O)O-, -C(=O)NR^A-, -NR^AC(=O)-, -NR^AC(=O)R^A-, -C(=O)R^A-, -NR^AC(=O)O-, -NR^AC(=O)N(R^A)-, -OC(=O)-, -OC(=O)O-, -

OC(=O)N(R^A)-, -S(O)₂NR^A-, -NR^AS(O)₂-, or a combination thereof; each R^A is independently hydrogen or substituted or unsubstituted alkyl. In certain embodiments, the spacer is a substituted or unsubstituted alkylene, substituted or unsubstituted heterocyclylene, substituted or unsubstituted heteroarylene, -O-, -N(R^A)-, or -C(=O)N(R^A)₂, or a combination thereof.

[000244] In some embodiments, the 5' or 3' nucleoside of any one of the oligonucleotides described herein is conjugated to a compound of the formula -NH₂-(CH₂)_n-, wherein n is an integer from 1 to 12. In some embodiments, n is 6, 7, 8, 9, 10, 11, or 12. In some embodiments, a phosphodiester linkage is present between the compound of the formula NH₂-(CH₂)_n- and the 5' or 3' nucleoside of the oligonucleotide. In some embodiments, a compound of the formula NH₂-(CH₂)₆- is conjugated to the oligonucleotide via a reaction between 6-amino-1-hexanol (NH₂-(CH₂)₆-OH) and the 5' phosphate of the oligonucleotide.

[000245] In some embodiments, the oligonucleotide is conjugated to a targeting agent, e.g., a muscle targeting agent such as an anti-TfR1 antibody, e.g., via the amine group.

a. Oligonucleotide Size/Sequence

[000246] Oligonucleotides may be of a variety of different lengths, e.g., depending on the format. In some embodiments, an oligonucleotide is 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, 75, or more nucleotides in length. In some embodiments, the oligonucleotide is 8 to 50 nucleotides in length, 8 to 40 nucleotides in length, 8 to 30 nucleotides in length, 10 to 15 nucleotides in length, 10 to 20 nucleotides in length, 15 to 25 nucleotides in length, 21 to 23 nucleotides in lengths, 20 to 25 nucleotides in length, etc.

[000247] In some embodiments, a nucleic acid sequence of an oligonucleotide for purposes of the present disclosure is "complementary" to a target nucleic acid when it is specifically hybridizable to the target nucleic acid. In some embodiments, an oligonucleotide hybridizing to a target nucleic acid (e.g., an mRNA or pre-mRNA molecule) results in modulation of activity or expression of the target (e.g., decreased mRNA translation, altered pre-mRNA splicing, exon skipping, target mRNA degradation, etc.). In some embodiments, a nucleic acid sequence of an oligonucleotide has a sufficient degree of complementarity to its target nucleic acid such that it does not hybridize non-target sequences under conditions in which avoidance of non-specific binding is desired, e.g., under physiological conditions. Thus, in some embodiments, an oligonucleotide may be at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% complementary to the consecutive nucleotides of a target nucleic acid. In some embodiments a complementary nucleotide sequence need not be 100% complementary to that of its target to be specifically hybridizable or specific for a target nucleic acid. In certain

embodiments, oligonucleotides comprise one or more mismatched nucleobases relative to the target nucleic acid. In certain embodiments, activity relating to the target is reduced by such mismatch, but activity relating to a non-target is reduced by a greater amount (*i.e.*, selectivity for the target nucleic acid is increased and off-target effects are decreased).

[000248] In some embodiments, an oligonucleotide comprises region of complementarity to a target nucleic acid that is in the range of 8 to 15, 8 to 30, 8 to 40, or 10 to 50, or 5 to 50, 15 to 20, 20 to 25, or 5 to 40 nucleotides in length. In some embodiments, a region of complementarity of an oligonucleotide to a target nucleic acid is 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 nucleotides in length. In some embodiments, the region of complementarity is complementary with at least 8 consecutive nucleotides of a target nucleic acid. In some embodiments, an oligonucleotide may contain 1, 2 or 3 base mismatches compared to the portion of the consecutive nucleotides of target nucleic acid. In some embodiments the oligonucleotide may have up to 3 mismatches over 15 bases, or up to 2 mismatches over 10 bases.

[000249] In some embodiments, the oligonucleotide is complementary (*e.g.*, at least 85% at least 90%, at least 95%, or 100%) to a target sequence of the any one of the oligonucleotides described herein (*e.g.*, the oligonucleotides listed in Table 8). In some embodiments, the oligonucleotide is complementary (*e.g.*, at least 85% at least 90%, at least 95%, or 100%) to a target sequence of the any one of the oligonucleotides provided by SEQ ID NO: 400-879. In some embodiments, such target sequence is 100% complementary to an oligonucleotide listed in Table 8. In some embodiments, such target sequence is 100% complementary to an oligonucleotide provided by SEQ ID NO: 400-879. In some embodiments, the oligonucleotide is complementary (*e.g.*, at least 85% at least 90%, at least 95%, or 100%) to a target sequence provided herein (*e.g.*, a target sequence listed in Table 8). In some embodiments, the oligonucleotide is complementary (*e.g.*, at least 85% at least 90%, at least 95%, or 100%) to any one of SEQ ID NO: 160-399.

[000250] In some embodiments, an oligonucleotide useful for targeting DMD (*e.g.*, for exon skipping) comprises a region of complementarity to a target sequence of a DMD RNA (*e.g.*, a target sequence provided by any one of SEQ ID NOs: 160-399). In some embodiments, an oligonucleotide useful for targeting DMD (*e.g.*, for exon skipping) comprises a region of complementarity to at least 8 (*e.g.*, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, or more) consecutive nucleosides of a target sequence of a DMD RNA (*e.g.*, a target sequence provided by any one of SEQ ID NOs: 160-399). In some embodiments, an

oligonucleotide useful for targeting DMD (*e.g.*, for exon skipping) is complementary to any one of SEQ ID NOs: 160-399.

[000251] In some embodiments, an oligonucleotide useful for targeting DMD (*e.g.*, for exon skipping) comprises a sequence comprising at least 8 (*e.g.*, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, or more) consecutive nucleobases of a DMD-targeting sequence provided herein (*e.g.*, an antisense sequence listed in Table 8). In some embodiments, the oligonucleotide comprises a sequence comprising at least 8 (*e.g.*, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, or more) consecutive nucleobases of any one of SEQ ID NOs: 400-897. In some embodiments, the oligonucleotide comprises the sequence of any one of SEQ ID NOs: 400-897.

[000252] In some embodiments, an oligonucleotide useful for targeting DMD (*e.g.*, for exon skipping) comprises a region of complementarity to a target sequence of a DMD RNA (*e.g.*, a target sequence provided by any one of SEQ ID NOs: 240, 236, 280, 211, 197, 212, 208, 217, 213, and 195). In some embodiments, an oligonucleotide useful for targeting DMD (*e.g.*, for exon skipping) comprises a region of complementarity to at least 8 (*e.g.*, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, or more) consecutive nucleosides of a target sequence of a DMD RNA (*e.g.*, a target sequence provided by any one of SEQ ID NOs: 240, 236, 280, 211, 197, 212, 208, 217, 213, and 195). In some embodiments, an oligonucleotide useful for targeting DMD (*e.g.*, for exon skipping) is complementary to any one of SEQ ID NOs: 240, 236, 280, 211, 197, 212, 208, 217, 213, and 195.

[000253] In some embodiments, an oligonucleotide useful for targeting DMD (*e.g.*, for exon skipping) comprises a sequence comprising at least 8 (*e.g.*, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, or more) contiguous nucleobases of a DMD-targeting sequence provided herein (*e.g.*, a sequence of any one of SEQ ID NOs: 720, 716, 760, 691, 677, 692, 688, 697, 693, and 675). In some embodiments, the oligonucleotide comprises at least 8 (*e.g.*, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, or more) consecutive nucleosides of a DMD-targeting sequence provided herein (*e.g.*, a sequence of any one of SEQ ID NOs: 720, 716, 760, 691, 677, 692, 688, 697, 693, and 675). In some embodiments, the oligonucleotide comprises the sequence of any one of SEQ ID NOs: 720, 716, 760, 691, 677, 692, 688, 697, 693, and 675.

[000254] In some embodiments, it should be appreciated that methylation of the nucleobase uracil at the C5 position forms thymine. Thus, in some embodiments, a nucleotide or nucleoside having a C5 methylated uracil (or 5-methyl-uracil) may be equivalently identified as a thymine nucleotide or nucleoside.

[000255] In some embodiments, any one or more of the thymine bases (T's) in any one of the oligonucleotides provided herein (e.g., the oligonucleotides listed in Table 8) may independently and optionally be uracil bases (U's), and/or any one or more of the U's in the oligonucleotides provided herein may independently and optionally be T's. In some embodiments, any one or more of the thymine bases (T's) in any one of the oligonucleotides provided by SEQ ID NOs: 640-879 or in an oligonucleotide complementary to any one of SEQ ID NOs: 160-399 may optionally be uracil bases (U's), and/or any one or more of the U's in the oligonucleotides may optionally be T's. In some embodiments, any one or more of the uracil bases (U's) in any one of the oligonucleotides provided by SEQ ID NOs: 400-639 or in an oligonucleotide complementary to any one of SEQ ID NOs: 160-399 may optionally be thymine bases (T's), and/or any one or more of the T's in the oligonucleotides may optionally be U's.

b. Oligonucleotide Modifications:

[000256] The oligonucleotides described herein may be modified, e.g., comprise a modified sugar moiety, a modified internucleoside linkage, a modified nucleotide or nucleoside and/or (e.g., and) combinations thereof. In addition, in some embodiments, oligonucleotides may exhibit one or more of the following properties: do not mediate alternative splicing; are not immune stimulatory; are nuclease resistant; have improved cell uptake compared to unmodified oligonucleotides; are not toxic to cells or mammals; have improved endosomal exit internally in a cell; minimizes TLR stimulation; or avoid pattern recognition receptors. Any of the modified chemistries or formats of oligonucleotides described herein can be combined with each other. For example, one, two, three, four, five, or more different types of modifications can be included within the same oligonucleotide.

[000257] In some embodiments, certain nucleotide or nucleoside modifications may be used that make an oligonucleotide into which they are incorporated more resistant to nuclease digestion than the native oligodeoxynucleotide or oligoribonucleotide molecules; these modified oligonucleotides survive intact for a longer time than unmodified oligonucleotides. Specific examples of modified oligonucleotides include those comprising modified backbones, for example, modified internucleoside linkages such as phosphorothioates, phosphotriesters, methyl phosphonates, short chain alkyl or cycloalkyl intersugar linkages or short chain heteroatomic or heterocyclic intersugar linkages. Accordingly, oligonucleotides of the disclosure can be stabilized against nucleolytic degradation such as by the incorporation of a modification, e.g., a nucleotide or nucleoside modification.

[000258] In some embodiments, an oligonucleotide may be of up to 50 or up to 100 nucleotides in length in which 2 to 10, 2 to 15, 2 to 16, 2 to 17, 2 to 18, 2 to 19, 2 to 20, 2 to 25, 2 to 30, 2 to 40, 2 to 45, or more nucleotides or nucleosides of the oligonucleotide are modified

nucleotides/nucleosides. The oligonucleotide may be of 8 to 30 nucleotides in length in which 2 to 10, 2 to 15, 2 to 16, 2 to 17, 2 to 18, 2 to 19, 2 to 20, 2 to 25, 2 to 30 nucleotides or nucleosides of the oligonucleotide are modified nucleotides/nucleosides. The oligonucleotide may be of 8 to 15 nucleotides in length in which 2 to 4, 2 to 5, 2 to 6, 2 to 7, 2 to 8, 2 to 9, 2 to 10, 2 to 11, 2 to 12, 2 to 13, 2 to 14 nucleotides or nucleosides of the oligonucleotide are modified nucleotides/nucleosides. Optionally, the oligonucleotides may have every nucleotide or nucleoside except 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 nucleotides/nucleosides modified. Oligonucleotide modifications are described further herein.

c. Modified Nucleosides

[000259] In some embodiments, the oligonucleotide described herein comprises at least one nucleoside modified at the 2' position of the sugar. In some embodiments, an oligonucleotide comprises at least one 2'-modified nucleoside. In some embodiments, all of the nucleosides in the oligonucleotide are 2'-modified nucleosides.

[000260] In some embodiments, the oligonucleotide described herein comprises one or more non-bicyclic 2'-modified nucleosides, e.g., 2'-deoxy, 2'-fluoro (2'-F), 2'-O-methyl (2'-O-Me), 2'-O-methoxyethyl (2'-MOE), 2'-O-aminopropyl (2'-O-AP), 2'-O-dimethylaminoethyl (2'-O-DMAOE), 2'-O-dimethylaminopropyl (2'-O-DMAP), 2'-O-dimethylaminoethoxyethyl (2'-O-DMAEOE), or 2'-O-N-methylacetamido (2'-O-NMA) modified nucleoside.

[000261] In some embodiments, the oligonucleotide described herein comprises one or more 2'-4' bicyclic nucleosides in which the ribose ring comprises a bridge moiety connecting two atoms in the ring, e.g., connecting the 2'-O atom to the 4'-C atom via a methylene (LNA) bridge, an ethylene (ENA) bridge, or a (S)-constrained ethyl (cEt) bridge. Examples of LNAs are described in International Patent Application Publication WO/2008/043753, published on April 17, 2008, and entitled "*RNA Antagonist Compounds For The Modulation Of PCSK9*", the contents of which are incorporated herein by reference in its entirety. Examples of ENAs are provided in International Patent Publication No. WO 2005/042777, published on May 12, 2005, and entitled "*APP/ENA Antisense*"; Morita et al., *Nucleic Acid Res.*, Suppl 1:241-242, 2001; Surono et al., *Hum. Gene Ther.*, 15:749-757, 2004; Koizumi, *Curr. Opin. Mol. Ther.*, 8:144-149, 2006 and Horie et al., *Nucleic Acids Symp. Ser (Oxf)*, 49:171-172, 2005; the disclosures of which are incorporated herein by reference in their entireties. Examples of cEt are provided in US Patents 7,101,993; 7,399,845 and 7,569,686, each of which is herein incorporated by reference in its entirety.

[000262] In some embodiments, the oligonucleotide comprises a modified nucleoside disclosed in one of the following United States Patent or Patent Application Publications: US Patent 7,399,845, issued on July 15, 2008, and entitled "*6-Modified Bicyclic Nucleic Acid*

Analogs"; US Patent 7,741,457, issued on June 22, 2010, and entitled "*6-Modified Bicyclic Nucleic Acid Analogs*"; US Patent 8,022,193, issued on September 20, 2011, and entitled "*6-Modified Bicyclic Nucleic Acid Analogs*"; US Patent 7,569,686, issued on August 4, 2009, and entitled "*Compounds And Methods For Synthesis Of Bicyclic Nucleic Acid Analogs*"; US Patent 7,335,765, issued on February 26, 2008, and entitled "*Novel Nucleoside And Oligonucleotide Analogues*"; US Patent 7,314,923, issued on January 1, 2008, and entitled "*Novel Nucleoside And Oligonucleotide Analogues*"; US Patent 7,816,333, issued on October 19, 2010, and entitled "*Oligonucleotide Analogues And Methods Utilizing The Same*" and US Publication Number 2011/0009471 now US Patent 8,957,201, issued on February 17, 2015, and entitled "*Oligonucleotide Analogues And Methods Utilizing The Same*", the entire contents of each of which are incorporated herein by reference for all purposes.

[000263] In some embodiments, the oligonucleotide comprises at least one modified nucleoside that results in an increase in T_m of the oligonucleotide in a range of 1 °C, 2 °C, 3 °C, 4 °C, or 5 °C compared with an oligonucleotide that does not have the at least one modified nucleoside. The oligonucleotide may have a plurality of modified nucleosides that result in a total increase in T_m of the oligonucleotide in a range of 2 °C, 3 °C, 4 °C, 5 °C, 6 °C, 7 °C, 8 °C, 9 °C, 10 °C, 15 °C, 20 °C, 25 °C, 30 °C, 35 °C, 40 °C, 45 °C or more compared with an oligonucleotide that does not have the modified nucleoside.

[000264] The oligonucleotide may comprise a mix of nucleosides of different kinds. For example, an oligonucleotide may comprise a mix of 2'-deoxyribonucleosides or ribonucleosides and 2'-fluoro modified nucleosides. An oligonucleotide may comprise a mix of deoxyribonucleosides or ribonucleosides and 2'-O-Me modified nucleosides. An oligonucleotide may comprise a mix of 2'-fluoro modified nucleosides and 2'-O-Me modified nucleosides. An oligonucleotide may comprise a mix of 2'-4' bicyclic nucleosides and 2'-MOE, 2'-fluoro, or 2'-O-Me modified nucleosides. An oligonucleotide may comprise a mix of non-bicyclic 2'-modified nucleosides (e.g., 2'-MOE, 2'-fluoro, or 2'-O-Me) and 2'-4' bicyclic nucleosides (e.g., LNA, ENA, cEt).

[000265] The oligonucleotide may comprise alternating nucleosides of different kinds. For example, an oligonucleotide may comprise alternating 2'-deoxyribonucleosides or ribonucleosides and 2'-fluoro modified nucleosides. An oligonucleotide may comprise alternating deoxyribonucleosides or ribonucleosides and 2'-O-Me modified nucleosides. An oligonucleotide may comprise alternating 2'-fluoro modified nucleosides and 2'-O-Me modified nucleosides. An oligonucleotide may comprise alternating 2'-4' bicyclic nucleosides and 2'-MOE, 2'-fluoro, or 2'-O-Me modified nucleosides. An oligonucleotide may comprise

alternating non-bicyclic 2'-modified nucleosides (e.g., 2'-MOE, 2'-fluoro, or 2'-O-Me) and 2'-4' bicyclic nucleosides (e.g., LNA, ENA, cEt).

[000266] In some embodiments, an oligonucleotide described herein comprises a 5'-vinylphosphonate modification, one or more abasic residues, and/or one or more inverted abasic residues.

d. Internucleoside Linkages / Backbones

[000267] In some embodiments, oligonucleotide may contain a phosphorothioate or other modified internucleoside linkage. In some embodiments, the oligonucleotide comprises phosphorothioate internucleoside linkages. In some embodiments, the oligonucleotide comprises phosphorothioate internucleoside linkages between at least two nucleosides. In some embodiments, the oligonucleotide comprises phosphorothioate internucleoside linkages between all nucleosides. For example, in some embodiments, oligonucleotides comprise modified internucleoside linkages at the first, second, and/or (e.g., and) third internucleoside linkage at the 5' or 3' end of the nucleotide sequence.

[000268] Phosphorus-containing linkages that may be used include, but are not limited to, phosphorothioates, chiral phosphorothioates, phosphorodithioates, phosphotriesters, aminoalkylphosphotriesters, methyl and other alkyl phosphonates comprising 3'-alkylene phosphonates and chiral phosphonates, phosphinates, phosphoramidates comprising 3'-amino phosphoramidate and aminoalkylphosphoramidates, thionophosphoramidates, thionoalkylphosphonates, thionoalkylphosphotriesters, and boranophosphates having normal 3'-5' linkages, 2'-5' linked analogs of these, and those having inverted polarity wherein the adjacent pairs of nucleoside units are linked 3'-5' to 5'-3' or 2'-5' to 5'-2'; see US patent nos. 3,687,808; 4,469,863; 4,476,301; 5,023,243; 5,177,196; 5,188,897; 5,264,423; 5,276,019; 5,278,302; 5,286,717; 5,321,131; 5,399,676; 5,405,939; 5,453,496; 5,455,233; 5,466,677; 5,476,925; 5,519,126; 5,536,821; 5,541,306; 5,550,111; 5,563,253; 5,571,799; 5,587,361; and 5,625,050.

[000269] In some embodiments, oligonucleotides may have heteroatom backbones, such as methylene(methylimino) or MMI backbones; amide backbones (see De Mesmaeker et al. *Ace. Chem. Res.* 1995, 28:366-374); morpholino backbones (see Summerton and Weller, U.S. Pat. No. 5,034,506); or peptide nucleic acid (PNA) backbones (wherein the phosphodiester backbone of the oligonucleotide is replaced with a polyamide backbone, the nucleotides being bound directly or indirectly to the aza nitrogen atoms of the polyamide backbone, see Nielsen et al., *Science* 1991, 254, 1497).

e. Stereospecific Oligonucleotides

[000270] In some embodiments, internucleotidic phosphorus atoms of oligonucleotides are chiral, and the properties of the oligonucleotides by adjusted based on the configuration of the

chiral phosphorus atoms. In some embodiments, appropriate methods may be used to synthesize P-chiral oligonucleotide analogs in a stereocontrolled manner (e.g., as described in Oka N, Wada T, Stereocontrolled synthesis of oligonucleotide analogs containing chiral internucleotidic phosphorus atoms. *Chem Soc Rev.* 2011 Dec;40(12):5829-43.) In some embodiments, phosphorothioate containing oligonucleotides comprise nucleoside units that are joined together by either substantially all Sp or substantially all Rp phosphorothioate intersugar linkages are provided. In some embodiments, such phosphorothioate oligonucleotides having substantially chirally pure intersugar linkages are prepared by enzymatic or chemical synthesis, as described, for example, in US Patent 5,587,261, issued on December 12, 1996, the contents of which are incorporated herein by reference in their entirety. In some embodiments, chirally controlled oligonucleotides provide selective cleavage patterns of a target nucleic acid. For example, in some embodiments, a chirally controlled oligonucleotide provides single site cleavage within a complementary sequence of a nucleic acid, as described, for example, in US Patent Application Publication 20170037399 A1, published on February 2, 2017, entitled "CHIRAL DESIGN", the contents of which are incorporated herein by reference in their entirety.

f. Morpholinos

[000271] In some embodiments, the oligonucleotide may be a morpholino-based compounds. Morpholino-based oligomeric compounds are described in Dwaine A. Braasch and David R. Corey, *Biochemistry*, 2002, 41(14), 4503-4510; *Genesis*, volume 30, issue 3, 2001; Heasman, J., *Dev. Biol.*, 2002, 243, 209-214; Nasevicius et al., *Nat. Genet.*, 2000, 26, 216-220; Lacerra et al., *Proc. Natl. Acad. Sci.*, 2000, 97, 9591-9596; and U.S. Pat. No. 5,034,506, issued Jul. 23, 1991. In some embodiments, the morpholino-based oligomeric compound is a phosphorodiamidate morpholino oligomer (PMO) (e.g., as described in Iverson, *Curr. Opin. Mol. Ther.*, 3:235-238, 2001; and Wang et al., *J. Gene Med.*, 12:354-364, 2010; the disclosures of which are incorporated herein by reference in their entireties).

g. Peptide Nucleic Acids (PNAs)

[000272] In some embodiments, both a sugar and an internucleoside linkage (the backbone) of the nucleotide units of an oligonucleotide are replaced with novel groups. In some embodiments, the base units are maintained for hybridization with an appropriate nucleic acid target compound. One such oligomeric compound, an oligonucleotide mimetic that has been shown to have excellent hybridization properties, is referred to as a peptide nucleic acid (PNA). In PNA compounds, the sugar-backbone of an oligonucleotide is replaced with an amide containing backbone, for example, an aminoethylglycine backbone. The nucleobases are retained and are bound directly or indirectly to aza nitrogen atoms of the amide portion of the

backbone. Representative publication that report the preparation of PNA compounds include, but are not limited to, US patent nos. 5,539,082; 5,714,331; and 5,719,262, each of which is herein incorporated by reference. Further teaching of PNA compounds can be found in Nielsen *et al.*, Science, 1991, 254, 1497-1500.

h. Mixmers

[000273] In some embodiments, an oligonucleotide described herein may be a mixmer or comprise a mixmer sequence pattern. In general, mixmers are oligonucleotides that comprise both naturally and non-naturally occurring nucleosides or comprise two different types of non-naturally occurring nucleosides typically in an alternating pattern. Mixmers generally have higher binding affinity than unmodified oligonucleotides and may be used to specifically bind a target molecule, *e.g.*, to block a binding site on the target molecule. Generally, mixmers do not recruit an RNase to the target molecule and thus do not promote cleavage of the target molecule. Such oligonucleotides that are incapable of recruiting RNase H have been described, for example, see WO2007/112754 or WO2007/112753.

[000274] In some embodiments, the mixmer comprises or consists of a repeating pattern of nucleoside analogues and naturally occurring nucleosides, or one type of nucleoside analogue and a second type of nucleoside analogue. However, a mixmer need not comprise a repeating pattern and may instead comprise any arrangement of modified nucleosides and naturally occurring nucleosides or any arrangement of one type of modified nucleoside and a second type of modified nucleoside. The repeating pattern, may, for instance be every second or every third nucleoside is a modified nucleoside, such as LNA, and the remaining nucleosides are naturally occurring nucleosides, such as DNA, or are a 2' substituted nucleoside analogue such as 2'-MOE or 2' fluoro analogues, or any other modified nucleoside described herein. It is recognized that the repeating pattern of modified nucleoside, such as LNA units, may be combined with modified nucleoside at fixed positions—*e.g.* at the 5' or 3' termini.

[000275] In some embodiments, a mixmer does not comprise a region of more than 5, more than 4, more than 3, or more than 2 consecutive naturally occurring nucleosides, such as DNA nucleosides. In some embodiments, the mixmer comprises at least a region consisting of at least two consecutive modified nucleosides, such as at least two consecutive LNAs. In some embodiments, the mixmer comprises at least a region consisting of at least three consecutive modified nucleoside units, such as at least three consecutive LNAs.

[000276] In some embodiments, the mixmer does not comprise a region of more than 7, more than 6, more than 5, more than 4, more than 3, or more than 2 consecutive nucleoside analogues, such as LNAs. In some embodiments, LNA units may be replaced with other nucleoside analogues, such as those referred to herein.

[000277] Mixmers may be designed to comprise a mixture of affinity enhancing modified nucleosides, such as in non-limiting example LNA nucleosides and 2'-O-Me nucleosides. In some embodiments, a mixmer comprises modified internucleoside linkages (e.g., phosphorothioate internucleoside linkages or other linkages) between at least two, at least three, at least four, at least five or more nucleosides.

[000278] A mixmer may be produced using any suitable method. Representative U.S. patents, U.S. patent publications, and PCT publications that teach the preparation of mixmers include U.S. patent publication Nos. US20060128646, US20090209748, US20090298916, US20110077288, and US20120322851, and U.S. patent No. 7687617.

[000279] In some embodiments, a mixmer comprises one or more morpholino nucleosides. For example, in some embodiments, a mixmer may comprise morpholino nucleosides mixed (e.g., in an alternating manner) with one or more other nucleosides (e.g., DNA, RNA nucleosides) or modified nucleosides (e.g., LNA, 2'-O-Me nucleosides).

[000280] In some embodiments, mixmers are useful for splice correcting or exon skipping, for example, as reported in Touznik A., et al., *LNA/DNA mixmer-based antisense oligonucleotides correct alternative splicing of the SMN2 gene and restore SMN protein expression in type 1 SMA fibroblasts* Scientific Reports, volume 7, Article number: 3672 (2017), Chen S. et al., *Synthesis of a Morpholino Nucleic Acid (MNA)-Uridine Phosphoramidite, and Exon Skipping Using MNA/2'-O-Methyl Mixmer Antisense Oligonucleotide*, Molecules 2016, 21, 1582, the contents of each which are incorporated herein by reference.

i. Multimers

[000281] In some embodiments, molecular payloads may comprise multimers (e.g., concatemers) of 2 or more oligonucleotides connected by a linker. In this way, in some embodiments, the oligonucleotide loading of a complex can be increased beyond the available linking sites on a targeting agent (e.g., available thiol sites on an antibody) or otherwise tuned to achieve a particular payload loading content. Oligonucleotides in a multimer can be the same or different (e.g., targeting different genes or different sites on the same gene or products thereof).

[000282] In some embodiments, multimers comprise 2 or more oligonucleotides linked together by a cleavable linker. However, in some embodiments, multimers comprise 2 or more oligonucleotides linked together by a non-cleavable linker. In some embodiments, a multimer comprises 2, 3, 4, 5, 6, 7, 8, 9, 10 or more oligonucleotides linked together. In some embodiments, a multimer comprises 2 to 5, 2 to 10 or 4 to 20 oligonucleotides linked together.

[000283] In some embodiments, a multimer comprises 2 or more oligonucleotides linked end-to-end (in a linear arrangement). In some embodiments, a multimer comprises 2 or more oligonucleotides linked end-to-end via an oligonucleotide based linker (e.g., poly-dT linker, an

abasic linker). In some embodiments, a multimer comprises a 5' end of one oligonucleotide linked to a 3' end of another oligonucleotide. In some embodiments, a multimer comprises a 3' end of one oligonucleotide linked to a 3' end of another oligonucleotide. In some embodiments, a multimer comprises a 5' end of one oligonucleotide linked to a 5' end of another oligonucleotide. Still, in some embodiments, multimers can comprise a branched structure comprising multiple oligonucleotides linked together by a branching linker.

[000284] Further examples of multimers that may be used in the complexes provided herein are disclosed, for example, in US Patent Application Number 2015/0315588 A1, entitled *Methods of delivering multiple targeting oligonucleotides to a cell using cleavable linkers*, which was published on November 5, 2015; US Patent Application Number 2015/0247141 A1, entitled *Multimeric Oligonucleotide Compounds*, which was published on September 3, 2015, US Patent Application Number US 2011/0158937 A1, entitled *Immunostimulatory Oligonucleotide Multimers*, which was published on June 30, 2011; and US Patent Number 5,693,773, entitled *Triplex-Forming Antisense Oligonucleotides Having Abasic Linkers Targeting Nucleic Acids Comprising Mixed Sequences Of Purines And Pyrimidines*, which issued on December 2, 1997, the contents of each of which are incorporated herein by reference in their entireties.

C. Linkers

[000285] Complexes described herein generally comprise a linker that covalently links any one of the anti-TfR1 antibodies described herein to a molecular payload. A linker comprises at least one covalent bond. In some embodiments, a linker may be a single bond, e.g., a disulfide bond or disulfide bridge, that covalently links an anti-TfR1 antibody to a molecular payload. However, in some embodiments, a linker may covalently link any one of the anti-TfR1 antibodies described herein to a molecular payload through multiple covalent bonds. In some embodiments, a linker may be a cleavable linker. However, in some embodiments, a linker may be a non-cleavable linker. A linker is typically stable *in vitro* and *in vivo*, and may be stable in certain cellular environments. Additionally, typically a linker does not negatively impact the functional properties of either the anti-TfR1 antibody or the molecular payload. Examples and methods of synthesis of linkers are known in the art (see, e.g. Kline, T. et al. "Methods to Make Homogenous Antibody Drug Conjugates." *Pharmaceutical Research*, 2015, 32:11, 3480–3493.; Jain, N. et al. "Current ADC Linker Chemistry" *Pharm Res.* 2015, 32:11, 3526–3540.; McCombs, J.R. and Owen, S.C. "Antibody Drug Conjugates: Design and Selection of Linker, Payload and Conjugation Chemistry" *AAPS J.* 2015, 17:2, 339–351.).

[000286] A linker typically will contain two different reactive species that allow for attachment to both the anti-TfR1 antibody and a molecular payload. In some embodiments, the

two different reactive species may be a nucleophile and/or an electrophile. In some embodiments, a linker contains two different electrophiles or nucleophiles that are specific for two different nucleophiles or electrophiles. In some embodiments, a linker is covalently linked to an anti-TfR1 antibody via conjugation to a lysine residue or a cysteine residue of the anti-TfR1 antibody. In some embodiments, a linker is covalently linked to a cysteine residue of an anti-TfR1 antibody via a maleimide-containing linker, wherein optionally the maleimide-containing linker comprises a maleimidocaproyl or maleimidomethyl cyclohexane-1-carboxylate group. In some embodiments, a linker is covalently linked to a cysteine residue of an anti-TfR1 antibody or thiol functionalized molecular payload via a 3-arylpropionitrile functional group. In some embodiments, a linker is covalently linked to a lysine residue of an anti-TfR1 antibody. In some embodiments, a linker is covalently linked to an anti-TfR1 antibody and/or (e.g., and) a molecular payload, independently, via an amide bond, a carbamate bond, a hydrazide, a triazole, a thioether, and/or a disulfide bond.

i. Cleavable Linkers

[000287] A cleavable linker may be a protease-sensitive linker, a pH-sensitive linker, or a glutathione-sensitive linker. These linkers are typically cleavable only intracellularly and are preferably stable in extracellular environments, e.g., extracellular to a muscle cell.


[000288] Protease-sensitive linkers are cleavable by protease enzymatic activity. These linkers typically comprise peptide sequences and may be 2-10 amino acids, about 2-5 amino acids, about 5-10 amino acids, about 10 amino acids, about 5 amino acids, about 3 amino acids, or about 2 amino acids in length. In some embodiments, a peptide sequence may comprise naturally-occurring amino acids, e.g. cysteine, alanine, or non-naturally-occurring or modified amino acids. Non-naturally occurring amino acids include β -amino acids, homo-amino acids, proline derivatives, 3-substituted alanine derivatives, linear core amino acids, N-methyl amino acids, and others known in the art. In some embodiments, a protease-sensitive linker comprises a valine-citrulline or alanine-citrulline sequence. In some embodiments, a protease-sensitive linker can be cleaved by a lysosomal protease, e.g. cathepsin B, and/or (e.g., and) an endosomal protease.

[000289] A pH-sensitive linker is a covalent linkage that readily degrades in high or low pH environments. In some embodiments, a pH-sensitive linker may be cleaved at a pH in a range of 4 to 6. In some embodiments, a pH-sensitive linker comprises a hydrazone or cyclic acetal. In some embodiments, a pH-sensitive linker is cleaved within an endosome or a lysosome.


[000290] In some embodiments, a glutathione-sensitive linker comprises a disulfide moiety. In some embodiments, a glutathione-sensitive linker is cleaved by a disulfide exchange

reaction with a glutathione species inside a cell. In some embodiments, the disulfide moiety further comprises at least one amino acid, e.g., a cysteine residue.


[000291] In some embodiments, a linker comprises a valine-citrulline sequence (e.g., as described in US Patent 6,214,345, incorporated herein by reference). In some embodiments, before conjugation, a linker comprises a structure of:



[000292] In some embodiments, after conjugation, a linker comprises a structure of:




[000293] In some embodiments, before conjugation, a linker comprises a structure of:



(A)


wherein n is any number from 0-10. In some embodiments, n is 3.

[000294] In some embodiments, a linker comprises a structure of:



wherein n is any number from 0-10, wherein m is any number from 0-10. In some embodiments, n is 3 and/or (e.g., and) m is 4.

[000295] In some embodiments, a linker comprises a structure of:



wherein n is any number from 0-10, wherein m is any number from 0-10. In some embodiments, n is 3 and/or (e.g., and) m is 4.

ii. Non-cleavable Linkers

[000296] In some embodiments, non-cleavable linkers may be used. Generally, a non-cleavable linker cannot be readily degraded in a cellular or physiological environment. In some embodiments, a non-cleavable linker comprises an optionally substituted alkyl group, wherein the substitutions may include halogens, hydroxyl groups, oxygen species, and other common substitutions. In some embodiments, a linker may comprise an optionally substituted alkyl, an optionally substituted alkylene, an optionally substituted arylene, a heteroarylene, a peptide sequence comprising at least one non-natural amino acid, a truncated glycan, a sugar or sugars that cannot be enzymatically degraded, an azide, an alkyne-azide, a peptide sequence comprising a LPXT sequence, a thioether, a biotin, a biphenyl, repeating units of polyethylene glycol or equivalent compounds, acid esters, acid amides, sulfamides, and/or an alkoxy-amine linker. In some embodiments, sortase-mediated ligation can be utilized to covalently link an anti-TfR1 antibody comprising a LPXT sequence to a molecular payload comprising a (G)_n sequence (see,

e.g. Proft T. Sortase-mediated protein ligation: an emerging biotechnology tool for protein modification and immobilization. *Biotechnol Lett.* 2010, 32(1):1-10.).

[000297] In some embodiments, a linker may comprise a substituted alkylene, an optionally substituted alkenylene, an optionally substituted alkynylene, an optionally substituted cycloalkylene, an optionally substituted cycloalkenylene, an optionally substituted arylene, an optionally substituted heteroarylene further comprising at least one heteroatom selected from N, O, and S.; an optionally substituted heterocyclylene further comprising at least one heteroatom selected from N, O, and S, an imino, an optionally substituted nitrogen species, an optionally substituted oxygen species O, an optionally substituted sulfur species, or a poly(alkylene oxide), e.g. polyethylene oxide or polypropylene oxide. In some embodiments, a linker may be a non-cleavable N-gamma-maleimidobutyryl-oxysuccinimide ester (GMBS) linker.

iii. Linker conjugation

[000298] In some embodiments, a linker is covalently linked to an anti-TfR1 antibody and/or (e.g., and) molecular payload via a phosphate, thioether, ether, carbon-carbon, carbamate, or amide bond. In some embodiments, a linker is covalently linked to an oligonucleotide through a phosphate or phosphorothioate group, e.g. a terminal phosphate of an oligonucleotide backbone. In some embodiments, a linker is covalently linked to an anti-TfR1 antibody, through a lysine or cysteine residue present on the anti-TfR1 antibody.

[000299] In some embodiments, a linker, or a portion thereof is covalently linked to an anti-TfR1 antibody and/or (e.g., and) molecular payload by a cycloaddition reaction between an azide and an alkyne to form a triazole, wherein the azide or the alkyne may be located on the anti-TfR1 antibody, molecular payload, or the linker. In some embodiments, an alkyne may be a cyclic alkyne, e.g., a cyclooctyne. In some embodiments, an alkyne may be bicyclononyne (also known as bicyclo[6.1.0]nonyne or BCN) or substituted bicyclononyne. In some embodiments, a cyclooctyne is as described in International Patent Application Publication WO2011136645, published on November 3, 2011, entitled, “*Fused Cyclooctyne Compounds And Their Use In Metal-free Click Reactions*”. In some embodiments, an azide may be a sugar or carbohydrate molecule that comprises an azide. In some embodiments, an azide may be 6-azido-6-deoxygalactose or 6-azido-N-acetylgalactosamine. In some embodiments, a sugar or carbohydrate molecule that comprises an azide is as described in International Patent Application Publication WO2016170186, published on October 27, 2016, entitled, “*Process For The Modification Of A Glycoprotein Using A Glycosyltransferase That Is Or Is Derived From A $\beta(1,4)$ -N-Acetylgalactosaminyltransferase*”. In some embodiments, a cycloaddition reaction between an azide and an alkyne to form a triazole, wherein the azide or the alkyne may be located on the anti-TfR1 antibody, molecular payload, or the linker is as described in

International Patent Application Publication WO2014065661, published on May 1, 2014, entitled, “*Modified antibody, antibody-conjugate and process for the preparation thereof*”; or International Patent Application Publication WO2016170186, published on October 27, 2016, entitled, “*Process For The Modification Of A Glycoprotein Using A Glycosyltransferase That Is Or Is Derived From A $\beta(1,4)$ -N-Acetylgalactosaminyltransferase*”.


[000300] In some embodiments, a linker comprises a spacer, *e.g.*, a polyethylene glycol spacer or an acyl/carbomoyl sulfamide spacer, *e.g.*, a HydraSpaceTM spacer. In some embodiments, a spacer is as described in Verkade, J.M.M. et al., “*A Polar Sulfamide Spacer Significantly Enhances the Manufacturability, Stability, and Therapeutic Index of Antibody-Drug Conjugates*”, *Antibodies*, 2018, 7, 12.

[000301] In some embodiments, a linker is covalently linked to an anti-TfR1 antibody and/or (*e.g.*, and) molecular payload by the Diels-Alder reaction between a dienophile and a diene/hetero-diene, wherein the dienophile or the diene/hetero-diene may be located on the anti-TfR1 antibody, molecular payload, or the linker. In some embodiments a linker is covalently linked to an anti-TfR1 antibody and/or (*e.g.*, and) molecular payload by other pericyclic reactions such as an ene reaction. In some embodiments, a linker is covalently linked to an anti-TfR1 antibody and/or (*e.g.*, and) molecular payload by an amide, thioamide, or sulfonamide bond reaction. In some embodiments, a linker is covalently linked to an anti-TfR1 antibody and/or (*e.g.*, and) molecular payload by a condensation reaction to form an oxime, hydrazone, or semicarbazide group existing between the linker and the anti-TfR1 antibody and/or (*e.g.*, and) molecular payload.

[000302] In some embodiments, a linker is covalently linked to an anti-TfR1 antibody and/or (*e.g.*, and) molecular payload by a conjugate addition reaction between a nucleophile, *e.g.* an amine or a hydroxyl group, and an electrophile, *e.g.* a carboxylic acid, carbonate, or an aldehyde. In some embodiments, a nucleophile may exist on a linker and an electrophile may exist on an anti-TfR1 antibody or molecular payload prior to a reaction between a linker and an anti-TfR1 antibody or molecular payload. In some embodiments, an electrophile may exist on a linker and a nucleophile may exist on an anti-TfR1 antibody or molecular payload prior to a reaction between a linker and an anti-TfR1 antibody or molecular payload. In some embodiments, an electrophile may be an azide, pentafluorophenyl, a silicon centers, a carbonyl, a carboxylic acid, an anhydride, an isocyanate, a thioisocyanate, a succinimidyl ester, a sulfosuccinimidyl ester, a maleimide, an alkyl halide, an alkyl pseudohalide, an epoxide, an episulfide, an aziridine, an aryl, an activated phosphorus center, and/or an activated sulfur center. In some embodiments, a nucleophile may be an optionally substituted alkene, an optionally substituted alkyne, an optionally substituted aryl, an optionally substituted


heterocyclyl, a hydroxyl group, an amino group, an alkylamino group, an anilido group, and/or a thiol group.

[000303] In some embodiments, a linker comprises a valine-citrulline sequence covalently linked to a reactive chemical moiety (e.g., an azide moiety or a BCN moiety for click chemistry). In some embodiments, a linker comprising a valine-citrulline sequence covalently linked to a reactive chemical moiety (e.g., an azide moiety for click chemistry) comprises a structure of:




wherein n is any number from 0-10. In some embodiments, n is 3.

[000304] In some embodiments, a linker comprising the structure of Formula (A) is covalently linked (e.g., optionally via additional chemical moieties) to a molecular payload (e.g., an oligonucleotide). In some embodiments, a linker comprising the structure of Formula (A) is covalently linked to an oligonucleotide, e.g., through a nucleophilic substitution with amine-L1-oligonucleotides forming a carbamate bond, yielding a compound comprising a structure of:




wherein n is any number from 0-10. In some embodiments, n is 3.

[000305] In some embodiments, the compound of Formula (B) is further covalently linked via a triazole to additional moieties, wherein the triazole is formed by a click reaction between the azide of Formula (A) or Formula (B) and an alkyne provided on a bicyclononyne. In some embodiments, a compound comprising a bicyclononyne comprises a structure of:




wherein m is any number from 0-10. In some embodiments, m is 4.

[000306] In some embodiments, the azide of the compound of structure (B) forms a triazole via a click reaction with the alkyne of the compound of structure (C), forming a compound comprising a structure of:




wherein n is any number from 0-10, and wherein m is any number from 0-10. In some embodiments, n is 3 and m is 4.

[000307] In some embodiments, the compound of structure (D) is further covalently linked to a lysine of the anti-TfR1 antibody, forming a complex comprising a structure of:




wherein n is any number from 0-10, wherein m is any number from 0-10. In some embodiments, n is 3 and/or (e.g., and) m is 4. It should be understood that the amide shown adjacent the anti-TfR1 antibody in Formula (E) results from a reaction with an amine of the anti-TfR1 antibody, such as a lysine epsilon amine.

[000308] In some embodiments, the compound of Formula (C) is further covalently linked to a lysine of the anti-TfR1 antibody, forming a compound comprising a structure of:




wherein m is 0-15 (e.g., 4). It should be understood that the amide shown adjacent the anti-TfR1 antibody in Formula (F) results from a reaction with an amine of the anti-TfR1 antibody, such as a lysine epsilon amine.

[000309] In some embodiments, the azide of the compound of structure (B) forms a triazole via a click reaction with the alkyne of the compound of structure (F), forming a complex comprising a structure of:



wherein n is any number from 0-10, wherein m is any number from 0-10. In some embodiments, n is 3 and/or (e.g., and) m is 4. It should be understood that the amide shown adjacent the anti-TfR1 antibody in Formula (E) results from a reaction with an amine of the anti-TfR1 antibody, such as a lysine epsilon amine.


[000310] In some embodiments, the azide of the compound of structure (A) forms a triazole via a click reaction with the alkyne of the compound of structure (F), forming a compound comprising a structure of:



wherein n is any number from 0-10, wherein m is any number from 0-10. In some embodiments, n is 3 and/or (e.g., and) m is 4. In some embodiments, an oligonucleotide is covalently linked to a compound comprising a structure of formula (G), thereby forming a complex comprising a structure of formula (E). It should be understood that the amide shown


adjacent the anti-TfR1 antibody in Formula (G) results from a reaction with an amine of the anti-TfR1 antibody, such as a lysine epsilon amine.

[000311] In some embodiments, in any one of the complexes described herein, the anti-TfR1 antibody is covalently linked via a lysine of the anti-TfR1 antibody to a molecular payload (e.g., an oligonucleotide) via a linker comprising a structure of:



wherein n is any number from 0-10, wherein m is any number from 0-10. In some embodiments, n is 3 and/or (e.g., and) m is 4.


[000312] In some embodiments, in any one of the complexes described herein, the anti-TfR1 antibody is covalently linked via a lysine of the anti-TfR1 antibody to a molecular payload (e.g., an oligonucleotide) via a linker comprising a structure of:




wherein n is any number from 0-10, wherein m is any number from 0-10. In some embodiments, n is 3 and/or (e.g., and) m is 4.


[000313] In some embodiments, in formulae (B), (D), (E), and (I), L1 is a spacer that is a substituted or unsubstituted aliphatic, substituted or unsubstituted heteroaliphatic, substituted or unsubstituted carbocyclylene, substituted or unsubstituted heterocyclylene, substituted or unsubstituted arylene, substituted or unsubstituted heteroarylene, -O-, -N(R^A)-, -S-, -C(=O)-, -C(=O)O-, -C(=O)NR^A-, -NR^AC(=O)-, -NR^AC(=O)R^A-, -C(=O)R^A-, -NR^AC(=O)O-, -NR^AC(=O)N(R^A)-, -OC(=O)-, -OC(=O)O-, -OC(=O)N(R^A)-, -S(O)₂NR^A-, -NR^AS(O)₂-, or a

combination thereof, wherein each R^A is independently hydrogen or substituted or unsubstituted alkyl. In some embodiments, L1 is




wherein L2 is ; wherein *a* labels the site directly linked to the carbamate moiety of formulae (B), (D), (E), and (I); and *b* labels the site covalently linked (directly or via additional chemical moieties) to the oligonucleotide.

[000314] In some embodiments, L1 is:




wherein *a* labels the site directly linked to the carbamate moiety of formulae (B), (D), (E), and (I); and *b* labels the site covalently linked (directly or via additional chemical moieties) to the oligonucleotide.

[000315] In some embodiments, L1 is .

[000316] In some embodiments, L1 is linked to a 5' phosphate of the oligonucleotide. In some embodiments, the phosphate is a phosphodiester. In some embodiments, L1 is linked to a 5' phosphorothioate of the oligonucleotide. In some embodiments, L1 is linked to a 5' phosphonoamidate of the oligonucleotide. In some embodiments, L1 is linked via a phosphorodiamidate linkage to the 5' end of the oligonucleotide.

[000317] In some embodiments, L1 is optional (e.g., need not be present).


[000318] In some embodiments, any one of the complexes described herein has a structure of:



(J),

wherein n is 0-15 (e.g., 3) and m is 0-15 (e.g., 4). It should be understood that the amide shown adjacent the anti-TfR1 antibody in Formula (J) results from a reaction with an amine of the anti-TfR1 antibody, such as a lysine epsilon amine.

[000319] In some embodiments, any one of the complexes described herein has a structure of:



(K),

wherein n is 0-15 (e.g., 3) and m is 0-15 (e.g., 4).

[000320] In some embodiments, the oligonucleotide is modified to comprise an amine group at the 5' end, the 3' end, or internally (e.g., as an amine functionalized nucleobase), prior to linking to a compound, e.g., a compound of formula (A) or formula (G).


[000321] Although linker conjugation is described in the context of anti-TfR1 antibodies and oligonucleotide molecular payloads, it should be understood that use of such linker conjugation on other muscle-targeting agents, such as other muscle-targeting antibodies, and/or on other molecular payloads is contemplated.

D. Examples of Antibody-Molecular Payload Complexes

[000322] Further provided herein are non-limiting examples of complexes comprising any one the anti-TfR1 antibodies described herein covalently linked to any of the molecular payloads (e.g., an oligonucleotide) described herein. In some embodiments, the anti-TfR1 antibody (e.g., any one of the anti-TfR1 antibodies provided in Tables 2-7) is covalently linked to a molecular


payload (e.g., an oligonucleotide such as the oligonucleotides provided in Table 8) via a linker. Any of the linkers described herein may be used. In some embodiments, if the molecular payload is an oligonucleotide, the linker is linked to the 5' end of the oligonucleotide, the 3' end of the oligonucleotide, or to an internal site of the oligonucleotide. In some embodiments, the linker is linked to the anti-TfR1 antibody via a thiol-reactive linkage (e.g., via a cysteine in the anti-TfR1 antibody). In some embodiments, the linker (e.g., a linker comprising a valine-citrulline sequence) is linked to the antibody (e.g., an anti-TfR1 antibody described herein) via an amine group (e.g., via a lysine in the antibody). In some embodiments, the molecular payload is a DMD-targeting oligonucleotide (e.g., a DMD-targeting oligonucleotide listed in Table 8, provided by any one of SEQ ID NO: 400-879, or complementary to any one of SEQ ID NO: 160-399).

[000323] An example of a structure of a complex comprising an anti-TfR1 antibody covalently linked to a molecular payload via a linker is provided below:



wherein the linker is linked to the antibody via a thiol-reactive linkage (e.g., via a cysteine in the antibody). In some embodiments, the molecular payload is a DMD-targeting oligonucleotide (e.g., a DMD-targeting oligonucleotide listed in Table 8, provided by any one of SEQ ID NO: 400-879, or complementary to any one of SEQ ID NO: 160-399).

[000324] Another example of a structure of a complex comprising an anti-TfR1 antibody covalently linked to a molecular payload via a linker is provided below:



(E)

wherein n is a number between 0-10, wherein m is a number between 0-10, wherein the linker is linked to the antibody via an amine group (e.g., on a lysine residue), and/or (e.g., and) wherein

the linker is linked to the oligonucleotide (e.g., at the 5' end, 3' end, or internally). In some embodiments, the linker is linked to the antibody via a lysine, the linker is linked to the oligonucleotide at the 5' end, n is 3, and m is 4. In some embodiments, the molecular payload is a DMD-targeting oligonucleotide (e.g., a DMD-targeting oligonucleotide listed in Table 8, provided by any one of SEQ ID NO: 400-879, or complementary to any one of SEQ ID NO: 160-399). It should be understood that the amide shown adjacent the anti-TfR1 antibody in Formula (E) results from a reaction with an amine of the anti-TfR1 antibody, such as a lysine epsilon amine.

[000325] It should be appreciated that antibodies can be linked to molecular payloads with different stoichiometries, a property that may be referred to as a drug to antibody ratios (DAR) with the “drug” being the molecular payload. In some embodiments, one molecular payload is linked to an antibody (DAR = 1). In some embodiments, two molecular payloads are linked to an antibody (DAR = 2). In some embodiments, three molecular payloads are linked to an antibody (DAR = 3). In some embodiments, four molecular payloads are linked to an antibody (DAR = 4). In some embodiments, a mixture of different complexes, each having a different DAR, is provided. In some embodiments, an average DAR of complexes in such a mixture may be in a range of 1 to 3, 1 to 4, 1 to 5 or more. An average DAR of complexes in a mixture need not be an integer value. DAR may be increased by conjugating molecular payloads to different sites on an antibody and/or (e.g., and) by conjugating multimers to one or more sites on antibody. For example, a DAR of 2 may be achieved by conjugating a single molecular payload to two different sites on an antibody or by conjugating a dimer molecular payload to a single site of an antibody.

[000326] In some embodiments, the complex described herein comprises an anti-TfR1 antibody described herein (e.g., the antibodies provided in Tables 2-7) covalently linked to a molecular payload. In some embodiments, the complex described herein comprises an anti-TfR1 antibody described herein (e.g., the antibodies provided in Tables 2-7) covalently linked to molecular payload via a linker (e.g., a linker comprising a valine-citrulline sequence). In some embodiments, the linker (e.g., a linker comprising a valine-citrulline sequence) is linked to the antibody (e.g., an anti-TfR1 antibody described herein) via a thiol-reactive linkage (e.g., via a cysteine in the antibody). In some embodiments, the linker (e.g., a linker comprising a valine-citrulline sequence) is linked to the antibody (e.g., an anti-TfR1 antibody described herein) via an amine group (e.g., via a lysine in the antibody). In some embodiments, the molecular payload is a DMD-targeting oligonucleotide (e.g., a DMD-targeting oligonucleotide listed in Table 8, provided by any one of SEQ ID NO: 400-879, or complementary to any one of SEQ ID NO: 160-399).

[000327] In some embodiments, the complex described herein comprises an anti-TfR1 antibody covalently linked to a molecular payload, wherein the anti-TfR1 antibody comprises a CDR-H1, a CDR-H2, a CDR-H3, a CDR-L1, a CDR-L2, and a CDR-L3 of any one of the antibodies listed in Table 2. In some embodiments, the molecular payload is a DMD-targeting oligonucleotide (e.g., a DMD-targeting oligonucleotide listed in Table 8, provided by any one of SEQ ID NO: 400-879, or complementary to any one of SEQ ID NO: 160-399).

[000328] In some embodiments, the complex described herein comprises an anti-TfR1 antibody covalently linked to a molecular payload, wherein the anti-TfR1 antibody comprises a VH comprising the amino acid sequence of SEQ ID NO: 69, SEQ ID NO: 71, or SEQ ID NO: 72, and a VL comprising the amino acid sequence of SEQ ID NO: 70. In some embodiments, the molecular payload is a DMD-targeting oligonucleotide (e.g., a DMD-targeting oligonucleotide listed in Table 8, provided by any one of SEQ ID NO: 400-879, or complementary to any one of SEQ ID NO: 160-399).

[000329] In some embodiments, the complex described herein comprises an anti-TfR1 antibody covalently linked to a molecular payload, wherein the anti-TfR1 antibody comprises a VH comprising the amino acid sequence of SEQ ID NO: 73 or SEQ ID NO: 76, and a VL comprising the amino acid sequence of SEQ ID NO: 74. In some embodiments, the molecular payload is a DMD-targeting oligonucleotide (e.g., a DMD-targeting oligonucleotide listed in Table 8, provided by any one of SEQ ID NO: 400-879, or complementary to any one of SEQ ID NO: 160-399).

[000330] In some embodiments, the complex described herein comprises an anti-TfR1 antibody covalently linked to a molecular payload, wherein the anti-TfR1 antibody comprises a VH comprising the amino acid sequence of SEQ ID NO: 73 or SEQ ID NO: 76, and a VL comprising the amino acid sequence of SEQ ID NO: 75. In some embodiments, the molecular payload is a DMD-targeting oligonucleotide (e.g., a DMD-targeting oligonucleotide listed in Table 8, provided by any one of SEQ ID NO: 400-879, or complementary to any one of SEQ ID NO: 160-399).

[000331] In some embodiments, the complex described herein comprises an anti-TfR1 antibody covalently linked to a molecular payload, wherein the anti-TfR1 antibody comprises a VH comprising the amino acid sequence of SEQ ID NO: 77, and a VL comprising the amino acid sequence of SEQ ID NO: 78. In some embodiments, the molecular payload is a DMD-targeting oligonucleotide (e.g., a DMD-targeting oligonucleotide listed in Table 8, provided by any one of SEQ ID NO: 400-879, or complementary to any one of SEQ ID NO: 160-399).

[000332] In some embodiments, the complex described herein comprises an anti-TfR1 antibody covalently linked to a molecular payload, wherein the anti-TfR1 antibody comprises a

VH comprising the amino acid sequence of SEQ ID NO: 77 or SEQ ID NO: 79, and a VL comprising the amino acid sequence of SEQ ID NO: 80. In some embodiments, the molecular payload is a DMD-targeting oligonucleotide (e.g., a DMD-targeting oligonucleotide listed in Table 8, provided by any one of SEQ ID NO: 400-879, or complementary to any one of SEQ ID NO: 160-399).

[000333] In some embodiments, the complex described herein comprises an anti-TfR1 antibody covalently linked to a molecular payload, wherein the anti-TfR1 antibody comprises a VH comprising the amino acid sequence of SEQ ID NO: 154, and a VL comprising the amino acid sequence of SEQ ID NO: 155. In some embodiments, the molecular payload is a DMD-targeting oligonucleotide (e.g., a DMD-targeting oligonucleotide listed in Table 8, provided by any one of SEQ ID NO: 400-879, or complementary to any one of SEQ ID NO: 160-399).

[000334] In some embodiments, the complex described herein comprises an anti-TfR1 antibody covalently linked to a molecular payload, wherein the anti-TfR1 antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 84, SEQ ID NO: 86 or SEQ ID NO: 87 and a light chain comprising the amino acid sequence of SEQ ID NO: 85. In some embodiments, the molecular payload is a DMD-targeting oligonucleotide (e.g., a DMD-targeting oligonucleotide listed in Table 8, provided by any one of SEQ ID NO: 400-879, or complementary to any one of SEQ ID NO: 160-399).

[000335] In some embodiments, the complex described herein comprises an anti-TfR1 antibody covalently linked to a molecular payload, wherein the anti-TfR1 antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 88 or SEQ ID NO: 91, and a light chain comprising the amino acid sequence of SEQ ID NO: 89. In some embodiments, the molecular payload is a DMD-targeting oligonucleotide (e.g., a DMD-targeting oligonucleotide listed in Table 8, provided by any one of SEQ ID NO: 400-879, or complementary to any one of SEQ ID NO: 160-399).

[000336] In some embodiments, the complex described herein comprises an anti-TfR1 antibody covalently linked to a molecular payload, wherein the anti-TfR1 antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 88 or SEQ ID NO: 91, and a light chain comprising the amino acid sequence of SEQ ID NO: 90. In some embodiments, the molecular payload is a DMD-targeting oligonucleotide (e.g., a DMD-targeting oligonucleotide listed in Table 8, provided by any one of SEQ ID NO: 400-879, or complementary to any one of SEQ ID NO: 160-399).

[000337] In some embodiments, the complex described herein comprises an anti-TfR1 antibody covalently linked to a molecular payload, wherein the anti-TfR1 antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 92 or SEQ ID NO: 94, and a

light chain comprising the amino acid sequence of SEQ ID NO: 95. In some embodiments, the molecular payload is a DMD-targeting oligonucleotide (e.g., a DMD-targeting oligonucleotide listed in Table 8, provided by any one of SEQ ID NO: 400-879, or complementary to any one of SEQ ID NO: 160-399).

[000338] In some embodiments, the complex described herein comprises an anti-TfR1 antibody covalently linked to a molecular payload, wherein the anti-TfR1 antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 92, and a light chain comprising the amino acid sequence of SEQ ID NO: 93. In some embodiments, the molecular payload is a DMD-targeting oligonucleotide (e.g., a DMD-targeting oligonucleotide listed in Table 8, provided by any one of SEQ ID NO: 400-879, or complementary to any one of SEQ ID NO: 160-399).

[000339] In some embodiments, the complex described herein comprises an anti-TfR1 antibody covalently linked to a molecular payload, wherein the anti-TfR1 antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 156, and a light chain comprising the amino acid sequence of SEQ ID NO: 157. In some embodiments, the molecular payload is a DMD-targeting oligonucleotide (e.g., a DMD-targeting oligonucleotide listed in Table 8, provided by any one of SEQ ID NO: 400-879, or complementary to any one of SEQ ID NO: 160-399).

[000340] In some embodiments, the complex described herein comprises an anti-TfR1 antibody covalently linked to a molecular payload, wherein the anti-TfR1 antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 97, SEQ ID NO: 98, or SEQ ID NO: 99 and a light chain comprising the amino acid sequence of SEQ ID NO: 85. In some embodiments, the molecular payload is a DMD-targeting oligonucleotide (e.g., a DMD-targeting oligonucleotide listed in Table 8, provided by any one of SEQ ID NO: 400-879, or complementary to any one of SEQ ID NO: 160-399).

[000341] In some embodiments, the complex described herein comprises an anti-TfR1 antibody covalently linked to a molecular payload, wherein the anti-TfR1 antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 100 or SEQ ID NO: 101 and a light chain comprising the amino acid sequence of SEQ ID NO: 89. In some embodiments, the molecular payload is a DMD-targeting oligonucleotide (e.g., a DMD-targeting oligonucleotide listed in Table 8, provided by any one of SEQ ID NO: 400-879, or complementary to any one of SEQ ID NO: 160-399).

[000342] In some embodiments, the complex described herein comprises an anti-TfR1 antibody covalently linked to a molecular payload, wherein the anti-TfR1 antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 100 or SEQ ID NO: 101 and a


light chain comprising the amino acid sequence of SEQ ID NO: 90. In some embodiments, the molecular payload is a DMD-targeting oligonucleotide (e.g., a DMD-targeting oligonucleotide listed in Table 8, provided by any one of SEQ ID NO: 400-879, or complementary to any one of SEQ ID NO: 160-399).

[000343] In some embodiments, the complex described herein comprises an anti-TfR1 antibody covalently linked to a molecular payload, wherein the anti-TfR1 antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 102 and a light chain comprising the amino acid sequence of SEQ ID NO: 93. In some embodiments, the molecular payload is a DMD-targeting oligonucleotide (e.g., a DMD-targeting oligonucleotide listed in Table 8, provided by any one of SEQ ID NO: 400-879, or complementary to any one of SEQ ID NO: 160-399).

[000344] In some embodiments, the complex described herein comprises an anti-TfR1 antibody covalently linked to a molecular payload, wherein the anti-TfR1 antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 102 or SEQ ID NO: 103 and a light chain comprising the amino acid sequence of SEQ ID NO: 95. In some embodiments, the molecular payload is a DMD-targeting oligonucleotide (e.g., a DMD-targeting oligonucleotide listed in Table 8, provided by any one of SEQ ID NO: 400-879, or complementary to any one of SEQ ID NO: 160-399).

[000345] In some embodiments, the complex described herein comprises an anti-TfR1 antibody covalently linked to a molecular payload, wherein the anti-TfR1 antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 158 or SEQ ID NO: 159 and a light chain comprising the amino acid sequence of SEQ ID NO: 157. In some embodiments, the molecular payload is a DMD-targeting oligonucleotide (e.g., a DMD-targeting oligonucleotide listed in Table 8, provided by any one of SEQ ID NO: 400-879, or complementary to any one of SEQ ID NO: 160-399).


[000346] In any of the example complexes described herein, in some embodiments, the anti-TfR1 antibody is covalently linked to the molecular payload via a linker comprising a structure of:



(I)

wherein n is 3, m is 4.


[000347] In some embodiments, the complex described herein comprises an anti-TfR1 antibody covalently linked to the 5' end of a DMD-targeting oligonucleotide (e.g., a DMD-targeting oligonucleotide listed in Table 8, provided by any one of SEQ ID NO: 400-879, or complementary to any one of SEQ ID NO: 160-399) via a lysine in the anti-TfR1 antibody, wherein the anti-TfR1 antibody comprises a CDR-H1, a CDR-H2, a CDR-H3, a CDR-L1, a CDR-L2, and a CDR-L3 of any one of the antibodies listed in Table 2, wherein the complex has a structure of:



(E)

wherein n is 3 and m is 4. It should be understood that the amide shown adjacent the anti-TfR1 antibody in Formula (E) results from a reaction with an amine of the anti-TfR1 antibody, such as a lysine epsilon amine.


[000348] In some embodiments, the complex described herein comprises an anti-TfR1 antibody covalently linked to the 5' end of a DMD-targeting oligonucleotide (e.g., a DMD-targeting oligonucleotide listed in Table 8, provided by any one of SEQ ID NO: 400-879, or complementary to any one of SEQ ID NO: 160-399) via a lysine in the anti-TfR1 antibody, wherein the anti-TfR1 antibody comprises a VH and VL of any one of the antibodies listed in Table 3, wherein the complex has a structure of:



(E)

wherein n is 3 and m is 4. It should be understood that the amide shown adjacent the anti-TfR1 antibody in Formula (E) results from a reaction with an amine of the anti-TfR1 antibody, such as a lysine epsilon amine.


[000349] In some embodiments, the complex described herein comprises an anti-TfR1 antibody covalently linked to the 5' end of a DMD-targeting oligonucleotide (e.g., a DMD-targeting oligonucleotide listed in Table 8, provided by any one of SEQ ID NO: 400-879, or complementary to any one of SEQ ID NO: 160-399) via a lysine in the anti-TfR1 antibody, wherein the anti-TfR1 antibody comprises a heavy chain and light chain of any one of the antibodies listed in Table 4, wherein the complex has a structure of:



(E)


wherein n is 3 and m is 4. It should be understood that the amide shown adjacent the anti-TfR1 antibody in Formula (E) results from a reaction with an amine of the anti-TfR1 antibody, such as a lysine epsilon amine.

[000350] In some embodiments, the complex described herein comprises an anti-TfR1 Fab covalently linked to the 5' end of a DMD-targeting oligonucleotide (e.g., a DMD-targeting oligonucleotide listed in Table 8, provided by any one of SEQ ID NO: 400-879, or complementary to any one of SEQ ID NO: 160-399) via a lysine in the anti-TfR1 antibody, wherein the anti-TfR1 Fab comprises a heavy chain and light chain of any one of the antibodies listed in Table 5, wherein the complex has a structure of:



wherein n is 3 and m is 4. It should be understood that the amide shown adjacent the anti-TfR1 antibody in Formula (E) results from a reaction with an amine of the anti-TfR1 antibody, such as a lysine epsilon amine.


[000351] In some embodiments, in any one of the examples of complexes described herein, L1 is:



wherein L2 is

wherein a labels the site directly linked to the carbamate moiety of formulae (B), (D), (E), and (I); and b labels the site covalently linked (directly or via additional chemical moieties) to the oligonucleotide.

[000352] In some embodiments, L1 is:



wherein *a* labels the site directly linked to the carbamate moiety of formulae (B), (D), (E), and (I); and *b* labels the site covalently linked (directly or via additional chemical moieties) to the oligonucleotide.

[000353] In some embodiments, L1 is linked to a 5' phosphate of the oligonucleotide. In some embodiments, the phosphate is a phosphodiester. In some embodiments, L1 is linked to a 5' phosphorothioate of the oligonucleotide. In some embodiments, L1 is linked to a 5' phosphonoamidate of the oligonucleotide. In some embodiments, L1 is linked via a phosphorodiamidate linkage to the 5' end of the oligonucleotide.

[000354] In some embodiments, L1 is optional (e.g., need not be present).

III. Formulations

[000355] Complexes provided herein may be formulated in any suitable manner. Generally, complexes provided herein are formulated in a manner suitable for pharmaceutical use. For example, complexes can be delivered to a subject using a formulation that minimizes degradation, facilitates delivery and/or (e.g., and) uptake, or provides another beneficial property to the complexes in the formulation. In some embodiments, provided herein are compositions comprising complexes and pharmaceutically acceptable carriers. Such compositions can be suitably formulated such that when administered to a subject, either into the immediate environment of a target cell or systemically, a sufficient amount of the complexes enter target muscle cells. In some embodiments, complexes are formulated in buffer solutions such as phosphate-buffered saline solutions, liposomes, micellar structures, and capsids.

[000356] It should be appreciated that, in some embodiments, compositions may include separately one or more components of complexes provided herein (e.g., muscle-targeting agents, linkers, molecular payloads, or precursor molecules of any one of them).

[000357] In some embodiments, complexes are formulated in water or in an aqueous solution (e.g., water with pH adjustments). In some embodiments, complexes are formulated in basic buffered aqueous solutions (e.g., PBS). In some embodiments, formulations as disclosed herein comprise an excipient. In some embodiments, an excipient confers to a composition improved stability, improved absorption, improved solubility and/or (e.g., and) therapeutic enhancement of the active ingredient. In some embodiments, an excipient is a buffering agent

(*e.g.*, sodium citrate, sodium phosphate, a tris base, or sodium hydroxide) or a vehicle (*e.g.*, a buffered solution, petrolatum, dimethyl sulfoxide, or mineral oil).

[000358] In some embodiments, a complex or component thereof (*e.g.*, oligonucleotide or antibody) is lyophilized for extending its shelf-life and then made into a solution before use (*e.g.*, administration to a subject). Accordingly, an excipient in a composition comprising a complex, or component thereof, described herein may be a lyoprotectant (*e.g.*, mannitol, lactose, polyethylene glycol, or polyvinyl pyrrolidone), or a collapse temperature modifier (*e.g.*, dextran, ficoll, or gelatin).

[000359] In some embodiments, a pharmaceutical composition is formulated to be compatible with its intended route of administration. Examples of routes of administration include parenteral, *e.g.*, intravenous, intradermal, subcutaneous, administration. Typically, the route of administration is intravenous or subcutaneous.

[000360] Pharmaceutical compositions suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), and suitable mixtures thereof. In some embodiments, formulations include isotonic agents, for example, sugars, polyalcohols such as mannitol, sorbitol, and sodium chloride in the composition. Sterile injectable solutions can be prepared by incorporating the complexes in a required amount in a selected solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization.

[000361] In some embodiments, a composition may contain at least about 0.1% of the complex, or component thereof, or more, although the percentage of the active ingredient(s) may be between about 1% and about 80% or more of the weight or volume of the total composition. Factors such as solubility, bioavailability, biological half-life, route of administration, product shelf life, as well as other pharmacological considerations will be contemplated by one skilled in the art of preparing such pharmaceutical formulations, and as such, a variety of dosages and treatment regimens may be desirable.

IV. Methods of Use / Treatment

[000362] Complexes comprising a muscle-targeting agent covalently linked to a molecular payload as described herein are effective in treating a subject having a dystrophinopathy, *e.g.*, Duchenne muscular dystrophy. In some embodiments, complexes comprise a molecular payload that is an oligonucleotide, *e.g.*, an antisense oligonucleotide that facilitates exon skipping of a pre-mRNA expressed from a mutated DMD allele.

[000363] In some embodiments, a subject may be a human subject, a non-human primate subject, a rodent subject, or any suitable mammalian subject. In some embodiments, a subject may have Duchenne muscular dystrophy or other dystrophinopathy. In some embodiments, a subject has a mutated DMD allele, which may optionally comprise at least one mutation in a DMD exon that causes a frameshift mutation and leads to improper RNA splicing/processing. In some embodiments, a subject is suffering from symptoms of a severe dystrophinopathy, e.g. muscle atrophy or muscle loss. In some embodiments, a subject has an asymptomatic increase in serum concentration of creatine phosphokinase (CK) and/or (e.g., and) muscle cramps with myoglobinuria. In some embodiments, a subject has a progressive muscle disease, such as Duchenne or Becker muscular dystrophy or DMD-associated dilated cardiomyopathy (DCM). In some embodiments, a subject is not suffering from symptoms of a dystrophinopathy.

[000364] In some embodiments, a subject has a mutation in a DMD gene that is amenable to exon 45 skipping. In some embodiments, a complex comprising a muscle-targeting agent covalently linked to a molecular payload as described herein is effective in treating a subject having a mutation in a DMD gene that is amenable to exon 45 skipping. In some embodiments, a complex comprises a molecular payload that is an oligonucleotide, e.g., an antisense oligonucleotide that facilitates skipping of exon 45 of a pre-mRNA, such as in a pre-mRNA encoded from a mutated DMD gene (e.g., a mutated DMD gene that is amenable to exon 45 skipping).

[000365] An aspect of the disclosure includes methods involving administering to a subject an effective amount of a complex as described herein. In some embodiments, an effective amount of a pharmaceutical composition that comprises a complex comprising a muscle-targeting agent covalently linked to a molecular payload can be administered to a subject in need of treatment. In some embodiments, a pharmaceutical composition comprising a complex as described herein may be administered by a suitable route, which may include intravenous administration, e.g., as a bolus or by continuous infusion over a period of time. In some embodiments, administration may be performed by intramuscular, intraperitoneal, intracerebrospinal, subcutaneous, intra-articular, intrasynovial, or intrathecal routes. In some embodiments, a pharmaceutical composition may be in solid form, aqueous form, or a liquid form. In some embodiments, an aqueous or liquid form may be nebulized or lyophilized. In some embodiments, a nebulized or lyophilized form may be reconstituted with an aqueous or liquid solution.

[000366] Compositions for intravenous administration may contain various carriers such as vegetable oils, dimethylamide, dimethylformamide, ethyl lactate, ethyl carbonate, isopropyl myristate, ethanol, and polyols (glycerol, propylene glycol, liquid polyethylene glycol, and the

like). For intravenous injection, water soluble antibodies can be administered by the drip method, whereby a pharmaceutical formulation containing the antibody and a physiologically acceptable excipients is infused. Physiologically acceptable excipients may include, for example, 5% dextrose, 0.9% saline, Ringer's solution or other suitable excipients. Intramuscular preparations, e.g., a sterile formulation of a suitable soluble salt form of the antibody, can be dissolved and administered in a pharmaceutical excipient such as Water-for-Injection, 0.9% saline, or 5% glucose solution.

[000367] In some embodiments, a pharmaceutical composition that comprises a complex comprising a muscle-targeting agent covalently linked to a molecular payload is administered via site-specific or local delivery techniques. Examples of these techniques include implantable depot sources of the complex, local delivery catheters, site specific carriers, direct injection, or direct application.

[000368] In some embodiments, a pharmaceutical composition that comprises a complex comprising a muscle-targeting agent covalently linked to a molecular payload is administered at an effective concentration that confers therapeutic effect on a subject. Effective amounts vary, as recognized by those skilled in the art, depending on the severity of the disease, unique characteristics of the subject being treated, e.g., age, physical conditions, health, or weight, the duration of the treatment, the nature of any concurrent therapies, the route of administration and related factors. These related factors are known to those in the art and may be addressed with no more than routine experimentation. In some embodiments, an effective concentration is the maximum dose that is considered to be safe for the patient. In some embodiments, an effective concentration will be the lowest possible concentration that provides maximum efficacy.

[000369] Empirical considerations, e.g., the half-life of the complex in a subject, generally will contribute to determination of the concentration of pharmaceutical composition that is used for treatment. The frequency of administration may be empirically determined and adjusted to maximize the efficacy of the treatment.

[000370] The efficacy of treatment may be assessed using any suitable methods. In some embodiments, the efficacy of treatment may be assessed by evaluation of observation of symptoms associated with a dystrophinopathy, e.g., muscle atrophy or muscle weakness, through measures of a subject's self-reported outcomes, e.g., mobility, self-care, usual activities, pain/discomfort, and anxiety/depression, or by quality-of-life indicators, e.g., lifespan.

[000371] In some embodiments, a pharmaceutical composition that comprises a complex comprising a muscle-targeting agent covalently linked to a molecular payload described herein is administered to a subject at an effective concentration sufficient to modulate activity or expression of a target gene by at least 10%, at least 20%, at least 30%, at least 40%, at least

50%, at least 60%, at least 70%, at least 80%, at least 90% or at least 95% relative to a control, e.g. baseline level of gene expression prior to treatment.

ADDITIONAL EMBODIMENTS

1. A complex comprising an anti-transferrin receptor 1 (TfR1) antibody covalently linked to a molecular payload configured for inducing skipping of exon 45 in a DMD pre-mRNA, wherein the anti-TfR1 antibody is an antibody identified in any one of Tables 2-7.
2. The complex of embodiment 1, wherein the anti-TfR1 antibody comprises:
 - (i) a heavy chain complementarity determining region 1 (CDR-H1) of SEQ ID NO: 33, a heavy chain complementarity determining region 2 (CDR-H2) of SEQ ID NO: 34, a heavy chain complementarity determining region 3 (CDR-H3) of SEQ ID NO: 35, a light chain complementarity determining region 1 (CDR-L1) of SEQ ID NO: 36, a light chain complementarity determining region 2 (CDR-L2) of SEQ ID NO: 37, and a light chain complementarity determining region 3 (CDR-L3) of SEQ ID NO: 32;
 - (ii) a CDR-H1 of SEQ ID NO: 7, a CDR-H2 of SEQ ID NO: 8, a CDR-H3 of SEQ ID NO: 9, a CDR-L1 of SEQ ID NO: 10, a CDR-L2 of SEQ ID NO: 11, and a CDR-L3 of SEQ ID NO: 6;
 - (iii) a CDR-H1 of SEQ ID NO: 7, a CDR-H2 of SEQ ID NO: 20, a CDR-H3 of SEQ ID NO: 9, a CDR-L1 of SEQ ID NO: 10, a CDR-L2 of SEQ ID NO: 11, and a CDR-L3 of SEQ ID NO: 6;
 - (iv) a CDR-H1 of SEQ ID NO: 7, a CDR-H2 of SEQ ID NO: 24, a CDR-H3 of SEQ ID NO: 9, a CDR-L1 of SEQ ID NO: 10, a CDR-L2 of SEQ ID NO: 11, and a CDR-L3 of SEQ ID NO: 6;
 - (v) a CDR-H1 of SEQ ID NO: 51, a CDR-H2 of SEQ ID NO: 52, a CDR-H3 of SEQ ID NO: 53, a CDR-L1 of SEQ ID NO: 54, a CDR-L2 of SEQ ID NO: 55, and a CDR-L3 of SEQ ID NO: 50;
 - (vi) a CDR-H1 of SEQ ID NO: 64, a CDR-H2 of SEQ ID NO: 52, a CDR-H3 of SEQ ID NO: 53, a CDR-L1 of SEQ ID NO: 54, a CDR-L2 of SEQ ID NO: 55, and a CDR-L3 of SEQ ID NO: 50; or
 - (vii) a CDR-H1 of SEQ ID NO: 67, a CDR-H2 of SEQ ID NO: 52, a CDR-H3 of SEQ ID NO: 53, a CDR-L1 of SEQ ID NO: 54, a CDR-L2 of SEQ ID NO: 55, and a CDR-L3 of SEQ ID NO: 50.

3. The complex of embodiment 1 or embodiment 2, wherein the anti-TfR1 antibody comprises:

- (i) a heavy chain variable region (VH) comprising an amino acid sequence at least 85% identical to SEQ ID NO: 76; and/or a light chain variable region (VL) comprising an amino acid sequence at least 85% identical to SEQ ID NO: 75;
- (ii) a VH comprising an amino acid sequence at least 85% identical to SEQ ID NO: 69; and/or a VL comprising an amino acid sequence at least 85% identical to SEQ ID NO: 70;
- (iii) a VH comprising an amino acid sequence at least 85% identical to SEQ ID NO: 71; and/or a VL comprising an amino acid sequence at least 85% identical to SEQ ID NO: 70;
- (iv) a VH comprising an amino acid sequence at least 85% identical to SEQ ID NO: 72; and/or a VL comprising an amino acid sequence at least 85% identical to SEQ ID NO: 70;
- (v) a VH comprising an amino acid sequence at least 85% identical to SEQ ID NO: 73; and/or a VL comprising an amino acid sequence at least 85% identical to SEQ ID NO: 74;
- (vi) a VH comprising an amino acid sequence at least 85% identical to SEQ ID NO: 73; and/or a VL comprising an amino acid sequence at least 85% identical to SEQ ID NO: 75;
- (vii) a VH comprising an amino acid sequence at least 85% identical to SEQ ID NO: 76; and/or a VL comprising an amino acid sequence at least 85% identical to SEQ ID NO: 74;
- (viii) a VH comprising an amino acid sequence at least 85% identical to SEQ ID NO: 77; and/or a VL comprising an amino acid sequence at least 85% identical to SEQ ID NO: 78;
- (ix) a VH comprising an amino acid sequence at least 85% identical to SEQ ID NO: 79; and/or a VL comprising an amino acid sequence at least 85% identical to SEQ ID NO: 80; or
- (x) a VH comprising an amino acid sequence at least 85% identical to SEQ ID NO: 77; and/or a VL comprising an amino acid sequence at least 85% identical to SEQ ID NO: 80.

4. The complex of any one of embodiments 1 to 3, wherein the anti-TfR1 antibody comprises:

- (i) a VH comprising the amino acid sequence of SEQ ID NO: 76 and a VL comprising the amino acid sequence of SEQ ID NO: 75;
- (ii) a VH comprising the amino acid sequence of SEQ ID NO: 69 and a VL comprising the amino acid sequence of SEQ ID NO: 70;
- (iii) a VH comprising the amino acid sequence of SEQ ID NO: 71 and a VL comprising the amino acid sequence of SEQ ID NO: 70;
- (iv) a VH comprising the amino acid sequence of SEQ ID NO: 72 and a VL comprising the amino acid sequence of SEQ ID NO: 70;

- (v) a VH comprising the amino acid sequence of SEQ ID NO: 73 and a VL comprising the amino acid sequence of SEQ ID NO: 74;
 - (vi) a VH comprising the amino acid sequence of SEQ ID NO: 73 and a VL comprising the amino acid sequence of SEQ ID NO: 75;
 - (vii) a VH comprising the amino acid sequence of SEQ ID NO: 76 and a VL comprising the amino acid sequence of SEQ ID NO: 74;
 - (viii) a VH comprising the amino acid sequence of SEQ ID NO: 77 and a VL comprising the amino acid sequence of SEQ ID NO: 78;
 - (ix) a VH comprising the amino acid sequence of SEQ ID NO: 79 and a VL comprising the amino acid sequence of SEQ ID NO: 80; or
 - (x) a VH comprising the amino acid sequence of SEQ ID NO: 77 and a VL comprising the amino acid sequence of SEQ ID NO: 80.
5. The complex of any one of embodiments 1 to 4, wherein the anti-TfR1 antibody is a Fab fragment, a Fab' fragment, a F(ab')₂ fragment, an scFv, an Fv, or a full-length IgG.
6. The complex of embodiment 5, wherein the anti-TfR1 antibody is a Fab fragment.
7. The complex of embodiment 6, wherein the anti-TfR1 antibody comprises:
- (i) a heavy chain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 101; and/or a light chain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 90;
 - (ii) a heavy chain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 97; and/or a light chain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 85;
 - (iii) a heavy chain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 98; and/or a light chain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 85;
 - (iv) a heavy chain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 99; and/or a light chain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 85;
 - (v) a heavy chain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 100; and/or a light chain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 89;

(vi) a heavy chain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 100; and/or a light chain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 90;

(vii) a heavy chain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 101; and/or a light chain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 89;

(viii) a heavy chain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 102; and/or a light chain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 93;

(ix) a heavy chain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 103; and/or a light chain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 95; or

(x) a heavy chain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 102; and/or a light chain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 95.

8. The complex of embodiment 6 or embodiment 7, wherein the anti-TfR1 antibody comprises:

(i) a heavy chain comprising the amino acid sequence of SEQ ID NO: 101; and a light chain comprising the amino acid sequence of SEQ ID NO: 90;

(ii) a heavy chain comprising the amino acid sequence of SEQ ID NO: 97; and a light chain comprising the amino acid sequence of SEQ ID NO: 85;

(iii) a heavy chain comprising the amino acid sequence of SEQ ID NO: 98; and a light chain comprising the amino acid sequence of SEQ ID NO: 85;

(iv) a heavy chain comprising the amino acid sequence of SEQ ID NO: 99; and a light chain comprising the amino acid sequence of SEQ ID NO: 85;

(v) a heavy chain comprising the amino acid sequence of SEQ ID NO: 100; and a light chain comprising the amino acid sequence of SEQ ID NO: 89;

(vi) a heavy chain comprising the amino acid sequence of SEQ ID NO: 100; and a light chain comprising the amino acid sequence of SEQ ID NO: 90;

(vii) a heavy chain comprising the amino acid sequence of SEQ ID NO: 101; and a light chain comprising the amino acid sequence of SEQ ID NO: 89;

(viii) a heavy chain comprising the amino acid sequence of SEQ ID NO: 102; and a light chain comprising the amino acid sequence of SEQ ID NO: 93;

(ix) a heavy chain comprising the amino acid sequence of SEQ ID NO: 103; and a light chain comprising the amino acid sequence of SEQ ID NO: 95; or

(x) a heavy chain comprising the amino acid sequence of SEQ ID NO: 102; and a light chain comprising the amino acid sequence of SEQ ID NO: 95.

9. The complex of any one of embodiments 1 to 8, wherein the anti-TfR1 antibody does not specifically bind to the transferrin binding site of the transferrin receptor 1 and/or wherein the anti-TfR1 antibody does not inhibit binding of transferrin to the transferrin receptor 1.

10. The complex of any one of embodiments 1 to 9, wherein the molecular payload comprises an oligonucleotide.

11. The complex of embodiment 10, wherein the oligonucleotide promotes antisense-mediated exon skipping in the DMD pre-RNA.

12. The complex of embodiment 10 or 11, wherein the oligonucleotide comprises a region of complementarity to a splicing feature of the DMD pre-mRNA.

13. The complex of embodiment 12, wherein the splicing feature is an exonic splicing enhancer (ESE) of the DMD pre-mRNA.

14. The complex of embodiment 13, wherein the splicing feature is in exon 45 of the DMD pre-mRNA, optionally wherein the ESE comprises a sequence of any one of SEQ ID NOs: 885-912.

15. The complex of embodiment 12, wherein the splicing feature is a branch point, a splice donor site, or a splice acceptor site.

16. The complex of embodiment 15, wherein the splicing feature is across the junction of exon 44 and intron 44, in intron 44, across the junction of intron 44 and exon 45, across the junction of exon 45 and intron 45, in intron 45, or across the junction of intron 45 and exon 46 of the DMD pre-mRNA, optionally wherein the splicing feature comprises a sequence of any one of SEQ ID NOs: 880-884 and 913-916.

17. The complex of any one of embodiments 12 to 16, wherein the region of complementarity comprises at least 4 consecutive nucleosides complementary to the splicing feature.
18. The complex of any one of embodiments 1 to 9, wherein the molecular payload comprises an oligonucleotide comprising a sequence complementary to any one of SEQ ID NOs: 160-399 or comprising a sequence of any one of SEQ ID NOs: 400-879, wherein each thymine base (T) may independently and optionally be replaced with a uracil base (U), and each U may independently and optionally be replaced with a T.
19. The complex of any one of embodiments 10 to 18, wherein the oligonucleotide comprises at least one modified internucleoside linkage.
20. The complex of embodiment 19, wherein the at least one modified internucleoside linkage is a phosphorothioate linkage.
21. The complex of any one of embodiments 10 to 20, wherein the oligonucleotide comprises one or more modified nucleosides.
22. The complex of embodiment 21, wherein the one or more modified nucleosides are 2'-modified nucleosides.
23. The complex of any one of embodiments 10 to 18, wherein the oligonucleotide comprises one or more phosphorodiamidate morpholinos, optionally wherein the oligonucleotide is a phosphorodiamidate morpholino oligomer (PMO).
24. The complex of any one of embodiments 1 to 23, wherein the anti-TfR1 antibody is covalently linked to the molecular payload via a cleavable linker.
25. The complex of embodiment 24, wherein the cleavable linker comprises a valine-citrulline sequence.
26. The complex of any one of embodiments 1 to 25, wherein the anti-TfR1 antibody is covalently linked to the molecular payload via conjugation to a lysine residue or a cysteine residue of the antibody.

27. A complex comprising an anti-TfR1 antibody covalently linked to an oligonucleotide configured for inducing skipping of exon 45 in a DMD pre-mRNA, wherein the oligonucleotide comprises a region of complementarity to any one of SEQ ID NOs: 160-399.
28. The complex of embodiment 27, wherein the anti-TfR1 antibody is an antibody identified in any one of Tables 2-7.
29. A complex comprising an anti-TfR1 antibody covalently linked to an oligonucleotide configured for inducing skipping of exon 45 in a DMD pre-mRNA, wherein the oligonucleotide comprises a region of complementarity to a splicing feature of the DMD pre-mRNA.
30. An oligonucleotide that targets DMD, wherein the oligonucleotide comprises a region of complementarity to any one of SEQ ID NOs: 160-399.
31. The oligonucleotide of embodiment 30, wherein the region of complementarity comprises at least 15 consecutive nucleosides complementary to any one of SEQ ID NOs: 160-399.
32. The oligonucleotide of embodiment 30 or 31, wherein the oligonucleotide comprises at least 15 consecutive nucleosides of any one of SEQ ID NOs: 400-879, optionally wherein the oligonucleotide comprises a sequence of any one of SEQ ID NOs: 400-879, wherein each thymine base (T) may independently and optionally be replaced with a uracil base (U), and each U may independently and optionally be replaced with a T.
33. A method of delivering a molecular payload to a cell, the method comprising contacting the cell with the complex of any one of embodiments 1 to 26.
34. A method of delivering an oligonucleotide to a cell, the method comprising contacting the cell with the complex of any one of embodiments 27 to 29.
35. A method of promoting the expression or activity of a dystrophin protein in a cell, the method comprising contacting the cell with the complex of any one of embodiments 1 to 26 in an amount effective for promoting internalization of the molecular payload to the cell, optionally wherein the cell is a muscle cell.

36. A method of promoting the expression or activity of a dystrophin protein in a cell, the method comprising contacting the cell with the complex of any one of embodiments 27 to 29 in an amount effective for promoting internalization of the oligonucleotide to the cell, optionally wherein the cell is a muscle cell.
37. The method of embodiment 35 or 36, wherein the cell is *in vitro*.
38. The method of embodiment 35 or 36, wherein the cell is in a subject.
39. The method of embodiment 38, wherein the subject is a human.
40. The method of embodiment 39, wherein the subject has a DMD gene that is amenable to skipping of exon 45.
41. The method of any one of embodiments 35 to 40, wherein the dystrophin protein is a truncated dystrophin protein.
42. A method of treating a subject having a mutated DMD allele that is associated with a dystrophinopathy, the method comprising administering to the subject an effective amount of the complex of any one of embodiments 1 to 29.
43. A method of promoting skipping of exon 45 of a DMD pre-mRNA transcript in a cell, the method comprising contacting the cell with an effective amount of the complex of any one of embodiments 1 to 29.
44. A method of treating a subject having a mutated DMD allele that is associated with a dystrophinopathy, the method comprising administering to the subject an effective amount of the complex of any one of embodiments 1 to 29.

EXAMPLES

Example 1. Exon-skipping activity of anti-TfR1 antibody conjugates in Duchenne muscular dystrophy patient myotubes

[000372] In this study, the exon-skipping activities of anti-TfR1 antibody conjugates comprising an anti-TfR1 Fab (3M12 VH4/Vκ3) covalently linked to a DMD exon 51-skipping

antisense oligonucleotide (ASO) were evaluated. The DMD exon 51-skipping ASO is a phosphorodiamidate morpholino oligomer (PMO) of 30 nucleotides in length and targets an ESE in DMD exon 51 having the sequence TGGAGGT (SEQ ID NO: 974). Immortalized human myoblasts bearing an exon 52 deletion in the DMD gene were thawed and seeded at a density of 1e6 cell/flask in Promocell Skeletal Cell Growth Media (with 5% FBS and 1x Pen-Strep) and allowed to grow to confluency. Once confluent, cells were trypsinized and pelleted via centrifugation and resuspended in fresh Promocell Skeletal Cell Growth Media. The cell number was counted and cells were seeded into Matrigel-coated 96-well plates at a density of 50,000 cells/well. Cells were allowed to recover for 24 hours. Cells were induced to differentiate into myotubes by aspirating the growth media and replacing with differentiation media with no serum. Cells were then treated with the DMD exon 51-skipping oligonucleotide (not covalently linked to an antibody – “naked”) at 10 μ M ASO or the anti-TfR1 Fab (3M12 VH4/V κ 3) covalently linked to the DMD exon 51-skipping oligonucleotide at 10 μ M ASO equivalent. Cells were incubated with test articles for ten days then total RNA was harvested from the 96 well plates. cDNA synthesis was performed on 75 ng of total RNA, and mutation specific PCRs were performed to evaluate the degree of exon 51 skipping in the cells. Mutation-specific PCR products were run on a 4% agarose gel and visualized using SYBR gold. Densitometry was used to calculate the relative amounts of the skipped and unskipped amplicon and exon skipping was determined as a ratio of the Exon 51 skipped amplicon divided by the total amount of amplicon present:

$$\%Exon\ Skipping = \frac{Skipped\ Amplicon}{(Skipped\ Amplicon + Unskipped\ Amplicon)} * 100.$$

[000373] The results demonstrate that the conjugate resulted in enhanced exon skipping compared to the naked DMD exon 51-skipping oligonucleotide in patient myotubes (FIG. 1). This indicates that anti-TfR1 Fab 3M12 VH4/V κ 3 enabled cellular internalization of the conjugate into muscle cells resulting in activity of the exon 51-skipping oligonucleotide in the muscle cells. Similarly, an anti-TfR1 antibody (*e.g.*, anti-TfR1 Fab 3M12 VH4/V κ 3) can enable internalization of a conjugate comprising the anti-TfR1 antibody covalently linked to other exon skipping oligonucleotides (*e.g.*, an exon skipping oligonucleotide provided herein, such as an exon 45 skipping oligonucleotide) into muscle cells and facilitate activity of the exon skipping oligonucleotide in the muscle cells.

Example 2. Exon skipping activity of anti-TfR1 Fab-ASO conjugate in vivo in cynomolgus monkeys

[000374] Anti-TfR1 Fab 3M12 VH4/V κ 3 was covalently linked to the DMD exon 51-skipping antisense oligonucleotide (ASO) that was used in Example 1. The exon skipping

activity of the conjugate was tested in vivo in healthy non-human primates. Naïve male cynomolgus monkeys (n= 4-5 per group) were administered two doses of vehicle, 30 mg/kg naked ASO (*i.e.*, not covalently linked to an antibody), or 122 mg/kg anti-TfR1 Fab (3M12 VH4/Vκ3) covalently linked to the DMD exon 51-skipping oligonucleotide (30 mg/kg ASO equivalent) via intravenous infusion on days 1 and 8. Animals were sacrificed and tissues harvested either 2 weeks or 4 weeks after the first dose was administered. Total RNA was collected from tissue samples using a Promega Maxwell® RSC instrument and cDNA synthesis was performed using qScript cDNA SuperMix. Assessment of exon 51 skipping was performed using end-point PCR.

[000375] Capillary electrophoresis of the PCR products was used to assess exon skipping, and % exon 51 skipping was calculated using the following formula:

$$\% \text{ Exon Skipping} = \frac{\text{Molarity of Skipped Band}}{\text{Molarity of Skipped Band} + \text{Molarity of Unskipped Band}} * 100.$$

Calculated exon 51 skipping results are shown in Table 10.

Table 10. Exon 51 skipping of DMD mRNA in cynomolgus monkey

Time	2 weeks			4 weeks	
Group	Vehicle	Naked ASO ^a	Conjugate	Naked ASO ^a	Conjugate
Conjugate dose ^b	0	n/a	122	n/a	122
ASO Dose ^c	0	30	30	30	30
Quadriceps ^d	0.00 (0.00)	1.216 (1.083)	4.906 (3.131)	0.840 (1.169)	1.708 (1.395)
Diaphragm ^d	0.00 (0.00)	1.891 (2.911)	7.315 (1.532)	0.717 (1.315)	9.225 (4.696)
Heart ^d	0.00 (0.00)	0.043 (0.096)	3.42 (1.192)	0.00 (0.00)	4.525 (1.400)
Biceps ^d	0.00 (0.00)	0.607 (0.615)	3.129 (0.912)	1.214 (1.441)	4.863 (3.881)
Tibialis anterior ^d	0.00 (0.00)	0.699 (0.997)	1.042 (0.685)	0.384 (0.615)	0.816 (0.915)
Gastrocnemius ^d	0.00 (0.00)	0.388 (0.573)	2.424 (2.329)	0.00 (0.00)	5.393 (2.695)

^aASO = antisense oligonucleotide.

^bConjugate doses are listed as mg/kg of anti-TfR1 Fab 3M12 VH4/Vκ3-ASO conjugate.

^cASO doses are listed as mg/kg ASO or ASO equivalent of the anti-TfR1 Fab 3M12 VH4/Vκ3-ASO dose.

^dExon skipping values are mean % exon 51 skipping with standard deviations (n=5) in parentheses.

[000376] Tissue ASO accumulation was also quantified using a hybridization ELISA with a probe complementary to the ASO sequence. A standard curve was generated and ASO levels (in ng/g) were derived from a linear regression of the standard curve. The ASO was distributed to all tissues evaluated at a higher level following the administration of the anti-TfR1 Fab VH4/Vκ3-ASO conjugate as compared to the administration of naked ASO. Intravenous administration of naked ASO resulted in levels of ASO that were close to background levels in all tissues evaluated at 2 and 4 weeks after the first dose was administered. Administration of anti-TfR1 Fab VH4/Vκ3-ASO conjugate resulted in distribution of ASO through the tissues

evaluated with a rank order of heart>diaphragm>bicep>quadriceps>gastrocnemius>tibialis anterior 2 weeks after first dosing. The duration of tissue concentration was also assessed. Concentrations of the ASO in quadriceps, bicep and diaphragm decreased by less than 50% over the time period evaluated (2 to 4 weeks), while levels of ASO in the heart, tibialis anterior, and gastrocnemius remained virtually unchanged (Table 11). This indicates that anti-TfR1 Fab 3M12 VH4/Vκ3 enabled cellular internalization of the conjugate into muscle cells *in vivo*, resulting in activity of the exon skipping oligonucleotide in the muscle cells. Similarly, an anti-TfR1 antibody (*e.g.*, anti-TfR1 Fab 3M12 VH4/Vκ3) *in vivo* can enable internalization of a conjugate comprising the anti-TfR1 antibody covalently linked to other exon skipping oligonucleotides (*e.g.*, an exon skipping oligonucleotide provided herein, such as an exon 45 skipping oligonucleotide) into muscle cells and facilitate activity of the exon skipping oligonucleotide in the muscle cells.

Table 11. Tissue distribution of DMD exon 51 skipping ASO in cynomolgus monkeys

Time	2 weeks			4 weeks	
Group	Vehicle	Naked ASO ^a	Conjugate	Naked ASO ^a	Conjugate
Conjugate Dose ^b	0	n/a	122	n/a	122
ASO Dose ^c	0	30	30	30	30
Quadriceps ^d	0 (59.05)	696.8 (868.15)	2436 (954.0)	197 (134)	682 (281)
Diaphragm ^d	0± (144.3)	580.02 (360.11)	6750 (2256)	60 (120)	3131 (1618)
Heart ^d	0 (396.03)	1449 (1337)	27138 (6315)	943 (1803)	30410 (9247)
Biceps ^d	0 (69.58)	615.63 (335.17)	2840 (980.31)	130 (80)	1326 (623)
Tibialis anterior ^d	0 (76.31)	564.71 (327.88)	1591 (253.50)	169 (110)	1087 (514)
Gastrocnemius ^d	0 (41.15)	705.47 (863.75)	2096 (474.04)	170 (69)	1265 (272)

^aASO = Antisense oligonucleotide.

^bConjugate doses are listed as mg/kg of anti-TfR1 Fab 3M12 VH4/Vκ3-ASO conjugate.

^cASO doses are listed as mg/kg ASO or ASO equivalent of the anti-TfR1 Fab 3M12 VH4/Vκ3-ASO conjugate dose.

^dASO values are mean concentrations of ASO in tissue as ng/g with standard deviations (n=5) in parentheses.

Example 3. Exon 45 skipping activity of antisense oligonucleotides

[000377] Immortalized human myoblasts were thawed and seeded at a density of 1e6 cell/flask in Promocell Skeletal Cell Growth Media (with 5% FBS and 1x Pen-Strep) and allowed to grow to confluency. Once confluent, cells were trypsinized and pelleted via centrifugation and resuspended in fresh Promocell Skeletal Cell Growth Media. The cell number was counted and cells were seeded into Matrigel-coated 96-well plates at a density of 50,000 cells/well. Cells were allowed to recover for 24 hours. Cells were induced to differentiate into myotubes by aspirating the growth media and replacing with differentiation media with no

serum. Cells were then treated with DMD exon 45-skipping oligonucleotides (ASOs; not covalently linked to an antibody – “naked”) comprising the nucleobase sequences provided in Table 12 at 10 μ M ASO. The exon 45-skipping ASOs are phosphorodiamidate morpholino oligomers (PMOs). Cells were incubated with test articles for ten days then total RNA was harvested from the 96 well plates. cDNA synthesis was performed on 75 ng of total RNA, and PCRs were performed to evaluate the degree of exon 45 skipping in the cells. PCR products were measured using capillary electrophoresis with UV detection. Molarity was calculated and relative amounts of the skipped and unskipped amplicon were determined. Exon skipping was determined as a ratio of the Exon 45 skipped amplicon divided by the total amount of amplicon present, according to the following formula:

$$\%Exon\ Skipping = \frac{Skipped\ Amplicon}{(Skipped\ Amplicon + Unskipped\ Amplicon)} * 100.$$

Table 12. Exon 45 skipping activity of ASOs

ASO Sequence	SEQ ID NO:	% Exon 45 Skipping
TTATTTCTTCCCCAGTTGCATTCA	720	100
TTATTTCTTCCCCAGTTGCATTCAA	716	100
TACTGGCATCTGTTTTTGAGGA	760	81.97831
CTGCCCAATGCCATCCTGGAGTTCC	691	99.59011
CCCAATGCCATCCTGGAGTTCCTGT	677	98.68205
CCAATGCCATCCTGGAGTTC	692	98.51852
CCAATGCCATCCTGGAGTTCC	688	98.14503
GCTGCCCAATGCCATCCTGGAGTTC	697	98.06374
CCCAATGCCATCCTGGAGTTC	693	96.36427
AATGCCATCCTGGAGTTCCTGT	675	95.96277

EQUIVALENTS AND TERMINOLOGY

[000378] The disclosure illustratively described herein suitably can be practiced in the absence of any element or elements, limitation or limitations that are not specifically disclosed herein. Thus, for example, in each instance herein any of the terms “comprising”, “consisting essentially of”, and “consisting of” may be replaced with either of the other two terms. The terms and expressions which have been employed are used as terms of description and not of limitation, and there is no intention that in the use of such terms and expressions of excluding any equivalents of the features shown and described or portions thereof, but it is recognized that various modifications are possible within the scope of the disclosure. Thus, it should be understood that although the present disclosure has been specifically disclosed by preferred embodiments, optional features, modification and variation of the concepts herein disclosed may be resorted to by those skilled in the art, and that such modifications and variations are considered to be within the scope of this disclosure.

[000379] In addition, where features or aspects of the disclosure are described in terms of Markush groups or other grouping of alternatives, those skilled in the art will recognize that the disclosure is also thereby described in terms of any individual member or subgroup of members of the Markush group or other group.

[000380] It should be appreciated that, in some embodiments, sequences presented in the sequence listing may be referred to in describing the structure of an oligonucleotide or other nucleic acid. In such embodiments, the actual oligonucleotide or other nucleic acid may have one or more alternative nucleotides or nucleosides (e.g., an RNA counterpart of a DNA nucleoside or a DNA counterpart of an RNA nucleoside) and/or (e.g., and) one or more modified nucleotides/nucleosides and/or (e.g., and) one or more modified internucleoside linkages and/or (e.g., and) one or more other modification compared with the specified sequence while retaining essentially same or similar complementary properties as the specified sequence.

[000381] The use of the terms “a” and “an” and “the” and similar referents in the context of describing the invention (especially in the context of the following claims) are to be construed to cover both the singular and the plural, unless otherwise indicated herein or clearly contradicted by context. The terms “comprising,” “having,” “including,” and “containing” are to be construed as open-ended terms (*i.e.*, meaning “including, but not limited to,”) unless otherwise noted. Recitation of ranges of values herein are merely intended to serve as a shorthand method of referring individually to each separate value falling within the range, unless otherwise indicated herein, and each separate value is incorporated into the specification as if it were individually recited herein. All methods described herein can be performed in any suitable order unless otherwise indicated herein or otherwise clearly contradicted by context. The use of any and all examples, or exemplary language (*e.g.*, “such as”) provided herein, is intended merely to better illuminate the invention and does not pose a limitation on the scope of the invention unless otherwise claimed. No language in the specification should be construed as indicating any non-claimed element as essential to the practice of the invention.

[000382] Embodiments of this invention are described herein. Variations of those embodiments may become apparent to those of ordinary skill in the art upon reading the foregoing description.

[000383] The inventors expect skilled artisans to employ such variations as appropriate, and the inventors intend for the invention to be practiced otherwise than as specifically described herein. Accordingly, this invention includes all modifications and equivalents of the subject matter recited in the claims appended hereto as permitted by applicable law. Moreover, any combination of the above-described elements in all possible variations thereof is encompassed by the invention unless otherwise indicated herein or otherwise clearly contradicted by context.

Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the following claims.

CLAIMS

What is claimed is:

1. A complex comprising an anti-transferrin receptor 1 (TfR1) antibody covalently linked to an oligonucleotide configured for inducing skipping of exon 45 in a DMD pre-mRNA, wherein the oligonucleotide comprises a region of complementarity that is complementary with at least 8 consecutive nucleotides of any one of SEQ ID NOs: 240, 236, 280, 211, 197, 212, 208, 217, 213, 195, 160-194, 196, 198-207, 209, 210, 214-216, 218-235, 237-239, 241-279, and 281-399.
2. The complex of claim 1, wherein the anti-TfR1 antibody comprises:
 - (i) a heavy chain complementarity determining region 1 (CDR-H1) of SEQ ID NO: 33, a heavy chain complementarity determining region 2 (CDR-H2) of SEQ ID NO: 34, a heavy chain complementarity determining region 3 (CDR-H3) of SEQ ID NO: 35, a light chain complementarity determining region 1 (CDR-L1) of SEQ ID NO: 36, a light chain complementarity determining region 2 (CDR-L2) of SEQ ID NO: 37, and a light chain complementarity determining region 3 (CDR-L3) of SEQ ID NO: 32;
 - (ii) a CDR-H1 of SEQ ID NO: 7, a CDR-H2 of SEQ ID NO: 8, a CDR-H3 of SEQ ID NO: 9, a CDR-L1 of SEQ ID NO: 10, a CDR-L2 of SEQ ID NO: 11, and a CDR-L3 of SEQ ID NO: 6;
 - (iii) a CDR-H1 of SEQ ID NO: 7, a CDR-H2 of SEQ ID NO: 20, a CDR-H3 of SEQ ID NO: 9, a CDR-L1 of SEQ ID NO: 10, a CDR-L2 of SEQ ID NO: 11, and a CDR-L3 of SEQ ID NO: 6;
 - (iv) a CDR-H1 of SEQ ID NO: 7, a CDR-H2 of SEQ ID NO: 24, a CDR-H3 of SEQ ID NO: 9, a CDR-L1 of SEQ ID NO: 10, a CDR-L2 of SEQ ID NO: 11, and a CDR-L3 of SEQ ID NO: 6;
 - (v) a CDR-H1 of SEQ ID NO: 51, a CDR-H2 of SEQ ID NO: 52, a CDR-H3 of SEQ ID NO: 53, a CDR-L1 of SEQ ID NO: 54, a CDR-L2 of SEQ ID NO: 55, and a CDR-L3 of SEQ ID NO: 50;
 - (vi) a CDR-H1 of SEQ ID NO: 64, a CDR-H2 of SEQ ID NO: 52, a CDR-H3 of SEQ ID NO: 53, a CDR-L1 of SEQ ID NO: 54, a CDR-L2 of SEQ ID NO: 55, and a CDR-L3 of SEQ ID NO: 50; or
 - (vii) a CDR-H1 of SEQ ID NO: 67, a CDR-H2 of SEQ ID NO: 52, a CDR-H3 of SEQ ID NO: 53, a CDR-L1 of SEQ ID NO: 54, a CDR-L2 of SEQ ID NO: 55, and a CDR-L3 of SEQ ID NO: 50.

3. The complex of claim 1 or claim 2, wherein the anti-TfR1 antibody comprises:
- (i) a heavy chain variable region (VH) comprising an amino acid sequence at least 85% identical to SEQ ID NO: 76; and/or a light chain variable region (VL) comprising an amino acid sequence at least 85% identical to SEQ ID NO: 75;
 - (ii) a VH comprising an amino acid sequence at least 85% identical to SEQ ID NO: 69; and/or a VL comprising an amino acid sequence at least 85% identical to SEQ ID NO: 70;
 - (iii) a VH comprising an amino acid sequence at least 85% identical to SEQ ID NO: 71; and/or a VL comprising an amino acid sequence at least 85% identical to SEQ ID NO: 70;
 - (iv) a VH comprising an amino acid sequence at least 85% identical to SEQ ID NO: 72; and/or a VL comprising an amino acid sequence at least 85% identical to SEQ ID NO: 70;
 - (v) a VH comprising an amino acid sequence at least 85% identical to SEQ ID NO: 73; and/or a VL comprising an amino acid sequence at least 85% identical to SEQ ID NO: 74;
 - (vi) a VH comprising an amino acid sequence at least 85% identical to SEQ ID NO: 73; and/or a VL comprising an amino acid sequence at least 85% identical to SEQ ID NO: 75;
 - (vii) a VH comprising an amino acid sequence at least 85% identical to SEQ ID NO: 76; and/or a VL comprising an amino acid sequence at least 85% identical to SEQ ID NO: 74;
 - (viii) a VH comprising an amino acid sequence at least 85% identical to SEQ ID NO: 77; and/or a VL comprising an amino acid sequence at least 85% identical to SEQ ID NO: 78;
 - (ix) a VH comprising an amino acid sequence at least 85% identical to SEQ ID NO: 79; and/or a VL comprising an amino acid sequence at least 85% identical to SEQ ID NO: 80; or
 - (x) a VH comprising an amino acid sequence at least 85% identical to SEQ ID NO: 77; and/or a VL comprising an amino acid sequence at least 85% identical to SEQ ID NO: 80.
4. The complex of any one of claims 1 to 3, wherein the anti-TfR1 antibody comprises:
- (i) a VH comprising the amino acid sequence of SEQ ID NO: 76 and a VL comprising the amino acid sequence of SEQ ID NO: 75;
 - (ii) a VH comprising the amino acid sequence of SEQ ID NO: 69 and a VL comprising the amino acid sequence of SEQ ID NO: 70;
 - (iii) a VH comprising the amino acid sequence of SEQ ID NO: 71 and a VL comprising the amino acid sequence of SEQ ID NO: 70;
 - (iv) a VH comprising the amino acid sequence of SEQ ID NO: 72 and a VL comprising the amino acid sequence of SEQ ID NO: 70;
 - (v) a VH comprising the amino acid sequence of SEQ ID NO: 73 and a VL comprising the amino acid sequence of SEQ ID NO: 74;

- (vi) a VH comprising the amino acid sequence of SEQ ID NO: 73 and a VL comprising the amino acid sequence of SEQ ID NO: 75;
- (vii) a VH comprising the amino acid sequence of SEQ ID NO: 76 and a VL comprising the amino acid sequence of SEQ ID NO: 74;
- (viii) a VH comprising the amino acid sequence of SEQ ID NO: 77 and a VL comprising the amino acid sequence of SEQ ID NO: 78;
- (ix) a VH comprising the amino acid sequence of SEQ ID NO: 79 and a VL comprising the amino acid sequence of SEQ ID NO: 80; or
- (x) a VH comprising the amino acid sequence of SEQ ID NO: 77 and a VL comprising the amino acid sequence of SEQ ID NO: 80.

5. The complex of any one of claims 1 to 4, wherein the anti-TfR1 antibody is a Fab fragment, a Fab' fragment, a F(ab')₂ fragment, an scFv, an Fv, or a full-length IgG.

6. The complex of claim 5, wherein the anti-TfR1 antibody is a Fab fragment.

7. The complex of claim 6, wherein the anti-TfR1 antibody comprises:

- (i) a heavy chain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 101; and/or a light chain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 90;

- (ii) a heavy chain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 97; and/or a light chain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 85;

- (iii) a heavy chain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 98; and/or a light chain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 85;

- (iv) a heavy chain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 99; and/or a light chain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 85;

- (v) a heavy chain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 100; and/or a light chain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 89;

- (vi) a heavy chain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 100; and/or a light chain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 90;

(vii) a heavy chain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 101; and/or a light chain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 89;

(viii) a heavy chain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 102; and/or a light chain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 93;

(ix) a heavy chain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 103; and/or a light chain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 95; or

(x) a heavy chain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 102; and/or a light chain comprising an amino acid sequence at least 85% identical to SEQ ID NO: 95.

8. The complex of claim 6 or claim 7, wherein the anti-TfR1 antibody comprises:

(i) a heavy chain comprising the amino acid sequence of SEQ ID NO: 101; and a light chain comprising the amino acid sequence of SEQ ID NO: 90;

(ii) a heavy chain comprising the amino acid sequence of SEQ ID NO: 97; and a light chain comprising the amino acid sequence of SEQ ID NO: 85;

(iii) a heavy chain comprising the amino acid sequence of SEQ ID NO: 98; and a light chain comprising the amino acid sequence of SEQ ID NO: 85;

(iv) a heavy chain comprising the amino acid sequence of SEQ ID NO: 99; and a light chain comprising the amino acid sequence of SEQ ID NO: 85;

(v) a heavy chain comprising the amino acid sequence of SEQ ID NO: 100; and a light chain comprising the amino acid sequence of SEQ ID NO: 89;

(vi) a heavy chain comprising the amino acid sequence of SEQ ID NO: 100; and a light chain comprising the amino acid sequence of SEQ ID NO: 90;

(vii) a heavy chain comprising the amino acid sequence of SEQ ID NO: 101; and a light chain comprising the amino acid sequence of SEQ ID NO: 89;

(viii) a heavy chain comprising the amino acid sequence of SEQ ID NO: 102; and a light chain comprising the amino acid sequence of SEQ ID NO: 93;

(ix) a heavy chain comprising the amino acid sequence of SEQ ID NO: 103; and a light chain comprising the amino acid sequence of SEQ ID NO: 95; or

(x) a heavy chain comprising the amino acid sequence of SEQ ID NO: 102; and a light chain comprising the amino acid sequence of SEQ ID NO: 95.

9. The complex of any one of claims 1 to 8, wherein the anti-TfR1 antibody does not specifically bind to the transferrin binding site of the transferrin receptor 1 and/or wherein the anti-TfR1 antibody does not inhibit binding of transferrin to the transferrin receptor 1.
10. The complex of any one of claims 1 to 9, wherein the oligonucleotide comprises a region of complementarity to at least 4 consecutive nucleotides of a splicing feature of the DMD pre-mRNA.
11. The complex of claim 10, wherein the splicing feature is an exonic splicing enhancer (ESE) in exon 45 of the DMD pre-mRNA, optionally wherein the ESE comprises a sequence of any one of SEQ ID NOs: 885-912.
12. The complex of claim 10, wherein the splicing feature is a branch point, a splice donor site, or a splice acceptor site, optionally wherein the splicing feature is across the junction of exon 44 and intron 44, in intron 44, across the junction of intron 44 and exon 45, across the junction of exon 45 and intron 45, in intron 45, or across the junction of intron 45 and exon 46 of the DMD pre-mRNA, and further optionally wherein the splicing feature comprises a sequence of any one of SEQ ID NOs: 880-884 and 913-916.
13. The complex of any one of claims 1 to 9, wherein the oligonucleotide comprises a sequence complementary to any one of SEQ ID NOs: 160-399 or comprises a sequence of any one of SEQ ID NOs: 400-879, wherein each thymine base (T) may independently and optionally be replaced with a uracil base (U), and each U may independently and optionally be replaced with a T.
14. The complex of any one of claims 1 to 9, wherein the oligonucleotide comprises a sequence of any one of SEQ ID NOs: 720, 712, 760, 691, 677, 692, 688, 697, 693, and 675, wherein each thymine base (T) may independently and optionally be replaced with a uracil base (U), and each U may independently and optionally be replaced with a T.
15. The complex of any one of claims 1 to 14, wherein the oligonucleotide comprises one or more phosphorodiamidate morpholinos, optionally wherein the oligonucleotide is a phosphorodiamidate morpholino oligomer (PMO).

16. The complex of any one of claims 1 to 15, wherein the anti-TfR1 antibody is covalently linked to the oligonucleotide via a cleavable linker, optionally wherein the cleavable linker comprises a valine-citrulline sequence.
17. The complex of any one of claims 1 to 16, wherein the anti-TfR1 antibody is covalently linked to the oligonucleotide via conjugation to a lysine residue or a cysteine residue of the antibody.
18. An oligonucleotide that targets DMD, wherein the oligonucleotide comprises a region of complementarity to any one of SEQ ID NOs: 160-399, optionally wherein the region of complementarity comprises at least 15 consecutive nucleosides complementary to any one of SEQ ID NOs: 160-399.
19. The oligonucleotide of claim 18, wherein the oligonucleotide comprises at least 15 consecutive nucleosides of any one of SEQ ID NOs: 400-879, optionally wherein the oligonucleotide comprises a sequence of any one of SEQ ID NOs: 400-879, wherein each thymine base (T) may independently and optionally be replaced with a uracil base (U), and each U may independently and optionally be replaced with a T.
20. A method of delivering an oligonucleotide to a cell, the method comprising contacting the cell with the complex of any one of claims 1 to 17 or with the oligonucleotide of claim 18 or claim 19.
21. A method of promoting the expression or activity of a dystrophin protein in a cell, the method comprising contacting the cell with the complex of any one of claims 1 to 17 or with the oligonucleotide of claim 18 or claim 19 in an amount effective for promoting internalization of the oligonucleotide to the cell, optionally wherein the cell is a muscle cell.